{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## NCPE Drugs Data Project\n",
    "#### David Regan\n",
    "#### 11/01/2019\n",
    "data from the NCPE website was loaded into a MySQL database. The database was then connected to this notebook with an sqlalchemy engine and the 2 tables were converted to Pandas dataframes (drugs and tas). Some data conversions and modifications were carried out. Finally, a series of data visualisations were created."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 1. Import The Data and Packages"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "from sqlalchemy import create_engine\n",
    "import warnings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "engine = create_engine(\"mysql+pymysql://root:password@localhost/salutemDB\")# MY PASSWORD"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "drugs = pd.read_sql_query(\"select * from scraped\", engine)\n",
    "tas = pd.read_sql_query(\"select * from therapyareas\", engine)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 1.1 ExploreThe Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 398 entries, 0 to 397\n",
      "Data columns (total 20 columns):\n",
      "id             398 non-null int64\n",
      "last_scrape    398 non-null datetime64[ns]\n",
      "url            398 non-null object\n",
      "rr_start       366 non-null object\n",
      "rr_end         398 non-null object\n",
      "rr_outcome     398 non-null object\n",
      "rr_dates       398 non-null object\n",
      "rr_multiple    398 non-null int64\n",
      "drug_name      398 non-null object\n",
      "trade_name     398 non-null object\n",
      "indication     398 non-null object\n",
      "ncpe_year      398 non-null int64\n",
      "eu_market      383 non-null object\n",
      "company        398 non-null object\n",
      "orphan         398 non-null int64\n",
      "earliest       398 non-null object\n",
      "latest         398 non-null object\n",
      "ema_url        398 non-null object\n",
      "ta_list        398 non-null object\n",
      "rr_status      398 non-null object\n",
      "dtypes: datetime64[ns](1), int64(4), object(15)\n",
      "memory usage: 62.3+ KB\n"
     ]
    }
   ],
   "source": [
    "drugs.info() "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 496 entries, 0 to 495\n",
      "Data columns (total 2 columns):\n",
      "trade_name     496 non-null object\n",
      "therapyarea    496 non-null object\n",
      "dtypes: object(2)\n",
      "memory usage: 7.8+ KB\n"
     ]
    }
   ],
   "source": [
    "tas.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>last_scrape</th>\n",
       "      <th>url</th>\n",
       "      <th>rr_start</th>\n",
       "      <th>rr_end</th>\n",
       "      <th>rr_outcome</th>\n",
       "      <th>rr_dates</th>\n",
       "      <th>rr_multiple</th>\n",
       "      <th>drug_name</th>\n",
       "      <th>trade_name</th>\n",
       "      <th>indication</th>\n",
       "      <th>ncpe_year</th>\n",
       "      <th>eu_market</th>\n",
       "      <th>company</th>\n",
       "      <th>orphan</th>\n",
       "      <th>earliest</th>\n",
       "      <th>latest</th>\n",
       "      <th>ema_url</th>\n",
       "      <th>ta_list</th>\n",
       "      <th>rr_status</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2164</td>\n",
       "      <td>2018-12-13 16:24:32</td>\n",
       "      <td>http://www.ncpe.ie/drugs/abatacept-orencia/</td>\n",
       "      <td>2012-11-28</td>\n",
       "      <td>2012-12-21</td>\n",
       "      <td>Full Pharmacoeconomic Assessment Recommended</td>\n",
       "      <td>2012-11-28, 2012-12-21</td>\n",
       "      <td>0</td>\n",
       "      <td>Abatacept (Orencia</td>\n",
       "      <td>Orencia</td>\n",
       "      <td>Subcutaneous Abatacept (Orencia</td>\n",
       "      <td>2015</td>\n",
       "      <td>2007-05-21</td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>2012-11-28</td>\n",
       "      <td>2015-11-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>HTA recommended at submitted price</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2165</td>\n",
       "      <td>2018-12-13 16:24:36</td>\n",
       "      <td>http://www.ncpe.ie/drugs/abiraterone-acetate-z...</td>\n",
       "      <td>2018-10-03</td>\n",
       "      <td>2018-11-15</td>\n",
       "      <td>A full pharmacoeconomic assessment is recommended</td>\n",
       "      <td>2018-10-03, 2018-11-15</td>\n",
       "      <td>0</td>\n",
       "      <td>Abiraterone acetate (Zytiga</td>\n",
       "      <td>Zytiga</td>\n",
       "      <td>Abiraterone acetate (Zytiga</td>\n",
       "      <td>2018</td>\n",
       "      <td>2011-09-05</td>\n",
       "      <td>Janssen-Cilag</td>\n",
       "      <td>0</td>\n",
       "      <td>2018-10-03</td>\n",
       "      <td>2018-11-15</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Prostatic Neoplasms</td>\n",
       "      <td>HTA recommended at submitted price</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2166</td>\n",
       "      <td>2018-12-13 16:24:41</td>\n",
       "      <td>http://www.ncpe.ie/drugs/abiratone-acetate-zyt...</td>\n",
       "      <td>2013-01-03</td>\n",
       "      <td>2013-02-01</td>\n",
       "      <td>Full Pharmacoeconomic Evaluation Recommended.</td>\n",
       "      <td>2013-01-03, 2013-02-01</td>\n",
       "      <td>0</td>\n",
       "      <td>Abiraterone acetate (Zytiga</td>\n",
       "      <td>Zytiga</td>\n",
       "      <td>Pharmacoeconomic evaluation of Abiratone aceta...</td>\n",
       "      <td>2015</td>\n",
       "      <td>2011-09-05</td>\n",
       "      <td>Janssen-Cilag</td>\n",
       "      <td>0</td>\n",
       "      <td>2013-01-03</td>\n",
       "      <td>2015-12-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Prostatic Neoplasms</td>\n",
       "      <td>HTA recommended at submitted price</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     id         last_scrape  \\\n",
       "0  2164 2018-12-13 16:24:32   \n",
       "1  2165 2018-12-13 16:24:36   \n",
       "2  2166 2018-12-13 16:24:41   \n",
       "\n",
       "                                                 url    rr_start      rr_end  \\\n",
       "0        http://www.ncpe.ie/drugs/abatacept-orencia/  2012-11-28  2012-12-21   \n",
       "1  http://www.ncpe.ie/drugs/abiraterone-acetate-z...  2018-10-03  2018-11-15   \n",
       "2  http://www.ncpe.ie/drugs/abiratone-acetate-zyt...  2013-01-03  2013-02-01   \n",
       "\n",
       "                                          rr_outcome                rr_dates  \\\n",
       "0       Full Pharmacoeconomic Assessment Recommended  2012-11-28, 2012-12-21   \n",
       "1  A full pharmacoeconomic assessment is recommended  2018-10-03, 2018-11-15   \n",
       "2      Full Pharmacoeconomic Evaluation Recommended.  2013-01-03, 2013-02-01   \n",
       "\n",
       "   rr_multiple                    drug_name trade_name  \\\n",
       "0            0           Abatacept (Orencia    Orencia   \n",
       "1            0  Abiraterone acetate (Zytiga     Zytiga   \n",
       "2            0  Abiraterone acetate (Zytiga     Zytiga   \n",
       "\n",
       "                                          indication  ncpe_year   eu_market  \\\n",
       "0                    Subcutaneous Abatacept (Orencia       2015  2007-05-21   \n",
       "1                        Abiraterone acetate (Zytiga       2018  2011-09-05   \n",
       "2  Pharmacoeconomic evaluation of Abiratone aceta...       2015  2011-09-05   \n",
       "\n",
       "         company  orphan    earliest      latest  \\\n",
       "0                      0  2012-11-28  2015-11-01   \n",
       "1  Janssen-Cilag       0  2018-10-03  2018-11-15   \n",
       "2  Janssen-Cilag       0  2013-01-03  2015-12-01   \n",
       "\n",
       "                                             ema_url              ta_list  \\\n",
       "0  https://www.ema.europa.eu/en/medicines/human/E...              Unknown   \n",
       "1  https://www.ema.europa.eu/en/medicines/human/E...  Prostatic Neoplasms   \n",
       "2  https://www.ema.europa.eu/en/medicines/human/E...  Prostatic Neoplasms   \n",
       "\n",
       "                            rr_status  \n",
       "0  HTA recommended at submitted price  \n",
       "1  HTA recommended at submitted price  \n",
       "2  HTA recommended at submitted price  "
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "drugs.head(3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>trade_name</th>\n",
       "      <th>therapyarea</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Kadcyla</td>\n",
       "      <td>Breast Neoplasms</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Loteprednol</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    trade_name       therapyarea\n",
       "0      Kadcyla  Breast Neoplasms\n",
       "1  Loteprednol           Unknown"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tas.head(2)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 1.2 Data Conversions and Clean-ups"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Converting to Datetime"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "drugs['rr_start'] = drugs['rr_start'].apply(pd.to_datetime)\n",
    "drugs['rr_end'] = drugs['rr_end'].apply(pd.to_datetime)\n",
    "drugs['eu_market'] = drugs['eu_market'].apply(pd.to_datetime)\n",
    "drugs['earliest'] = drugs['earliest'].apply(pd.to_datetime)\n",
    "drugs['latest'] = drugs['latest'].apply(pd.to_datetime)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Breast Neoplasms', 'Unknown', 'Ovarian Neoplasms',\n",
       "       'Hepatitis C, Chronic', 'Influenza, Human',\n",
       "       'Pulmonary Disease, Chronic Obstructive',\n",
       "       'Hepatic Veno-Occlusive Disease', 'Immunization',\n",
       "       'Migraine Disorders', 'Hypertension, Pulmonary',\n",
       "       'Gram-Negative Bacterial Infections', 'Diabetes Mellitus, Type 2',\n",
       "       'Psoriasis', 'Arthritis, Rheumatoid', 'Spondylitis, Ankylosing',\n",
       "       'Hodgkin Disease', 'Multiple Sclerosis', 'Radionuclide Imaging',\n",
       "       'Prostatic Neoplasms', 'Multiple Myeloma', 'Lymphoma, Mantle-Cell',\n",
       "       'Hyperkalemia', 'Epilepsy', 'Carcinoma, Non-Small-Cell Lung',\n",
       "       'Melanoma', 'Disease Outbreaks', 'Hypercholesterolemia',\n",
       "       'Reproductive Techniques, Assisted', 'Aspergillosis',\n",
       "       'Osteosarcoma', 'Leukemia, Myeloid', 'Asthma',\n",
       "       'Colitis, Ulcerative', 'Macular Edema', 'Anemia, Iron-Deficiency',\n",
       "       'Cross Infection', 'Bipolar Disorder', 'Pneumonia',\n",
       "       'Bone Resorption',\n",
       "       'Leukemia, Myelogenous, Chronic, BCR-ABL Positive',\n",
       "       'Carcinoma, Renal Cell', 'Venous Thromboembolism',\n",
       "       'Colorectal Neoplasms', 'Arthritis, Psoriatic',\n",
       "       'Muscular Atrophy, Spinal', 'Community-Acquired Infections',\n",
       "       'Amyloidosis', 'Myocardial Perfusion Imaging',\n",
       "       'Idiopathic Pulmonary Fibrosis', 'Lymphoma, Non-Hodgkin',\n",
       "       'Constipation', 'Keratosis, Actinic', 'Gout', 'Cystic Fibrosis',\n",
       "       'Contraception', 'Lupus Erythematosus, Systemic', 'Mastocytosis',\n",
       "       'Pain, Postoperative', 'Obesity', 'Fractures, Bone',\n",
       "       'Arthroplasty, Replacement', 'Skin Diseases, Infectious',\n",
       "       'Rectal Fistula', 'Skin Diseases, Bacterial', 'Skin Diseases',\n",
       "       'Leukemia, Myeloid, Acute', 'Liver Cirrhosis, Biliary',\n",
       "       'Crohn Disease', 'HIV Infections', 'Mucopolysaccharidosis IV',\n",
       "       'Phenylketonurias', 'Pancreatic Neoplasms',\n",
       "       'Polycystic Kidney, Autosomal Dominant', 'Pneumococcal Infections',\n",
       "       'Cancer', 'Hyperuricemia', 'Myeloproliferative Disorders',\n",
       "       'Neuroendocrine Tumors', 'Arthritis, Juvenile Rheumatoid',\n",
       "       'Pneumonia, Bacterial', 'Conscious Sedation', 'Schizophrenia',\n",
       "       'Respiratory Tract Infections', 'Alcohol-Related Disorders',\n",
       "       'Lung Diseases', 'Myelodysplastic Syndromes',\n",
       "       'Acute Coronary Syndrome', 'Keratosis', 'Angioedemas, Hereditary',\n",
       "       'Urticaria', 'Arthroplasty', 'Angina, Unstable',\n",
       "       'Soft Tissue Infections', 'Stomach Neoplasms', 'Narcolepsy',\n",
       "       'Nausea', 'Enterocolitis, Pseudomembranous', 'Tuberous Sclerosis',\n",
       "       'Overweight', 'Diabetes Mellitus', 'Peritoneal Neoplasms',\n",
       "       'Purpura, Thrombocytopenic, Idiopathic', 'Adrenal Insufficiency',\n",
       "       'Depressive Disorder, Major', 'Lymphoma, Large B-Cell, Diffuse',\n",
       "       'Bacterial Infections', 'Hypertension', 'Neoplasm Metastasis',\n",
       "       'Precursor B-Cell Lymphoblastic Leukemia-Lymphoma', 'Vomiting',\n",
       "       'Liposarcoma', 'Cystinosis', 'Ovulation Induction', 'Stroke',\n",
       "       'Dermatitis, Atopic', 'Thyroid Neoplasms', 'Heart Failure',\n",
       "       'Kidney Transplantation', 'Corneal Diseases',\n",
       "       'Atrial Fibrillation', 'Lipid Metabolism, Inborn Errors',\n",
       "       'Osteoporosis, Postmenopausal',\n",
       "       'Tuberculosis, Multidrug-Resistant', 'Opioid-Related Disorders',\n",
       "       'Irritable Bowel Syndrome',\n",
       "       'Sleep Initiation and Maintenance Disorders',\n",
       "       'Cytomegalovirus Infections', 'Carcinoma, Transitional Cell',\n",
       "       'Anovulation', 'Neuralgia',\n",
       "       'Leukemia, Lymphocytic, Chronic, B-Cell', 'Uveitis',\n",
       "       'Gastrointestinal Stromal Tumors', 'Lymphoma, Follicular',\n",
       "       'Leukemia, Lymphoid', 'Hemoglobinuria, Paroxysmal',\n",
       "       'Precursor Cell Lymphoblastic Leukemia-Lymphoma',\n",
       "       'Retinal Diseases', 'Peripheral Vascular Diseases',\n",
       "       'Anxiety Disorders', 'Fabry Disease', 'Diabetes Complications',\n",
       "       'Urinary Bladder, Overactive', 'Anemia, Sickle Cell', 'Malaria',\n",
       "       'Scleroderma, Systemic', 'Clostridium Infections',\n",
       "       'Myocardial Infarction',\n",
       "       'Attention Deficit Disorder with Hyperactivity',\n",
       "       'Hyperphosphatemia', 'Ascites', 'Dupuytren Contracture',\n",
       "       'Fallopian Tube Neoplasms', 'Sialorrhea',\n",
       "       'Carbamoyl-Phosphate Synthase I Deficiency Disease',\n",
       "       'Gaucher Disease', 'Genetic Diseases, Inborn',\n",
       "       'Wet Macular Degeneration', 'Urinary Tract Infections',\n",
       "       'Carcinoma, Basal Cell', 'Renal Dialysis', 'Parkinson Disease',\n",
       "       'Neuronal Ceroid-Lipofuscinoses', 'Hyperparathyroidism, Secondary',\n",
       "       'Epilepsies, Partial', 'Urea Cycle Disorders, Inborn',\n",
       "       'Ophthalmologic Surgical Procedures', 'Graft Rejection',\n",
       "       'Optic Atrophy, Hereditary, Leber', 'Hemorrhage', 'Leiomyoma',\n",
       "       'Neutropenia', 'Dyslipidemias', 'Erectile Dysfunction',\n",
       "       'Myoclonic Epilepsy, Juvenile', 'Malabsorption Syndromes'],\n",
       "      dtype=object)"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tas.therapyarea.unique()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Reduce complexity in column: \"rr_outcome\".\n",
    "Column contains drug assessment/recommendation.\n",
    "Intially the column has 96 unique values, we can reduce this."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "96 unique values.\n"
     ]
    }
   ],
   "source": [
    "print(len(drugs['rr_outcome'].unique()),\"unique values.\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Transformation: Remove Blank space"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "87 unique values.\n"
     ]
    }
   ],
   "source": [
    "drugs['rr_outcome'] = drugs['rr_outcome'].apply(lambda x: x.strip())\n",
    "print(len(drugs['rr_outcome'].unique()),\"unique values.\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Transformation: Uppercase"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "70 unique values.\n"
     ]
    }
   ],
   "source": [
    "drugs['rr_outcome'] = drugs['rr_outcome'].apply(lambda x: x.upper())\n",
    "print(len(drugs['rr_outcome'].unique()),\"unique values.\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Transformation: \"Evaluation\" and \"Assesment\" used interchangeably. Use \"Assesment\" only."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "64 unique values.\n"
     ]
    }
   ],
   "source": [
    "drugs['rr_outcome'] = drugs['rr_outcome'].apply(lambda x: x.replace(\" EVALUATION \", \" ASSESSMENT \"))\n",
    "print(len(drugs['rr_outcome'].unique()),\"unique values.\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Transformation: \"A full\" and \"Full\" used interchangeably. Use \"Full\" only."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "def change_a_full(txt):\n",
    "    if txt[0:7] == \"A FULL \":\n",
    "        return \"FULL \" + txt[7:]   \n",
    "    else:\n",
    "        return txt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "63 unique values.\n"
     ]
    }
   ],
   "source": [
    "drugs['rr_outcome'] = drugs['rr_outcome'].apply(lambda x: change_a_full(x))\n",
    "print(len(drugs['rr_outcome'].unique()),\"unique values.\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Replacing other redundances"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "60 unique values.\n"
     ]
    }
   ],
   "source": [
    "drugs['rr_outcome'] = drugs['rr_outcome'].apply(lambda x: x.replace(\"ASSESSMENT IS RECOMMENDED\",\"ASSESSMENT RECOMMENDED\"))\n",
    "print(len(drugs['rr_outcome'].unique()),\"unique values.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "60 unique values.\n"
     ]
    }
   ],
   "source": [
    "drugs['rr_outcome'] = drugs['rr_outcome'].apply(lambda x: x.replace(\"ASSESSMENT IS NOT RECOMMENDED\",\"ASSESSMENT NOT RECOMMENDED\"))\n",
    "print(len(drugs['rr_outcome'].unique()),\"unique values.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "59 unique values.\n"
     ]
    }
   ],
   "source": [
    "drugs['rr_outcome'] = drugs['rr_outcome'].apply(lambda x: x.replace(\"RECOMMENDED AT THE SUBMITTED PRICE.\",\"RECOMMENDED AT SUBMITTED PRICE\"))\n",
    "print(len(drugs['rr_outcome'].unique()),\"unique values.\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### VERIFY DRUGS & TAS DATA: \n",
    "Drugs = 398 entries and all fields are-non null.\n",
    "Tas = 496 entries and all fields are-non null."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 398 entries, 0 to 397\n",
      "Data columns (total 20 columns):\n",
      "id             398 non-null int64\n",
      "last_scrape    398 non-null datetime64[ns]\n",
      "url            398 non-null object\n",
      "rr_start       366 non-null datetime64[ns]\n",
      "rr_end         398 non-null datetime64[ns]\n",
      "rr_outcome     398 non-null object\n",
      "rr_dates       398 non-null object\n",
      "rr_multiple    398 non-null int64\n",
      "drug_name      398 non-null object\n",
      "trade_name     398 non-null object\n",
      "indication     398 non-null object\n",
      "ncpe_year      398 non-null int64\n",
      "eu_market      383 non-null datetime64[ns]\n",
      "company        398 non-null object\n",
      "orphan         398 non-null int64\n",
      "earliest       398 non-null datetime64[ns]\n",
      "latest         398 non-null datetime64[ns]\n",
      "ema_url        398 non-null object\n",
      "ta_list        398 non-null object\n",
      "rr_status      398 non-null object\n",
      "dtypes: datetime64[ns](6), int64(4), object(10)\n",
      "memory usage: 62.3+ KB\n"
     ]
    }
   ],
   "source": [
    "drugs.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 496 entries, 0 to 495\n",
      "Data columns (total 2 columns):\n",
      "trade_name     496 non-null object\n",
      "therapyarea    496 non-null object\n",
      "dtypes: object(2)\n",
      "memory usage: 7.8+ KB\n"
     ]
    }
   ],
   "source": [
    "tas.info()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 2.0 Data Visualisation with Altair"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "import altair as alt\n",
    "from altair import Color, Scale"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "def rgb_to_hex(rgb):\n",
    "    return '#%02x%02x%02x' % rgb"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "RendererRegistry.enable('notebook')"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "alt.renderers.enable('notebook')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'HTA recommended at submitted price',\n",
       " 'No HTA',\n",
       " 'No HTA at submitted price',\n",
       " 'No HTA until more evidence',\n",
       " 'RR not conducted',\n",
       " 'Reimbursement not recommended',\n",
       " 'Reimbursement without HTA',\n",
       " 'Unknown'}"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "set(drugs.rr_status.values)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 2.1 Count Drugs by NCPE Year \n",
    "The total number of drugs by year"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "var spec = {\"config\": {\"view\": {\"width\": 400, \"height\": 300}}, \"data\": {\"name\": \"data-1fb11c1b30e9c74b6a5173f2568cb7ab\"}, \"mark\": \"bar\", \"encoding\": {\"x\": {\"type\": \"ordinal\", \"axis\": {\"title\": \"NCPE Year\"}, \"field\": \"ncpe_year\"}, \"y\": {\"type\": \"quantitative\", \"aggregate\": \"count\", \"field\": \"id\", \"title\": \"Count\"}}, \"height\": 400, \"title\": \"Count Drugs by NCPE Year\", \"width\": 700, \"$schema\": \"https://vega.github.io/schema/vega-lite/v2.6.0.json\", \"datasets\": {\"data-1fb11c1b30e9c74b6a5173f2568cb7ab\": [{\"id\": 2164, \"last_scrape\": \"2018-12-13T16:24:32\", \"url\": \"http://www.ncpe.ie/drugs/abatacept-orencia/\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Abatacept (Orencia\", \"trade_name\": \"Orencia\", \"indication\": \"Subcutaneous Abatacept (Orencia\", \"ncpe_year\": 2015, \"eu_market\": \"2007-05-21T00:00:00\", \"company\": \"\", \"orphan\": 0, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/orencia\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2165, \"last_scrape\": \"2018-12-13T16:24:36\", \"url\": \"http://www.ncpe.ie/drugs/abiraterone-acetate-zytiga-for-mhspc/\", \"rr_start\": \"2018-10-03T00:00:00\", \"rr_end\": \"2018-11-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-10-03, 2018-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Abiraterone acetate (Zytiga\", \"ncpe_year\": 2018, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2018-10-03T00:00:00\", \"latest\": \"2018-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2166, \"last_scrape\": \"2018-12-13T16:24:41\", \"url\": \"http://www.ncpe.ie/drugs/abiratone-acetate-zytiga-for-mcrpc-post-adt/\", \"rr_start\": \"2013-01-03T00:00:00\", \"rr_end\": \"2013-02-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-01-03, 2013-02-01\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation of Abiratone acetate (Zytiga\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-01-03T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2167, \"last_scrape\": \"2018-12-13T16:24:46\", \"url\": \"http://www.ncpe.ie/drugs/abiratone-acetate-zytiga/\", \"rr_start\": \"2011-10-21T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-10-21, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone Acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation and resource implications of Zytiga \", \"ncpe_year\": 2014, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-21T00:00:00\", \"latest\": \"2014-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2168, \"last_scrape\": \"2018-12-13T16:24:49\", \"url\": \"http://www.ncpe.ie/drugs/aceclofenac-vitafen/\", \"rr_start\": \"2016-12-21T00:00:00\", \"rr_end\": \"2017-01-24T00:00:00\", \"rr_outcome\": \"FOLLOWING A RESUBMISSION OF THE RAPID REVIEW A FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-12-21, 2017-01-24\", \"rr_multiple\": 0, \"drug_name\": \"Aceclofenac (Vitafen\", \"trade_name\": \"Vitafen\", \"indication\": \"Aceclofenac (Vitafen\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-07-22T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2169, \"last_scrape\": \"2018-12-13T16:24:56\", \"url\": \"http://www.ncpe.ie/drugs/aclidinium-bromide-eklira-genuair/\", \"rr_start\": \"2012-10-23T00:00:00\", \"rr_end\": \"2012-10-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-23, 2012-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide (Eklira Genuair\", \"trade_name\": \"Eklira Genuair\", \"indication\": \"Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)\", \"ncpe_year\": 2012, \"eu_market\": \"2012-07-20T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-23T00:00:00\", \"latest\": \"2012-10-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"id\": 2170, \"last_scrape\": \"2018-12-13T16:25:00\", \"url\": \"http://www.ncpe.ie/drugs/aclidinium-bromide-formoterol-fumarate-dihydrate-brimica-genuair/\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE.\", \"rr_dates\": \"2015-01-05, 2015-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide / formoterol fumarate dihydrate (Brimica\", \"trade_name\": \"Brimica Genuair\", \"indication\": \"Brimica\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2015-02-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brimica-genuair\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2171, \"last_scrape\": \"2018-12-13T16:25:37\", \"url\": \"http://www.ncpe.ie/drugs/adalimumab-humira/\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-20, 2011-06-02\", \"rr_multiple\": 0, \"drug_name\": \"Adalimumab (Humira\", \"trade_name\": \"Humira\", \"indication\": \"Economic evaluation of Adalimumab (Humira\", \"ncpe_year\": 2011, \"eu_market\": \"2003-09-07T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/humira\", \"ta_list\": \"Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"id\": 2172, \"last_scrape\": \"2018-12-13T16:25:40\", \"url\": \"http://www.ncpe.ie/drugs/adenuric-febuxostat/\", \"rr_start\": \"2009-12-08T00:00:00\", \"rr_end\": \"2009-12-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-12-08\", \"rr_multiple\": 0, \"drug_name\": \"Adenuric (Febuxostat\", \"trade_name\": \"Febuxostat\", \"indication\": \"NCPE review of Adenuric (Febuxostat\", \"ncpe_year\": 2009, \"eu_market\": \"2008-04-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2009-12-08T00:00:00\", \"latest\": \"2009-12-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adenuric\", \"ta_list\": \"Gout\", \"rr_status\": \"No HTA\"}, {\"id\": 2173, \"last_scrape\": \"2018-12-13T16:25:45\", \"url\": \"http://www.ncpe.ie/drugs/afatinib-giotrif/\", \"rr_start\": \"2013-10-01T00:00:00\", \"rr_end\": \"2013-10-13T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-10-01, 2013-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Afatinib (Giotrif\", \"trade_name\": \"Giotrif\", \"indication\": \"GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-na\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-25T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2013-10-01T00:00:00\", \"latest\": \"2013-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2174, \"last_scrape\": \"2018-12-13T16:25:49\", \"url\": \"http://www.ncpe.ie/drugs/aflibercept-eylea/\", \"rr_start\": \"2012-12-10T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-10, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept (Eylea\", \"trade_name\": \"Eylea\", \"indication\": \"Aflibercept (Eylea\", \"ncpe_year\": 2012, \"eu_market\": \"2012-11-21T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2012-12-10T00:00:00\", \"latest\": \"2012-12-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eylea\", \"ta_list\": \"Wet Macular Degeneration; Macular Edema; Diabetes Complications\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2175, \"last_scrape\": \"2018-12-13T16:25:52\", \"url\": \"http://www.ncpe.ie/drugs/aflibercept-zaltrap/\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept (Zaltrap\", \"trade_name\": \"Zaltrap\", \"indication\": \"Aflibercept for the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-01T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-02-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zaltrap\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2176, \"last_scrape\": \"2018-12-13T16:25:58\", \"url\": \"http://www.ncpe.ie/drugs/agomelatine-valdoxan-4/\", \"rr_start\": \"\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Agomelatine (Valdoxan\", \"trade_name\": \"Valdoxan\", \"indication\": \"Economic evaluation of Agomelatine (Valdoxan\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-19T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2009-09-03T00:00:00\", \"latest\": \"2009-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/valdoxan\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2177, \"last_scrape\": \"2018-12-13T16:26:06\", \"url\": \"http://www.ncpe.ie/drugs/alectinib-alecensa/\", \"rr_start\": \"2017-01-03T00:00:00\", \"rr_end\": \"2017-12-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-01-03, 2017-02-27, 2017-11-08, 2017-12-04\", \"rr_multiple\": 1, \"drug_name\": \"Alectinib (Alecensa\", \"trade_name\": \"Alecensa\", \"indication\": \"Alectinib (Alecensa \", \"ncpe_year\": 2018, \"eu_market\": \"2017-02-16T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2178, \"last_scrape\": \"2018-12-13T16:26:12\", \"url\": \"http://www.ncpe.ie/drugs/alemtuzumab-lemtrada/\", \"rr_start\": \"2013-11-08T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-11-08, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Alemtuzumab (Lemtrada\", \"trade_name\": \"Lemtrada\", \"indication\": \"Alemtuzumab (Lemtrada\", \"ncpe_year\": 2014, \"eu_market\": \"2013-09-12T00:00:00\", \"company\": \"Sanofi\", \"orphan\": 0, \"earliest\": \"2013-11-08T00:00:00\", \"latest\": \"2014-06-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2179, \"last_scrape\": \"2018-12-13T16:26:14\", \"url\": \"http://www.ncpe.ie/drugs/alirocumab-praluent/\", \"rr_start\": \"2015-10-13T00:00:00\", \"rr_end\": \"2015-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-10-13, 2015-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Alirocumab (Praluent\", \"trade_name\": \"Praluent\", \"indication\": \"Praluent\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2015-10-13T00:00:00\", \"latest\": \"2018-03-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/praluent\", \"ta_list\": \"Dyslipidemias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2180, \"last_scrape\": \"2018-12-13T16:26:16\", \"url\": \"http://www.ncpe.ie/drugs/alogliptin-vipidia/\", \"rr_start\": \"2013-09-27T00:00:00\", \"rr_end\": \"2013-10-30T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-09-27, 2013-10-30\", \"rr_multiple\": 0, \"drug_name\": \"Alogliptin (Vipidia\", \"trade_name\": \"Vipidia\", \"indication\": \"Alogliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-18T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2013-09-27T00:00:00\", \"latest\": \"2013-10-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vipidia\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2181, \"last_scrape\": \"2018-12-13T16:26:21\", \"url\": \"http://www.ncpe.ie/drugs/ambrisentan-volibris/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-05-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Ambrisentan (Volibris\", \"trade_name\": \"Volibris\", \"indication\": \"Cost Effectiveness of ambrisentan (Volibris\", \"ncpe_year\": 2014, \"eu_market\": \"2008-04-20T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 1, \"earliest\": \"2008-10-01T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/volibris\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2182, \"last_scrape\": \"2018-12-13T16:26:23\", \"url\": \"http://www.ncpe.ie/drugs/amifampridine-firdapse/\", \"rr_start\": \"2011-11-07T00:00:00\", \"rr_end\": \"2011-12-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-11-07, 2011-12-09\", \"rr_multiple\": 0, \"drug_name\": \"Amifampridine (Firdapse\", \"trade_name\": \"Firdapse\", \"indication\": \"For Lambert Eaton Myasthenic Syndrome (LEMS).  This high cost drug is likely to require a full HTA due to significant budget impact.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-11-07T00:00:00\", \"latest\": \"2011-12-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2183, \"last_scrape\": \"2018-12-13T16:26:29\", \"url\": \"http://www.ncpe.ie/drugs/amsacrine-amsidine/\", \"rr_start\": \"2017-01-10T00:00:00\", \"rr_end\": \"2017-02-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-01-10, 2017-02-15\", \"rr_multiple\": 0, \"drug_name\": \"Amsacrine (Amsidine\", \"trade_name\": \"Amsidine\", \"indication\": \"Amsidine\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2017-01-10T00:00:00\", \"latest\": \"2017-02-15T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2184, \"last_scrape\": \"2018-12-13T16:26:35\", \"url\": \"http://www.ncpe.ie/drugs/apixaban-eliquis-for-treatment-of-deep-vein-thrombosis-dvt-and-pulmonary-embolism-pe-and-prevention-of-recurrent-dvt-and-pe-in-adults/\", \"rr_start\": \"2014-07-29T00:00:00\", \"rr_end\": \"2014-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-07-29, 2014-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban (Eliquis\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban (Eliquis\", \"ncpe_year\": 2014, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-07-29T00:00:00\", \"latest\": \"2014-08-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2185, \"last_scrape\": \"2018-12-13T16:26:39\", \"url\": \"http://www.ncpe.ie/drugs/apixaban-eliquis/\", \"rr_start\": \"2011-10-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-10-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban (Eliquis\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban (Eliquis\", \"ncpe_year\": 2012, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-10-19T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2186, \"last_scrape\": \"2018-12-13T16:26:45\", \"url\": \"http://www.ncpe.ie/drugs/apremilast-otezla-for-moderate-to-severe-chronic-plaque-psoriasis/\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast (Otezla\", \"trade_name\": \"Otezla\", \"indication\": \"Indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to systemic non-biologic therapies including cyclosporine, methotrexate or psoralen and ultraviolet A light (PUVA).\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/otezla\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2187, \"last_scrape\": \"2018-12-13T16:26:47\", \"url\": \"http://www.ncpe.ie/drugs/apremilast-otezla-for-psoriatic-arthritis/\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast (Otezla\", \"trade_name\": \"Otezla\", \"indication\": \"Apremilist (Otezla\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/otezla\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2188, \"last_scrape\": \"2018-12-13T16:26:49\", \"url\": \"http://www.ncpe.ie/drugs/aripiprazole-abilify-maintena/\", \"rr_start\": \"2014-07-02T00:00:00\", \"rr_end\": \"2014-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-07-02, 2014-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Aripiprazole (Abilify Maintena\", \"trade_name\": \"Abilify Maintena\", \"indication\": \"Aripiprazole (Abilify Maintena\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-14T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2014-07-02T00:00:00\", \"latest\": \"2014-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2189, \"last_scrape\": \"2018-12-13T16:26:55\", \"url\": \"http://www.ncpe.ie/drugs/asenapine-sycrest/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-08-17, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Asenapine (Sycrest\", \"trade_name\": \"Sycrest\", \"indication\": \"Asenapine (Sycrest\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Organon\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sycrest\", \"ta_list\": \"Bipolar Disorder\", \"rr_status\": \"No HTA\"}, {\"id\": 2190, \"last_scrape\": \"2018-12-13T16:27:00\", \"url\": \"http://www.ncpe.ie/drugs/atezolizumab-tecentriq/\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-10-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-08, 2017-10-09\", \"rr_multiple\": 0, \"drug_name\": \"Atezolizumab (Tecentriq\", \"trade_name\": \"Tecentriq\", \"indication\": \"Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK?positive tumour mutations should also have received targeted therapy before receiving atezolizumab.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-21T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq\", \"ta_list\": \"Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2191, \"last_scrape\": \"2018-12-13T16:27:05\", \"url\": \"http://www.ncpe.ie/drugs/avanafil-spedra/\", \"rr_start\": \"2014-02-19T00:00:00\", \"rr_end\": \"2014-03-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-19, 2014-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Avanafil (Spedra\", \"trade_name\": \"Spedra\", \"indication\": \"Avanafil (Spedra\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2014-02-19T00:00:00\", \"latest\": \"2014-03-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/spedra\", \"ta_list\": \"Erectile Dysfunction\", \"rr_status\": \"No HTA\"}, {\"id\": 2192, \"last_scrape\": \"2018-12-13T16:27:06\", \"url\": \"http://www.ncpe.ie/drugs/avelumab-bavencio/\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-10-17, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Avelumab (Bavencio\", \"trade_name\": \"Bavencio\", \"indication\": \"Avelumab (Bavencio\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2018-10-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2193, \"last_scrape\": \"2018-12-13T16:27:08\", \"url\": \"http://www.ncpe.ie/drugs/axanum-aspirin-81mgesomeprazole-20mg/\", \"rr_start\": \"2012-04-12T00:00:00\", \"rr_end\": \"2012-04-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-04-12, 2012-04-20\", \"rr_multiple\": 0, \"drug_name\": \"Aspirin 81mg/Esomeprazole 20mg (Axanum\", \"trade_name\": \"Axanum\", \"indication\": \"Prevention of thrombotic cardiovascular and cerebrovascular events in patients requiring continuous low-dose acetylsalicylic acid treatment, and who are in need of prophylaxis against acetylsalicylic acid associated gastric and /or duodenal ulcers.\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-04-12T00:00:00\", \"latest\": \"2012-04-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2194, \"last_scrape\": \"2018-12-13T16:27:14\", \"url\": \"http://www.ncpe.ie/drugs/axicabtagene-ciloleucel-yescarta/\", \"rr_start\": \"2018-09-10T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF  AXI-CEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-10, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Axicabtagene Ciloleucel (Yescarta\", \"trade_name\": \"Yescarta\", \"indication\": \"Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Kite\", \"orphan\": 1, \"earliest\": \"2018-09-10T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta\", \"ta_list\": \"Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2195, \"last_scrape\": \"2018-12-13T16:27:23\", \"url\": \"http://www.ncpe.ie/drugs/axitinib-inlyta/\", \"rr_start\": \"2012-11-07T00:00:00\", \"rr_end\": \"2012-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-07, 2012-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Axitinib (Inlyta\", \"trade_name\": \"Inlyta\", \"indication\": \"For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-03T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-11-07T00:00:00\", \"latest\": \"2012-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2196, \"last_scrape\": \"2018-12-13T16:27:24\", \"url\": \"http://www.ncpe.ie/drugs/azelastine-hydrochloride-and-fluticasone-propionate-nasal-spray-dymista/\", \"rr_start\": \"2013-02-12T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2013-02-12, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Azelastine hydrochloride and fluticasone propionate (nasal spray) (Dymista\", \"trade_name\": \"Dymista\", \"indication\": \"Indicated for symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-02-12T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2197, \"last_scrape\": \"2018-12-13T16:27:25\", \"url\": \"http://www.ncpe.ie/drugs/azilsartan-edarbi/\", \"rr_start\": \"2012-01-10T00:00:00\", \"rr_end\": \"2012-01-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-01-10, 2012-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Azilsartan (Edarbi\", \"trade_name\": \"Edarbi\", \"indication\": \"Edarbi is indicated for the treatment of essential hypertension in adults.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-12-07T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2012-01-10T00:00:00\", \"latest\": \"2012-01-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/edarbi\", \"ta_list\": \"Hypertension\", \"rr_status\": \"No HTA\"}, {\"id\": 2198, \"last_scrape\": \"2018-12-13T16:27:27\", \"url\": \"http://www.ncpe.ie/drugs/baricitinib-olumiant/\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-06-14, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Baricitinib (Olumiant\", \"trade_name\": \"Olumiant\", \"indication\": \"Baricitinib (Olumiant\", \"ncpe_year\": 2017, \"eu_market\": \"2017-02-12T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2199, \"last_scrape\": \"2018-12-13T16:27:33\", \"url\": \"http://www.ncpe.ie/drugs/bazedoxifene-conbriza/\", \"rr_start\": \"2011-09-20T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-09-20, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Bazedoxifene (Conbriza\", \"trade_name\": \"Conbriza\", \"indication\": \"Bazedoxifene (Conbriza\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-17T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-09-20T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza\", \"ta_list\": \"Osteoporosis, Postmenopausal\", \"rr_status\": \"No HTA\"}, {\"id\": 2200, \"last_scrape\": \"2018-12-13T16:27:36\", \"url\": \"http://www.ncpe.ie/drugs/bedaquiline-sirturo/\", \"rr_start\": \"2015-01-23T00:00:00\", \"rr_end\": \"2015-02-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-01-23, 2015-02-20\", \"rr_multiple\": 0, \"drug_name\": \"Bedaquiline (Sirturo\", \"trade_name\": \"Sirturo\", \"indication\": \"Bedaquiline (Sirturo\", \"ncpe_year\": 2015, \"eu_market\": \"2014-03-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2015-01-23T00:00:00\", \"latest\": \"2015-02-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo\", \"ta_list\": \"Tuberculosis, Multidrug-Resistant\", \"rr_status\": \"No HTA\"}, {\"id\": 2201, \"last_scrape\": \"2018-12-13T16:27:37\", \"url\": \"http://www.ncpe.ie/drugs/belatacept-nulojix/\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2012-01-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-11-15, 2012-01-23\", \"rr_multiple\": 0, \"drug_name\": \"Belatacept (Nulojix\", \"trade_name\": \"Nulojix\", \"indication\": \"Belatacept, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen.\\n\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2012-01-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nulojix\", \"ta_list\": \"Graft Rejection; Kidney Transplantation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2202, \"last_scrape\": \"2018-12-13T16:27:40\", \"url\": \"http://www.ncpe.ie/drugs/belimumab-benlysta/\", \"rr_start\": \"2011-08-11T00:00:00\", \"rr_end\": \"2011-08-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-11, 2011-08-11\", \"rr_multiple\": 0, \"drug_name\": \"Belimumab (Benlysta\", \"trade_name\": \"Benlysta\", \"indication\": \"Cost-effectiveness of Belimumab (Benlysta\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-08-01T00:00:00\", \"latest\": \"2011-08-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta\", \"ta_list\": \"Lupus Erythematosus, Systemic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2203, \"last_scrape\": \"2018-12-13T16:27:46\", \"url\": \"http://www.ncpe.ie/drugs/bendamustine-levact/\", \"rr_start\": \"2011-03-21T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-03-21, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Bendamustine (Levact\", \"trade_name\": \"Levact\", \"indication\": \"Bendamustine (Levact\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2012-11-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2204, \"last_scrape\": \"2018-12-13T16:27:50\", \"url\": \"http://www.ncpe.ie/drugs/benralizumab-fasenra/\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-14T00:00:00\", \"rr_outcome\": \"FULL PHARAMCOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2018-01-15, 2018-02-14\", \"rr_multiple\": 0, \"drug_name\": \"Benralizumab (Fasenra\", \"trade_name\": \"Fasenra\", \"indication\": \"Benralizumab (Fasenra\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fasenra\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2205, \"last_scrape\": \"2018-12-13T16:27:56\", \"url\": \"http://www.ncpe.ie/drugs/bezlotoxumab-zinplava/\", \"rr_start\": \"2017-05-11T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-05-11, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Bezlotoxumab (Zinplava\", \"trade_name\": \"Zinplava\", \"indication\": \"Bezlotoxumab (Zinplava\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-05-11T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinplava\", \"ta_list\": \"Enterocolitis, Pseudomembranous\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2206, \"last_scrape\": \"2018-12-13T16:27:58\", \"url\": \"http://www.ncpe.ie/drugs/bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy/\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT BIKTARVY\", \"rr_dates\": \"2018-04-30, 2018-06-07\", \"rr_multiple\": 0, \"drug_name\": \"Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy\", \"trade_name\": \"Biktarvy\", \"indication\": \"Biktarvy\", \"ncpe_year\": 2018, \"eu_market\": \"2018-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2207, \"last_scrape\": \"2018-12-13T16:28:01\", \"url\": \"http://www.ncpe.ie/drugs/bilastine-drynol/\", \"rr_start\": \"2011-03-10T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-10, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Bilastine (Drynol\", \"trade_name\": \"Drynol\", \"indication\": \" Bilastine (Drynol\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-03-10T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2208, \"last_scrape\": \"2018-12-13T16:28:05\", \"url\": \"http://www.ncpe.ie/drugs/blinatumomab-blincyto/\", \"rr_start\": \"2015-12-08T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.  THE NCPE CANNOT RECOMMEND REIMBURSEMENT OF BLINCTYO\", \"rr_dates\": \"2015-12-08, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Blinatumomab (Blincyto\", \"trade_name\": \"Blincyto\", \"indication\": \"Blincyto\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-23T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-08T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2209, \"last_scrape\": \"2018-12-13T16:28:11\", \"url\": \"http://www.ncpe.ie/drugs/boceprevir-victrelis/\", \"rr_start\": \"\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Boceprevir (Victrelis\", \"trade_name\": \"Victrelis\", \"indication\": \"Economic evaluation of Boceprevir (Victrelis\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2011-08-19T00:00:00\", \"latest\": \"2012-01-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2210, \"last_scrape\": \"2018-12-13T16:28:16\", \"url\": \"http://www.ncpe.ie/drugs/bosentan-tracleer/\", \"rr_start\": \"2014-06-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-06-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Bosentan (Tracleer\", \"trade_name\": \"Tracleer\", \"indication\": \"Bosentan (Tracleer\", \"ncpe_year\": 2014, \"eu_market\": \"2002-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-06-27T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tracleer\", \"ta_list\": \"Scleroderma, Systemic; Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2211, \"last_scrape\": \"2018-12-13T16:28:18\", \"url\": \"http://www.ncpe.ie/drugs/bosutinib-bosulif/\", \"rr_start\": \"2013-08-09T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"AT THE CURRENT PRICE A FULL HTA WOULD BE REQUIRED.\", \"rr_dates\": \"2013-08-09, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Bosutinib (Bosulif\", \"trade_name\": \"Bosulif\", \"indication\": \"Bosutinib is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-26T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2212, \"last_scrape\": \"2018-12-13T16:28:19\", \"url\": \"http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris-for-cd30-cutaneous-t-cell-lymphoma-ctcl/\", \"rr_start\": \"2018-02-07T00:00:00\", \"rr_end\": \"2018-03-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-02-07, 2018-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin (Adcetris\", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin (Adcetris\", \"ncpe_year\": 2018, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-02-07T00:00:00\", \"latest\": \"2018-03-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2213, \"last_scrape\": \"2018-12-13T16:28:23\", \"url\": \"http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris/\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin (Adcetris\", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin (Adcetris\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2214, \"last_scrape\": \"2018-12-13T16:28:29\", \"url\": \"http://www.ncpe.ie/drugs/brigatinib-alunbrig/\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF BRIGATINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-11-19, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Brigatinib (Alunbrig\", \"trade_name\": \"Alunbrig\", \"indication\": \"Brigatinib (Alunbrig \", \"ncpe_year\": 2018, \"eu_market\": \"2018-11-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2215, \"last_scrape\": \"2018-12-13T16:28:30\", \"url\": \"http://www.ncpe.ie/drugs/brimonidine-3-3-mgg-gel-mirvaso/\", \"rr_start\": \"2014-04-09T00:00:00\", \"rr_end\": \"2014-04-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-09\", \"rr_multiple\": 0, \"drug_name\": \"Brimonidine 3.3 mg/g gel (Mirvaso\", \"trade_name\": \"Mirvaso\", \"indication\": \"Brimonidine 3.3 mg/g gel (Mirvaso\", \"ncpe_year\": 2014, \"eu_market\": \"2014-02-20T00:00:00\", \"company\": \"Galderma\", \"orphan\": 0, \"earliest\": \"2014-04-09T00:00:00\", \"latest\": \"2014-04-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mirvaso\", \"ta_list\": \"Skin Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2216, \"last_scrape\": \"2018-12-13T16:28:36\", \"url\": \"http://www.ncpe.ie/drugs/brivaracetam-briviact/\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-02-15, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Brivaracetam (Briviact\", \"trade_name\": \"Briviact\", \"indication\": \"Brivaracetam (Briviact\", \"ncpe_year\": 2016, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2217, \"last_scrape\": \"2018-12-13T16:28:40\", \"url\": \"http://www.ncpe.ie/drugs/brodalumab-kyntheum/\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-07-25, 2017-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Brodalumab (Kyntheum\", \"trade_name\": \"Kyntheum\", \"indication\": \"Brodalumab (Kyntheum\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-17T00:00:00\", \"company\": \"LEO\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2218, \"last_scrape\": \"2018-12-13T16:28:44\", \"url\": \"http://www.ncpe.ie/drugs/bronchitol/\", \"rr_start\": \"2012-09-11T00:00:00\", \"rr_end\": \"2012-09-21T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2012-09-11, 2012-09-21\", \"rr_multiple\": 0, \"drug_name\": \"Mannitol Dry Powder (Bronchitol\", \"trade_name\": \"Bronchitol\", \"indication\": \"Bronchitol\", \"ncpe_year\": 2014, \"eu_market\": \"2012-04-13T00:00:00\", \"company\": \"Pharmaxis\", \"orphan\": 1, \"earliest\": \"2012-09-11T00:00:00\", \"latest\": \"2014-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bronchitol\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2219, \"last_scrape\": \"2018-12-13T16:28:46\", \"url\": \"http://www.ncpe.ie/drugs/c-drugs/calcipotriol-and-betamethasone-dipropionate-cutaneous-foam-enstilar/\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-06-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-05-17, 2016-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Calcipotriol and betamethasone dipropionate cutaneous foam (Enstilar \", \"trade_name\": \"Enstilar\", \"indication\": \"Calcipotriol and betamethasone dipropionate cutaneous foam is indicated for the topical treatment of psoriasis vulgaris in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-06-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2220, \"last_scrape\": \"2018-12-13T16:28:53\", \"url\": \"http://www.ncpe.ie/drugs/c1inhibitor-human-cinryze/\", \"rr_start\": \"2012-10-22T00:00:00\", \"rr_end\": \"2012-11-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-22, 2012-11-14\", \"rr_multiple\": 0, \"drug_name\": \"C1inhibitor (human) (Cinryze\", \"trade_name\": \"Cinryze\", \"indication\": \"C1inhibitor (human) (Cinryze\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-15T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2012-10-22T00:00:00\", \"latest\": \"2012-11-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"id\": 2221, \"last_scrape\": \"2018-12-13T16:28:55\", \"url\": \"http://www.ncpe.ie/drugs/cabozantinib-cabometyx/\", \"rr_start\": \"2017-03-20T00:00:00\", \"rr_end\": \"2017-04-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT\\nRECOMMENDED\", \"rr_dates\": \"2017-03-20, 2017-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib (Cabometyx\", \"trade_name\": \"Cabometyx\", \"indication\": \"Cabozantinib (Cabometyx\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-03-20T00:00:00\", \"latest\": \"2018-07-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2222, \"last_scrape\": \"2018-12-13T16:28:58\", \"url\": \"http://www.ncpe.ie/drugs/cabozantinib-cometriq/\", \"rr_start\": \"2014-07-10T00:00:00\", \"rr_end\": \"2014-08-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2014-07-10, 2014-08-12\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib (Cometriq\", \"trade_name\": \"Cometriq\", \"indication\": \"Cabozantinib (COMETRIQ\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-21T00:00:00\", \"company\": \"Ipsen\", \"orphan\": 1, \"earliest\": \"2014-07-10T00:00:00\", \"latest\": \"2014-08-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2223, \"last_scrape\": \"2018-12-13T16:29:01\", \"url\": \"http://www.ncpe.ie/drugs/camellia-sinensis-folium-green-tea-leaf-catephen-10/\", \"rr_start\": \"2015-05-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-05-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Camellia sinensis, folium (green tea leaf) (Catephen 10%\", \"trade_name\": \"Catephen 10%\", \"indication\": \"Catephen 10%\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-05-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2224, \"last_scrape\": \"2018-12-13T16:29:04\", \"url\": \"http://www.ncpe.ie/drugs/canagliflozin-invokana/\", \"rr_start\": \"2013-11-25T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-11-25, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Canagliflozin (Invokana\", \"trade_name\": \"Invokana\", \"indication\": \"Canagliflozin (Invokana\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-11-25T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/invokana\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2225, \"last_scrape\": \"2018-12-13T16:29:09\", \"url\": \"http://www.ncpe.ie/drugs/capsaicin-8ww-patch-qutenza/\", \"rr_start\": \"2012-06-15T00:00:00\", \"rr_end\": \"2012-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-06-15, 2012-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Capsaicin 8%w/w patch (Qutenza\", \"trade_name\": \"Qutenza\", \"indication\": \"Capsaicin 8% w/w patch (Qutenza\", \"ncpe_year\": 2012, \"eu_market\": \"2009-05-15T00:00:00\", \"company\": \"Grunenthal\", \"orphan\": 0, \"earliest\": \"2012-06-15T00:00:00\", \"latest\": \"2012-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza\", \"ta_list\": \"Neuralgia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2226, \"last_scrape\": \"2018-12-13T16:29:11\", \"url\": \"http://www.ncpe.ie/drugs/carbazitaxel-jevtana-for-prostate-cancer/\", \"rr_start\": \"2011-06-02T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-06-02, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Cabazitaxel (Jevtana\", \"trade_name\": \"Jevtana\", \"indication\": \"Economic Evaluation of cabazitaxel (Jevtana\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2011-06-02T00:00:00\", \"latest\": \"2014-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jevtana\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2227, \"last_scrape\": \"2018-12-13T16:29:16\", \"url\": \"http://www.ncpe.ie/drugs/carfilzomib-kyprolis/\", \"rr_start\": \"2015-12-07T00:00:00\", \"rr_end\": \"2016-01-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-12-07, 2016-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Carfilzomib (Kyprolis\", \"trade_name\": \"Kyprolis\", \"indication\": \"Kyprolis\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-07T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2228, \"last_scrape\": \"2018-12-13T16:29:22\", \"url\": \"http://www.ncpe.ie/drugs/catumaxomab-removab/\", \"rr_start\": \"2011-08-05T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-08-05, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Catumaxomab (Removab\", \"trade_name\": \"Removab\", \"indication\": \"Catumazomab (Removab\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-20T00:00:00\", \"company\": \"Neovii\", \"orphan\": 0, \"earliest\": \"2011-08-05T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/removab\", \"ta_list\": \"Ascites; Cancer\", \"rr_status\": \"No HTA\"}, {\"id\": 2229, \"last_scrape\": \"2018-12-13T16:29:25\", \"url\": \"http://www.ncpe.ie/drugs/ceftaroline-zinforo/\", \"rr_start\": \"2012-10-08T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-08, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Ceftaroline (Zinforo\", \"trade_name\": \"Zinforo\", \"indication\": \"For the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP).\", \"ncpe_year\": 2012, \"eu_market\": \"2012-08-22T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-10-08T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinforo\", \"ta_list\": \"Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia\", \"rr_status\": \"No HTA\"}, {\"id\": 2230, \"last_scrape\": \"2018-12-13T16:29:29\", \"url\": \"http://www.ncpe.ie/drugs/ceftazidime-avibactam-cef-avizavicefta/\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-17, 2017-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Ceftazidime-avibactam (CEF-AVI)(Zavicefta\", \"trade_name\": \"Zavicefta\", \"indication\": \"Ceftazidime-avibactam (CEF-AVI)(Zavicefta\", \"ncpe_year\": 2017, \"eu_market\": \"2016-06-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta\", \"ta_list\": \"Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2231, \"last_scrape\": \"2018-12-13T16:29:34\", \"url\": \"http://www.ncpe.ie/drugs/ceftolozanetazobactam-zerbaxa/\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-03-03, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Ceftolozane/tazobactam (Zerbaxa\", \"trade_name\": \"Zerbaxa\", \"indication\": \"Zerbaxa\", \"ncpe_year\": 2016, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa\", \"ta_list\": \"Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2232, \"last_scrape\": \"2018-12-13T16:29:36\", \"url\": \"http://www.ncpe.ie/drugs/ceritinib-zykadia/\", \"rr_start\": \"2015-05-29T00:00:00\", \"rr_end\": \"2015-07-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2015-05-29, 2015-07-22\", \"rr_multiple\": 0, \"drug_name\": \"Ceritinib (Zykadia\", \"trade_name\": \"Zykadia\", \"indication\": \"Zykadia\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-06T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-05-29T00:00:00\", \"latest\": \"2015-07-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2233, \"last_scrape\": \"2018-12-13T16:29:40\", \"url\": \"http://www.ncpe.ie/drugs/cerliponase-alfa-brineura/\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2017-10-11, 2017-11-27\", \"rr_multiple\": 0, \"drug_name\": \"Cerliponase alfa (Brineura\", \"trade_name\": \"Brineura\", \"indication\": \"Cerliponase alfa (Brineura\", \"ncpe_year\": 2018, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-08-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brineura\", \"ta_list\": \"Neuronal Ceroid-Lipofuscinoses\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2234, \"last_scrape\": \"2018-12-13T16:29:44\", \"url\": \"http://www.ncpe.ie/drugs/certolizumab-pegol-cimzia/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Certolizumab pegol (Cimzia\", \"trade_name\": \"Cimzia\", \"indication\": \"Cost-effectiveness of certolizumab pegol (Cimzia\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2010-03-13T00:00:00\", \"latest\": \"2010-09-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia-0\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2235, \"last_scrape\": \"2018-12-13T16:29:49\", \"url\": \"http://www.ncpe.ie/drugs/ciclosporin-1mgml-eye-drops-ikervis/\", \"rr_start\": \"2015-01-07T00:00:00\", \"rr_end\": \"2016-01-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-01-07, 2016-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Ciclosporin 1mg/ml eye drops (Ikervis\", \"trade_name\": \"Ikervis\", \"indication\": \"Ikervis\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-19T00:00:00\", \"company\": \"Santen\", \"orphan\": 0, \"earliest\": \"2015-01-07T00:00:00\", \"latest\": \"2016-01-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis\", \"ta_list\": \"Corneal Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2236, \"last_scrape\": \"2018-12-13T16:29:54\", \"url\": \"http://www.ncpe.ie/drugs/cladribine-mavenclad/\", \"rr_start\": \"2017-08-22T00:00:00\", \"rr_end\": \"2017-09-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-22, 2017-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Cladribine (Mavenclad\", \"trade_name\": \"Mavenclad\", \"indication\": \"Cladribine (Mavenclad\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-08-22T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2237, \"last_scrape\": \"2018-12-13T16:29:58\", \"url\": \"http://www.ncpe.ie/drugs/clindamycin-1-with-tretinoin-0-025-treclinac/\", \"rr_start\": \"2014-04-08T00:00:00\", \"rr_end\": \"2014-05-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-08, 2014-05-06\", \"rr_multiple\": 0, \"drug_name\": \"Clindamycin 1% with tretinoin 0.025% (Treclinac\", \"trade_name\": \"Treclinac\", \"indication\": \"Clindamycin 1% with tretinoin 0.025% (Treclinac\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-04-08T00:00:00\", \"latest\": \"2014-05-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2238, \"last_scrape\": \"2018-12-13T16:30:02\", \"url\": \"http://www.ncpe.ie/drugs/cobimetinib-cotellic/\", \"rr_start\": \"2016-04-19T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-04-19, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Cobimetinib (Cotellic\", \"trade_name\": \"Cotellic\", \"indication\": \"Cotellic\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2016-04-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2239, \"last_scrape\": \"2018-12-13T16:30:03\", \"url\": \"http://www.ncpe.ie/drugs/colesevelam-cholestagel/\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Colesevelam (Cholestagel\", \"trade_name\": \"Cholestagel\", \"indication\": \"Cost-effectiveness of Colesevelam (Cholestagel\", \"ncpe_year\": 2010, \"eu_market\": \"2004-03-09T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cholestagel\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"No HTA\"}, {\"id\": 2240, \"last_scrape\": \"2018-12-13T16:30:06\", \"url\": \"http://www.ncpe.ie/drugs/colistimethate-sodium-colobreathe/\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Colistimethate sodium (Colobreathe\", \"trade_name\": \"Colobreathe\", \"indication\": \"Colistimethate sodium (colobreathe\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-13T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/colobreathe\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2241, \"last_scrape\": \"2018-12-13T16:30:17\", \"url\": \"http://www.ncpe.ie/drugs/collagenase-clostridium-histolyticum-xiapex/\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-20, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Collagenase Clostridium Histolyticum (Xiapex\", \"trade_name\": \"Xiapex\", \"indication\": \" Collagenase Clostridium Histolyticum (Xiapex\", \"ncpe_year\": 2011, \"eu_market\": \"2011-02-28T00:00:00\", \"company\": \"Swedish\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xiapex\", \"ta_list\": \"Dupuytren Contracture\", \"rr_status\": \"No HTA\"}, {\"id\": 2242, \"last_scrape\": \"2018-12-13T16:30:20\", \"url\": \"http://www.ncpe.ie/drugs/corifollitropin-alfa-elonva/\", \"rr_start\": \"2010-10-22T00:00:00\", \"rr_end\": \"2010-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-10-22, 2010-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Corifollitropin alfa (Elonva\", \"trade_name\": \"Elonva\", \"indication\": \"Cost-effectiveness of Corifollitropin alfa (Elonva\", \"ncpe_year\": 2010, \"eu_market\": \"2010-01-25T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2010-09-01T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/elonva\", \"ta_list\": \"Reproductive Techniques, Assisted; Ovulation Induction\", \"rr_status\": \"No HTA\"}, {\"id\": 2243, \"last_scrape\": \"2018-12-13T16:30:24\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori-for-first-line-alk-nsclc/\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2244, \"last_scrape\": \"2018-12-13T16:30:29\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori-for-ros1-nsclc/\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2245, \"last_scrape\": \"2018-12-13T16:30:34\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori/\", \"rr_start\": \"2013-01-09T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-01-09, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"For the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-01-09T00:00:00\", \"latest\": \"2015-08-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2246, \"last_scrape\": \"2018-12-13T16:30:37\", \"url\": \"http://www.ncpe.ie/drugs/cysteamine-bitartrate-procysbi/\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2015-12-01, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Cysteamine bitartrate delayed-release (Procysbi\", \"trade_name\": \"Procysbi\", \"indication\": \"Procysbi\", \"ncpe_year\": 2017, \"eu_market\": \"2013-09-05T00:00:00\", \"company\": \"Chiesi\", \"orphan\": 1, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/procysbi\", \"ta_list\": \"Cystinosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2247, \"last_scrape\": \"2018-12-13T16:30:43\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-2/\", \"rr_start\": \"2014-05-09T00:00:00\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-09, 2014-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate (Pradaxa\", \"ncpe_year\": 2014, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-09T00:00:00\", \"latest\": \"2014-06-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2248, \"last_scrape\": \"2018-12-13T16:30:51\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-for-the-prevention-of-stroke-and-systematic-embolisom-in-atrial-fibrillation/\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate (Pradaxa\", \"ncpe_year\": 2012, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2010-11-02T00:00:00\", \"latest\": \"2012-10-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2249, \"last_scrape\": \"2018-12-13T16:30:57\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-vte-prevention/\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Economic Evaluation of the Cost Effectiveness of Dabigatran Etexilate (Pradaxa\", \"ncpe_year\": 2008, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2008-07-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2250, \"last_scrape\": \"2018-12-13T16:30:59\", \"url\": \"http://www.ncpe.ie/drugs/dabrafenib-tafinlar/\", \"rr_start\": \"2013-09-11T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-11, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Dabrafenib (Tafinlar\", \"trade_name\": \"Tafinlar\", \"indication\": \"Dabrafenib (Tafinlar\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2013-09-11T00:00:00\", \"latest\": \"2014-06-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2251, \"last_scrape\": \"2018-12-13T16:31:02\", \"url\": \"http://www.ncpe.ie/drugs/daclatasvir-daklinza/\", \"rr_start\": \"2014-08-05T00:00:00\", \"rr_end\": \"2014-09-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-08-05, 2014-09-12\", \"rr_multiple\": 0, \"drug_name\": \"Daclatasvir (Daklinza\", \"trade_name\": \"Daklinza\", \"indication\": \"Daclatasvir (Daklinza\", \"ncpe_year\": 2015, \"eu_market\": \"2014-08-22T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-08-05T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/daklinza\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2252, \"last_scrape\": \"2018-12-13T16:31:08\", \"url\": \"http://www.ncpe.ie/drugs/daclizumab-zinbryta/\", \"rr_start\": \"2016-09-26T00:00:00\", \"rr_end\": \"2016-11-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-09-26, 2016-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Daclizumab (Zinbryta\", \"trade_name\": \"Zinbryta\", \"indication\": \"Daclizumab is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-07-01T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2016-09-26T00:00:00\", \"latest\": \"2018-03-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinbryta\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2253, \"last_scrape\": \"2018-12-13T16:31:12\", \"url\": \"http://www.ncpe.ie/drugs/dalbavancin-xydalba/\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-07, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Dalbavancin (Xydalba\", \"trade_name\": \"Xydalba\", \"indication\": \"Dalbavancin (Xydalba\", \"ncpe_year\": 2017, \"eu_market\": \"2015-02-19T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xydalba\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2254, \"last_scrape\": \"2018-12-13T16:31:18\", \"url\": \"http://www.ncpe.ie/drugs/dapagliflozin-forxiga/\", \"rr_start\": \"2012-10-10T00:00:00\", \"rr_end\": \"2012-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-10-10, 2012-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Dapagliflozin (Forxiga\", \"trade_name\": \"Forxiga\", \"indication\": \"Dapagliflozin (Forxiga\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-11T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-10T00:00:00\", \"latest\": \"2013-12-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2255, \"last_scrape\": \"2018-12-13T16:31:21\", \"url\": \"http://www.ncpe.ie/drugs/daratumumab-darzalex/\", \"rr_start\": \"2016-05-31T00:00:00\", \"rr_end\": \"2016-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-05-31, 2016-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Daratumumab (Darzalex\", \"trade_name\": \"Darzalex\", \"indication\": \"Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-04-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-05-31T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2256, \"last_scrape\": \"2018-12-13T16:31:25\", \"url\": \"http://www.ncpe.ie/drugs/darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-symtuza/\", \"rr_start\": \"2017-09-27T00:00:00\", \"rr_end\": \"2017-10-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-27, 2017-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza\", \"trade_name\": \"Symtuza\", \"indication\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza\", \"ncpe_year\": 2017, \"eu_market\": \"2017-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-09-27T00:00:00\", \"latest\": \"2017-10-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/symtuza\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2257, \"last_scrape\": \"2018-12-13T16:31:30\", \"url\": \"http://www.ncpe.ie/drugs/darunavir-cobicistat-rezolsta/\", \"rr_start\": \"2014-12-02T00:00:00\", \"rr_end\": \"2015-01-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-12-02, 2015-01-08\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir & cobicistat (Rezolsta\", \"trade_name\": \"Rezolsta\", \"indication\": \"Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-12-02T00:00:00\", \"latest\": \"2015-01-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2258, \"last_scrape\": \"2018-12-13T16:31:35\", \"url\": \"http://www.ncpe.ie/drugs/darvadstrocel-alofisel/\", \"rr_start\": \"2018-06-14T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF DARVADSTROCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-14, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Darvadstrocel (Alofisel\", \"trade_name\": \"Alofisel\", \"indication\": \"Darvadstrocel (Alofisel\", \"ncpe_year\": 2018, \"eu_market\": \"2018-03-23T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-06-14T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel\", \"ta_list\": \"Rectal Fistula\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2259, \"last_scrape\": \"2018-12-13T16:31:40\", \"url\": \"http://www.ncpe.ie/drugs/decitabine-dacogen/\", \"rr_start\": \"2012-11-08T00:00:00\", \"rr_end\": \"2012-12-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-08, 2012-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Decitabine (Dacogen\", \"trade_name\": \"Dacogen\", \"indication\": \"Decitabine (Dacogen\", \"ncpe_year\": 2013, \"eu_market\": \"2012-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2012-11-08T00:00:00\", \"latest\": \"2013-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2260, \"last_scrape\": \"2018-12-13T16:31:44\", \"url\": \"http://www.ncpe.ie/drugs/defibrotide-defitelio/\", \"rr_start\": \"2014-05-12T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2014-05-12, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Defibrotide (Defitelio\", \"trade_name\": \"Defitelio\", \"indication\": \"Defibrotide (Defitelio\", \"ncpe_year\": 2014, \"eu_market\": \"2013-10-18T00:00:00\", \"company\": \"Gentium\", \"orphan\": 1, \"earliest\": \"2014-05-12T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio\", \"ta_list\": \"Hepatic Veno-Occlusive Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2261, \"last_scrape\": \"2018-12-13T16:31:47\", \"url\": \"http://www.ncpe.ie/drugs/degarelix-firmagon/\", \"rr_start\": \"2009-10-15T00:00:00\", \"rr_end\": \"2009-10-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-10-15\", \"rr_multiple\": 0, \"drug_name\": \"Degarelix (Firmagon\", \"trade_name\": \"Firmagon\", \"indication\": \"Cost-effectiveness of Degarelix (Firmagon\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-17T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2009-10-15T00:00:00\", \"latest\": \"2009-10-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2262, \"last_scrape\": \"2018-12-13T16:31:52\", \"url\": \"http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-cannabidiol-thc-cbd-sativex/\", \"rr_start\": \"2018-02-12T00:00:00\", \"rr_end\": \"2018-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF SATIVEX\", \"rr_dates\": \"2018-02-12, 2018-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex\", \"trade_name\": \"Sativex\", \"indication\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-02-12T00:00:00\", \"latest\": \"2018-04-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2263, \"last_scrape\": \"2018-12-13T16:31:59\", \"url\": \"http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-thccannabidiol-cbd-sativex/\", \"rr_start\": \"2012-12-05T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-05, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol (THC) /Cannabidiol (CBD) (Sativex\", \"trade_name\": \"Sativex\", \"indication\": \"For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-12-05T00:00:00\", \"latest\": \"2014-09-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2264, \"last_scrape\": \"2018-12-13T16:32:04\", \"url\": \"http://www.ncpe.ie/drugs/denosumab-prolia/\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab (Prolia\", \"trade_name\": \"Prolia\", \"indication\": \"The Cost-effectiveness of Denosumab (Prolia\", \"ncpe_year\": 2010, \"eu_market\": \"2010-05-26T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2010-05-27T00:00:00\", \"latest\": \"2010-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prolia\", \"ta_list\": \"Bone Resorption; Osteoporosis, Postmenopausal\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2265, \"last_scrape\": \"2018-12-13T16:32:08\", \"url\": \"http://www.ncpe.ie/drugs/denosumab-xgeva-3/\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab (Xgeva\", \"trade_name\": \"Xgeva\", \"indication\": \"Cost-effectiveness of denosumab (Xgeva\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2011-08-15T00:00:00\", \"latest\": \"2011-12-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva\", \"ta_list\": \"Fractures, Bone; Neoplasm Metastasis\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2266, \"last_scrape\": \"2018-12-13T16:32:12\", \"url\": \"http://www.ncpe.ie/drugs/dexamethasone-intravitreal-implant-ozurdex/\", \"rr_start\": \"2010-11-12T00:00:00\", \"rr_end\": \"2010-12-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-11-12, 2010-12-16\", \"rr_multiple\": 0, \"drug_name\": \"Dexamethasone Intravitreal Implant (Ozurdex\", \"trade_name\": \"Ozurdex\", \"indication\": \"Cost-effectiveness of Ozurdex\", \"ncpe_year\": 2012, \"eu_market\": \"2010-07-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2010-11-12T00:00:00\", \"latest\": \"2012-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ozurdex\", \"ta_list\": \"Macular Edema; Uveitis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2267, \"last_scrape\": \"2018-12-13T16:32:15\", \"url\": \"http://www.ncpe.ie/drugs/dexmedetomidine-dexdor/\", \"rr_start\": \"2011-07-08T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-07-08, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Dexmedetomidine (Dexdor\", \"trade_name\": \"Dexdor\", \"indication\": \"Dexmedetomidine (Dexdor\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-15T00:00:00\", \"company\": \"Orion\", \"orphan\": 0, \"earliest\": \"2011-07-08T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dexdor\", \"ta_list\": \"Conscious Sedation\", \"rr_status\": \"No HTA\"}, {\"id\": 2268, \"last_scrape\": \"2018-12-13T16:32:21\", \"url\": \"http://www.ncpe.ie/drugs/dienogest-visanne/\", \"rr_start\": \"2010-09-17T00:00:00\", \"rr_end\": \"2010-10-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-09-17, 2010-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Dienogest (Visanne\", \"trade_name\": \"Visanne\", \"indication\": \"Dienogest (Visanne\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-09-17T00:00:00\", \"latest\": \"2010-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2269, \"last_scrape\": \"2018-12-13T16:32:24\", \"url\": \"http://www.ncpe.ie/drugs/dimethyl-fumarate-skilarence/\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-01-15, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate (Skilarence\", \"trade_name\": \"Skilarence\", \"indication\": \"Dimethyl fumarate (Skilarence\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"Almirall\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/skilarence\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2270, \"last_scrape\": \"2018-12-13T16:32:26\", \"url\": \"http://www.ncpe.ie/drugs/dimethyl-fumarate-tecfidera/\", \"rr_start\": \"2014-02-04T00:00:00\", \"rr_end\": \"2014-03-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-02-04, 2014-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate (Tecfidera\", \"trade_name\": \"Tecfidera\", \"indication\": \"Dimethyl fumarate (Tecfidera\", \"ncpe_year\": 2015, \"eu_market\": \"2014-01-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-02-04T00:00:00\", \"latest\": \"2015-04-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2271, \"last_scrape\": \"2018-12-13T16:32:29\", \"url\": \"http://www.ncpe.ie/drugs/dinutuximab-beta-dinutuximab-beta-eusa/\", \"rr_start\": \"2017-10-19T00:00:00\", \"rr_end\": \"2017-11-23T00:00:00\", \"rr_outcome\": \"FOLLOWING ASSESSMENT OF THE APPLICANT\", \"rr_dates\": \"2017-10-19, 2017-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Dinutuximab beta (Qarziba\", \"trade_name\": \"Qarziba\", \"indication\": \"Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients ? 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-10-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2272, \"last_scrape\": \"2018-12-13T16:32:34\", \"url\": \"http://www.ncpe.ie/drugs/dolutegravir-rilpivirine-juluca/\", \"rr_start\": \"2018-06-08T00:00:00\", \"rr_end\": \"2018-07-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT JULUCA\", \"rr_dates\": \"2018-06-08, 2018-07-12\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir/Rilpivirine (Juluca\", \"trade_name\": \"Juluca\", \"indication\": \"Dolutegravir/rilpivirine (Juluca\", \"ncpe_year\": 2018, \"eu_market\": \"2018-05-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2018-06-08T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/juluca\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2273, \"last_scrape\": \"2018-12-13T16:32:36\", \"url\": \"http://www.ncpe.ie/drugs/dolutegravir-tivicay/\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-10, 2014-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir (Tivicay\", \"trade_name\": \"Tivicay\", \"indication\": \"Dolutegravir (Tivicay\", \"ncpe_year\": 2014, \"eu_market\": \"2014-01-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2274, \"last_scrape\": \"2018-12-13T16:32:39\", \"url\": \"http://www.ncpe.ie/drugs/dronedarone-multaq/\", \"rr_start\": \"2010-01-12T00:00:00\", \"rr_end\": \"2010-01-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-01-12, 2010-01-01\", \"rr_multiple\": 0, \"drug_name\": \"Dronedarone (Multaq\", \"trade_name\": \"Multaq\", \"indication\": \"Rapid Review\", \"ncpe_year\": 2010, \"eu_market\": \"2009-11-25T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2010-01-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"No HTA\"}, {\"id\": 2275, \"last_scrape\": \"2018-12-13T16:32:42\", \"url\": \"http://www.ncpe.ie/drugs/dulaglutide-trulicity/\", \"rr_start\": \"2015-03-04T00:00:00\", \"rr_end\": \"2015-04-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-03-04, 2015-04-29\", \"rr_multiple\": 0, \"drug_name\": \"Dulaglutide (Trulicity\", \"trade_name\": \"Trulicity\", \"indication\": \"Dulaglutide is indicated as monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2015-03-04T00:00:00\", \"latest\": \"2015-04-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2276, \"last_scrape\": \"2018-12-13T16:32:46\", \"url\": \"http://www.ncpe.ie/drugs/dupilumab-dupixent/\", \"rr_start\": \"2017-11-13T00:00:00\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-13, 2017-11-24\", \"rr_multiple\": 0, \"drug_name\": \"Dupilumab (Dupixent\", \"trade_name\": \"Dupixent\", \"indication\": \"Dupilumab (Dupixent\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-27T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-11-13T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent\", \"ta_list\": \"Dermatitis, Atopic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2277, \"last_scrape\": \"2018-12-13T16:32:53\", \"url\": \"http://www.ncpe.ie/drugs/eculizumab-soliris/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Eculizumab (Soliris\", \"trade_name\": \"Soliris\", \"indication\": \"An Economic Evaluation of Eculizumab (Soliris\", \"ncpe_year\": 2013, \"eu_market\": \"2007-06-20T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2013-10-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/soliris\", \"ta_list\": \"Hemoglobinuria, Paroxysmal\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2278, \"last_scrape\": \"2018-12-13T16:32:55\", \"url\": \"http://www.ncpe.ie/drugs/edoxaban-lixiana/\", \"rr_start\": \"2015-06-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-06-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Edoxaban (Lixiana\", \"trade_name\": \"Lixiana\", \"indication\": \"Edoxaban is indicated for the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2015-06-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana\", \"ta_list\": \"Stroke; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2279, \"last_scrape\": \"2018-12-13T16:33:00\", \"url\": \"http://www.ncpe.ie/drugs/elbasvirgrazoprevir-zepatier-2/\", \"rr_start\": \"2016-08-10T00:00:00\", \"rr_end\": \"2016-10-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-08-10, 2016-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Elbasvir/Grazoprevir (Zepatier\", \"trade_name\": \"Zepatier\", \"indication\": \"Elbasvir 50mg/100mg grazoprevir (EBR/GZR)(Zepatier\", \"ncpe_year\": 2016, \"eu_market\": \"2016-07-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-10T00:00:00\", \"latest\": \"2016-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2280, \"last_scrape\": \"2018-12-13T16:33:03\", \"url\": \"http://www.ncpe.ie/drugs/eliglustat-cerdelga/\", \"rr_start\": \"2016-03-21T00:00:00\", \"rr_end\": \"2016-05-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-03-21, 2016-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Eliglustat (Cerdelga\", \"trade_name\": \"Cerdelga\", \"indication\": \"Eliglustat (Cerdelga\", \"ncpe_year\": 2018, \"eu_market\": \"2015-01-19T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 1, \"earliest\": \"2016-03-21T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga\", \"ta_list\": \"Gaucher Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2281, \"last_scrape\": \"2018-12-13T16:33:05\", \"url\": \"http://www.ncpe.ie/drugs/elosulfase-alfa-vimizim/\", \"rr_start\": \"2015-03-30T00:00:00\", \"rr_end\": \"2015-05-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-03-30, 2015-05-08\", \"rr_multiple\": 0, \"drug_name\": \"Elosulfase alfa (Vimizim\", \"trade_name\": \"Vimizim\", \"indication\": \"Elosulfase alfa (Vimzim\", \"ncpe_year\": 2018, \"eu_market\": \"2014-04-27T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2015-03-30T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vimizim\", \"ta_list\": \"Mucopolysaccharidosis IV\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2282, \"last_scrape\": \"2018-12-13T16:33:12\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade-2/\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-02-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-01-10, 2014-02-13\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Eltrombopag (Revolade\", \"ncpe_year\": 2014, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-02-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"id\": 2283, \"last_scrape\": \"2018-12-13T16:33:17\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade-3/\", \"rr_start\": \"2016-02-05T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-02-05, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Revolade\", \"ncpe_year\": 2016, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-02-05T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"id\": 2284, \"last_scrape\": \"2018-12-13T16:33:23\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade/\", \"rr_start\": \"2017-12-04T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, WHICH IS NOT COMPARABLE WITH CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2017-12-04, 2018-04-16, 2017-12-01\", \"rr_multiple\": 1, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Cost-effectiveness of eltrombopag (Revolade\", \"ncpe_year\": 2018, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-07-30T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2285, \"last_scrape\": \"2018-12-13T16:33:26\", \"url\": \"http://www.ncpe.ie/drugs/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya/\", \"rr_start\": \"2015-11-24T00:00:00\", \"rr_end\": \"2016-01-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-11-24, 2016-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide (Genvoya\", \"trade_name\": \"Genvoya\", \"indication\": \"Genvoya\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2015-11-24T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2286, \"last_scrape\": \"2018-12-13T16:33:32\", \"url\": \"http://www.ncpe.ie/drugs/empagliflozin-jardiance/\", \"rr_start\": \"2014-05-22T00:00:00\", \"rr_end\": \"2014-06-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-22, 2014-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Empagliflozin (Jardiance\", \"trade_name\": \"Jardiance\", \"indication\": \"Add-on combination therapy \", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-22T00:00:00\", \"latest\": \"2014-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2287, \"last_scrape\": \"2018-12-13T16:33:37\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabine-tenofovir-disoproxil-fumarate-truvada/\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-07-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-12, 2017-07-18\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine / tenofovir disoproxil fumarate (Truvada\", \"trade_name\": \"Truvada\", \"indication\": \"Truvada\", \"ncpe_year\": 2017, \"eu_market\": \"2005-02-20T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-07-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/truvada\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2288, \"last_scrape\": \"2018-12-13T16:33:43\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabine-tenovir-disoproxil-teva/\", \"rr_start\": \"2017-12-11T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-12-11, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir disoproxil (TEVA\", \"trade_name\": \"TEVA\", \"indication\": \"Emtricitabine/tenofovir disoproxil (TEVA\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-12-11T00:00:00\", \"latest\": \"2017-12-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2289, \"last_scrape\": \"2018-12-13T16:33:48\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabinetenofovir-alafenamide-descovy/\", \"rr_start\": \"2016-04-26T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-04-26, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir alafenamide (Descovy\", \"trade_name\": \"Descovy\", \"indication\": \"Descovy\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-04-26T00:00:00\", \"latest\": \"2016-04-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/descovy\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2290, \"last_scrape\": \"2018-12-13T16:33:52\", \"url\": \"http://www.ncpe.ie/drugs/enzalutamide-xtandi/\", \"rr_start\": \"2013-06-28T00:00:00\", \"rr_end\": \"2013-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-28, 2013-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Enzalutamide (Xtandi\", \"trade_name\": \"Xtandi\", \"indication\": \"Enzalutamide (Xtandi\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2013-06-28T00:00:00\", \"latest\": \"2014-04-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2291, \"last_scrape\": \"2018-12-13T16:33:59\", \"url\": \"http://www.ncpe.ie/drugs/epoprostenol-veletri/\", \"rr_start\": \"2016-12-13T00:00:00\", \"rr_end\": \"2017-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-12-13, 2017-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Epoprostenol (Veletri\", \"trade_name\": \"Veletri\", \"indication\": \"Veletri\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-12-13T00:00:00\", \"latest\": \"2017-02-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2292, \"last_scrape\": \"2018-12-13T16:34:03\", \"url\": \"http://www.ncpe.ie/drugs/erenumab-aimovig/\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-15T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF ERENUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-19, 2018-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Erenumab (Aimovig\", \"trade_name\": \"Aimovig\", \"indication\": \"Erenumab (Aimovig\", \"ncpe_year\": 2018, \"eu_market\": \"2018-07-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig\", \"ta_list\": \"Migraine Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2293, \"last_scrape\": \"2018-12-13T16:34:07\", \"url\": \"http://www.ncpe.ie/drugs/eribulin-halaven/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-03-11, 2011-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Eribulin (Halaven\", \"trade_name\": \"Halaven\", \"indication\": \"Eribulin (Halaven\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2011-02-09T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/halaven\", \"ta_list\": \"Breast Neoplasms; Liposarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2294, \"last_scrape\": \"2018-12-13T16:34:09\", \"url\": \"http://www.ncpe.ie/drugs/eslicarbazepine-zebinix/\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-08-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2009-09-01, 2009-08-01\", \"rr_multiple\": 0, \"drug_name\": \"Eslicarbazepine (Zebinix\", \"trade_name\": \"Zebinix\", \"indication\": \"Eslicarbazepine (Zebinix\", \"ncpe_year\": 2009, \"eu_market\": \"2009-04-21T00:00:00\", \"company\": \"BIAL\", \"orphan\": 0, \"earliest\": \"2009-08-01T00:00:00\", \"latest\": \"2009-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2295, \"last_scrape\": \"2018-12-13T16:34:12\", \"url\": \"http://www.ncpe.ie/drugs/etanercept-benepali/\", \"rr_start\": \"2016-03-22T00:00:00\", \"rr_end\": \"2016-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-03-22, 2016-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Etanercept (Benepali\", \"trade_name\": \"Benepali\", \"indication\": \"Benepali\", \"ncpe_year\": 2016, \"eu_market\": \"2016-01-13T00:00:00\", \"company\": \"Samsung\", \"orphan\": 0, \"earliest\": \"2016-03-22T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/benepali\", \"ta_list\": \"Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis\", \"rr_status\": \"No HTA\"}, {\"id\": 2296, \"last_scrape\": \"2018-12-13T16:34:15\", \"url\": \"http://www.ncpe.ie/drugs/etelcalcetide-parsabiv/\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-06-14, 2017-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Etelcalcetide (Parsabiv\", \"trade_name\": \"Parsabiv\", \"indication\": \"Etelcalcitide (Parsabiv\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-11T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/parsabiv\", \"ta_list\": \"Hyperparathyroidism, Secondary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2297, \"last_scrape\": \"2018-12-13T16:34:21\", \"url\": \"http://www.ncpe.ie/drugs/eurartesim-piperaquine-tetraphosphatedihidroartemisinin/\", \"rr_start\": \"2012-05-22T00:00:00\", \"rr_end\": \"2012-05-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-05-22, 2012-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Piperaquine tetraphosphate/dihidroartemisinin (Eurartesim\", \"trade_name\": \"Eurartesim\", \"indication\": \"Eurartesim\", \"ncpe_year\": 2012, \"eu_market\": \"2011-10-27T00:00:00\", \"company\": \"Alfasigma\", \"orphan\": 0, \"earliest\": \"2012-05-22T00:00:00\", \"latest\": \"2012-05-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eurartesim\", \"ta_list\": \"Malaria\", \"rr_status\": \"No HTA\"}, {\"id\": 2298, \"last_scrape\": \"2018-12-13T16:34:24\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-afinitor/\", \"rr_start\": \"2012-09-21T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-09-21, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Afinitor\", \"trade_name\": \"Afinitor\", \"indication\": \"Treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor\", \"ncpe_year\": 2012, \"eu_market\": \"2009-08-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-09-21T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/afinitor\", \"ta_list\": \"Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2299, \"last_scrape\": \"2018-12-13T16:34:26\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-votubia-for-refractory-seizures-associated-with-tuberous-sclerosis-complex-tsc/\", \"rr_start\": \"2017-04-19T00:00:00\", \"rr_end\": \"2017-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-04-19, 2017-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Votubia \", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus (Votubia\", \"ncpe_year\": 2017, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2017-04-19T00:00:00\", \"latest\": \"2017-04-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/votubia\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2300, \"last_scrape\": \"2018-12-13T16:34:29\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-votubia/\", \"rr_start\": \"2011-09-30T00:00:00\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-09-30, 2011-10-14\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Votubia\", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus (Votubia\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2011-09-30T00:00:00\", \"latest\": \"2011-10-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/votubia\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2301, \"last_scrape\": \"2018-12-13T16:34:36\", \"url\": \"http://www.ncpe.ie/drugs/evolocumab-repatha/\", \"rr_start\": \"\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Evolocumab (Repatha\", \"trade_name\": \"Repatha\", \"indication\": \"Evolocumab (Repatha\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-17T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-01-01T00:00:00\", \"latest\": \"2018-05-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/repatha\", \"ta_list\": \"Dyslipidemias; Hypercholesterolemia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2302, \"last_scrape\": \"2018-12-13T16:34:41\", \"url\": \"http://www.ncpe.ie/drugs/exenatide-bydureon/\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Exenatide (Bydureon\", \"trade_name\": \"Bydureon\", \"indication\": \"Exenatide (Bydureon\", \"ncpe_year\": 2011, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2303, \"last_scrape\": \"2018-12-13T16:34:44\", \"url\": \"http://www.ncpe.ie/drugs/fampridine-fampyra/\", \"rr_start\": \"2011-09-11T00:00:00\", \"rr_end\": \"2011-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-09-11, 2011-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Fampridine (Fampyra\", \"trade_name\": \"Fampyra\", \"indication\": \"Fampridine (Fampyra\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-20T00:00:00\", \"company\": \"Blogen\", \"orphan\": 0, \"earliest\": \"2011-09-01T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fampyra\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2304, \"last_scrape\": \"2018-12-13T16:34:48\", \"url\": \"http://www.ncpe.ie/drugs/ferric-maltol-feraccru_/\", \"rr_start\": \"2016-08-12T00:00:00\", \"rr_end\": \"2016-09-06T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-08-12, 2016-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Ferric maltol (Feraccru\", \"trade_name\": \"Feraccru\", \"indication\": \"Ferric maltol indicated for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) in adult patients.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Shield\", \"orphan\": 0, \"earliest\": \"2016-08-12T00:00:00\", \"latest\": \"2016-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/feraccru\", \"ta_list\": \"Anemia, Iron-Deficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2305, \"last_scrape\": \"2018-12-13T16:34:51\", \"url\": \"http://www.ncpe.ie/drugs/fidaxomicin-dificlir/\", \"rr_start\": \"2012-03-09T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2012-03-09, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Fidaxomicin (Dificlir\", \"trade_name\": \"Dificlir\", \"indication\": \"Fidaxomicin is indicated for the treatment of CDI also known as CDAD in adult patients.\", \"ncpe_year\": 2013, \"eu_market\": \"2011-12-05T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-03-09T00:00:00\", \"latest\": \"2013-02-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dificlir\", \"ta_list\": \"Clostridium Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2306, \"last_scrape\": \"2018-12-13T16:34:56\", \"url\": \"http://www.ncpe.ie/drugs/fingolimod-gilenya-4/\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2010-12-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-01-10, 2010-12-03\", \"rr_multiple\": 0, \"drug_name\": \"Fingolimod (Gilenya\", \"trade_name\": \"Gilenya\", \"indication\": \"Cost effectiveness of Fingolimod (Gilenya\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2010-12-03T00:00:00\", \"latest\": \"2011-09-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2307, \"last_scrape\": \"2018-12-13T16:35:01\", \"url\": \"http://www.ncpe.ie/drugs/fluocinolone-acetonide-iluvien/\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-02-15, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Fluocinolone acetonide (Iluvien\", \"trade_name\": \"Iluvien\", \"indication\": \"Iluvien\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2308, \"last_scrape\": \"2018-12-13T16:35:05\", \"url\": \"http://www.ncpe.ie/drugs/fluticasone-furoate-umeclidinium-vilantero-trelegy-ellipta/\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT TRELEGY\", \"rr_dates\": \"2018-04-30, 2018-06-18\", \"rr_multiple\": 0, \"drug_name\": \"Fluticasone furoate/ umeclidinium/ vilantero (Trelegy\", \"trade_name\": \"Trelegy Ellipta\", \"indication\": \"Trelegy\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-15T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"Reimbursement without HTA\"}, {\"id\": 2309, \"last_scrape\": \"2018-12-13T16:35:09\", \"url\": \"http://www.ncpe.ie/drugs/follitropin-delta-rekovelle/\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-07-25, 2017-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Follitropin delta (Rekovelle\", \"trade_name\": \"Rekovelle\", \"indication\": \"Follitropin delta (Rekovelle \", \"ncpe_year\": 2019, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2019-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rekovelle\", \"ta_list\": \"Anovulation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2310, \"last_scrape\": \"2018-12-13T16:35:12\", \"url\": \"http://www.ncpe.ie/drugs/gefitinib-iressa/\", \"rr_start\": \"\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Gefitinib (Iressa\", \"trade_name\": \"Iressa\", \"indication\": \"A review of the economic evaluation of oral gefitinib (Iressa\", \"ncpe_year\": 2010, \"eu_market\": \"2009-06-24T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-16T00:00:00\", \"latest\": \"2010-11-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/iressa\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2311, \"last_scrape\": \"2018-12-13T16:35:15\", \"url\": \"http://www.ncpe.ie/drugs/gemtuzumab-ozogamicin-mylotarg/\", \"rr_start\": \"2018-06-21T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF GEMTUZUMAB OZOGAMICIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-21, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Gemtuzumab ozogamicin (Mylotarg\", \"trade_name\": \"Mylotarg\", \"indication\": \"Gemtuzumab ozogamicin (Mylotarg\", \"ncpe_year\": 2018, \"eu_market\": \"2018-04-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-06-21T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2312, \"last_scrape\": \"2018-12-13T16:35:19\", \"url\": \"http://www.ncpe.ie/drugs/glecaprevirpibrentasvir-maviret/\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-07-11, 2017-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glecaprevir/Pibrentasvir (Maviret\", \"trade_name\": \"Maviret\", \"indication\": \"Glecaprevir/pibrentasvir (Maviret\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/maviret\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2313, \"last_scrape\": \"2018-12-13T16:35:25\", \"url\": \"http://www.ncpe.ie/drugs/glucosamine-sulfate-dona/\", \"rr_start\": \"\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Glucosamine sulfate (Dona\", \"trade_name\": \"Dona\", \"indication\": \"Economic evalution of glucosamine sulfate (Dona\", \"ncpe_year\": 2009, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2009-04-01T00:00:00\", \"latest\": \"2009-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2314, \"last_scrape\": \"2018-12-13T16:35:32\", \"url\": \"http://www.ncpe.ie/drugs/glycerol-phenylbutyrate-ravicti/\", \"rr_start\": \"2018-03-26T00:00:00\", \"rr_end\": \"2018-06-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT GLYCEROL PHENYLBUTYRATE (RAVICTI\", \"rr_dates\": \"2018-03-26, 2018-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Glycerol Phenylbutyrate (Ravicti\", \"trade_name\": \"Ravicti\", \"indication\": \"Glycerol phenylbutyrate (Ravicti\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-26T00:00:00\", \"company\": \"Horizon\", \"orphan\": 1, \"earliest\": \"2018-03-26T00:00:00\", \"latest\": \"2018-06-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti\", \"ta_list\": \"Urea Cycle Disorders, Inborn\", \"rr_status\": \"Reimbursement without HTA\"}, {\"id\": 2315, \"last_scrape\": \"2018-12-13T16:35:38\", \"url\": \"http://www.ncpe.ie/drugs/glycopyrronium-bromide-seebri-breezhaler/\", \"rr_start\": \"2012-08-12T00:00:00\", \"rr_end\": \"2012-08-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-08-12, 2012-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide (Seebri Breezhaler\", \"trade_name\": \"Seebri Breezhaler\", \"indication\": \"Seebri Breezhaler\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-08-12T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"id\": 2316, \"last_scrape\": \"2018-12-13T16:35:40\", \"url\": \"http://www.ncpe.ie/drugs/glypyrronium-bromide-sialanar/\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-07, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide (Sialanar\", \"trade_name\": \"Sialanar\", \"indication\": \"Glycopyrronium bromide (Sialanar\", \"ncpe_year\": 2017, \"eu_market\": \"2016-09-15T00:00:00\", \"company\": \"Proveca\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar\", \"ta_list\": \"Sialorrhea\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2317, \"last_scrape\": \"2018-12-13T16:35:47\", \"url\": \"http://www.ncpe.ie/drugs/golimumab-simponi-2/\", \"rr_start\": \"2013-10-11T00:00:00\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-10-11, 2013-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab (Simponi\", \"trade_name\": \"Simponi\", \"indication\": \"Golimumab is indicated for the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments.\", \"ncpe_year\": 2013, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2013-10-11T00:00:00\", \"latest\": \"2013-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/simponi\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"id\": 2318, \"last_scrape\": \"2018-12-13T16:35:54\", \"url\": \"http://www.ncpe.ie/drugs/golimumab-simponi/\", \"rr_start\": \"\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab (Simponi\", \"trade_name\": \"Simponi\", \"indication\": \"Cost-effectiveness of golimumab (Simponi\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2009-11-20T00:00:00\", \"latest\": \"2010-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/simponi\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2319, \"last_scrape\": \"2018-12-13T16:35:56\", \"url\": \"http://www.ncpe.ie/drugs/grass-pollen-allergen-extract-oralair/\", \"rr_start\": \"2011-10-11T00:00:00\", \"rr_end\": \"2011-09-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-10-11, 2011-09-26\", \"rr_multiple\": 0, \"drug_name\": \"Grass pollen allergen extract (Oralair\", \"trade_name\": \"Oralair\", \"indication\": \" Grass pollen allegen extract (Oralair\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-09-26T00:00:00\", \"latest\": \"2011-10-01T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2320, \"last_scrape\": \"2018-12-13T16:36:00\", \"url\": \"http://www.ncpe.ie/drugs/guanfacine-hydrochloride-intuniv/\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-01, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Guanfacine hydrochloride (Intuniv\", \"trade_name\": \"Intuniv\", \"indication\": \"Intuniv\", \"ncpe_year\": 2015, \"eu_market\": \"2015-09-17T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/intuniv\", \"ta_list\": \"Attention Deficit Disorder with Hyperactivity\", \"rr_status\": \"No HTA\"}, {\"id\": 2321, \"last_scrape\": \"2018-12-13T16:36:02\", \"url\": \"http://www.ncpe.ie/drugs/guselkumab-tremfya/\", \"rr_start\": \"2017-12-01T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-12-01, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Guselkumab (Tremfya\", \"trade_name\": \"Tremfya\", \"indication\": \"Guselkumab (Tremfya\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-10T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-12-01T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2322, \"last_scrape\": \"2018-12-13T16:36:07\", \"url\": \"http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-a1pi-prolastin/\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-06-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-05, 2017-06-08\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor (A1PI) (Prolastin\", \"trade_name\": \"Prolastin\", \"indication\": \"Human A1PI (Prolastin \", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-06-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2323, \"last_scrape\": \"2018-12-13T16:36:14\", \"url\": \"http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-respreeza/\", \"rr_start\": \"2016-01-20T00:00:00\", \"rr_end\": \"2016-02-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-20, 2016-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor (Respreeza\", \"trade_name\": \"Respreeza\", \"indication\": \"Respreeza\", \"ncpe_year\": 2017, \"eu_market\": \"2015-08-20T00:00:00\", \"company\": \"CSL\", \"orphan\": 0, \"earliest\": \"2016-01-20T00:00:00\", \"latest\": \"2017-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza\", \"ta_list\": \"Genetic Diseases, Inborn; Lung Diseases\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2324, \"last_scrape\": \"2018-12-13T16:36:17\", \"url\": \"http://www.ncpe.ie/drugs/hyaluronic-acid-and-co-enzyme-q10-visuxl/\", \"rr_start\": \"2017-11-06T00:00:00\", \"rr_end\": \"2017-11-30T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-11-06, 2017-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Hyaluronic acid and co enzyme Q10 (VisuXL\", \"trade_name\": \"VisuXL\", \"indication\": \"Cross linked hyaluronic acid and co enzyme Q10 (VisuXL\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-11-06T00:00:00\", \"latest\": \"2017-11-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2325, \"last_scrape\": \"2018-12-13T16:36:22\", \"url\": \"http://www.ncpe.ie/drugs/hydrocortisone-plenadren/\", \"rr_start\": \"2017-11-08T00:00:00\", \"rr_end\": \"2017-11-01T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-11-08, 2018-01-11, 2017-11-01\", \"rr_multiple\": 1, \"drug_name\": \"Modified Release Hydrocortisone  (Plenadren\", \"trade_name\": \"Plenadren\", \"indication\": \"Modified release hydrocortisone (Plenadren\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-03T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2018-01-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/plenadren\", \"ta_list\": \"Adrenal Insufficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2326, \"last_scrape\": \"2018-12-13T16:36:27\", \"url\": \"http://www.ncpe.ie/drugs/hydroxcarbamide-siklos/\", \"rr_start\": \"2011-08-22T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-08-22, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Hydroxycarbamide (Siklos\", \"trade_name\": \"Siklos\", \"indication\": \" Hydroxycarbamide (Siklos\", \"ncpe_year\": 2011, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"Addmedica\", \"orphan\": 1, \"earliest\": \"2011-08-22T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/siklos\", \"ta_list\": \"Anemia, Sickle Cell\", \"rr_status\": \"No HTA\"}, {\"id\": 2327, \"last_scrape\": \"2018-12-13T16:36:32\", \"url\": \"http://www.ncpe.ie/drugs/ibrutinib-imbruivca-for-previously-untreated-cll/\", \"rr_start\": \"2016-08-02T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-08-02, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib (Imbruvica\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib (Imbruvica\", \"ncpe_year\": 2016, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-08-02T00:00:00\", \"latest\": \"2016-08-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2328, \"last_scrape\": \"2018-12-13T16:36:36\", \"url\": \"http://www.ncpe.ie/drugs/ibrutinib-imbruvica-for-mcl/\", \"rr_start\": \"2014-11-07T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-11-07, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib (Imbruvica\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib (Imbruvica\", \"ncpe_year\": 2015, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-11-07T00:00:00\", \"latest\": \"2015-10-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2329, \"last_scrape\": \"2018-12-13T16:36:40\", \"url\": \"http://www.ncpe.ie/drugs/icatibant-firazyr/\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Icatibant (Firazyr\", \"trade_name\": \"Firazyr\", \"indication\": \"Icatibant (Firazyr\", \"ncpe_year\": 2013, \"eu_market\": \"2008-07-11T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"id\": 2330, \"last_scrape\": \"2018-12-13T16:36:43\", \"url\": \"http://www.ncpe.ie/drugs/idarucizumab-praxbind/\", \"rr_start\": \"2015-12-11T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-11, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Idarucizumab (Praxbind\", \"trade_name\": \"Praxbind\", \"indication\": \"Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required:\", \"ncpe_year\": 2015, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-12-11T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/praxbind\", \"ta_list\": \"Hemorrhage\", \"rr_status\": \"No HTA\"}, {\"id\": 2331, \"last_scrape\": \"2018-12-13T16:36:50\", \"url\": \"http://www.ncpe.ie/drugs/idebenone-raxone/\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-04-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-10, 2016-04-14\", \"rr_multiple\": 0, \"drug_name\": \"Idebenone (Raxone\", \"trade_name\": \"Raxone\", \"indication\": \"Raxone\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-08T00:00:00\", \"company\": \"Santhera\", \"orphan\": 1, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2018-08-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/raxone\", \"ta_list\": \"Optic Atrophy, Hereditary, Leber\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2332, \"last_scrape\": \"2018-12-13T16:36:56\", \"url\": \"http://www.ncpe.ie/drugs/idelalisib-zydelig/\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2014-12-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-08, 2014-12-30\", \"rr_multiple\": 0, \"drug_name\": \"Idelalisib (Zydelig\", \"trade_name\": \"Zydelig\", \"indication\": \"Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2016-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2333, \"last_scrape\": \"2018-12-13T16:36:59\", \"url\": \"http://www.ncpe.ie/drugs/imiquimod-zyclara/\", \"rr_start\": \"2013-09-10T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-09-10, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Imiquimod 3.75% (Zyclara\", \"trade_name\": \"Zyclara\", \"indication\": \"Imiquimod 3.75%(Zyclara\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Meda\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara\", \"ta_list\": \"Keratosis; Keratosis, Actinic\", \"rr_status\": \"No HTA\"}, {\"id\": 2334, \"last_scrape\": \"2018-12-13T16:37:01\", \"url\": \"http://www.ncpe.ie/drugs/incobotulinum-toxin-type-a-xeomin/\", \"rr_start\": \"2014-02-07T00:00:00\", \"rr_end\": \"2014-03-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-07, 2014-03-05\", \"rr_multiple\": 0, \"drug_name\": \"Incobotulinum Toxin Type A (Xeomin\", \"trade_name\": \"Xeomin\", \"indication\": \"Incobotulinum Toxin Type A (Xeomin\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-02-07T00:00:00\", \"latest\": \"2014-03-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2335, \"last_scrape\": \"2018-12-13T16:37:04\", \"url\": \"http://www.ncpe.ie/drugs/indacaterol-onbrez/\", \"rr_start\": \"2010-01-15T00:00:00\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-01-15\", \"rr_multiple\": 0, \"drug_name\": \"Indacaterol (Onbrez\", \"trade_name\": \"Onbrez\", \"indication\": \"Review of Indacaterol (Onbrez\", \"ncpe_year\": 2010, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-01-15T00:00:00\", \"latest\": \"2010-01-15T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2336, \"last_scrape\": \"2018-12-13T16:37:07\", \"url\": \"http://www.ncpe.ie/drugs/infliximab-inflectra/\", \"rr_start\": \"\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Infliximab (Inflectra\", \"trade_name\": \"Inflectra\", \"indication\": \"Inflectra\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2337, \"last_scrape\": \"2018-12-13T16:37:09\", \"url\": \"http://www.ncpe.ie/drugs/inotuzumab-ozogamicin-besponsa/\", \"rr_start\": \"2017-07-03T00:00:00\", \"rr_end\": \"2017-09-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-03, 2017-09-08\", \"rr_multiple\": 0, \"drug_name\": \"Inotuzumab ozogamicin (Besponsa\", \"trade_name\": \"Besponsa\", \"indication\": \"Inotuzumab ozogamicin (Besponsa\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2017-07-03T00:00:00\", \"latest\": \"2018-09-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2338, \"last_scrape\": \"2018-12-13T16:37:16\", \"url\": \"http://www.ncpe.ie/drugs/insulin-aspart-fiasp/\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-05-17, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart (Fiasp\", \"trade_name\": \"Fiasp\", \"indication\": \"Insulin aspart (Fiasp\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-09T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fiasp\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"No HTA\"}, {\"id\": 2339, \"last_scrape\": \"2018-12-13T16:37:21\", \"url\": \"http://www.ncpe.ie/drugs/insulin-aspart-novorapid-flextouch/\", \"rr_start\": \"2014-07-22T00:00:00\", \"rr_end\": \"2014-08-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2014-07-22, 2014-08-28\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart (NovoRapid\", \"trade_name\": \"NovoRapid FlexTouch\", \"indication\": \"Insulin aspart (NovoRapid\", \"ncpe_year\": 2014, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2014-07-22T00:00:00\", \"latest\": \"2014-08-28T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2340, \"last_scrape\": \"2018-12-13T16:37:25\", \"url\": \"http://www.ncpe.ie/drugs/insulin-degludec-tresiba/\", \"rr_start\": \"2012-12-17T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-17, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Degludec (Tresiba\", \"trade_name\": \"Tresiba\", \"indication\": \"Treatment of diabetes mellitus\", \"ncpe_year\": 2015, \"eu_market\": \"2013-01-20T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2012-12-17T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2341, \"last_scrape\": \"2018-12-13T16:37:30\", \"url\": \"http://www.ncpe.ie/drugs/insulin-degludecliraglutide-ideglira-xultophy/\", \"rr_start\": \"2016-09-19T00:00:00\", \"rr_end\": \"2016-10-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-09-19, 2016-10-17\", \"rr_multiple\": 0, \"drug_name\": \"Insulin degludec/liraglutide (IDegLira) (Xultophy\", \"trade_name\": \"Xultophy\", \"indication\": \"IDegLira is indicated for the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2016-09-19T00:00:00\", \"latest\": \"2016-10-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xultophy\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2342, \"last_scrape\": \"2018-12-13T16:37:36\", \"url\": \"http://www.ncpe.ie/drugs/insulin-glargine-abasaglar/\", \"rr_start\": \"2015-09-04T00:00:00\", \"rr_end\": \"2015-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-09-04, 2015-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine (Abasaglar\", \"trade_name\": \"Abasaglar\", \"indication\": \"Abasaglar\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-09-04T00:00:00\", \"latest\": \"2015-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2343, \"last_scrape\": \"2018-12-13T16:37:40\", \"url\": \"http://www.ncpe.ie/drugs/insulin-glargine-u300-toujeo/\", \"rr_start\": \"2015-05-14T00:00:00\", \"rr_end\": \"2015-07-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2015-05-14, 2015-07-02\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine U300 (Toujeo\", \"trade_name\": \"Toujeo\", \"indication\": \"Toujeo\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-05-14T00:00:00\", \"latest\": \"2015-07-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2344, \"last_scrape\": \"2018-12-13T16:37:43\", \"url\": \"http://www.ncpe.ie/drugs/ipilimumab-yervoy/\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Ipilimumab (Yervoy\", \"trade_name\": \"Yervoy\", \"indication\": \"Pharmacoeconomic evaluation of Ipilimumab (Yervoy\", \"ncpe_year\": 2013, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2013-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2345, \"last_scrape\": \"2018-12-13T16:37:49\", \"url\": \"http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-diafer/\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron (III) isomaltoside 1000 (Diafer\", \"trade_name\": \"Diafer\", \"indication\": \"Diafer\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2346, \"last_scrape\": \"2018-12-13T16:37:52\", \"url\": \"http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-monover/\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron (III) isomaltoside 1000 (Monover\", \"trade_name\": \"Monover\", \"indication\": \"Monover\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2347, \"last_scrape\": \"2018-12-13T16:38:02\", \"url\": \"http://www.ncpe.ie/drugs/iron-isomaltoside-1000-monover/\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2011-02-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-01-10, 2011-02-02\", \"rr_multiple\": 0, \"drug_name\": \"Iron isomaltoside 1000 (MonoVer\", \"trade_name\": \"MonoVer\", \"indication\": \"MonoVer is indicated for the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-01-10T00:00:00\", \"latest\": \"2011-02-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2348, \"last_scrape\": \"2018-12-13T16:38:07\", \"url\": \"http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-invasive-aspergillosis/\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole (Cresemba\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole (Cresemba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2349, \"last_scrape\": \"2018-12-13T16:38:09\", \"url\": \"http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-mucormycosis/\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole (Cresemba\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole (Cresemba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2350, \"last_scrape\": \"2018-12-13T16:38:15\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kaldeco/\", \"rr_start\": \"2012-08-13T00:00:00\", \"rr_end\": \"2012-08-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-08-13, 2012-08-22\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2012-08-13T00:00:00\", \"latest\": \"2013-01-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2351, \"last_scrape\": \"2018-12-13T16:38:21\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-patients-with-cf-2-years/\", \"rr_start\": \"2015-11-19T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMAOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-19, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\", \"ncpe_year\": 2016, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2015-11-19T00:00:00\", \"latest\": \"2016-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2352, \"last_scrape\": \"2018-12-13T16:38:24\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-the-treatment-of-cf-patients-with-the-r117h-mutation/\", \"rr_start\": \"2016-01-14T00:00:00\", \"rr_end\": \"2016-02-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-14, 2016-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\", \"ncpe_year\": 2017, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2016-01-14T00:00:00\", \"latest\": \"2017-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2353, \"last_scrape\": \"2018-12-13T16:38:29\", \"url\": \"http://www.ncpe.ie/drugs/ixazomib-ninlaro/\", \"rr_start\": \"2016-11-23T00:00:00\", \"rr_end\": \"2017-01-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-23, 2017-01-16\", \"rr_multiple\": 0, \"drug_name\": \"Ixazomib (Ninlaro\", \"trade_name\": \"Ninlaro\", \"indication\": \"Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-21T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2016-11-23T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2354, \"last_scrape\": \"2018-12-13T16:38:34\", \"url\": \"http://www.ncpe.ie/drugs/ixekizumab-taltz-for-psoriatic-arthritis/\", \"rr_start\": \"2018-10-16T00:00:00\", \"rr_end\": \"2018-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT IXEKIZUMAB NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE. THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013\", \"rr_dates\": \"2018-10-16, 2018-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab (Taltz\", \"trade_name\": \"Taltz\", \"indication\": \"Ixekizumab (Taltz\", \"ncpe_year\": 2018, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2018-10-16T00:00:00\", \"latest\": \"2018-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/taltz\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2355, \"last_scrape\": \"2018-12-13T16:38:37\", \"url\": \"http://www.ncpe.ie/drugs/ixekizumab-taltz/\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-06-28, 2016-07-26\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab (Taltz\", \"trade_name\": \"Taltz\", \"indication\": \"Taltz\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/taltz\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2356, \"last_scrape\": \"2018-12-13T16:38:39\", \"url\": \"http://www.ncpe.ie/drugs/l/lisdexamfetamine-dimesylate-tyvense/\", \"rr_start\": \"2013-02-09T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-02-09, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Lisdexamfetamine dimesylate (Tyvense\", \"trade_name\": \"Tyvense\", \"indication\": \"Lisdexamfetamine dimesylate (Tyvense\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-02-09T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2357, \"last_scrape\": \"2018-12-13T16:38:44\", \"url\": \"http://www.ncpe.ie/drugs/lacosamide-vimpat/\", \"rr_start\": \"2017-09-11T00:00:00\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-09-11, 2017-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Lacosamide (Vimpat \", \"trade_name\": \"Vimpat\", \"indication\": \"Vimpat \", \"ncpe_year\": 2017, \"eu_market\": \"2008-08-29T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2017-09-11T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2358, \"last_scrape\": \"2018-12-13T16:38:50\", \"url\": \"http://www.ncpe.ie/drugs/lapatinib-tyverb/\", \"rr_start\": \"\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Lapatinib (Tyverb\", \"trade_name\": \"Tyverb\", \"indication\": \"Cost-effectiveness of Lapatinib (Tyverb\", \"ncpe_year\": 2008, \"eu_market\": \"2008-06-10T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2359, \"last_scrape\": \"2018-12-13T16:38:56\", \"url\": \"http://www.ncpe.ie/drugs/ledipasvirsofosbuvir-harvoni/\", \"rr_start\": \"2014-11-14T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-11-14, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ledipasvir/sofosbuvir (Harvoni\", \"trade_name\": \"Harvoni\", \"indication\": \"Ledipasvir/sofosbuvir (Harvoni\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-17T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-11-14T00:00:00\", \"latest\": \"2015-11-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2360, \"last_scrape\": \"2018-12-13T16:39:05\", \"url\": \"http://www.ncpe.ie/drugs/lenalidomide-revlimid/\", \"rr_start\": \"2015-10-05T00:00:00\", \"rr_end\": \"2015-11-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE.\", \"rr_dates\": \"2015-10-05, 2015-11-20\", \"rr_multiple\": 0, \"drug_name\": \"Lenalidomide (Revlimid\", \"trade_name\": \"Revlimid\", \"indication\": \"Revlimid\", \"ncpe_year\": 2018, \"eu_market\": \"2007-06-14T00:00:00\", \"company\": \"Celgene\", \"orphan\": 1, \"earliest\": \"2015-10-05T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid\", \"ta_list\": \"Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2361, \"last_scrape\": \"2018-12-13T16:39:07\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-kisplyx/\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-05-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-05-05, 2017-05-18\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Kisplyx\", \"trade_name\": \"Kisplyx\", \"indication\": \"Lenvatinib (Kisplyx\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-25T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-05-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2362, \"last_scrape\": \"2018-12-13T16:39:11\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-lenvima-2/\", \"rr_start\": \"2018-08-07T00:00:00\", \"rr_end\": \"2018-08-16T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF LENVATINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-08-07, 2018-08-16\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Lenvima\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib (Lenvima\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2018-08-07T00:00:00\", \"latest\": \"2018-08-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2363, \"last_scrape\": \"2018-12-13T16:39:15\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-lenvima/\", \"rr_start\": \"2015-05-05T00:00:00\", \"rr_end\": \"2015-07-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2015-05-05, 2015-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Lenvima\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/H\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2015-05-05T00:00:00\", \"latest\": \"2015-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2364, \"last_scrape\": \"2018-12-13T16:39:20\", \"url\": \"http://www.ncpe.ie/drugs/lesinurad-zurampic/\", \"rr_start\": \"2017-03-15T00:00:00\", \"rr_end\": \"2017-03-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-15, 2017-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Lesinurad (Zurampic\", \"trade_name\": \"Zurampic\", \"indication\": \"Lesinurad (Zurampic\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Gr\", \"orphan\": 0, \"earliest\": \"2017-03-15T00:00:00\", \"latest\": \"2018-12-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zurampic\", \"ta_list\": \"Hyperuricemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2365, \"last_scrape\": \"2018-12-13T16:39:25\", \"url\": \"http://www.ncpe.ie/drugs/letermovir-prevymis/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Letermovir (Prevymis\", \"trade_name\": \"Prevymis\", \"indication\": \"Letermovir for the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevymis\", \"ta_list\": \"Cytomegalovirus Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2366, \"last_scrape\": \"2018-12-13T16:39:28\", \"url\": \"http://www.ncpe.ie/drugs/levodopa-20mgml-carbidopa-monohydrate-5mg-intestinal-gel-duodopa/\", \"rr_start\": \"2013-03-13T00:00:00\", \"rr_end\": \"2013-04-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-03-13, 2013-04-16\", \"rr_multiple\": 0, \"drug_name\": \"Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel (Duodopa\", \"trade_name\": \"Duodopa\", \"indication\": \"For the treatment of advanced levodopa-responsive Parkinson\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-13T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2367, \"last_scrape\": \"2018-12-13T16:39:34\", \"url\": \"http://www.ncpe.ie/drugs/levofloxacin-quinsair/\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-02-10, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Levofloxacin (Quinsair\", \"trade_name\": \"Quinsair\", \"indication\": \"Levofloxacin (Quinsair\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-25T00:00:00\", \"company\": \"Horizon\", \"orphan\": 0, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/quinsair\", \"ta_list\": \"Cystic Fibrosis; Respiratory Tract Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2368, \"last_scrape\": \"2018-12-13T16:39:39\", \"url\": \"http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-delivery-system-lng-ius-12-kyleena/\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-02-08, 2017-03-16\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine delivery system LNG IUS 12 (Kyleena\", \"trade_name\": \"Kyleena\", \"indication\": \"Kyleena\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2017-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2369, \"last_scrape\": \"2018-12-13T16:39:44\", \"url\": \"http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-system-lng-ius-jaydess/\", \"rr_start\": \"2013-03-07T00:00:00\", \"rr_end\": \"2013-03-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-03-07, 2013-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine system LNG-IUS (Jaydess\", \"trade_name\": \"Jaydess\", \"indication\": \"Levonorgestrel Intrauterine System LNG-IUS (Jaydess\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-07T00:00:00\", \"latest\": \"2013-03-25T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2370, \"last_scrape\": \"2018-12-13T16:39:46\", \"url\": \"http://www.ncpe.ie/drugs/lidocaine-5-plasters-versatis/\", \"rr_start\": \"2010-09-09T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2010-09-09, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Lidocaine 5% plasters (Versatis\", \"trade_name\": \"Versatis\", \"indication\": \"Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN).\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-09-09T00:00:00\", \"latest\": \"2015-09-24T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2371, \"last_scrape\": \"2018-12-13T16:39:51\", \"url\": \"http://www.ncpe.ie/drugs/linaclotide-clonstella/\", \"rr_start\": \"2013-05-28T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-05-28, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Linaclotide (Constella\", \"trade_name\": \"Constella\", \"indication\": \"Linaclotide (Constella\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2013-05-28T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/constella\", \"ta_list\": \"Irritable Bowel Syndrome\", \"rr_status\": \"No HTA\"}, {\"id\": 2372, \"last_scrape\": \"2018-12-13T16:39:54\", \"url\": \"http://www.ncpe.ie/drugs/linagliptin-trajenta/\", \"rr_start\": \"2011-08-18T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-08-18, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Linagliptin (Trajenta\", \"trade_name\": \"Trajenta\", \"indication\": \"Lingagliptin (Trajenta\", \"ncpe_year\": 2011, \"eu_market\": \"2011-08-23T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2011-08-18T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2373, \"last_scrape\": \"2018-12-13T16:39:57\", \"url\": \"http://www.ncpe.ie/drugs/lipegfilgrastim-lonquex/\", \"rr_start\": \"2013-08-20T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-08-20, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Lipegfilgrastim (Lonquex\", \"trade_name\": \"Lonquex\", \"indication\": \"Lonquex\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-25T00:00:00\", \"company\": \"Sicor\", \"orphan\": 0, \"earliest\": \"2013-08-20T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex\", \"ta_list\": \"Neutropenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2374, \"last_scrape\": \"2018-12-13T16:40:00\", \"url\": \"http://www.ncpe.ie/drugs/liposomal-daunorubicin-and-cytarabine-cpx-351vyxeos/\", \"rr_start\": \"2018-09-28T00:00:00\", \"rr_end\": \"2018-11-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-09-28, 2018-11-08\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos\", \"trade_name\": \"Vyxeos\", \"indication\": \"Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Jazz\", \"orphan\": 1, \"earliest\": \"2018-09-28T00:00:00\", \"latest\": \"2018-11-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2375, \"last_scrape\": \"2018-12-13T16:40:06\", \"url\": \"http://www.ncpe.ie/drugs/liposomal-irinotecan-nal-iri-onivyde/\", \"rr_start\": \"2017-06-13T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-13, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal irinotecan (Onivyde\", \"trade_name\": \"Onivyde\", \"indication\": \"Liposomal irinotecan (Onivyde\", \"ncpe_year\": 2017, \"eu_market\": \"2016-10-14T00:00:00\", \"company\": \"Baxalta\", \"orphan\": 1, \"earliest\": \"2017-06-13T00:00:00\", \"latest\": \"2017-07-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-0\", \"ta_list\": \"Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2376, \"last_scrape\": \"2018-12-13T16:40:09\", \"url\": \"http://www.ncpe.ie/drugs/liquid-paraffin-ointment-vita-pos-opthalmic/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Liquid Paraffin Ointment (VitA-POS Opthalmic\", \"trade_name\": \"VitA-POS Opthalmic\", \"indication\": \"Liquid Paraffin Ointment (VitA-POS Opthalmic\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2377, \"last_scrape\": \"2018-12-13T16:40:13\", \"url\": \"http://www.ncpe.ie/drugs/liraglutide-victoza/\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-10-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-09-01, 2009-10-07\", \"rr_multiple\": 0, \"drug_name\": \"Liraglutide (Victoza\", \"trade_name\": \"Victoza\", \"indication\": \"Victoza\", \"ncpe_year\": 2018, \"eu_market\": \"2009-06-30T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2009-09-01T00:00:00\", \"latest\": \"2018-10-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/victoza\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2378, \"last_scrape\": \"2018-12-13T16:40:17\", \"url\": \"http://www.ncpe.ie/drugs/lixisenatide-lyxumia/\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Lixisenatide (Lyxumia\", \"trade_name\": \"Lyxumia\", \"indication\": \"Lixisenatide (Lyxumia\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-08-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2379, \"last_scrape\": \"2018-12-13T16:40:19\", \"url\": \"http://www.ncpe.ie/drugs/lomitapide-lojuxta/\", \"rr_start\": \"2014-09-09T00:00:00\", \"rr_end\": \"2014-09-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-09-09, 2014-09-15\", \"rr_multiple\": 0, \"drug_name\": \"Lomitapide (Lojuxta\", \"trade_name\": \"Lojuxta\", \"indication\": \"Lojuxta\", \"ncpe_year\": 2014, \"eu_market\": \"2013-07-31T00:00:00\", \"company\": \"Amryt\", \"orphan\": 0, \"earliest\": \"2014-09-09T00:00:00\", \"latest\": \"2014-09-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2380, \"last_scrape\": \"2018-12-13T16:40:22\", \"url\": \"http://www.ncpe.ie/drugs/lornoxicam-xefo/\", \"rr_start\": \"2011-06-23T00:00:00\", \"rr_end\": \"2011-07-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-06-23, 2011-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Lornoxicam (Xefo\", \"trade_name\": \"Xefo\", \"indication\": \" Lornoxicam (Xefo\", \"ncpe_year\": 2011, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-06-23T00:00:00\", \"latest\": \"2011-07-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA\"}, {\"id\": 2381, \"last_scrape\": \"2018-12-13T16:40:24\", \"url\": \"http://www.ncpe.ie/drugs/lotemax-0-5-eye-drops-suspension-loteprednol/\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2011-12-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-11-15, 2011-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Lotemax 0.5% eye drops suspension (Loteprednol)\", \"trade_name\": \"Loteprednol\", \"indication\": \" Indicated for treatment of post-operative inflammation following ocular surgery.\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2011-12-05T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2382, \"last_scrape\": \"2018-12-13T16:40:30\", \"url\": \"http://www.ncpe.ie/drugs/loxapine-inhalation-powder-adasuve/\", \"rr_start\": \"2016-06-21T00:00:00\", \"rr_end\": \"2016-07-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-06-21, 2016-07-28\", \"rr_multiple\": 0, \"drug_name\": \"Loxapine inhalation powder (Adasuve\", \"trade_name\": \"Adasuve\", \"indication\": \"Inhaled loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-02-20T00:00:00\", \"company\": \"Ferrer\", \"orphan\": 0, \"earliest\": \"2016-06-21T00:00:00\", \"latest\": \"2016-07-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve\", \"ta_list\": \"Schizophrenia; Bipolar Disorder\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2383, \"last_scrape\": \"2018-12-13T16:40:34\", \"url\": \"http://www.ncpe.ie/drugs/lumacaftorivacaftor-orkambi/\", \"rr_start\": \"2015-11-26T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-26, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Lumacaftor/ivacaftor (Orkambi\", \"trade_name\": \"Orkambi\", \"indication\": \"Orkambi\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Vertex\", \"orphan\": 0, \"earliest\": \"2015-11-26T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/orkambi\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2384, \"last_scrape\": \"2018-12-13T16:40:36\", \"url\": \"http://www.ncpe.ie/drugs/lutetium-177lu-oxodotreotide-lutathera/\", \"rr_start\": \"2018-10-23T00:00:00\", \"rr_end\": \"2018-11-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-10-23, 2018-11-16\", \"rr_multiple\": 0, \"drug_name\": \"Lutetium (177Lu) Oxodotreotide (Lutathera\", \"trade_name\": \"Lutathera\", \"indication\": \"Lutetium (177Lu) Oxodotreotide (Lutathera\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-26T00:00:00\", \"company\": \"Advanced\", \"orphan\": 1, \"earliest\": \"2018-10-23T00:00:00\", \"latest\": \"2018-11-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2385, \"last_scrape\": \"2018-12-13T16:40:41\", \"url\": \"http://www.ncpe.ie/drugs/macitentan-opsumit/\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-10, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Macitentan (Opsumit\", \"trade_name\": \"Opsumit\", \"indication\": \"Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-12-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2386, \"last_scrape\": \"2018-12-13T16:40:43\", \"url\": \"http://www.ncpe.ie/drugs/melatonin-circadin/\", \"rr_start\": \"\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Melatonin (Circadin\", \"trade_name\": \"Circadin\", \"indication\": \"A Review of the Economic Evaluation of Prolonged Release Melatonin (Circadin\", \"ncpe_year\": 2008, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"RAD\", \"orphan\": 0, \"earliest\": \"2008-08-01T00:00:00\", \"latest\": \"2008-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/circadin\", \"ta_list\": \"Sleep Initiation and Maintenance Disorders\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2387, \"last_scrape\": \"2018-12-13T16:40:45\", \"url\": \"http://www.ncpe.ie/drugs/mepolizumab-nucala/\", \"rr_start\": \"2016-03-16T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-03-16, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Mepolizumab (Nucala\", \"trade_name\": \"Nucala\", \"indication\": \"Mepolizumab (Nucala\", \"ncpe_year\": 2018, \"eu_market\": \"2015-12-01T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-03-16T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nucala\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2388, \"last_scrape\": \"2018-12-13T16:40:51\", \"url\": \"http://www.ncpe.ie/drugs/methoxyflurane-penthrox/\", \"rr_start\": \"2015-11-23T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-11-23, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Methoxyflurane (Penthrox\", \"trade_name\": \"Penthrox\", \"indication\": \"Penthrox\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2015-11-23T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2389, \"last_scrape\": \"2018-12-13T16:40:56\", \"url\": \"http://www.ncpe.ie/drugs/midostaurin-rydapt-for-aml/\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF MIDOSTAURIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin (Rydapt\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin (Rydapt\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2390, \"last_scrape\": \"2018-12-13T16:41:02\", \"url\": \"http://www.ncpe.ie/drugs/midostaurin-rydapt-for-asm/\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF MIDOSTAURIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin (Rydapt\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin (Rydapt\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2391, \"last_scrape\": \"2018-12-13T16:41:04\", \"url\": \"http://www.ncpe.ie/drugs/mifamurtide-mepact/\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-06-22, 2010-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Mifamurtide (Mepact\", \"trade_name\": \"Mepact\", \"indication\": \"Mifamurtide (Meptact\", \"ncpe_year\": 2010, \"eu_market\": \"2009-03-06T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2010-06-22T00:00:00\", \"latest\": \"2010-07-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mepact\", \"ta_list\": \"Osteosarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2392, \"last_scrape\": \"2018-12-13T16:41:06\", \"url\": \"http://www.ncpe.ie/drugs/migalastat-galafold/\", \"rr_start\": \"2016-07-14T00:00:00\", \"rr_end\": \"2016-08-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-07-14, 2016-08-18\", \"rr_multiple\": 0, \"drug_name\": \"Migalastat (Galafold\", \"trade_name\": \"Galafold\", \"indication\": \"Migalastat is indicated for the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-05-25T00:00:00\", \"company\": \"Amicus\", \"orphan\": 1, \"earliest\": \"2016-07-14T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/galafold\", \"ta_list\": \"Fabry Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2393, \"last_scrape\": \"2018-12-13T16:41:13\", \"url\": \"http://www.ncpe.ie/drugs/mirabegron-betmiga/\", \"rr_start\": \"2012-12-19T00:00:00\", \"rr_end\": \"2013-03-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-12-19, 2013-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Mirabegron (Betmiga\", \"trade_name\": \"Betmiga\", \"indication\": \"Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome\", \"ncpe_year\": 2013, \"eu_market\": \"2012-12-20T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-12-19T00:00:00\", \"latest\": \"2013-03-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga\", \"ta_list\": \"Urinary Bladder, Overactive\", \"rr_status\": \"No HTA\"}, {\"id\": 2394, \"last_scrape\": \"2018-12-13T16:41:15\", \"url\": \"http://www.ncpe.ie/drugs/nab-paclitaxel-abraxane/\", \"rr_start\": \"2014-01-23T00:00:00\", \"rr_end\": \"2014-03-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-01-23, 2014-03-02\", \"rr_multiple\": 0, \"drug_name\": \"Nab-paclitaxel (Abraxane\", \"trade_name\": \"Abraxane\", \"indication\": \"Nab-paclitaxel (Abraxane\", \"ncpe_year\": 2015, \"eu_market\": \"2008-01-10T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2014-01-23T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane\", \"ta_list\": \"Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2395, \"last_scrape\": \"2018-12-13T16:41:18\", \"url\": \"http://www.ncpe.ie/drugs/nalmefene-selincro/\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Nalmefene (Selincro\", \"trade_name\": \"Selincro\", \"indication\": \"Nalmefene (Selincro\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-24T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2014-04-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/selincro\", \"ta_list\": \"Alcohol-Related Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2396, \"last_scrape\": \"2018-12-13T16:41:24\", \"url\": \"http://www.ncpe.ie/drugs/naloxegel-moventig/\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-04-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-02-10, 2015-04-13\", \"rr_multiple\": 0, \"drug_name\": \"Naloxegel (Moventig\", \"trade_name\": \"Moventig\", \"indication\": \"Naloxegel (Moventiq\", \"ncpe_year\": 2015, \"eu_market\": \"2014-12-07T00:00:00\", \"company\": \"Kyowa\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-04-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/moventig\", \"ta_list\": \"Constipation; Opioid-Related Disorders\", \"rr_status\": \"No HTA\"}, {\"id\": 2397, \"last_scrape\": \"2018-12-13T16:41:26\", \"url\": \"http://www.ncpe.ie/drugs/naltrexone-bupropion-mysimba/\", \"rr_start\": \"2017-03-12T00:00:00\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-12, 2017-03-28\", \"rr_multiple\": 0, \"drug_name\": \"Naltrexone / bupropion (Mysimba\", \"trade_name\": \"Mysimba\", \"indication\": \"Naltrexone / bupropion (Mysimba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-03-26T00:00:00\", \"company\": \"Orexigen\", \"orphan\": 0, \"earliest\": \"2017-03-12T00:00:00\", \"latest\": \"2018-05-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba\", \"ta_list\": \"Obesity; Overweight\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2398, \"last_scrape\": \"2018-12-13T16:41:30\", \"url\": \"http://www.ncpe.ie/drugs/natalizumab-tysabri/\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Natalizumab (Tysabri\", \"trade_name\": \"Tysabri\", \"indication\": \" Economic Evaluation of Natalizumab (Tysabri\", \"ncpe_year\": 2007, \"eu_market\": \"2006-06-27T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2007-01-01T00:00:00\", \"latest\": \"2007-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2399, \"last_scrape\": \"2018-12-13T16:41:35\", \"url\": \"http://www.ncpe.ie/drugs/ncpe-inhaled-insulin-exubera-assessment/\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Inhaled insulin (Exubera\", \"trade_name\": \"Exubera\", \"indication\": \"In April 2006, Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin (Exubera\", \"ncpe_year\": 2006, \"eu_market\": \"2006-01-24T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-03-01T00:00:00\", \"latest\": \"2006-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/exubera\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2400, \"last_scrape\": \"2018-12-13T16:41:38\", \"url\": \"http://www.ncpe.ie/drugs/nepafenac-nevanac-2/\", \"rr_start\": \"2011-06-14T00:00:00\", \"rr_end\": \"2011-06-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-06-14, 2011-06-27\", \"rr_multiple\": 0, \"drug_name\": \"Nepafenac (Nevanac\", \"trade_name\": \"Nevanac\", \"indication\": \"Nepafenac (Nevanac\", \"ncpe_year\": 2011, \"eu_market\": \"2007-12-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2011-06-14T00:00:00\", \"latest\": \"2011-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac\", \"ta_list\": \"Pain, Postoperative; Ophthalmologic Surgical Procedures\", \"rr_status\": \"No HTA\"}, {\"id\": 2401, \"last_scrape\": \"2018-12-13T16:41:41\", \"url\": \"http://www.ncpe.ie/drugs/netupitantpalonosetron-akynzeo/\", \"rr_start\": \"2015-08-26T00:00:00\", \"rr_end\": \"2015-10-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-08-26, 2015-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Netupitant/palonosetron (Akynzeo\", \"trade_name\": \"Akynzeo\", \"indication\": \"Akynzeo\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Helsinn\", \"orphan\": 0, \"earliest\": \"2015-08-26T00:00:00\", \"latest\": \"2015-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo\", \"ta_list\": \"Vomiting; Cancer; Nausea\", \"rr_status\": \"No HTA\"}, {\"id\": 2402, \"last_scrape\": \"2018-12-13T16:41:44\", \"url\": \"http://www.ncpe.ie/drugs/nilotinib-tasigna-newly-diagnosed-cml/\", \"rr_start\": \"2010-10-06T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2010-10-06, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib (Tasigna\", \"trade_name\": \"Tasigna\", \"indication\": \"Nilotinib (Tasigna\", \"ncpe_year\": 2010, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-10-06T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2403, \"last_scrape\": \"2018-12-13T16:41:51\", \"url\": \"http://www.ncpe.ie/drugs/nilotinib-tasigna/\", \"rr_start\": \"\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib (Tasigna\", \"trade_name\": \"Tasigna\", \"indication\": \"Cost-effectiveness of Nilotinib (Tasigna\", \"ncpe_year\": 2008, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2404, \"last_scrape\": \"2018-12-13T16:41:53\", \"url\": \"http://www.ncpe.ie/drugs/nintedanib-ofev/\", \"rr_start\": \"2015-01-30T00:00:00\", \"rr_end\": \"2015-02-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-30, 2015-02-18\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib (Ofev\", \"trade_name\": \"Ofev\", \"indication\": \"Nintedanib (Ofev\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 1, \"earliest\": \"2015-01-30T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ofev\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2405, \"last_scrape\": \"2018-12-13T16:41:56\", \"url\": \"http://www.ncpe.ie/drugs/nintedanib-vargatef/\", \"rr_start\": \"2015-01-02T00:00:00\", \"rr_end\": \"2015-02-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-02, 2015-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib (Vargatef\", \"trade_name\": \"Vargatef\", \"indication\": \"Nintedanib (Vargatef\", \"ncpe_year\": 2017, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-01-02T00:00:00\", \"latest\": \"2017-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2406, \"last_scrape\": \"2018-12-13T16:42:00\", \"url\": \"http://www.ncpe.ie/drugs/niraparib-zejula/\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF NIRAPARIB COMPARED WITH THE CURRENT STANDARD OF CARE\", \"rr_dates\": \"2018-06-01, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Niraparib (Zejula\", \"trade_name\": \"Zejula\", \"indication\": \"Niraparib (Zejula\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-16T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 1, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zejula\", \"ta_list\": \"Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2407, \"last_scrape\": \"2018-12-13T16:42:06\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-melanoma/\", \"rr_start\": \"2015-05-28T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-05-28, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-05-28T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2408, \"last_scrape\": \"2018-12-13T16:42:13\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-non-squamous-nsclc/\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-03-03, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2409, \"last_scrape\": \"2018-12-13T16:42:20\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-nsclc/\", \"rr_start\": \"2015-07-02T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-07-02, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-07-02T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2410, \"last_scrape\": \"2018-12-13T16:42:26\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-as-monotherapy-for-the-adjuvant-treatment-of-adults-with-melanoma/\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF NIVOLUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-09, 2018-07-27\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-11-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2411, \"last_scrape\": \"2018-12-13T16:42:31\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-advanced-renal-cell-carcinoma/\", \"rr_start\": \"2016-04-27T00:00:00\", \"rr_end\": \"2016-05-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-04-27, 2016-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-04-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2412, \"last_scrape\": \"2018-12-13T16:42:33\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-classical-hodgkin-lymphoma/\", \"rr_start\": \"2016-11-22T00:00:00\", \"rr_end\": \"2017-01-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-11-22, 2017-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-11-22T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2413, \"last_scrape\": \"2018-12-13T16:42:36\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-head-and-neck-cancer/\", \"rr_start\": \"2017-05-03T00:00:00\", \"rr_end\": \"2017-05-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-03, 2017-05-30\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-05-03T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2414, \"last_scrape\": \"2018-12-13T16:42:41\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-urothelial-carcinoma/\", \"rr_start\": \"2017-06-28T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-28, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-06-28T00:00:00\", \"latest\": \"2018-09-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2415, \"last_scrape\": \"2018-12-13T16:42:46\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-in-combination-with-ipilimumab-yervoy/\", \"rr_start\": \"2018-11-28T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-11-28, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Yervoy\", \"indication\": \"Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).\", \"ncpe_year\": 2018, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-11-28T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy\", \"ta_list\": \"Melanoma\", \"rr_status\": \"Unknown\"}, {\"id\": 2416, \"last_scrape\": \"2018-12-13T16:42:51\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-plus-ipilimumab-opdivio-plus-yervoy/\", \"rr_start\": \"\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab plus ipilimumab (Opdivo\", \"trade_name\": \"Opdivo plus Yervoy\", \"indication\": \"Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-06-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2417, \"last_scrape\": \"2018-12-13T16:42:56\", \"url\": \"http://www.ncpe.ie/drugs/nomace2-zoely/\", \"rr_start\": \"2011-12-08T00:00:00\", \"rr_end\": \"2012-01-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-12-08, 2012-01-03\", \"rr_multiple\": 0, \"drug_name\": \"Nomegestrol acetate/estradiol (Zoely\", \"trade_name\": \"Zoely\", \"indication\": \"Nomegestrol acetate/estradiol (Zoely\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-26T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2011-12-08T00:00:00\", \"latest\": \"2012-01-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zoely\", \"ta_list\": \"Contraception\", \"rr_status\": \"No HTA\"}, {\"id\": 2418, \"last_scrape\": \"2018-12-13T16:43:02\", \"url\": \"http://www.ncpe.ie/drugs/nusinersin-spinraza/\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-11, 2017-08-02\", \"rr_multiple\": 0, \"drug_name\": \"Nusinersin (Spinraza\", \"trade_name\": \"Spinraza\", \"indication\": \"Nusinersen (Spinraza\", \"ncpe_year\": 2017, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 1, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-12-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza\", \"ta_list\": \"Muscular Atrophy, Spinal\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2419, \"last_scrape\": \"2018-12-13T16:43:07\", \"url\": \"http://www.ncpe.ie/drugs/obeticholic-acid-ocaliva/\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-18, 2016-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Obeticholic acid (Ocaliva\", \"trade_name\": \"Ocaliva\", \"indication\": \"Obeticholic acid is indicated for the treatment of primary biliary cirrhosis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Intercept\", \"orphan\": 1, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocaliva\", \"ta_list\": \"Liver Cirrhosis, Biliary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2420, \"last_scrape\": \"2018-12-13T16:43:10\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-follicular-lymphoma/\", \"rr_start\": \"2016-05-11T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-05-11, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (in combination with bendamustine) followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2016-05-11T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2421, \"last_scrape\": \"2018-12-13T16:43:15\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-previously-untreated-advanced-follicular-lymphoma/\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-09-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-08, 2017-09-13\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (Gazyvaro\", \"ncpe_year\": 2018, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2422, \"last_scrape\": \"2018-12-13T16:43:21\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro/\", \"rr_start\": \"2014-08-08T00:00:00\", \"rr_end\": \"2014-09-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-08-08, 2014-09-11\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (Gazyvaro\", \"ncpe_year\": 2015, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2014-08-08T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2423, \"last_scrape\": \"2018-12-13T16:43:24\", \"url\": \"http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-ppms/\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab (Ocrevus\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab (Ocrevus\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2424, \"last_scrape\": \"2018-12-13T16:43:30\", \"url\": \"http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-rms/\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab (Ocrevus\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab (Ocrevus\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2425, \"last_scrape\": \"2018-12-13T16:43:34\", \"url\": \"http://www.ncpe.ie/drugs/ocriplasmin-jetrea/\", \"rr_start\": \"2013-06-12T00:00:00\", \"rr_end\": \"2013-07-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-06-12, 2013-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Ocriplasmin (Jetrea\", \"trade_name\": \"Jetrea\", \"indication\": \"Ocriplasmin (Jetrea\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-13T00:00:00\", \"company\": \"ThromboGenics\", \"orphan\": 0, \"earliest\": \"2013-06-12T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea\", \"ta_list\": \"Retinal Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2426, \"last_scrape\": \"2018-12-13T16:43:39\", \"url\": \"http://www.ncpe.ie/drugs/ofatumumab-arzerra-previously-untreated-chronic-lymphocytic-leukaemia/\", \"rr_start\": \"2014-10-13T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2014-10-13, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab (Arzerra\", \"trade_name\": \"Arzerra\", \"indication\": \"Ofatumumab (Arzerra\", \"ncpe_year\": 2014, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-10-13T00:00:00\", \"latest\": \"2014-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2427, \"last_scrape\": \"2018-12-13T16:43:46\", \"url\": \"http://www.ncpe.ie/drugs/ofatumumab-arzerra/\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-06-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-06-22, 2010-06-01\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab (Arzerra\", \"trade_name\": \"Arzerra\", \"indication\": \"Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-06-01T00:00:00\", \"latest\": \"2010-06-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2428, \"last_scrape\": \"2018-12-13T16:43:52\", \"url\": \"http://www.ncpe.ie/drugs/oladaterol-striverdi-respimat/\", \"rr_start\": \"2014-04-07T00:00:00\", \"rr_end\": \"2014-05-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-07, 2014-05-02\", \"rr_multiple\": 0, \"drug_name\": \"Oladaterol (Striverdi\", \"trade_name\": \"Striverdi, Respimat\", \"indication\": \"Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-04-07T00:00:00\", \"latest\": \"2014-05-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2429, \"last_scrape\": \"2018-12-13T16:43:57\", \"url\": \"http://www.ncpe.ie/drugs/olaparib-lynparza-2/\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-05, 2015-02-19\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib (Lynparza\", \"trade_name\": \"Lynparza\", \"indication\": \"Lynparza\", \"ncpe_year\": 2017, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2430, \"last_scrape\": \"2018-12-13T16:44:03\", \"url\": \"http://www.ncpe.ie/drugs/olaparib-lynparza-for-platinum-sensitive-relapsed-ovarian-cancer/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"THE NCPE RECOMMEND  A FULL HTA TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF OLAPARIB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib (Lynparza\", \"trade_name\": \"Lynparza\", \"indication\": \"Olaparib (Lynparza\", \"ncpe_year\": 2018, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2431, \"last_scrape\": \"2018-12-13T16:44:08\", \"url\": \"http://www.ncpe.ie/drugs/omalizumab-xolair-for-the-treatment-of-severe-allergic-asthma/\", \"rr_start\": \"\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab (Xolair\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab is indicated as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1<80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.\", \"ncpe_year\": 2015, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-08-22T00:00:00\", \"latest\": \"2015-06-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xolair\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2432, \"last_scrape\": \"2018-12-13T16:44:14\", \"url\": \"http://www.ncpe.ie/drugs/omalizumab-xolair/\", \"rr_start\": \"2014-03-25T00:00:00\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED FOR THIS INDICATION.\", \"rr_dates\": \"2014-03-25, 2014-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab (Xolair\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab (Xolair\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-03-25T00:00:00\", \"latest\": \"2014-04-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xolair\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"No HTA\"}, {\"id\": 2433, \"last_scrape\": \"2018-12-13T16:44:19\", \"url\": \"http://www.ncpe.ie/drugs/oral-oxycodonenaloxone-targin/\", \"rr_start\": \"\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Oxycodone/naloxone (Targin\", \"trade_name\": \"Targin\", \"indication\": \"Cost-effectiveness of oral oxycodone/naloxone prolonged release tablet (Targin\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-05-05T00:00:00\", \"latest\": \"2010-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2434, \"last_scrape\": \"2018-12-13T16:44:22\", \"url\": \"http://www.ncpe.ie/drugs/osimertinib-tagrisso-for-the-first-line-treatment-of-metastatic-nsclc/\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-07T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF OSIMERTINIB FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WITH ACTIVATING EGFR MUTATIONS COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-19, 2018-08-07\", \"rr_multiple\": 0, \"drug_name\": \"Osimertinib (Tagrisso\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib (Tagrisso\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2435, \"last_scrape\": \"2018-12-13T16:44:39\", \"url\": \"http://www.ncpe.ie/drugs/osimertinib-tagrisso/\", \"rr_start\": \"2016-02-26T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-26, 2016-03-22, 2017-01-10\", \"rr_multiple\": 1, \"drug_name\": \"Osimertinib (Tagrisso\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib (Tagrisso\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-26T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2436, \"last_scrape\": \"2018-12-13T16:44:40\", \"url\": \"http://www.ncpe.ie/drugs/ozenoxacin-dubine/\", \"rr_start\": \"2018-11-12T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"FULL HTA IS NOT RECOMMENDED. THE NCPE RECOMMENDS THAT OZENOXACIN CREAM NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE.  THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013.\", \"rr_dates\": \"2018-11-12, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ozenoxacin (Dubine\", \"trade_name\": \"Dubine\", \"indication\": \"Ozenoxacin (Dubine\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-12T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"id\": 2437, \"last_scrape\": \"2018-12-13T16:44:43\", \"url\": \"http://www.ncpe.ie/drugs/p-drugs/pegylated-interferon-b-1a-plegridy/\", \"rr_start\": \"2014-11-25T00:00:00\", \"rr_end\": \"2014-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-11-25, 2014-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Pegylated Interferon beta-1a (Plegridy \", \"trade_name\": \"Plegridy\", \"indication\": \"Treatment of adult patients with relapsing remitting multiple sclerosis\", \"ncpe_year\": 2014, \"eu_market\": \"2014-07-17T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-11-25T00:00:00\", \"latest\": \"2014-12-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2438, \"last_scrape\": \"2018-12-13T16:44:47\", \"url\": \"http://www.ncpe.ie/drugs/palbociclib-ibrance/\", \"rr_start\": \"2016-09-10T00:00:00\", \"rr_end\": \"2016-09-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-09-10, 2016-09-28\", \"rr_multiple\": 0, \"drug_name\": \"Palbociclib (Ibrance\", \"trade_name\": \"Ibrance\", \"indication\": \"Palbociclib is indicated for the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-11-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2016-09-10T00:00:00\", \"latest\": \"2017-07-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2439, \"last_scrape\": \"2018-12-13T16:44:53\", \"url\": \"http://www.ncpe.ie/drugs/paliperidone-palmitate-xeplion/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Paliperidone palmitate (Xeplion\", \"trade_name\": \"Xeplion\", \"indication\": \"Paliperidone palmitate (Xeplion\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-04T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeplion\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2440, \"last_scrape\": \"2018-12-13T16:44:57\", \"url\": \"http://www.ncpe.ie/drugs/panobinostat-farydak/\", \"rr_start\": \"2016-01-26T00:00:00\", \"rr_end\": \"2016-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-26, 2016-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Panobinostat (Farydak\", \"trade_name\": \"Farydak\", \"indication\": \"Panobinostat in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-01-26T00:00:00\", \"latest\": \"2016-02-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/farydak\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2441, \"last_scrape\": \"2018-12-13T16:45:01\", \"url\": \"http://www.ncpe.ie/drugs/paritaprevir-boosted-with-ritonavir-and-ombitasvir-vierkirax-with-or-without-dasabuvir-exviera/\", \"rr_start\": \"2014-12-21T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-21, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Paritaprevir boosted with ritonavir and ombitasvir (Vierkirax\", \"trade_name\": \"Exviera\", \"indication\": \"Exviera\", \"ncpe_year\": 2016, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2014-12-21T00:00:00\", \"latest\": \"2016-02-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/exviera\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2442, \"last_scrape\": \"2018-12-13T16:45:07\", \"url\": \"http://www.ncpe.ie/drugs/patiromer-veltassa/\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT\\nRECOMMENDED\", \"rr_dates\": \"2017-10-11, 2017-11-17\", \"rr_multiple\": 0, \"drug_name\": \"Patiromer (Veltassa\", \"trade_name\": \"Veltassa\", \"indication\": \"Patiromer (Veltassa\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-19T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-11-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/veltassa\", \"ta_list\": \"Hyperkalemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2443, \"last_scrape\": \"2018-12-13T16:45:10\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-1l-nsclc-with-chemotherapy/\", \"rr_start\": \"2018-08-14T00:00:00\", \"rr_end\": \"2018-08-29T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-14, 2018-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-08-14T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2444, \"last_scrape\": \"2018-12-13T16:45:15\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-adjuvant-melanoma/\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-07T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-11-19, 2018-12-07\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizuma (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2445, \"last_scrape\": \"2018-12-13T16:45:18\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-classical-hodgkin-lymphoma/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2446, \"last_scrape\": \"2018-12-13T16:45:23\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-first-line-nsclc/\", \"rr_start\": \"2016-12-19T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-12-19, 2017-01-10\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-12-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2447, \"last_scrape\": \"2018-12-13T16:45:28\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-nsclc/\", \"rr_start\": \"2016-08-03T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-08-03, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-03T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2448, \"last_scrape\": \"2018-12-13T16:45:31\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-the-treatment-of-unresectable-or-advanced-metastatic-melanoma-in-adults-refractory-to-ipilimumab/\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2449, \"last_scrape\": \"2018-12-13T16:45:36\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-uc-1l/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES\", \"rr_dates\": \"2017-12-06, 2017-12-21, 2018-06-21, 2018-07-10, 2018-07-27\", \"rr_multiple\": 1, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-07-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2450, \"last_scrape\": \"2018-12-13T16:45:38\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-urothelial-carcinoma-2l/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda \", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2451, \"last_scrape\": \"2018-12-13T16:45:45\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda/\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-02-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2452, \"last_scrape\": \"2018-12-13T16:45:50\", \"url\": \"http://www.ncpe.ie/drugs/perampanel-fycompa/\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Perampanel (Fycompa\", \"trade_name\": \"Fycompa\", \"indication\": \"Perampanel (Fycompa\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-23T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa\", \"ta_list\": \"Epilepsies, Partial\", \"rr_status\": \"No HTA\"}, {\"id\": 2453, \"last_scrape\": \"2018-12-13T16:45:56\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta-for-her2-positive-breast-cancer/\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PERTUZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-01, 2018-06-22\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab  (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.\", \"ncpe_year\": 2018, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-12-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2454, \"last_scrape\": \"2018-12-13T16:46:02\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta-in-neoadjuvant-her2-positive-breast-cancer/\", \"rr_start\": \"2015-08-10T00:00:00\", \"rr_end\": \"2015-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-10, 2015-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"Perjeta (pertuzumab) is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2015-08-10T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2455, \"last_scrape\": \"2018-12-13T16:46:04\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta/\", \"rr_start\": \"2013-01-14T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-01-14, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"The proposed licensed indication is for use (in combination with trastuzumab and docetaxel) in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. \", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-01-14T00:00:00\", \"latest\": \"2013-08-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2456, \"last_scrape\": \"2018-12-13T16:46:09\", \"url\": \"http://www.ncpe.ie/drugs/phenylephrine-hydrochloride-tropicamide-lidocaine-hydrochloride-fydrane/\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-19T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-11-18, 2016-12-19\", \"rr_multiple\": 0, \"drug_name\": \"Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride (Fydrane\", \"trade_name\": \"Fydrane\", \"indication\": \"Fydrane\", \"ncpe_year\": 2016, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2016-12-19T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2457, \"last_scrape\": \"2018-12-13T16:46:11\", \"url\": \"http://www.ncpe.ie/drugs/pirfenidone-esbriet/\", \"rr_start\": \"2011-12-15T00:00:00\", \"rr_end\": \"2012-01-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-12-15, 2012-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Pirfenidone (Esbriet\", \"trade_name\": \"Esbriet\", \"indication\": \"Pirfenidone has been licensed by the European Medicines Agency (EMA) for the treatment of mild to moderate idiopathic pulmonary fibrosis.\", \"ncpe_year\": 2015, \"eu_market\": \"2011-02-27T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2011-12-15T00:00:00\", \"latest\": \"2015-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esbriet\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2458, \"last_scrape\": \"2018-12-13T16:46:14\", \"url\": \"http://www.ncpe.ie/drugs/pitavastatin-livazo/\", \"rr_start\": \"2010-12-22T00:00:00\", \"rr_end\": \"2010-12-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-12-22, 2010-12-24\", \"rr_multiple\": 0, \"drug_name\": \"Pitavastatin (Livazo\", \"trade_name\": \"Livazo\", \"indication\": \"Pitavastatin is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined (mixed) dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-12-22T00:00:00\", \"latest\": \"2010-12-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2459, \"last_scrape\": \"2018-12-13T16:46:20\", \"url\": \"http://www.ncpe.ie/drugs/pitolisant-wakix/\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-06-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-06-12, 2017-06-15\", \"rr_multiple\": 0, \"drug_name\": \"Pitolisant hydrochloride (Wakix\", \"trade_name\": \"Wakix\", \"indication\": \"Pitolisant hydrochloride (Wakix\", \"ncpe_year\": 2017, \"eu_market\": \"2016-03-31T00:00:00\", \"company\": \"Bioprojet\", \"orphan\": 1, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-06-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/wakix\", \"ta_list\": \"Narcolepsy\", \"rr_status\": \"No HTA\"}, {\"id\": 2460, \"last_scrape\": \"2018-12-13T16:46:24\", \"url\": \"http://www.ncpe.ie/drugs/pixantrone-pixuvri/\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-03-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-02-10, 2015-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Pixantrone (Pixuvri\", \"trade_name\": \"Pixuvri\", \"indication\": \"Pixurvi\", \"ncpe_year\": 2015, \"eu_market\": \"2012-05-10T00:00:00\", \"company\": \"CTI\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-03-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri\", \"ta_list\": \"Lymphoma, Non-Hodgkin\", \"rr_status\": \"No HTA\"}, {\"id\": 2461, \"last_scrape\": \"2018-12-13T16:46:27\", \"url\": \"http://www.ncpe.ie/drugs/polynuclear-ironiii-oxyhydroxide-pn-feooh-velphoro/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-09-12, 2014-10-08\", \"rr_multiple\": 0, \"drug_name\": \"Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro\", \"trade_name\": \"Velphoro\", \"indication\": \"Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro\", \"ncpe_year\": 2014, \"eu_market\": \"2014-08-26T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-10-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/velphoro\", \"ta_list\": \"Hyperphosphatemia; Renal Dialysis\", \"rr_status\": \"No HTA\"}, {\"id\": 2462, \"last_scrape\": \"2018-12-13T16:46:30\", \"url\": \"http://www.ncpe.ie/drugs/pomalidomide-imnovid/\", \"rr_start\": \"2013-09-20T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-20, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Pomalidomide (Imnovid\", \"trade_name\": \"Imnovid\", \"indication\": \"Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-09-20T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2463, \"last_scrape\": \"2018-12-13T16:46:32\", \"url\": \"http://www.ncpe.ie/drugs/ponatinib-iclusig/\", \"rr_start\": \"2013-10-02T00:00:00\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-10-02, 2013-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Ponatinib (Iclusig\", \"trade_name\": \"Iclusig\", \"indication\": \"Ponatinib (Iclusig\", \"ncpe_year\": 2016, \"eu_market\": \"2013-07-01T00:00:00\", \"company\": \"Incyte\", \"orphan\": 1, \"earliest\": \"2013-10-02T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig\", \"ta_list\": \"Leukemia, Myeloid; Leukemia, Lymphoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2464, \"last_scrape\": \"2018-12-13T16:46:38\", \"url\": \"http://www.ncpe.ie/drugs/prasugrel-efient/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Prasugrel (Efient\", \"trade_name\": \"Efient\", \"indication\": \"Economic Evaluation of Prasugrel (Efient\", \"ncpe_year\": 2010, \"eu_market\": \"2009-02-24T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2010-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/efient\", \"ta_list\": \"Acute Coronary Syndrome; Angina, Unstable; Myocardial Infarction\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2465, \"last_scrape\": \"2018-12-13T16:46:46\", \"url\": \"http://www.ncpe.ie/drugs/pregabalin-lyrica-2/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin (Lyrica\", \"trade_name\": \"Lyrica\", \"indication\": \"Lyrica\", \"ncpe_year\": 2015, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-30T00:00:00\", \"latest\": \"2015-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2466, \"last_scrape\": \"2018-12-13T16:46:52\", \"url\": \"http://www.ncpe.ie/drugs/pregabalin-lyrica-for-the-treatment-of-generalised-anxiety-disorder/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin (Lyrica\", \"trade_name\": \"Lyrica\", \"indication\": \"Pregabalin (Lyrica\", \"ncpe_year\": 2014, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-12-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2467, \"last_scrape\": \"2018-12-13T16:46:58\", \"url\": \"http://www.ncpe.ie/drugs/prucalopride-resolor/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-01-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-01-17\", \"rr_multiple\": 0, \"drug_name\": \"Prucalopride (Resolor\", \"trade_name\": \"Resolor\", \"indication\": \"Prucalopride (Resolor\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-14T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2011-01-17T00:00:00\", \"latest\": \"2011-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/resolor\", \"ta_list\": \"Constipation\", \"rr_status\": \"No HTA\"}, {\"id\": 2468, \"last_scrape\": \"2018-12-13T16:47:00\", \"url\": \"http://www.ncpe.ie/drugs/radium-223-xofigo/\", \"rr_start\": \"2013-11-28T00:00:00\", \"rr_end\": \"2013-12-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-11-28, 2013-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Radium-223 (Xofigo\", \"trade_name\": \"Xofigo\", \"indication\": \"Radium-223 (Xofigo\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-13T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2469, \"last_scrape\": \"2018-12-13T16:47:03\", \"url\": \"http://www.ncpe.ie/drugs/ramucirumab-cyramza/\", \"rr_start\": \"2014-12-20T00:00:00\", \"rr_end\": \"2014-12-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-20, 2014-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Ramucirumab (Cyramza\", \"trade_name\": \"Cyramza\", \"indication\": \"Indicated in combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction (GEJ) adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-12-19T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2014-12-20T00:00:00\", \"latest\": \"2016-07-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2470, \"last_scrape\": \"2018-12-13T16:47:06\", \"url\": \"http://www.ncpe.ie/drugs/ranolazine-ranexa/\", \"rr_start\": \"2009-11-19T00:00:00\", \"rr_end\": \"2009-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ranolazine (Ranexa\", \"trade_name\": \"Ranexa\", \"indication\": \"Cost-effectiveness of Ranolazine (Ranexa\", \"ncpe_year\": 2009, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2009-11-19T00:00:00\", \"latest\": \"2009-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2471, \"last_scrape\": \"2018-12-13T16:47:13\", \"url\": \"http://www.ncpe.ie/drugs/regadenoson-rapiscan/\", \"rr_start\": \"2011-09-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-09-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Regadenoson (Rapiscan\", \"trade_name\": \"Rapiscan\", \"indication\": \"Cost-effectiveness of Regadenoson (Rapiscan\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-06T00:00:00\", \"company\": \"GE\", \"orphan\": 0, \"earliest\": \"2011-09-19T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rapiscan\", \"ta_list\": \"Myocardial Perfusion Imaging\", \"rr_status\": \"No HTA\"}, {\"id\": 2472, \"last_scrape\": \"2018-12-13T16:47:17\", \"url\": \"http://www.ncpe.ie/drugs/regorafenib-stivarga-for-gist/\", \"rr_start\": \"2014-09-18T00:00:00\", \"rr_end\": \"2014-10-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-09-18, 2014-10-06\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib (Stivarga\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib (Stivarga\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2014-09-18T00:00:00\", \"latest\": \"2014-10-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2473, \"last_scrape\": \"2018-12-13T16:47:23\", \"url\": \"http://www.ncpe.ie/drugs/reslizumab-cinqaero/\", \"rr_start\": \"2017-01-23T00:00:00\", \"rr_end\": \"2017-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-01-23, 2017-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Reslizumab (Cinqaero\", \"trade_name\": \"Cinqaero\", \"indication\": \"Cinqaero\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-15T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2017-01-23T00:00:00\", \"latest\": \"2017-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cinqaero\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2474, \"last_scrape\": \"2018-12-13T16:47:27\", \"url\": \"http://www.ncpe.ie/drugs/retigabine-trobalt/\", \"rr_start\": \"2011-04-06T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-04-06, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Retigabine (Trobalt\", \"trade_name\": \"Trobalt\", \"indication\": \"Cost-effectiveness of Retigabine (Trobalt\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-27T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-04-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"No HTA\"}, {\"id\": 2475, \"last_scrape\": \"2018-12-13T16:47:29\", \"url\": \"http://www.ncpe.ie/drugs/ribociclib-kisqali/\", \"rr_start\": \"2017-09-04T00:00:00\", \"rr_end\": \"2017-09-19T00:00:00\", \"rr_outcome\": \"FOLLOWING NCPE ASSESSMENT OF THE COMPANY SUBMISSION, THE NCPE RECOMMENDS THAT RIBOCICLIB (IN COMBINATION WITH AN AROMATASE INHIBITOR) FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR+/HER2- LOCALLY ADVANCED OR METASTATIC BC AS INITIAL ENDOCRINE-BASED THERAPY, NOT BE CONSIDERED FOR REIMBURSEMENT UNLESS COST EFFECTIVENESS CAN BE IMPROVED RELATIVE TO EXISTING TREATMENTS. THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2017-09-04, 2017-09-19\", \"rr_multiple\": 0, \"drug_name\": \"Ribociclib (Kisqali\", \"trade_name\": \"Kisqali\", \"indication\": \"Ribociclib (Kisqali\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2017-09-04T00:00:00\", \"latest\": \"2018-08-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2476, \"last_scrape\": \"2018-12-13T16:47:35\", \"url\": \"http://www.ncpe.ie/drugs/rifaximin-targaxan-2/\", \"rr_start\": \"2013-07-09T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-09, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Rifaximin (Targaxan\", \"trade_name\": \"Targaxan\", \"indication\": \"Rifaximin (Targaxan\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-07-09T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2477, \"last_scrape\": \"2018-12-13T16:47:38\", \"url\": \"http://www.ncpe.ie/drugs/rigorafenib-stivarga/\", \"rr_start\": \"2013-09-12T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-12, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib (Stivarga\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib (Stivarga\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-09-12T00:00:00\", \"latest\": \"2014-06-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2478, \"last_scrape\": \"2018-12-13T16:47:42\", \"url\": \"http://www.ncpe.ie/drugs/rilpivirine-edurant/\", \"rr_start\": \"2011-12-14T00:00:00\", \"rr_end\": \"2012-01-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-12-14, 2012-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine (Edurant\", \"trade_name\": \"Edurant\", \"indication\": \"Rilpivirine in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ? 100,000 HIV-1 RNA copies/ml.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-11-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-12-14T00:00:00\", \"latest\": \"2012-01-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/edurant\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2479, \"last_scrape\": \"2018-12-13T16:47:45\", \"url\": \"http://www.ncpe.ie/drugs/rilpivirine-r-emtricitabine-f-tenofovir-alafenamide-taf-odefsey/\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMEDED\", \"rr_dates\": \"2016-06-28, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) (Odefsey\", \"trade_name\": \"Odefsey\", \"indication\": \"Odefsey\", \"ncpe_year\": 2016, \"eu_market\": \"2016-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2480, \"last_scrape\": \"2018-12-13T16:47:48\", \"url\": \"http://www.ncpe.ie/drugs/rimonabant-acomplia-2/\", \"rr_start\": \"\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rimonabant (Acomplia\", \"trade_name\": \"Acomplia\", \"indication\": \"In June 2006, Sanofi-Aventis submitted an evaluation of the cost-effectiveness of rimonabant (in addition to diet and exercise) in the management of multiple cardiovascular risks in overweight or obese patients in Ireland, to support its application for reimbursement of rimonabant under the Community Drugs Schemes. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-06-19T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2006-06-01T00:00:00\", \"latest\": \"2006-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/acomplia\", \"ta_list\": \"Obesity\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2481, \"last_scrape\": \"2018-12-13T16:47:53\", \"url\": \"http://www.ncpe.ie/drugs/riociguat-adempas/\", \"rr_start\": \"2014-04-11T00:00:00\", \"rr_end\": \"2014-05-16T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED AT THE CURRENT PRICE.\", \"rr_dates\": \"2014-04-11, 2014-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Riociguat (Adempas\", \"trade_name\": \"Adempas\", \"indication\": \"Riociguat (Adempas\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-27T00:00:00\", \"company\": \"Bayer\", \"orphan\": 1, \"earliest\": \"2014-04-11T00:00:00\", \"latest\": \"2014-05-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adempas\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2482, \"last_scrape\": \"2018-12-13T16:47:59\", \"url\": \"http://www.ncpe.ie/drugs/rituximab-mabthera/\", \"rr_start\": \"2014-05-26T00:00:00\", \"rr_end\": \"2014-09-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-26, 2014-09-22\", \"rr_multiple\": 0, \"drug_name\": \"Rituximab (MabThera\", \"trade_name\": \"MabThera\", \"indication\": \"Rituximab (MabThera\", \"ncpe_year\": 2014, \"eu_market\": \"1998-06-02T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-05-26T00:00:00\", \"latest\": \"2014-09-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"No HTA\"}, {\"id\": 2483, \"last_scrape\": \"2018-12-13T16:48:05\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-atrial-fibrillation-patients-undergoing-pci/\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2484, \"last_scrape\": \"2018-12-13T16:48:10\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-dvt/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Economic evaluation of Rivaroxaban (Xarelto\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-02-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2485, \"last_scrape\": \"2018-12-13T16:48:15\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-spaf-2/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban (Xarelto\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2486, \"last_scrape\": \"2018-12-13T16:48:18\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-the-prevention-of-atherothrombotic-events/\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-11T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF RIVAROXABAN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-26, 2018-10-11\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban (Xarelto\", \"ncpe_year\": 2018, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2487, \"last_scrape\": \"2018-12-13T16:48:25\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-low-dose-for-prevention-of-recurrent-venous-thromboembolism/\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2488, \"last_scrape\": \"2018-12-13T16:48:30\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban (Xarelto\", \"ncpe_year\": 2008, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2008-04-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2489, \"last_scrape\": \"2018-12-13T16:48:33\", \"url\": \"http://www.ncpe.ie/drugs/roflumilast-daxas/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Roflumilast (Daxas\", \"trade_name\": \"Daxas\", \"indication\": \"Cost Effectiveness of Roflumilast (Daxas\", \"ncpe_year\": 2010, \"eu_market\": \"2010-07-05T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-11T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/daxas\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2490, \"last_scrape\": \"2018-12-13T16:48:40\", \"url\": \"http://www.ncpe.ie/drugs/rolapitant-varuby/\", \"rr_start\": \"2017-05-15T00:00:00\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-05-15, 2017-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Rolapitant (Varuby\", \"trade_name\": \"Varuby\", \"indication\": \"Rolapitant (Varuby\", \"ncpe_year\": 2017, \"eu_market\": \"2017-04-19T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 0, \"earliest\": \"2017-05-15T00:00:00\", \"latest\": \"2017-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/varuby\", \"ta_list\": \"Vomiting; Nausea; Cancer\", \"rr_status\": \"No HTA\"}, {\"id\": 2491, \"last_scrape\": \"2018-12-13T16:48:43\", \"url\": \"http://www.ncpe.ie/drugs/romiplostim-nplate/\", \"rr_start\": \"\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Romiplostim (Nplate\", \"trade_name\": \"Nplate\", \"indication\": \"Romiplostim (Nplate\", \"ncpe_year\": 2015, \"eu_market\": \"2009-02-04T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-04-02T00:00:00\", \"latest\": \"2015-05-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nplate\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2492, \"last_scrape\": \"2018-12-13T16:48:47\", \"url\": \"http://www.ncpe.ie/drugs/ropivacaine-readyfusor/\", \"rr_start\": \"2018-11-09T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"FULL HTA IS NOT RECOMMENDED. THE NCPE RECOMMENDS THAT ROPIVICAINE READYFUSOR NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE.  THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013.\", \"rr_dates\": \"2018-11-09, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ropivacaine Readyfusor\", \"trade_name\": \"Ropivacaine Readyfusor\", \"indication\": \"Ropivacaine Readyfusor for acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block (CPNB) via a continuous infusion.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-09T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"id\": 2493, \"last_scrape\": \"2018-12-13T16:48:50\", \"url\": \"http://www.ncpe.ie/drugs/ruxolitinib-jakavi-for-polycythaemia-vera/\", \"rr_start\": \"2015-04-15T00:00:00\", \"rr_end\": \"2015-05-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-04-15, 2015-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib (Jakavi\", \"trade_name\": \"Jakavi\", \"indication\": \"Jakavi\", \"ncpe_year\": 2016, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2015-04-15T00:00:00\", \"latest\": \"2016-08-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2494, \"last_scrape\": \"2018-12-13T16:48:55\", \"url\": \"http://www.ncpe.ie/drugs/ruxolitinib-jakavi/\", \"rr_start\": \"2012-08-01T00:00:00\", \"rr_end\": \"2012-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-08-01, 2012-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib (Jakavi\", \"trade_name\": \"Jakavi\", \"indication\": \"Ruxolitinib (Jakavi\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2012-08-01T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2495, \"last_scrape\": \"2018-12-13T16:48:58\", \"url\": \"http://www.ncpe.ie/drugs/sacubitrilvalsartan-entresto/\", \"rr_start\": \"2015-11-06T00:00:00\", \"rr_end\": \"2015-11-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-06, 2015-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Sacubitril/valsartan (Entresto\", \"trade_name\": \"Entresto\", \"indication\": \"Entresto\", \"ncpe_year\": 2017, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-06T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entresto\", \"ta_list\": \"Heart Failure\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2496, \"last_scrape\": \"2018-12-13T16:49:04\", \"url\": \"http://www.ncpe.ie/drugs/safinamide-methansulfonate-xadago/\", \"rr_start\": \"2016-06-14T00:00:00\", \"rr_end\": \"2016-07-06T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED.\", \"rr_dates\": \"2016-06-14, 2016-07-06\", \"rr_multiple\": 0, \"drug_name\": \"Safinamide methansulfonate (Xadago\", \"trade_name\": \"Xadago\", \"indication\": \"Xadago\", \"ncpe_year\": 2016, \"eu_market\": \"2015-02-23T00:00:00\", \"company\": \"Zambon\", \"orphan\": 0, \"earliest\": \"2016-06-14T00:00:00\", \"latest\": \"2016-07-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xadago\", \"ta_list\": \"Parkinson Disease\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2497, \"last_scrape\": \"2018-12-13T16:49:07\", \"url\": \"http://www.ncpe.ie/drugs/sapropterin-kuvan/\", \"rr_start\": \"2015-07-14T00:00:00\", \"rr_end\": \"2015-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-07-14, 2015-08-14, 2015-07-01\", \"rr_multiple\": 1, \"drug_name\": \"Sapropterin (Kuvan\", \"trade_name\": \"Kuvan\", \"indication\": \"Sapropterin (Kuvan\", \"ncpe_year\": 2017, \"eu_market\": \"2008-12-02T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2009-01-01T00:00:00\", \"latest\": \"2017-09-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kuvan\", \"ta_list\": \"Phenylketonurias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2498, \"last_scrape\": \"2018-12-13T16:49:11\", \"url\": \"http://www.ncpe.ie/drugs/sarilumab-kevzara/\", \"rr_start\": \"2017-08-18T00:00:00\", \"rr_end\": \"2017-10-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-08-18, 2017-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Sarilumab (Kevzara\", \"trade_name\": \"Kevzara\", \"indication\": \"Sarilumab (Kevzara\", \"ncpe_year\": 2017, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-08-18T00:00:00\", \"latest\": \"2017-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2499, \"last_scrape\": \"2018-12-13T16:49:16\", \"url\": \"http://www.ncpe.ie/drugs/sebelipase-alfa-kanuma/\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-02-08, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Sebelipase alfa (Kanuma\", \"trade_name\": \"Kanuma\", \"indication\": \"Sebelipase alfa is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2018-06-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kanuma\", \"ta_list\": \"Lipid Metabolism, Inborn Errors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2500, \"last_scrape\": \"2018-12-13T16:49:20\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-ankylosing-spondylitis/\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-02, 2015-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"id\": 2501, \"last_scrape\": \"2018-12-13T16:49:25\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-psoriatic-arthritis/\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-02, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"id\": 2502, \"last_scrape\": \"2018-12-13T16:49:31\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx/\", \"rr_start\": \"2014-12-19T00:00:00\", \"rr_end\": \"2015-02-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-19, 2015-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-12-19T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2503, \"last_scrape\": \"2018-12-13T16:49:34\", \"url\": \"http://www.ncpe.ie/drugs/selexipag-uptravi/\", \"rr_start\": \"2016-11-01T00:00:00\", \"rr_end\": \"2016-12-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-01, 2016-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Selexipag (Uptravi\", \"trade_name\": \"Uptravi\", \"indication\": \"Selexipag (Uptravi\", \"ncpe_year\": 2018, \"eu_market\": \"2016-05-12T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2016-11-01T00:00:00\", \"latest\": \"2018-05-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2504, \"last_scrape\": \"2018-12-13T16:49:39\", \"url\": \"http://www.ncpe.ie/drugs/semaglutide-ozempic/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-03-12, 2018-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Semaglutide (Ozempic\", \"trade_name\": \"Ozempic\", \"indication\": \"Semaglutide (Ozempic\", \"ncpe_year\": 2018, \"eu_market\": \"2018-02-08T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-04-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2505, \"last_scrape\": \"2018-12-13T16:49:44\", \"url\": \"http://www.ncpe.ie/drugs/sildenafil-revatio/\", \"rr_start\": \"2014-04-16T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-04-16, 2014-05-23\", \"rr_multiple\": 0, \"drug_name\": \"Sildenafil (Revatio\", \"trade_name\": \"Revatio\", \"indication\": \"Sildenafil (Revatio\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2014-04-16T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revatio\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2506, \"last_scrape\": \"2018-12-13T16:49:49\", \"url\": \"http://www.ncpe.ie/drugs/simeprevir-olysio-in-combination-with-sofosbuvir/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir (Olysio\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir (Olysio\", \"ncpe_year\": 2015, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2015-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olysio\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2507, \"last_scrape\": \"2018-12-13T16:49:53\", \"url\": \"http://www.ncpe.ie/drugs/simeprevir-olysio/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED WHEN USED IN TRIPLE THERAPY WITH PEG-INTERFERON AND RIBAVIRIN.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir (Olysio\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir (Olysio\", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2014-07-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olysio\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2508, \"last_scrape\": \"2018-12-13T16:50:00\", \"url\": \"http://www.ncpe.ie/drugs/sodium-chloride-70mgml-sodium-hyaluronate-1mgml-hyaneb/\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-10, 2014-03-19\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml (Hyaneb\", \"trade_name\": \"Hyaneb\", \"indication\": \"Hyaneb\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2509, \"last_scrape\": \"2018-12-13T16:50:06\", \"url\": \"http://www.ncpe.ie/drugs/sodium-hyaluronate-hyloforte-0-2/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate (Hyloforte\", \"trade_name\": \"Hyloforte 0.2%\", \"indication\": \"Sodium Hyaluronate (Hyloforte\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2510, \"last_scrape\": \"2018-12-13T16:50:09\", \"url\": \"http://www.ncpe.ie/drugs/sodium-hyaluronate-hylotear-0-1/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate (Hylotear\", \"trade_name\": \"Hylotear 0.1%\", \"indication\": \"Sodium Hyaluronate (Hylotear\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2511, \"last_scrape\": \"2018-12-13T16:50:15\", \"url\": \"http://www.ncpe.ie/drugs/sodium-phenylbutyrate-pheburane/\", \"rr_start\": \"2013-07-17T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-17, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Sodium phenylbutyrate (Pheburane\", \"trade_name\": \"Pheburane\", \"indication\": \"Sodium phenylbutyrate (Pheburane\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-30T00:00:00\", \"company\": \"Lucane\", \"orphan\": 0, \"earliest\": \"2013-07-17T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pheburane\", \"ta_list\": \"Carbamoyl-Phosphate Synthase I Deficiency Disease\", \"rr_status\": \"No HTA\"}, {\"id\": 2512, \"last_scrape\": \"2018-12-13T16:50:18\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvir-solvaldi/\", \"rr_start\": \"2014-02-12T00:00:00\", \"rr_end\": \"2014-03-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-02-12, 2014-03-10\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir (Solvaldi\", \"trade_name\": \"Solvaldi\", \"indication\": \"Sofosbuvir (Solvaldi\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-02-12T00:00:00\", \"latest\": \"2014-10-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2513, \"last_scrape\": \"2018-12-13T16:50:22\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvirvelpatasvir-epclusa-chronic-hepatitis-c-virus-hcv-pangenotypic/\", \"rr_start\": \"2017-09-05T00:00:00\", \"rr_end\": \"2017-10-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-05, 2017-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir (Epclusa\", \"trade_name\": \"Epclusa\", \"indication\": \"Sofosbuvir/velpatasvir (Epclusa\", \"ncpe_year\": 2017, \"eu_market\": \"2016-07-06T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-05T00:00:00\", \"latest\": \"2017-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2514, \"last_scrape\": \"2018-12-13T16:50:26\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvirvelpatasvirvoxilaprevir-vosevi/\", \"rr_start\": \"2017-09-19T00:00:00\", \"rr_end\": \"2017-11-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-19, 2017-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi\", \"trade_name\": \"Vosevi\", \"indication\": \"Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-19T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vosevi\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2515, \"last_scrape\": \"2018-12-13T16:50:32\", \"url\": \"http://www.ncpe.ie/drugs/st-johns-wort-pafica/\", \"rr_start\": \"2015-04-14T00:00:00\", \"rr_end\": \"2015-05-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-04-14, 2015-05-29\", \"rr_multiple\": 0, \"drug_name\": \"St Johns Wort (Pacifa\", \"trade_name\": \"Pacifa\", \"indication\": \"Pacifa\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-04-14T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2516, \"last_scrape\": \"2018-12-13T16:50:38\", \"url\": \"http://www.ncpe.ie/drugs/stiripentol-diacomit/\", \"rr_start\": \"2017-07-06T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-06, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Stiripentol (Diacomit\", \"trade_name\": \"Diacomit\", \"indication\": \"Stiripentol (Diacomit\", \"ncpe_year\": 2018, \"eu_market\": \"2007-01-03T00:00:00\", \"company\": \"Biocodex\", \"orphan\": 1, \"earliest\": \"2017-07-06T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/diacomit\", \"ta_list\": \"Myoclonic Epilepsy, Juvenile\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2517, \"last_scrape\": \"2018-12-13T16:50:43\", \"url\": \"http://www.ncpe.ie/drugs/stribild-elvitegravircobicistatemtricitabinetenofovir-disoproxil-as-fumarate/\", \"rr_start\": \"2013-04-28T00:00:00\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-04-28, 2013-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumarate)(Stribild\", \"trade_name\": \"Stribild\", \"indication\": \"Indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-na\", \"ncpe_year\": 2013, \"eu_market\": \"2013-05-24T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2013-04-28T00:00:00\", \"latest\": \"2013-12-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stribild\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2518, \"last_scrape\": \"2018-12-13T16:50:49\", \"url\": \"http://www.ncpe.ie/drugs/sublingual-immunotherapy-grazax/\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sublingual Immunotherapy (Grazax\", \"trade_name\": \"Grazax\", \"indication\": \"A Review of the Cost-Effectiveness of Sublingual Immunotherapy (Grazax\", \"ncpe_year\": 2007, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2007-09-01T00:00:00\", \"latest\": \"2007-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2519, \"last_scrape\": \"2018-12-13T16:50:50\", \"url\": \"http://www.ncpe.ie/drugs/suboxone-buprenorphinenaloxone/\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Buprenorphine/naloxone (Suboxone\", \"trade_name\": \"Suboxone\", \"indication\": \"An economic evaluation of suboxone for the management of opiate addiction.\", \"ncpe_year\": 2014, \"eu_market\": \"2006-09-26T00:00:00\", \"company\": \"Indivior\", \"orphan\": 0, \"earliest\": \"2007-11-01T00:00:00\", \"latest\": \"2014-05-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/suboxone\", \"ta_list\": \"Opioid-Related Disorders\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2520, \"last_scrape\": \"2018-12-13T16:50:54\", \"url\": \"http://www.ncpe.ie/drugs/sufentanil-zalviso/\", \"rr_start\": \"2016-03-14T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-03-14, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Sufentanil (Zalviso\", \"trade_name\": \"Zalviso\", \"indication\": \"Sufentanil (Zalviso\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Gr\", \"orphan\": 0, \"earliest\": \"2016-03-14T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zalviso\", \"ta_list\": \"Pain, Postoperative\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2521, \"last_scrape\": \"2018-12-13T16:50:59\", \"url\": \"http://www.ncpe.ie/drugs/sunitinib-sutent/\", \"rr_start\": \"\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sunitinib (Sutent\", \"trade_name\": \"Sutent\", \"indication\": \"In September 2006, Pfizer Healthcare Ireland submitted an evaluation of the cost-effectiveness and budget impact of sunitinib as second-line treatment of patients with gastro-intestinal stromal tumours (GIST). Data on the cost-effectiveness and budget impact of sutinitinib as second line treatment for patients with metastatic renal cell carcinoma (mRCC) was also presented. The purpose of the submission was to support an application for reimbursement under the High Tech Drug Scheme. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-07-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-09-01T00:00:00\", \"latest\": \"2006-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sutent\", \"ta_list\": \"Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2522, \"last_scrape\": \"2018-12-13T16:51:04\", \"url\": \"http://www.ncpe.ie/drugs/tadalafil-adcirca-2/\", \"rr_start\": \"2011-07-13T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-07-13, 2011-09-21, 2014-05-09, 2014-05-23\", \"rr_multiple\": 1, \"drug_name\": \"Tadalafil (Adcirca\", \"trade_name\": \"Adcirca\", \"indication\": \"Tadalafil (Adcirca\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-07-13T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2523, \"last_scrape\": \"2018-12-13T16:51:09\", \"url\": \"http://www.ncpe.ie/drugs/tafamadis-meglumine-vyndaqel/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED UNTIL ADDITIONAL EFFICACY AND/OR SAFETY DATA IS SUBMITTED. ON THE BASIS OF CURRENT EVIDENCE, THE NCPE RECOMMENDS THAT TAFAMIDIS NOT BE CONSIDERED FOR REIMBURSEMENT IN ACCORDANCE WITH THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Tafamadis meglumine (Vyndaqel\", \"trade_name\": \"Vyndaqel\", \"indication\": \"Tafamadis meglumine (Vyndaqel\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-16T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel\", \"ta_list\": \"Amyloidosis\", \"rr_status\": \"No HTA until more evidence\"}, {\"id\": 2524, \"last_scrape\": \"2018-12-13T16:51:15\", \"url\": \"http://www.ncpe.ie/drugs/tafluprost-saflutan/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Tafluprost (Saflutan\", \"trade_name\": \"Saflutan\", \"indication\": \"Tafluoprost (Salflutan\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2525, \"last_scrape\": \"2018-12-13T16:51:24\", \"url\": \"http://www.ncpe.ie/drugs/talimogene-laherparepvec-imlygic/\", \"rr_start\": \"2016-02-16T00:00:00\", \"rr_end\": \"2016-03-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-02-16, 2016-03-14\", \"rr_multiple\": 0, \"drug_name\": \"Talimogene Laherparepvec (Imlygic\", \"trade_name\": \"Imlygic\", \"indication\": \"Talimogene laherparepvec (Imlygic\", \"ncpe_year\": 2016, \"eu_market\": \"2015-12-16T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-02-16T00:00:00\", \"latest\": \"2016-03-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2526, \"last_scrape\": \"2018-12-13T16:51:28\", \"url\": \"http://www.ncpe.ie/drugs/tapentadol-palexia/\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Tapentadol (Palexia\", \"trade_name\": \"Palexia\", \"indication\": \"Economic evaluation of oral tapentadol (Palexia\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2011-04-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2527, \"last_scrape\": \"2018-12-13T16:51:34\", \"url\": \"http://www.ncpe.ie/drugs/tedizolid-phosphate-sivextro/\", \"rr_start\": \"2015-05-07T00:00:00\", \"rr_end\": \"2015-07-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-05-07, 2015-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Tedizolid phosphate (Sivextro\", \"trade_name\": \"Sivextro\", \"indication\": \"Tedizolid phosphate (Sivextro\", \"ncpe_year\": 2015, \"eu_market\": \"2015-03-23T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-05-07T00:00:00\", \"latest\": \"2015-07-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sivextro\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"No HTA\"}, {\"id\": 2528, \"last_scrape\": \"2018-12-13T16:51:38\", \"url\": \"http://www.ncpe.ie/drugs/teduglutide-revestive/\", \"rr_start\": \"2017-03-13T00:00:00\", \"rr_end\": \"2017-04-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-13, 2017-04-12\", \"rr_multiple\": 0, \"drug_name\": \"Teduglutide (Revestive\", \"trade_name\": \"Revestive\", \"indication\": \"Teduglutide (Revestive\", \"ncpe_year\": 2018, \"eu_market\": \"2012-08-30T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2017-03-13T00:00:00\", \"latest\": \"2018-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revestive\", \"ta_list\": \"Malabsorption Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2529, \"last_scrape\": \"2018-12-13T16:51:44\", \"url\": \"http://www.ncpe.ie/drugs/tegafurgimeraciloteracil-teysuno/\", \"rr_start\": \"2012-02-27T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-02-27, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Tegafur/Gimeracil/Oteracil (Teysuno\", \"trade_name\": \"Teysuno\", \"indication\": \"Teysuno is indicated in adults for the treatment of advanced gastric cancer.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-03-14T00:00:00\", \"company\": \"Nordic\", \"orphan\": 0, \"earliest\": \"2012-02-27T00:00:00\", \"latest\": \"2012-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2530, \"last_scrape\": \"2018-12-13T16:51:48\", \"url\": \"http://www.ncpe.ie/drugs/telapravir/\", \"rr_start\": \"2011-10-28T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-10-28, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Telaprevir (Incivo\", \"trade_name\": \"Incivo\", \"indication\": \"Economic evaluation of Telaprevir (Incivo\", \"ncpe_year\": 2012, \"eu_market\": \"2011-09-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-28T00:00:00\", \"latest\": \"2012-01-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/incivo\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2531, \"last_scrape\": \"2018-12-13T16:51:52\", \"url\": \"http://www.ncpe.ie/drugs/telavancin-vibativ/\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-12-08, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Telavancin (Vibativ\", \"trade_name\": \"Vibativ\", \"indication\": \"Indicated for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumomia, known or suspended to be caused by methicillin-resistant Staphylococcus aureas (MRSA).  Vabitiv\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Theravance\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2015-01-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vibativ-0\", \"ta_list\": \"Pneumonia, Bacterial; Cross Infection\", \"rr_status\": \"No HTA\"}, {\"id\": 2532, \"last_scrape\": \"2018-12-13T16:51:56\", \"url\": \"http://www.ncpe.ie/drugs/teriflunomide-aubagio/\", \"rr_start\": \"2013-08-27T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-08-27, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Teriflunomide (Aubagio\", \"trade_name\": \"Aubagio\", \"indication\": \"Aubagio\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2013-08-27T00:00:00\", \"latest\": \"2014-09-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2533, \"last_scrape\": \"2018-12-13T16:51:58\", \"url\": \"http://www.ncpe.ie/drugs/ticagrelor-brilique-2/\", \"rr_start\": \"2016-02-29T00:00:00\", \"rr_end\": \"2016-05-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-29, 2016-05-04\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor (Brilique\", \"trade_name\": \"Brilique\", \"indication\": \"Ticagrelor (Brilique\", \"ncpe_year\": 2016, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-29T00:00:00\", \"latest\": \"2016-05-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brilique\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2534, \"last_scrape\": \"2018-12-13T16:52:01\", \"url\": \"http://www.ncpe.ie/drugs/ticagrelor-brilique/\", \"rr_start\": \"2010-11-25T00:00:00\", \"rr_end\": \"2011-01-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-11-25, 2011-01-20\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor (Brilique\", \"trade_name\": \"Brilique\", \"indication\": \"Economic Evaluation of Ticagrelor (Brilique\", \"ncpe_year\": 2011, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-11-25T00:00:00\", \"latest\": \"2011-10-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brilique\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2535, \"last_scrape\": \"2018-12-13T16:52:07\", \"url\": \"http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-all/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-19T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TISAGENLECLEUCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel (Kymriah\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel (Kymriah\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2536, \"last_scrape\": \"2018-12-13T16:52:13\", \"url\": \"http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-dlbcl/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TISAGENLECLEUCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel (Kymriah\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel (Kymriah\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2537, \"last_scrape\": \"2018-12-13T16:52:19\", \"url\": \"http://www.ncpe.ie/drugs/tobramycin-tobi-podhaler/\", \"rr_start\": \"2010-11-10T00:00:00\", \"rr_end\": \"2010-11-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2010-11-10, 2010-11-03\", \"rr_multiple\": 0, \"drug_name\": \"Tobramycin (TOBI Podhaler\", \"trade_name\": \"TOBI Podhaler\", \"indication\": \"Tobramycin (TOBI Podhaler\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-11-01T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2538, \"last_scrape\": \"2018-12-13T16:52:24\", \"url\": \"http://www.ncpe.ie/drugs/tocilizumab-sc-roactemra/\", \"rr_start\": \"2014-04-28T00:00:00\", \"rr_end\": \"2014-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THESUBMITTED PRICE.\", \"rr_dates\": \"2014-04-28, 2014-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Tocilizumab SC (RoActemra\", \"trade_name\": \"RoActemra\", \"indication\": \"It is licensed for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.  It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-04-28T00:00:00\", \"latest\": \"2014-07-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra\", \"ta_list\": \"Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2539, \"last_scrape\": \"2018-12-13T16:52:30\", \"url\": \"http://www.ncpe.ie/drugs/tofacitinib-xeljanz-for-ulcerative-colitis/\", \"rr_start\": \"2018-07-16T00:00:00\", \"rr_end\": \"2018-09-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TOFACITINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-07-16, 2018-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib (Xeljanz\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy (i.e. corticosteroids, azathioprine, 6-mercaptopurine) or a biologic agent (i.e. TNF inhibitor).\", \"ncpe_year\": 2018, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2018-07-16T00:00:00\", \"latest\": \"2018-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2540, \"last_scrape\": \"2018-12-13T16:52:35\", \"url\": \"http://www.ncpe.ie/drugs/tofacitinib-xeljanz/\", \"rr_start\": \"2017-03-08T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-08, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib (Xeljanz\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib (Xeljanz\", \"ncpe_year\": 2017, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-03-08T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2541, \"last_scrape\": \"2018-12-13T16:52:40\", \"url\": \"http://www.ncpe.ie/drugs/tolvaptan-jinarc/\", \"rr_start\": \"2016-01-04T00:00:00\", \"rr_end\": \"2016-01-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-04, 2016-01-12\", \"rr_multiple\": 0, \"drug_name\": \"Tolvaptan (Jinarc\", \"trade_name\": \"Jinarc\", \"indication\": \"Jinarc\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2016-01-04T00:00:00\", \"latest\": \"2018-09-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc\", \"ta_list\": \"Polycystic Kidney, Autosomal Dominant\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2542, \"last_scrape\": \"2018-12-13T16:52:45\", \"url\": \"http://www.ncpe.ie/drugs/tramadol-hydrochloridedexketoprofen-skudexa/\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"REIMURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-10-17, 2017-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Tramadol hydrochloride/dexketoprofen (Skudexa\", \"trade_name\": \"Skudexa\", \"indication\": \"Tramadol hydrochloride/dexketoprofen (Skudexa \", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2017-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2543, \"last_scrape\": \"2018-12-13T16:52:51\", \"url\": \"http://www.ncpe.ie/drugs/trametinib-mekinist/\", \"rr_start\": \"2015-11-27T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-27, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Trametinib (Mekinist\", \"trade_name\": \"Mekinist\", \"indication\": \"Mekinist\", \"ncpe_year\": 2018, \"eu_market\": \"2014-06-30T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-27T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2544, \"last_scrape\": \"2018-12-13T16:52:56\", \"url\": \"http://www.ncpe.ie/drugs/trastuzumab-emtansine-kadcyla/\", \"rr_start\": \"2013-09-25T00:00:00\", \"rr_end\": \"2013-10-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-25, 2013-10-24\", \"rr_multiple\": 0, \"drug_name\": \"Trastuzumab emtansine (Kadcyla\", \"trade_name\": \"Kadcyla\", \"indication\": \"Trastuzumab emtansine (Kadcyla\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-09-25T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2545, \"last_scrape\": \"2018-12-13T16:53:00\", \"url\": \"http://www.ncpe.ie/drugs/trifluridinetipiracil-lonsurf/\", \"rr_start\": \"2016-06-10T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-06-10, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Trifluridine/tipiracil (Lonsurf\", \"trade_name\": \"Lonsurf\", \"indication\": \"Trifluridine/tipiracil (Lonsurf\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2016-06-10T00:00:00\", \"latest\": \"2016-07-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2546, \"last_scrape\": \"2018-12-13T16:53:04\", \"url\": \"http://www.ncpe.ie/drugs/ulipristal-acetate-esmya-2/\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-05-17, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate (Esmya \", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate is indicated for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-05-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esmya\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2547, \"last_scrape\": \"2018-12-13T16:53:08\", \"url\": \"http://www.ncpe.ie/drugs/ulipristal-acetate-esmya/\", \"rr_start\": \"2013-09-03T00:00:00\", \"rr_end\": \"2013-10-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-09-03, 2013-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate (Esmya\", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate (Esmya\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2013-09-03T00:00:00\", \"latest\": \"2013-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esmya\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2548, \"last_scrape\": \"2018-12-13T16:53:10\", \"url\": \"http://www.ncpe.ie/drugs/umeclidiniumvilanterol-anoro/\", \"rr_start\": \"2014-06-11T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-06-11, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Umeclidinium/vilanterol (Anoro\", \"trade_name\": \"Anoro\", \"indication\": \"Umeclidinium/vilanterol (Anoro\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-06-11T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2549, \"last_scrape\": \"2018-12-13T16:53:12\", \"url\": \"http://www.ncpe.ie/drugs/urea-glucorx-allpresan/\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT GLUCORX ALLPRESAN DIABETIC FOAM CREAM NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE IN ACCORDANCE WITH THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2018-07-09, 2018-07-24\", \"rr_multiple\": 0, \"drug_name\": \"Urea (GlucoRx Allpresan\", \"trade_name\": \"GlucoRx Allpresan\", \"indication\": \"GlucoRx Allpresan\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-07-24T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2550, \"last_scrape\": \"2018-12-13T16:53:17\", \"url\": \"http://www.ncpe.ie/drugs/ustekinumab-stelara-2/\", \"rr_start\": \"2016-11-28T00:00:00\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-11-28, 2017-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab (Stelara\", \"trade_name\": \"Stelara\", \"indication\": \"Ustekinumab is indicated for the treatment of adult patients with moderately to severely active Crohn\", \"ncpe_year\": 2017, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2016-11-28T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stelara\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2551, \"last_scrape\": \"2018-12-13T16:53:23\", \"url\": \"http://www.ncpe.ie/drugs/ustekinumab-stelara/\", \"rr_start\": \"\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab (Stelara\", \"trade_name\": \"Stelara\", \"indication\": \"Cost-effectiveness of Ustekinumab (Stelara\", \"ncpe_year\": 2009, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2009-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stelara\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2552, \"last_scrape\": \"2018-12-13T16:53:29\", \"url\": \"http://www.ncpe.ie/drugs/vandetanib-caprelsa/\", \"rr_start\": \"2013-06-06T00:00:00\", \"rr_end\": \"2013-07-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-06, 2013-07-03\", \"rr_multiple\": 0, \"drug_name\": \"Vandetanib (Caprelsa\", \"trade_name\": \"Caprelsa\", \"indication\": \"Vandetanib (Caprelsa\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-16T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2013-06-06T00:00:00\", \"latest\": \"2013-07-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2553, \"last_scrape\": \"2018-12-13T16:53:32\", \"url\": \"http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-crohns-disease/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab (Entyvio\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab (Entyvio\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2554, \"last_scrape\": \"2018-12-13T16:53:39\", \"url\": \"http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-ulcerative-colitis/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab (Entyvio\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab (Entyvio\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2555, \"last_scrape\": \"2018-12-13T16:53:45\", \"url\": \"http://www.ncpe.ie/drugs/velaglucerase-alfa-vpriv-2/\", \"rr_start\": \"2011-04-26T00:00:00\", \"rr_end\": \"2011-06-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-04-26, 2011-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Velaglucerase Alfa (VPRIV\", \"trade_name\": \"VPRIV\", \"indication\": \"VPRIV is indicated for long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-04-26T00:00:00\", \"latest\": \"2011-06-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2556, \"last_scrape\": \"2018-12-13T16:53:49\", \"url\": \"http://www.ncpe.ie/drugs/venetoclax-venclyxto-in-combination-with-rituximab/\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF VENETOCLAX COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-26, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax (Venclyxto\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax (Venclyxto\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2557, \"last_scrape\": \"2018-12-13T16:53:52\", \"url\": \"http://www.ncpe.ie/drugs/venetoclax-venclyxto/\", \"rr_start\": \"2018-05-08T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"FOLLOWING A RESUBMISSION OF THE RAPID REVIEW A FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, WHICH IS NOT COMPARABLE WITH CURRENT AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-05-08, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax (Venclyxto\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL)\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2558, \"last_scrape\": \"2018-12-13T16:53:58\", \"url\": \"http://www.ncpe.ie/drugs/vermurafenib-zelboraf/\", \"rr_start\": \"2011-12-23T00:00:00\", \"rr_end\": \"2012-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-12-23, 2012-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Vemurafenib (Zelboraf\", \"trade_name\": \"Zelboraf\", \"indication\": \"Vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\", \"ncpe_year\": 2014, \"eu_market\": \"2012-02-17T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2011-12-23T00:00:00\", \"latest\": \"2014-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2559, \"last_scrape\": \"2018-12-13T16:54:00\", \"url\": \"http://www.ncpe.ie/drugs/vernakalant-brinavess/\", \"rr_start\": \"2010-10-26T00:00:00\", \"rr_end\": \"2010-11-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-10-26, 2010-11-04\", \"rr_multiple\": 0, \"drug_name\": \"Vernakalant (Brinavess\", \"trade_name\": \"Brinavess\", \"indication\": \"Economic evaluation of Vernakalant (Brinavess\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Cardiome\", \"orphan\": 0, \"earliest\": \"2010-10-26T00:00:00\", \"latest\": \"2011-05-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2560, \"last_scrape\": \"2018-12-13T16:54:04\", \"url\": \"http://www.ncpe.ie/drugs/vismodegib-erivedge/\", \"rr_start\": \"2013-05-02T00:00:00\", \"rr_end\": \"2013-05-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-05-02, 2013-05-20\", \"rr_multiple\": 0, \"drug_name\": \"Vismodegib (Erivedge\", \"trade_name\": \"Erivedge\", \"indication\": \"Vismodegib (Erivedge\", \"ncpe_year\": 2017, \"eu_market\": \"2013-07-12T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-05-02T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge\", \"ta_list\": \"Carcinoma, Basal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2561, \"last_scrape\": \"2018-12-13T16:54:11\", \"url\": \"http://www.ncpe.ie/drugs/vortioxetine-brintellix/\", \"rr_start\": \"2014-10-01T00:00:00\", \"rr_end\": \"2014-11-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-10-01, 2014-11-14\", \"rr_multiple\": 0, \"drug_name\": \"Vortioxetine (Brintellix\", \"trade_name\": \"Brintellix\", \"indication\": \"Vortioxetine (Brintellix\", \"ncpe_year\": 2017, \"eu_market\": \"2013-12-18T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2014-10-01T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"HTA recommended at submitted price\"}]}};\n",
       "var opt = {};\n",
       "var type = \"vega-lite\";\n",
       "var id = \"b2d16295-5544-41aa-ad0b-8ab0f23449bd\";\n",
       "\n",
       "var output_area = this;\n",
       "\n",
       "require([\"nbextensions/jupyter-vega/index\"], function(vega) {\n",
       "  var target = document.createElement(\"div\");\n",
       "  target.id = id;\n",
       "  target.className = \"vega-embed\";\n",
       "\n",
       "  var style = document.createElement(\"style\");\n",
       "  style.textContent = [\n",
       "    \".vega-embed .error p {\",\n",
       "    \"  color: firebrick;\",\n",
       "    \"  font-size: 14px;\",\n",
       "    \"}\",\n",
       "  ].join(\"\\\\n\");\n",
       "\n",
       "  // element is a jQuery wrapped DOM element inside the output area\n",
       "  // see http://ipython.readthedocs.io/en/stable/api/generated/\\\n",
       "  // IPython.display.html#IPython.display.Javascript.__init__\n",
       "  element[0].appendChild(target);\n",
       "  element[0].appendChild(style);\n",
       "\n",
       "  vega.render(\"#\" + id, spec, type, opt, output_area);\n",
       "}, function (err) {\n",
       "  if (err.requireType !== \"scripterror\") {\n",
       "    throw(err);\n",
       "  }\n",
       "});\n"
      ],
      "text/plain": [
       "<vega.vegalite.VegaLite at 0x24581df6908>"
      ]
     },
     "metadata": {
      "jupyter-vega": "#b2d16295-5544-41aa-ad0b-8ab0f23449bd"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": []
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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"
     },
     "metadata": {
      "jupyter-vega": "#b2d16295-5544-41aa-ad0b-8ab0f23449bd"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "warnings.filterwarnings('ignore')\n",
    "alt.Chart(drugs,title=\"Count Drugs by NCPE Year\").mark_bar().encode(\n",
    "    alt.X('ncpe_year:O',axis=alt.Axis(title='NCPE Year')),    \n",
    "    alt.Y('count(id)', title=\"Count\")).properties(width=700,height=400)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 2.2 Count Drugs by NCPE Year with Status\n",
    "The total number of drugs by year with status highlighted using colour variation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "var spec = {\"config\": {\"view\": {\"width\": 400, \"height\": 300}}, \"data\": {\"name\": \"data-1fb11c1b30e9c74b6a5173f2568cb7ab\"}, \"mark\": \"bar\", \"encoding\": {\"color\": {\"type\": \"nominal\", \"field\": \"rr_status\", \"title\": \"Status\"}, \"x\": {\"type\": \"ordinal\", \"axis\": {\"title\": \"NCPE Year\"}, \"field\": \"ncpe_year\"}, \"y\": {\"type\": \"nominal\", \"aggregate\": \"count\", \"field\": \"rr_status\", \"title\": \"Count\"}}, \"height\": 400, \"title\": \"Count Drugs by NCPE Year with Status\", \"width\": 700, \"$schema\": \"https://vega.github.io/schema/vega-lite/v2.6.0.json\", \"datasets\": {\"data-1fb11c1b30e9c74b6a5173f2568cb7ab\": [{\"id\": 2164, \"last_scrape\": \"2018-12-13T16:24:32\", \"url\": \"http://www.ncpe.ie/drugs/abatacept-orencia/\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Abatacept (Orencia\", \"trade_name\": \"Orencia\", \"indication\": \"Subcutaneous Abatacept (Orencia\", \"ncpe_year\": 2015, \"eu_market\": \"2007-05-21T00:00:00\", \"company\": \"\", \"orphan\": 0, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/orencia\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2165, \"last_scrape\": \"2018-12-13T16:24:36\", \"url\": \"http://www.ncpe.ie/drugs/abiraterone-acetate-zytiga-for-mhspc/\", \"rr_start\": \"2018-10-03T00:00:00\", \"rr_end\": \"2018-11-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-10-03, 2018-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Abiraterone acetate (Zytiga\", \"ncpe_year\": 2018, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2018-10-03T00:00:00\", \"latest\": \"2018-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2166, \"last_scrape\": \"2018-12-13T16:24:41\", \"url\": \"http://www.ncpe.ie/drugs/abiratone-acetate-zytiga-for-mcrpc-post-adt/\", \"rr_start\": \"2013-01-03T00:00:00\", \"rr_end\": \"2013-02-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-01-03, 2013-02-01\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation of Abiratone acetate (Zytiga\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-01-03T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2167, \"last_scrape\": \"2018-12-13T16:24:46\", \"url\": \"http://www.ncpe.ie/drugs/abiratone-acetate-zytiga/\", \"rr_start\": \"2011-10-21T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-10-21, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone Acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation and resource implications of Zytiga \", \"ncpe_year\": 2014, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-21T00:00:00\", \"latest\": \"2014-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2168, \"last_scrape\": \"2018-12-13T16:24:49\", \"url\": \"http://www.ncpe.ie/drugs/aceclofenac-vitafen/\", \"rr_start\": \"2016-12-21T00:00:00\", \"rr_end\": \"2017-01-24T00:00:00\", \"rr_outcome\": \"FOLLOWING A RESUBMISSION OF THE RAPID REVIEW A FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-12-21, 2017-01-24\", \"rr_multiple\": 0, \"drug_name\": \"Aceclofenac (Vitafen\", \"trade_name\": \"Vitafen\", \"indication\": \"Aceclofenac (Vitafen\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-07-22T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2169, \"last_scrape\": \"2018-12-13T16:24:56\", \"url\": \"http://www.ncpe.ie/drugs/aclidinium-bromide-eklira-genuair/\", \"rr_start\": \"2012-10-23T00:00:00\", \"rr_end\": \"2012-10-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-23, 2012-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide (Eklira Genuair\", \"trade_name\": \"Eklira Genuair\", \"indication\": \"Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)\", \"ncpe_year\": 2012, \"eu_market\": \"2012-07-20T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-23T00:00:00\", \"latest\": \"2012-10-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"id\": 2170, \"last_scrape\": \"2018-12-13T16:25:00\", \"url\": \"http://www.ncpe.ie/drugs/aclidinium-bromide-formoterol-fumarate-dihydrate-brimica-genuair/\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE.\", \"rr_dates\": \"2015-01-05, 2015-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide / formoterol fumarate dihydrate (Brimica\", \"trade_name\": \"Brimica Genuair\", \"indication\": \"Brimica\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2015-02-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brimica-genuair\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2171, \"last_scrape\": \"2018-12-13T16:25:37\", \"url\": \"http://www.ncpe.ie/drugs/adalimumab-humira/\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-20, 2011-06-02\", \"rr_multiple\": 0, \"drug_name\": \"Adalimumab (Humira\", \"trade_name\": \"Humira\", \"indication\": \"Economic evaluation of Adalimumab (Humira\", \"ncpe_year\": 2011, \"eu_market\": \"2003-09-07T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/humira\", \"ta_list\": \"Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"id\": 2172, \"last_scrape\": \"2018-12-13T16:25:40\", \"url\": \"http://www.ncpe.ie/drugs/adenuric-febuxostat/\", \"rr_start\": \"2009-12-08T00:00:00\", \"rr_end\": \"2009-12-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-12-08\", \"rr_multiple\": 0, \"drug_name\": \"Adenuric (Febuxostat\", \"trade_name\": \"Febuxostat\", \"indication\": \"NCPE review of Adenuric (Febuxostat\", \"ncpe_year\": 2009, \"eu_market\": \"2008-04-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2009-12-08T00:00:00\", \"latest\": \"2009-12-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adenuric\", \"ta_list\": \"Gout\", \"rr_status\": \"No HTA\"}, {\"id\": 2173, \"last_scrape\": \"2018-12-13T16:25:45\", \"url\": \"http://www.ncpe.ie/drugs/afatinib-giotrif/\", \"rr_start\": \"2013-10-01T00:00:00\", \"rr_end\": \"2013-10-13T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-10-01, 2013-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Afatinib (Giotrif\", \"trade_name\": \"Giotrif\", \"indication\": \"GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-na\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-25T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2013-10-01T00:00:00\", \"latest\": \"2013-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2174, \"last_scrape\": \"2018-12-13T16:25:49\", \"url\": \"http://www.ncpe.ie/drugs/aflibercept-eylea/\", \"rr_start\": \"2012-12-10T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-10, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept (Eylea\", \"trade_name\": \"Eylea\", \"indication\": \"Aflibercept (Eylea\", \"ncpe_year\": 2012, \"eu_market\": \"2012-11-21T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2012-12-10T00:00:00\", \"latest\": \"2012-12-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eylea\", \"ta_list\": \"Wet Macular Degeneration; Macular Edema; Diabetes Complications\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2175, \"last_scrape\": \"2018-12-13T16:25:52\", \"url\": \"http://www.ncpe.ie/drugs/aflibercept-zaltrap/\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept (Zaltrap\", \"trade_name\": \"Zaltrap\", \"indication\": \"Aflibercept for the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-01T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-02-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zaltrap\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2176, \"last_scrape\": \"2018-12-13T16:25:58\", \"url\": \"http://www.ncpe.ie/drugs/agomelatine-valdoxan-4/\", \"rr_start\": \"\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Agomelatine (Valdoxan\", \"trade_name\": \"Valdoxan\", \"indication\": \"Economic evaluation of Agomelatine (Valdoxan\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-19T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2009-09-03T00:00:00\", \"latest\": \"2009-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/valdoxan\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2177, \"last_scrape\": \"2018-12-13T16:26:06\", \"url\": \"http://www.ncpe.ie/drugs/alectinib-alecensa/\", \"rr_start\": \"2017-01-03T00:00:00\", \"rr_end\": \"2017-12-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-01-03, 2017-02-27, 2017-11-08, 2017-12-04\", \"rr_multiple\": 1, \"drug_name\": \"Alectinib (Alecensa\", \"trade_name\": \"Alecensa\", \"indication\": \"Alectinib (Alecensa \", \"ncpe_year\": 2018, \"eu_market\": \"2017-02-16T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2178, \"last_scrape\": \"2018-12-13T16:26:12\", \"url\": \"http://www.ncpe.ie/drugs/alemtuzumab-lemtrada/\", \"rr_start\": \"2013-11-08T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-11-08, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Alemtuzumab (Lemtrada\", \"trade_name\": \"Lemtrada\", \"indication\": \"Alemtuzumab (Lemtrada\", \"ncpe_year\": 2014, \"eu_market\": \"2013-09-12T00:00:00\", \"company\": \"Sanofi\", \"orphan\": 0, \"earliest\": \"2013-11-08T00:00:00\", \"latest\": \"2014-06-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2179, \"last_scrape\": \"2018-12-13T16:26:14\", \"url\": \"http://www.ncpe.ie/drugs/alirocumab-praluent/\", \"rr_start\": \"2015-10-13T00:00:00\", \"rr_end\": \"2015-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-10-13, 2015-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Alirocumab (Praluent\", \"trade_name\": \"Praluent\", \"indication\": \"Praluent\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2015-10-13T00:00:00\", \"latest\": \"2018-03-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/praluent\", \"ta_list\": \"Dyslipidemias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2180, \"last_scrape\": \"2018-12-13T16:26:16\", \"url\": \"http://www.ncpe.ie/drugs/alogliptin-vipidia/\", \"rr_start\": \"2013-09-27T00:00:00\", \"rr_end\": \"2013-10-30T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-09-27, 2013-10-30\", \"rr_multiple\": 0, \"drug_name\": \"Alogliptin (Vipidia\", \"trade_name\": \"Vipidia\", \"indication\": \"Alogliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-18T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2013-09-27T00:00:00\", \"latest\": \"2013-10-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vipidia\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2181, \"last_scrape\": \"2018-12-13T16:26:21\", \"url\": \"http://www.ncpe.ie/drugs/ambrisentan-volibris/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-05-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Ambrisentan (Volibris\", \"trade_name\": \"Volibris\", \"indication\": \"Cost Effectiveness of ambrisentan (Volibris\", \"ncpe_year\": 2014, \"eu_market\": \"2008-04-20T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 1, \"earliest\": \"2008-10-01T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/volibris\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2182, \"last_scrape\": \"2018-12-13T16:26:23\", \"url\": \"http://www.ncpe.ie/drugs/amifampridine-firdapse/\", \"rr_start\": \"2011-11-07T00:00:00\", \"rr_end\": \"2011-12-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-11-07, 2011-12-09\", \"rr_multiple\": 0, \"drug_name\": \"Amifampridine (Firdapse\", \"trade_name\": \"Firdapse\", \"indication\": \"For Lambert Eaton Myasthenic Syndrome (LEMS).  This high cost drug is likely to require a full HTA due to significant budget impact.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-11-07T00:00:00\", \"latest\": \"2011-12-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2183, \"last_scrape\": \"2018-12-13T16:26:29\", \"url\": \"http://www.ncpe.ie/drugs/amsacrine-amsidine/\", \"rr_start\": \"2017-01-10T00:00:00\", \"rr_end\": \"2017-02-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-01-10, 2017-02-15\", \"rr_multiple\": 0, \"drug_name\": \"Amsacrine (Amsidine\", \"trade_name\": \"Amsidine\", \"indication\": \"Amsidine\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2017-01-10T00:00:00\", \"latest\": \"2017-02-15T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2184, \"last_scrape\": \"2018-12-13T16:26:35\", \"url\": \"http://www.ncpe.ie/drugs/apixaban-eliquis-for-treatment-of-deep-vein-thrombosis-dvt-and-pulmonary-embolism-pe-and-prevention-of-recurrent-dvt-and-pe-in-adults/\", \"rr_start\": \"2014-07-29T00:00:00\", \"rr_end\": \"2014-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-07-29, 2014-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban (Eliquis\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban (Eliquis\", \"ncpe_year\": 2014, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-07-29T00:00:00\", \"latest\": \"2014-08-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2185, \"last_scrape\": \"2018-12-13T16:26:39\", \"url\": \"http://www.ncpe.ie/drugs/apixaban-eliquis/\", \"rr_start\": \"2011-10-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-10-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban (Eliquis\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban (Eliquis\", \"ncpe_year\": 2012, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-10-19T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2186, \"last_scrape\": \"2018-12-13T16:26:45\", \"url\": \"http://www.ncpe.ie/drugs/apremilast-otezla-for-moderate-to-severe-chronic-plaque-psoriasis/\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast (Otezla\", \"trade_name\": \"Otezla\", \"indication\": \"Indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to systemic non-biologic therapies including cyclosporine, methotrexate or psoralen and ultraviolet A light (PUVA).\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/otezla\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2187, \"last_scrape\": \"2018-12-13T16:26:47\", \"url\": \"http://www.ncpe.ie/drugs/apremilast-otezla-for-psoriatic-arthritis/\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast (Otezla\", \"trade_name\": \"Otezla\", \"indication\": \"Apremilist (Otezla\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/otezla\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2188, \"last_scrape\": \"2018-12-13T16:26:49\", \"url\": \"http://www.ncpe.ie/drugs/aripiprazole-abilify-maintena/\", \"rr_start\": \"2014-07-02T00:00:00\", \"rr_end\": \"2014-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-07-02, 2014-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Aripiprazole (Abilify Maintena\", \"trade_name\": \"Abilify Maintena\", \"indication\": \"Aripiprazole (Abilify Maintena\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-14T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2014-07-02T00:00:00\", \"latest\": \"2014-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2189, \"last_scrape\": \"2018-12-13T16:26:55\", \"url\": \"http://www.ncpe.ie/drugs/asenapine-sycrest/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-08-17, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Asenapine (Sycrest\", \"trade_name\": \"Sycrest\", \"indication\": \"Asenapine (Sycrest\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Organon\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sycrest\", \"ta_list\": \"Bipolar Disorder\", \"rr_status\": \"No HTA\"}, {\"id\": 2190, \"last_scrape\": \"2018-12-13T16:27:00\", \"url\": \"http://www.ncpe.ie/drugs/atezolizumab-tecentriq/\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-10-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-08, 2017-10-09\", \"rr_multiple\": 0, \"drug_name\": \"Atezolizumab (Tecentriq\", \"trade_name\": \"Tecentriq\", \"indication\": \"Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK?positive tumour mutations should also have received targeted therapy before receiving atezolizumab.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-21T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq\", \"ta_list\": \"Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2191, \"last_scrape\": \"2018-12-13T16:27:05\", \"url\": \"http://www.ncpe.ie/drugs/avanafil-spedra/\", \"rr_start\": \"2014-02-19T00:00:00\", \"rr_end\": \"2014-03-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-19, 2014-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Avanafil (Spedra\", \"trade_name\": \"Spedra\", \"indication\": \"Avanafil (Spedra\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2014-02-19T00:00:00\", \"latest\": \"2014-03-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/spedra\", \"ta_list\": \"Erectile Dysfunction\", \"rr_status\": \"No HTA\"}, {\"id\": 2192, \"last_scrape\": \"2018-12-13T16:27:06\", \"url\": \"http://www.ncpe.ie/drugs/avelumab-bavencio/\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-10-17, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Avelumab (Bavencio\", \"trade_name\": \"Bavencio\", \"indication\": \"Avelumab (Bavencio\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2018-10-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2193, \"last_scrape\": \"2018-12-13T16:27:08\", \"url\": \"http://www.ncpe.ie/drugs/axanum-aspirin-81mgesomeprazole-20mg/\", \"rr_start\": \"2012-04-12T00:00:00\", \"rr_end\": \"2012-04-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-04-12, 2012-04-20\", \"rr_multiple\": 0, \"drug_name\": \"Aspirin 81mg/Esomeprazole 20mg (Axanum\", \"trade_name\": \"Axanum\", \"indication\": \"Prevention of thrombotic cardiovascular and cerebrovascular events in patients requiring continuous low-dose acetylsalicylic acid treatment, and who are in need of prophylaxis against acetylsalicylic acid associated gastric and /or duodenal ulcers.\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-04-12T00:00:00\", \"latest\": \"2012-04-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2194, \"last_scrape\": \"2018-12-13T16:27:14\", \"url\": \"http://www.ncpe.ie/drugs/axicabtagene-ciloleucel-yescarta/\", \"rr_start\": \"2018-09-10T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF  AXI-CEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-10, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Axicabtagene Ciloleucel (Yescarta\", \"trade_name\": \"Yescarta\", \"indication\": \"Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Kite\", \"orphan\": 1, \"earliest\": \"2018-09-10T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta\", \"ta_list\": \"Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2195, \"last_scrape\": \"2018-12-13T16:27:23\", \"url\": \"http://www.ncpe.ie/drugs/axitinib-inlyta/\", \"rr_start\": \"2012-11-07T00:00:00\", \"rr_end\": \"2012-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-07, 2012-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Axitinib (Inlyta\", \"trade_name\": \"Inlyta\", \"indication\": \"For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-03T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-11-07T00:00:00\", \"latest\": \"2012-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2196, \"last_scrape\": \"2018-12-13T16:27:24\", \"url\": \"http://www.ncpe.ie/drugs/azelastine-hydrochloride-and-fluticasone-propionate-nasal-spray-dymista/\", \"rr_start\": \"2013-02-12T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2013-02-12, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Azelastine hydrochloride and fluticasone propionate (nasal spray) (Dymista\", \"trade_name\": \"Dymista\", \"indication\": \"Indicated for symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-02-12T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2197, \"last_scrape\": \"2018-12-13T16:27:25\", \"url\": \"http://www.ncpe.ie/drugs/azilsartan-edarbi/\", \"rr_start\": \"2012-01-10T00:00:00\", \"rr_end\": \"2012-01-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-01-10, 2012-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Azilsartan (Edarbi\", \"trade_name\": \"Edarbi\", \"indication\": \"Edarbi is indicated for the treatment of essential hypertension in adults.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-12-07T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2012-01-10T00:00:00\", \"latest\": \"2012-01-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/edarbi\", \"ta_list\": \"Hypertension\", \"rr_status\": \"No HTA\"}, {\"id\": 2198, \"last_scrape\": \"2018-12-13T16:27:27\", \"url\": \"http://www.ncpe.ie/drugs/baricitinib-olumiant/\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-06-14, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Baricitinib (Olumiant\", \"trade_name\": \"Olumiant\", \"indication\": \"Baricitinib (Olumiant\", \"ncpe_year\": 2017, \"eu_market\": \"2017-02-12T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2199, \"last_scrape\": \"2018-12-13T16:27:33\", \"url\": \"http://www.ncpe.ie/drugs/bazedoxifene-conbriza/\", \"rr_start\": \"2011-09-20T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-09-20, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Bazedoxifene (Conbriza\", \"trade_name\": \"Conbriza\", \"indication\": \"Bazedoxifene (Conbriza\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-17T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-09-20T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza\", \"ta_list\": \"Osteoporosis, Postmenopausal\", \"rr_status\": \"No HTA\"}, {\"id\": 2200, \"last_scrape\": \"2018-12-13T16:27:36\", \"url\": \"http://www.ncpe.ie/drugs/bedaquiline-sirturo/\", \"rr_start\": \"2015-01-23T00:00:00\", \"rr_end\": \"2015-02-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-01-23, 2015-02-20\", \"rr_multiple\": 0, \"drug_name\": \"Bedaquiline (Sirturo\", \"trade_name\": \"Sirturo\", \"indication\": \"Bedaquiline (Sirturo\", \"ncpe_year\": 2015, \"eu_market\": \"2014-03-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2015-01-23T00:00:00\", \"latest\": \"2015-02-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo\", \"ta_list\": \"Tuberculosis, Multidrug-Resistant\", \"rr_status\": \"No HTA\"}, {\"id\": 2201, \"last_scrape\": \"2018-12-13T16:27:37\", \"url\": \"http://www.ncpe.ie/drugs/belatacept-nulojix/\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2012-01-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-11-15, 2012-01-23\", \"rr_multiple\": 0, \"drug_name\": \"Belatacept (Nulojix\", \"trade_name\": \"Nulojix\", \"indication\": \"Belatacept, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen.\\n\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2012-01-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nulojix\", \"ta_list\": \"Graft Rejection; Kidney Transplantation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2202, \"last_scrape\": \"2018-12-13T16:27:40\", \"url\": \"http://www.ncpe.ie/drugs/belimumab-benlysta/\", \"rr_start\": \"2011-08-11T00:00:00\", \"rr_end\": \"2011-08-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-11, 2011-08-11\", \"rr_multiple\": 0, \"drug_name\": \"Belimumab (Benlysta\", \"trade_name\": \"Benlysta\", \"indication\": \"Cost-effectiveness of Belimumab (Benlysta\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-08-01T00:00:00\", \"latest\": \"2011-08-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta\", \"ta_list\": \"Lupus Erythematosus, Systemic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2203, \"last_scrape\": \"2018-12-13T16:27:46\", \"url\": \"http://www.ncpe.ie/drugs/bendamustine-levact/\", \"rr_start\": \"2011-03-21T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-03-21, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Bendamustine (Levact\", \"trade_name\": \"Levact\", \"indication\": \"Bendamustine (Levact\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2012-11-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2204, \"last_scrape\": \"2018-12-13T16:27:50\", \"url\": \"http://www.ncpe.ie/drugs/benralizumab-fasenra/\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-14T00:00:00\", \"rr_outcome\": \"FULL PHARAMCOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2018-01-15, 2018-02-14\", \"rr_multiple\": 0, \"drug_name\": \"Benralizumab (Fasenra\", \"trade_name\": \"Fasenra\", \"indication\": \"Benralizumab (Fasenra\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fasenra\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2205, \"last_scrape\": \"2018-12-13T16:27:56\", \"url\": \"http://www.ncpe.ie/drugs/bezlotoxumab-zinplava/\", \"rr_start\": \"2017-05-11T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-05-11, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Bezlotoxumab (Zinplava\", \"trade_name\": \"Zinplava\", \"indication\": \"Bezlotoxumab (Zinplava\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-05-11T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinplava\", \"ta_list\": \"Enterocolitis, Pseudomembranous\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2206, \"last_scrape\": \"2018-12-13T16:27:58\", \"url\": \"http://www.ncpe.ie/drugs/bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy/\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT BIKTARVY\", \"rr_dates\": \"2018-04-30, 2018-06-07\", \"rr_multiple\": 0, \"drug_name\": \"Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy\", \"trade_name\": \"Biktarvy\", \"indication\": \"Biktarvy\", \"ncpe_year\": 2018, \"eu_market\": \"2018-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2207, \"last_scrape\": \"2018-12-13T16:28:01\", \"url\": \"http://www.ncpe.ie/drugs/bilastine-drynol/\", \"rr_start\": \"2011-03-10T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-10, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Bilastine (Drynol\", \"trade_name\": \"Drynol\", \"indication\": \" Bilastine (Drynol\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-03-10T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2208, \"last_scrape\": \"2018-12-13T16:28:05\", \"url\": \"http://www.ncpe.ie/drugs/blinatumomab-blincyto/\", \"rr_start\": \"2015-12-08T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.  THE NCPE CANNOT RECOMMEND REIMBURSEMENT OF BLINCTYO\", \"rr_dates\": \"2015-12-08, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Blinatumomab (Blincyto\", \"trade_name\": \"Blincyto\", \"indication\": \"Blincyto\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-23T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-08T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2209, \"last_scrape\": \"2018-12-13T16:28:11\", \"url\": \"http://www.ncpe.ie/drugs/boceprevir-victrelis/\", \"rr_start\": \"\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Boceprevir (Victrelis\", \"trade_name\": \"Victrelis\", \"indication\": \"Economic evaluation of Boceprevir (Victrelis\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2011-08-19T00:00:00\", \"latest\": \"2012-01-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2210, \"last_scrape\": \"2018-12-13T16:28:16\", \"url\": \"http://www.ncpe.ie/drugs/bosentan-tracleer/\", \"rr_start\": \"2014-06-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-06-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Bosentan (Tracleer\", \"trade_name\": \"Tracleer\", \"indication\": \"Bosentan (Tracleer\", \"ncpe_year\": 2014, \"eu_market\": \"2002-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-06-27T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tracleer\", \"ta_list\": \"Scleroderma, Systemic; Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2211, \"last_scrape\": \"2018-12-13T16:28:18\", \"url\": \"http://www.ncpe.ie/drugs/bosutinib-bosulif/\", \"rr_start\": \"2013-08-09T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"AT THE CURRENT PRICE A FULL HTA WOULD BE REQUIRED.\", \"rr_dates\": \"2013-08-09, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Bosutinib (Bosulif\", \"trade_name\": \"Bosulif\", \"indication\": \"Bosutinib is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-26T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2212, \"last_scrape\": \"2018-12-13T16:28:19\", \"url\": \"http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris-for-cd30-cutaneous-t-cell-lymphoma-ctcl/\", \"rr_start\": \"2018-02-07T00:00:00\", \"rr_end\": \"2018-03-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-02-07, 2018-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin (Adcetris\", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin (Adcetris\", \"ncpe_year\": 2018, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-02-07T00:00:00\", \"latest\": \"2018-03-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2213, \"last_scrape\": \"2018-12-13T16:28:23\", \"url\": \"http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris/\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin (Adcetris\", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin (Adcetris\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2214, \"last_scrape\": \"2018-12-13T16:28:29\", \"url\": \"http://www.ncpe.ie/drugs/brigatinib-alunbrig/\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF BRIGATINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-11-19, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Brigatinib (Alunbrig\", \"trade_name\": \"Alunbrig\", \"indication\": \"Brigatinib (Alunbrig \", \"ncpe_year\": 2018, \"eu_market\": \"2018-11-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2215, \"last_scrape\": \"2018-12-13T16:28:30\", \"url\": \"http://www.ncpe.ie/drugs/brimonidine-3-3-mgg-gel-mirvaso/\", \"rr_start\": \"2014-04-09T00:00:00\", \"rr_end\": \"2014-04-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-09\", \"rr_multiple\": 0, \"drug_name\": \"Brimonidine 3.3 mg/g gel (Mirvaso\", \"trade_name\": \"Mirvaso\", \"indication\": \"Brimonidine 3.3 mg/g gel (Mirvaso\", \"ncpe_year\": 2014, \"eu_market\": \"2014-02-20T00:00:00\", \"company\": \"Galderma\", \"orphan\": 0, \"earliest\": \"2014-04-09T00:00:00\", \"latest\": \"2014-04-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mirvaso\", \"ta_list\": \"Skin Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2216, \"last_scrape\": \"2018-12-13T16:28:36\", \"url\": \"http://www.ncpe.ie/drugs/brivaracetam-briviact/\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-02-15, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Brivaracetam (Briviact\", \"trade_name\": \"Briviact\", \"indication\": \"Brivaracetam (Briviact\", \"ncpe_year\": 2016, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2217, \"last_scrape\": \"2018-12-13T16:28:40\", \"url\": \"http://www.ncpe.ie/drugs/brodalumab-kyntheum/\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-07-25, 2017-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Brodalumab (Kyntheum\", \"trade_name\": \"Kyntheum\", \"indication\": \"Brodalumab (Kyntheum\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-17T00:00:00\", \"company\": \"LEO\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2218, \"last_scrape\": \"2018-12-13T16:28:44\", \"url\": \"http://www.ncpe.ie/drugs/bronchitol/\", \"rr_start\": \"2012-09-11T00:00:00\", \"rr_end\": \"2012-09-21T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2012-09-11, 2012-09-21\", \"rr_multiple\": 0, \"drug_name\": \"Mannitol Dry Powder (Bronchitol\", \"trade_name\": \"Bronchitol\", \"indication\": \"Bronchitol\", \"ncpe_year\": 2014, \"eu_market\": \"2012-04-13T00:00:00\", \"company\": \"Pharmaxis\", \"orphan\": 1, \"earliest\": \"2012-09-11T00:00:00\", \"latest\": \"2014-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bronchitol\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2219, \"last_scrape\": \"2018-12-13T16:28:46\", \"url\": \"http://www.ncpe.ie/drugs/c-drugs/calcipotriol-and-betamethasone-dipropionate-cutaneous-foam-enstilar/\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-06-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-05-17, 2016-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Calcipotriol and betamethasone dipropionate cutaneous foam (Enstilar \", \"trade_name\": \"Enstilar\", \"indication\": \"Calcipotriol and betamethasone dipropionate cutaneous foam is indicated for the topical treatment of psoriasis vulgaris in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-06-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2220, \"last_scrape\": \"2018-12-13T16:28:53\", \"url\": \"http://www.ncpe.ie/drugs/c1inhibitor-human-cinryze/\", \"rr_start\": \"2012-10-22T00:00:00\", \"rr_end\": \"2012-11-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-22, 2012-11-14\", \"rr_multiple\": 0, \"drug_name\": \"C1inhibitor (human) (Cinryze\", \"trade_name\": \"Cinryze\", \"indication\": \"C1inhibitor (human) (Cinryze\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-15T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2012-10-22T00:00:00\", \"latest\": \"2012-11-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"id\": 2221, \"last_scrape\": \"2018-12-13T16:28:55\", \"url\": \"http://www.ncpe.ie/drugs/cabozantinib-cabometyx/\", \"rr_start\": \"2017-03-20T00:00:00\", \"rr_end\": \"2017-04-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT\\nRECOMMENDED\", \"rr_dates\": \"2017-03-20, 2017-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib (Cabometyx\", \"trade_name\": \"Cabometyx\", \"indication\": \"Cabozantinib (Cabometyx\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-03-20T00:00:00\", \"latest\": \"2018-07-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2222, \"last_scrape\": \"2018-12-13T16:28:58\", \"url\": \"http://www.ncpe.ie/drugs/cabozantinib-cometriq/\", \"rr_start\": \"2014-07-10T00:00:00\", \"rr_end\": \"2014-08-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2014-07-10, 2014-08-12\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib (Cometriq\", \"trade_name\": \"Cometriq\", \"indication\": \"Cabozantinib (COMETRIQ\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-21T00:00:00\", \"company\": \"Ipsen\", \"orphan\": 1, \"earliest\": \"2014-07-10T00:00:00\", \"latest\": \"2014-08-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2223, \"last_scrape\": \"2018-12-13T16:29:01\", \"url\": \"http://www.ncpe.ie/drugs/camellia-sinensis-folium-green-tea-leaf-catephen-10/\", \"rr_start\": \"2015-05-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-05-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Camellia sinensis, folium (green tea leaf) (Catephen 10%\", \"trade_name\": \"Catephen 10%\", \"indication\": \"Catephen 10%\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-05-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2224, \"last_scrape\": \"2018-12-13T16:29:04\", \"url\": \"http://www.ncpe.ie/drugs/canagliflozin-invokana/\", \"rr_start\": \"2013-11-25T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-11-25, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Canagliflozin (Invokana\", \"trade_name\": \"Invokana\", \"indication\": \"Canagliflozin (Invokana\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-11-25T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/invokana\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2225, \"last_scrape\": \"2018-12-13T16:29:09\", \"url\": \"http://www.ncpe.ie/drugs/capsaicin-8ww-patch-qutenza/\", \"rr_start\": \"2012-06-15T00:00:00\", \"rr_end\": \"2012-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-06-15, 2012-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Capsaicin 8%w/w patch (Qutenza\", \"trade_name\": \"Qutenza\", \"indication\": \"Capsaicin 8% w/w patch (Qutenza\", \"ncpe_year\": 2012, \"eu_market\": \"2009-05-15T00:00:00\", \"company\": \"Grunenthal\", \"orphan\": 0, \"earliest\": \"2012-06-15T00:00:00\", \"latest\": \"2012-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza\", \"ta_list\": \"Neuralgia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2226, \"last_scrape\": \"2018-12-13T16:29:11\", \"url\": \"http://www.ncpe.ie/drugs/carbazitaxel-jevtana-for-prostate-cancer/\", \"rr_start\": \"2011-06-02T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-06-02, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Cabazitaxel (Jevtana\", \"trade_name\": \"Jevtana\", \"indication\": \"Economic Evaluation of cabazitaxel (Jevtana\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2011-06-02T00:00:00\", \"latest\": \"2014-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jevtana\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2227, \"last_scrape\": \"2018-12-13T16:29:16\", \"url\": \"http://www.ncpe.ie/drugs/carfilzomib-kyprolis/\", \"rr_start\": \"2015-12-07T00:00:00\", \"rr_end\": \"2016-01-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-12-07, 2016-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Carfilzomib (Kyprolis\", \"trade_name\": \"Kyprolis\", \"indication\": \"Kyprolis\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-07T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2228, \"last_scrape\": \"2018-12-13T16:29:22\", \"url\": \"http://www.ncpe.ie/drugs/catumaxomab-removab/\", \"rr_start\": \"2011-08-05T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-08-05, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Catumaxomab (Removab\", \"trade_name\": \"Removab\", \"indication\": \"Catumazomab (Removab\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-20T00:00:00\", \"company\": \"Neovii\", \"orphan\": 0, \"earliest\": \"2011-08-05T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/removab\", \"ta_list\": \"Ascites; Cancer\", \"rr_status\": \"No HTA\"}, {\"id\": 2229, \"last_scrape\": \"2018-12-13T16:29:25\", \"url\": \"http://www.ncpe.ie/drugs/ceftaroline-zinforo/\", \"rr_start\": \"2012-10-08T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-08, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Ceftaroline (Zinforo\", \"trade_name\": \"Zinforo\", \"indication\": \"For the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP).\", \"ncpe_year\": 2012, \"eu_market\": \"2012-08-22T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-10-08T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinforo\", \"ta_list\": \"Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia\", \"rr_status\": \"No HTA\"}, {\"id\": 2230, \"last_scrape\": \"2018-12-13T16:29:29\", \"url\": \"http://www.ncpe.ie/drugs/ceftazidime-avibactam-cef-avizavicefta/\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-17, 2017-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Ceftazidime-avibactam (CEF-AVI)(Zavicefta\", \"trade_name\": \"Zavicefta\", \"indication\": \"Ceftazidime-avibactam (CEF-AVI)(Zavicefta\", \"ncpe_year\": 2017, \"eu_market\": \"2016-06-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta\", \"ta_list\": \"Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2231, \"last_scrape\": \"2018-12-13T16:29:34\", \"url\": \"http://www.ncpe.ie/drugs/ceftolozanetazobactam-zerbaxa/\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-03-03, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Ceftolozane/tazobactam (Zerbaxa\", \"trade_name\": \"Zerbaxa\", \"indication\": \"Zerbaxa\", \"ncpe_year\": 2016, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa\", \"ta_list\": \"Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2232, \"last_scrape\": \"2018-12-13T16:29:36\", \"url\": \"http://www.ncpe.ie/drugs/ceritinib-zykadia/\", \"rr_start\": \"2015-05-29T00:00:00\", \"rr_end\": \"2015-07-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2015-05-29, 2015-07-22\", \"rr_multiple\": 0, \"drug_name\": \"Ceritinib (Zykadia\", \"trade_name\": \"Zykadia\", \"indication\": \"Zykadia\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-06T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-05-29T00:00:00\", \"latest\": \"2015-07-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2233, \"last_scrape\": \"2018-12-13T16:29:40\", \"url\": \"http://www.ncpe.ie/drugs/cerliponase-alfa-brineura/\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2017-10-11, 2017-11-27\", \"rr_multiple\": 0, \"drug_name\": \"Cerliponase alfa (Brineura\", \"trade_name\": \"Brineura\", \"indication\": \"Cerliponase alfa (Brineura\", \"ncpe_year\": 2018, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-08-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brineura\", \"ta_list\": \"Neuronal Ceroid-Lipofuscinoses\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2234, \"last_scrape\": \"2018-12-13T16:29:44\", \"url\": \"http://www.ncpe.ie/drugs/certolizumab-pegol-cimzia/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Certolizumab pegol (Cimzia\", \"trade_name\": \"Cimzia\", \"indication\": \"Cost-effectiveness of certolizumab pegol (Cimzia\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2010-03-13T00:00:00\", \"latest\": \"2010-09-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia-0\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2235, \"last_scrape\": \"2018-12-13T16:29:49\", \"url\": \"http://www.ncpe.ie/drugs/ciclosporin-1mgml-eye-drops-ikervis/\", \"rr_start\": \"2015-01-07T00:00:00\", \"rr_end\": \"2016-01-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-01-07, 2016-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Ciclosporin 1mg/ml eye drops (Ikervis\", \"trade_name\": \"Ikervis\", \"indication\": \"Ikervis\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-19T00:00:00\", \"company\": \"Santen\", \"orphan\": 0, \"earliest\": \"2015-01-07T00:00:00\", \"latest\": \"2016-01-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis\", \"ta_list\": \"Corneal Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2236, \"last_scrape\": \"2018-12-13T16:29:54\", \"url\": \"http://www.ncpe.ie/drugs/cladribine-mavenclad/\", \"rr_start\": \"2017-08-22T00:00:00\", \"rr_end\": \"2017-09-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-22, 2017-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Cladribine (Mavenclad\", \"trade_name\": \"Mavenclad\", \"indication\": \"Cladribine (Mavenclad\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-08-22T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2237, \"last_scrape\": \"2018-12-13T16:29:58\", \"url\": \"http://www.ncpe.ie/drugs/clindamycin-1-with-tretinoin-0-025-treclinac/\", \"rr_start\": \"2014-04-08T00:00:00\", \"rr_end\": \"2014-05-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-08, 2014-05-06\", \"rr_multiple\": 0, \"drug_name\": \"Clindamycin 1% with tretinoin 0.025% (Treclinac\", \"trade_name\": \"Treclinac\", \"indication\": \"Clindamycin 1% with tretinoin 0.025% (Treclinac\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-04-08T00:00:00\", \"latest\": \"2014-05-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2238, \"last_scrape\": \"2018-12-13T16:30:02\", \"url\": \"http://www.ncpe.ie/drugs/cobimetinib-cotellic/\", \"rr_start\": \"2016-04-19T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-04-19, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Cobimetinib (Cotellic\", \"trade_name\": \"Cotellic\", \"indication\": \"Cotellic\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2016-04-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2239, \"last_scrape\": \"2018-12-13T16:30:03\", \"url\": \"http://www.ncpe.ie/drugs/colesevelam-cholestagel/\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Colesevelam (Cholestagel\", \"trade_name\": \"Cholestagel\", \"indication\": \"Cost-effectiveness of Colesevelam (Cholestagel\", \"ncpe_year\": 2010, \"eu_market\": \"2004-03-09T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cholestagel\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"No HTA\"}, {\"id\": 2240, \"last_scrape\": \"2018-12-13T16:30:06\", \"url\": \"http://www.ncpe.ie/drugs/colistimethate-sodium-colobreathe/\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Colistimethate sodium (Colobreathe\", \"trade_name\": \"Colobreathe\", \"indication\": \"Colistimethate sodium (colobreathe\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-13T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/colobreathe\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2241, \"last_scrape\": \"2018-12-13T16:30:17\", \"url\": \"http://www.ncpe.ie/drugs/collagenase-clostridium-histolyticum-xiapex/\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-20, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Collagenase Clostridium Histolyticum (Xiapex\", \"trade_name\": \"Xiapex\", \"indication\": \" Collagenase Clostridium Histolyticum (Xiapex\", \"ncpe_year\": 2011, \"eu_market\": \"2011-02-28T00:00:00\", \"company\": \"Swedish\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xiapex\", \"ta_list\": \"Dupuytren Contracture\", \"rr_status\": \"No HTA\"}, {\"id\": 2242, \"last_scrape\": \"2018-12-13T16:30:20\", \"url\": \"http://www.ncpe.ie/drugs/corifollitropin-alfa-elonva/\", \"rr_start\": \"2010-10-22T00:00:00\", \"rr_end\": \"2010-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-10-22, 2010-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Corifollitropin alfa (Elonva\", \"trade_name\": \"Elonva\", \"indication\": \"Cost-effectiveness of Corifollitropin alfa (Elonva\", \"ncpe_year\": 2010, \"eu_market\": \"2010-01-25T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2010-09-01T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/elonva\", \"ta_list\": \"Reproductive Techniques, Assisted; Ovulation Induction\", \"rr_status\": \"No HTA\"}, {\"id\": 2243, \"last_scrape\": \"2018-12-13T16:30:24\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori-for-first-line-alk-nsclc/\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2244, \"last_scrape\": \"2018-12-13T16:30:29\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori-for-ros1-nsclc/\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2245, \"last_scrape\": \"2018-12-13T16:30:34\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori/\", \"rr_start\": \"2013-01-09T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-01-09, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"For the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-01-09T00:00:00\", \"latest\": \"2015-08-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2246, \"last_scrape\": \"2018-12-13T16:30:37\", \"url\": \"http://www.ncpe.ie/drugs/cysteamine-bitartrate-procysbi/\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2015-12-01, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Cysteamine bitartrate delayed-release (Procysbi\", \"trade_name\": \"Procysbi\", \"indication\": \"Procysbi\", \"ncpe_year\": 2017, \"eu_market\": \"2013-09-05T00:00:00\", \"company\": \"Chiesi\", \"orphan\": 1, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/procysbi\", \"ta_list\": \"Cystinosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2247, \"last_scrape\": \"2018-12-13T16:30:43\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-2/\", \"rr_start\": \"2014-05-09T00:00:00\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-09, 2014-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate (Pradaxa\", \"ncpe_year\": 2014, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-09T00:00:00\", \"latest\": \"2014-06-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2248, \"last_scrape\": \"2018-12-13T16:30:51\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-for-the-prevention-of-stroke-and-systematic-embolisom-in-atrial-fibrillation/\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate (Pradaxa\", \"ncpe_year\": 2012, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2010-11-02T00:00:00\", \"latest\": \"2012-10-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2249, \"last_scrape\": \"2018-12-13T16:30:57\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-vte-prevention/\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Economic Evaluation of the Cost Effectiveness of Dabigatran Etexilate (Pradaxa\", \"ncpe_year\": 2008, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2008-07-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2250, \"last_scrape\": \"2018-12-13T16:30:59\", \"url\": \"http://www.ncpe.ie/drugs/dabrafenib-tafinlar/\", \"rr_start\": \"2013-09-11T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-11, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Dabrafenib (Tafinlar\", \"trade_name\": \"Tafinlar\", \"indication\": \"Dabrafenib (Tafinlar\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2013-09-11T00:00:00\", \"latest\": \"2014-06-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2251, \"last_scrape\": \"2018-12-13T16:31:02\", \"url\": \"http://www.ncpe.ie/drugs/daclatasvir-daklinza/\", \"rr_start\": \"2014-08-05T00:00:00\", \"rr_end\": \"2014-09-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-08-05, 2014-09-12\", \"rr_multiple\": 0, \"drug_name\": \"Daclatasvir (Daklinza\", \"trade_name\": \"Daklinza\", \"indication\": \"Daclatasvir (Daklinza\", \"ncpe_year\": 2015, \"eu_market\": \"2014-08-22T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-08-05T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/daklinza\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2252, \"last_scrape\": \"2018-12-13T16:31:08\", \"url\": \"http://www.ncpe.ie/drugs/daclizumab-zinbryta/\", \"rr_start\": \"2016-09-26T00:00:00\", \"rr_end\": \"2016-11-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-09-26, 2016-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Daclizumab (Zinbryta\", \"trade_name\": \"Zinbryta\", \"indication\": \"Daclizumab is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-07-01T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2016-09-26T00:00:00\", \"latest\": \"2018-03-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinbryta\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2253, \"last_scrape\": \"2018-12-13T16:31:12\", \"url\": \"http://www.ncpe.ie/drugs/dalbavancin-xydalba/\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-07, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Dalbavancin (Xydalba\", \"trade_name\": \"Xydalba\", \"indication\": \"Dalbavancin (Xydalba\", \"ncpe_year\": 2017, \"eu_market\": \"2015-02-19T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xydalba\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2254, \"last_scrape\": \"2018-12-13T16:31:18\", \"url\": \"http://www.ncpe.ie/drugs/dapagliflozin-forxiga/\", \"rr_start\": \"2012-10-10T00:00:00\", \"rr_end\": \"2012-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-10-10, 2012-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Dapagliflozin (Forxiga\", \"trade_name\": \"Forxiga\", \"indication\": \"Dapagliflozin (Forxiga\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-11T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-10T00:00:00\", \"latest\": \"2013-12-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2255, \"last_scrape\": \"2018-12-13T16:31:21\", \"url\": \"http://www.ncpe.ie/drugs/daratumumab-darzalex/\", \"rr_start\": \"2016-05-31T00:00:00\", \"rr_end\": \"2016-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-05-31, 2016-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Daratumumab (Darzalex\", \"trade_name\": \"Darzalex\", \"indication\": \"Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-04-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-05-31T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2256, \"last_scrape\": \"2018-12-13T16:31:25\", \"url\": \"http://www.ncpe.ie/drugs/darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-symtuza/\", \"rr_start\": \"2017-09-27T00:00:00\", \"rr_end\": \"2017-10-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-27, 2017-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza\", \"trade_name\": \"Symtuza\", \"indication\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza\", \"ncpe_year\": 2017, \"eu_market\": \"2017-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-09-27T00:00:00\", \"latest\": \"2017-10-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/symtuza\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2257, \"last_scrape\": \"2018-12-13T16:31:30\", \"url\": \"http://www.ncpe.ie/drugs/darunavir-cobicistat-rezolsta/\", \"rr_start\": \"2014-12-02T00:00:00\", \"rr_end\": \"2015-01-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-12-02, 2015-01-08\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir & cobicistat (Rezolsta\", \"trade_name\": \"Rezolsta\", \"indication\": \"Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-12-02T00:00:00\", \"latest\": \"2015-01-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2258, \"last_scrape\": \"2018-12-13T16:31:35\", \"url\": \"http://www.ncpe.ie/drugs/darvadstrocel-alofisel/\", \"rr_start\": \"2018-06-14T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF DARVADSTROCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-14, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Darvadstrocel (Alofisel\", \"trade_name\": \"Alofisel\", \"indication\": \"Darvadstrocel (Alofisel\", \"ncpe_year\": 2018, \"eu_market\": \"2018-03-23T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-06-14T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel\", \"ta_list\": \"Rectal Fistula\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2259, \"last_scrape\": \"2018-12-13T16:31:40\", \"url\": \"http://www.ncpe.ie/drugs/decitabine-dacogen/\", \"rr_start\": \"2012-11-08T00:00:00\", \"rr_end\": \"2012-12-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-08, 2012-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Decitabine (Dacogen\", \"trade_name\": \"Dacogen\", \"indication\": \"Decitabine (Dacogen\", \"ncpe_year\": 2013, \"eu_market\": \"2012-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2012-11-08T00:00:00\", \"latest\": \"2013-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2260, \"last_scrape\": \"2018-12-13T16:31:44\", \"url\": \"http://www.ncpe.ie/drugs/defibrotide-defitelio/\", \"rr_start\": \"2014-05-12T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2014-05-12, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Defibrotide (Defitelio\", \"trade_name\": \"Defitelio\", \"indication\": \"Defibrotide (Defitelio\", \"ncpe_year\": 2014, \"eu_market\": \"2013-10-18T00:00:00\", \"company\": \"Gentium\", \"orphan\": 1, \"earliest\": \"2014-05-12T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio\", \"ta_list\": \"Hepatic Veno-Occlusive Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2261, \"last_scrape\": \"2018-12-13T16:31:47\", \"url\": \"http://www.ncpe.ie/drugs/degarelix-firmagon/\", \"rr_start\": \"2009-10-15T00:00:00\", \"rr_end\": \"2009-10-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-10-15\", \"rr_multiple\": 0, \"drug_name\": \"Degarelix (Firmagon\", \"trade_name\": \"Firmagon\", \"indication\": \"Cost-effectiveness of Degarelix (Firmagon\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-17T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2009-10-15T00:00:00\", \"latest\": \"2009-10-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2262, \"last_scrape\": \"2018-12-13T16:31:52\", \"url\": \"http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-cannabidiol-thc-cbd-sativex/\", \"rr_start\": \"2018-02-12T00:00:00\", \"rr_end\": \"2018-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF SATIVEX\", \"rr_dates\": \"2018-02-12, 2018-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex\", \"trade_name\": \"Sativex\", \"indication\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-02-12T00:00:00\", \"latest\": \"2018-04-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2263, \"last_scrape\": \"2018-12-13T16:31:59\", \"url\": \"http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-thccannabidiol-cbd-sativex/\", \"rr_start\": \"2012-12-05T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-05, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol (THC) /Cannabidiol (CBD) (Sativex\", \"trade_name\": \"Sativex\", \"indication\": \"For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-12-05T00:00:00\", \"latest\": \"2014-09-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2264, \"last_scrape\": \"2018-12-13T16:32:04\", \"url\": \"http://www.ncpe.ie/drugs/denosumab-prolia/\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab (Prolia\", \"trade_name\": \"Prolia\", \"indication\": \"The Cost-effectiveness of Denosumab (Prolia\", \"ncpe_year\": 2010, \"eu_market\": \"2010-05-26T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2010-05-27T00:00:00\", \"latest\": \"2010-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prolia\", \"ta_list\": \"Bone Resorption; Osteoporosis, Postmenopausal\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2265, \"last_scrape\": \"2018-12-13T16:32:08\", \"url\": \"http://www.ncpe.ie/drugs/denosumab-xgeva-3/\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab (Xgeva\", \"trade_name\": \"Xgeva\", \"indication\": \"Cost-effectiveness of denosumab (Xgeva\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2011-08-15T00:00:00\", \"latest\": \"2011-12-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva\", \"ta_list\": \"Fractures, Bone; Neoplasm Metastasis\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2266, \"last_scrape\": \"2018-12-13T16:32:12\", \"url\": \"http://www.ncpe.ie/drugs/dexamethasone-intravitreal-implant-ozurdex/\", \"rr_start\": \"2010-11-12T00:00:00\", \"rr_end\": \"2010-12-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-11-12, 2010-12-16\", \"rr_multiple\": 0, \"drug_name\": \"Dexamethasone Intravitreal Implant (Ozurdex\", \"trade_name\": \"Ozurdex\", \"indication\": \"Cost-effectiveness of Ozurdex\", \"ncpe_year\": 2012, \"eu_market\": \"2010-07-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2010-11-12T00:00:00\", \"latest\": \"2012-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ozurdex\", \"ta_list\": \"Macular Edema; Uveitis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2267, \"last_scrape\": \"2018-12-13T16:32:15\", \"url\": \"http://www.ncpe.ie/drugs/dexmedetomidine-dexdor/\", \"rr_start\": \"2011-07-08T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-07-08, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Dexmedetomidine (Dexdor\", \"trade_name\": \"Dexdor\", \"indication\": \"Dexmedetomidine (Dexdor\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-15T00:00:00\", \"company\": \"Orion\", \"orphan\": 0, \"earliest\": \"2011-07-08T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dexdor\", \"ta_list\": \"Conscious Sedation\", \"rr_status\": \"No HTA\"}, {\"id\": 2268, \"last_scrape\": \"2018-12-13T16:32:21\", \"url\": \"http://www.ncpe.ie/drugs/dienogest-visanne/\", \"rr_start\": \"2010-09-17T00:00:00\", \"rr_end\": \"2010-10-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-09-17, 2010-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Dienogest (Visanne\", \"trade_name\": \"Visanne\", \"indication\": \"Dienogest (Visanne\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-09-17T00:00:00\", \"latest\": \"2010-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2269, \"last_scrape\": \"2018-12-13T16:32:24\", \"url\": \"http://www.ncpe.ie/drugs/dimethyl-fumarate-skilarence/\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-01-15, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate (Skilarence\", \"trade_name\": \"Skilarence\", \"indication\": \"Dimethyl fumarate (Skilarence\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"Almirall\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/skilarence\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2270, \"last_scrape\": \"2018-12-13T16:32:26\", \"url\": \"http://www.ncpe.ie/drugs/dimethyl-fumarate-tecfidera/\", \"rr_start\": \"2014-02-04T00:00:00\", \"rr_end\": \"2014-03-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-02-04, 2014-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate (Tecfidera\", \"trade_name\": \"Tecfidera\", \"indication\": \"Dimethyl fumarate (Tecfidera\", \"ncpe_year\": 2015, \"eu_market\": \"2014-01-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-02-04T00:00:00\", \"latest\": \"2015-04-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2271, \"last_scrape\": \"2018-12-13T16:32:29\", \"url\": \"http://www.ncpe.ie/drugs/dinutuximab-beta-dinutuximab-beta-eusa/\", \"rr_start\": \"2017-10-19T00:00:00\", \"rr_end\": \"2017-11-23T00:00:00\", \"rr_outcome\": \"FOLLOWING ASSESSMENT OF THE APPLICANT\", \"rr_dates\": \"2017-10-19, 2017-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Dinutuximab beta (Qarziba\", \"trade_name\": \"Qarziba\", \"indication\": \"Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients ? 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-10-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2272, \"last_scrape\": \"2018-12-13T16:32:34\", \"url\": \"http://www.ncpe.ie/drugs/dolutegravir-rilpivirine-juluca/\", \"rr_start\": \"2018-06-08T00:00:00\", \"rr_end\": \"2018-07-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT JULUCA\", \"rr_dates\": \"2018-06-08, 2018-07-12\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir/Rilpivirine (Juluca\", \"trade_name\": \"Juluca\", \"indication\": \"Dolutegravir/rilpivirine (Juluca\", \"ncpe_year\": 2018, \"eu_market\": \"2018-05-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2018-06-08T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/juluca\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2273, \"last_scrape\": \"2018-12-13T16:32:36\", \"url\": \"http://www.ncpe.ie/drugs/dolutegravir-tivicay/\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-10, 2014-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir (Tivicay\", \"trade_name\": \"Tivicay\", \"indication\": \"Dolutegravir (Tivicay\", \"ncpe_year\": 2014, \"eu_market\": \"2014-01-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2274, \"last_scrape\": \"2018-12-13T16:32:39\", \"url\": \"http://www.ncpe.ie/drugs/dronedarone-multaq/\", \"rr_start\": \"2010-01-12T00:00:00\", \"rr_end\": \"2010-01-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-01-12, 2010-01-01\", \"rr_multiple\": 0, \"drug_name\": \"Dronedarone (Multaq\", \"trade_name\": \"Multaq\", \"indication\": \"Rapid Review\", \"ncpe_year\": 2010, \"eu_market\": \"2009-11-25T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2010-01-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"No HTA\"}, {\"id\": 2275, \"last_scrape\": \"2018-12-13T16:32:42\", \"url\": \"http://www.ncpe.ie/drugs/dulaglutide-trulicity/\", \"rr_start\": \"2015-03-04T00:00:00\", \"rr_end\": \"2015-04-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-03-04, 2015-04-29\", \"rr_multiple\": 0, \"drug_name\": \"Dulaglutide (Trulicity\", \"trade_name\": \"Trulicity\", \"indication\": \"Dulaglutide is indicated as monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2015-03-04T00:00:00\", \"latest\": \"2015-04-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2276, \"last_scrape\": \"2018-12-13T16:32:46\", \"url\": \"http://www.ncpe.ie/drugs/dupilumab-dupixent/\", \"rr_start\": \"2017-11-13T00:00:00\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-13, 2017-11-24\", \"rr_multiple\": 0, \"drug_name\": \"Dupilumab (Dupixent\", \"trade_name\": \"Dupixent\", \"indication\": \"Dupilumab (Dupixent\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-27T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-11-13T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent\", \"ta_list\": \"Dermatitis, Atopic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2277, \"last_scrape\": \"2018-12-13T16:32:53\", \"url\": \"http://www.ncpe.ie/drugs/eculizumab-soliris/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Eculizumab (Soliris\", \"trade_name\": \"Soliris\", \"indication\": \"An Economic Evaluation of Eculizumab (Soliris\", \"ncpe_year\": 2013, \"eu_market\": \"2007-06-20T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2013-10-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/soliris\", \"ta_list\": \"Hemoglobinuria, Paroxysmal\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2278, \"last_scrape\": \"2018-12-13T16:32:55\", \"url\": \"http://www.ncpe.ie/drugs/edoxaban-lixiana/\", \"rr_start\": \"2015-06-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-06-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Edoxaban (Lixiana\", \"trade_name\": \"Lixiana\", \"indication\": \"Edoxaban is indicated for the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2015-06-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana\", \"ta_list\": \"Stroke; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2279, \"last_scrape\": \"2018-12-13T16:33:00\", \"url\": \"http://www.ncpe.ie/drugs/elbasvirgrazoprevir-zepatier-2/\", \"rr_start\": \"2016-08-10T00:00:00\", \"rr_end\": \"2016-10-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-08-10, 2016-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Elbasvir/Grazoprevir (Zepatier\", \"trade_name\": \"Zepatier\", \"indication\": \"Elbasvir 50mg/100mg grazoprevir (EBR/GZR)(Zepatier\", \"ncpe_year\": 2016, \"eu_market\": \"2016-07-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-10T00:00:00\", \"latest\": \"2016-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2280, \"last_scrape\": \"2018-12-13T16:33:03\", \"url\": \"http://www.ncpe.ie/drugs/eliglustat-cerdelga/\", \"rr_start\": \"2016-03-21T00:00:00\", \"rr_end\": \"2016-05-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-03-21, 2016-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Eliglustat (Cerdelga\", \"trade_name\": \"Cerdelga\", \"indication\": \"Eliglustat (Cerdelga\", \"ncpe_year\": 2018, \"eu_market\": \"2015-01-19T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 1, \"earliest\": \"2016-03-21T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga\", \"ta_list\": \"Gaucher Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2281, \"last_scrape\": \"2018-12-13T16:33:05\", \"url\": \"http://www.ncpe.ie/drugs/elosulfase-alfa-vimizim/\", \"rr_start\": \"2015-03-30T00:00:00\", \"rr_end\": \"2015-05-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-03-30, 2015-05-08\", \"rr_multiple\": 0, \"drug_name\": \"Elosulfase alfa (Vimizim\", \"trade_name\": \"Vimizim\", \"indication\": \"Elosulfase alfa (Vimzim\", \"ncpe_year\": 2018, \"eu_market\": \"2014-04-27T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2015-03-30T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vimizim\", \"ta_list\": \"Mucopolysaccharidosis IV\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2282, \"last_scrape\": \"2018-12-13T16:33:12\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade-2/\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-02-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-01-10, 2014-02-13\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Eltrombopag (Revolade\", \"ncpe_year\": 2014, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-02-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"id\": 2283, \"last_scrape\": \"2018-12-13T16:33:17\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade-3/\", \"rr_start\": \"2016-02-05T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-02-05, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Revolade\", \"ncpe_year\": 2016, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-02-05T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"id\": 2284, \"last_scrape\": \"2018-12-13T16:33:23\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade/\", \"rr_start\": \"2017-12-04T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, WHICH IS NOT COMPARABLE WITH CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2017-12-04, 2018-04-16, 2017-12-01\", \"rr_multiple\": 1, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Cost-effectiveness of eltrombopag (Revolade\", \"ncpe_year\": 2018, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-07-30T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2285, \"last_scrape\": \"2018-12-13T16:33:26\", \"url\": \"http://www.ncpe.ie/drugs/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya/\", \"rr_start\": \"2015-11-24T00:00:00\", \"rr_end\": \"2016-01-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-11-24, 2016-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide (Genvoya\", \"trade_name\": \"Genvoya\", \"indication\": \"Genvoya\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2015-11-24T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2286, \"last_scrape\": \"2018-12-13T16:33:32\", \"url\": \"http://www.ncpe.ie/drugs/empagliflozin-jardiance/\", \"rr_start\": \"2014-05-22T00:00:00\", \"rr_end\": \"2014-06-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-22, 2014-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Empagliflozin (Jardiance\", \"trade_name\": \"Jardiance\", \"indication\": \"Add-on combination therapy \", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-22T00:00:00\", \"latest\": \"2014-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2287, \"last_scrape\": \"2018-12-13T16:33:37\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabine-tenofovir-disoproxil-fumarate-truvada/\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-07-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-12, 2017-07-18\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine / tenofovir disoproxil fumarate (Truvada\", \"trade_name\": \"Truvada\", \"indication\": \"Truvada\", \"ncpe_year\": 2017, \"eu_market\": \"2005-02-20T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-07-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/truvada\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2288, \"last_scrape\": \"2018-12-13T16:33:43\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabine-tenovir-disoproxil-teva/\", \"rr_start\": \"2017-12-11T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-12-11, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir disoproxil (TEVA\", \"trade_name\": \"TEVA\", \"indication\": \"Emtricitabine/tenofovir disoproxil (TEVA\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-12-11T00:00:00\", \"latest\": \"2017-12-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2289, \"last_scrape\": \"2018-12-13T16:33:48\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabinetenofovir-alafenamide-descovy/\", \"rr_start\": \"2016-04-26T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-04-26, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir alafenamide (Descovy\", \"trade_name\": \"Descovy\", \"indication\": \"Descovy\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-04-26T00:00:00\", \"latest\": \"2016-04-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/descovy\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2290, \"last_scrape\": \"2018-12-13T16:33:52\", \"url\": \"http://www.ncpe.ie/drugs/enzalutamide-xtandi/\", \"rr_start\": \"2013-06-28T00:00:00\", \"rr_end\": \"2013-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-28, 2013-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Enzalutamide (Xtandi\", \"trade_name\": \"Xtandi\", \"indication\": \"Enzalutamide (Xtandi\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2013-06-28T00:00:00\", \"latest\": \"2014-04-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2291, \"last_scrape\": \"2018-12-13T16:33:59\", \"url\": \"http://www.ncpe.ie/drugs/epoprostenol-veletri/\", \"rr_start\": \"2016-12-13T00:00:00\", \"rr_end\": \"2017-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-12-13, 2017-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Epoprostenol (Veletri\", \"trade_name\": \"Veletri\", \"indication\": \"Veletri\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-12-13T00:00:00\", \"latest\": \"2017-02-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2292, \"last_scrape\": \"2018-12-13T16:34:03\", \"url\": \"http://www.ncpe.ie/drugs/erenumab-aimovig/\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-15T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF ERENUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-19, 2018-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Erenumab (Aimovig\", \"trade_name\": \"Aimovig\", \"indication\": \"Erenumab (Aimovig\", \"ncpe_year\": 2018, \"eu_market\": \"2018-07-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig\", \"ta_list\": \"Migraine Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2293, \"last_scrape\": \"2018-12-13T16:34:07\", \"url\": \"http://www.ncpe.ie/drugs/eribulin-halaven/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-03-11, 2011-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Eribulin (Halaven\", \"trade_name\": \"Halaven\", \"indication\": \"Eribulin (Halaven\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2011-02-09T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/halaven\", \"ta_list\": \"Breast Neoplasms; Liposarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2294, \"last_scrape\": \"2018-12-13T16:34:09\", \"url\": \"http://www.ncpe.ie/drugs/eslicarbazepine-zebinix/\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-08-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2009-09-01, 2009-08-01\", \"rr_multiple\": 0, \"drug_name\": \"Eslicarbazepine (Zebinix\", \"trade_name\": \"Zebinix\", \"indication\": \"Eslicarbazepine (Zebinix\", \"ncpe_year\": 2009, \"eu_market\": \"2009-04-21T00:00:00\", \"company\": \"BIAL\", \"orphan\": 0, \"earliest\": \"2009-08-01T00:00:00\", \"latest\": \"2009-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2295, \"last_scrape\": \"2018-12-13T16:34:12\", \"url\": \"http://www.ncpe.ie/drugs/etanercept-benepali/\", \"rr_start\": \"2016-03-22T00:00:00\", \"rr_end\": \"2016-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-03-22, 2016-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Etanercept (Benepali\", \"trade_name\": \"Benepali\", \"indication\": \"Benepali\", \"ncpe_year\": 2016, \"eu_market\": \"2016-01-13T00:00:00\", \"company\": \"Samsung\", \"orphan\": 0, \"earliest\": \"2016-03-22T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/benepali\", \"ta_list\": \"Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis\", \"rr_status\": \"No HTA\"}, {\"id\": 2296, \"last_scrape\": \"2018-12-13T16:34:15\", \"url\": \"http://www.ncpe.ie/drugs/etelcalcetide-parsabiv/\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-06-14, 2017-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Etelcalcetide (Parsabiv\", \"trade_name\": \"Parsabiv\", \"indication\": \"Etelcalcitide (Parsabiv\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-11T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/parsabiv\", \"ta_list\": \"Hyperparathyroidism, Secondary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2297, \"last_scrape\": \"2018-12-13T16:34:21\", \"url\": \"http://www.ncpe.ie/drugs/eurartesim-piperaquine-tetraphosphatedihidroartemisinin/\", \"rr_start\": \"2012-05-22T00:00:00\", \"rr_end\": \"2012-05-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-05-22, 2012-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Piperaquine tetraphosphate/dihidroartemisinin (Eurartesim\", \"trade_name\": \"Eurartesim\", \"indication\": \"Eurartesim\", \"ncpe_year\": 2012, \"eu_market\": \"2011-10-27T00:00:00\", \"company\": \"Alfasigma\", \"orphan\": 0, \"earliest\": \"2012-05-22T00:00:00\", \"latest\": \"2012-05-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eurartesim\", \"ta_list\": \"Malaria\", \"rr_status\": \"No HTA\"}, {\"id\": 2298, \"last_scrape\": \"2018-12-13T16:34:24\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-afinitor/\", \"rr_start\": \"2012-09-21T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-09-21, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Afinitor\", \"trade_name\": \"Afinitor\", \"indication\": \"Treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor\", \"ncpe_year\": 2012, \"eu_market\": \"2009-08-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-09-21T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/afinitor\", \"ta_list\": \"Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2299, \"last_scrape\": \"2018-12-13T16:34:26\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-votubia-for-refractory-seizures-associated-with-tuberous-sclerosis-complex-tsc/\", \"rr_start\": \"2017-04-19T00:00:00\", \"rr_end\": \"2017-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-04-19, 2017-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Votubia \", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus (Votubia\", \"ncpe_year\": 2017, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2017-04-19T00:00:00\", \"latest\": \"2017-04-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/votubia\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2300, \"last_scrape\": \"2018-12-13T16:34:29\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-votubia/\", \"rr_start\": \"2011-09-30T00:00:00\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-09-30, 2011-10-14\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Votubia\", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus (Votubia\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2011-09-30T00:00:00\", \"latest\": \"2011-10-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/votubia\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2301, \"last_scrape\": \"2018-12-13T16:34:36\", \"url\": \"http://www.ncpe.ie/drugs/evolocumab-repatha/\", \"rr_start\": \"\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Evolocumab (Repatha\", \"trade_name\": \"Repatha\", \"indication\": \"Evolocumab (Repatha\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-17T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-01-01T00:00:00\", \"latest\": \"2018-05-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/repatha\", \"ta_list\": \"Dyslipidemias; Hypercholesterolemia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2302, \"last_scrape\": \"2018-12-13T16:34:41\", \"url\": \"http://www.ncpe.ie/drugs/exenatide-bydureon/\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Exenatide (Bydureon\", \"trade_name\": \"Bydureon\", \"indication\": \"Exenatide (Bydureon\", \"ncpe_year\": 2011, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2303, \"last_scrape\": \"2018-12-13T16:34:44\", \"url\": \"http://www.ncpe.ie/drugs/fampridine-fampyra/\", \"rr_start\": \"2011-09-11T00:00:00\", \"rr_end\": \"2011-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-09-11, 2011-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Fampridine (Fampyra\", \"trade_name\": \"Fampyra\", \"indication\": \"Fampridine (Fampyra\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-20T00:00:00\", \"company\": \"Blogen\", \"orphan\": 0, \"earliest\": \"2011-09-01T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fampyra\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2304, \"last_scrape\": \"2018-12-13T16:34:48\", \"url\": \"http://www.ncpe.ie/drugs/ferric-maltol-feraccru_/\", \"rr_start\": \"2016-08-12T00:00:00\", \"rr_end\": \"2016-09-06T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-08-12, 2016-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Ferric maltol (Feraccru\", \"trade_name\": \"Feraccru\", \"indication\": \"Ferric maltol indicated for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) in adult patients.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Shield\", \"orphan\": 0, \"earliest\": \"2016-08-12T00:00:00\", \"latest\": \"2016-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/feraccru\", \"ta_list\": \"Anemia, Iron-Deficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2305, \"last_scrape\": \"2018-12-13T16:34:51\", \"url\": \"http://www.ncpe.ie/drugs/fidaxomicin-dificlir/\", \"rr_start\": \"2012-03-09T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2012-03-09, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Fidaxomicin (Dificlir\", \"trade_name\": \"Dificlir\", \"indication\": \"Fidaxomicin is indicated for the treatment of CDI also known as CDAD in adult patients.\", \"ncpe_year\": 2013, \"eu_market\": \"2011-12-05T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-03-09T00:00:00\", \"latest\": \"2013-02-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dificlir\", \"ta_list\": \"Clostridium Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2306, \"last_scrape\": \"2018-12-13T16:34:56\", \"url\": \"http://www.ncpe.ie/drugs/fingolimod-gilenya-4/\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2010-12-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-01-10, 2010-12-03\", \"rr_multiple\": 0, \"drug_name\": \"Fingolimod (Gilenya\", \"trade_name\": \"Gilenya\", \"indication\": \"Cost effectiveness of Fingolimod (Gilenya\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2010-12-03T00:00:00\", \"latest\": \"2011-09-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2307, \"last_scrape\": \"2018-12-13T16:35:01\", \"url\": \"http://www.ncpe.ie/drugs/fluocinolone-acetonide-iluvien/\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-02-15, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Fluocinolone acetonide (Iluvien\", \"trade_name\": \"Iluvien\", \"indication\": \"Iluvien\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2308, \"last_scrape\": \"2018-12-13T16:35:05\", \"url\": \"http://www.ncpe.ie/drugs/fluticasone-furoate-umeclidinium-vilantero-trelegy-ellipta/\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT TRELEGY\", \"rr_dates\": \"2018-04-30, 2018-06-18\", \"rr_multiple\": 0, \"drug_name\": \"Fluticasone furoate/ umeclidinium/ vilantero (Trelegy\", \"trade_name\": \"Trelegy Ellipta\", \"indication\": \"Trelegy\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-15T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"Reimbursement without HTA\"}, {\"id\": 2309, \"last_scrape\": \"2018-12-13T16:35:09\", \"url\": \"http://www.ncpe.ie/drugs/follitropin-delta-rekovelle/\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-07-25, 2017-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Follitropin delta (Rekovelle\", \"trade_name\": \"Rekovelle\", \"indication\": \"Follitropin delta (Rekovelle \", \"ncpe_year\": 2019, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2019-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rekovelle\", \"ta_list\": \"Anovulation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2310, \"last_scrape\": \"2018-12-13T16:35:12\", \"url\": \"http://www.ncpe.ie/drugs/gefitinib-iressa/\", \"rr_start\": \"\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Gefitinib (Iressa\", \"trade_name\": \"Iressa\", \"indication\": \"A review of the economic evaluation of oral gefitinib (Iressa\", \"ncpe_year\": 2010, \"eu_market\": \"2009-06-24T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-16T00:00:00\", \"latest\": \"2010-11-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/iressa\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2311, \"last_scrape\": \"2018-12-13T16:35:15\", \"url\": \"http://www.ncpe.ie/drugs/gemtuzumab-ozogamicin-mylotarg/\", \"rr_start\": \"2018-06-21T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF GEMTUZUMAB OZOGAMICIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-21, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Gemtuzumab ozogamicin (Mylotarg\", \"trade_name\": \"Mylotarg\", \"indication\": \"Gemtuzumab ozogamicin (Mylotarg\", \"ncpe_year\": 2018, \"eu_market\": \"2018-04-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-06-21T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2312, \"last_scrape\": \"2018-12-13T16:35:19\", \"url\": \"http://www.ncpe.ie/drugs/glecaprevirpibrentasvir-maviret/\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-07-11, 2017-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glecaprevir/Pibrentasvir (Maviret\", \"trade_name\": \"Maviret\", \"indication\": \"Glecaprevir/pibrentasvir (Maviret\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/maviret\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2313, \"last_scrape\": \"2018-12-13T16:35:25\", \"url\": \"http://www.ncpe.ie/drugs/glucosamine-sulfate-dona/\", \"rr_start\": \"\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Glucosamine sulfate (Dona\", \"trade_name\": \"Dona\", \"indication\": \"Economic evalution of glucosamine sulfate (Dona\", \"ncpe_year\": 2009, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2009-04-01T00:00:00\", \"latest\": \"2009-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2314, \"last_scrape\": \"2018-12-13T16:35:32\", \"url\": \"http://www.ncpe.ie/drugs/glycerol-phenylbutyrate-ravicti/\", \"rr_start\": \"2018-03-26T00:00:00\", \"rr_end\": \"2018-06-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT GLYCEROL PHENYLBUTYRATE (RAVICTI\", \"rr_dates\": \"2018-03-26, 2018-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Glycerol Phenylbutyrate (Ravicti\", \"trade_name\": \"Ravicti\", \"indication\": \"Glycerol phenylbutyrate (Ravicti\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-26T00:00:00\", \"company\": \"Horizon\", \"orphan\": 1, \"earliest\": \"2018-03-26T00:00:00\", \"latest\": \"2018-06-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti\", \"ta_list\": \"Urea Cycle Disorders, Inborn\", \"rr_status\": \"Reimbursement without HTA\"}, {\"id\": 2315, \"last_scrape\": \"2018-12-13T16:35:38\", \"url\": \"http://www.ncpe.ie/drugs/glycopyrronium-bromide-seebri-breezhaler/\", \"rr_start\": \"2012-08-12T00:00:00\", \"rr_end\": \"2012-08-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-08-12, 2012-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide (Seebri Breezhaler\", \"trade_name\": \"Seebri Breezhaler\", \"indication\": \"Seebri Breezhaler\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-08-12T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"id\": 2316, \"last_scrape\": \"2018-12-13T16:35:40\", \"url\": \"http://www.ncpe.ie/drugs/glypyrronium-bromide-sialanar/\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-07, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide (Sialanar\", \"trade_name\": \"Sialanar\", \"indication\": \"Glycopyrronium bromide (Sialanar\", \"ncpe_year\": 2017, \"eu_market\": \"2016-09-15T00:00:00\", \"company\": \"Proveca\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar\", \"ta_list\": \"Sialorrhea\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2317, \"last_scrape\": \"2018-12-13T16:35:47\", \"url\": \"http://www.ncpe.ie/drugs/golimumab-simponi-2/\", \"rr_start\": \"2013-10-11T00:00:00\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-10-11, 2013-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab (Simponi\", \"trade_name\": \"Simponi\", \"indication\": \"Golimumab is indicated for the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments.\", \"ncpe_year\": 2013, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2013-10-11T00:00:00\", \"latest\": \"2013-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/simponi\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"id\": 2318, \"last_scrape\": \"2018-12-13T16:35:54\", \"url\": \"http://www.ncpe.ie/drugs/golimumab-simponi/\", \"rr_start\": \"\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab (Simponi\", \"trade_name\": \"Simponi\", \"indication\": \"Cost-effectiveness of golimumab (Simponi\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2009-11-20T00:00:00\", \"latest\": \"2010-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/simponi\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2319, \"last_scrape\": \"2018-12-13T16:35:56\", \"url\": \"http://www.ncpe.ie/drugs/grass-pollen-allergen-extract-oralair/\", \"rr_start\": \"2011-10-11T00:00:00\", \"rr_end\": \"2011-09-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-10-11, 2011-09-26\", \"rr_multiple\": 0, \"drug_name\": \"Grass pollen allergen extract (Oralair\", \"trade_name\": \"Oralair\", \"indication\": \" Grass pollen allegen extract (Oralair\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-09-26T00:00:00\", \"latest\": \"2011-10-01T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2320, \"last_scrape\": \"2018-12-13T16:36:00\", \"url\": \"http://www.ncpe.ie/drugs/guanfacine-hydrochloride-intuniv/\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-01, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Guanfacine hydrochloride (Intuniv\", \"trade_name\": \"Intuniv\", \"indication\": \"Intuniv\", \"ncpe_year\": 2015, \"eu_market\": \"2015-09-17T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/intuniv\", \"ta_list\": \"Attention Deficit Disorder with Hyperactivity\", \"rr_status\": \"No HTA\"}, {\"id\": 2321, \"last_scrape\": \"2018-12-13T16:36:02\", \"url\": \"http://www.ncpe.ie/drugs/guselkumab-tremfya/\", \"rr_start\": \"2017-12-01T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-12-01, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Guselkumab (Tremfya\", \"trade_name\": \"Tremfya\", \"indication\": \"Guselkumab (Tremfya\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-10T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-12-01T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2322, \"last_scrape\": \"2018-12-13T16:36:07\", \"url\": \"http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-a1pi-prolastin/\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-06-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-05, 2017-06-08\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor (A1PI) (Prolastin\", \"trade_name\": \"Prolastin\", \"indication\": \"Human A1PI (Prolastin \", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-06-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2323, \"last_scrape\": \"2018-12-13T16:36:14\", \"url\": \"http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-respreeza/\", \"rr_start\": \"2016-01-20T00:00:00\", \"rr_end\": \"2016-02-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-20, 2016-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor (Respreeza\", \"trade_name\": \"Respreeza\", \"indication\": \"Respreeza\", \"ncpe_year\": 2017, \"eu_market\": \"2015-08-20T00:00:00\", \"company\": \"CSL\", \"orphan\": 0, \"earliest\": \"2016-01-20T00:00:00\", \"latest\": \"2017-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza\", \"ta_list\": \"Genetic Diseases, Inborn; Lung Diseases\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2324, \"last_scrape\": \"2018-12-13T16:36:17\", \"url\": \"http://www.ncpe.ie/drugs/hyaluronic-acid-and-co-enzyme-q10-visuxl/\", \"rr_start\": \"2017-11-06T00:00:00\", \"rr_end\": \"2017-11-30T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-11-06, 2017-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Hyaluronic acid and co enzyme Q10 (VisuXL\", \"trade_name\": \"VisuXL\", \"indication\": \"Cross linked hyaluronic acid and co enzyme Q10 (VisuXL\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-11-06T00:00:00\", \"latest\": \"2017-11-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2325, \"last_scrape\": \"2018-12-13T16:36:22\", \"url\": \"http://www.ncpe.ie/drugs/hydrocortisone-plenadren/\", \"rr_start\": \"2017-11-08T00:00:00\", \"rr_end\": \"2017-11-01T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-11-08, 2018-01-11, 2017-11-01\", \"rr_multiple\": 1, \"drug_name\": \"Modified Release Hydrocortisone  (Plenadren\", \"trade_name\": \"Plenadren\", \"indication\": \"Modified release hydrocortisone (Plenadren\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-03T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2018-01-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/plenadren\", \"ta_list\": \"Adrenal Insufficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2326, \"last_scrape\": \"2018-12-13T16:36:27\", \"url\": \"http://www.ncpe.ie/drugs/hydroxcarbamide-siklos/\", \"rr_start\": \"2011-08-22T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-08-22, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Hydroxycarbamide (Siklos\", \"trade_name\": \"Siklos\", \"indication\": \" Hydroxycarbamide (Siklos\", \"ncpe_year\": 2011, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"Addmedica\", \"orphan\": 1, \"earliest\": \"2011-08-22T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/siklos\", \"ta_list\": \"Anemia, Sickle Cell\", \"rr_status\": \"No HTA\"}, {\"id\": 2327, \"last_scrape\": \"2018-12-13T16:36:32\", \"url\": \"http://www.ncpe.ie/drugs/ibrutinib-imbruivca-for-previously-untreated-cll/\", \"rr_start\": \"2016-08-02T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-08-02, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib (Imbruvica\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib (Imbruvica\", \"ncpe_year\": 2016, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-08-02T00:00:00\", \"latest\": \"2016-08-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2328, \"last_scrape\": \"2018-12-13T16:36:36\", \"url\": \"http://www.ncpe.ie/drugs/ibrutinib-imbruvica-for-mcl/\", \"rr_start\": \"2014-11-07T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-11-07, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib (Imbruvica\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib (Imbruvica\", \"ncpe_year\": 2015, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-11-07T00:00:00\", \"latest\": \"2015-10-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2329, \"last_scrape\": \"2018-12-13T16:36:40\", \"url\": \"http://www.ncpe.ie/drugs/icatibant-firazyr/\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Icatibant (Firazyr\", \"trade_name\": \"Firazyr\", \"indication\": \"Icatibant (Firazyr\", \"ncpe_year\": 2013, \"eu_market\": \"2008-07-11T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"id\": 2330, \"last_scrape\": \"2018-12-13T16:36:43\", \"url\": \"http://www.ncpe.ie/drugs/idarucizumab-praxbind/\", \"rr_start\": \"2015-12-11T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-11, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Idarucizumab (Praxbind\", \"trade_name\": \"Praxbind\", \"indication\": \"Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required:\", \"ncpe_year\": 2015, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-12-11T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/praxbind\", \"ta_list\": \"Hemorrhage\", \"rr_status\": \"No HTA\"}, {\"id\": 2331, \"last_scrape\": \"2018-12-13T16:36:50\", \"url\": \"http://www.ncpe.ie/drugs/idebenone-raxone/\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-04-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-10, 2016-04-14\", \"rr_multiple\": 0, \"drug_name\": \"Idebenone (Raxone\", \"trade_name\": \"Raxone\", \"indication\": \"Raxone\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-08T00:00:00\", \"company\": \"Santhera\", \"orphan\": 1, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2018-08-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/raxone\", \"ta_list\": \"Optic Atrophy, Hereditary, Leber\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2332, \"last_scrape\": \"2018-12-13T16:36:56\", \"url\": \"http://www.ncpe.ie/drugs/idelalisib-zydelig/\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2014-12-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-08, 2014-12-30\", \"rr_multiple\": 0, \"drug_name\": \"Idelalisib (Zydelig\", \"trade_name\": \"Zydelig\", \"indication\": \"Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2016-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2333, \"last_scrape\": \"2018-12-13T16:36:59\", \"url\": \"http://www.ncpe.ie/drugs/imiquimod-zyclara/\", \"rr_start\": \"2013-09-10T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-09-10, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Imiquimod 3.75% (Zyclara\", \"trade_name\": \"Zyclara\", \"indication\": \"Imiquimod 3.75%(Zyclara\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Meda\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara\", \"ta_list\": \"Keratosis; Keratosis, Actinic\", \"rr_status\": \"No HTA\"}, {\"id\": 2334, \"last_scrape\": \"2018-12-13T16:37:01\", \"url\": \"http://www.ncpe.ie/drugs/incobotulinum-toxin-type-a-xeomin/\", \"rr_start\": \"2014-02-07T00:00:00\", \"rr_end\": \"2014-03-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-07, 2014-03-05\", \"rr_multiple\": 0, \"drug_name\": \"Incobotulinum Toxin Type A (Xeomin\", \"trade_name\": \"Xeomin\", \"indication\": \"Incobotulinum Toxin Type A (Xeomin\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-02-07T00:00:00\", \"latest\": \"2014-03-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2335, \"last_scrape\": \"2018-12-13T16:37:04\", \"url\": \"http://www.ncpe.ie/drugs/indacaterol-onbrez/\", \"rr_start\": \"2010-01-15T00:00:00\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-01-15\", \"rr_multiple\": 0, \"drug_name\": \"Indacaterol (Onbrez\", \"trade_name\": \"Onbrez\", \"indication\": \"Review of Indacaterol (Onbrez\", \"ncpe_year\": 2010, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-01-15T00:00:00\", \"latest\": \"2010-01-15T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2336, \"last_scrape\": \"2018-12-13T16:37:07\", \"url\": \"http://www.ncpe.ie/drugs/infliximab-inflectra/\", \"rr_start\": \"\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Infliximab (Inflectra\", \"trade_name\": \"Inflectra\", \"indication\": \"Inflectra\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2337, \"last_scrape\": \"2018-12-13T16:37:09\", \"url\": \"http://www.ncpe.ie/drugs/inotuzumab-ozogamicin-besponsa/\", \"rr_start\": \"2017-07-03T00:00:00\", \"rr_end\": \"2017-09-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-03, 2017-09-08\", \"rr_multiple\": 0, \"drug_name\": \"Inotuzumab ozogamicin (Besponsa\", \"trade_name\": \"Besponsa\", \"indication\": \"Inotuzumab ozogamicin (Besponsa\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2017-07-03T00:00:00\", \"latest\": \"2018-09-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2338, \"last_scrape\": \"2018-12-13T16:37:16\", \"url\": \"http://www.ncpe.ie/drugs/insulin-aspart-fiasp/\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-05-17, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart (Fiasp\", \"trade_name\": \"Fiasp\", \"indication\": \"Insulin aspart (Fiasp\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-09T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fiasp\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"No HTA\"}, {\"id\": 2339, \"last_scrape\": \"2018-12-13T16:37:21\", \"url\": \"http://www.ncpe.ie/drugs/insulin-aspart-novorapid-flextouch/\", \"rr_start\": \"2014-07-22T00:00:00\", \"rr_end\": \"2014-08-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2014-07-22, 2014-08-28\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart (NovoRapid\", \"trade_name\": \"NovoRapid FlexTouch\", \"indication\": \"Insulin aspart (NovoRapid\", \"ncpe_year\": 2014, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2014-07-22T00:00:00\", \"latest\": \"2014-08-28T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2340, \"last_scrape\": \"2018-12-13T16:37:25\", \"url\": \"http://www.ncpe.ie/drugs/insulin-degludec-tresiba/\", \"rr_start\": \"2012-12-17T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-17, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Degludec (Tresiba\", \"trade_name\": \"Tresiba\", \"indication\": \"Treatment of diabetes mellitus\", \"ncpe_year\": 2015, \"eu_market\": \"2013-01-20T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2012-12-17T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2341, \"last_scrape\": \"2018-12-13T16:37:30\", \"url\": \"http://www.ncpe.ie/drugs/insulin-degludecliraglutide-ideglira-xultophy/\", \"rr_start\": \"2016-09-19T00:00:00\", \"rr_end\": \"2016-10-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-09-19, 2016-10-17\", \"rr_multiple\": 0, \"drug_name\": \"Insulin degludec/liraglutide (IDegLira) (Xultophy\", \"trade_name\": \"Xultophy\", \"indication\": \"IDegLira is indicated for the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2016-09-19T00:00:00\", \"latest\": \"2016-10-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xultophy\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2342, \"last_scrape\": \"2018-12-13T16:37:36\", \"url\": \"http://www.ncpe.ie/drugs/insulin-glargine-abasaglar/\", \"rr_start\": \"2015-09-04T00:00:00\", \"rr_end\": \"2015-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-09-04, 2015-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine (Abasaglar\", \"trade_name\": \"Abasaglar\", \"indication\": \"Abasaglar\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-09-04T00:00:00\", \"latest\": \"2015-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2343, \"last_scrape\": \"2018-12-13T16:37:40\", \"url\": \"http://www.ncpe.ie/drugs/insulin-glargine-u300-toujeo/\", \"rr_start\": \"2015-05-14T00:00:00\", \"rr_end\": \"2015-07-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2015-05-14, 2015-07-02\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine U300 (Toujeo\", \"trade_name\": \"Toujeo\", \"indication\": \"Toujeo\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-05-14T00:00:00\", \"latest\": \"2015-07-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2344, \"last_scrape\": \"2018-12-13T16:37:43\", \"url\": \"http://www.ncpe.ie/drugs/ipilimumab-yervoy/\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Ipilimumab (Yervoy\", \"trade_name\": \"Yervoy\", \"indication\": \"Pharmacoeconomic evaluation of Ipilimumab (Yervoy\", \"ncpe_year\": 2013, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2013-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2345, \"last_scrape\": \"2018-12-13T16:37:49\", \"url\": \"http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-diafer/\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron (III) isomaltoside 1000 (Diafer\", \"trade_name\": \"Diafer\", \"indication\": \"Diafer\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2346, \"last_scrape\": \"2018-12-13T16:37:52\", \"url\": \"http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-monover/\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron (III) isomaltoside 1000 (Monover\", \"trade_name\": \"Monover\", \"indication\": \"Monover\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2347, \"last_scrape\": \"2018-12-13T16:38:02\", \"url\": \"http://www.ncpe.ie/drugs/iron-isomaltoside-1000-monover/\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2011-02-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-01-10, 2011-02-02\", \"rr_multiple\": 0, \"drug_name\": \"Iron isomaltoside 1000 (MonoVer\", \"trade_name\": \"MonoVer\", \"indication\": \"MonoVer is indicated for the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-01-10T00:00:00\", \"latest\": \"2011-02-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2348, \"last_scrape\": \"2018-12-13T16:38:07\", \"url\": \"http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-invasive-aspergillosis/\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole (Cresemba\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole (Cresemba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2349, \"last_scrape\": \"2018-12-13T16:38:09\", \"url\": \"http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-mucormycosis/\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole (Cresemba\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole (Cresemba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2350, \"last_scrape\": \"2018-12-13T16:38:15\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kaldeco/\", \"rr_start\": \"2012-08-13T00:00:00\", \"rr_end\": \"2012-08-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-08-13, 2012-08-22\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2012-08-13T00:00:00\", \"latest\": \"2013-01-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2351, \"last_scrape\": \"2018-12-13T16:38:21\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-patients-with-cf-2-years/\", \"rr_start\": \"2015-11-19T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMAOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-19, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\", \"ncpe_year\": 2016, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2015-11-19T00:00:00\", \"latest\": \"2016-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2352, \"last_scrape\": \"2018-12-13T16:38:24\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-the-treatment-of-cf-patients-with-the-r117h-mutation/\", \"rr_start\": \"2016-01-14T00:00:00\", \"rr_end\": \"2016-02-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-14, 2016-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\", \"ncpe_year\": 2017, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2016-01-14T00:00:00\", \"latest\": \"2017-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2353, \"last_scrape\": \"2018-12-13T16:38:29\", \"url\": \"http://www.ncpe.ie/drugs/ixazomib-ninlaro/\", \"rr_start\": \"2016-11-23T00:00:00\", \"rr_end\": \"2017-01-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-23, 2017-01-16\", \"rr_multiple\": 0, \"drug_name\": \"Ixazomib (Ninlaro\", \"trade_name\": \"Ninlaro\", \"indication\": \"Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-21T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2016-11-23T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2354, \"last_scrape\": \"2018-12-13T16:38:34\", \"url\": \"http://www.ncpe.ie/drugs/ixekizumab-taltz-for-psoriatic-arthritis/\", \"rr_start\": \"2018-10-16T00:00:00\", \"rr_end\": \"2018-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT IXEKIZUMAB NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE. THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013\", \"rr_dates\": \"2018-10-16, 2018-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab (Taltz\", \"trade_name\": \"Taltz\", \"indication\": \"Ixekizumab (Taltz\", \"ncpe_year\": 2018, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2018-10-16T00:00:00\", \"latest\": \"2018-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/taltz\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2355, \"last_scrape\": \"2018-12-13T16:38:37\", \"url\": \"http://www.ncpe.ie/drugs/ixekizumab-taltz/\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-06-28, 2016-07-26\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab (Taltz\", \"trade_name\": \"Taltz\", \"indication\": \"Taltz\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/taltz\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2356, \"last_scrape\": \"2018-12-13T16:38:39\", \"url\": \"http://www.ncpe.ie/drugs/l/lisdexamfetamine-dimesylate-tyvense/\", \"rr_start\": \"2013-02-09T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-02-09, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Lisdexamfetamine dimesylate (Tyvense\", \"trade_name\": \"Tyvense\", \"indication\": \"Lisdexamfetamine dimesylate (Tyvense\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-02-09T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2357, \"last_scrape\": \"2018-12-13T16:38:44\", \"url\": \"http://www.ncpe.ie/drugs/lacosamide-vimpat/\", \"rr_start\": \"2017-09-11T00:00:00\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-09-11, 2017-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Lacosamide (Vimpat \", \"trade_name\": \"Vimpat\", \"indication\": \"Vimpat \", \"ncpe_year\": 2017, \"eu_market\": \"2008-08-29T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2017-09-11T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2358, \"last_scrape\": \"2018-12-13T16:38:50\", \"url\": \"http://www.ncpe.ie/drugs/lapatinib-tyverb/\", \"rr_start\": \"\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Lapatinib (Tyverb\", \"trade_name\": \"Tyverb\", \"indication\": \"Cost-effectiveness of Lapatinib (Tyverb\", \"ncpe_year\": 2008, \"eu_market\": \"2008-06-10T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2359, \"last_scrape\": \"2018-12-13T16:38:56\", \"url\": \"http://www.ncpe.ie/drugs/ledipasvirsofosbuvir-harvoni/\", \"rr_start\": \"2014-11-14T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-11-14, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ledipasvir/sofosbuvir (Harvoni\", \"trade_name\": \"Harvoni\", \"indication\": \"Ledipasvir/sofosbuvir (Harvoni\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-17T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-11-14T00:00:00\", \"latest\": \"2015-11-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2360, \"last_scrape\": \"2018-12-13T16:39:05\", \"url\": \"http://www.ncpe.ie/drugs/lenalidomide-revlimid/\", \"rr_start\": \"2015-10-05T00:00:00\", \"rr_end\": \"2015-11-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE.\", \"rr_dates\": \"2015-10-05, 2015-11-20\", \"rr_multiple\": 0, \"drug_name\": \"Lenalidomide (Revlimid\", \"trade_name\": \"Revlimid\", \"indication\": \"Revlimid\", \"ncpe_year\": 2018, \"eu_market\": \"2007-06-14T00:00:00\", \"company\": \"Celgene\", \"orphan\": 1, \"earliest\": \"2015-10-05T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid\", \"ta_list\": \"Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2361, \"last_scrape\": \"2018-12-13T16:39:07\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-kisplyx/\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-05-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-05-05, 2017-05-18\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Kisplyx\", \"trade_name\": \"Kisplyx\", \"indication\": \"Lenvatinib (Kisplyx\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-25T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-05-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2362, \"last_scrape\": \"2018-12-13T16:39:11\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-lenvima-2/\", \"rr_start\": \"2018-08-07T00:00:00\", \"rr_end\": \"2018-08-16T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF LENVATINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-08-07, 2018-08-16\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Lenvima\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib (Lenvima\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2018-08-07T00:00:00\", \"latest\": \"2018-08-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2363, \"last_scrape\": \"2018-12-13T16:39:15\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-lenvima/\", \"rr_start\": \"2015-05-05T00:00:00\", \"rr_end\": \"2015-07-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2015-05-05, 2015-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Lenvima\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/H\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2015-05-05T00:00:00\", \"latest\": \"2015-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2364, \"last_scrape\": \"2018-12-13T16:39:20\", \"url\": \"http://www.ncpe.ie/drugs/lesinurad-zurampic/\", \"rr_start\": \"2017-03-15T00:00:00\", \"rr_end\": \"2017-03-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-15, 2017-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Lesinurad (Zurampic\", \"trade_name\": \"Zurampic\", \"indication\": \"Lesinurad (Zurampic\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Gr\", \"orphan\": 0, \"earliest\": \"2017-03-15T00:00:00\", \"latest\": \"2018-12-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zurampic\", \"ta_list\": \"Hyperuricemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2365, \"last_scrape\": \"2018-12-13T16:39:25\", \"url\": \"http://www.ncpe.ie/drugs/letermovir-prevymis/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Letermovir (Prevymis\", \"trade_name\": \"Prevymis\", \"indication\": \"Letermovir for the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevymis\", \"ta_list\": \"Cytomegalovirus Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2366, \"last_scrape\": \"2018-12-13T16:39:28\", \"url\": \"http://www.ncpe.ie/drugs/levodopa-20mgml-carbidopa-monohydrate-5mg-intestinal-gel-duodopa/\", \"rr_start\": \"2013-03-13T00:00:00\", \"rr_end\": \"2013-04-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-03-13, 2013-04-16\", \"rr_multiple\": 0, \"drug_name\": \"Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel (Duodopa\", \"trade_name\": \"Duodopa\", \"indication\": \"For the treatment of advanced levodopa-responsive Parkinson\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-13T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2367, \"last_scrape\": \"2018-12-13T16:39:34\", \"url\": \"http://www.ncpe.ie/drugs/levofloxacin-quinsair/\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-02-10, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Levofloxacin (Quinsair\", \"trade_name\": \"Quinsair\", \"indication\": \"Levofloxacin (Quinsair\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-25T00:00:00\", \"company\": \"Horizon\", \"orphan\": 0, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/quinsair\", \"ta_list\": \"Cystic Fibrosis; Respiratory Tract Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2368, \"last_scrape\": \"2018-12-13T16:39:39\", \"url\": \"http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-delivery-system-lng-ius-12-kyleena/\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-02-08, 2017-03-16\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine delivery system LNG IUS 12 (Kyleena\", \"trade_name\": \"Kyleena\", \"indication\": \"Kyleena\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2017-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2369, \"last_scrape\": \"2018-12-13T16:39:44\", \"url\": \"http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-system-lng-ius-jaydess/\", \"rr_start\": \"2013-03-07T00:00:00\", \"rr_end\": \"2013-03-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-03-07, 2013-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine system LNG-IUS (Jaydess\", \"trade_name\": \"Jaydess\", \"indication\": \"Levonorgestrel Intrauterine System LNG-IUS (Jaydess\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-07T00:00:00\", \"latest\": \"2013-03-25T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2370, \"last_scrape\": \"2018-12-13T16:39:46\", \"url\": \"http://www.ncpe.ie/drugs/lidocaine-5-plasters-versatis/\", \"rr_start\": \"2010-09-09T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2010-09-09, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Lidocaine 5% plasters (Versatis\", \"trade_name\": \"Versatis\", \"indication\": \"Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN).\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-09-09T00:00:00\", \"latest\": \"2015-09-24T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2371, \"last_scrape\": \"2018-12-13T16:39:51\", \"url\": \"http://www.ncpe.ie/drugs/linaclotide-clonstella/\", \"rr_start\": \"2013-05-28T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-05-28, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Linaclotide (Constella\", \"trade_name\": \"Constella\", \"indication\": \"Linaclotide (Constella\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2013-05-28T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/constella\", \"ta_list\": \"Irritable Bowel Syndrome\", \"rr_status\": \"No HTA\"}, {\"id\": 2372, \"last_scrape\": \"2018-12-13T16:39:54\", \"url\": \"http://www.ncpe.ie/drugs/linagliptin-trajenta/\", \"rr_start\": \"2011-08-18T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-08-18, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Linagliptin (Trajenta\", \"trade_name\": \"Trajenta\", \"indication\": \"Lingagliptin (Trajenta\", \"ncpe_year\": 2011, \"eu_market\": \"2011-08-23T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2011-08-18T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2373, \"last_scrape\": \"2018-12-13T16:39:57\", \"url\": \"http://www.ncpe.ie/drugs/lipegfilgrastim-lonquex/\", \"rr_start\": \"2013-08-20T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-08-20, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Lipegfilgrastim (Lonquex\", \"trade_name\": \"Lonquex\", \"indication\": \"Lonquex\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-25T00:00:00\", \"company\": \"Sicor\", \"orphan\": 0, \"earliest\": \"2013-08-20T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex\", \"ta_list\": \"Neutropenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2374, \"last_scrape\": \"2018-12-13T16:40:00\", \"url\": \"http://www.ncpe.ie/drugs/liposomal-daunorubicin-and-cytarabine-cpx-351vyxeos/\", \"rr_start\": \"2018-09-28T00:00:00\", \"rr_end\": \"2018-11-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-09-28, 2018-11-08\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos\", \"trade_name\": \"Vyxeos\", \"indication\": \"Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Jazz\", \"orphan\": 1, \"earliest\": \"2018-09-28T00:00:00\", \"latest\": \"2018-11-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2375, \"last_scrape\": \"2018-12-13T16:40:06\", \"url\": \"http://www.ncpe.ie/drugs/liposomal-irinotecan-nal-iri-onivyde/\", \"rr_start\": \"2017-06-13T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-13, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal irinotecan (Onivyde\", \"trade_name\": \"Onivyde\", \"indication\": \"Liposomal irinotecan (Onivyde\", \"ncpe_year\": 2017, \"eu_market\": \"2016-10-14T00:00:00\", \"company\": \"Baxalta\", \"orphan\": 1, \"earliest\": \"2017-06-13T00:00:00\", \"latest\": \"2017-07-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-0\", \"ta_list\": \"Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2376, \"last_scrape\": \"2018-12-13T16:40:09\", \"url\": \"http://www.ncpe.ie/drugs/liquid-paraffin-ointment-vita-pos-opthalmic/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Liquid Paraffin Ointment (VitA-POS Opthalmic\", \"trade_name\": \"VitA-POS Opthalmic\", \"indication\": \"Liquid Paraffin Ointment (VitA-POS Opthalmic\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2377, \"last_scrape\": \"2018-12-13T16:40:13\", \"url\": \"http://www.ncpe.ie/drugs/liraglutide-victoza/\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-10-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-09-01, 2009-10-07\", \"rr_multiple\": 0, \"drug_name\": \"Liraglutide (Victoza\", \"trade_name\": \"Victoza\", \"indication\": \"Victoza\", \"ncpe_year\": 2018, \"eu_market\": \"2009-06-30T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2009-09-01T00:00:00\", \"latest\": \"2018-10-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/victoza\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2378, \"last_scrape\": \"2018-12-13T16:40:17\", \"url\": \"http://www.ncpe.ie/drugs/lixisenatide-lyxumia/\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Lixisenatide (Lyxumia\", \"trade_name\": \"Lyxumia\", \"indication\": \"Lixisenatide (Lyxumia\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-08-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2379, \"last_scrape\": \"2018-12-13T16:40:19\", \"url\": \"http://www.ncpe.ie/drugs/lomitapide-lojuxta/\", \"rr_start\": \"2014-09-09T00:00:00\", \"rr_end\": \"2014-09-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-09-09, 2014-09-15\", \"rr_multiple\": 0, \"drug_name\": \"Lomitapide (Lojuxta\", \"trade_name\": \"Lojuxta\", \"indication\": \"Lojuxta\", \"ncpe_year\": 2014, \"eu_market\": \"2013-07-31T00:00:00\", \"company\": \"Amryt\", \"orphan\": 0, \"earliest\": \"2014-09-09T00:00:00\", \"latest\": \"2014-09-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2380, \"last_scrape\": \"2018-12-13T16:40:22\", \"url\": \"http://www.ncpe.ie/drugs/lornoxicam-xefo/\", \"rr_start\": \"2011-06-23T00:00:00\", \"rr_end\": \"2011-07-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-06-23, 2011-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Lornoxicam (Xefo\", \"trade_name\": \"Xefo\", \"indication\": \" Lornoxicam (Xefo\", \"ncpe_year\": 2011, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-06-23T00:00:00\", \"latest\": \"2011-07-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA\"}, {\"id\": 2381, \"last_scrape\": \"2018-12-13T16:40:24\", \"url\": \"http://www.ncpe.ie/drugs/lotemax-0-5-eye-drops-suspension-loteprednol/\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2011-12-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-11-15, 2011-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Lotemax 0.5% eye drops suspension (Loteprednol)\", \"trade_name\": \"Loteprednol\", \"indication\": \" Indicated for treatment of post-operative inflammation following ocular surgery.\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2011-12-05T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2382, \"last_scrape\": \"2018-12-13T16:40:30\", \"url\": \"http://www.ncpe.ie/drugs/loxapine-inhalation-powder-adasuve/\", \"rr_start\": \"2016-06-21T00:00:00\", \"rr_end\": \"2016-07-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-06-21, 2016-07-28\", \"rr_multiple\": 0, \"drug_name\": \"Loxapine inhalation powder (Adasuve\", \"trade_name\": \"Adasuve\", \"indication\": \"Inhaled loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-02-20T00:00:00\", \"company\": \"Ferrer\", \"orphan\": 0, \"earliest\": \"2016-06-21T00:00:00\", \"latest\": \"2016-07-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve\", \"ta_list\": \"Schizophrenia; Bipolar Disorder\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2383, \"last_scrape\": \"2018-12-13T16:40:34\", \"url\": \"http://www.ncpe.ie/drugs/lumacaftorivacaftor-orkambi/\", \"rr_start\": \"2015-11-26T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-26, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Lumacaftor/ivacaftor (Orkambi\", \"trade_name\": \"Orkambi\", \"indication\": \"Orkambi\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Vertex\", \"orphan\": 0, \"earliest\": \"2015-11-26T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/orkambi\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2384, \"last_scrape\": \"2018-12-13T16:40:36\", \"url\": \"http://www.ncpe.ie/drugs/lutetium-177lu-oxodotreotide-lutathera/\", \"rr_start\": \"2018-10-23T00:00:00\", \"rr_end\": \"2018-11-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-10-23, 2018-11-16\", \"rr_multiple\": 0, \"drug_name\": \"Lutetium (177Lu) Oxodotreotide (Lutathera\", \"trade_name\": \"Lutathera\", \"indication\": \"Lutetium (177Lu) Oxodotreotide (Lutathera\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-26T00:00:00\", \"company\": \"Advanced\", \"orphan\": 1, \"earliest\": \"2018-10-23T00:00:00\", \"latest\": \"2018-11-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2385, \"last_scrape\": \"2018-12-13T16:40:41\", \"url\": \"http://www.ncpe.ie/drugs/macitentan-opsumit/\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-10, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Macitentan (Opsumit\", \"trade_name\": \"Opsumit\", \"indication\": \"Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-12-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2386, \"last_scrape\": \"2018-12-13T16:40:43\", \"url\": \"http://www.ncpe.ie/drugs/melatonin-circadin/\", \"rr_start\": \"\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Melatonin (Circadin\", \"trade_name\": \"Circadin\", \"indication\": \"A Review of the Economic Evaluation of Prolonged Release Melatonin (Circadin\", \"ncpe_year\": 2008, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"RAD\", \"orphan\": 0, \"earliest\": \"2008-08-01T00:00:00\", \"latest\": \"2008-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/circadin\", \"ta_list\": \"Sleep Initiation and Maintenance Disorders\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2387, \"last_scrape\": \"2018-12-13T16:40:45\", \"url\": \"http://www.ncpe.ie/drugs/mepolizumab-nucala/\", \"rr_start\": \"2016-03-16T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-03-16, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Mepolizumab (Nucala\", \"trade_name\": \"Nucala\", \"indication\": \"Mepolizumab (Nucala\", \"ncpe_year\": 2018, \"eu_market\": \"2015-12-01T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-03-16T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nucala\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2388, \"last_scrape\": \"2018-12-13T16:40:51\", \"url\": \"http://www.ncpe.ie/drugs/methoxyflurane-penthrox/\", \"rr_start\": \"2015-11-23T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-11-23, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Methoxyflurane (Penthrox\", \"trade_name\": \"Penthrox\", \"indication\": \"Penthrox\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2015-11-23T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2389, \"last_scrape\": \"2018-12-13T16:40:56\", \"url\": \"http://www.ncpe.ie/drugs/midostaurin-rydapt-for-aml/\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF MIDOSTAURIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin (Rydapt\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin (Rydapt\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2390, \"last_scrape\": \"2018-12-13T16:41:02\", \"url\": \"http://www.ncpe.ie/drugs/midostaurin-rydapt-for-asm/\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF MIDOSTAURIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin (Rydapt\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin (Rydapt\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2391, \"last_scrape\": \"2018-12-13T16:41:04\", \"url\": \"http://www.ncpe.ie/drugs/mifamurtide-mepact/\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-06-22, 2010-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Mifamurtide (Mepact\", \"trade_name\": \"Mepact\", \"indication\": \"Mifamurtide (Meptact\", \"ncpe_year\": 2010, \"eu_market\": \"2009-03-06T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2010-06-22T00:00:00\", \"latest\": \"2010-07-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mepact\", \"ta_list\": \"Osteosarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2392, \"last_scrape\": \"2018-12-13T16:41:06\", \"url\": \"http://www.ncpe.ie/drugs/migalastat-galafold/\", \"rr_start\": \"2016-07-14T00:00:00\", \"rr_end\": \"2016-08-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-07-14, 2016-08-18\", \"rr_multiple\": 0, \"drug_name\": \"Migalastat (Galafold\", \"trade_name\": \"Galafold\", \"indication\": \"Migalastat is indicated for the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-05-25T00:00:00\", \"company\": \"Amicus\", \"orphan\": 1, \"earliest\": \"2016-07-14T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/galafold\", \"ta_list\": \"Fabry Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2393, \"last_scrape\": \"2018-12-13T16:41:13\", \"url\": \"http://www.ncpe.ie/drugs/mirabegron-betmiga/\", \"rr_start\": \"2012-12-19T00:00:00\", \"rr_end\": \"2013-03-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-12-19, 2013-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Mirabegron (Betmiga\", \"trade_name\": \"Betmiga\", \"indication\": \"Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome\", \"ncpe_year\": 2013, \"eu_market\": \"2012-12-20T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-12-19T00:00:00\", \"latest\": \"2013-03-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga\", \"ta_list\": \"Urinary Bladder, Overactive\", \"rr_status\": \"No HTA\"}, {\"id\": 2394, \"last_scrape\": \"2018-12-13T16:41:15\", \"url\": \"http://www.ncpe.ie/drugs/nab-paclitaxel-abraxane/\", \"rr_start\": \"2014-01-23T00:00:00\", \"rr_end\": \"2014-03-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-01-23, 2014-03-02\", \"rr_multiple\": 0, \"drug_name\": \"Nab-paclitaxel (Abraxane\", \"trade_name\": \"Abraxane\", \"indication\": \"Nab-paclitaxel (Abraxane\", \"ncpe_year\": 2015, \"eu_market\": \"2008-01-10T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2014-01-23T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane\", \"ta_list\": \"Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2395, \"last_scrape\": \"2018-12-13T16:41:18\", \"url\": \"http://www.ncpe.ie/drugs/nalmefene-selincro/\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Nalmefene (Selincro\", \"trade_name\": \"Selincro\", \"indication\": \"Nalmefene (Selincro\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-24T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2014-04-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/selincro\", \"ta_list\": \"Alcohol-Related Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2396, \"last_scrape\": \"2018-12-13T16:41:24\", \"url\": \"http://www.ncpe.ie/drugs/naloxegel-moventig/\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-04-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-02-10, 2015-04-13\", \"rr_multiple\": 0, \"drug_name\": \"Naloxegel (Moventig\", \"trade_name\": \"Moventig\", \"indication\": \"Naloxegel (Moventiq\", \"ncpe_year\": 2015, \"eu_market\": \"2014-12-07T00:00:00\", \"company\": \"Kyowa\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-04-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/moventig\", \"ta_list\": \"Constipation; Opioid-Related Disorders\", \"rr_status\": \"No HTA\"}, {\"id\": 2397, \"last_scrape\": \"2018-12-13T16:41:26\", \"url\": \"http://www.ncpe.ie/drugs/naltrexone-bupropion-mysimba/\", \"rr_start\": \"2017-03-12T00:00:00\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-12, 2017-03-28\", \"rr_multiple\": 0, \"drug_name\": \"Naltrexone / bupropion (Mysimba\", \"trade_name\": \"Mysimba\", \"indication\": \"Naltrexone / bupropion (Mysimba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-03-26T00:00:00\", \"company\": \"Orexigen\", \"orphan\": 0, \"earliest\": \"2017-03-12T00:00:00\", \"latest\": \"2018-05-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba\", \"ta_list\": \"Obesity; Overweight\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2398, \"last_scrape\": \"2018-12-13T16:41:30\", \"url\": \"http://www.ncpe.ie/drugs/natalizumab-tysabri/\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Natalizumab (Tysabri\", \"trade_name\": \"Tysabri\", \"indication\": \" Economic Evaluation of Natalizumab (Tysabri\", \"ncpe_year\": 2007, \"eu_market\": \"2006-06-27T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2007-01-01T00:00:00\", \"latest\": \"2007-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2399, \"last_scrape\": \"2018-12-13T16:41:35\", \"url\": \"http://www.ncpe.ie/drugs/ncpe-inhaled-insulin-exubera-assessment/\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Inhaled insulin (Exubera\", \"trade_name\": \"Exubera\", \"indication\": \"In April 2006, Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin (Exubera\", \"ncpe_year\": 2006, \"eu_market\": \"2006-01-24T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-03-01T00:00:00\", \"latest\": \"2006-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/exubera\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2400, \"last_scrape\": \"2018-12-13T16:41:38\", \"url\": \"http://www.ncpe.ie/drugs/nepafenac-nevanac-2/\", \"rr_start\": \"2011-06-14T00:00:00\", \"rr_end\": \"2011-06-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-06-14, 2011-06-27\", \"rr_multiple\": 0, \"drug_name\": \"Nepafenac (Nevanac\", \"trade_name\": \"Nevanac\", \"indication\": \"Nepafenac (Nevanac\", \"ncpe_year\": 2011, \"eu_market\": \"2007-12-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2011-06-14T00:00:00\", \"latest\": \"2011-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac\", \"ta_list\": \"Pain, Postoperative; Ophthalmologic Surgical Procedures\", \"rr_status\": \"No HTA\"}, {\"id\": 2401, \"last_scrape\": \"2018-12-13T16:41:41\", \"url\": \"http://www.ncpe.ie/drugs/netupitantpalonosetron-akynzeo/\", \"rr_start\": \"2015-08-26T00:00:00\", \"rr_end\": \"2015-10-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-08-26, 2015-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Netupitant/palonosetron (Akynzeo\", \"trade_name\": \"Akynzeo\", \"indication\": \"Akynzeo\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Helsinn\", \"orphan\": 0, \"earliest\": \"2015-08-26T00:00:00\", \"latest\": \"2015-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo\", \"ta_list\": \"Vomiting; Cancer; Nausea\", \"rr_status\": \"No HTA\"}, {\"id\": 2402, \"last_scrape\": \"2018-12-13T16:41:44\", \"url\": \"http://www.ncpe.ie/drugs/nilotinib-tasigna-newly-diagnosed-cml/\", \"rr_start\": \"2010-10-06T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2010-10-06, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib (Tasigna\", \"trade_name\": \"Tasigna\", \"indication\": \"Nilotinib (Tasigna\", \"ncpe_year\": 2010, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-10-06T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2403, \"last_scrape\": \"2018-12-13T16:41:51\", \"url\": \"http://www.ncpe.ie/drugs/nilotinib-tasigna/\", \"rr_start\": \"\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib (Tasigna\", \"trade_name\": \"Tasigna\", \"indication\": \"Cost-effectiveness of Nilotinib (Tasigna\", \"ncpe_year\": 2008, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2404, \"last_scrape\": \"2018-12-13T16:41:53\", \"url\": \"http://www.ncpe.ie/drugs/nintedanib-ofev/\", \"rr_start\": \"2015-01-30T00:00:00\", \"rr_end\": \"2015-02-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-30, 2015-02-18\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib (Ofev\", \"trade_name\": \"Ofev\", \"indication\": \"Nintedanib (Ofev\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 1, \"earliest\": \"2015-01-30T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ofev\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2405, \"last_scrape\": \"2018-12-13T16:41:56\", \"url\": \"http://www.ncpe.ie/drugs/nintedanib-vargatef/\", \"rr_start\": \"2015-01-02T00:00:00\", \"rr_end\": \"2015-02-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-02, 2015-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib (Vargatef\", \"trade_name\": \"Vargatef\", \"indication\": \"Nintedanib (Vargatef\", \"ncpe_year\": 2017, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-01-02T00:00:00\", \"latest\": \"2017-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2406, \"last_scrape\": \"2018-12-13T16:42:00\", \"url\": \"http://www.ncpe.ie/drugs/niraparib-zejula/\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF NIRAPARIB COMPARED WITH THE CURRENT STANDARD OF CARE\", \"rr_dates\": \"2018-06-01, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Niraparib (Zejula\", \"trade_name\": \"Zejula\", \"indication\": \"Niraparib (Zejula\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-16T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 1, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zejula\", \"ta_list\": \"Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2407, \"last_scrape\": \"2018-12-13T16:42:06\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-melanoma/\", \"rr_start\": \"2015-05-28T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-05-28, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-05-28T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2408, \"last_scrape\": \"2018-12-13T16:42:13\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-non-squamous-nsclc/\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-03-03, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2409, \"last_scrape\": \"2018-12-13T16:42:20\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-nsclc/\", \"rr_start\": \"2015-07-02T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-07-02, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-07-02T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2410, \"last_scrape\": \"2018-12-13T16:42:26\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-as-monotherapy-for-the-adjuvant-treatment-of-adults-with-melanoma/\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF NIVOLUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-09, 2018-07-27\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-11-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2411, \"last_scrape\": \"2018-12-13T16:42:31\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-advanced-renal-cell-carcinoma/\", \"rr_start\": \"2016-04-27T00:00:00\", \"rr_end\": \"2016-05-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-04-27, 2016-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-04-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2412, \"last_scrape\": \"2018-12-13T16:42:33\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-classical-hodgkin-lymphoma/\", \"rr_start\": \"2016-11-22T00:00:00\", \"rr_end\": \"2017-01-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-11-22, 2017-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-11-22T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2413, \"last_scrape\": \"2018-12-13T16:42:36\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-head-and-neck-cancer/\", \"rr_start\": \"2017-05-03T00:00:00\", \"rr_end\": \"2017-05-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-03, 2017-05-30\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-05-03T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2414, \"last_scrape\": \"2018-12-13T16:42:41\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-urothelial-carcinoma/\", \"rr_start\": \"2017-06-28T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-28, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-06-28T00:00:00\", \"latest\": \"2018-09-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2415, \"last_scrape\": \"2018-12-13T16:42:46\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-in-combination-with-ipilimumab-yervoy/\", \"rr_start\": \"2018-11-28T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-11-28, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Yervoy\", \"indication\": \"Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).\", \"ncpe_year\": 2018, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-11-28T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy\", \"ta_list\": \"Melanoma\", \"rr_status\": \"Unknown\"}, {\"id\": 2416, \"last_scrape\": \"2018-12-13T16:42:51\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-plus-ipilimumab-opdivio-plus-yervoy/\", \"rr_start\": \"\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab plus ipilimumab (Opdivo\", \"trade_name\": \"Opdivo plus Yervoy\", \"indication\": \"Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-06-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2417, \"last_scrape\": \"2018-12-13T16:42:56\", \"url\": \"http://www.ncpe.ie/drugs/nomace2-zoely/\", \"rr_start\": \"2011-12-08T00:00:00\", \"rr_end\": \"2012-01-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-12-08, 2012-01-03\", \"rr_multiple\": 0, \"drug_name\": \"Nomegestrol acetate/estradiol (Zoely\", \"trade_name\": \"Zoely\", \"indication\": \"Nomegestrol acetate/estradiol (Zoely\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-26T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2011-12-08T00:00:00\", \"latest\": \"2012-01-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zoely\", \"ta_list\": \"Contraception\", \"rr_status\": \"No HTA\"}, {\"id\": 2418, \"last_scrape\": \"2018-12-13T16:43:02\", \"url\": \"http://www.ncpe.ie/drugs/nusinersin-spinraza/\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-11, 2017-08-02\", \"rr_multiple\": 0, \"drug_name\": \"Nusinersin (Spinraza\", \"trade_name\": \"Spinraza\", \"indication\": \"Nusinersen (Spinraza\", \"ncpe_year\": 2017, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 1, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-12-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza\", \"ta_list\": \"Muscular Atrophy, Spinal\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2419, \"last_scrape\": \"2018-12-13T16:43:07\", \"url\": \"http://www.ncpe.ie/drugs/obeticholic-acid-ocaliva/\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-18, 2016-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Obeticholic acid (Ocaliva\", \"trade_name\": \"Ocaliva\", \"indication\": \"Obeticholic acid is indicated for the treatment of primary biliary cirrhosis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Intercept\", \"orphan\": 1, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocaliva\", \"ta_list\": \"Liver Cirrhosis, Biliary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2420, \"last_scrape\": \"2018-12-13T16:43:10\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-follicular-lymphoma/\", \"rr_start\": \"2016-05-11T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-05-11, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (in combination with bendamustine) followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2016-05-11T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2421, \"last_scrape\": \"2018-12-13T16:43:15\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-previously-untreated-advanced-follicular-lymphoma/\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-09-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-08, 2017-09-13\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (Gazyvaro\", \"ncpe_year\": 2018, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2422, \"last_scrape\": \"2018-12-13T16:43:21\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro/\", \"rr_start\": \"2014-08-08T00:00:00\", \"rr_end\": \"2014-09-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-08-08, 2014-09-11\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (Gazyvaro\", \"ncpe_year\": 2015, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2014-08-08T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2423, \"last_scrape\": \"2018-12-13T16:43:24\", \"url\": \"http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-ppms/\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab (Ocrevus\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab (Ocrevus\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2424, \"last_scrape\": \"2018-12-13T16:43:30\", \"url\": \"http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-rms/\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab (Ocrevus\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab (Ocrevus\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2425, \"last_scrape\": \"2018-12-13T16:43:34\", \"url\": \"http://www.ncpe.ie/drugs/ocriplasmin-jetrea/\", \"rr_start\": \"2013-06-12T00:00:00\", \"rr_end\": \"2013-07-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-06-12, 2013-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Ocriplasmin (Jetrea\", \"trade_name\": \"Jetrea\", \"indication\": \"Ocriplasmin (Jetrea\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-13T00:00:00\", \"company\": \"ThromboGenics\", \"orphan\": 0, \"earliest\": \"2013-06-12T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea\", \"ta_list\": \"Retinal Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2426, \"last_scrape\": \"2018-12-13T16:43:39\", \"url\": \"http://www.ncpe.ie/drugs/ofatumumab-arzerra-previously-untreated-chronic-lymphocytic-leukaemia/\", \"rr_start\": \"2014-10-13T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2014-10-13, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab (Arzerra\", \"trade_name\": \"Arzerra\", \"indication\": \"Ofatumumab (Arzerra\", \"ncpe_year\": 2014, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-10-13T00:00:00\", \"latest\": \"2014-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2427, \"last_scrape\": \"2018-12-13T16:43:46\", \"url\": \"http://www.ncpe.ie/drugs/ofatumumab-arzerra/\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-06-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-06-22, 2010-06-01\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab (Arzerra\", \"trade_name\": \"Arzerra\", \"indication\": \"Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-06-01T00:00:00\", \"latest\": \"2010-06-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2428, \"last_scrape\": \"2018-12-13T16:43:52\", \"url\": \"http://www.ncpe.ie/drugs/oladaterol-striverdi-respimat/\", \"rr_start\": \"2014-04-07T00:00:00\", \"rr_end\": \"2014-05-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-07, 2014-05-02\", \"rr_multiple\": 0, \"drug_name\": \"Oladaterol (Striverdi\", \"trade_name\": \"Striverdi, Respimat\", \"indication\": \"Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-04-07T00:00:00\", \"latest\": \"2014-05-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2429, \"last_scrape\": \"2018-12-13T16:43:57\", \"url\": \"http://www.ncpe.ie/drugs/olaparib-lynparza-2/\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-05, 2015-02-19\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib (Lynparza\", \"trade_name\": \"Lynparza\", \"indication\": \"Lynparza\", \"ncpe_year\": 2017, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2430, \"last_scrape\": \"2018-12-13T16:44:03\", \"url\": \"http://www.ncpe.ie/drugs/olaparib-lynparza-for-platinum-sensitive-relapsed-ovarian-cancer/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"THE NCPE RECOMMEND  A FULL HTA TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF OLAPARIB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib (Lynparza\", \"trade_name\": \"Lynparza\", \"indication\": \"Olaparib (Lynparza\", \"ncpe_year\": 2018, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2431, \"last_scrape\": \"2018-12-13T16:44:08\", \"url\": \"http://www.ncpe.ie/drugs/omalizumab-xolair-for-the-treatment-of-severe-allergic-asthma/\", \"rr_start\": \"\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab (Xolair\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab is indicated as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1<80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.\", \"ncpe_year\": 2015, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-08-22T00:00:00\", \"latest\": \"2015-06-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xolair\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2432, \"last_scrape\": \"2018-12-13T16:44:14\", \"url\": \"http://www.ncpe.ie/drugs/omalizumab-xolair/\", \"rr_start\": \"2014-03-25T00:00:00\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED FOR THIS INDICATION.\", \"rr_dates\": \"2014-03-25, 2014-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab (Xolair\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab (Xolair\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-03-25T00:00:00\", \"latest\": \"2014-04-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xolair\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"No HTA\"}, {\"id\": 2433, \"last_scrape\": \"2018-12-13T16:44:19\", \"url\": \"http://www.ncpe.ie/drugs/oral-oxycodonenaloxone-targin/\", \"rr_start\": \"\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Oxycodone/naloxone (Targin\", \"trade_name\": \"Targin\", \"indication\": \"Cost-effectiveness of oral oxycodone/naloxone prolonged release tablet (Targin\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-05-05T00:00:00\", \"latest\": \"2010-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2434, \"last_scrape\": \"2018-12-13T16:44:22\", \"url\": \"http://www.ncpe.ie/drugs/osimertinib-tagrisso-for-the-first-line-treatment-of-metastatic-nsclc/\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-07T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF OSIMERTINIB FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WITH ACTIVATING EGFR MUTATIONS COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-19, 2018-08-07\", \"rr_multiple\": 0, \"drug_name\": \"Osimertinib (Tagrisso\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib (Tagrisso\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2435, \"last_scrape\": \"2018-12-13T16:44:39\", \"url\": \"http://www.ncpe.ie/drugs/osimertinib-tagrisso/\", \"rr_start\": \"2016-02-26T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-26, 2016-03-22, 2017-01-10\", \"rr_multiple\": 1, \"drug_name\": \"Osimertinib (Tagrisso\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib (Tagrisso\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-26T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2436, \"last_scrape\": \"2018-12-13T16:44:40\", \"url\": \"http://www.ncpe.ie/drugs/ozenoxacin-dubine/\", \"rr_start\": \"2018-11-12T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"FULL HTA IS NOT RECOMMENDED. THE NCPE RECOMMENDS THAT OZENOXACIN CREAM NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE.  THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013.\", \"rr_dates\": \"2018-11-12, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ozenoxacin (Dubine\", \"trade_name\": \"Dubine\", \"indication\": \"Ozenoxacin (Dubine\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-12T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"id\": 2437, \"last_scrape\": \"2018-12-13T16:44:43\", \"url\": \"http://www.ncpe.ie/drugs/p-drugs/pegylated-interferon-b-1a-plegridy/\", \"rr_start\": \"2014-11-25T00:00:00\", \"rr_end\": \"2014-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-11-25, 2014-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Pegylated Interferon beta-1a (Plegridy \", \"trade_name\": \"Plegridy\", \"indication\": \"Treatment of adult patients with relapsing remitting multiple sclerosis\", \"ncpe_year\": 2014, \"eu_market\": \"2014-07-17T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-11-25T00:00:00\", \"latest\": \"2014-12-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2438, \"last_scrape\": \"2018-12-13T16:44:47\", \"url\": \"http://www.ncpe.ie/drugs/palbociclib-ibrance/\", \"rr_start\": \"2016-09-10T00:00:00\", \"rr_end\": \"2016-09-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-09-10, 2016-09-28\", \"rr_multiple\": 0, \"drug_name\": \"Palbociclib (Ibrance\", \"trade_name\": \"Ibrance\", \"indication\": \"Palbociclib is indicated for the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-11-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2016-09-10T00:00:00\", \"latest\": \"2017-07-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2439, \"last_scrape\": \"2018-12-13T16:44:53\", \"url\": \"http://www.ncpe.ie/drugs/paliperidone-palmitate-xeplion/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Paliperidone palmitate (Xeplion\", \"trade_name\": \"Xeplion\", \"indication\": \"Paliperidone palmitate (Xeplion\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-04T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeplion\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2440, \"last_scrape\": \"2018-12-13T16:44:57\", \"url\": \"http://www.ncpe.ie/drugs/panobinostat-farydak/\", \"rr_start\": \"2016-01-26T00:00:00\", \"rr_end\": \"2016-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-26, 2016-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Panobinostat (Farydak\", \"trade_name\": \"Farydak\", \"indication\": \"Panobinostat in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-01-26T00:00:00\", \"latest\": \"2016-02-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/farydak\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2441, \"last_scrape\": \"2018-12-13T16:45:01\", \"url\": \"http://www.ncpe.ie/drugs/paritaprevir-boosted-with-ritonavir-and-ombitasvir-vierkirax-with-or-without-dasabuvir-exviera/\", \"rr_start\": \"2014-12-21T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-21, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Paritaprevir boosted with ritonavir and ombitasvir (Vierkirax\", \"trade_name\": \"Exviera\", \"indication\": \"Exviera\", \"ncpe_year\": 2016, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2014-12-21T00:00:00\", \"latest\": \"2016-02-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/exviera\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2442, \"last_scrape\": \"2018-12-13T16:45:07\", \"url\": \"http://www.ncpe.ie/drugs/patiromer-veltassa/\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT\\nRECOMMENDED\", \"rr_dates\": \"2017-10-11, 2017-11-17\", \"rr_multiple\": 0, \"drug_name\": \"Patiromer (Veltassa\", \"trade_name\": \"Veltassa\", \"indication\": \"Patiromer (Veltassa\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-19T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-11-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/veltassa\", \"ta_list\": \"Hyperkalemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2443, \"last_scrape\": \"2018-12-13T16:45:10\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-1l-nsclc-with-chemotherapy/\", \"rr_start\": \"2018-08-14T00:00:00\", \"rr_end\": \"2018-08-29T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-14, 2018-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-08-14T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2444, \"last_scrape\": \"2018-12-13T16:45:15\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-adjuvant-melanoma/\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-07T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-11-19, 2018-12-07\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizuma (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2445, \"last_scrape\": \"2018-12-13T16:45:18\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-classical-hodgkin-lymphoma/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2446, \"last_scrape\": \"2018-12-13T16:45:23\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-first-line-nsclc/\", \"rr_start\": \"2016-12-19T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-12-19, 2017-01-10\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-12-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2447, \"last_scrape\": \"2018-12-13T16:45:28\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-nsclc/\", \"rr_start\": \"2016-08-03T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-08-03, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-03T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2448, \"last_scrape\": \"2018-12-13T16:45:31\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-the-treatment-of-unresectable-or-advanced-metastatic-melanoma-in-adults-refractory-to-ipilimumab/\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2449, \"last_scrape\": \"2018-12-13T16:45:36\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-uc-1l/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES\", \"rr_dates\": \"2017-12-06, 2017-12-21, 2018-06-21, 2018-07-10, 2018-07-27\", \"rr_multiple\": 1, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-07-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2450, \"last_scrape\": \"2018-12-13T16:45:38\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-urothelial-carcinoma-2l/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda \", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2451, \"last_scrape\": \"2018-12-13T16:45:45\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda/\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-02-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2452, \"last_scrape\": \"2018-12-13T16:45:50\", \"url\": \"http://www.ncpe.ie/drugs/perampanel-fycompa/\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Perampanel (Fycompa\", \"trade_name\": \"Fycompa\", \"indication\": \"Perampanel (Fycompa\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-23T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa\", \"ta_list\": \"Epilepsies, Partial\", \"rr_status\": \"No HTA\"}, {\"id\": 2453, \"last_scrape\": \"2018-12-13T16:45:56\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta-for-her2-positive-breast-cancer/\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PERTUZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-01, 2018-06-22\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab  (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.\", \"ncpe_year\": 2018, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-12-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2454, \"last_scrape\": \"2018-12-13T16:46:02\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta-in-neoadjuvant-her2-positive-breast-cancer/\", \"rr_start\": \"2015-08-10T00:00:00\", \"rr_end\": \"2015-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-10, 2015-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"Perjeta (pertuzumab) is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2015-08-10T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2455, \"last_scrape\": \"2018-12-13T16:46:04\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta/\", \"rr_start\": \"2013-01-14T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-01-14, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"The proposed licensed indication is for use (in combination with trastuzumab and docetaxel) in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. \", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-01-14T00:00:00\", \"latest\": \"2013-08-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2456, \"last_scrape\": \"2018-12-13T16:46:09\", \"url\": \"http://www.ncpe.ie/drugs/phenylephrine-hydrochloride-tropicamide-lidocaine-hydrochloride-fydrane/\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-19T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-11-18, 2016-12-19\", \"rr_multiple\": 0, \"drug_name\": \"Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride (Fydrane\", \"trade_name\": \"Fydrane\", \"indication\": \"Fydrane\", \"ncpe_year\": 2016, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2016-12-19T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2457, \"last_scrape\": \"2018-12-13T16:46:11\", \"url\": \"http://www.ncpe.ie/drugs/pirfenidone-esbriet/\", \"rr_start\": \"2011-12-15T00:00:00\", \"rr_end\": \"2012-01-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-12-15, 2012-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Pirfenidone (Esbriet\", \"trade_name\": \"Esbriet\", \"indication\": \"Pirfenidone has been licensed by the European Medicines Agency (EMA) for the treatment of mild to moderate idiopathic pulmonary fibrosis.\", \"ncpe_year\": 2015, \"eu_market\": \"2011-02-27T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2011-12-15T00:00:00\", \"latest\": \"2015-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esbriet\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2458, \"last_scrape\": \"2018-12-13T16:46:14\", \"url\": \"http://www.ncpe.ie/drugs/pitavastatin-livazo/\", \"rr_start\": \"2010-12-22T00:00:00\", \"rr_end\": \"2010-12-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-12-22, 2010-12-24\", \"rr_multiple\": 0, \"drug_name\": \"Pitavastatin (Livazo\", \"trade_name\": \"Livazo\", \"indication\": \"Pitavastatin is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined (mixed) dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-12-22T00:00:00\", \"latest\": \"2010-12-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2459, \"last_scrape\": \"2018-12-13T16:46:20\", \"url\": \"http://www.ncpe.ie/drugs/pitolisant-wakix/\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-06-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-06-12, 2017-06-15\", \"rr_multiple\": 0, \"drug_name\": \"Pitolisant hydrochloride (Wakix\", \"trade_name\": \"Wakix\", \"indication\": \"Pitolisant hydrochloride (Wakix\", \"ncpe_year\": 2017, \"eu_market\": \"2016-03-31T00:00:00\", \"company\": \"Bioprojet\", \"orphan\": 1, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-06-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/wakix\", \"ta_list\": \"Narcolepsy\", \"rr_status\": \"No HTA\"}, {\"id\": 2460, \"last_scrape\": \"2018-12-13T16:46:24\", \"url\": \"http://www.ncpe.ie/drugs/pixantrone-pixuvri/\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-03-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-02-10, 2015-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Pixantrone (Pixuvri\", \"trade_name\": \"Pixuvri\", \"indication\": \"Pixurvi\", \"ncpe_year\": 2015, \"eu_market\": \"2012-05-10T00:00:00\", \"company\": \"CTI\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-03-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri\", \"ta_list\": \"Lymphoma, Non-Hodgkin\", \"rr_status\": \"No HTA\"}, {\"id\": 2461, \"last_scrape\": \"2018-12-13T16:46:27\", \"url\": \"http://www.ncpe.ie/drugs/polynuclear-ironiii-oxyhydroxide-pn-feooh-velphoro/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-09-12, 2014-10-08\", \"rr_multiple\": 0, \"drug_name\": \"Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro\", \"trade_name\": \"Velphoro\", \"indication\": \"Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro\", \"ncpe_year\": 2014, \"eu_market\": \"2014-08-26T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-10-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/velphoro\", \"ta_list\": \"Hyperphosphatemia; Renal Dialysis\", \"rr_status\": \"No HTA\"}, {\"id\": 2462, \"last_scrape\": \"2018-12-13T16:46:30\", \"url\": \"http://www.ncpe.ie/drugs/pomalidomide-imnovid/\", \"rr_start\": \"2013-09-20T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-20, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Pomalidomide (Imnovid\", \"trade_name\": \"Imnovid\", \"indication\": \"Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-09-20T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2463, \"last_scrape\": \"2018-12-13T16:46:32\", \"url\": \"http://www.ncpe.ie/drugs/ponatinib-iclusig/\", \"rr_start\": \"2013-10-02T00:00:00\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-10-02, 2013-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Ponatinib (Iclusig\", \"trade_name\": \"Iclusig\", \"indication\": \"Ponatinib (Iclusig\", \"ncpe_year\": 2016, \"eu_market\": \"2013-07-01T00:00:00\", \"company\": \"Incyte\", \"orphan\": 1, \"earliest\": \"2013-10-02T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig\", \"ta_list\": \"Leukemia, Myeloid; Leukemia, Lymphoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2464, \"last_scrape\": \"2018-12-13T16:46:38\", \"url\": \"http://www.ncpe.ie/drugs/prasugrel-efient/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Prasugrel (Efient\", \"trade_name\": \"Efient\", \"indication\": \"Economic Evaluation of Prasugrel (Efient\", \"ncpe_year\": 2010, \"eu_market\": \"2009-02-24T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2010-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/efient\", \"ta_list\": \"Acute Coronary Syndrome; Angina, Unstable; Myocardial Infarction\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2465, \"last_scrape\": \"2018-12-13T16:46:46\", \"url\": \"http://www.ncpe.ie/drugs/pregabalin-lyrica-2/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin (Lyrica\", \"trade_name\": \"Lyrica\", \"indication\": \"Lyrica\", \"ncpe_year\": 2015, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-30T00:00:00\", \"latest\": \"2015-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2466, \"last_scrape\": \"2018-12-13T16:46:52\", \"url\": \"http://www.ncpe.ie/drugs/pregabalin-lyrica-for-the-treatment-of-generalised-anxiety-disorder/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin (Lyrica\", \"trade_name\": \"Lyrica\", \"indication\": \"Pregabalin (Lyrica\", \"ncpe_year\": 2014, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-12-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2467, \"last_scrape\": \"2018-12-13T16:46:58\", \"url\": \"http://www.ncpe.ie/drugs/prucalopride-resolor/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-01-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-01-17\", \"rr_multiple\": 0, \"drug_name\": \"Prucalopride (Resolor\", \"trade_name\": \"Resolor\", \"indication\": \"Prucalopride (Resolor\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-14T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2011-01-17T00:00:00\", \"latest\": \"2011-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/resolor\", \"ta_list\": \"Constipation\", \"rr_status\": \"No HTA\"}, {\"id\": 2468, \"last_scrape\": \"2018-12-13T16:47:00\", \"url\": \"http://www.ncpe.ie/drugs/radium-223-xofigo/\", \"rr_start\": \"2013-11-28T00:00:00\", \"rr_end\": \"2013-12-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-11-28, 2013-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Radium-223 (Xofigo\", \"trade_name\": \"Xofigo\", \"indication\": \"Radium-223 (Xofigo\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-13T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2469, \"last_scrape\": \"2018-12-13T16:47:03\", \"url\": \"http://www.ncpe.ie/drugs/ramucirumab-cyramza/\", \"rr_start\": \"2014-12-20T00:00:00\", \"rr_end\": \"2014-12-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-20, 2014-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Ramucirumab (Cyramza\", \"trade_name\": \"Cyramza\", \"indication\": \"Indicated in combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction (GEJ) adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-12-19T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2014-12-20T00:00:00\", \"latest\": \"2016-07-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2470, \"last_scrape\": \"2018-12-13T16:47:06\", \"url\": \"http://www.ncpe.ie/drugs/ranolazine-ranexa/\", \"rr_start\": \"2009-11-19T00:00:00\", \"rr_end\": \"2009-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ranolazine (Ranexa\", \"trade_name\": \"Ranexa\", \"indication\": \"Cost-effectiveness of Ranolazine (Ranexa\", \"ncpe_year\": 2009, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2009-11-19T00:00:00\", \"latest\": \"2009-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2471, \"last_scrape\": \"2018-12-13T16:47:13\", \"url\": \"http://www.ncpe.ie/drugs/regadenoson-rapiscan/\", \"rr_start\": \"2011-09-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-09-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Regadenoson (Rapiscan\", \"trade_name\": \"Rapiscan\", \"indication\": \"Cost-effectiveness of Regadenoson (Rapiscan\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-06T00:00:00\", \"company\": \"GE\", \"orphan\": 0, \"earliest\": \"2011-09-19T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rapiscan\", \"ta_list\": \"Myocardial Perfusion Imaging\", \"rr_status\": \"No HTA\"}, {\"id\": 2472, \"last_scrape\": \"2018-12-13T16:47:17\", \"url\": \"http://www.ncpe.ie/drugs/regorafenib-stivarga-for-gist/\", \"rr_start\": \"2014-09-18T00:00:00\", \"rr_end\": \"2014-10-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-09-18, 2014-10-06\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib (Stivarga\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib (Stivarga\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2014-09-18T00:00:00\", \"latest\": \"2014-10-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2473, \"last_scrape\": \"2018-12-13T16:47:23\", \"url\": \"http://www.ncpe.ie/drugs/reslizumab-cinqaero/\", \"rr_start\": \"2017-01-23T00:00:00\", \"rr_end\": \"2017-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-01-23, 2017-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Reslizumab (Cinqaero\", \"trade_name\": \"Cinqaero\", \"indication\": \"Cinqaero\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-15T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2017-01-23T00:00:00\", \"latest\": \"2017-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cinqaero\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2474, \"last_scrape\": \"2018-12-13T16:47:27\", \"url\": \"http://www.ncpe.ie/drugs/retigabine-trobalt/\", \"rr_start\": \"2011-04-06T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-04-06, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Retigabine (Trobalt\", \"trade_name\": \"Trobalt\", \"indication\": \"Cost-effectiveness of Retigabine (Trobalt\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-27T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-04-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"No HTA\"}, {\"id\": 2475, \"last_scrape\": \"2018-12-13T16:47:29\", \"url\": \"http://www.ncpe.ie/drugs/ribociclib-kisqali/\", \"rr_start\": \"2017-09-04T00:00:00\", \"rr_end\": \"2017-09-19T00:00:00\", \"rr_outcome\": \"FOLLOWING NCPE ASSESSMENT OF THE COMPANY SUBMISSION, THE NCPE RECOMMENDS THAT RIBOCICLIB (IN COMBINATION WITH AN AROMATASE INHIBITOR) FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR+/HER2- LOCALLY ADVANCED OR METASTATIC BC AS INITIAL ENDOCRINE-BASED THERAPY, NOT BE CONSIDERED FOR REIMBURSEMENT UNLESS COST EFFECTIVENESS CAN BE IMPROVED RELATIVE TO EXISTING TREATMENTS. THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2017-09-04, 2017-09-19\", \"rr_multiple\": 0, \"drug_name\": \"Ribociclib (Kisqali\", \"trade_name\": \"Kisqali\", \"indication\": \"Ribociclib (Kisqali\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2017-09-04T00:00:00\", \"latest\": \"2018-08-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2476, \"last_scrape\": \"2018-12-13T16:47:35\", \"url\": \"http://www.ncpe.ie/drugs/rifaximin-targaxan-2/\", \"rr_start\": \"2013-07-09T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-09, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Rifaximin (Targaxan\", \"trade_name\": \"Targaxan\", \"indication\": \"Rifaximin (Targaxan\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-07-09T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2477, \"last_scrape\": \"2018-12-13T16:47:38\", \"url\": \"http://www.ncpe.ie/drugs/rigorafenib-stivarga/\", \"rr_start\": \"2013-09-12T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-12, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib (Stivarga\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib (Stivarga\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-09-12T00:00:00\", \"latest\": \"2014-06-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2478, \"last_scrape\": \"2018-12-13T16:47:42\", \"url\": \"http://www.ncpe.ie/drugs/rilpivirine-edurant/\", \"rr_start\": \"2011-12-14T00:00:00\", \"rr_end\": \"2012-01-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-12-14, 2012-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine (Edurant\", \"trade_name\": \"Edurant\", \"indication\": \"Rilpivirine in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ? 100,000 HIV-1 RNA copies/ml.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-11-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-12-14T00:00:00\", \"latest\": \"2012-01-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/edurant\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2479, \"last_scrape\": \"2018-12-13T16:47:45\", \"url\": \"http://www.ncpe.ie/drugs/rilpivirine-r-emtricitabine-f-tenofovir-alafenamide-taf-odefsey/\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMEDED\", \"rr_dates\": \"2016-06-28, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) (Odefsey\", \"trade_name\": \"Odefsey\", \"indication\": \"Odefsey\", \"ncpe_year\": 2016, \"eu_market\": \"2016-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2480, \"last_scrape\": \"2018-12-13T16:47:48\", \"url\": \"http://www.ncpe.ie/drugs/rimonabant-acomplia-2/\", \"rr_start\": \"\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rimonabant (Acomplia\", \"trade_name\": \"Acomplia\", \"indication\": \"In June 2006, Sanofi-Aventis submitted an evaluation of the cost-effectiveness of rimonabant (in addition to diet and exercise) in the management of multiple cardiovascular risks in overweight or obese patients in Ireland, to support its application for reimbursement of rimonabant under the Community Drugs Schemes. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-06-19T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2006-06-01T00:00:00\", \"latest\": \"2006-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/acomplia\", \"ta_list\": \"Obesity\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2481, \"last_scrape\": \"2018-12-13T16:47:53\", \"url\": \"http://www.ncpe.ie/drugs/riociguat-adempas/\", \"rr_start\": \"2014-04-11T00:00:00\", \"rr_end\": \"2014-05-16T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED AT THE CURRENT PRICE.\", \"rr_dates\": \"2014-04-11, 2014-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Riociguat (Adempas\", \"trade_name\": \"Adempas\", \"indication\": \"Riociguat (Adempas\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-27T00:00:00\", \"company\": \"Bayer\", \"orphan\": 1, \"earliest\": \"2014-04-11T00:00:00\", \"latest\": \"2014-05-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adempas\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2482, \"last_scrape\": \"2018-12-13T16:47:59\", \"url\": \"http://www.ncpe.ie/drugs/rituximab-mabthera/\", \"rr_start\": \"2014-05-26T00:00:00\", \"rr_end\": \"2014-09-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-26, 2014-09-22\", \"rr_multiple\": 0, \"drug_name\": \"Rituximab (MabThera\", \"trade_name\": \"MabThera\", \"indication\": \"Rituximab (MabThera\", \"ncpe_year\": 2014, \"eu_market\": \"1998-06-02T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-05-26T00:00:00\", \"latest\": \"2014-09-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"No HTA\"}, {\"id\": 2483, \"last_scrape\": \"2018-12-13T16:48:05\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-atrial-fibrillation-patients-undergoing-pci/\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2484, \"last_scrape\": \"2018-12-13T16:48:10\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-dvt/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Economic evaluation of Rivaroxaban (Xarelto\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-02-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2485, \"last_scrape\": \"2018-12-13T16:48:15\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-spaf-2/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban (Xarelto\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2486, \"last_scrape\": \"2018-12-13T16:48:18\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-the-prevention-of-atherothrombotic-events/\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-11T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF RIVAROXABAN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-26, 2018-10-11\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban (Xarelto\", \"ncpe_year\": 2018, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2487, \"last_scrape\": \"2018-12-13T16:48:25\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-low-dose-for-prevention-of-recurrent-venous-thromboembolism/\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2488, \"last_scrape\": \"2018-12-13T16:48:30\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban (Xarelto\", \"ncpe_year\": 2008, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2008-04-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2489, \"last_scrape\": \"2018-12-13T16:48:33\", \"url\": \"http://www.ncpe.ie/drugs/roflumilast-daxas/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Roflumilast (Daxas\", \"trade_name\": \"Daxas\", \"indication\": \"Cost Effectiveness of Roflumilast (Daxas\", \"ncpe_year\": 2010, \"eu_market\": \"2010-07-05T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-11T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/daxas\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2490, \"last_scrape\": \"2018-12-13T16:48:40\", \"url\": \"http://www.ncpe.ie/drugs/rolapitant-varuby/\", \"rr_start\": \"2017-05-15T00:00:00\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-05-15, 2017-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Rolapitant (Varuby\", \"trade_name\": \"Varuby\", \"indication\": \"Rolapitant (Varuby\", \"ncpe_year\": 2017, \"eu_market\": \"2017-04-19T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 0, \"earliest\": \"2017-05-15T00:00:00\", \"latest\": \"2017-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/varuby\", \"ta_list\": \"Vomiting; Nausea; Cancer\", \"rr_status\": \"No HTA\"}, {\"id\": 2491, \"last_scrape\": \"2018-12-13T16:48:43\", \"url\": \"http://www.ncpe.ie/drugs/romiplostim-nplate/\", \"rr_start\": \"\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Romiplostim (Nplate\", \"trade_name\": \"Nplate\", \"indication\": \"Romiplostim (Nplate\", \"ncpe_year\": 2015, \"eu_market\": \"2009-02-04T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-04-02T00:00:00\", \"latest\": \"2015-05-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nplate\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2492, \"last_scrape\": \"2018-12-13T16:48:47\", \"url\": \"http://www.ncpe.ie/drugs/ropivacaine-readyfusor/\", \"rr_start\": \"2018-11-09T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"FULL HTA IS NOT RECOMMENDED. THE NCPE RECOMMENDS THAT ROPIVICAINE READYFUSOR NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE.  THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013.\", \"rr_dates\": \"2018-11-09, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ropivacaine Readyfusor\", \"trade_name\": \"Ropivacaine Readyfusor\", \"indication\": \"Ropivacaine Readyfusor for acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block (CPNB) via a continuous infusion.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-09T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"id\": 2493, \"last_scrape\": \"2018-12-13T16:48:50\", \"url\": \"http://www.ncpe.ie/drugs/ruxolitinib-jakavi-for-polycythaemia-vera/\", \"rr_start\": \"2015-04-15T00:00:00\", \"rr_end\": \"2015-05-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-04-15, 2015-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib (Jakavi\", \"trade_name\": \"Jakavi\", \"indication\": \"Jakavi\", \"ncpe_year\": 2016, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2015-04-15T00:00:00\", \"latest\": \"2016-08-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2494, \"last_scrape\": \"2018-12-13T16:48:55\", \"url\": \"http://www.ncpe.ie/drugs/ruxolitinib-jakavi/\", \"rr_start\": \"2012-08-01T00:00:00\", \"rr_end\": \"2012-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-08-01, 2012-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib (Jakavi\", \"trade_name\": \"Jakavi\", \"indication\": \"Ruxolitinib (Jakavi\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2012-08-01T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2495, \"last_scrape\": \"2018-12-13T16:48:58\", \"url\": \"http://www.ncpe.ie/drugs/sacubitrilvalsartan-entresto/\", \"rr_start\": \"2015-11-06T00:00:00\", \"rr_end\": \"2015-11-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-06, 2015-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Sacubitril/valsartan (Entresto\", \"trade_name\": \"Entresto\", \"indication\": \"Entresto\", \"ncpe_year\": 2017, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-06T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entresto\", \"ta_list\": \"Heart Failure\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2496, \"last_scrape\": \"2018-12-13T16:49:04\", \"url\": \"http://www.ncpe.ie/drugs/safinamide-methansulfonate-xadago/\", \"rr_start\": \"2016-06-14T00:00:00\", \"rr_end\": \"2016-07-06T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED.\", \"rr_dates\": \"2016-06-14, 2016-07-06\", \"rr_multiple\": 0, \"drug_name\": \"Safinamide methansulfonate (Xadago\", \"trade_name\": \"Xadago\", \"indication\": \"Xadago\", \"ncpe_year\": 2016, \"eu_market\": \"2015-02-23T00:00:00\", \"company\": \"Zambon\", \"orphan\": 0, \"earliest\": \"2016-06-14T00:00:00\", \"latest\": \"2016-07-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xadago\", \"ta_list\": \"Parkinson Disease\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2497, \"last_scrape\": \"2018-12-13T16:49:07\", \"url\": \"http://www.ncpe.ie/drugs/sapropterin-kuvan/\", \"rr_start\": \"2015-07-14T00:00:00\", \"rr_end\": \"2015-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-07-14, 2015-08-14, 2015-07-01\", \"rr_multiple\": 1, \"drug_name\": \"Sapropterin (Kuvan\", \"trade_name\": \"Kuvan\", \"indication\": \"Sapropterin (Kuvan\", \"ncpe_year\": 2017, \"eu_market\": \"2008-12-02T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2009-01-01T00:00:00\", \"latest\": \"2017-09-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kuvan\", \"ta_list\": \"Phenylketonurias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2498, \"last_scrape\": \"2018-12-13T16:49:11\", \"url\": \"http://www.ncpe.ie/drugs/sarilumab-kevzara/\", \"rr_start\": \"2017-08-18T00:00:00\", \"rr_end\": \"2017-10-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-08-18, 2017-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Sarilumab (Kevzara\", \"trade_name\": \"Kevzara\", \"indication\": \"Sarilumab (Kevzara\", \"ncpe_year\": 2017, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-08-18T00:00:00\", \"latest\": \"2017-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2499, \"last_scrape\": \"2018-12-13T16:49:16\", \"url\": \"http://www.ncpe.ie/drugs/sebelipase-alfa-kanuma/\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-02-08, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Sebelipase alfa (Kanuma\", \"trade_name\": \"Kanuma\", \"indication\": \"Sebelipase alfa is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2018-06-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kanuma\", \"ta_list\": \"Lipid Metabolism, Inborn Errors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2500, \"last_scrape\": \"2018-12-13T16:49:20\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-ankylosing-spondylitis/\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-02, 2015-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"id\": 2501, \"last_scrape\": \"2018-12-13T16:49:25\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-psoriatic-arthritis/\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-02, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"id\": 2502, \"last_scrape\": \"2018-12-13T16:49:31\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx/\", \"rr_start\": \"2014-12-19T00:00:00\", \"rr_end\": \"2015-02-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-19, 2015-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-12-19T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2503, \"last_scrape\": \"2018-12-13T16:49:34\", \"url\": \"http://www.ncpe.ie/drugs/selexipag-uptravi/\", \"rr_start\": \"2016-11-01T00:00:00\", \"rr_end\": \"2016-12-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-01, 2016-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Selexipag (Uptravi\", \"trade_name\": \"Uptravi\", \"indication\": \"Selexipag (Uptravi\", \"ncpe_year\": 2018, \"eu_market\": \"2016-05-12T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2016-11-01T00:00:00\", \"latest\": \"2018-05-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2504, \"last_scrape\": \"2018-12-13T16:49:39\", \"url\": \"http://www.ncpe.ie/drugs/semaglutide-ozempic/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-03-12, 2018-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Semaglutide (Ozempic\", \"trade_name\": \"Ozempic\", \"indication\": \"Semaglutide (Ozempic\", \"ncpe_year\": 2018, \"eu_market\": \"2018-02-08T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-04-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2505, \"last_scrape\": \"2018-12-13T16:49:44\", \"url\": \"http://www.ncpe.ie/drugs/sildenafil-revatio/\", \"rr_start\": \"2014-04-16T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-04-16, 2014-05-23\", \"rr_multiple\": 0, \"drug_name\": \"Sildenafil (Revatio\", \"trade_name\": \"Revatio\", \"indication\": \"Sildenafil (Revatio\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2014-04-16T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revatio\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2506, \"last_scrape\": \"2018-12-13T16:49:49\", \"url\": \"http://www.ncpe.ie/drugs/simeprevir-olysio-in-combination-with-sofosbuvir/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir (Olysio\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir (Olysio\", \"ncpe_year\": 2015, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2015-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olysio\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2507, \"last_scrape\": \"2018-12-13T16:49:53\", \"url\": \"http://www.ncpe.ie/drugs/simeprevir-olysio/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED WHEN USED IN TRIPLE THERAPY WITH PEG-INTERFERON AND RIBAVIRIN.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir (Olysio\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir (Olysio\", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2014-07-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olysio\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2508, \"last_scrape\": \"2018-12-13T16:50:00\", \"url\": \"http://www.ncpe.ie/drugs/sodium-chloride-70mgml-sodium-hyaluronate-1mgml-hyaneb/\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-10, 2014-03-19\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml (Hyaneb\", \"trade_name\": \"Hyaneb\", \"indication\": \"Hyaneb\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2509, \"last_scrape\": \"2018-12-13T16:50:06\", \"url\": \"http://www.ncpe.ie/drugs/sodium-hyaluronate-hyloforte-0-2/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate (Hyloforte\", \"trade_name\": \"Hyloforte 0.2%\", \"indication\": \"Sodium Hyaluronate (Hyloforte\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2510, \"last_scrape\": \"2018-12-13T16:50:09\", \"url\": \"http://www.ncpe.ie/drugs/sodium-hyaluronate-hylotear-0-1/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate (Hylotear\", \"trade_name\": \"Hylotear 0.1%\", \"indication\": \"Sodium Hyaluronate (Hylotear\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2511, \"last_scrape\": \"2018-12-13T16:50:15\", \"url\": \"http://www.ncpe.ie/drugs/sodium-phenylbutyrate-pheburane/\", \"rr_start\": \"2013-07-17T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-17, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Sodium phenylbutyrate (Pheburane\", \"trade_name\": \"Pheburane\", \"indication\": \"Sodium phenylbutyrate (Pheburane\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-30T00:00:00\", \"company\": \"Lucane\", \"orphan\": 0, \"earliest\": \"2013-07-17T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pheburane\", \"ta_list\": \"Carbamoyl-Phosphate Synthase I Deficiency Disease\", \"rr_status\": \"No HTA\"}, {\"id\": 2512, \"last_scrape\": \"2018-12-13T16:50:18\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvir-solvaldi/\", \"rr_start\": \"2014-02-12T00:00:00\", \"rr_end\": \"2014-03-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-02-12, 2014-03-10\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir (Solvaldi\", \"trade_name\": \"Solvaldi\", \"indication\": \"Sofosbuvir (Solvaldi\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-02-12T00:00:00\", \"latest\": \"2014-10-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2513, \"last_scrape\": \"2018-12-13T16:50:22\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvirvelpatasvir-epclusa-chronic-hepatitis-c-virus-hcv-pangenotypic/\", \"rr_start\": \"2017-09-05T00:00:00\", \"rr_end\": \"2017-10-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-05, 2017-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir (Epclusa\", \"trade_name\": \"Epclusa\", \"indication\": \"Sofosbuvir/velpatasvir (Epclusa\", \"ncpe_year\": 2017, \"eu_market\": \"2016-07-06T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-05T00:00:00\", \"latest\": \"2017-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2514, \"last_scrape\": \"2018-12-13T16:50:26\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvirvelpatasvirvoxilaprevir-vosevi/\", \"rr_start\": \"2017-09-19T00:00:00\", \"rr_end\": \"2017-11-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-19, 2017-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi\", \"trade_name\": \"Vosevi\", \"indication\": \"Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-19T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vosevi\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2515, \"last_scrape\": \"2018-12-13T16:50:32\", \"url\": \"http://www.ncpe.ie/drugs/st-johns-wort-pafica/\", \"rr_start\": \"2015-04-14T00:00:00\", \"rr_end\": \"2015-05-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-04-14, 2015-05-29\", \"rr_multiple\": 0, \"drug_name\": \"St Johns Wort (Pacifa\", \"trade_name\": \"Pacifa\", \"indication\": \"Pacifa\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-04-14T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2516, \"last_scrape\": \"2018-12-13T16:50:38\", \"url\": \"http://www.ncpe.ie/drugs/stiripentol-diacomit/\", \"rr_start\": \"2017-07-06T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-06, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Stiripentol (Diacomit\", \"trade_name\": \"Diacomit\", \"indication\": \"Stiripentol (Diacomit\", \"ncpe_year\": 2018, \"eu_market\": \"2007-01-03T00:00:00\", \"company\": \"Biocodex\", \"orphan\": 1, \"earliest\": \"2017-07-06T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/diacomit\", \"ta_list\": \"Myoclonic Epilepsy, Juvenile\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2517, \"last_scrape\": \"2018-12-13T16:50:43\", \"url\": \"http://www.ncpe.ie/drugs/stribild-elvitegravircobicistatemtricitabinetenofovir-disoproxil-as-fumarate/\", \"rr_start\": \"2013-04-28T00:00:00\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-04-28, 2013-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumarate)(Stribild\", \"trade_name\": \"Stribild\", \"indication\": \"Indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-na\", \"ncpe_year\": 2013, \"eu_market\": \"2013-05-24T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2013-04-28T00:00:00\", \"latest\": \"2013-12-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stribild\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2518, \"last_scrape\": \"2018-12-13T16:50:49\", \"url\": \"http://www.ncpe.ie/drugs/sublingual-immunotherapy-grazax/\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sublingual Immunotherapy (Grazax\", \"trade_name\": \"Grazax\", \"indication\": \"A Review of the Cost-Effectiveness of Sublingual Immunotherapy (Grazax\", \"ncpe_year\": 2007, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2007-09-01T00:00:00\", \"latest\": \"2007-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2519, \"last_scrape\": \"2018-12-13T16:50:50\", \"url\": \"http://www.ncpe.ie/drugs/suboxone-buprenorphinenaloxone/\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Buprenorphine/naloxone (Suboxone\", \"trade_name\": \"Suboxone\", \"indication\": \"An economic evaluation of suboxone for the management of opiate addiction.\", \"ncpe_year\": 2014, \"eu_market\": \"2006-09-26T00:00:00\", \"company\": \"Indivior\", \"orphan\": 0, \"earliest\": \"2007-11-01T00:00:00\", \"latest\": \"2014-05-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/suboxone\", \"ta_list\": \"Opioid-Related Disorders\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2520, \"last_scrape\": \"2018-12-13T16:50:54\", \"url\": \"http://www.ncpe.ie/drugs/sufentanil-zalviso/\", \"rr_start\": \"2016-03-14T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-03-14, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Sufentanil (Zalviso\", \"trade_name\": \"Zalviso\", \"indication\": \"Sufentanil (Zalviso\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Gr\", \"orphan\": 0, \"earliest\": \"2016-03-14T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zalviso\", \"ta_list\": \"Pain, Postoperative\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2521, \"last_scrape\": \"2018-12-13T16:50:59\", \"url\": \"http://www.ncpe.ie/drugs/sunitinib-sutent/\", \"rr_start\": \"\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sunitinib (Sutent\", \"trade_name\": \"Sutent\", \"indication\": \"In September 2006, Pfizer Healthcare Ireland submitted an evaluation of the cost-effectiveness and budget impact of sunitinib as second-line treatment of patients with gastro-intestinal stromal tumours (GIST). Data on the cost-effectiveness and budget impact of sutinitinib as second line treatment for patients with metastatic renal cell carcinoma (mRCC) was also presented. The purpose of the submission was to support an application for reimbursement under the High Tech Drug Scheme. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-07-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-09-01T00:00:00\", \"latest\": \"2006-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sutent\", \"ta_list\": \"Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2522, \"last_scrape\": \"2018-12-13T16:51:04\", \"url\": \"http://www.ncpe.ie/drugs/tadalafil-adcirca-2/\", \"rr_start\": \"2011-07-13T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-07-13, 2011-09-21, 2014-05-09, 2014-05-23\", \"rr_multiple\": 1, \"drug_name\": \"Tadalafil (Adcirca\", \"trade_name\": \"Adcirca\", \"indication\": \"Tadalafil (Adcirca\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-07-13T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2523, \"last_scrape\": \"2018-12-13T16:51:09\", \"url\": \"http://www.ncpe.ie/drugs/tafamadis-meglumine-vyndaqel/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED UNTIL ADDITIONAL EFFICACY AND/OR SAFETY DATA IS SUBMITTED. ON THE BASIS OF CURRENT EVIDENCE, THE NCPE RECOMMENDS THAT TAFAMIDIS NOT BE CONSIDERED FOR REIMBURSEMENT IN ACCORDANCE WITH THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Tafamadis meglumine (Vyndaqel\", \"trade_name\": \"Vyndaqel\", \"indication\": \"Tafamadis meglumine (Vyndaqel\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-16T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel\", \"ta_list\": \"Amyloidosis\", \"rr_status\": \"No HTA until more evidence\"}, {\"id\": 2524, \"last_scrape\": \"2018-12-13T16:51:15\", \"url\": \"http://www.ncpe.ie/drugs/tafluprost-saflutan/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Tafluprost (Saflutan\", \"trade_name\": \"Saflutan\", \"indication\": \"Tafluoprost (Salflutan\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2525, \"last_scrape\": \"2018-12-13T16:51:24\", \"url\": \"http://www.ncpe.ie/drugs/talimogene-laherparepvec-imlygic/\", \"rr_start\": \"2016-02-16T00:00:00\", \"rr_end\": \"2016-03-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-02-16, 2016-03-14\", \"rr_multiple\": 0, \"drug_name\": \"Talimogene Laherparepvec (Imlygic\", \"trade_name\": \"Imlygic\", \"indication\": \"Talimogene laherparepvec (Imlygic\", \"ncpe_year\": 2016, \"eu_market\": \"2015-12-16T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-02-16T00:00:00\", \"latest\": \"2016-03-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2526, \"last_scrape\": \"2018-12-13T16:51:28\", \"url\": \"http://www.ncpe.ie/drugs/tapentadol-palexia/\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Tapentadol (Palexia\", \"trade_name\": \"Palexia\", \"indication\": \"Economic evaluation of oral tapentadol (Palexia\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2011-04-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2527, \"last_scrape\": \"2018-12-13T16:51:34\", \"url\": \"http://www.ncpe.ie/drugs/tedizolid-phosphate-sivextro/\", \"rr_start\": \"2015-05-07T00:00:00\", \"rr_end\": \"2015-07-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-05-07, 2015-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Tedizolid phosphate (Sivextro\", \"trade_name\": \"Sivextro\", \"indication\": \"Tedizolid phosphate (Sivextro\", \"ncpe_year\": 2015, \"eu_market\": \"2015-03-23T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-05-07T00:00:00\", \"latest\": \"2015-07-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sivextro\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"No HTA\"}, {\"id\": 2528, \"last_scrape\": \"2018-12-13T16:51:38\", \"url\": \"http://www.ncpe.ie/drugs/teduglutide-revestive/\", \"rr_start\": \"2017-03-13T00:00:00\", \"rr_end\": \"2017-04-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-13, 2017-04-12\", \"rr_multiple\": 0, \"drug_name\": \"Teduglutide (Revestive\", \"trade_name\": \"Revestive\", \"indication\": \"Teduglutide (Revestive\", \"ncpe_year\": 2018, \"eu_market\": \"2012-08-30T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2017-03-13T00:00:00\", \"latest\": \"2018-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revestive\", \"ta_list\": \"Malabsorption Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2529, \"last_scrape\": \"2018-12-13T16:51:44\", \"url\": \"http://www.ncpe.ie/drugs/tegafurgimeraciloteracil-teysuno/\", \"rr_start\": \"2012-02-27T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-02-27, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Tegafur/Gimeracil/Oteracil (Teysuno\", \"trade_name\": \"Teysuno\", \"indication\": \"Teysuno is indicated in adults for the treatment of advanced gastric cancer.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-03-14T00:00:00\", \"company\": \"Nordic\", \"orphan\": 0, \"earliest\": \"2012-02-27T00:00:00\", \"latest\": \"2012-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2530, \"last_scrape\": \"2018-12-13T16:51:48\", \"url\": \"http://www.ncpe.ie/drugs/telapravir/\", \"rr_start\": \"2011-10-28T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-10-28, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Telaprevir (Incivo\", \"trade_name\": \"Incivo\", \"indication\": \"Economic evaluation of Telaprevir (Incivo\", \"ncpe_year\": 2012, \"eu_market\": \"2011-09-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-28T00:00:00\", \"latest\": \"2012-01-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/incivo\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2531, \"last_scrape\": \"2018-12-13T16:51:52\", \"url\": \"http://www.ncpe.ie/drugs/telavancin-vibativ/\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-12-08, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Telavancin (Vibativ\", \"trade_name\": \"Vibativ\", \"indication\": \"Indicated for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumomia, known or suspended to be caused by methicillin-resistant Staphylococcus aureas (MRSA).  Vabitiv\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Theravance\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2015-01-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vibativ-0\", \"ta_list\": \"Pneumonia, Bacterial; Cross Infection\", \"rr_status\": \"No HTA\"}, {\"id\": 2532, \"last_scrape\": \"2018-12-13T16:51:56\", \"url\": \"http://www.ncpe.ie/drugs/teriflunomide-aubagio/\", \"rr_start\": \"2013-08-27T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-08-27, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Teriflunomide (Aubagio\", \"trade_name\": \"Aubagio\", \"indication\": \"Aubagio\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2013-08-27T00:00:00\", \"latest\": \"2014-09-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2533, \"last_scrape\": \"2018-12-13T16:51:58\", \"url\": \"http://www.ncpe.ie/drugs/ticagrelor-brilique-2/\", \"rr_start\": \"2016-02-29T00:00:00\", \"rr_end\": \"2016-05-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-29, 2016-05-04\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor (Brilique\", \"trade_name\": \"Brilique\", \"indication\": \"Ticagrelor (Brilique\", \"ncpe_year\": 2016, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-29T00:00:00\", \"latest\": \"2016-05-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brilique\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2534, \"last_scrape\": \"2018-12-13T16:52:01\", \"url\": \"http://www.ncpe.ie/drugs/ticagrelor-brilique/\", \"rr_start\": \"2010-11-25T00:00:00\", \"rr_end\": \"2011-01-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-11-25, 2011-01-20\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor (Brilique\", \"trade_name\": \"Brilique\", \"indication\": \"Economic Evaluation of Ticagrelor (Brilique\", \"ncpe_year\": 2011, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-11-25T00:00:00\", \"latest\": \"2011-10-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brilique\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2535, \"last_scrape\": \"2018-12-13T16:52:07\", \"url\": \"http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-all/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-19T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TISAGENLECLEUCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel (Kymriah\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel (Kymriah\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2536, \"last_scrape\": \"2018-12-13T16:52:13\", \"url\": \"http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-dlbcl/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TISAGENLECLEUCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel (Kymriah\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel (Kymriah\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2537, \"last_scrape\": \"2018-12-13T16:52:19\", \"url\": \"http://www.ncpe.ie/drugs/tobramycin-tobi-podhaler/\", \"rr_start\": \"2010-11-10T00:00:00\", \"rr_end\": \"2010-11-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2010-11-10, 2010-11-03\", \"rr_multiple\": 0, \"drug_name\": \"Tobramycin (TOBI Podhaler\", \"trade_name\": \"TOBI Podhaler\", \"indication\": \"Tobramycin (TOBI Podhaler\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-11-01T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2538, \"last_scrape\": \"2018-12-13T16:52:24\", \"url\": \"http://www.ncpe.ie/drugs/tocilizumab-sc-roactemra/\", \"rr_start\": \"2014-04-28T00:00:00\", \"rr_end\": \"2014-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THESUBMITTED PRICE.\", \"rr_dates\": \"2014-04-28, 2014-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Tocilizumab SC (RoActemra\", \"trade_name\": \"RoActemra\", \"indication\": \"It is licensed for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.  It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-04-28T00:00:00\", \"latest\": \"2014-07-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra\", \"ta_list\": \"Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2539, \"last_scrape\": \"2018-12-13T16:52:30\", \"url\": \"http://www.ncpe.ie/drugs/tofacitinib-xeljanz-for-ulcerative-colitis/\", \"rr_start\": \"2018-07-16T00:00:00\", \"rr_end\": \"2018-09-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TOFACITINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-07-16, 2018-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib (Xeljanz\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy (i.e. corticosteroids, azathioprine, 6-mercaptopurine) or a biologic agent (i.e. TNF inhibitor).\", \"ncpe_year\": 2018, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2018-07-16T00:00:00\", \"latest\": \"2018-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2540, \"last_scrape\": \"2018-12-13T16:52:35\", \"url\": \"http://www.ncpe.ie/drugs/tofacitinib-xeljanz/\", \"rr_start\": \"2017-03-08T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-08, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib (Xeljanz\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib (Xeljanz\", \"ncpe_year\": 2017, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-03-08T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2541, \"last_scrape\": \"2018-12-13T16:52:40\", \"url\": \"http://www.ncpe.ie/drugs/tolvaptan-jinarc/\", \"rr_start\": \"2016-01-04T00:00:00\", \"rr_end\": \"2016-01-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-04, 2016-01-12\", \"rr_multiple\": 0, \"drug_name\": \"Tolvaptan (Jinarc\", \"trade_name\": \"Jinarc\", \"indication\": \"Jinarc\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2016-01-04T00:00:00\", \"latest\": \"2018-09-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc\", \"ta_list\": \"Polycystic Kidney, Autosomal Dominant\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2542, \"last_scrape\": \"2018-12-13T16:52:45\", \"url\": \"http://www.ncpe.ie/drugs/tramadol-hydrochloridedexketoprofen-skudexa/\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"REIMURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-10-17, 2017-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Tramadol hydrochloride/dexketoprofen (Skudexa\", \"trade_name\": \"Skudexa\", \"indication\": \"Tramadol hydrochloride/dexketoprofen (Skudexa \", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2017-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2543, \"last_scrape\": \"2018-12-13T16:52:51\", \"url\": \"http://www.ncpe.ie/drugs/trametinib-mekinist/\", \"rr_start\": \"2015-11-27T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-27, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Trametinib (Mekinist\", \"trade_name\": \"Mekinist\", \"indication\": \"Mekinist\", \"ncpe_year\": 2018, \"eu_market\": \"2014-06-30T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-27T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2544, \"last_scrape\": \"2018-12-13T16:52:56\", \"url\": \"http://www.ncpe.ie/drugs/trastuzumab-emtansine-kadcyla/\", \"rr_start\": \"2013-09-25T00:00:00\", \"rr_end\": \"2013-10-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-25, 2013-10-24\", \"rr_multiple\": 0, \"drug_name\": \"Trastuzumab emtansine (Kadcyla\", \"trade_name\": \"Kadcyla\", \"indication\": \"Trastuzumab emtansine (Kadcyla\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-09-25T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2545, \"last_scrape\": \"2018-12-13T16:53:00\", \"url\": \"http://www.ncpe.ie/drugs/trifluridinetipiracil-lonsurf/\", \"rr_start\": \"2016-06-10T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-06-10, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Trifluridine/tipiracil (Lonsurf\", \"trade_name\": \"Lonsurf\", \"indication\": \"Trifluridine/tipiracil (Lonsurf\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2016-06-10T00:00:00\", \"latest\": \"2016-07-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2546, \"last_scrape\": \"2018-12-13T16:53:04\", \"url\": \"http://www.ncpe.ie/drugs/ulipristal-acetate-esmya-2/\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-05-17, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate (Esmya \", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate is indicated for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-05-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esmya\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2547, \"last_scrape\": \"2018-12-13T16:53:08\", \"url\": \"http://www.ncpe.ie/drugs/ulipristal-acetate-esmya/\", \"rr_start\": \"2013-09-03T00:00:00\", \"rr_end\": \"2013-10-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-09-03, 2013-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate (Esmya\", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate (Esmya\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2013-09-03T00:00:00\", \"latest\": \"2013-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esmya\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2548, \"last_scrape\": \"2018-12-13T16:53:10\", \"url\": \"http://www.ncpe.ie/drugs/umeclidiniumvilanterol-anoro/\", \"rr_start\": \"2014-06-11T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-06-11, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Umeclidinium/vilanterol (Anoro\", \"trade_name\": \"Anoro\", \"indication\": \"Umeclidinium/vilanterol (Anoro\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-06-11T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2549, \"last_scrape\": \"2018-12-13T16:53:12\", \"url\": \"http://www.ncpe.ie/drugs/urea-glucorx-allpresan/\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT GLUCORX ALLPRESAN DIABETIC FOAM CREAM NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE IN ACCORDANCE WITH THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2018-07-09, 2018-07-24\", \"rr_multiple\": 0, \"drug_name\": \"Urea (GlucoRx Allpresan\", \"trade_name\": \"GlucoRx Allpresan\", \"indication\": \"GlucoRx Allpresan\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-07-24T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2550, \"last_scrape\": \"2018-12-13T16:53:17\", \"url\": \"http://www.ncpe.ie/drugs/ustekinumab-stelara-2/\", \"rr_start\": \"2016-11-28T00:00:00\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-11-28, 2017-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab (Stelara\", \"trade_name\": \"Stelara\", \"indication\": \"Ustekinumab is indicated for the treatment of adult patients with moderately to severely active Crohn\", \"ncpe_year\": 2017, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2016-11-28T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stelara\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2551, \"last_scrape\": \"2018-12-13T16:53:23\", \"url\": \"http://www.ncpe.ie/drugs/ustekinumab-stelara/\", \"rr_start\": \"\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab (Stelara\", \"trade_name\": \"Stelara\", \"indication\": \"Cost-effectiveness of Ustekinumab (Stelara\", \"ncpe_year\": 2009, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2009-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stelara\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2552, \"last_scrape\": \"2018-12-13T16:53:29\", \"url\": \"http://www.ncpe.ie/drugs/vandetanib-caprelsa/\", \"rr_start\": \"2013-06-06T00:00:00\", \"rr_end\": \"2013-07-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-06, 2013-07-03\", \"rr_multiple\": 0, \"drug_name\": \"Vandetanib (Caprelsa\", \"trade_name\": \"Caprelsa\", \"indication\": \"Vandetanib (Caprelsa\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-16T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2013-06-06T00:00:00\", \"latest\": \"2013-07-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2553, \"last_scrape\": \"2018-12-13T16:53:32\", \"url\": \"http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-crohns-disease/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab (Entyvio\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab (Entyvio\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2554, \"last_scrape\": \"2018-12-13T16:53:39\", \"url\": \"http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-ulcerative-colitis/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab (Entyvio\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab (Entyvio\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2555, \"last_scrape\": \"2018-12-13T16:53:45\", \"url\": \"http://www.ncpe.ie/drugs/velaglucerase-alfa-vpriv-2/\", \"rr_start\": \"2011-04-26T00:00:00\", \"rr_end\": \"2011-06-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-04-26, 2011-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Velaglucerase Alfa (VPRIV\", \"trade_name\": \"VPRIV\", \"indication\": \"VPRIV is indicated for long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-04-26T00:00:00\", \"latest\": \"2011-06-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2556, \"last_scrape\": \"2018-12-13T16:53:49\", \"url\": \"http://www.ncpe.ie/drugs/venetoclax-venclyxto-in-combination-with-rituximab/\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF VENETOCLAX COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-26, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax (Venclyxto\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax (Venclyxto\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2557, \"last_scrape\": \"2018-12-13T16:53:52\", \"url\": \"http://www.ncpe.ie/drugs/venetoclax-venclyxto/\", \"rr_start\": \"2018-05-08T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"FOLLOWING A RESUBMISSION OF THE RAPID REVIEW A FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, WHICH IS NOT COMPARABLE WITH CURRENT AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-05-08, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax (Venclyxto\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL)\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2558, \"last_scrape\": \"2018-12-13T16:53:58\", \"url\": \"http://www.ncpe.ie/drugs/vermurafenib-zelboraf/\", \"rr_start\": \"2011-12-23T00:00:00\", \"rr_end\": \"2012-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-12-23, 2012-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Vemurafenib (Zelboraf\", \"trade_name\": \"Zelboraf\", \"indication\": \"Vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\", \"ncpe_year\": 2014, \"eu_market\": \"2012-02-17T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2011-12-23T00:00:00\", \"latest\": \"2014-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2559, \"last_scrape\": \"2018-12-13T16:54:00\", \"url\": \"http://www.ncpe.ie/drugs/vernakalant-brinavess/\", \"rr_start\": \"2010-10-26T00:00:00\", \"rr_end\": \"2010-11-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-10-26, 2010-11-04\", \"rr_multiple\": 0, \"drug_name\": \"Vernakalant (Brinavess\", \"trade_name\": \"Brinavess\", \"indication\": \"Economic evaluation of Vernakalant (Brinavess\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Cardiome\", \"orphan\": 0, \"earliest\": \"2010-10-26T00:00:00\", \"latest\": \"2011-05-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2560, \"last_scrape\": \"2018-12-13T16:54:04\", \"url\": \"http://www.ncpe.ie/drugs/vismodegib-erivedge/\", \"rr_start\": \"2013-05-02T00:00:00\", \"rr_end\": \"2013-05-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-05-02, 2013-05-20\", \"rr_multiple\": 0, \"drug_name\": \"Vismodegib (Erivedge\", \"trade_name\": \"Erivedge\", \"indication\": \"Vismodegib (Erivedge\", \"ncpe_year\": 2017, \"eu_market\": \"2013-07-12T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-05-02T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge\", \"ta_list\": \"Carcinoma, Basal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2561, \"last_scrape\": \"2018-12-13T16:54:11\", \"url\": \"http://www.ncpe.ie/drugs/vortioxetine-brintellix/\", \"rr_start\": \"2014-10-01T00:00:00\", \"rr_end\": \"2014-11-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-10-01, 2014-11-14\", \"rr_multiple\": 0, \"drug_name\": \"Vortioxetine (Brintellix\", \"trade_name\": \"Brintellix\", \"indication\": \"Vortioxetine (Brintellix\", \"ncpe_year\": 2017, \"eu_market\": \"2013-12-18T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2014-10-01T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"HTA recommended at submitted price\"}]}};\n",
       "var opt = {};\n",
       "var type = \"vega-lite\";\n",
       "var id = \"45990416-14f0-4b48-92fb-3aaaa944ff2d\";\n",
       "\n",
       "var output_area = this;\n",
       "\n",
       "require([\"nbextensions/jupyter-vega/index\"], function(vega) {\n",
       "  var target = document.createElement(\"div\");\n",
       "  target.id = id;\n",
       "  target.className = \"vega-embed\";\n",
       "\n",
       "  var style = document.createElement(\"style\");\n",
       "  style.textContent = [\n",
       "    \".vega-embed .error p {\",\n",
       "    \"  color: firebrick;\",\n",
       "    \"  font-size: 14px;\",\n",
       "    \"}\",\n",
       "  ].join(\"\\\\n\");\n",
       "\n",
       "  // element is a jQuery wrapped DOM element inside the output area\n",
       "  // see http://ipython.readthedocs.io/en/stable/api/generated/\\\n",
       "  // IPython.display.html#IPython.display.Javascript.__init__\n",
       "  element[0].appendChild(target);\n",
       "  element[0].appendChild(style);\n",
       "\n",
       "  vega.render(\"#\" + id, spec, type, opt, output_area);\n",
       "}, function (err) {\n",
       "  if (err.requireType !== \"scripterror\") {\n",
       "    throw(err);\n",
       "  }\n",
       "});\n"
      ],
      "text/plain": [
       "<vega.vegalite.VegaLite at 0x24582100e80>"
      ]
     },
     "metadata": {
      "jupyter-vega": "#45990416-14f0-4b48-92fb-3aaaa944ff2d"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": []
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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"
     },
     "metadata": {
      "jupyter-vega": "#45990416-14f0-4b48-92fb-3aaaa944ff2d"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "alt.Chart(drugs,title=\"Count Drugs by NCPE Year with Status\").mark_bar().encode(\n",
    "    alt.X('ncpe_year:O',axis=alt.Axis(title='NCPE Year')),\n",
    "    alt.Y('count(rr_status)', title=\"Count\"),\n",
    "    alt.Color(\"rr_status\",title=\"Status\")).properties(width=700,height=400)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 2.3 Count: Drugs by Company\n",
    "A simple chart, number of drugs by company"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "var spec = {\"config\": {\"view\": {\"width\": 400, \"height\": 300}}, \"data\": {\"name\": \"data-1fb11c1b30e9c74b6a5173f2568cb7ab\"}, \"mark\": {\"type\": \"bar\", \"color\": \"lightblue\"}, \"encoding\": {\"x\": {\"type\": \"nominal\", \"axis\": {\"title\": \"Drug Company\"}, \"field\": \"company\", \"sort\": {\"op\": \"count\", \"field\": \"company\", \"order\": \"descending\"}}, \"y\": {\"type\": \"nominal\", \"aggregate\": \"count\", \"axis\": {\"title\": \"Number of Drugs\"}, \"field\": \"rr_status\"}}, \"height\": 300, \"title\": \"Count of Drugs By Company\", \"width\": 4000, \"$schema\": \"https://vega.github.io/schema/vega-lite/v2.6.0.json\", \"datasets\": {\"data-1fb11c1b30e9c74b6a5173f2568cb7ab\": [{\"id\": 2164, \"last_scrape\": \"2018-12-13T16:24:32\", \"url\": \"http://www.ncpe.ie/drugs/abatacept-orencia/\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Abatacept (Orencia\", \"trade_name\": \"Orencia\", \"indication\": \"Subcutaneous Abatacept (Orencia\", \"ncpe_year\": 2015, \"eu_market\": \"2007-05-21T00:00:00\", \"company\": \"\", \"orphan\": 0, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/orencia\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2165, \"last_scrape\": \"2018-12-13T16:24:36\", \"url\": \"http://www.ncpe.ie/drugs/abiraterone-acetate-zytiga-for-mhspc/\", \"rr_start\": \"2018-10-03T00:00:00\", \"rr_end\": \"2018-11-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-10-03, 2018-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Abiraterone acetate (Zytiga\", \"ncpe_year\": 2018, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2018-10-03T00:00:00\", \"latest\": \"2018-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2166, \"last_scrape\": \"2018-12-13T16:24:41\", \"url\": \"http://www.ncpe.ie/drugs/abiratone-acetate-zytiga-for-mcrpc-post-adt/\", \"rr_start\": \"2013-01-03T00:00:00\", \"rr_end\": \"2013-02-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-01-03, 2013-02-01\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation of Abiratone acetate (Zytiga\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-01-03T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2167, \"last_scrape\": \"2018-12-13T16:24:46\", \"url\": \"http://www.ncpe.ie/drugs/abiratone-acetate-zytiga/\", \"rr_start\": \"2011-10-21T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-10-21, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone Acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation and resource implications of Zytiga \", \"ncpe_year\": 2014, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-21T00:00:00\", \"latest\": \"2014-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2168, \"last_scrape\": \"2018-12-13T16:24:49\", \"url\": \"http://www.ncpe.ie/drugs/aceclofenac-vitafen/\", \"rr_start\": \"2016-12-21T00:00:00\", \"rr_end\": \"2017-01-24T00:00:00\", \"rr_outcome\": \"FOLLOWING A RESUBMISSION OF THE RAPID REVIEW A FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-12-21, 2017-01-24\", \"rr_multiple\": 0, \"drug_name\": \"Aceclofenac (Vitafen\", \"trade_name\": \"Vitafen\", \"indication\": \"Aceclofenac (Vitafen\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-07-22T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2169, \"last_scrape\": \"2018-12-13T16:24:56\", \"url\": \"http://www.ncpe.ie/drugs/aclidinium-bromide-eklira-genuair/\", \"rr_start\": \"2012-10-23T00:00:00\", \"rr_end\": \"2012-10-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-23, 2012-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide (Eklira Genuair\", \"trade_name\": \"Eklira Genuair\", \"indication\": \"Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)\", \"ncpe_year\": 2012, \"eu_market\": \"2012-07-20T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-23T00:00:00\", \"latest\": \"2012-10-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"id\": 2170, \"last_scrape\": \"2018-12-13T16:25:00\", \"url\": \"http://www.ncpe.ie/drugs/aclidinium-bromide-formoterol-fumarate-dihydrate-brimica-genuair/\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE.\", \"rr_dates\": \"2015-01-05, 2015-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide / formoterol fumarate dihydrate (Brimica\", \"trade_name\": \"Brimica Genuair\", \"indication\": \"Brimica\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2015-02-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brimica-genuair\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2171, \"last_scrape\": \"2018-12-13T16:25:37\", \"url\": \"http://www.ncpe.ie/drugs/adalimumab-humira/\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-20, 2011-06-02\", \"rr_multiple\": 0, \"drug_name\": \"Adalimumab (Humira\", \"trade_name\": \"Humira\", \"indication\": \"Economic evaluation of Adalimumab (Humira\", \"ncpe_year\": 2011, \"eu_market\": \"2003-09-07T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/humira\", \"ta_list\": \"Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"id\": 2172, \"last_scrape\": \"2018-12-13T16:25:40\", \"url\": \"http://www.ncpe.ie/drugs/adenuric-febuxostat/\", \"rr_start\": \"2009-12-08T00:00:00\", \"rr_end\": \"2009-12-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-12-08\", \"rr_multiple\": 0, \"drug_name\": \"Adenuric (Febuxostat\", \"trade_name\": \"Febuxostat\", \"indication\": \"NCPE review of Adenuric (Febuxostat\", \"ncpe_year\": 2009, \"eu_market\": \"2008-04-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2009-12-08T00:00:00\", \"latest\": \"2009-12-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adenuric\", \"ta_list\": \"Gout\", \"rr_status\": \"No HTA\"}, {\"id\": 2173, \"last_scrape\": \"2018-12-13T16:25:45\", \"url\": \"http://www.ncpe.ie/drugs/afatinib-giotrif/\", \"rr_start\": \"2013-10-01T00:00:00\", \"rr_end\": \"2013-10-13T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-10-01, 2013-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Afatinib (Giotrif\", \"trade_name\": \"Giotrif\", \"indication\": \"GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-na\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-25T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2013-10-01T00:00:00\", \"latest\": \"2013-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2174, \"last_scrape\": \"2018-12-13T16:25:49\", \"url\": \"http://www.ncpe.ie/drugs/aflibercept-eylea/\", \"rr_start\": \"2012-12-10T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-10, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept (Eylea\", \"trade_name\": \"Eylea\", \"indication\": \"Aflibercept (Eylea\", \"ncpe_year\": 2012, \"eu_market\": \"2012-11-21T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2012-12-10T00:00:00\", \"latest\": \"2012-12-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eylea\", \"ta_list\": \"Wet Macular Degeneration; Macular Edema; Diabetes Complications\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2175, \"last_scrape\": \"2018-12-13T16:25:52\", \"url\": \"http://www.ncpe.ie/drugs/aflibercept-zaltrap/\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept (Zaltrap\", \"trade_name\": \"Zaltrap\", \"indication\": \"Aflibercept for the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-01T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-02-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zaltrap\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2176, \"last_scrape\": \"2018-12-13T16:25:58\", \"url\": \"http://www.ncpe.ie/drugs/agomelatine-valdoxan-4/\", \"rr_start\": \"\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Agomelatine (Valdoxan\", \"trade_name\": \"Valdoxan\", \"indication\": \"Economic evaluation of Agomelatine (Valdoxan\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-19T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2009-09-03T00:00:00\", \"latest\": \"2009-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/valdoxan\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2177, \"last_scrape\": \"2018-12-13T16:26:06\", \"url\": \"http://www.ncpe.ie/drugs/alectinib-alecensa/\", \"rr_start\": \"2017-01-03T00:00:00\", \"rr_end\": \"2017-12-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-01-03, 2017-02-27, 2017-11-08, 2017-12-04\", \"rr_multiple\": 1, \"drug_name\": \"Alectinib (Alecensa\", \"trade_name\": \"Alecensa\", \"indication\": \"Alectinib (Alecensa \", \"ncpe_year\": 2018, \"eu_market\": \"2017-02-16T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2178, \"last_scrape\": \"2018-12-13T16:26:12\", \"url\": \"http://www.ncpe.ie/drugs/alemtuzumab-lemtrada/\", \"rr_start\": \"2013-11-08T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-11-08, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Alemtuzumab (Lemtrada\", \"trade_name\": \"Lemtrada\", \"indication\": \"Alemtuzumab (Lemtrada\", \"ncpe_year\": 2014, \"eu_market\": \"2013-09-12T00:00:00\", \"company\": \"Sanofi\", \"orphan\": 0, \"earliest\": \"2013-11-08T00:00:00\", \"latest\": \"2014-06-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2179, \"last_scrape\": \"2018-12-13T16:26:14\", \"url\": \"http://www.ncpe.ie/drugs/alirocumab-praluent/\", \"rr_start\": \"2015-10-13T00:00:00\", \"rr_end\": \"2015-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-10-13, 2015-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Alirocumab (Praluent\", \"trade_name\": \"Praluent\", \"indication\": \"Praluent\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2015-10-13T00:00:00\", \"latest\": \"2018-03-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/praluent\", \"ta_list\": \"Dyslipidemias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2180, \"last_scrape\": \"2018-12-13T16:26:16\", \"url\": \"http://www.ncpe.ie/drugs/alogliptin-vipidia/\", \"rr_start\": \"2013-09-27T00:00:00\", \"rr_end\": \"2013-10-30T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-09-27, 2013-10-30\", \"rr_multiple\": 0, \"drug_name\": \"Alogliptin (Vipidia\", \"trade_name\": \"Vipidia\", \"indication\": \"Alogliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-18T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2013-09-27T00:00:00\", \"latest\": \"2013-10-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vipidia\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2181, \"last_scrape\": \"2018-12-13T16:26:21\", \"url\": \"http://www.ncpe.ie/drugs/ambrisentan-volibris/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-05-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Ambrisentan (Volibris\", \"trade_name\": \"Volibris\", \"indication\": \"Cost Effectiveness of ambrisentan (Volibris\", \"ncpe_year\": 2014, \"eu_market\": \"2008-04-20T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 1, \"earliest\": \"2008-10-01T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/volibris\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2182, \"last_scrape\": \"2018-12-13T16:26:23\", \"url\": \"http://www.ncpe.ie/drugs/amifampridine-firdapse/\", \"rr_start\": \"2011-11-07T00:00:00\", \"rr_end\": \"2011-12-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-11-07, 2011-12-09\", \"rr_multiple\": 0, \"drug_name\": \"Amifampridine (Firdapse\", \"trade_name\": \"Firdapse\", \"indication\": \"For Lambert Eaton Myasthenic Syndrome (LEMS).  This high cost drug is likely to require a full HTA due to significant budget impact.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-11-07T00:00:00\", \"latest\": \"2011-12-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2183, \"last_scrape\": \"2018-12-13T16:26:29\", \"url\": \"http://www.ncpe.ie/drugs/amsacrine-amsidine/\", \"rr_start\": \"2017-01-10T00:00:00\", \"rr_end\": \"2017-02-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-01-10, 2017-02-15\", \"rr_multiple\": 0, \"drug_name\": \"Amsacrine (Amsidine\", \"trade_name\": \"Amsidine\", \"indication\": \"Amsidine\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2017-01-10T00:00:00\", \"latest\": \"2017-02-15T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2184, \"last_scrape\": \"2018-12-13T16:26:35\", \"url\": \"http://www.ncpe.ie/drugs/apixaban-eliquis-for-treatment-of-deep-vein-thrombosis-dvt-and-pulmonary-embolism-pe-and-prevention-of-recurrent-dvt-and-pe-in-adults/\", \"rr_start\": \"2014-07-29T00:00:00\", \"rr_end\": \"2014-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-07-29, 2014-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban (Eliquis\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban (Eliquis\", \"ncpe_year\": 2014, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-07-29T00:00:00\", \"latest\": \"2014-08-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2185, \"last_scrape\": \"2018-12-13T16:26:39\", \"url\": \"http://www.ncpe.ie/drugs/apixaban-eliquis/\", \"rr_start\": \"2011-10-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-10-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban (Eliquis\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban (Eliquis\", \"ncpe_year\": 2012, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-10-19T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2186, \"last_scrape\": \"2018-12-13T16:26:45\", \"url\": \"http://www.ncpe.ie/drugs/apremilast-otezla-for-moderate-to-severe-chronic-plaque-psoriasis/\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast (Otezla\", \"trade_name\": \"Otezla\", \"indication\": \"Indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to systemic non-biologic therapies including cyclosporine, methotrexate or psoralen and ultraviolet A light (PUVA).\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/otezla\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2187, \"last_scrape\": \"2018-12-13T16:26:47\", \"url\": \"http://www.ncpe.ie/drugs/apremilast-otezla-for-psoriatic-arthritis/\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast (Otezla\", \"trade_name\": \"Otezla\", \"indication\": \"Apremilist (Otezla\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/otezla\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2188, \"last_scrape\": \"2018-12-13T16:26:49\", \"url\": \"http://www.ncpe.ie/drugs/aripiprazole-abilify-maintena/\", \"rr_start\": \"2014-07-02T00:00:00\", \"rr_end\": \"2014-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-07-02, 2014-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Aripiprazole (Abilify Maintena\", \"trade_name\": \"Abilify Maintena\", \"indication\": \"Aripiprazole (Abilify Maintena\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-14T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2014-07-02T00:00:00\", \"latest\": \"2014-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2189, \"last_scrape\": \"2018-12-13T16:26:55\", \"url\": \"http://www.ncpe.ie/drugs/asenapine-sycrest/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-08-17, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Asenapine (Sycrest\", \"trade_name\": \"Sycrest\", \"indication\": \"Asenapine (Sycrest\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Organon\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sycrest\", \"ta_list\": \"Bipolar Disorder\", \"rr_status\": \"No HTA\"}, {\"id\": 2190, \"last_scrape\": \"2018-12-13T16:27:00\", \"url\": \"http://www.ncpe.ie/drugs/atezolizumab-tecentriq/\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-10-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-08, 2017-10-09\", \"rr_multiple\": 0, \"drug_name\": \"Atezolizumab (Tecentriq\", \"trade_name\": \"Tecentriq\", \"indication\": \"Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK?positive tumour mutations should also have received targeted therapy before receiving atezolizumab.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-21T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq\", \"ta_list\": \"Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2191, \"last_scrape\": \"2018-12-13T16:27:05\", \"url\": \"http://www.ncpe.ie/drugs/avanafil-spedra/\", \"rr_start\": \"2014-02-19T00:00:00\", \"rr_end\": \"2014-03-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-19, 2014-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Avanafil (Spedra\", \"trade_name\": \"Spedra\", \"indication\": \"Avanafil (Spedra\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2014-02-19T00:00:00\", \"latest\": \"2014-03-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/spedra\", \"ta_list\": \"Erectile Dysfunction\", \"rr_status\": \"No HTA\"}, {\"id\": 2192, \"last_scrape\": \"2018-12-13T16:27:06\", \"url\": \"http://www.ncpe.ie/drugs/avelumab-bavencio/\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-10-17, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Avelumab (Bavencio\", \"trade_name\": \"Bavencio\", \"indication\": \"Avelumab (Bavencio\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2018-10-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2193, \"last_scrape\": \"2018-12-13T16:27:08\", \"url\": \"http://www.ncpe.ie/drugs/axanum-aspirin-81mgesomeprazole-20mg/\", \"rr_start\": \"2012-04-12T00:00:00\", \"rr_end\": \"2012-04-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-04-12, 2012-04-20\", \"rr_multiple\": 0, \"drug_name\": \"Aspirin 81mg/Esomeprazole 20mg (Axanum\", \"trade_name\": \"Axanum\", \"indication\": \"Prevention of thrombotic cardiovascular and cerebrovascular events in patients requiring continuous low-dose acetylsalicylic acid treatment, and who are in need of prophylaxis against acetylsalicylic acid associated gastric and /or duodenal ulcers.\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-04-12T00:00:00\", \"latest\": \"2012-04-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2194, \"last_scrape\": \"2018-12-13T16:27:14\", \"url\": \"http://www.ncpe.ie/drugs/axicabtagene-ciloleucel-yescarta/\", \"rr_start\": \"2018-09-10T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF  AXI-CEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-10, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Axicabtagene Ciloleucel (Yescarta\", \"trade_name\": \"Yescarta\", \"indication\": \"Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Kite\", \"orphan\": 1, \"earliest\": \"2018-09-10T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta\", \"ta_list\": \"Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2195, \"last_scrape\": \"2018-12-13T16:27:23\", \"url\": \"http://www.ncpe.ie/drugs/axitinib-inlyta/\", \"rr_start\": \"2012-11-07T00:00:00\", \"rr_end\": \"2012-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-07, 2012-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Axitinib (Inlyta\", \"trade_name\": \"Inlyta\", \"indication\": \"For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-03T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-11-07T00:00:00\", \"latest\": \"2012-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2196, \"last_scrape\": \"2018-12-13T16:27:24\", \"url\": \"http://www.ncpe.ie/drugs/azelastine-hydrochloride-and-fluticasone-propionate-nasal-spray-dymista/\", \"rr_start\": \"2013-02-12T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2013-02-12, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Azelastine hydrochloride and fluticasone propionate (nasal spray) (Dymista\", \"trade_name\": \"Dymista\", \"indication\": \"Indicated for symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-02-12T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2197, \"last_scrape\": \"2018-12-13T16:27:25\", \"url\": \"http://www.ncpe.ie/drugs/azilsartan-edarbi/\", \"rr_start\": \"2012-01-10T00:00:00\", \"rr_end\": \"2012-01-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-01-10, 2012-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Azilsartan (Edarbi\", \"trade_name\": \"Edarbi\", \"indication\": \"Edarbi is indicated for the treatment of essential hypertension in adults.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-12-07T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2012-01-10T00:00:00\", \"latest\": \"2012-01-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/edarbi\", \"ta_list\": \"Hypertension\", \"rr_status\": \"No HTA\"}, {\"id\": 2198, \"last_scrape\": \"2018-12-13T16:27:27\", \"url\": \"http://www.ncpe.ie/drugs/baricitinib-olumiant/\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-06-14, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Baricitinib (Olumiant\", \"trade_name\": \"Olumiant\", \"indication\": \"Baricitinib (Olumiant\", \"ncpe_year\": 2017, \"eu_market\": \"2017-02-12T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2199, \"last_scrape\": \"2018-12-13T16:27:33\", \"url\": \"http://www.ncpe.ie/drugs/bazedoxifene-conbriza/\", \"rr_start\": \"2011-09-20T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-09-20, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Bazedoxifene (Conbriza\", \"trade_name\": \"Conbriza\", \"indication\": \"Bazedoxifene (Conbriza\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-17T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-09-20T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza\", \"ta_list\": \"Osteoporosis, Postmenopausal\", \"rr_status\": \"No HTA\"}, {\"id\": 2200, \"last_scrape\": \"2018-12-13T16:27:36\", \"url\": \"http://www.ncpe.ie/drugs/bedaquiline-sirturo/\", \"rr_start\": \"2015-01-23T00:00:00\", \"rr_end\": \"2015-02-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-01-23, 2015-02-20\", \"rr_multiple\": 0, \"drug_name\": \"Bedaquiline (Sirturo\", \"trade_name\": \"Sirturo\", \"indication\": \"Bedaquiline (Sirturo\", \"ncpe_year\": 2015, \"eu_market\": \"2014-03-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2015-01-23T00:00:00\", \"latest\": \"2015-02-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo\", \"ta_list\": \"Tuberculosis, Multidrug-Resistant\", \"rr_status\": \"No HTA\"}, {\"id\": 2201, \"last_scrape\": \"2018-12-13T16:27:37\", \"url\": \"http://www.ncpe.ie/drugs/belatacept-nulojix/\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2012-01-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-11-15, 2012-01-23\", \"rr_multiple\": 0, \"drug_name\": \"Belatacept (Nulojix\", \"trade_name\": \"Nulojix\", \"indication\": \"Belatacept, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen.\\n\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2012-01-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nulojix\", \"ta_list\": \"Graft Rejection; Kidney Transplantation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2202, \"last_scrape\": \"2018-12-13T16:27:40\", \"url\": \"http://www.ncpe.ie/drugs/belimumab-benlysta/\", \"rr_start\": \"2011-08-11T00:00:00\", \"rr_end\": \"2011-08-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-11, 2011-08-11\", \"rr_multiple\": 0, \"drug_name\": \"Belimumab (Benlysta\", \"trade_name\": \"Benlysta\", \"indication\": \"Cost-effectiveness of Belimumab (Benlysta\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-08-01T00:00:00\", \"latest\": \"2011-08-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta\", \"ta_list\": \"Lupus Erythematosus, Systemic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2203, \"last_scrape\": \"2018-12-13T16:27:46\", \"url\": \"http://www.ncpe.ie/drugs/bendamustine-levact/\", \"rr_start\": \"2011-03-21T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-03-21, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Bendamustine (Levact\", \"trade_name\": \"Levact\", \"indication\": \"Bendamustine (Levact\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2012-11-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2204, \"last_scrape\": \"2018-12-13T16:27:50\", \"url\": \"http://www.ncpe.ie/drugs/benralizumab-fasenra/\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-14T00:00:00\", \"rr_outcome\": \"FULL PHARAMCOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2018-01-15, 2018-02-14\", \"rr_multiple\": 0, \"drug_name\": \"Benralizumab (Fasenra\", \"trade_name\": \"Fasenra\", \"indication\": \"Benralizumab (Fasenra\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fasenra\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2205, \"last_scrape\": \"2018-12-13T16:27:56\", \"url\": \"http://www.ncpe.ie/drugs/bezlotoxumab-zinplava/\", \"rr_start\": \"2017-05-11T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-05-11, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Bezlotoxumab (Zinplava\", \"trade_name\": \"Zinplava\", \"indication\": \"Bezlotoxumab (Zinplava\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-05-11T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinplava\", \"ta_list\": \"Enterocolitis, Pseudomembranous\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2206, \"last_scrape\": \"2018-12-13T16:27:58\", \"url\": \"http://www.ncpe.ie/drugs/bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy/\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT BIKTARVY\", \"rr_dates\": \"2018-04-30, 2018-06-07\", \"rr_multiple\": 0, \"drug_name\": \"Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy\", \"trade_name\": \"Biktarvy\", \"indication\": \"Biktarvy\", \"ncpe_year\": 2018, \"eu_market\": \"2018-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2207, \"last_scrape\": \"2018-12-13T16:28:01\", \"url\": \"http://www.ncpe.ie/drugs/bilastine-drynol/\", \"rr_start\": \"2011-03-10T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-10, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Bilastine (Drynol\", \"trade_name\": \"Drynol\", \"indication\": \" Bilastine (Drynol\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-03-10T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2208, \"last_scrape\": \"2018-12-13T16:28:05\", \"url\": \"http://www.ncpe.ie/drugs/blinatumomab-blincyto/\", \"rr_start\": \"2015-12-08T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.  THE NCPE CANNOT RECOMMEND REIMBURSEMENT OF BLINCTYO\", \"rr_dates\": \"2015-12-08, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Blinatumomab (Blincyto\", \"trade_name\": \"Blincyto\", \"indication\": \"Blincyto\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-23T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-08T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2209, \"last_scrape\": \"2018-12-13T16:28:11\", \"url\": \"http://www.ncpe.ie/drugs/boceprevir-victrelis/\", \"rr_start\": \"\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Boceprevir (Victrelis\", \"trade_name\": \"Victrelis\", \"indication\": \"Economic evaluation of Boceprevir (Victrelis\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2011-08-19T00:00:00\", \"latest\": \"2012-01-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2210, \"last_scrape\": \"2018-12-13T16:28:16\", \"url\": \"http://www.ncpe.ie/drugs/bosentan-tracleer/\", \"rr_start\": \"2014-06-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-06-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Bosentan (Tracleer\", \"trade_name\": \"Tracleer\", \"indication\": \"Bosentan (Tracleer\", \"ncpe_year\": 2014, \"eu_market\": \"2002-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-06-27T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tracleer\", \"ta_list\": \"Scleroderma, Systemic; Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2211, \"last_scrape\": \"2018-12-13T16:28:18\", \"url\": \"http://www.ncpe.ie/drugs/bosutinib-bosulif/\", \"rr_start\": \"2013-08-09T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"AT THE CURRENT PRICE A FULL HTA WOULD BE REQUIRED.\", \"rr_dates\": \"2013-08-09, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Bosutinib (Bosulif\", \"trade_name\": \"Bosulif\", \"indication\": \"Bosutinib is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-26T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2212, \"last_scrape\": \"2018-12-13T16:28:19\", \"url\": \"http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris-for-cd30-cutaneous-t-cell-lymphoma-ctcl/\", \"rr_start\": \"2018-02-07T00:00:00\", \"rr_end\": \"2018-03-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-02-07, 2018-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin (Adcetris\", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin (Adcetris\", \"ncpe_year\": 2018, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-02-07T00:00:00\", \"latest\": \"2018-03-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2213, \"last_scrape\": \"2018-12-13T16:28:23\", \"url\": \"http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris/\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin (Adcetris\", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin (Adcetris\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2214, \"last_scrape\": \"2018-12-13T16:28:29\", \"url\": \"http://www.ncpe.ie/drugs/brigatinib-alunbrig/\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF BRIGATINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-11-19, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Brigatinib (Alunbrig\", \"trade_name\": \"Alunbrig\", \"indication\": \"Brigatinib (Alunbrig \", \"ncpe_year\": 2018, \"eu_market\": \"2018-11-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2215, \"last_scrape\": \"2018-12-13T16:28:30\", \"url\": \"http://www.ncpe.ie/drugs/brimonidine-3-3-mgg-gel-mirvaso/\", \"rr_start\": \"2014-04-09T00:00:00\", \"rr_end\": \"2014-04-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-09\", \"rr_multiple\": 0, \"drug_name\": \"Brimonidine 3.3 mg/g gel (Mirvaso\", \"trade_name\": \"Mirvaso\", \"indication\": \"Brimonidine 3.3 mg/g gel (Mirvaso\", \"ncpe_year\": 2014, \"eu_market\": \"2014-02-20T00:00:00\", \"company\": \"Galderma\", \"orphan\": 0, \"earliest\": \"2014-04-09T00:00:00\", \"latest\": \"2014-04-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mirvaso\", \"ta_list\": \"Skin Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2216, \"last_scrape\": \"2018-12-13T16:28:36\", \"url\": \"http://www.ncpe.ie/drugs/brivaracetam-briviact/\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-02-15, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Brivaracetam (Briviact\", \"trade_name\": \"Briviact\", \"indication\": \"Brivaracetam (Briviact\", \"ncpe_year\": 2016, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2217, \"last_scrape\": \"2018-12-13T16:28:40\", \"url\": \"http://www.ncpe.ie/drugs/brodalumab-kyntheum/\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-07-25, 2017-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Brodalumab (Kyntheum\", \"trade_name\": \"Kyntheum\", \"indication\": \"Brodalumab (Kyntheum\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-17T00:00:00\", \"company\": \"LEO\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2218, \"last_scrape\": \"2018-12-13T16:28:44\", \"url\": \"http://www.ncpe.ie/drugs/bronchitol/\", \"rr_start\": \"2012-09-11T00:00:00\", \"rr_end\": \"2012-09-21T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2012-09-11, 2012-09-21\", \"rr_multiple\": 0, \"drug_name\": \"Mannitol Dry Powder (Bronchitol\", \"trade_name\": \"Bronchitol\", \"indication\": \"Bronchitol\", \"ncpe_year\": 2014, \"eu_market\": \"2012-04-13T00:00:00\", \"company\": \"Pharmaxis\", \"orphan\": 1, \"earliest\": \"2012-09-11T00:00:00\", \"latest\": \"2014-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bronchitol\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2219, \"last_scrape\": \"2018-12-13T16:28:46\", \"url\": \"http://www.ncpe.ie/drugs/c-drugs/calcipotriol-and-betamethasone-dipropionate-cutaneous-foam-enstilar/\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-06-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-05-17, 2016-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Calcipotriol and betamethasone dipropionate cutaneous foam (Enstilar \", \"trade_name\": \"Enstilar\", \"indication\": \"Calcipotriol and betamethasone dipropionate cutaneous foam is indicated for the topical treatment of psoriasis vulgaris in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-06-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2220, \"last_scrape\": \"2018-12-13T16:28:53\", \"url\": \"http://www.ncpe.ie/drugs/c1inhibitor-human-cinryze/\", \"rr_start\": \"2012-10-22T00:00:00\", \"rr_end\": \"2012-11-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-22, 2012-11-14\", \"rr_multiple\": 0, \"drug_name\": \"C1inhibitor (human) (Cinryze\", \"trade_name\": \"Cinryze\", \"indication\": \"C1inhibitor (human) (Cinryze\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-15T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2012-10-22T00:00:00\", \"latest\": \"2012-11-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"id\": 2221, \"last_scrape\": \"2018-12-13T16:28:55\", \"url\": \"http://www.ncpe.ie/drugs/cabozantinib-cabometyx/\", \"rr_start\": \"2017-03-20T00:00:00\", \"rr_end\": \"2017-04-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT\\nRECOMMENDED\", \"rr_dates\": \"2017-03-20, 2017-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib (Cabometyx\", \"trade_name\": \"Cabometyx\", \"indication\": \"Cabozantinib (Cabometyx\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-03-20T00:00:00\", \"latest\": \"2018-07-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2222, \"last_scrape\": \"2018-12-13T16:28:58\", \"url\": \"http://www.ncpe.ie/drugs/cabozantinib-cometriq/\", \"rr_start\": \"2014-07-10T00:00:00\", \"rr_end\": \"2014-08-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2014-07-10, 2014-08-12\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib (Cometriq\", \"trade_name\": \"Cometriq\", \"indication\": \"Cabozantinib (COMETRIQ\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-21T00:00:00\", \"company\": \"Ipsen\", \"orphan\": 1, \"earliest\": \"2014-07-10T00:00:00\", \"latest\": \"2014-08-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2223, \"last_scrape\": \"2018-12-13T16:29:01\", \"url\": \"http://www.ncpe.ie/drugs/camellia-sinensis-folium-green-tea-leaf-catephen-10/\", \"rr_start\": \"2015-05-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-05-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Camellia sinensis, folium (green tea leaf) (Catephen 10%\", \"trade_name\": \"Catephen 10%\", \"indication\": \"Catephen 10%\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-05-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2224, \"last_scrape\": \"2018-12-13T16:29:04\", \"url\": \"http://www.ncpe.ie/drugs/canagliflozin-invokana/\", \"rr_start\": \"2013-11-25T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-11-25, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Canagliflozin (Invokana\", \"trade_name\": \"Invokana\", \"indication\": \"Canagliflozin (Invokana\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-11-25T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/invokana\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2225, \"last_scrape\": \"2018-12-13T16:29:09\", \"url\": \"http://www.ncpe.ie/drugs/capsaicin-8ww-patch-qutenza/\", \"rr_start\": \"2012-06-15T00:00:00\", \"rr_end\": \"2012-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-06-15, 2012-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Capsaicin 8%w/w patch (Qutenza\", \"trade_name\": \"Qutenza\", \"indication\": \"Capsaicin 8% w/w patch (Qutenza\", \"ncpe_year\": 2012, \"eu_market\": \"2009-05-15T00:00:00\", \"company\": \"Grunenthal\", \"orphan\": 0, \"earliest\": \"2012-06-15T00:00:00\", \"latest\": \"2012-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza\", \"ta_list\": \"Neuralgia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2226, \"last_scrape\": \"2018-12-13T16:29:11\", \"url\": \"http://www.ncpe.ie/drugs/carbazitaxel-jevtana-for-prostate-cancer/\", \"rr_start\": \"2011-06-02T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-06-02, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Cabazitaxel (Jevtana\", \"trade_name\": \"Jevtana\", \"indication\": \"Economic Evaluation of cabazitaxel (Jevtana\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2011-06-02T00:00:00\", \"latest\": \"2014-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jevtana\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2227, \"last_scrape\": \"2018-12-13T16:29:16\", \"url\": \"http://www.ncpe.ie/drugs/carfilzomib-kyprolis/\", \"rr_start\": \"2015-12-07T00:00:00\", \"rr_end\": \"2016-01-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-12-07, 2016-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Carfilzomib (Kyprolis\", \"trade_name\": \"Kyprolis\", \"indication\": \"Kyprolis\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-07T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2228, \"last_scrape\": \"2018-12-13T16:29:22\", \"url\": \"http://www.ncpe.ie/drugs/catumaxomab-removab/\", \"rr_start\": \"2011-08-05T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-08-05, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Catumaxomab (Removab\", \"trade_name\": \"Removab\", \"indication\": \"Catumazomab (Removab\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-20T00:00:00\", \"company\": \"Neovii\", \"orphan\": 0, \"earliest\": \"2011-08-05T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/removab\", \"ta_list\": \"Ascites; Cancer\", \"rr_status\": \"No HTA\"}, {\"id\": 2229, \"last_scrape\": \"2018-12-13T16:29:25\", \"url\": \"http://www.ncpe.ie/drugs/ceftaroline-zinforo/\", \"rr_start\": \"2012-10-08T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-08, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Ceftaroline (Zinforo\", \"trade_name\": \"Zinforo\", \"indication\": \"For the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP).\", \"ncpe_year\": 2012, \"eu_market\": \"2012-08-22T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-10-08T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinforo\", \"ta_list\": \"Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia\", \"rr_status\": \"No HTA\"}, {\"id\": 2230, \"last_scrape\": \"2018-12-13T16:29:29\", \"url\": \"http://www.ncpe.ie/drugs/ceftazidime-avibactam-cef-avizavicefta/\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-17, 2017-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Ceftazidime-avibactam (CEF-AVI)(Zavicefta\", \"trade_name\": \"Zavicefta\", \"indication\": \"Ceftazidime-avibactam (CEF-AVI)(Zavicefta\", \"ncpe_year\": 2017, \"eu_market\": \"2016-06-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta\", \"ta_list\": \"Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2231, \"last_scrape\": \"2018-12-13T16:29:34\", \"url\": \"http://www.ncpe.ie/drugs/ceftolozanetazobactam-zerbaxa/\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-03-03, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Ceftolozane/tazobactam (Zerbaxa\", \"trade_name\": \"Zerbaxa\", \"indication\": \"Zerbaxa\", \"ncpe_year\": 2016, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa\", \"ta_list\": \"Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2232, \"last_scrape\": \"2018-12-13T16:29:36\", \"url\": \"http://www.ncpe.ie/drugs/ceritinib-zykadia/\", \"rr_start\": \"2015-05-29T00:00:00\", \"rr_end\": \"2015-07-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2015-05-29, 2015-07-22\", \"rr_multiple\": 0, \"drug_name\": \"Ceritinib (Zykadia\", \"trade_name\": \"Zykadia\", \"indication\": \"Zykadia\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-06T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-05-29T00:00:00\", \"latest\": \"2015-07-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2233, \"last_scrape\": \"2018-12-13T16:29:40\", \"url\": \"http://www.ncpe.ie/drugs/cerliponase-alfa-brineura/\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2017-10-11, 2017-11-27\", \"rr_multiple\": 0, \"drug_name\": \"Cerliponase alfa (Brineura\", \"trade_name\": \"Brineura\", \"indication\": \"Cerliponase alfa (Brineura\", \"ncpe_year\": 2018, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-08-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brineura\", \"ta_list\": \"Neuronal Ceroid-Lipofuscinoses\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2234, \"last_scrape\": \"2018-12-13T16:29:44\", \"url\": \"http://www.ncpe.ie/drugs/certolizumab-pegol-cimzia/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Certolizumab pegol (Cimzia\", \"trade_name\": \"Cimzia\", \"indication\": \"Cost-effectiveness of certolizumab pegol (Cimzia\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2010-03-13T00:00:00\", \"latest\": \"2010-09-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia-0\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2235, \"last_scrape\": \"2018-12-13T16:29:49\", \"url\": \"http://www.ncpe.ie/drugs/ciclosporin-1mgml-eye-drops-ikervis/\", \"rr_start\": \"2015-01-07T00:00:00\", \"rr_end\": \"2016-01-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-01-07, 2016-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Ciclosporin 1mg/ml eye drops (Ikervis\", \"trade_name\": \"Ikervis\", \"indication\": \"Ikervis\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-19T00:00:00\", \"company\": \"Santen\", \"orphan\": 0, \"earliest\": \"2015-01-07T00:00:00\", \"latest\": \"2016-01-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis\", \"ta_list\": \"Corneal Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2236, \"last_scrape\": \"2018-12-13T16:29:54\", \"url\": \"http://www.ncpe.ie/drugs/cladribine-mavenclad/\", \"rr_start\": \"2017-08-22T00:00:00\", \"rr_end\": \"2017-09-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-22, 2017-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Cladribine (Mavenclad\", \"trade_name\": \"Mavenclad\", \"indication\": \"Cladribine (Mavenclad\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-08-22T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2237, \"last_scrape\": \"2018-12-13T16:29:58\", \"url\": \"http://www.ncpe.ie/drugs/clindamycin-1-with-tretinoin-0-025-treclinac/\", \"rr_start\": \"2014-04-08T00:00:00\", \"rr_end\": \"2014-05-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-08, 2014-05-06\", \"rr_multiple\": 0, \"drug_name\": \"Clindamycin 1% with tretinoin 0.025% (Treclinac\", \"trade_name\": \"Treclinac\", \"indication\": \"Clindamycin 1% with tretinoin 0.025% (Treclinac\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-04-08T00:00:00\", \"latest\": \"2014-05-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2238, \"last_scrape\": \"2018-12-13T16:30:02\", \"url\": \"http://www.ncpe.ie/drugs/cobimetinib-cotellic/\", \"rr_start\": \"2016-04-19T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-04-19, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Cobimetinib (Cotellic\", \"trade_name\": \"Cotellic\", \"indication\": \"Cotellic\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2016-04-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2239, \"last_scrape\": \"2018-12-13T16:30:03\", \"url\": \"http://www.ncpe.ie/drugs/colesevelam-cholestagel/\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Colesevelam (Cholestagel\", \"trade_name\": \"Cholestagel\", \"indication\": \"Cost-effectiveness of Colesevelam (Cholestagel\", \"ncpe_year\": 2010, \"eu_market\": \"2004-03-09T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cholestagel\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"No HTA\"}, {\"id\": 2240, \"last_scrape\": \"2018-12-13T16:30:06\", \"url\": \"http://www.ncpe.ie/drugs/colistimethate-sodium-colobreathe/\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Colistimethate sodium (Colobreathe\", \"trade_name\": \"Colobreathe\", \"indication\": \"Colistimethate sodium (colobreathe\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-13T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/colobreathe\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2241, \"last_scrape\": \"2018-12-13T16:30:17\", \"url\": \"http://www.ncpe.ie/drugs/collagenase-clostridium-histolyticum-xiapex/\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-20, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Collagenase Clostridium Histolyticum (Xiapex\", \"trade_name\": \"Xiapex\", \"indication\": \" Collagenase Clostridium Histolyticum (Xiapex\", \"ncpe_year\": 2011, \"eu_market\": \"2011-02-28T00:00:00\", \"company\": \"Swedish\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xiapex\", \"ta_list\": \"Dupuytren Contracture\", \"rr_status\": \"No HTA\"}, {\"id\": 2242, \"last_scrape\": \"2018-12-13T16:30:20\", \"url\": \"http://www.ncpe.ie/drugs/corifollitropin-alfa-elonva/\", \"rr_start\": \"2010-10-22T00:00:00\", \"rr_end\": \"2010-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-10-22, 2010-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Corifollitropin alfa (Elonva\", \"trade_name\": \"Elonva\", \"indication\": \"Cost-effectiveness of Corifollitropin alfa (Elonva\", \"ncpe_year\": 2010, \"eu_market\": \"2010-01-25T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2010-09-01T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/elonva\", \"ta_list\": \"Reproductive Techniques, Assisted; Ovulation Induction\", \"rr_status\": \"No HTA\"}, {\"id\": 2243, \"last_scrape\": \"2018-12-13T16:30:24\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori-for-first-line-alk-nsclc/\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2244, \"last_scrape\": \"2018-12-13T16:30:29\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori-for-ros1-nsclc/\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2245, \"last_scrape\": \"2018-12-13T16:30:34\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori/\", \"rr_start\": \"2013-01-09T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-01-09, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"For the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-01-09T00:00:00\", \"latest\": \"2015-08-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2246, \"last_scrape\": \"2018-12-13T16:30:37\", \"url\": \"http://www.ncpe.ie/drugs/cysteamine-bitartrate-procysbi/\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2015-12-01, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Cysteamine bitartrate delayed-release (Procysbi\", \"trade_name\": \"Procysbi\", \"indication\": \"Procysbi\", \"ncpe_year\": 2017, \"eu_market\": \"2013-09-05T00:00:00\", \"company\": \"Chiesi\", \"orphan\": 1, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/procysbi\", \"ta_list\": \"Cystinosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2247, \"last_scrape\": \"2018-12-13T16:30:43\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-2/\", \"rr_start\": \"2014-05-09T00:00:00\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-09, 2014-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate (Pradaxa\", \"ncpe_year\": 2014, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-09T00:00:00\", \"latest\": \"2014-06-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2248, \"last_scrape\": \"2018-12-13T16:30:51\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-for-the-prevention-of-stroke-and-systematic-embolisom-in-atrial-fibrillation/\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate (Pradaxa\", \"ncpe_year\": 2012, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2010-11-02T00:00:00\", \"latest\": \"2012-10-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2249, \"last_scrape\": \"2018-12-13T16:30:57\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-vte-prevention/\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Economic Evaluation of the Cost Effectiveness of Dabigatran Etexilate (Pradaxa\", \"ncpe_year\": 2008, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2008-07-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2250, \"last_scrape\": \"2018-12-13T16:30:59\", \"url\": \"http://www.ncpe.ie/drugs/dabrafenib-tafinlar/\", \"rr_start\": \"2013-09-11T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-11, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Dabrafenib (Tafinlar\", \"trade_name\": \"Tafinlar\", \"indication\": \"Dabrafenib (Tafinlar\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2013-09-11T00:00:00\", \"latest\": \"2014-06-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2251, \"last_scrape\": \"2018-12-13T16:31:02\", \"url\": \"http://www.ncpe.ie/drugs/daclatasvir-daklinza/\", \"rr_start\": \"2014-08-05T00:00:00\", \"rr_end\": \"2014-09-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-08-05, 2014-09-12\", \"rr_multiple\": 0, \"drug_name\": \"Daclatasvir (Daklinza\", \"trade_name\": \"Daklinza\", \"indication\": \"Daclatasvir (Daklinza\", \"ncpe_year\": 2015, \"eu_market\": \"2014-08-22T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-08-05T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/daklinza\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2252, \"last_scrape\": \"2018-12-13T16:31:08\", \"url\": \"http://www.ncpe.ie/drugs/daclizumab-zinbryta/\", \"rr_start\": \"2016-09-26T00:00:00\", \"rr_end\": \"2016-11-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-09-26, 2016-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Daclizumab (Zinbryta\", \"trade_name\": \"Zinbryta\", \"indication\": \"Daclizumab is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-07-01T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2016-09-26T00:00:00\", \"latest\": \"2018-03-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinbryta\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2253, \"last_scrape\": \"2018-12-13T16:31:12\", \"url\": \"http://www.ncpe.ie/drugs/dalbavancin-xydalba/\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-07, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Dalbavancin (Xydalba\", \"trade_name\": \"Xydalba\", \"indication\": \"Dalbavancin (Xydalba\", \"ncpe_year\": 2017, \"eu_market\": \"2015-02-19T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xydalba\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2254, \"last_scrape\": \"2018-12-13T16:31:18\", \"url\": \"http://www.ncpe.ie/drugs/dapagliflozin-forxiga/\", \"rr_start\": \"2012-10-10T00:00:00\", \"rr_end\": \"2012-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-10-10, 2012-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Dapagliflozin (Forxiga\", \"trade_name\": \"Forxiga\", \"indication\": \"Dapagliflozin (Forxiga\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-11T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-10T00:00:00\", \"latest\": \"2013-12-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2255, \"last_scrape\": \"2018-12-13T16:31:21\", \"url\": \"http://www.ncpe.ie/drugs/daratumumab-darzalex/\", \"rr_start\": \"2016-05-31T00:00:00\", \"rr_end\": \"2016-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-05-31, 2016-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Daratumumab (Darzalex\", \"trade_name\": \"Darzalex\", \"indication\": \"Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-04-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-05-31T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2256, \"last_scrape\": \"2018-12-13T16:31:25\", \"url\": \"http://www.ncpe.ie/drugs/darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-symtuza/\", \"rr_start\": \"2017-09-27T00:00:00\", \"rr_end\": \"2017-10-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-27, 2017-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza\", \"trade_name\": \"Symtuza\", \"indication\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza\", \"ncpe_year\": 2017, \"eu_market\": \"2017-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-09-27T00:00:00\", \"latest\": \"2017-10-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/symtuza\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2257, \"last_scrape\": \"2018-12-13T16:31:30\", \"url\": \"http://www.ncpe.ie/drugs/darunavir-cobicistat-rezolsta/\", \"rr_start\": \"2014-12-02T00:00:00\", \"rr_end\": \"2015-01-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-12-02, 2015-01-08\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir & cobicistat (Rezolsta\", \"trade_name\": \"Rezolsta\", \"indication\": \"Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-12-02T00:00:00\", \"latest\": \"2015-01-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2258, \"last_scrape\": \"2018-12-13T16:31:35\", \"url\": \"http://www.ncpe.ie/drugs/darvadstrocel-alofisel/\", \"rr_start\": \"2018-06-14T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF DARVADSTROCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-14, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Darvadstrocel (Alofisel\", \"trade_name\": \"Alofisel\", \"indication\": \"Darvadstrocel (Alofisel\", \"ncpe_year\": 2018, \"eu_market\": \"2018-03-23T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-06-14T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel\", \"ta_list\": \"Rectal Fistula\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2259, \"last_scrape\": \"2018-12-13T16:31:40\", \"url\": \"http://www.ncpe.ie/drugs/decitabine-dacogen/\", \"rr_start\": \"2012-11-08T00:00:00\", \"rr_end\": \"2012-12-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-08, 2012-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Decitabine (Dacogen\", \"trade_name\": \"Dacogen\", \"indication\": \"Decitabine (Dacogen\", \"ncpe_year\": 2013, \"eu_market\": \"2012-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2012-11-08T00:00:00\", \"latest\": \"2013-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2260, \"last_scrape\": \"2018-12-13T16:31:44\", \"url\": \"http://www.ncpe.ie/drugs/defibrotide-defitelio/\", \"rr_start\": \"2014-05-12T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2014-05-12, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Defibrotide (Defitelio\", \"trade_name\": \"Defitelio\", \"indication\": \"Defibrotide (Defitelio\", \"ncpe_year\": 2014, \"eu_market\": \"2013-10-18T00:00:00\", \"company\": \"Gentium\", \"orphan\": 1, \"earliest\": \"2014-05-12T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio\", \"ta_list\": \"Hepatic Veno-Occlusive Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2261, \"last_scrape\": \"2018-12-13T16:31:47\", \"url\": \"http://www.ncpe.ie/drugs/degarelix-firmagon/\", \"rr_start\": \"2009-10-15T00:00:00\", \"rr_end\": \"2009-10-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-10-15\", \"rr_multiple\": 0, \"drug_name\": \"Degarelix (Firmagon\", \"trade_name\": \"Firmagon\", \"indication\": \"Cost-effectiveness of Degarelix (Firmagon\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-17T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2009-10-15T00:00:00\", \"latest\": \"2009-10-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2262, \"last_scrape\": \"2018-12-13T16:31:52\", \"url\": \"http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-cannabidiol-thc-cbd-sativex/\", \"rr_start\": \"2018-02-12T00:00:00\", \"rr_end\": \"2018-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF SATIVEX\", \"rr_dates\": \"2018-02-12, 2018-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex\", \"trade_name\": \"Sativex\", \"indication\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-02-12T00:00:00\", \"latest\": \"2018-04-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2263, \"last_scrape\": \"2018-12-13T16:31:59\", \"url\": \"http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-thccannabidiol-cbd-sativex/\", \"rr_start\": \"2012-12-05T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-05, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol (THC) /Cannabidiol (CBD) (Sativex\", \"trade_name\": \"Sativex\", \"indication\": \"For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-12-05T00:00:00\", \"latest\": \"2014-09-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2264, \"last_scrape\": \"2018-12-13T16:32:04\", \"url\": \"http://www.ncpe.ie/drugs/denosumab-prolia/\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab (Prolia\", \"trade_name\": \"Prolia\", \"indication\": \"The Cost-effectiveness of Denosumab (Prolia\", \"ncpe_year\": 2010, \"eu_market\": \"2010-05-26T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2010-05-27T00:00:00\", \"latest\": \"2010-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prolia\", \"ta_list\": \"Bone Resorption; Osteoporosis, Postmenopausal\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2265, \"last_scrape\": \"2018-12-13T16:32:08\", \"url\": \"http://www.ncpe.ie/drugs/denosumab-xgeva-3/\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab (Xgeva\", \"trade_name\": \"Xgeva\", \"indication\": \"Cost-effectiveness of denosumab (Xgeva\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2011-08-15T00:00:00\", \"latest\": \"2011-12-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva\", \"ta_list\": \"Fractures, Bone; Neoplasm Metastasis\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2266, \"last_scrape\": \"2018-12-13T16:32:12\", \"url\": \"http://www.ncpe.ie/drugs/dexamethasone-intravitreal-implant-ozurdex/\", \"rr_start\": \"2010-11-12T00:00:00\", \"rr_end\": \"2010-12-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-11-12, 2010-12-16\", \"rr_multiple\": 0, \"drug_name\": \"Dexamethasone Intravitreal Implant (Ozurdex\", \"trade_name\": \"Ozurdex\", \"indication\": \"Cost-effectiveness of Ozurdex\", \"ncpe_year\": 2012, \"eu_market\": \"2010-07-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2010-11-12T00:00:00\", \"latest\": \"2012-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ozurdex\", \"ta_list\": \"Macular Edema; Uveitis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2267, \"last_scrape\": \"2018-12-13T16:32:15\", \"url\": \"http://www.ncpe.ie/drugs/dexmedetomidine-dexdor/\", \"rr_start\": \"2011-07-08T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-07-08, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Dexmedetomidine (Dexdor\", \"trade_name\": \"Dexdor\", \"indication\": \"Dexmedetomidine (Dexdor\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-15T00:00:00\", \"company\": \"Orion\", \"orphan\": 0, \"earliest\": \"2011-07-08T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dexdor\", \"ta_list\": \"Conscious Sedation\", \"rr_status\": \"No HTA\"}, {\"id\": 2268, \"last_scrape\": \"2018-12-13T16:32:21\", \"url\": \"http://www.ncpe.ie/drugs/dienogest-visanne/\", \"rr_start\": \"2010-09-17T00:00:00\", \"rr_end\": \"2010-10-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-09-17, 2010-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Dienogest (Visanne\", \"trade_name\": \"Visanne\", \"indication\": \"Dienogest (Visanne\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-09-17T00:00:00\", \"latest\": \"2010-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2269, \"last_scrape\": \"2018-12-13T16:32:24\", \"url\": \"http://www.ncpe.ie/drugs/dimethyl-fumarate-skilarence/\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-01-15, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate (Skilarence\", \"trade_name\": \"Skilarence\", \"indication\": \"Dimethyl fumarate (Skilarence\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"Almirall\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/skilarence\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2270, \"last_scrape\": \"2018-12-13T16:32:26\", \"url\": \"http://www.ncpe.ie/drugs/dimethyl-fumarate-tecfidera/\", \"rr_start\": \"2014-02-04T00:00:00\", \"rr_end\": \"2014-03-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-02-04, 2014-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate (Tecfidera\", \"trade_name\": \"Tecfidera\", \"indication\": \"Dimethyl fumarate (Tecfidera\", \"ncpe_year\": 2015, \"eu_market\": \"2014-01-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-02-04T00:00:00\", \"latest\": \"2015-04-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2271, \"last_scrape\": \"2018-12-13T16:32:29\", \"url\": \"http://www.ncpe.ie/drugs/dinutuximab-beta-dinutuximab-beta-eusa/\", \"rr_start\": \"2017-10-19T00:00:00\", \"rr_end\": \"2017-11-23T00:00:00\", \"rr_outcome\": \"FOLLOWING ASSESSMENT OF THE APPLICANT\", \"rr_dates\": \"2017-10-19, 2017-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Dinutuximab beta (Qarziba\", \"trade_name\": \"Qarziba\", \"indication\": \"Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients ? 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-10-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2272, \"last_scrape\": \"2018-12-13T16:32:34\", \"url\": \"http://www.ncpe.ie/drugs/dolutegravir-rilpivirine-juluca/\", \"rr_start\": \"2018-06-08T00:00:00\", \"rr_end\": \"2018-07-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT JULUCA\", \"rr_dates\": \"2018-06-08, 2018-07-12\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir/Rilpivirine (Juluca\", \"trade_name\": \"Juluca\", \"indication\": \"Dolutegravir/rilpivirine (Juluca\", \"ncpe_year\": 2018, \"eu_market\": \"2018-05-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2018-06-08T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/juluca\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2273, \"last_scrape\": \"2018-12-13T16:32:36\", \"url\": \"http://www.ncpe.ie/drugs/dolutegravir-tivicay/\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-10, 2014-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir (Tivicay\", \"trade_name\": \"Tivicay\", \"indication\": \"Dolutegravir (Tivicay\", \"ncpe_year\": 2014, \"eu_market\": \"2014-01-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2274, \"last_scrape\": \"2018-12-13T16:32:39\", \"url\": \"http://www.ncpe.ie/drugs/dronedarone-multaq/\", \"rr_start\": \"2010-01-12T00:00:00\", \"rr_end\": \"2010-01-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-01-12, 2010-01-01\", \"rr_multiple\": 0, \"drug_name\": \"Dronedarone (Multaq\", \"trade_name\": \"Multaq\", \"indication\": \"Rapid Review\", \"ncpe_year\": 2010, \"eu_market\": \"2009-11-25T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2010-01-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"No HTA\"}, {\"id\": 2275, \"last_scrape\": \"2018-12-13T16:32:42\", \"url\": \"http://www.ncpe.ie/drugs/dulaglutide-trulicity/\", \"rr_start\": \"2015-03-04T00:00:00\", \"rr_end\": \"2015-04-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-03-04, 2015-04-29\", \"rr_multiple\": 0, \"drug_name\": \"Dulaglutide (Trulicity\", \"trade_name\": \"Trulicity\", \"indication\": \"Dulaglutide is indicated as monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2015-03-04T00:00:00\", \"latest\": \"2015-04-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2276, \"last_scrape\": \"2018-12-13T16:32:46\", \"url\": \"http://www.ncpe.ie/drugs/dupilumab-dupixent/\", \"rr_start\": \"2017-11-13T00:00:00\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-13, 2017-11-24\", \"rr_multiple\": 0, \"drug_name\": \"Dupilumab (Dupixent\", \"trade_name\": \"Dupixent\", \"indication\": \"Dupilumab (Dupixent\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-27T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-11-13T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent\", \"ta_list\": \"Dermatitis, Atopic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2277, \"last_scrape\": \"2018-12-13T16:32:53\", \"url\": \"http://www.ncpe.ie/drugs/eculizumab-soliris/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Eculizumab (Soliris\", \"trade_name\": \"Soliris\", \"indication\": \"An Economic Evaluation of Eculizumab (Soliris\", \"ncpe_year\": 2013, \"eu_market\": \"2007-06-20T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2013-10-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/soliris\", \"ta_list\": \"Hemoglobinuria, Paroxysmal\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2278, \"last_scrape\": \"2018-12-13T16:32:55\", \"url\": \"http://www.ncpe.ie/drugs/edoxaban-lixiana/\", \"rr_start\": \"2015-06-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-06-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Edoxaban (Lixiana\", \"trade_name\": \"Lixiana\", \"indication\": \"Edoxaban is indicated for the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2015-06-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana\", \"ta_list\": \"Stroke; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2279, \"last_scrape\": \"2018-12-13T16:33:00\", \"url\": \"http://www.ncpe.ie/drugs/elbasvirgrazoprevir-zepatier-2/\", \"rr_start\": \"2016-08-10T00:00:00\", \"rr_end\": \"2016-10-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-08-10, 2016-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Elbasvir/Grazoprevir (Zepatier\", \"trade_name\": \"Zepatier\", \"indication\": \"Elbasvir 50mg/100mg grazoprevir (EBR/GZR)(Zepatier\", \"ncpe_year\": 2016, \"eu_market\": \"2016-07-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-10T00:00:00\", \"latest\": \"2016-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2280, \"last_scrape\": \"2018-12-13T16:33:03\", \"url\": \"http://www.ncpe.ie/drugs/eliglustat-cerdelga/\", \"rr_start\": \"2016-03-21T00:00:00\", \"rr_end\": \"2016-05-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-03-21, 2016-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Eliglustat (Cerdelga\", \"trade_name\": \"Cerdelga\", \"indication\": \"Eliglustat (Cerdelga\", \"ncpe_year\": 2018, \"eu_market\": \"2015-01-19T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 1, \"earliest\": \"2016-03-21T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga\", \"ta_list\": \"Gaucher Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2281, \"last_scrape\": \"2018-12-13T16:33:05\", \"url\": \"http://www.ncpe.ie/drugs/elosulfase-alfa-vimizim/\", \"rr_start\": \"2015-03-30T00:00:00\", \"rr_end\": \"2015-05-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-03-30, 2015-05-08\", \"rr_multiple\": 0, \"drug_name\": \"Elosulfase alfa (Vimizim\", \"trade_name\": \"Vimizim\", \"indication\": \"Elosulfase alfa (Vimzim\", \"ncpe_year\": 2018, \"eu_market\": \"2014-04-27T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2015-03-30T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vimizim\", \"ta_list\": \"Mucopolysaccharidosis IV\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2282, \"last_scrape\": \"2018-12-13T16:33:12\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade-2/\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-02-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-01-10, 2014-02-13\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Eltrombopag (Revolade\", \"ncpe_year\": 2014, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-02-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"id\": 2283, \"last_scrape\": \"2018-12-13T16:33:17\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade-3/\", \"rr_start\": \"2016-02-05T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-02-05, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Revolade\", \"ncpe_year\": 2016, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-02-05T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"id\": 2284, \"last_scrape\": \"2018-12-13T16:33:23\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade/\", \"rr_start\": \"2017-12-04T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, WHICH IS NOT COMPARABLE WITH CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2017-12-04, 2018-04-16, 2017-12-01\", \"rr_multiple\": 1, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Cost-effectiveness of eltrombopag (Revolade\", \"ncpe_year\": 2018, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-07-30T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2285, \"last_scrape\": \"2018-12-13T16:33:26\", \"url\": \"http://www.ncpe.ie/drugs/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya/\", \"rr_start\": \"2015-11-24T00:00:00\", \"rr_end\": \"2016-01-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-11-24, 2016-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide (Genvoya\", \"trade_name\": \"Genvoya\", \"indication\": \"Genvoya\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2015-11-24T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2286, \"last_scrape\": \"2018-12-13T16:33:32\", \"url\": \"http://www.ncpe.ie/drugs/empagliflozin-jardiance/\", \"rr_start\": \"2014-05-22T00:00:00\", \"rr_end\": \"2014-06-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-22, 2014-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Empagliflozin (Jardiance\", \"trade_name\": \"Jardiance\", \"indication\": \"Add-on combination therapy \", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-22T00:00:00\", \"latest\": \"2014-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2287, \"last_scrape\": \"2018-12-13T16:33:37\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabine-tenofovir-disoproxil-fumarate-truvada/\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-07-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-12, 2017-07-18\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine / tenofovir disoproxil fumarate (Truvada\", \"trade_name\": \"Truvada\", \"indication\": \"Truvada\", \"ncpe_year\": 2017, \"eu_market\": \"2005-02-20T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-07-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/truvada\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2288, \"last_scrape\": \"2018-12-13T16:33:43\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabine-tenovir-disoproxil-teva/\", \"rr_start\": \"2017-12-11T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-12-11, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir disoproxil (TEVA\", \"trade_name\": \"TEVA\", \"indication\": \"Emtricitabine/tenofovir disoproxil (TEVA\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-12-11T00:00:00\", \"latest\": \"2017-12-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2289, \"last_scrape\": \"2018-12-13T16:33:48\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabinetenofovir-alafenamide-descovy/\", \"rr_start\": \"2016-04-26T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-04-26, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir alafenamide (Descovy\", \"trade_name\": \"Descovy\", \"indication\": \"Descovy\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-04-26T00:00:00\", \"latest\": \"2016-04-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/descovy\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2290, \"last_scrape\": \"2018-12-13T16:33:52\", \"url\": \"http://www.ncpe.ie/drugs/enzalutamide-xtandi/\", \"rr_start\": \"2013-06-28T00:00:00\", \"rr_end\": \"2013-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-28, 2013-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Enzalutamide (Xtandi\", \"trade_name\": \"Xtandi\", \"indication\": \"Enzalutamide (Xtandi\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2013-06-28T00:00:00\", \"latest\": \"2014-04-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2291, \"last_scrape\": \"2018-12-13T16:33:59\", \"url\": \"http://www.ncpe.ie/drugs/epoprostenol-veletri/\", \"rr_start\": \"2016-12-13T00:00:00\", \"rr_end\": \"2017-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-12-13, 2017-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Epoprostenol (Veletri\", \"trade_name\": \"Veletri\", \"indication\": \"Veletri\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-12-13T00:00:00\", \"latest\": \"2017-02-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2292, \"last_scrape\": \"2018-12-13T16:34:03\", \"url\": \"http://www.ncpe.ie/drugs/erenumab-aimovig/\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-15T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF ERENUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-19, 2018-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Erenumab (Aimovig\", \"trade_name\": \"Aimovig\", \"indication\": \"Erenumab (Aimovig\", \"ncpe_year\": 2018, \"eu_market\": \"2018-07-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig\", \"ta_list\": \"Migraine Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2293, \"last_scrape\": \"2018-12-13T16:34:07\", \"url\": \"http://www.ncpe.ie/drugs/eribulin-halaven/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-03-11, 2011-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Eribulin (Halaven\", \"trade_name\": \"Halaven\", \"indication\": \"Eribulin (Halaven\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2011-02-09T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/halaven\", \"ta_list\": \"Breast Neoplasms; Liposarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2294, \"last_scrape\": \"2018-12-13T16:34:09\", \"url\": \"http://www.ncpe.ie/drugs/eslicarbazepine-zebinix/\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-08-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2009-09-01, 2009-08-01\", \"rr_multiple\": 0, \"drug_name\": \"Eslicarbazepine (Zebinix\", \"trade_name\": \"Zebinix\", \"indication\": \"Eslicarbazepine (Zebinix\", \"ncpe_year\": 2009, \"eu_market\": \"2009-04-21T00:00:00\", \"company\": \"BIAL\", \"orphan\": 0, \"earliest\": \"2009-08-01T00:00:00\", \"latest\": \"2009-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2295, \"last_scrape\": \"2018-12-13T16:34:12\", \"url\": \"http://www.ncpe.ie/drugs/etanercept-benepali/\", \"rr_start\": \"2016-03-22T00:00:00\", \"rr_end\": \"2016-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-03-22, 2016-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Etanercept (Benepali\", \"trade_name\": \"Benepali\", \"indication\": \"Benepali\", \"ncpe_year\": 2016, \"eu_market\": \"2016-01-13T00:00:00\", \"company\": \"Samsung\", \"orphan\": 0, \"earliest\": \"2016-03-22T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/benepali\", \"ta_list\": \"Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis\", \"rr_status\": \"No HTA\"}, {\"id\": 2296, \"last_scrape\": \"2018-12-13T16:34:15\", \"url\": \"http://www.ncpe.ie/drugs/etelcalcetide-parsabiv/\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-06-14, 2017-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Etelcalcetide (Parsabiv\", \"trade_name\": \"Parsabiv\", \"indication\": \"Etelcalcitide (Parsabiv\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-11T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/parsabiv\", \"ta_list\": \"Hyperparathyroidism, Secondary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2297, \"last_scrape\": \"2018-12-13T16:34:21\", \"url\": \"http://www.ncpe.ie/drugs/eurartesim-piperaquine-tetraphosphatedihidroartemisinin/\", \"rr_start\": \"2012-05-22T00:00:00\", \"rr_end\": \"2012-05-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-05-22, 2012-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Piperaquine tetraphosphate/dihidroartemisinin (Eurartesim\", \"trade_name\": \"Eurartesim\", \"indication\": \"Eurartesim\", \"ncpe_year\": 2012, \"eu_market\": \"2011-10-27T00:00:00\", \"company\": \"Alfasigma\", \"orphan\": 0, \"earliest\": \"2012-05-22T00:00:00\", \"latest\": \"2012-05-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eurartesim\", \"ta_list\": \"Malaria\", \"rr_status\": \"No HTA\"}, {\"id\": 2298, \"last_scrape\": \"2018-12-13T16:34:24\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-afinitor/\", \"rr_start\": \"2012-09-21T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-09-21, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Afinitor\", \"trade_name\": \"Afinitor\", \"indication\": \"Treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor\", \"ncpe_year\": 2012, \"eu_market\": \"2009-08-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-09-21T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/afinitor\", \"ta_list\": \"Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2299, \"last_scrape\": \"2018-12-13T16:34:26\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-votubia-for-refractory-seizures-associated-with-tuberous-sclerosis-complex-tsc/\", \"rr_start\": \"2017-04-19T00:00:00\", \"rr_end\": \"2017-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-04-19, 2017-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Votubia \", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus (Votubia\", \"ncpe_year\": 2017, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2017-04-19T00:00:00\", \"latest\": \"2017-04-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/votubia\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2300, \"last_scrape\": \"2018-12-13T16:34:29\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-votubia/\", \"rr_start\": \"2011-09-30T00:00:00\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-09-30, 2011-10-14\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Votubia\", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus (Votubia\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2011-09-30T00:00:00\", \"latest\": \"2011-10-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/votubia\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2301, \"last_scrape\": \"2018-12-13T16:34:36\", \"url\": \"http://www.ncpe.ie/drugs/evolocumab-repatha/\", \"rr_start\": \"\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Evolocumab (Repatha\", \"trade_name\": \"Repatha\", \"indication\": \"Evolocumab (Repatha\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-17T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-01-01T00:00:00\", \"latest\": \"2018-05-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/repatha\", \"ta_list\": \"Dyslipidemias; Hypercholesterolemia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2302, \"last_scrape\": \"2018-12-13T16:34:41\", \"url\": \"http://www.ncpe.ie/drugs/exenatide-bydureon/\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Exenatide (Bydureon\", \"trade_name\": \"Bydureon\", \"indication\": \"Exenatide (Bydureon\", \"ncpe_year\": 2011, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2303, \"last_scrape\": \"2018-12-13T16:34:44\", \"url\": \"http://www.ncpe.ie/drugs/fampridine-fampyra/\", \"rr_start\": \"2011-09-11T00:00:00\", \"rr_end\": \"2011-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-09-11, 2011-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Fampridine (Fampyra\", \"trade_name\": \"Fampyra\", \"indication\": \"Fampridine (Fampyra\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-20T00:00:00\", \"company\": \"Blogen\", \"orphan\": 0, \"earliest\": \"2011-09-01T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fampyra\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2304, \"last_scrape\": \"2018-12-13T16:34:48\", \"url\": \"http://www.ncpe.ie/drugs/ferric-maltol-feraccru_/\", \"rr_start\": \"2016-08-12T00:00:00\", \"rr_end\": \"2016-09-06T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-08-12, 2016-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Ferric maltol (Feraccru\", \"trade_name\": \"Feraccru\", \"indication\": \"Ferric maltol indicated for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) in adult patients.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Shield\", \"orphan\": 0, \"earliest\": \"2016-08-12T00:00:00\", \"latest\": \"2016-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/feraccru\", \"ta_list\": \"Anemia, Iron-Deficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2305, \"last_scrape\": \"2018-12-13T16:34:51\", \"url\": \"http://www.ncpe.ie/drugs/fidaxomicin-dificlir/\", \"rr_start\": \"2012-03-09T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2012-03-09, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Fidaxomicin (Dificlir\", \"trade_name\": \"Dificlir\", \"indication\": \"Fidaxomicin is indicated for the treatment of CDI also known as CDAD in adult patients.\", \"ncpe_year\": 2013, \"eu_market\": \"2011-12-05T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-03-09T00:00:00\", \"latest\": \"2013-02-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dificlir\", \"ta_list\": \"Clostridium Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2306, \"last_scrape\": \"2018-12-13T16:34:56\", \"url\": \"http://www.ncpe.ie/drugs/fingolimod-gilenya-4/\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2010-12-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-01-10, 2010-12-03\", \"rr_multiple\": 0, \"drug_name\": \"Fingolimod (Gilenya\", \"trade_name\": \"Gilenya\", \"indication\": \"Cost effectiveness of Fingolimod (Gilenya\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2010-12-03T00:00:00\", \"latest\": \"2011-09-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2307, \"last_scrape\": \"2018-12-13T16:35:01\", \"url\": \"http://www.ncpe.ie/drugs/fluocinolone-acetonide-iluvien/\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-02-15, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Fluocinolone acetonide (Iluvien\", \"trade_name\": \"Iluvien\", \"indication\": \"Iluvien\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2308, \"last_scrape\": \"2018-12-13T16:35:05\", \"url\": \"http://www.ncpe.ie/drugs/fluticasone-furoate-umeclidinium-vilantero-trelegy-ellipta/\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT TRELEGY\", \"rr_dates\": \"2018-04-30, 2018-06-18\", \"rr_multiple\": 0, \"drug_name\": \"Fluticasone furoate/ umeclidinium/ vilantero (Trelegy\", \"trade_name\": \"Trelegy Ellipta\", \"indication\": \"Trelegy\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-15T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"Reimbursement without HTA\"}, {\"id\": 2309, \"last_scrape\": \"2018-12-13T16:35:09\", \"url\": \"http://www.ncpe.ie/drugs/follitropin-delta-rekovelle/\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-07-25, 2017-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Follitropin delta (Rekovelle\", \"trade_name\": \"Rekovelle\", \"indication\": \"Follitropin delta (Rekovelle \", \"ncpe_year\": 2019, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2019-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rekovelle\", \"ta_list\": \"Anovulation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2310, \"last_scrape\": \"2018-12-13T16:35:12\", \"url\": \"http://www.ncpe.ie/drugs/gefitinib-iressa/\", \"rr_start\": \"\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Gefitinib (Iressa\", \"trade_name\": \"Iressa\", \"indication\": \"A review of the economic evaluation of oral gefitinib (Iressa\", \"ncpe_year\": 2010, \"eu_market\": \"2009-06-24T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-16T00:00:00\", \"latest\": \"2010-11-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/iressa\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2311, \"last_scrape\": \"2018-12-13T16:35:15\", \"url\": \"http://www.ncpe.ie/drugs/gemtuzumab-ozogamicin-mylotarg/\", \"rr_start\": \"2018-06-21T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF GEMTUZUMAB OZOGAMICIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-21, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Gemtuzumab ozogamicin (Mylotarg\", \"trade_name\": \"Mylotarg\", \"indication\": \"Gemtuzumab ozogamicin (Mylotarg\", \"ncpe_year\": 2018, \"eu_market\": \"2018-04-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-06-21T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2312, \"last_scrape\": \"2018-12-13T16:35:19\", \"url\": \"http://www.ncpe.ie/drugs/glecaprevirpibrentasvir-maviret/\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-07-11, 2017-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glecaprevir/Pibrentasvir (Maviret\", \"trade_name\": \"Maviret\", \"indication\": \"Glecaprevir/pibrentasvir (Maviret\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/maviret\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2313, \"last_scrape\": \"2018-12-13T16:35:25\", \"url\": \"http://www.ncpe.ie/drugs/glucosamine-sulfate-dona/\", \"rr_start\": \"\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Glucosamine sulfate (Dona\", \"trade_name\": \"Dona\", \"indication\": \"Economic evalution of glucosamine sulfate (Dona\", \"ncpe_year\": 2009, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2009-04-01T00:00:00\", \"latest\": \"2009-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2314, \"last_scrape\": \"2018-12-13T16:35:32\", \"url\": \"http://www.ncpe.ie/drugs/glycerol-phenylbutyrate-ravicti/\", \"rr_start\": \"2018-03-26T00:00:00\", \"rr_end\": \"2018-06-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT GLYCEROL PHENYLBUTYRATE (RAVICTI\", \"rr_dates\": \"2018-03-26, 2018-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Glycerol Phenylbutyrate (Ravicti\", \"trade_name\": \"Ravicti\", \"indication\": \"Glycerol phenylbutyrate (Ravicti\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-26T00:00:00\", \"company\": \"Horizon\", \"orphan\": 1, \"earliest\": \"2018-03-26T00:00:00\", \"latest\": \"2018-06-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti\", \"ta_list\": \"Urea Cycle Disorders, Inborn\", \"rr_status\": \"Reimbursement without HTA\"}, {\"id\": 2315, \"last_scrape\": \"2018-12-13T16:35:38\", \"url\": \"http://www.ncpe.ie/drugs/glycopyrronium-bromide-seebri-breezhaler/\", \"rr_start\": \"2012-08-12T00:00:00\", \"rr_end\": \"2012-08-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-08-12, 2012-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide (Seebri Breezhaler\", \"trade_name\": \"Seebri Breezhaler\", \"indication\": \"Seebri Breezhaler\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-08-12T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"id\": 2316, \"last_scrape\": \"2018-12-13T16:35:40\", \"url\": \"http://www.ncpe.ie/drugs/glypyrronium-bromide-sialanar/\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-07, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide (Sialanar\", \"trade_name\": \"Sialanar\", \"indication\": \"Glycopyrronium bromide (Sialanar\", \"ncpe_year\": 2017, \"eu_market\": \"2016-09-15T00:00:00\", \"company\": \"Proveca\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar\", \"ta_list\": \"Sialorrhea\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2317, \"last_scrape\": \"2018-12-13T16:35:47\", \"url\": \"http://www.ncpe.ie/drugs/golimumab-simponi-2/\", \"rr_start\": \"2013-10-11T00:00:00\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-10-11, 2013-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab (Simponi\", \"trade_name\": \"Simponi\", \"indication\": \"Golimumab is indicated for the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments.\", \"ncpe_year\": 2013, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2013-10-11T00:00:00\", \"latest\": \"2013-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/simponi\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"id\": 2318, \"last_scrape\": \"2018-12-13T16:35:54\", \"url\": \"http://www.ncpe.ie/drugs/golimumab-simponi/\", \"rr_start\": \"\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab (Simponi\", \"trade_name\": \"Simponi\", \"indication\": \"Cost-effectiveness of golimumab (Simponi\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2009-11-20T00:00:00\", \"latest\": \"2010-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/simponi\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2319, \"last_scrape\": \"2018-12-13T16:35:56\", \"url\": \"http://www.ncpe.ie/drugs/grass-pollen-allergen-extract-oralair/\", \"rr_start\": \"2011-10-11T00:00:00\", \"rr_end\": \"2011-09-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-10-11, 2011-09-26\", \"rr_multiple\": 0, \"drug_name\": \"Grass pollen allergen extract (Oralair\", \"trade_name\": \"Oralair\", \"indication\": \" Grass pollen allegen extract (Oralair\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-09-26T00:00:00\", \"latest\": \"2011-10-01T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2320, \"last_scrape\": \"2018-12-13T16:36:00\", \"url\": \"http://www.ncpe.ie/drugs/guanfacine-hydrochloride-intuniv/\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-01, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Guanfacine hydrochloride (Intuniv\", \"trade_name\": \"Intuniv\", \"indication\": \"Intuniv\", \"ncpe_year\": 2015, \"eu_market\": \"2015-09-17T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/intuniv\", \"ta_list\": \"Attention Deficit Disorder with Hyperactivity\", \"rr_status\": \"No HTA\"}, {\"id\": 2321, \"last_scrape\": \"2018-12-13T16:36:02\", \"url\": \"http://www.ncpe.ie/drugs/guselkumab-tremfya/\", \"rr_start\": \"2017-12-01T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-12-01, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Guselkumab (Tremfya\", \"trade_name\": \"Tremfya\", \"indication\": \"Guselkumab (Tremfya\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-10T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-12-01T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2322, \"last_scrape\": \"2018-12-13T16:36:07\", \"url\": \"http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-a1pi-prolastin/\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-06-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-05, 2017-06-08\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor (A1PI) (Prolastin\", \"trade_name\": \"Prolastin\", \"indication\": \"Human A1PI (Prolastin \", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-06-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2323, \"last_scrape\": \"2018-12-13T16:36:14\", \"url\": \"http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-respreeza/\", \"rr_start\": \"2016-01-20T00:00:00\", \"rr_end\": \"2016-02-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-20, 2016-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor (Respreeza\", \"trade_name\": \"Respreeza\", \"indication\": \"Respreeza\", \"ncpe_year\": 2017, \"eu_market\": \"2015-08-20T00:00:00\", \"company\": \"CSL\", \"orphan\": 0, \"earliest\": \"2016-01-20T00:00:00\", \"latest\": \"2017-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza\", \"ta_list\": \"Genetic Diseases, Inborn; Lung Diseases\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2324, \"last_scrape\": \"2018-12-13T16:36:17\", \"url\": \"http://www.ncpe.ie/drugs/hyaluronic-acid-and-co-enzyme-q10-visuxl/\", \"rr_start\": \"2017-11-06T00:00:00\", \"rr_end\": \"2017-11-30T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-11-06, 2017-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Hyaluronic acid and co enzyme Q10 (VisuXL\", \"trade_name\": \"VisuXL\", \"indication\": \"Cross linked hyaluronic acid and co enzyme Q10 (VisuXL\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-11-06T00:00:00\", \"latest\": \"2017-11-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2325, \"last_scrape\": \"2018-12-13T16:36:22\", \"url\": \"http://www.ncpe.ie/drugs/hydrocortisone-plenadren/\", \"rr_start\": \"2017-11-08T00:00:00\", \"rr_end\": \"2017-11-01T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-11-08, 2018-01-11, 2017-11-01\", \"rr_multiple\": 1, \"drug_name\": \"Modified Release Hydrocortisone  (Plenadren\", \"trade_name\": \"Plenadren\", \"indication\": \"Modified release hydrocortisone (Plenadren\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-03T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2018-01-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/plenadren\", \"ta_list\": \"Adrenal Insufficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2326, \"last_scrape\": \"2018-12-13T16:36:27\", \"url\": \"http://www.ncpe.ie/drugs/hydroxcarbamide-siklos/\", \"rr_start\": \"2011-08-22T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-08-22, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Hydroxycarbamide (Siklos\", \"trade_name\": \"Siklos\", \"indication\": \" Hydroxycarbamide (Siklos\", \"ncpe_year\": 2011, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"Addmedica\", \"orphan\": 1, \"earliest\": \"2011-08-22T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/siklos\", \"ta_list\": \"Anemia, Sickle Cell\", \"rr_status\": \"No HTA\"}, {\"id\": 2327, \"last_scrape\": \"2018-12-13T16:36:32\", \"url\": \"http://www.ncpe.ie/drugs/ibrutinib-imbruivca-for-previously-untreated-cll/\", \"rr_start\": \"2016-08-02T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-08-02, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib (Imbruvica\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib (Imbruvica\", \"ncpe_year\": 2016, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-08-02T00:00:00\", \"latest\": \"2016-08-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2328, \"last_scrape\": \"2018-12-13T16:36:36\", \"url\": \"http://www.ncpe.ie/drugs/ibrutinib-imbruvica-for-mcl/\", \"rr_start\": \"2014-11-07T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-11-07, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib (Imbruvica\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib (Imbruvica\", \"ncpe_year\": 2015, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-11-07T00:00:00\", \"latest\": \"2015-10-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2329, \"last_scrape\": \"2018-12-13T16:36:40\", \"url\": \"http://www.ncpe.ie/drugs/icatibant-firazyr/\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Icatibant (Firazyr\", \"trade_name\": \"Firazyr\", \"indication\": \"Icatibant (Firazyr\", \"ncpe_year\": 2013, \"eu_market\": \"2008-07-11T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"id\": 2330, \"last_scrape\": \"2018-12-13T16:36:43\", \"url\": \"http://www.ncpe.ie/drugs/idarucizumab-praxbind/\", \"rr_start\": \"2015-12-11T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-11, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Idarucizumab (Praxbind\", \"trade_name\": \"Praxbind\", \"indication\": \"Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required:\", \"ncpe_year\": 2015, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-12-11T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/praxbind\", \"ta_list\": \"Hemorrhage\", \"rr_status\": \"No HTA\"}, {\"id\": 2331, \"last_scrape\": \"2018-12-13T16:36:50\", \"url\": \"http://www.ncpe.ie/drugs/idebenone-raxone/\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-04-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-10, 2016-04-14\", \"rr_multiple\": 0, \"drug_name\": \"Idebenone (Raxone\", \"trade_name\": \"Raxone\", \"indication\": \"Raxone\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-08T00:00:00\", \"company\": \"Santhera\", \"orphan\": 1, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2018-08-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/raxone\", \"ta_list\": \"Optic Atrophy, Hereditary, Leber\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2332, \"last_scrape\": \"2018-12-13T16:36:56\", \"url\": \"http://www.ncpe.ie/drugs/idelalisib-zydelig/\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2014-12-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-08, 2014-12-30\", \"rr_multiple\": 0, \"drug_name\": \"Idelalisib (Zydelig\", \"trade_name\": \"Zydelig\", \"indication\": \"Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2016-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2333, \"last_scrape\": \"2018-12-13T16:36:59\", \"url\": \"http://www.ncpe.ie/drugs/imiquimod-zyclara/\", \"rr_start\": \"2013-09-10T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-09-10, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Imiquimod 3.75% (Zyclara\", \"trade_name\": \"Zyclara\", \"indication\": \"Imiquimod 3.75%(Zyclara\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Meda\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara\", \"ta_list\": \"Keratosis; Keratosis, Actinic\", \"rr_status\": \"No HTA\"}, {\"id\": 2334, \"last_scrape\": \"2018-12-13T16:37:01\", \"url\": \"http://www.ncpe.ie/drugs/incobotulinum-toxin-type-a-xeomin/\", \"rr_start\": \"2014-02-07T00:00:00\", \"rr_end\": \"2014-03-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-07, 2014-03-05\", \"rr_multiple\": 0, \"drug_name\": \"Incobotulinum Toxin Type A (Xeomin\", \"trade_name\": \"Xeomin\", \"indication\": \"Incobotulinum Toxin Type A (Xeomin\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-02-07T00:00:00\", \"latest\": \"2014-03-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2335, \"last_scrape\": \"2018-12-13T16:37:04\", \"url\": \"http://www.ncpe.ie/drugs/indacaterol-onbrez/\", \"rr_start\": \"2010-01-15T00:00:00\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-01-15\", \"rr_multiple\": 0, \"drug_name\": \"Indacaterol (Onbrez\", \"trade_name\": \"Onbrez\", \"indication\": \"Review of Indacaterol (Onbrez\", \"ncpe_year\": 2010, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-01-15T00:00:00\", \"latest\": \"2010-01-15T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2336, \"last_scrape\": \"2018-12-13T16:37:07\", \"url\": \"http://www.ncpe.ie/drugs/infliximab-inflectra/\", \"rr_start\": \"\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Infliximab (Inflectra\", \"trade_name\": \"Inflectra\", \"indication\": \"Inflectra\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2337, \"last_scrape\": \"2018-12-13T16:37:09\", \"url\": \"http://www.ncpe.ie/drugs/inotuzumab-ozogamicin-besponsa/\", \"rr_start\": \"2017-07-03T00:00:00\", \"rr_end\": \"2017-09-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-03, 2017-09-08\", \"rr_multiple\": 0, \"drug_name\": \"Inotuzumab ozogamicin (Besponsa\", \"trade_name\": \"Besponsa\", \"indication\": \"Inotuzumab ozogamicin (Besponsa\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2017-07-03T00:00:00\", \"latest\": \"2018-09-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2338, \"last_scrape\": \"2018-12-13T16:37:16\", \"url\": \"http://www.ncpe.ie/drugs/insulin-aspart-fiasp/\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-05-17, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart (Fiasp\", \"trade_name\": \"Fiasp\", \"indication\": \"Insulin aspart (Fiasp\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-09T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fiasp\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"No HTA\"}, {\"id\": 2339, \"last_scrape\": \"2018-12-13T16:37:21\", \"url\": \"http://www.ncpe.ie/drugs/insulin-aspart-novorapid-flextouch/\", \"rr_start\": \"2014-07-22T00:00:00\", \"rr_end\": \"2014-08-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2014-07-22, 2014-08-28\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart (NovoRapid\", \"trade_name\": \"NovoRapid FlexTouch\", \"indication\": \"Insulin aspart (NovoRapid\", \"ncpe_year\": 2014, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2014-07-22T00:00:00\", \"latest\": \"2014-08-28T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2340, \"last_scrape\": \"2018-12-13T16:37:25\", \"url\": \"http://www.ncpe.ie/drugs/insulin-degludec-tresiba/\", \"rr_start\": \"2012-12-17T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-17, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Degludec (Tresiba\", \"trade_name\": \"Tresiba\", \"indication\": \"Treatment of diabetes mellitus\", \"ncpe_year\": 2015, \"eu_market\": \"2013-01-20T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2012-12-17T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2341, \"last_scrape\": \"2018-12-13T16:37:30\", \"url\": \"http://www.ncpe.ie/drugs/insulin-degludecliraglutide-ideglira-xultophy/\", \"rr_start\": \"2016-09-19T00:00:00\", \"rr_end\": \"2016-10-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-09-19, 2016-10-17\", \"rr_multiple\": 0, \"drug_name\": \"Insulin degludec/liraglutide (IDegLira) (Xultophy\", \"trade_name\": \"Xultophy\", \"indication\": \"IDegLira is indicated for the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2016-09-19T00:00:00\", \"latest\": \"2016-10-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xultophy\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2342, \"last_scrape\": \"2018-12-13T16:37:36\", \"url\": \"http://www.ncpe.ie/drugs/insulin-glargine-abasaglar/\", \"rr_start\": \"2015-09-04T00:00:00\", \"rr_end\": \"2015-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-09-04, 2015-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine (Abasaglar\", \"trade_name\": \"Abasaglar\", \"indication\": \"Abasaglar\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-09-04T00:00:00\", \"latest\": \"2015-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2343, \"last_scrape\": \"2018-12-13T16:37:40\", \"url\": \"http://www.ncpe.ie/drugs/insulin-glargine-u300-toujeo/\", \"rr_start\": \"2015-05-14T00:00:00\", \"rr_end\": \"2015-07-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2015-05-14, 2015-07-02\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine U300 (Toujeo\", \"trade_name\": \"Toujeo\", \"indication\": \"Toujeo\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-05-14T00:00:00\", \"latest\": \"2015-07-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2344, \"last_scrape\": \"2018-12-13T16:37:43\", \"url\": \"http://www.ncpe.ie/drugs/ipilimumab-yervoy/\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Ipilimumab (Yervoy\", \"trade_name\": \"Yervoy\", \"indication\": \"Pharmacoeconomic evaluation of Ipilimumab (Yervoy\", \"ncpe_year\": 2013, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2013-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2345, \"last_scrape\": \"2018-12-13T16:37:49\", \"url\": \"http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-diafer/\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron (III) isomaltoside 1000 (Diafer\", \"trade_name\": \"Diafer\", \"indication\": \"Diafer\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2346, \"last_scrape\": \"2018-12-13T16:37:52\", \"url\": \"http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-monover/\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron (III) isomaltoside 1000 (Monover\", \"trade_name\": \"Monover\", \"indication\": \"Monover\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2347, \"last_scrape\": \"2018-12-13T16:38:02\", \"url\": \"http://www.ncpe.ie/drugs/iron-isomaltoside-1000-monover/\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2011-02-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-01-10, 2011-02-02\", \"rr_multiple\": 0, \"drug_name\": \"Iron isomaltoside 1000 (MonoVer\", \"trade_name\": \"MonoVer\", \"indication\": \"MonoVer is indicated for the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-01-10T00:00:00\", \"latest\": \"2011-02-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2348, \"last_scrape\": \"2018-12-13T16:38:07\", \"url\": \"http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-invasive-aspergillosis/\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole (Cresemba\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole (Cresemba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2349, \"last_scrape\": \"2018-12-13T16:38:09\", \"url\": \"http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-mucormycosis/\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole (Cresemba\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole (Cresemba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2350, \"last_scrape\": \"2018-12-13T16:38:15\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kaldeco/\", \"rr_start\": \"2012-08-13T00:00:00\", \"rr_end\": \"2012-08-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-08-13, 2012-08-22\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2012-08-13T00:00:00\", \"latest\": \"2013-01-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2351, \"last_scrape\": \"2018-12-13T16:38:21\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-patients-with-cf-2-years/\", \"rr_start\": \"2015-11-19T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMAOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-19, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\", \"ncpe_year\": 2016, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2015-11-19T00:00:00\", \"latest\": \"2016-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2352, \"last_scrape\": \"2018-12-13T16:38:24\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-the-treatment-of-cf-patients-with-the-r117h-mutation/\", \"rr_start\": \"2016-01-14T00:00:00\", \"rr_end\": \"2016-02-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-14, 2016-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\", \"ncpe_year\": 2017, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2016-01-14T00:00:00\", \"latest\": \"2017-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2353, \"last_scrape\": \"2018-12-13T16:38:29\", \"url\": \"http://www.ncpe.ie/drugs/ixazomib-ninlaro/\", \"rr_start\": \"2016-11-23T00:00:00\", \"rr_end\": \"2017-01-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-23, 2017-01-16\", \"rr_multiple\": 0, \"drug_name\": \"Ixazomib (Ninlaro\", \"trade_name\": \"Ninlaro\", \"indication\": \"Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-21T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2016-11-23T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2354, \"last_scrape\": \"2018-12-13T16:38:34\", \"url\": \"http://www.ncpe.ie/drugs/ixekizumab-taltz-for-psoriatic-arthritis/\", \"rr_start\": \"2018-10-16T00:00:00\", \"rr_end\": \"2018-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT IXEKIZUMAB NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE. THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013\", \"rr_dates\": \"2018-10-16, 2018-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab (Taltz\", \"trade_name\": \"Taltz\", \"indication\": \"Ixekizumab (Taltz\", \"ncpe_year\": 2018, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2018-10-16T00:00:00\", \"latest\": \"2018-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/taltz\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2355, \"last_scrape\": \"2018-12-13T16:38:37\", \"url\": \"http://www.ncpe.ie/drugs/ixekizumab-taltz/\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-06-28, 2016-07-26\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab (Taltz\", \"trade_name\": \"Taltz\", \"indication\": \"Taltz\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/taltz\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2356, \"last_scrape\": \"2018-12-13T16:38:39\", \"url\": \"http://www.ncpe.ie/drugs/l/lisdexamfetamine-dimesylate-tyvense/\", \"rr_start\": \"2013-02-09T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-02-09, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Lisdexamfetamine dimesylate (Tyvense\", \"trade_name\": \"Tyvense\", \"indication\": \"Lisdexamfetamine dimesylate (Tyvense\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-02-09T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2357, \"last_scrape\": \"2018-12-13T16:38:44\", \"url\": \"http://www.ncpe.ie/drugs/lacosamide-vimpat/\", \"rr_start\": \"2017-09-11T00:00:00\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-09-11, 2017-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Lacosamide (Vimpat \", \"trade_name\": \"Vimpat\", \"indication\": \"Vimpat \", \"ncpe_year\": 2017, \"eu_market\": \"2008-08-29T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2017-09-11T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2358, \"last_scrape\": \"2018-12-13T16:38:50\", \"url\": \"http://www.ncpe.ie/drugs/lapatinib-tyverb/\", \"rr_start\": \"\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Lapatinib (Tyverb\", \"trade_name\": \"Tyverb\", \"indication\": \"Cost-effectiveness of Lapatinib (Tyverb\", \"ncpe_year\": 2008, \"eu_market\": \"2008-06-10T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2359, \"last_scrape\": \"2018-12-13T16:38:56\", \"url\": \"http://www.ncpe.ie/drugs/ledipasvirsofosbuvir-harvoni/\", \"rr_start\": \"2014-11-14T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-11-14, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ledipasvir/sofosbuvir (Harvoni\", \"trade_name\": \"Harvoni\", \"indication\": \"Ledipasvir/sofosbuvir (Harvoni\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-17T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-11-14T00:00:00\", \"latest\": \"2015-11-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2360, \"last_scrape\": \"2018-12-13T16:39:05\", \"url\": \"http://www.ncpe.ie/drugs/lenalidomide-revlimid/\", \"rr_start\": \"2015-10-05T00:00:00\", \"rr_end\": \"2015-11-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE.\", \"rr_dates\": \"2015-10-05, 2015-11-20\", \"rr_multiple\": 0, \"drug_name\": \"Lenalidomide (Revlimid\", \"trade_name\": \"Revlimid\", \"indication\": \"Revlimid\", \"ncpe_year\": 2018, \"eu_market\": \"2007-06-14T00:00:00\", \"company\": \"Celgene\", \"orphan\": 1, \"earliest\": \"2015-10-05T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid\", \"ta_list\": \"Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2361, \"last_scrape\": \"2018-12-13T16:39:07\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-kisplyx/\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-05-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-05-05, 2017-05-18\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Kisplyx\", \"trade_name\": \"Kisplyx\", \"indication\": \"Lenvatinib (Kisplyx\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-25T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-05-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2362, \"last_scrape\": \"2018-12-13T16:39:11\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-lenvima-2/\", \"rr_start\": \"2018-08-07T00:00:00\", \"rr_end\": \"2018-08-16T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF LENVATINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-08-07, 2018-08-16\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Lenvima\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib (Lenvima\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2018-08-07T00:00:00\", \"latest\": \"2018-08-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2363, \"last_scrape\": \"2018-12-13T16:39:15\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-lenvima/\", \"rr_start\": \"2015-05-05T00:00:00\", \"rr_end\": \"2015-07-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2015-05-05, 2015-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Lenvima\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/H\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2015-05-05T00:00:00\", \"latest\": \"2015-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2364, \"last_scrape\": \"2018-12-13T16:39:20\", \"url\": \"http://www.ncpe.ie/drugs/lesinurad-zurampic/\", \"rr_start\": \"2017-03-15T00:00:00\", \"rr_end\": \"2017-03-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-15, 2017-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Lesinurad (Zurampic\", \"trade_name\": \"Zurampic\", \"indication\": \"Lesinurad (Zurampic\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Gr\", \"orphan\": 0, \"earliest\": \"2017-03-15T00:00:00\", \"latest\": \"2018-12-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zurampic\", \"ta_list\": \"Hyperuricemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2365, \"last_scrape\": \"2018-12-13T16:39:25\", \"url\": \"http://www.ncpe.ie/drugs/letermovir-prevymis/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Letermovir (Prevymis\", \"trade_name\": \"Prevymis\", \"indication\": \"Letermovir for the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevymis\", \"ta_list\": \"Cytomegalovirus Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2366, \"last_scrape\": \"2018-12-13T16:39:28\", \"url\": \"http://www.ncpe.ie/drugs/levodopa-20mgml-carbidopa-monohydrate-5mg-intestinal-gel-duodopa/\", \"rr_start\": \"2013-03-13T00:00:00\", \"rr_end\": \"2013-04-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-03-13, 2013-04-16\", \"rr_multiple\": 0, \"drug_name\": \"Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel (Duodopa\", \"trade_name\": \"Duodopa\", \"indication\": \"For the treatment of advanced levodopa-responsive Parkinson\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-13T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2367, \"last_scrape\": \"2018-12-13T16:39:34\", \"url\": \"http://www.ncpe.ie/drugs/levofloxacin-quinsair/\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-02-10, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Levofloxacin (Quinsair\", \"trade_name\": \"Quinsair\", \"indication\": \"Levofloxacin (Quinsair\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-25T00:00:00\", \"company\": \"Horizon\", \"orphan\": 0, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/quinsair\", \"ta_list\": \"Cystic Fibrosis; Respiratory Tract Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2368, \"last_scrape\": \"2018-12-13T16:39:39\", \"url\": \"http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-delivery-system-lng-ius-12-kyleena/\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-02-08, 2017-03-16\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine delivery system LNG IUS 12 (Kyleena\", \"trade_name\": \"Kyleena\", \"indication\": \"Kyleena\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2017-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2369, \"last_scrape\": \"2018-12-13T16:39:44\", \"url\": \"http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-system-lng-ius-jaydess/\", \"rr_start\": \"2013-03-07T00:00:00\", \"rr_end\": \"2013-03-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-03-07, 2013-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine system LNG-IUS (Jaydess\", \"trade_name\": \"Jaydess\", \"indication\": \"Levonorgestrel Intrauterine System LNG-IUS (Jaydess\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-07T00:00:00\", \"latest\": \"2013-03-25T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2370, \"last_scrape\": \"2018-12-13T16:39:46\", \"url\": \"http://www.ncpe.ie/drugs/lidocaine-5-plasters-versatis/\", \"rr_start\": \"2010-09-09T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2010-09-09, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Lidocaine 5% plasters (Versatis\", \"trade_name\": \"Versatis\", \"indication\": \"Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN).\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-09-09T00:00:00\", \"latest\": \"2015-09-24T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2371, \"last_scrape\": \"2018-12-13T16:39:51\", \"url\": \"http://www.ncpe.ie/drugs/linaclotide-clonstella/\", \"rr_start\": \"2013-05-28T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-05-28, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Linaclotide (Constella\", \"trade_name\": \"Constella\", \"indication\": \"Linaclotide (Constella\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2013-05-28T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/constella\", \"ta_list\": \"Irritable Bowel Syndrome\", \"rr_status\": \"No HTA\"}, {\"id\": 2372, \"last_scrape\": \"2018-12-13T16:39:54\", \"url\": \"http://www.ncpe.ie/drugs/linagliptin-trajenta/\", \"rr_start\": \"2011-08-18T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-08-18, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Linagliptin (Trajenta\", \"trade_name\": \"Trajenta\", \"indication\": \"Lingagliptin (Trajenta\", \"ncpe_year\": 2011, \"eu_market\": \"2011-08-23T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2011-08-18T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2373, \"last_scrape\": \"2018-12-13T16:39:57\", \"url\": \"http://www.ncpe.ie/drugs/lipegfilgrastim-lonquex/\", \"rr_start\": \"2013-08-20T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-08-20, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Lipegfilgrastim (Lonquex\", \"trade_name\": \"Lonquex\", \"indication\": \"Lonquex\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-25T00:00:00\", \"company\": \"Sicor\", \"orphan\": 0, \"earliest\": \"2013-08-20T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex\", \"ta_list\": \"Neutropenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2374, \"last_scrape\": \"2018-12-13T16:40:00\", \"url\": \"http://www.ncpe.ie/drugs/liposomal-daunorubicin-and-cytarabine-cpx-351vyxeos/\", \"rr_start\": \"2018-09-28T00:00:00\", \"rr_end\": \"2018-11-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-09-28, 2018-11-08\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos\", \"trade_name\": \"Vyxeos\", \"indication\": \"Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Jazz\", \"orphan\": 1, \"earliest\": \"2018-09-28T00:00:00\", \"latest\": \"2018-11-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2375, \"last_scrape\": \"2018-12-13T16:40:06\", \"url\": \"http://www.ncpe.ie/drugs/liposomal-irinotecan-nal-iri-onivyde/\", \"rr_start\": \"2017-06-13T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-13, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal irinotecan (Onivyde\", \"trade_name\": \"Onivyde\", \"indication\": \"Liposomal irinotecan (Onivyde\", \"ncpe_year\": 2017, \"eu_market\": \"2016-10-14T00:00:00\", \"company\": \"Baxalta\", \"orphan\": 1, \"earliest\": \"2017-06-13T00:00:00\", \"latest\": \"2017-07-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-0\", \"ta_list\": \"Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2376, \"last_scrape\": \"2018-12-13T16:40:09\", \"url\": \"http://www.ncpe.ie/drugs/liquid-paraffin-ointment-vita-pos-opthalmic/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Liquid Paraffin Ointment (VitA-POS Opthalmic\", \"trade_name\": \"VitA-POS Opthalmic\", \"indication\": \"Liquid Paraffin Ointment (VitA-POS Opthalmic\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2377, \"last_scrape\": \"2018-12-13T16:40:13\", \"url\": \"http://www.ncpe.ie/drugs/liraglutide-victoza/\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-10-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-09-01, 2009-10-07\", \"rr_multiple\": 0, \"drug_name\": \"Liraglutide (Victoza\", \"trade_name\": \"Victoza\", \"indication\": \"Victoza\", \"ncpe_year\": 2018, \"eu_market\": \"2009-06-30T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2009-09-01T00:00:00\", \"latest\": \"2018-10-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/victoza\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2378, \"last_scrape\": \"2018-12-13T16:40:17\", \"url\": \"http://www.ncpe.ie/drugs/lixisenatide-lyxumia/\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Lixisenatide (Lyxumia\", \"trade_name\": \"Lyxumia\", \"indication\": \"Lixisenatide (Lyxumia\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-08-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2379, \"last_scrape\": \"2018-12-13T16:40:19\", \"url\": \"http://www.ncpe.ie/drugs/lomitapide-lojuxta/\", \"rr_start\": \"2014-09-09T00:00:00\", \"rr_end\": \"2014-09-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-09-09, 2014-09-15\", \"rr_multiple\": 0, \"drug_name\": \"Lomitapide (Lojuxta\", \"trade_name\": \"Lojuxta\", \"indication\": \"Lojuxta\", \"ncpe_year\": 2014, \"eu_market\": \"2013-07-31T00:00:00\", \"company\": \"Amryt\", \"orphan\": 0, \"earliest\": \"2014-09-09T00:00:00\", \"latest\": \"2014-09-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2380, \"last_scrape\": \"2018-12-13T16:40:22\", \"url\": \"http://www.ncpe.ie/drugs/lornoxicam-xefo/\", \"rr_start\": \"2011-06-23T00:00:00\", \"rr_end\": \"2011-07-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-06-23, 2011-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Lornoxicam (Xefo\", \"trade_name\": \"Xefo\", \"indication\": \" Lornoxicam (Xefo\", \"ncpe_year\": 2011, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-06-23T00:00:00\", \"latest\": \"2011-07-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA\"}, {\"id\": 2381, \"last_scrape\": \"2018-12-13T16:40:24\", \"url\": \"http://www.ncpe.ie/drugs/lotemax-0-5-eye-drops-suspension-loteprednol/\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2011-12-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-11-15, 2011-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Lotemax 0.5% eye drops suspension (Loteprednol)\", \"trade_name\": \"Loteprednol\", \"indication\": \" Indicated for treatment of post-operative inflammation following ocular surgery.\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2011-12-05T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2382, \"last_scrape\": \"2018-12-13T16:40:30\", \"url\": \"http://www.ncpe.ie/drugs/loxapine-inhalation-powder-adasuve/\", \"rr_start\": \"2016-06-21T00:00:00\", \"rr_end\": \"2016-07-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-06-21, 2016-07-28\", \"rr_multiple\": 0, \"drug_name\": \"Loxapine inhalation powder (Adasuve\", \"trade_name\": \"Adasuve\", \"indication\": \"Inhaled loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-02-20T00:00:00\", \"company\": \"Ferrer\", \"orphan\": 0, \"earliest\": \"2016-06-21T00:00:00\", \"latest\": \"2016-07-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve\", \"ta_list\": \"Schizophrenia; Bipolar Disorder\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2383, \"last_scrape\": \"2018-12-13T16:40:34\", \"url\": \"http://www.ncpe.ie/drugs/lumacaftorivacaftor-orkambi/\", \"rr_start\": \"2015-11-26T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-26, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Lumacaftor/ivacaftor (Orkambi\", \"trade_name\": \"Orkambi\", \"indication\": \"Orkambi\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Vertex\", \"orphan\": 0, \"earliest\": \"2015-11-26T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/orkambi\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2384, \"last_scrape\": \"2018-12-13T16:40:36\", \"url\": \"http://www.ncpe.ie/drugs/lutetium-177lu-oxodotreotide-lutathera/\", \"rr_start\": \"2018-10-23T00:00:00\", \"rr_end\": \"2018-11-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-10-23, 2018-11-16\", \"rr_multiple\": 0, \"drug_name\": \"Lutetium (177Lu) Oxodotreotide (Lutathera\", \"trade_name\": \"Lutathera\", \"indication\": \"Lutetium (177Lu) Oxodotreotide (Lutathera\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-26T00:00:00\", \"company\": \"Advanced\", \"orphan\": 1, \"earliest\": \"2018-10-23T00:00:00\", \"latest\": \"2018-11-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2385, \"last_scrape\": \"2018-12-13T16:40:41\", \"url\": \"http://www.ncpe.ie/drugs/macitentan-opsumit/\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-10, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Macitentan (Opsumit\", \"trade_name\": \"Opsumit\", \"indication\": \"Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-12-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2386, \"last_scrape\": \"2018-12-13T16:40:43\", \"url\": \"http://www.ncpe.ie/drugs/melatonin-circadin/\", \"rr_start\": \"\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Melatonin (Circadin\", \"trade_name\": \"Circadin\", \"indication\": \"A Review of the Economic Evaluation of Prolonged Release Melatonin (Circadin\", \"ncpe_year\": 2008, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"RAD\", \"orphan\": 0, \"earliest\": \"2008-08-01T00:00:00\", \"latest\": \"2008-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/circadin\", \"ta_list\": \"Sleep Initiation and Maintenance Disorders\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2387, \"last_scrape\": \"2018-12-13T16:40:45\", \"url\": \"http://www.ncpe.ie/drugs/mepolizumab-nucala/\", \"rr_start\": \"2016-03-16T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-03-16, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Mepolizumab (Nucala\", \"trade_name\": \"Nucala\", \"indication\": \"Mepolizumab (Nucala\", \"ncpe_year\": 2018, \"eu_market\": \"2015-12-01T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-03-16T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nucala\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2388, \"last_scrape\": \"2018-12-13T16:40:51\", \"url\": \"http://www.ncpe.ie/drugs/methoxyflurane-penthrox/\", \"rr_start\": \"2015-11-23T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-11-23, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Methoxyflurane (Penthrox\", \"trade_name\": \"Penthrox\", \"indication\": \"Penthrox\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2015-11-23T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2389, \"last_scrape\": \"2018-12-13T16:40:56\", \"url\": \"http://www.ncpe.ie/drugs/midostaurin-rydapt-for-aml/\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF MIDOSTAURIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin (Rydapt\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin (Rydapt\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2390, \"last_scrape\": \"2018-12-13T16:41:02\", \"url\": \"http://www.ncpe.ie/drugs/midostaurin-rydapt-for-asm/\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF MIDOSTAURIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin (Rydapt\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin (Rydapt\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2391, \"last_scrape\": \"2018-12-13T16:41:04\", \"url\": \"http://www.ncpe.ie/drugs/mifamurtide-mepact/\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-06-22, 2010-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Mifamurtide (Mepact\", \"trade_name\": \"Mepact\", \"indication\": \"Mifamurtide (Meptact\", \"ncpe_year\": 2010, \"eu_market\": \"2009-03-06T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2010-06-22T00:00:00\", \"latest\": \"2010-07-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mepact\", \"ta_list\": \"Osteosarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2392, \"last_scrape\": \"2018-12-13T16:41:06\", \"url\": \"http://www.ncpe.ie/drugs/migalastat-galafold/\", \"rr_start\": \"2016-07-14T00:00:00\", \"rr_end\": \"2016-08-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-07-14, 2016-08-18\", \"rr_multiple\": 0, \"drug_name\": \"Migalastat (Galafold\", \"trade_name\": \"Galafold\", \"indication\": \"Migalastat is indicated for the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-05-25T00:00:00\", \"company\": \"Amicus\", \"orphan\": 1, \"earliest\": \"2016-07-14T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/galafold\", \"ta_list\": \"Fabry Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2393, \"last_scrape\": \"2018-12-13T16:41:13\", \"url\": \"http://www.ncpe.ie/drugs/mirabegron-betmiga/\", \"rr_start\": \"2012-12-19T00:00:00\", \"rr_end\": \"2013-03-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-12-19, 2013-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Mirabegron (Betmiga\", \"trade_name\": \"Betmiga\", \"indication\": \"Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome\", \"ncpe_year\": 2013, \"eu_market\": \"2012-12-20T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-12-19T00:00:00\", \"latest\": \"2013-03-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga\", \"ta_list\": \"Urinary Bladder, Overactive\", \"rr_status\": \"No HTA\"}, {\"id\": 2394, \"last_scrape\": \"2018-12-13T16:41:15\", \"url\": \"http://www.ncpe.ie/drugs/nab-paclitaxel-abraxane/\", \"rr_start\": \"2014-01-23T00:00:00\", \"rr_end\": \"2014-03-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-01-23, 2014-03-02\", \"rr_multiple\": 0, \"drug_name\": \"Nab-paclitaxel (Abraxane\", \"trade_name\": \"Abraxane\", \"indication\": \"Nab-paclitaxel (Abraxane\", \"ncpe_year\": 2015, \"eu_market\": \"2008-01-10T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2014-01-23T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane\", \"ta_list\": \"Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2395, \"last_scrape\": \"2018-12-13T16:41:18\", \"url\": \"http://www.ncpe.ie/drugs/nalmefene-selincro/\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Nalmefene (Selincro\", \"trade_name\": \"Selincro\", \"indication\": \"Nalmefene (Selincro\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-24T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2014-04-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/selincro\", \"ta_list\": \"Alcohol-Related Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2396, \"last_scrape\": \"2018-12-13T16:41:24\", \"url\": \"http://www.ncpe.ie/drugs/naloxegel-moventig/\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-04-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-02-10, 2015-04-13\", \"rr_multiple\": 0, \"drug_name\": \"Naloxegel (Moventig\", \"trade_name\": \"Moventig\", \"indication\": \"Naloxegel (Moventiq\", \"ncpe_year\": 2015, \"eu_market\": \"2014-12-07T00:00:00\", \"company\": \"Kyowa\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-04-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/moventig\", \"ta_list\": \"Constipation; Opioid-Related Disorders\", \"rr_status\": \"No HTA\"}, {\"id\": 2397, \"last_scrape\": \"2018-12-13T16:41:26\", \"url\": \"http://www.ncpe.ie/drugs/naltrexone-bupropion-mysimba/\", \"rr_start\": \"2017-03-12T00:00:00\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-12, 2017-03-28\", \"rr_multiple\": 0, \"drug_name\": \"Naltrexone / bupropion (Mysimba\", \"trade_name\": \"Mysimba\", \"indication\": \"Naltrexone / bupropion (Mysimba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-03-26T00:00:00\", \"company\": \"Orexigen\", \"orphan\": 0, \"earliest\": \"2017-03-12T00:00:00\", \"latest\": \"2018-05-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba\", \"ta_list\": \"Obesity; Overweight\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2398, \"last_scrape\": \"2018-12-13T16:41:30\", \"url\": \"http://www.ncpe.ie/drugs/natalizumab-tysabri/\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Natalizumab (Tysabri\", \"trade_name\": \"Tysabri\", \"indication\": \" Economic Evaluation of Natalizumab (Tysabri\", \"ncpe_year\": 2007, \"eu_market\": \"2006-06-27T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2007-01-01T00:00:00\", \"latest\": \"2007-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2399, \"last_scrape\": \"2018-12-13T16:41:35\", \"url\": \"http://www.ncpe.ie/drugs/ncpe-inhaled-insulin-exubera-assessment/\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Inhaled insulin (Exubera\", \"trade_name\": \"Exubera\", \"indication\": \"In April 2006, Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin (Exubera\", \"ncpe_year\": 2006, \"eu_market\": \"2006-01-24T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-03-01T00:00:00\", \"latest\": \"2006-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/exubera\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2400, \"last_scrape\": \"2018-12-13T16:41:38\", \"url\": \"http://www.ncpe.ie/drugs/nepafenac-nevanac-2/\", \"rr_start\": \"2011-06-14T00:00:00\", \"rr_end\": \"2011-06-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-06-14, 2011-06-27\", \"rr_multiple\": 0, \"drug_name\": \"Nepafenac (Nevanac\", \"trade_name\": \"Nevanac\", \"indication\": \"Nepafenac (Nevanac\", \"ncpe_year\": 2011, \"eu_market\": \"2007-12-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2011-06-14T00:00:00\", \"latest\": \"2011-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac\", \"ta_list\": \"Pain, Postoperative; Ophthalmologic Surgical Procedures\", \"rr_status\": \"No HTA\"}, {\"id\": 2401, \"last_scrape\": \"2018-12-13T16:41:41\", \"url\": \"http://www.ncpe.ie/drugs/netupitantpalonosetron-akynzeo/\", \"rr_start\": \"2015-08-26T00:00:00\", \"rr_end\": \"2015-10-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-08-26, 2015-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Netupitant/palonosetron (Akynzeo\", \"trade_name\": \"Akynzeo\", \"indication\": \"Akynzeo\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Helsinn\", \"orphan\": 0, \"earliest\": \"2015-08-26T00:00:00\", \"latest\": \"2015-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo\", \"ta_list\": \"Vomiting; Cancer; Nausea\", \"rr_status\": \"No HTA\"}, {\"id\": 2402, \"last_scrape\": \"2018-12-13T16:41:44\", \"url\": \"http://www.ncpe.ie/drugs/nilotinib-tasigna-newly-diagnosed-cml/\", \"rr_start\": \"2010-10-06T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2010-10-06, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib (Tasigna\", \"trade_name\": \"Tasigna\", \"indication\": \"Nilotinib (Tasigna\", \"ncpe_year\": 2010, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-10-06T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2403, \"last_scrape\": \"2018-12-13T16:41:51\", \"url\": \"http://www.ncpe.ie/drugs/nilotinib-tasigna/\", \"rr_start\": \"\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib (Tasigna\", \"trade_name\": \"Tasigna\", \"indication\": \"Cost-effectiveness of Nilotinib (Tasigna\", \"ncpe_year\": 2008, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2404, \"last_scrape\": \"2018-12-13T16:41:53\", \"url\": \"http://www.ncpe.ie/drugs/nintedanib-ofev/\", \"rr_start\": \"2015-01-30T00:00:00\", \"rr_end\": \"2015-02-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-30, 2015-02-18\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib (Ofev\", \"trade_name\": \"Ofev\", \"indication\": \"Nintedanib (Ofev\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 1, \"earliest\": \"2015-01-30T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ofev\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2405, \"last_scrape\": \"2018-12-13T16:41:56\", \"url\": \"http://www.ncpe.ie/drugs/nintedanib-vargatef/\", \"rr_start\": \"2015-01-02T00:00:00\", \"rr_end\": \"2015-02-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-02, 2015-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib (Vargatef\", \"trade_name\": \"Vargatef\", \"indication\": \"Nintedanib (Vargatef\", \"ncpe_year\": 2017, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-01-02T00:00:00\", \"latest\": \"2017-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2406, \"last_scrape\": \"2018-12-13T16:42:00\", \"url\": \"http://www.ncpe.ie/drugs/niraparib-zejula/\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF NIRAPARIB COMPARED WITH THE CURRENT STANDARD OF CARE\", \"rr_dates\": \"2018-06-01, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Niraparib (Zejula\", \"trade_name\": \"Zejula\", \"indication\": \"Niraparib (Zejula\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-16T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 1, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zejula\", \"ta_list\": \"Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2407, \"last_scrape\": \"2018-12-13T16:42:06\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-melanoma/\", \"rr_start\": \"2015-05-28T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-05-28, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-05-28T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2408, \"last_scrape\": \"2018-12-13T16:42:13\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-non-squamous-nsclc/\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-03-03, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2409, \"last_scrape\": \"2018-12-13T16:42:20\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-nsclc/\", \"rr_start\": \"2015-07-02T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-07-02, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-07-02T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2410, \"last_scrape\": \"2018-12-13T16:42:26\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-as-monotherapy-for-the-adjuvant-treatment-of-adults-with-melanoma/\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF NIVOLUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-09, 2018-07-27\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-11-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2411, \"last_scrape\": \"2018-12-13T16:42:31\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-advanced-renal-cell-carcinoma/\", \"rr_start\": \"2016-04-27T00:00:00\", \"rr_end\": \"2016-05-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-04-27, 2016-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-04-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2412, \"last_scrape\": \"2018-12-13T16:42:33\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-classical-hodgkin-lymphoma/\", \"rr_start\": \"2016-11-22T00:00:00\", \"rr_end\": \"2017-01-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-11-22, 2017-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-11-22T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2413, \"last_scrape\": \"2018-12-13T16:42:36\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-head-and-neck-cancer/\", \"rr_start\": \"2017-05-03T00:00:00\", \"rr_end\": \"2017-05-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-03, 2017-05-30\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-05-03T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2414, \"last_scrape\": \"2018-12-13T16:42:41\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-urothelial-carcinoma/\", \"rr_start\": \"2017-06-28T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-28, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-06-28T00:00:00\", \"latest\": \"2018-09-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2415, \"last_scrape\": \"2018-12-13T16:42:46\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-in-combination-with-ipilimumab-yervoy/\", \"rr_start\": \"2018-11-28T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-11-28, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Yervoy\", \"indication\": \"Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).\", \"ncpe_year\": 2018, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-11-28T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy\", \"ta_list\": \"Melanoma\", \"rr_status\": \"Unknown\"}, {\"id\": 2416, \"last_scrape\": \"2018-12-13T16:42:51\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-plus-ipilimumab-opdivio-plus-yervoy/\", \"rr_start\": \"\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab plus ipilimumab (Opdivo\", \"trade_name\": \"Opdivo plus Yervoy\", \"indication\": \"Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-06-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2417, \"last_scrape\": \"2018-12-13T16:42:56\", \"url\": \"http://www.ncpe.ie/drugs/nomace2-zoely/\", \"rr_start\": \"2011-12-08T00:00:00\", \"rr_end\": \"2012-01-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-12-08, 2012-01-03\", \"rr_multiple\": 0, \"drug_name\": \"Nomegestrol acetate/estradiol (Zoely\", \"trade_name\": \"Zoely\", \"indication\": \"Nomegestrol acetate/estradiol (Zoely\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-26T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2011-12-08T00:00:00\", \"latest\": \"2012-01-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zoely\", \"ta_list\": \"Contraception\", \"rr_status\": \"No HTA\"}, {\"id\": 2418, \"last_scrape\": \"2018-12-13T16:43:02\", \"url\": \"http://www.ncpe.ie/drugs/nusinersin-spinraza/\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-11, 2017-08-02\", \"rr_multiple\": 0, \"drug_name\": \"Nusinersin (Spinraza\", \"trade_name\": \"Spinraza\", \"indication\": \"Nusinersen (Spinraza\", \"ncpe_year\": 2017, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 1, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-12-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza\", \"ta_list\": \"Muscular Atrophy, Spinal\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2419, \"last_scrape\": \"2018-12-13T16:43:07\", \"url\": \"http://www.ncpe.ie/drugs/obeticholic-acid-ocaliva/\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-18, 2016-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Obeticholic acid (Ocaliva\", \"trade_name\": \"Ocaliva\", \"indication\": \"Obeticholic acid is indicated for the treatment of primary biliary cirrhosis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Intercept\", \"orphan\": 1, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocaliva\", \"ta_list\": \"Liver Cirrhosis, Biliary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2420, \"last_scrape\": \"2018-12-13T16:43:10\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-follicular-lymphoma/\", \"rr_start\": \"2016-05-11T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-05-11, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (in combination with bendamustine) followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2016-05-11T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2421, \"last_scrape\": \"2018-12-13T16:43:15\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-previously-untreated-advanced-follicular-lymphoma/\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-09-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-08, 2017-09-13\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (Gazyvaro\", \"ncpe_year\": 2018, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2422, \"last_scrape\": \"2018-12-13T16:43:21\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro/\", \"rr_start\": \"2014-08-08T00:00:00\", \"rr_end\": \"2014-09-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-08-08, 2014-09-11\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (Gazyvaro\", \"ncpe_year\": 2015, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2014-08-08T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2423, \"last_scrape\": \"2018-12-13T16:43:24\", \"url\": \"http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-ppms/\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab (Ocrevus\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab (Ocrevus\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2424, \"last_scrape\": \"2018-12-13T16:43:30\", \"url\": \"http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-rms/\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab (Ocrevus\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab (Ocrevus\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2425, \"last_scrape\": \"2018-12-13T16:43:34\", \"url\": \"http://www.ncpe.ie/drugs/ocriplasmin-jetrea/\", \"rr_start\": \"2013-06-12T00:00:00\", \"rr_end\": \"2013-07-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-06-12, 2013-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Ocriplasmin (Jetrea\", \"trade_name\": \"Jetrea\", \"indication\": \"Ocriplasmin (Jetrea\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-13T00:00:00\", \"company\": \"ThromboGenics\", \"orphan\": 0, \"earliest\": \"2013-06-12T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea\", \"ta_list\": \"Retinal Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2426, \"last_scrape\": \"2018-12-13T16:43:39\", \"url\": \"http://www.ncpe.ie/drugs/ofatumumab-arzerra-previously-untreated-chronic-lymphocytic-leukaemia/\", \"rr_start\": \"2014-10-13T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2014-10-13, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab (Arzerra\", \"trade_name\": \"Arzerra\", \"indication\": \"Ofatumumab (Arzerra\", \"ncpe_year\": 2014, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-10-13T00:00:00\", \"latest\": \"2014-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2427, \"last_scrape\": \"2018-12-13T16:43:46\", \"url\": \"http://www.ncpe.ie/drugs/ofatumumab-arzerra/\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-06-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-06-22, 2010-06-01\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab (Arzerra\", \"trade_name\": \"Arzerra\", \"indication\": \"Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-06-01T00:00:00\", \"latest\": \"2010-06-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2428, \"last_scrape\": \"2018-12-13T16:43:52\", \"url\": \"http://www.ncpe.ie/drugs/oladaterol-striverdi-respimat/\", \"rr_start\": \"2014-04-07T00:00:00\", \"rr_end\": \"2014-05-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-07, 2014-05-02\", \"rr_multiple\": 0, \"drug_name\": \"Oladaterol (Striverdi\", \"trade_name\": \"Striverdi, Respimat\", \"indication\": \"Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-04-07T00:00:00\", \"latest\": \"2014-05-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2429, \"last_scrape\": \"2018-12-13T16:43:57\", \"url\": \"http://www.ncpe.ie/drugs/olaparib-lynparza-2/\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-05, 2015-02-19\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib (Lynparza\", \"trade_name\": \"Lynparza\", \"indication\": \"Lynparza\", \"ncpe_year\": 2017, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2430, \"last_scrape\": \"2018-12-13T16:44:03\", \"url\": \"http://www.ncpe.ie/drugs/olaparib-lynparza-for-platinum-sensitive-relapsed-ovarian-cancer/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"THE NCPE RECOMMEND  A FULL HTA TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF OLAPARIB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib (Lynparza\", \"trade_name\": \"Lynparza\", \"indication\": \"Olaparib (Lynparza\", \"ncpe_year\": 2018, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2431, \"last_scrape\": \"2018-12-13T16:44:08\", \"url\": \"http://www.ncpe.ie/drugs/omalizumab-xolair-for-the-treatment-of-severe-allergic-asthma/\", \"rr_start\": \"\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab (Xolair\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab is indicated as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1<80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.\", \"ncpe_year\": 2015, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-08-22T00:00:00\", \"latest\": \"2015-06-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xolair\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2432, \"last_scrape\": \"2018-12-13T16:44:14\", \"url\": \"http://www.ncpe.ie/drugs/omalizumab-xolair/\", \"rr_start\": \"2014-03-25T00:00:00\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED FOR THIS INDICATION.\", \"rr_dates\": \"2014-03-25, 2014-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab (Xolair\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab (Xolair\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-03-25T00:00:00\", \"latest\": \"2014-04-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xolair\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"No HTA\"}, {\"id\": 2433, \"last_scrape\": \"2018-12-13T16:44:19\", \"url\": \"http://www.ncpe.ie/drugs/oral-oxycodonenaloxone-targin/\", \"rr_start\": \"\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Oxycodone/naloxone (Targin\", \"trade_name\": \"Targin\", \"indication\": \"Cost-effectiveness of oral oxycodone/naloxone prolonged release tablet (Targin\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-05-05T00:00:00\", \"latest\": \"2010-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2434, \"last_scrape\": \"2018-12-13T16:44:22\", \"url\": \"http://www.ncpe.ie/drugs/osimertinib-tagrisso-for-the-first-line-treatment-of-metastatic-nsclc/\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-07T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF OSIMERTINIB FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WITH ACTIVATING EGFR MUTATIONS COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-19, 2018-08-07\", \"rr_multiple\": 0, \"drug_name\": \"Osimertinib (Tagrisso\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib (Tagrisso\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2435, \"last_scrape\": \"2018-12-13T16:44:39\", \"url\": \"http://www.ncpe.ie/drugs/osimertinib-tagrisso/\", \"rr_start\": \"2016-02-26T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-26, 2016-03-22, 2017-01-10\", \"rr_multiple\": 1, \"drug_name\": \"Osimertinib (Tagrisso\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib (Tagrisso\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-26T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2436, \"last_scrape\": \"2018-12-13T16:44:40\", \"url\": \"http://www.ncpe.ie/drugs/ozenoxacin-dubine/\", \"rr_start\": \"2018-11-12T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"FULL HTA IS NOT RECOMMENDED. THE NCPE RECOMMENDS THAT OZENOXACIN CREAM NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE.  THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013.\", \"rr_dates\": \"2018-11-12, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ozenoxacin (Dubine\", \"trade_name\": \"Dubine\", \"indication\": \"Ozenoxacin (Dubine\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-12T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"id\": 2437, \"last_scrape\": \"2018-12-13T16:44:43\", \"url\": \"http://www.ncpe.ie/drugs/p-drugs/pegylated-interferon-b-1a-plegridy/\", \"rr_start\": \"2014-11-25T00:00:00\", \"rr_end\": \"2014-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-11-25, 2014-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Pegylated Interferon beta-1a (Plegridy \", \"trade_name\": \"Plegridy\", \"indication\": \"Treatment of adult patients with relapsing remitting multiple sclerosis\", \"ncpe_year\": 2014, \"eu_market\": \"2014-07-17T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-11-25T00:00:00\", \"latest\": \"2014-12-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2438, \"last_scrape\": \"2018-12-13T16:44:47\", \"url\": \"http://www.ncpe.ie/drugs/palbociclib-ibrance/\", \"rr_start\": \"2016-09-10T00:00:00\", \"rr_end\": \"2016-09-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-09-10, 2016-09-28\", \"rr_multiple\": 0, \"drug_name\": \"Palbociclib (Ibrance\", \"trade_name\": \"Ibrance\", \"indication\": \"Palbociclib is indicated for the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-11-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2016-09-10T00:00:00\", \"latest\": \"2017-07-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2439, \"last_scrape\": \"2018-12-13T16:44:53\", \"url\": \"http://www.ncpe.ie/drugs/paliperidone-palmitate-xeplion/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Paliperidone palmitate (Xeplion\", \"trade_name\": \"Xeplion\", \"indication\": \"Paliperidone palmitate (Xeplion\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-04T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeplion\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2440, \"last_scrape\": \"2018-12-13T16:44:57\", \"url\": \"http://www.ncpe.ie/drugs/panobinostat-farydak/\", \"rr_start\": \"2016-01-26T00:00:00\", \"rr_end\": \"2016-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-26, 2016-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Panobinostat (Farydak\", \"trade_name\": \"Farydak\", \"indication\": \"Panobinostat in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-01-26T00:00:00\", \"latest\": \"2016-02-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/farydak\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2441, \"last_scrape\": \"2018-12-13T16:45:01\", \"url\": \"http://www.ncpe.ie/drugs/paritaprevir-boosted-with-ritonavir-and-ombitasvir-vierkirax-with-or-without-dasabuvir-exviera/\", \"rr_start\": \"2014-12-21T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-21, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Paritaprevir boosted with ritonavir and ombitasvir (Vierkirax\", \"trade_name\": \"Exviera\", \"indication\": \"Exviera\", \"ncpe_year\": 2016, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2014-12-21T00:00:00\", \"latest\": \"2016-02-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/exviera\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2442, \"last_scrape\": \"2018-12-13T16:45:07\", \"url\": \"http://www.ncpe.ie/drugs/patiromer-veltassa/\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT\\nRECOMMENDED\", \"rr_dates\": \"2017-10-11, 2017-11-17\", \"rr_multiple\": 0, \"drug_name\": \"Patiromer (Veltassa\", \"trade_name\": \"Veltassa\", \"indication\": \"Patiromer (Veltassa\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-19T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-11-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/veltassa\", \"ta_list\": \"Hyperkalemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2443, \"last_scrape\": \"2018-12-13T16:45:10\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-1l-nsclc-with-chemotherapy/\", \"rr_start\": \"2018-08-14T00:00:00\", \"rr_end\": \"2018-08-29T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-14, 2018-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-08-14T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2444, \"last_scrape\": \"2018-12-13T16:45:15\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-adjuvant-melanoma/\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-07T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-11-19, 2018-12-07\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizuma (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2445, \"last_scrape\": \"2018-12-13T16:45:18\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-classical-hodgkin-lymphoma/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2446, \"last_scrape\": \"2018-12-13T16:45:23\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-first-line-nsclc/\", \"rr_start\": \"2016-12-19T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-12-19, 2017-01-10\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-12-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2447, \"last_scrape\": \"2018-12-13T16:45:28\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-nsclc/\", \"rr_start\": \"2016-08-03T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-08-03, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-03T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2448, \"last_scrape\": \"2018-12-13T16:45:31\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-the-treatment-of-unresectable-or-advanced-metastatic-melanoma-in-adults-refractory-to-ipilimumab/\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2449, \"last_scrape\": \"2018-12-13T16:45:36\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-uc-1l/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES\", \"rr_dates\": \"2017-12-06, 2017-12-21, 2018-06-21, 2018-07-10, 2018-07-27\", \"rr_multiple\": 1, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-07-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2450, \"last_scrape\": \"2018-12-13T16:45:38\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-urothelial-carcinoma-2l/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda \", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2451, \"last_scrape\": \"2018-12-13T16:45:45\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda/\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-02-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2452, \"last_scrape\": \"2018-12-13T16:45:50\", \"url\": \"http://www.ncpe.ie/drugs/perampanel-fycompa/\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Perampanel (Fycompa\", \"trade_name\": \"Fycompa\", \"indication\": \"Perampanel (Fycompa\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-23T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa\", \"ta_list\": \"Epilepsies, Partial\", \"rr_status\": \"No HTA\"}, {\"id\": 2453, \"last_scrape\": \"2018-12-13T16:45:56\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta-for-her2-positive-breast-cancer/\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PERTUZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-01, 2018-06-22\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab  (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.\", \"ncpe_year\": 2018, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-12-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2454, \"last_scrape\": \"2018-12-13T16:46:02\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta-in-neoadjuvant-her2-positive-breast-cancer/\", \"rr_start\": \"2015-08-10T00:00:00\", \"rr_end\": \"2015-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-10, 2015-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"Perjeta (pertuzumab) is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2015-08-10T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2455, \"last_scrape\": \"2018-12-13T16:46:04\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta/\", \"rr_start\": \"2013-01-14T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-01-14, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"The proposed licensed indication is for use (in combination with trastuzumab and docetaxel) in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. \", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-01-14T00:00:00\", \"latest\": \"2013-08-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2456, \"last_scrape\": \"2018-12-13T16:46:09\", \"url\": \"http://www.ncpe.ie/drugs/phenylephrine-hydrochloride-tropicamide-lidocaine-hydrochloride-fydrane/\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-19T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-11-18, 2016-12-19\", \"rr_multiple\": 0, \"drug_name\": \"Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride (Fydrane\", \"trade_name\": \"Fydrane\", \"indication\": \"Fydrane\", \"ncpe_year\": 2016, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2016-12-19T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2457, \"last_scrape\": \"2018-12-13T16:46:11\", \"url\": \"http://www.ncpe.ie/drugs/pirfenidone-esbriet/\", \"rr_start\": \"2011-12-15T00:00:00\", \"rr_end\": \"2012-01-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-12-15, 2012-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Pirfenidone (Esbriet\", \"trade_name\": \"Esbriet\", \"indication\": \"Pirfenidone has been licensed by the European Medicines Agency (EMA) for the treatment of mild to moderate idiopathic pulmonary fibrosis.\", \"ncpe_year\": 2015, \"eu_market\": \"2011-02-27T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2011-12-15T00:00:00\", \"latest\": \"2015-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esbriet\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2458, \"last_scrape\": \"2018-12-13T16:46:14\", \"url\": \"http://www.ncpe.ie/drugs/pitavastatin-livazo/\", \"rr_start\": \"2010-12-22T00:00:00\", \"rr_end\": \"2010-12-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-12-22, 2010-12-24\", \"rr_multiple\": 0, \"drug_name\": \"Pitavastatin (Livazo\", \"trade_name\": \"Livazo\", \"indication\": \"Pitavastatin is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined (mixed) dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-12-22T00:00:00\", \"latest\": \"2010-12-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2459, \"last_scrape\": \"2018-12-13T16:46:20\", \"url\": \"http://www.ncpe.ie/drugs/pitolisant-wakix/\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-06-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-06-12, 2017-06-15\", \"rr_multiple\": 0, \"drug_name\": \"Pitolisant hydrochloride (Wakix\", \"trade_name\": \"Wakix\", \"indication\": \"Pitolisant hydrochloride (Wakix\", \"ncpe_year\": 2017, \"eu_market\": \"2016-03-31T00:00:00\", \"company\": \"Bioprojet\", \"orphan\": 1, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-06-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/wakix\", \"ta_list\": \"Narcolepsy\", \"rr_status\": \"No HTA\"}, {\"id\": 2460, \"last_scrape\": \"2018-12-13T16:46:24\", \"url\": \"http://www.ncpe.ie/drugs/pixantrone-pixuvri/\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-03-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-02-10, 2015-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Pixantrone (Pixuvri\", \"trade_name\": \"Pixuvri\", \"indication\": \"Pixurvi\", \"ncpe_year\": 2015, \"eu_market\": \"2012-05-10T00:00:00\", \"company\": \"CTI\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-03-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri\", \"ta_list\": \"Lymphoma, Non-Hodgkin\", \"rr_status\": \"No HTA\"}, {\"id\": 2461, \"last_scrape\": \"2018-12-13T16:46:27\", \"url\": \"http://www.ncpe.ie/drugs/polynuclear-ironiii-oxyhydroxide-pn-feooh-velphoro/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-09-12, 2014-10-08\", \"rr_multiple\": 0, \"drug_name\": \"Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro\", \"trade_name\": \"Velphoro\", \"indication\": \"Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro\", \"ncpe_year\": 2014, \"eu_market\": \"2014-08-26T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-10-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/velphoro\", \"ta_list\": \"Hyperphosphatemia; Renal Dialysis\", \"rr_status\": \"No HTA\"}, {\"id\": 2462, \"last_scrape\": \"2018-12-13T16:46:30\", \"url\": \"http://www.ncpe.ie/drugs/pomalidomide-imnovid/\", \"rr_start\": \"2013-09-20T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-20, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Pomalidomide (Imnovid\", \"trade_name\": \"Imnovid\", \"indication\": \"Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-09-20T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2463, \"last_scrape\": \"2018-12-13T16:46:32\", \"url\": \"http://www.ncpe.ie/drugs/ponatinib-iclusig/\", \"rr_start\": \"2013-10-02T00:00:00\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-10-02, 2013-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Ponatinib (Iclusig\", \"trade_name\": \"Iclusig\", \"indication\": \"Ponatinib (Iclusig\", \"ncpe_year\": 2016, \"eu_market\": \"2013-07-01T00:00:00\", \"company\": \"Incyte\", \"orphan\": 1, \"earliest\": \"2013-10-02T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig\", \"ta_list\": \"Leukemia, Myeloid; Leukemia, Lymphoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2464, \"last_scrape\": \"2018-12-13T16:46:38\", \"url\": \"http://www.ncpe.ie/drugs/prasugrel-efient/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Prasugrel (Efient\", \"trade_name\": \"Efient\", \"indication\": \"Economic Evaluation of Prasugrel (Efient\", \"ncpe_year\": 2010, \"eu_market\": \"2009-02-24T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2010-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/efient\", \"ta_list\": \"Acute Coronary Syndrome; Angina, Unstable; Myocardial Infarction\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2465, \"last_scrape\": \"2018-12-13T16:46:46\", \"url\": \"http://www.ncpe.ie/drugs/pregabalin-lyrica-2/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin (Lyrica\", \"trade_name\": \"Lyrica\", \"indication\": \"Lyrica\", \"ncpe_year\": 2015, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-30T00:00:00\", \"latest\": \"2015-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2466, \"last_scrape\": \"2018-12-13T16:46:52\", \"url\": \"http://www.ncpe.ie/drugs/pregabalin-lyrica-for-the-treatment-of-generalised-anxiety-disorder/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin (Lyrica\", \"trade_name\": \"Lyrica\", \"indication\": \"Pregabalin (Lyrica\", \"ncpe_year\": 2014, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-12-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2467, \"last_scrape\": \"2018-12-13T16:46:58\", \"url\": \"http://www.ncpe.ie/drugs/prucalopride-resolor/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-01-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-01-17\", \"rr_multiple\": 0, \"drug_name\": \"Prucalopride (Resolor\", \"trade_name\": \"Resolor\", \"indication\": \"Prucalopride (Resolor\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-14T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2011-01-17T00:00:00\", \"latest\": \"2011-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/resolor\", \"ta_list\": \"Constipation\", \"rr_status\": \"No HTA\"}, {\"id\": 2468, \"last_scrape\": \"2018-12-13T16:47:00\", \"url\": \"http://www.ncpe.ie/drugs/radium-223-xofigo/\", \"rr_start\": \"2013-11-28T00:00:00\", \"rr_end\": \"2013-12-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-11-28, 2013-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Radium-223 (Xofigo\", \"trade_name\": \"Xofigo\", \"indication\": \"Radium-223 (Xofigo\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-13T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2469, \"last_scrape\": \"2018-12-13T16:47:03\", \"url\": \"http://www.ncpe.ie/drugs/ramucirumab-cyramza/\", \"rr_start\": \"2014-12-20T00:00:00\", \"rr_end\": \"2014-12-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-20, 2014-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Ramucirumab (Cyramza\", \"trade_name\": \"Cyramza\", \"indication\": \"Indicated in combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction (GEJ) adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-12-19T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2014-12-20T00:00:00\", \"latest\": \"2016-07-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2470, \"last_scrape\": \"2018-12-13T16:47:06\", \"url\": \"http://www.ncpe.ie/drugs/ranolazine-ranexa/\", \"rr_start\": \"2009-11-19T00:00:00\", \"rr_end\": \"2009-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ranolazine (Ranexa\", \"trade_name\": \"Ranexa\", \"indication\": \"Cost-effectiveness of Ranolazine (Ranexa\", \"ncpe_year\": 2009, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2009-11-19T00:00:00\", \"latest\": \"2009-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2471, \"last_scrape\": \"2018-12-13T16:47:13\", \"url\": \"http://www.ncpe.ie/drugs/regadenoson-rapiscan/\", \"rr_start\": \"2011-09-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-09-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Regadenoson (Rapiscan\", \"trade_name\": \"Rapiscan\", \"indication\": \"Cost-effectiveness of Regadenoson (Rapiscan\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-06T00:00:00\", \"company\": \"GE\", \"orphan\": 0, \"earliest\": \"2011-09-19T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rapiscan\", \"ta_list\": \"Myocardial Perfusion Imaging\", \"rr_status\": \"No HTA\"}, {\"id\": 2472, \"last_scrape\": \"2018-12-13T16:47:17\", \"url\": \"http://www.ncpe.ie/drugs/regorafenib-stivarga-for-gist/\", \"rr_start\": \"2014-09-18T00:00:00\", \"rr_end\": \"2014-10-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-09-18, 2014-10-06\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib (Stivarga\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib (Stivarga\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2014-09-18T00:00:00\", \"latest\": \"2014-10-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2473, \"last_scrape\": \"2018-12-13T16:47:23\", \"url\": \"http://www.ncpe.ie/drugs/reslizumab-cinqaero/\", \"rr_start\": \"2017-01-23T00:00:00\", \"rr_end\": \"2017-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-01-23, 2017-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Reslizumab (Cinqaero\", \"trade_name\": \"Cinqaero\", \"indication\": \"Cinqaero\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-15T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2017-01-23T00:00:00\", \"latest\": \"2017-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cinqaero\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2474, \"last_scrape\": \"2018-12-13T16:47:27\", \"url\": \"http://www.ncpe.ie/drugs/retigabine-trobalt/\", \"rr_start\": \"2011-04-06T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-04-06, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Retigabine (Trobalt\", \"trade_name\": \"Trobalt\", \"indication\": \"Cost-effectiveness of Retigabine (Trobalt\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-27T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-04-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"No HTA\"}, {\"id\": 2475, \"last_scrape\": \"2018-12-13T16:47:29\", \"url\": \"http://www.ncpe.ie/drugs/ribociclib-kisqali/\", \"rr_start\": \"2017-09-04T00:00:00\", \"rr_end\": \"2017-09-19T00:00:00\", \"rr_outcome\": \"FOLLOWING NCPE ASSESSMENT OF THE COMPANY SUBMISSION, THE NCPE RECOMMENDS THAT RIBOCICLIB (IN COMBINATION WITH AN AROMATASE INHIBITOR) FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR+/HER2- LOCALLY ADVANCED OR METASTATIC BC AS INITIAL ENDOCRINE-BASED THERAPY, NOT BE CONSIDERED FOR REIMBURSEMENT UNLESS COST EFFECTIVENESS CAN BE IMPROVED RELATIVE TO EXISTING TREATMENTS. THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2017-09-04, 2017-09-19\", \"rr_multiple\": 0, \"drug_name\": \"Ribociclib (Kisqali\", \"trade_name\": \"Kisqali\", \"indication\": \"Ribociclib (Kisqali\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2017-09-04T00:00:00\", \"latest\": \"2018-08-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2476, \"last_scrape\": \"2018-12-13T16:47:35\", \"url\": \"http://www.ncpe.ie/drugs/rifaximin-targaxan-2/\", \"rr_start\": \"2013-07-09T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-09, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Rifaximin (Targaxan\", \"trade_name\": \"Targaxan\", \"indication\": \"Rifaximin (Targaxan\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-07-09T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2477, \"last_scrape\": \"2018-12-13T16:47:38\", \"url\": \"http://www.ncpe.ie/drugs/rigorafenib-stivarga/\", \"rr_start\": \"2013-09-12T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-12, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib (Stivarga\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib (Stivarga\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-09-12T00:00:00\", \"latest\": \"2014-06-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2478, \"last_scrape\": \"2018-12-13T16:47:42\", \"url\": \"http://www.ncpe.ie/drugs/rilpivirine-edurant/\", \"rr_start\": \"2011-12-14T00:00:00\", \"rr_end\": \"2012-01-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-12-14, 2012-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine (Edurant\", \"trade_name\": \"Edurant\", \"indication\": \"Rilpivirine in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ? 100,000 HIV-1 RNA copies/ml.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-11-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-12-14T00:00:00\", \"latest\": \"2012-01-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/edurant\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2479, \"last_scrape\": \"2018-12-13T16:47:45\", \"url\": \"http://www.ncpe.ie/drugs/rilpivirine-r-emtricitabine-f-tenofovir-alafenamide-taf-odefsey/\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMEDED\", \"rr_dates\": \"2016-06-28, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) (Odefsey\", \"trade_name\": \"Odefsey\", \"indication\": \"Odefsey\", \"ncpe_year\": 2016, \"eu_market\": \"2016-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2480, \"last_scrape\": \"2018-12-13T16:47:48\", \"url\": \"http://www.ncpe.ie/drugs/rimonabant-acomplia-2/\", \"rr_start\": \"\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rimonabant (Acomplia\", \"trade_name\": \"Acomplia\", \"indication\": \"In June 2006, Sanofi-Aventis submitted an evaluation of the cost-effectiveness of rimonabant (in addition to diet and exercise) in the management of multiple cardiovascular risks in overweight or obese patients in Ireland, to support its application for reimbursement of rimonabant under the Community Drugs Schemes. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-06-19T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2006-06-01T00:00:00\", \"latest\": \"2006-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/acomplia\", \"ta_list\": \"Obesity\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2481, \"last_scrape\": \"2018-12-13T16:47:53\", \"url\": \"http://www.ncpe.ie/drugs/riociguat-adempas/\", \"rr_start\": \"2014-04-11T00:00:00\", \"rr_end\": \"2014-05-16T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED AT THE CURRENT PRICE.\", \"rr_dates\": \"2014-04-11, 2014-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Riociguat (Adempas\", \"trade_name\": \"Adempas\", \"indication\": \"Riociguat (Adempas\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-27T00:00:00\", \"company\": \"Bayer\", \"orphan\": 1, \"earliest\": \"2014-04-11T00:00:00\", \"latest\": \"2014-05-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adempas\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2482, \"last_scrape\": \"2018-12-13T16:47:59\", \"url\": \"http://www.ncpe.ie/drugs/rituximab-mabthera/\", \"rr_start\": \"2014-05-26T00:00:00\", \"rr_end\": \"2014-09-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-26, 2014-09-22\", \"rr_multiple\": 0, \"drug_name\": \"Rituximab (MabThera\", \"trade_name\": \"MabThera\", \"indication\": \"Rituximab (MabThera\", \"ncpe_year\": 2014, \"eu_market\": \"1998-06-02T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-05-26T00:00:00\", \"latest\": \"2014-09-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"No HTA\"}, {\"id\": 2483, \"last_scrape\": \"2018-12-13T16:48:05\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-atrial-fibrillation-patients-undergoing-pci/\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2484, \"last_scrape\": \"2018-12-13T16:48:10\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-dvt/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Economic evaluation of Rivaroxaban (Xarelto\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-02-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2485, \"last_scrape\": \"2018-12-13T16:48:15\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-spaf-2/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban (Xarelto\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2486, \"last_scrape\": \"2018-12-13T16:48:18\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-the-prevention-of-atherothrombotic-events/\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-11T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF RIVAROXABAN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-26, 2018-10-11\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban (Xarelto\", \"ncpe_year\": 2018, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2487, \"last_scrape\": \"2018-12-13T16:48:25\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-low-dose-for-prevention-of-recurrent-venous-thromboembolism/\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2488, \"last_scrape\": \"2018-12-13T16:48:30\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban (Xarelto\", \"ncpe_year\": 2008, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2008-04-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2489, \"last_scrape\": \"2018-12-13T16:48:33\", \"url\": \"http://www.ncpe.ie/drugs/roflumilast-daxas/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Roflumilast (Daxas\", \"trade_name\": \"Daxas\", \"indication\": \"Cost Effectiveness of Roflumilast (Daxas\", \"ncpe_year\": 2010, \"eu_market\": \"2010-07-05T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-11T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/daxas\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2490, \"last_scrape\": \"2018-12-13T16:48:40\", \"url\": \"http://www.ncpe.ie/drugs/rolapitant-varuby/\", \"rr_start\": \"2017-05-15T00:00:00\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-05-15, 2017-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Rolapitant (Varuby\", \"trade_name\": \"Varuby\", \"indication\": \"Rolapitant (Varuby\", \"ncpe_year\": 2017, \"eu_market\": \"2017-04-19T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 0, \"earliest\": \"2017-05-15T00:00:00\", \"latest\": \"2017-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/varuby\", \"ta_list\": \"Vomiting; Nausea; Cancer\", \"rr_status\": \"No HTA\"}, {\"id\": 2491, \"last_scrape\": \"2018-12-13T16:48:43\", \"url\": \"http://www.ncpe.ie/drugs/romiplostim-nplate/\", \"rr_start\": \"\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Romiplostim (Nplate\", \"trade_name\": \"Nplate\", \"indication\": \"Romiplostim (Nplate\", \"ncpe_year\": 2015, \"eu_market\": \"2009-02-04T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-04-02T00:00:00\", \"latest\": \"2015-05-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nplate\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2492, \"last_scrape\": \"2018-12-13T16:48:47\", \"url\": \"http://www.ncpe.ie/drugs/ropivacaine-readyfusor/\", \"rr_start\": \"2018-11-09T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"FULL HTA IS NOT RECOMMENDED. THE NCPE RECOMMENDS THAT ROPIVICAINE READYFUSOR NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE.  THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013.\", \"rr_dates\": \"2018-11-09, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ropivacaine Readyfusor\", \"trade_name\": \"Ropivacaine Readyfusor\", \"indication\": \"Ropivacaine Readyfusor for acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block (CPNB) via a continuous infusion.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-09T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"id\": 2493, \"last_scrape\": \"2018-12-13T16:48:50\", \"url\": \"http://www.ncpe.ie/drugs/ruxolitinib-jakavi-for-polycythaemia-vera/\", \"rr_start\": \"2015-04-15T00:00:00\", \"rr_end\": \"2015-05-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-04-15, 2015-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib (Jakavi\", \"trade_name\": \"Jakavi\", \"indication\": \"Jakavi\", \"ncpe_year\": 2016, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2015-04-15T00:00:00\", \"latest\": \"2016-08-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2494, \"last_scrape\": \"2018-12-13T16:48:55\", \"url\": \"http://www.ncpe.ie/drugs/ruxolitinib-jakavi/\", \"rr_start\": \"2012-08-01T00:00:00\", \"rr_end\": \"2012-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-08-01, 2012-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib (Jakavi\", \"trade_name\": \"Jakavi\", \"indication\": \"Ruxolitinib (Jakavi\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2012-08-01T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2495, \"last_scrape\": \"2018-12-13T16:48:58\", \"url\": \"http://www.ncpe.ie/drugs/sacubitrilvalsartan-entresto/\", \"rr_start\": \"2015-11-06T00:00:00\", \"rr_end\": \"2015-11-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-06, 2015-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Sacubitril/valsartan (Entresto\", \"trade_name\": \"Entresto\", \"indication\": \"Entresto\", \"ncpe_year\": 2017, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-06T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entresto\", \"ta_list\": \"Heart Failure\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2496, \"last_scrape\": \"2018-12-13T16:49:04\", \"url\": \"http://www.ncpe.ie/drugs/safinamide-methansulfonate-xadago/\", \"rr_start\": \"2016-06-14T00:00:00\", \"rr_end\": \"2016-07-06T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED.\", \"rr_dates\": \"2016-06-14, 2016-07-06\", \"rr_multiple\": 0, \"drug_name\": \"Safinamide methansulfonate (Xadago\", \"trade_name\": \"Xadago\", \"indication\": \"Xadago\", \"ncpe_year\": 2016, \"eu_market\": \"2015-02-23T00:00:00\", \"company\": \"Zambon\", \"orphan\": 0, \"earliest\": \"2016-06-14T00:00:00\", \"latest\": \"2016-07-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xadago\", \"ta_list\": \"Parkinson Disease\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2497, \"last_scrape\": \"2018-12-13T16:49:07\", \"url\": \"http://www.ncpe.ie/drugs/sapropterin-kuvan/\", \"rr_start\": \"2015-07-14T00:00:00\", \"rr_end\": \"2015-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-07-14, 2015-08-14, 2015-07-01\", \"rr_multiple\": 1, \"drug_name\": \"Sapropterin (Kuvan\", \"trade_name\": \"Kuvan\", \"indication\": \"Sapropterin (Kuvan\", \"ncpe_year\": 2017, \"eu_market\": \"2008-12-02T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2009-01-01T00:00:00\", \"latest\": \"2017-09-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kuvan\", \"ta_list\": \"Phenylketonurias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2498, \"last_scrape\": \"2018-12-13T16:49:11\", \"url\": \"http://www.ncpe.ie/drugs/sarilumab-kevzara/\", \"rr_start\": \"2017-08-18T00:00:00\", \"rr_end\": \"2017-10-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-08-18, 2017-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Sarilumab (Kevzara\", \"trade_name\": \"Kevzara\", \"indication\": \"Sarilumab (Kevzara\", \"ncpe_year\": 2017, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-08-18T00:00:00\", \"latest\": \"2017-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2499, \"last_scrape\": \"2018-12-13T16:49:16\", \"url\": \"http://www.ncpe.ie/drugs/sebelipase-alfa-kanuma/\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-02-08, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Sebelipase alfa (Kanuma\", \"trade_name\": \"Kanuma\", \"indication\": \"Sebelipase alfa is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2018-06-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kanuma\", \"ta_list\": \"Lipid Metabolism, Inborn Errors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2500, \"last_scrape\": \"2018-12-13T16:49:20\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-ankylosing-spondylitis/\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-02, 2015-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"id\": 2501, \"last_scrape\": \"2018-12-13T16:49:25\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-psoriatic-arthritis/\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-02, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"id\": 2502, \"last_scrape\": \"2018-12-13T16:49:31\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx/\", \"rr_start\": \"2014-12-19T00:00:00\", \"rr_end\": \"2015-02-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-19, 2015-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-12-19T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2503, \"last_scrape\": \"2018-12-13T16:49:34\", \"url\": \"http://www.ncpe.ie/drugs/selexipag-uptravi/\", \"rr_start\": \"2016-11-01T00:00:00\", \"rr_end\": \"2016-12-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-01, 2016-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Selexipag (Uptravi\", \"trade_name\": \"Uptravi\", \"indication\": \"Selexipag (Uptravi\", \"ncpe_year\": 2018, \"eu_market\": \"2016-05-12T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2016-11-01T00:00:00\", \"latest\": \"2018-05-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2504, \"last_scrape\": \"2018-12-13T16:49:39\", \"url\": \"http://www.ncpe.ie/drugs/semaglutide-ozempic/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-03-12, 2018-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Semaglutide (Ozempic\", \"trade_name\": \"Ozempic\", \"indication\": \"Semaglutide (Ozempic\", \"ncpe_year\": 2018, \"eu_market\": \"2018-02-08T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-04-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2505, \"last_scrape\": \"2018-12-13T16:49:44\", \"url\": \"http://www.ncpe.ie/drugs/sildenafil-revatio/\", \"rr_start\": \"2014-04-16T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-04-16, 2014-05-23\", \"rr_multiple\": 0, \"drug_name\": \"Sildenafil (Revatio\", \"trade_name\": \"Revatio\", \"indication\": \"Sildenafil (Revatio\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2014-04-16T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revatio\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2506, \"last_scrape\": \"2018-12-13T16:49:49\", \"url\": \"http://www.ncpe.ie/drugs/simeprevir-olysio-in-combination-with-sofosbuvir/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir (Olysio\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir (Olysio\", \"ncpe_year\": 2015, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2015-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olysio\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2507, \"last_scrape\": \"2018-12-13T16:49:53\", \"url\": \"http://www.ncpe.ie/drugs/simeprevir-olysio/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED WHEN USED IN TRIPLE THERAPY WITH PEG-INTERFERON AND RIBAVIRIN.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir (Olysio\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir (Olysio\", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2014-07-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olysio\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2508, \"last_scrape\": \"2018-12-13T16:50:00\", \"url\": \"http://www.ncpe.ie/drugs/sodium-chloride-70mgml-sodium-hyaluronate-1mgml-hyaneb/\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-10, 2014-03-19\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml (Hyaneb\", \"trade_name\": \"Hyaneb\", \"indication\": \"Hyaneb\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2509, \"last_scrape\": \"2018-12-13T16:50:06\", \"url\": \"http://www.ncpe.ie/drugs/sodium-hyaluronate-hyloforte-0-2/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate (Hyloforte\", \"trade_name\": \"Hyloforte 0.2%\", \"indication\": \"Sodium Hyaluronate (Hyloforte\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2510, \"last_scrape\": \"2018-12-13T16:50:09\", \"url\": \"http://www.ncpe.ie/drugs/sodium-hyaluronate-hylotear-0-1/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate (Hylotear\", \"trade_name\": \"Hylotear 0.1%\", \"indication\": \"Sodium Hyaluronate (Hylotear\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2511, \"last_scrape\": \"2018-12-13T16:50:15\", \"url\": \"http://www.ncpe.ie/drugs/sodium-phenylbutyrate-pheburane/\", \"rr_start\": \"2013-07-17T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-17, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Sodium phenylbutyrate (Pheburane\", \"trade_name\": \"Pheburane\", \"indication\": \"Sodium phenylbutyrate (Pheburane\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-30T00:00:00\", \"company\": \"Lucane\", \"orphan\": 0, \"earliest\": \"2013-07-17T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pheburane\", \"ta_list\": \"Carbamoyl-Phosphate Synthase I Deficiency Disease\", \"rr_status\": \"No HTA\"}, {\"id\": 2512, \"last_scrape\": \"2018-12-13T16:50:18\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvir-solvaldi/\", \"rr_start\": \"2014-02-12T00:00:00\", \"rr_end\": \"2014-03-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-02-12, 2014-03-10\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir (Solvaldi\", \"trade_name\": \"Solvaldi\", \"indication\": \"Sofosbuvir (Solvaldi\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-02-12T00:00:00\", \"latest\": \"2014-10-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2513, \"last_scrape\": \"2018-12-13T16:50:22\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvirvelpatasvir-epclusa-chronic-hepatitis-c-virus-hcv-pangenotypic/\", \"rr_start\": \"2017-09-05T00:00:00\", \"rr_end\": \"2017-10-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-05, 2017-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir (Epclusa\", \"trade_name\": \"Epclusa\", \"indication\": \"Sofosbuvir/velpatasvir (Epclusa\", \"ncpe_year\": 2017, \"eu_market\": \"2016-07-06T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-05T00:00:00\", \"latest\": \"2017-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2514, \"last_scrape\": \"2018-12-13T16:50:26\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvirvelpatasvirvoxilaprevir-vosevi/\", \"rr_start\": \"2017-09-19T00:00:00\", \"rr_end\": \"2017-11-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-19, 2017-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi\", \"trade_name\": \"Vosevi\", \"indication\": \"Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-19T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vosevi\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2515, \"last_scrape\": \"2018-12-13T16:50:32\", \"url\": \"http://www.ncpe.ie/drugs/st-johns-wort-pafica/\", \"rr_start\": \"2015-04-14T00:00:00\", \"rr_end\": \"2015-05-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-04-14, 2015-05-29\", \"rr_multiple\": 0, \"drug_name\": \"St Johns Wort (Pacifa\", \"trade_name\": \"Pacifa\", \"indication\": \"Pacifa\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-04-14T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2516, \"last_scrape\": \"2018-12-13T16:50:38\", \"url\": \"http://www.ncpe.ie/drugs/stiripentol-diacomit/\", \"rr_start\": \"2017-07-06T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-06, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Stiripentol (Diacomit\", \"trade_name\": \"Diacomit\", \"indication\": \"Stiripentol (Diacomit\", \"ncpe_year\": 2018, \"eu_market\": \"2007-01-03T00:00:00\", \"company\": \"Biocodex\", \"orphan\": 1, \"earliest\": \"2017-07-06T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/diacomit\", \"ta_list\": \"Myoclonic Epilepsy, Juvenile\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2517, \"last_scrape\": \"2018-12-13T16:50:43\", \"url\": \"http://www.ncpe.ie/drugs/stribild-elvitegravircobicistatemtricitabinetenofovir-disoproxil-as-fumarate/\", \"rr_start\": \"2013-04-28T00:00:00\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-04-28, 2013-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumarate)(Stribild\", \"trade_name\": \"Stribild\", \"indication\": \"Indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-na\", \"ncpe_year\": 2013, \"eu_market\": \"2013-05-24T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2013-04-28T00:00:00\", \"latest\": \"2013-12-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stribild\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2518, \"last_scrape\": \"2018-12-13T16:50:49\", \"url\": \"http://www.ncpe.ie/drugs/sublingual-immunotherapy-grazax/\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sublingual Immunotherapy (Grazax\", \"trade_name\": \"Grazax\", \"indication\": \"A Review of the Cost-Effectiveness of Sublingual Immunotherapy (Grazax\", \"ncpe_year\": 2007, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2007-09-01T00:00:00\", \"latest\": \"2007-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2519, \"last_scrape\": \"2018-12-13T16:50:50\", \"url\": \"http://www.ncpe.ie/drugs/suboxone-buprenorphinenaloxone/\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Buprenorphine/naloxone (Suboxone\", \"trade_name\": \"Suboxone\", \"indication\": \"An economic evaluation of suboxone for the management of opiate addiction.\", \"ncpe_year\": 2014, \"eu_market\": \"2006-09-26T00:00:00\", \"company\": \"Indivior\", \"orphan\": 0, \"earliest\": \"2007-11-01T00:00:00\", \"latest\": \"2014-05-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/suboxone\", \"ta_list\": \"Opioid-Related Disorders\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2520, \"last_scrape\": \"2018-12-13T16:50:54\", \"url\": \"http://www.ncpe.ie/drugs/sufentanil-zalviso/\", \"rr_start\": \"2016-03-14T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-03-14, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Sufentanil (Zalviso\", \"trade_name\": \"Zalviso\", \"indication\": \"Sufentanil (Zalviso\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Gr\", \"orphan\": 0, \"earliest\": \"2016-03-14T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zalviso\", \"ta_list\": \"Pain, Postoperative\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2521, \"last_scrape\": \"2018-12-13T16:50:59\", \"url\": \"http://www.ncpe.ie/drugs/sunitinib-sutent/\", \"rr_start\": \"\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sunitinib (Sutent\", \"trade_name\": \"Sutent\", \"indication\": \"In September 2006, Pfizer Healthcare Ireland submitted an evaluation of the cost-effectiveness and budget impact of sunitinib as second-line treatment of patients with gastro-intestinal stromal tumours (GIST). Data on the cost-effectiveness and budget impact of sutinitinib as second line treatment for patients with metastatic renal cell carcinoma (mRCC) was also presented. The purpose of the submission was to support an application for reimbursement under the High Tech Drug Scheme. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-07-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-09-01T00:00:00\", \"latest\": \"2006-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sutent\", \"ta_list\": \"Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2522, \"last_scrape\": \"2018-12-13T16:51:04\", \"url\": \"http://www.ncpe.ie/drugs/tadalafil-adcirca-2/\", \"rr_start\": \"2011-07-13T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-07-13, 2011-09-21, 2014-05-09, 2014-05-23\", \"rr_multiple\": 1, \"drug_name\": \"Tadalafil (Adcirca\", \"trade_name\": \"Adcirca\", \"indication\": \"Tadalafil (Adcirca\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-07-13T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2523, \"last_scrape\": \"2018-12-13T16:51:09\", \"url\": \"http://www.ncpe.ie/drugs/tafamadis-meglumine-vyndaqel/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED UNTIL ADDITIONAL EFFICACY AND/OR SAFETY DATA IS SUBMITTED. ON THE BASIS OF CURRENT EVIDENCE, THE NCPE RECOMMENDS THAT TAFAMIDIS NOT BE CONSIDERED FOR REIMBURSEMENT IN ACCORDANCE WITH THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Tafamadis meglumine (Vyndaqel\", \"trade_name\": \"Vyndaqel\", \"indication\": \"Tafamadis meglumine (Vyndaqel\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-16T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel\", \"ta_list\": \"Amyloidosis\", \"rr_status\": \"No HTA until more evidence\"}, {\"id\": 2524, \"last_scrape\": \"2018-12-13T16:51:15\", \"url\": \"http://www.ncpe.ie/drugs/tafluprost-saflutan/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Tafluprost (Saflutan\", \"trade_name\": \"Saflutan\", \"indication\": \"Tafluoprost (Salflutan\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2525, \"last_scrape\": \"2018-12-13T16:51:24\", \"url\": \"http://www.ncpe.ie/drugs/talimogene-laherparepvec-imlygic/\", \"rr_start\": \"2016-02-16T00:00:00\", \"rr_end\": \"2016-03-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-02-16, 2016-03-14\", \"rr_multiple\": 0, \"drug_name\": \"Talimogene Laherparepvec (Imlygic\", \"trade_name\": \"Imlygic\", \"indication\": \"Talimogene laherparepvec (Imlygic\", \"ncpe_year\": 2016, \"eu_market\": \"2015-12-16T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-02-16T00:00:00\", \"latest\": \"2016-03-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2526, \"last_scrape\": \"2018-12-13T16:51:28\", \"url\": \"http://www.ncpe.ie/drugs/tapentadol-palexia/\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Tapentadol (Palexia\", \"trade_name\": \"Palexia\", \"indication\": \"Economic evaluation of oral tapentadol (Palexia\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2011-04-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2527, \"last_scrape\": \"2018-12-13T16:51:34\", \"url\": \"http://www.ncpe.ie/drugs/tedizolid-phosphate-sivextro/\", \"rr_start\": \"2015-05-07T00:00:00\", \"rr_end\": \"2015-07-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-05-07, 2015-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Tedizolid phosphate (Sivextro\", \"trade_name\": \"Sivextro\", \"indication\": \"Tedizolid phosphate (Sivextro\", \"ncpe_year\": 2015, \"eu_market\": \"2015-03-23T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-05-07T00:00:00\", \"latest\": \"2015-07-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sivextro\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"No HTA\"}, {\"id\": 2528, \"last_scrape\": \"2018-12-13T16:51:38\", \"url\": \"http://www.ncpe.ie/drugs/teduglutide-revestive/\", \"rr_start\": \"2017-03-13T00:00:00\", \"rr_end\": \"2017-04-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-13, 2017-04-12\", \"rr_multiple\": 0, \"drug_name\": \"Teduglutide (Revestive\", \"trade_name\": \"Revestive\", \"indication\": \"Teduglutide (Revestive\", \"ncpe_year\": 2018, \"eu_market\": \"2012-08-30T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2017-03-13T00:00:00\", \"latest\": \"2018-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revestive\", \"ta_list\": \"Malabsorption Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2529, \"last_scrape\": \"2018-12-13T16:51:44\", \"url\": \"http://www.ncpe.ie/drugs/tegafurgimeraciloteracil-teysuno/\", \"rr_start\": \"2012-02-27T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-02-27, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Tegafur/Gimeracil/Oteracil (Teysuno\", \"trade_name\": \"Teysuno\", \"indication\": \"Teysuno is indicated in adults for the treatment of advanced gastric cancer.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-03-14T00:00:00\", \"company\": \"Nordic\", \"orphan\": 0, \"earliest\": \"2012-02-27T00:00:00\", \"latest\": \"2012-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2530, \"last_scrape\": \"2018-12-13T16:51:48\", \"url\": \"http://www.ncpe.ie/drugs/telapravir/\", \"rr_start\": \"2011-10-28T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-10-28, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Telaprevir (Incivo\", \"trade_name\": \"Incivo\", \"indication\": \"Economic evaluation of Telaprevir (Incivo\", \"ncpe_year\": 2012, \"eu_market\": \"2011-09-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-28T00:00:00\", \"latest\": \"2012-01-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/incivo\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2531, \"last_scrape\": \"2018-12-13T16:51:52\", \"url\": \"http://www.ncpe.ie/drugs/telavancin-vibativ/\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-12-08, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Telavancin (Vibativ\", \"trade_name\": \"Vibativ\", \"indication\": \"Indicated for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumomia, known or suspended to be caused by methicillin-resistant Staphylococcus aureas (MRSA).  Vabitiv\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Theravance\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2015-01-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vibativ-0\", \"ta_list\": \"Pneumonia, Bacterial; Cross Infection\", \"rr_status\": \"No HTA\"}, {\"id\": 2532, \"last_scrape\": \"2018-12-13T16:51:56\", \"url\": \"http://www.ncpe.ie/drugs/teriflunomide-aubagio/\", \"rr_start\": \"2013-08-27T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-08-27, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Teriflunomide (Aubagio\", \"trade_name\": \"Aubagio\", \"indication\": \"Aubagio\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2013-08-27T00:00:00\", \"latest\": \"2014-09-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2533, \"last_scrape\": \"2018-12-13T16:51:58\", \"url\": \"http://www.ncpe.ie/drugs/ticagrelor-brilique-2/\", \"rr_start\": \"2016-02-29T00:00:00\", \"rr_end\": \"2016-05-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-29, 2016-05-04\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor (Brilique\", \"trade_name\": \"Brilique\", \"indication\": \"Ticagrelor (Brilique\", \"ncpe_year\": 2016, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-29T00:00:00\", \"latest\": \"2016-05-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brilique\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2534, \"last_scrape\": \"2018-12-13T16:52:01\", \"url\": \"http://www.ncpe.ie/drugs/ticagrelor-brilique/\", \"rr_start\": \"2010-11-25T00:00:00\", \"rr_end\": \"2011-01-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-11-25, 2011-01-20\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor (Brilique\", \"trade_name\": \"Brilique\", \"indication\": \"Economic Evaluation of Ticagrelor (Brilique\", \"ncpe_year\": 2011, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-11-25T00:00:00\", \"latest\": \"2011-10-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brilique\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2535, \"last_scrape\": \"2018-12-13T16:52:07\", \"url\": \"http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-all/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-19T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TISAGENLECLEUCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel (Kymriah\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel (Kymriah\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2536, \"last_scrape\": \"2018-12-13T16:52:13\", \"url\": \"http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-dlbcl/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TISAGENLECLEUCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel (Kymriah\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel (Kymriah\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2537, \"last_scrape\": \"2018-12-13T16:52:19\", \"url\": \"http://www.ncpe.ie/drugs/tobramycin-tobi-podhaler/\", \"rr_start\": \"2010-11-10T00:00:00\", \"rr_end\": \"2010-11-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2010-11-10, 2010-11-03\", \"rr_multiple\": 0, \"drug_name\": \"Tobramycin (TOBI Podhaler\", \"trade_name\": \"TOBI Podhaler\", \"indication\": \"Tobramycin (TOBI Podhaler\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-11-01T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2538, \"last_scrape\": \"2018-12-13T16:52:24\", \"url\": \"http://www.ncpe.ie/drugs/tocilizumab-sc-roactemra/\", \"rr_start\": \"2014-04-28T00:00:00\", \"rr_end\": \"2014-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THESUBMITTED PRICE.\", \"rr_dates\": \"2014-04-28, 2014-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Tocilizumab SC (RoActemra\", \"trade_name\": \"RoActemra\", \"indication\": \"It is licensed for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.  It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-04-28T00:00:00\", \"latest\": \"2014-07-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra\", \"ta_list\": \"Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2539, \"last_scrape\": \"2018-12-13T16:52:30\", \"url\": \"http://www.ncpe.ie/drugs/tofacitinib-xeljanz-for-ulcerative-colitis/\", \"rr_start\": \"2018-07-16T00:00:00\", \"rr_end\": \"2018-09-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TOFACITINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-07-16, 2018-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib (Xeljanz\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy (i.e. corticosteroids, azathioprine, 6-mercaptopurine) or a biologic agent (i.e. TNF inhibitor).\", \"ncpe_year\": 2018, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2018-07-16T00:00:00\", \"latest\": \"2018-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2540, \"last_scrape\": \"2018-12-13T16:52:35\", \"url\": \"http://www.ncpe.ie/drugs/tofacitinib-xeljanz/\", \"rr_start\": \"2017-03-08T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-08, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib (Xeljanz\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib (Xeljanz\", \"ncpe_year\": 2017, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-03-08T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2541, \"last_scrape\": \"2018-12-13T16:52:40\", \"url\": \"http://www.ncpe.ie/drugs/tolvaptan-jinarc/\", \"rr_start\": \"2016-01-04T00:00:00\", \"rr_end\": \"2016-01-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-04, 2016-01-12\", \"rr_multiple\": 0, \"drug_name\": \"Tolvaptan (Jinarc\", \"trade_name\": \"Jinarc\", \"indication\": \"Jinarc\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2016-01-04T00:00:00\", \"latest\": \"2018-09-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc\", \"ta_list\": \"Polycystic Kidney, Autosomal Dominant\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2542, \"last_scrape\": \"2018-12-13T16:52:45\", \"url\": \"http://www.ncpe.ie/drugs/tramadol-hydrochloridedexketoprofen-skudexa/\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"REIMURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-10-17, 2017-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Tramadol hydrochloride/dexketoprofen (Skudexa\", \"trade_name\": \"Skudexa\", \"indication\": \"Tramadol hydrochloride/dexketoprofen (Skudexa \", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2017-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2543, \"last_scrape\": \"2018-12-13T16:52:51\", \"url\": \"http://www.ncpe.ie/drugs/trametinib-mekinist/\", \"rr_start\": \"2015-11-27T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-27, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Trametinib (Mekinist\", \"trade_name\": \"Mekinist\", \"indication\": \"Mekinist\", \"ncpe_year\": 2018, \"eu_market\": \"2014-06-30T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-27T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2544, \"last_scrape\": \"2018-12-13T16:52:56\", \"url\": \"http://www.ncpe.ie/drugs/trastuzumab-emtansine-kadcyla/\", \"rr_start\": \"2013-09-25T00:00:00\", \"rr_end\": \"2013-10-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-25, 2013-10-24\", \"rr_multiple\": 0, \"drug_name\": \"Trastuzumab emtansine (Kadcyla\", \"trade_name\": \"Kadcyla\", \"indication\": \"Trastuzumab emtansine (Kadcyla\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-09-25T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2545, \"last_scrape\": \"2018-12-13T16:53:00\", \"url\": \"http://www.ncpe.ie/drugs/trifluridinetipiracil-lonsurf/\", \"rr_start\": \"2016-06-10T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-06-10, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Trifluridine/tipiracil (Lonsurf\", \"trade_name\": \"Lonsurf\", \"indication\": \"Trifluridine/tipiracil (Lonsurf\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2016-06-10T00:00:00\", \"latest\": \"2016-07-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2546, \"last_scrape\": \"2018-12-13T16:53:04\", \"url\": \"http://www.ncpe.ie/drugs/ulipristal-acetate-esmya-2/\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-05-17, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate (Esmya \", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate is indicated for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-05-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esmya\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2547, \"last_scrape\": \"2018-12-13T16:53:08\", \"url\": \"http://www.ncpe.ie/drugs/ulipristal-acetate-esmya/\", \"rr_start\": \"2013-09-03T00:00:00\", \"rr_end\": \"2013-10-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-09-03, 2013-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate (Esmya\", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate (Esmya\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2013-09-03T00:00:00\", \"latest\": \"2013-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esmya\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2548, \"last_scrape\": \"2018-12-13T16:53:10\", \"url\": \"http://www.ncpe.ie/drugs/umeclidiniumvilanterol-anoro/\", \"rr_start\": \"2014-06-11T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-06-11, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Umeclidinium/vilanterol (Anoro\", \"trade_name\": \"Anoro\", \"indication\": \"Umeclidinium/vilanterol (Anoro\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-06-11T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2549, \"last_scrape\": \"2018-12-13T16:53:12\", \"url\": \"http://www.ncpe.ie/drugs/urea-glucorx-allpresan/\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT GLUCORX ALLPRESAN DIABETIC FOAM CREAM NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE IN ACCORDANCE WITH THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2018-07-09, 2018-07-24\", \"rr_multiple\": 0, \"drug_name\": \"Urea (GlucoRx Allpresan\", \"trade_name\": \"GlucoRx Allpresan\", \"indication\": \"GlucoRx Allpresan\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-07-24T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2550, \"last_scrape\": \"2018-12-13T16:53:17\", \"url\": \"http://www.ncpe.ie/drugs/ustekinumab-stelara-2/\", \"rr_start\": \"2016-11-28T00:00:00\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-11-28, 2017-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab (Stelara\", \"trade_name\": \"Stelara\", \"indication\": \"Ustekinumab is indicated for the treatment of adult patients with moderately to severely active Crohn\", \"ncpe_year\": 2017, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2016-11-28T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stelara\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2551, \"last_scrape\": \"2018-12-13T16:53:23\", \"url\": \"http://www.ncpe.ie/drugs/ustekinumab-stelara/\", \"rr_start\": \"\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab (Stelara\", \"trade_name\": \"Stelara\", \"indication\": \"Cost-effectiveness of Ustekinumab (Stelara\", \"ncpe_year\": 2009, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2009-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stelara\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2552, \"last_scrape\": \"2018-12-13T16:53:29\", \"url\": \"http://www.ncpe.ie/drugs/vandetanib-caprelsa/\", \"rr_start\": \"2013-06-06T00:00:00\", \"rr_end\": \"2013-07-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-06, 2013-07-03\", \"rr_multiple\": 0, \"drug_name\": \"Vandetanib (Caprelsa\", \"trade_name\": \"Caprelsa\", \"indication\": \"Vandetanib (Caprelsa\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-16T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2013-06-06T00:00:00\", \"latest\": \"2013-07-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2553, \"last_scrape\": \"2018-12-13T16:53:32\", \"url\": \"http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-crohns-disease/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab (Entyvio\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab (Entyvio\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2554, \"last_scrape\": \"2018-12-13T16:53:39\", \"url\": \"http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-ulcerative-colitis/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab (Entyvio\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab (Entyvio\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2555, \"last_scrape\": \"2018-12-13T16:53:45\", \"url\": \"http://www.ncpe.ie/drugs/velaglucerase-alfa-vpriv-2/\", \"rr_start\": \"2011-04-26T00:00:00\", \"rr_end\": \"2011-06-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-04-26, 2011-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Velaglucerase Alfa (VPRIV\", \"trade_name\": \"VPRIV\", \"indication\": \"VPRIV is indicated for long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-04-26T00:00:00\", \"latest\": \"2011-06-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2556, \"last_scrape\": \"2018-12-13T16:53:49\", \"url\": \"http://www.ncpe.ie/drugs/venetoclax-venclyxto-in-combination-with-rituximab/\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF VENETOCLAX COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-26, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax (Venclyxto\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax (Venclyxto\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2557, \"last_scrape\": \"2018-12-13T16:53:52\", \"url\": \"http://www.ncpe.ie/drugs/venetoclax-venclyxto/\", \"rr_start\": \"2018-05-08T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"FOLLOWING A RESUBMISSION OF THE RAPID REVIEW A FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, WHICH IS NOT COMPARABLE WITH CURRENT AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-05-08, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax (Venclyxto\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL)\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2558, \"last_scrape\": \"2018-12-13T16:53:58\", \"url\": \"http://www.ncpe.ie/drugs/vermurafenib-zelboraf/\", \"rr_start\": \"2011-12-23T00:00:00\", \"rr_end\": \"2012-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-12-23, 2012-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Vemurafenib (Zelboraf\", \"trade_name\": \"Zelboraf\", \"indication\": \"Vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\", \"ncpe_year\": 2014, \"eu_market\": \"2012-02-17T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2011-12-23T00:00:00\", \"latest\": \"2014-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2559, \"last_scrape\": \"2018-12-13T16:54:00\", \"url\": \"http://www.ncpe.ie/drugs/vernakalant-brinavess/\", \"rr_start\": \"2010-10-26T00:00:00\", \"rr_end\": \"2010-11-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-10-26, 2010-11-04\", \"rr_multiple\": 0, \"drug_name\": \"Vernakalant (Brinavess\", \"trade_name\": \"Brinavess\", \"indication\": \"Economic evaluation of Vernakalant (Brinavess\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Cardiome\", \"orphan\": 0, \"earliest\": \"2010-10-26T00:00:00\", \"latest\": \"2011-05-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2560, \"last_scrape\": \"2018-12-13T16:54:04\", \"url\": \"http://www.ncpe.ie/drugs/vismodegib-erivedge/\", \"rr_start\": \"2013-05-02T00:00:00\", \"rr_end\": \"2013-05-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-05-02, 2013-05-20\", \"rr_multiple\": 0, \"drug_name\": \"Vismodegib (Erivedge\", \"trade_name\": \"Erivedge\", \"indication\": \"Vismodegib (Erivedge\", \"ncpe_year\": 2017, \"eu_market\": \"2013-07-12T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-05-02T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge\", \"ta_list\": \"Carcinoma, Basal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2561, \"last_scrape\": \"2018-12-13T16:54:11\", \"url\": \"http://www.ncpe.ie/drugs/vortioxetine-brintellix/\", \"rr_start\": \"2014-10-01T00:00:00\", \"rr_end\": \"2014-11-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-10-01, 2014-11-14\", \"rr_multiple\": 0, \"drug_name\": \"Vortioxetine (Brintellix\", \"trade_name\": \"Brintellix\", \"indication\": \"Vortioxetine (Brintellix\", \"ncpe_year\": 2017, \"eu_market\": \"2013-12-18T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2014-10-01T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"HTA recommended at submitted price\"}]}};\n",
       "var opt = {};\n",
       "var type = \"vega-lite\";\n",
       "var id = \"739baab1-3235-468a-8f95-a9ffd5e3ab3e\";\n",
       "\n",
       "var output_area = this;\n",
       "\n",
       "require([\"nbextensions/jupyter-vega/index\"], function(vega) {\n",
       "  var target = document.createElement(\"div\");\n",
       "  target.id = id;\n",
       "  target.className = \"vega-embed\";\n",
       "\n",
       "  var style = document.createElement(\"style\");\n",
       "  style.textContent = [\n",
       "    \".vega-embed .error p {\",\n",
       "    \"  color: firebrick;\",\n",
       "    \"  font-size: 14px;\",\n",
       "    \"}\",\n",
       "  ].join(\"\\\\n\");\n",
       "\n",
       "  // element is a jQuery wrapped DOM element inside the output area\n",
       "  // see http://ipython.readthedocs.io/en/stable/api/generated/\\\n",
       "  // IPython.display.html#IPython.display.Javascript.__init__\n",
       "  element[0].appendChild(target);\n",
       "  element[0].appendChild(style);\n",
       "\n",
       "  vega.render(\"#\" + id, spec, type, opt, output_area);\n",
       "}, function (err) {\n",
       "  if (err.requireType !== \"scripterror\") {\n",
       "    throw(err);\n",
       "  }\n",
       "});\n"
      ],
      "text/plain": [
       "<vega.vegalite.VegaLite at 0x2458213d278>"
      ]
     },
     "metadata": {
      "jupyter-vega": "#739baab1-3235-468a-8f95-a9ffd5e3ab3e"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": []
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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"
     },
     "metadata": {
      "jupyter-vega": "#739baab1-3235-468a-8f95-a9ffd5e3ab3e"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "alt.Chart(drugs,title=\"Count of Drugs By Company\").mark_bar(color='lightblue').encode(\n",
    "    alt.X('company', sort=alt.EncodingSortField(field=\"company\", op=\"count\", order='descending'),\n",
    "          axis=alt.Axis(title='Drug Company')),\n",
    "    alt.Y('count(rr_status)',\n",
    "          axis=alt.Axis(title='Number of Drugs'))).properties(width=4000,height=300)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Same chart with axes changed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "var spec = {\"config\": {\"view\": {\"width\": 400, \"height\": 300}}, \"data\": {\"name\": \"data-1fb11c1b30e9c74b6a5173f2568cb7ab\"}, \"mark\": {\"type\": \"bar\", \"color\": \"lightblue\"}, \"encoding\": {\"x\": {\"type\": \"nominal\", \"aggregate\": \"count\", \"axis\": {\"title\": \"Records\"}, \"field\": \"rr_status\"}, \"y\": {\"type\": \"nominal\", \"axis\": {\"title\": \"Drug Company\"}, \"field\": \"company\", \"sort\": {\"op\": \"count\", \"field\": \"company\", \"order\": \"descending\"}}}, \"height\": 3000, \"title\": \"Count Drugs By Company\", \"width\": 700, \"$schema\": \"https://vega.github.io/schema/vega-lite/v2.6.0.json\", \"datasets\": {\"data-1fb11c1b30e9c74b6a5173f2568cb7ab\": [{\"id\": 2164, \"last_scrape\": \"2018-12-13T16:24:32\", \"url\": \"http://www.ncpe.ie/drugs/abatacept-orencia/\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Abatacept (Orencia\", \"trade_name\": \"Orencia\", \"indication\": \"Subcutaneous Abatacept (Orencia\", \"ncpe_year\": 2015, \"eu_market\": \"2007-05-21T00:00:00\", \"company\": \"\", \"orphan\": 0, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/orencia\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2165, \"last_scrape\": \"2018-12-13T16:24:36\", \"url\": \"http://www.ncpe.ie/drugs/abiraterone-acetate-zytiga-for-mhspc/\", \"rr_start\": \"2018-10-03T00:00:00\", \"rr_end\": \"2018-11-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-10-03, 2018-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Abiraterone acetate (Zytiga\", \"ncpe_year\": 2018, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2018-10-03T00:00:00\", \"latest\": \"2018-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2166, \"last_scrape\": \"2018-12-13T16:24:41\", \"url\": \"http://www.ncpe.ie/drugs/abiratone-acetate-zytiga-for-mcrpc-post-adt/\", \"rr_start\": \"2013-01-03T00:00:00\", \"rr_end\": \"2013-02-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-01-03, 2013-02-01\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation of Abiratone acetate (Zytiga\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-01-03T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2167, \"last_scrape\": \"2018-12-13T16:24:46\", \"url\": \"http://www.ncpe.ie/drugs/abiratone-acetate-zytiga/\", \"rr_start\": \"2011-10-21T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-10-21, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone Acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation and resource implications of Zytiga \", \"ncpe_year\": 2014, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-21T00:00:00\", \"latest\": \"2014-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2168, \"last_scrape\": \"2018-12-13T16:24:49\", \"url\": \"http://www.ncpe.ie/drugs/aceclofenac-vitafen/\", \"rr_start\": \"2016-12-21T00:00:00\", \"rr_end\": \"2017-01-24T00:00:00\", \"rr_outcome\": \"FOLLOWING A RESUBMISSION OF THE RAPID REVIEW A FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-12-21, 2017-01-24\", \"rr_multiple\": 0, \"drug_name\": \"Aceclofenac (Vitafen\", \"trade_name\": \"Vitafen\", \"indication\": \"Aceclofenac (Vitafen\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-07-22T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2169, \"last_scrape\": \"2018-12-13T16:24:56\", \"url\": \"http://www.ncpe.ie/drugs/aclidinium-bromide-eklira-genuair/\", \"rr_start\": \"2012-10-23T00:00:00\", \"rr_end\": \"2012-10-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-23, 2012-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide (Eklira Genuair\", \"trade_name\": \"Eklira Genuair\", \"indication\": \"Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)\", \"ncpe_year\": 2012, \"eu_market\": \"2012-07-20T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-23T00:00:00\", \"latest\": \"2012-10-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"id\": 2170, \"last_scrape\": \"2018-12-13T16:25:00\", \"url\": \"http://www.ncpe.ie/drugs/aclidinium-bromide-formoterol-fumarate-dihydrate-brimica-genuair/\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE.\", \"rr_dates\": \"2015-01-05, 2015-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide / formoterol fumarate dihydrate (Brimica\", \"trade_name\": \"Brimica Genuair\", \"indication\": \"Brimica\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2015-02-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brimica-genuair\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2171, \"last_scrape\": \"2018-12-13T16:25:37\", \"url\": \"http://www.ncpe.ie/drugs/adalimumab-humira/\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-20, 2011-06-02\", \"rr_multiple\": 0, \"drug_name\": \"Adalimumab (Humira\", \"trade_name\": \"Humira\", \"indication\": \"Economic evaluation of Adalimumab (Humira\", \"ncpe_year\": 2011, \"eu_market\": \"2003-09-07T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/humira\", \"ta_list\": \"Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"id\": 2172, \"last_scrape\": \"2018-12-13T16:25:40\", \"url\": \"http://www.ncpe.ie/drugs/adenuric-febuxostat/\", \"rr_start\": \"2009-12-08T00:00:00\", \"rr_end\": \"2009-12-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-12-08\", \"rr_multiple\": 0, \"drug_name\": \"Adenuric (Febuxostat\", \"trade_name\": \"Febuxostat\", \"indication\": \"NCPE review of Adenuric (Febuxostat\", \"ncpe_year\": 2009, \"eu_market\": \"2008-04-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2009-12-08T00:00:00\", \"latest\": \"2009-12-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adenuric\", \"ta_list\": \"Gout\", \"rr_status\": \"No HTA\"}, {\"id\": 2173, \"last_scrape\": \"2018-12-13T16:25:45\", \"url\": \"http://www.ncpe.ie/drugs/afatinib-giotrif/\", \"rr_start\": \"2013-10-01T00:00:00\", \"rr_end\": \"2013-10-13T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-10-01, 2013-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Afatinib (Giotrif\", \"trade_name\": \"Giotrif\", \"indication\": \"GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-na\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-25T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2013-10-01T00:00:00\", \"latest\": \"2013-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2174, \"last_scrape\": \"2018-12-13T16:25:49\", \"url\": \"http://www.ncpe.ie/drugs/aflibercept-eylea/\", \"rr_start\": \"2012-12-10T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-10, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept (Eylea\", \"trade_name\": \"Eylea\", \"indication\": \"Aflibercept (Eylea\", \"ncpe_year\": 2012, \"eu_market\": \"2012-11-21T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2012-12-10T00:00:00\", \"latest\": \"2012-12-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eylea\", \"ta_list\": \"Wet Macular Degeneration; Macular Edema; Diabetes Complications\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2175, \"last_scrape\": \"2018-12-13T16:25:52\", \"url\": \"http://www.ncpe.ie/drugs/aflibercept-zaltrap/\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept (Zaltrap\", \"trade_name\": \"Zaltrap\", \"indication\": \"Aflibercept for the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-01T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-02-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zaltrap\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2176, \"last_scrape\": \"2018-12-13T16:25:58\", \"url\": \"http://www.ncpe.ie/drugs/agomelatine-valdoxan-4/\", \"rr_start\": \"\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Agomelatine (Valdoxan\", \"trade_name\": \"Valdoxan\", \"indication\": \"Economic evaluation of Agomelatine (Valdoxan\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-19T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2009-09-03T00:00:00\", \"latest\": \"2009-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/valdoxan\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2177, \"last_scrape\": \"2018-12-13T16:26:06\", \"url\": \"http://www.ncpe.ie/drugs/alectinib-alecensa/\", \"rr_start\": \"2017-01-03T00:00:00\", \"rr_end\": \"2017-12-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-01-03, 2017-02-27, 2017-11-08, 2017-12-04\", \"rr_multiple\": 1, \"drug_name\": \"Alectinib (Alecensa\", \"trade_name\": \"Alecensa\", \"indication\": \"Alectinib (Alecensa \", \"ncpe_year\": 2018, \"eu_market\": \"2017-02-16T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2178, \"last_scrape\": \"2018-12-13T16:26:12\", \"url\": \"http://www.ncpe.ie/drugs/alemtuzumab-lemtrada/\", \"rr_start\": \"2013-11-08T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-11-08, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Alemtuzumab (Lemtrada\", \"trade_name\": \"Lemtrada\", \"indication\": \"Alemtuzumab (Lemtrada\", \"ncpe_year\": 2014, \"eu_market\": \"2013-09-12T00:00:00\", \"company\": \"Sanofi\", \"orphan\": 0, \"earliest\": \"2013-11-08T00:00:00\", \"latest\": \"2014-06-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2179, \"last_scrape\": \"2018-12-13T16:26:14\", \"url\": \"http://www.ncpe.ie/drugs/alirocumab-praluent/\", \"rr_start\": \"2015-10-13T00:00:00\", \"rr_end\": \"2015-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-10-13, 2015-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Alirocumab (Praluent\", \"trade_name\": \"Praluent\", \"indication\": \"Praluent\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2015-10-13T00:00:00\", \"latest\": \"2018-03-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/praluent\", \"ta_list\": \"Dyslipidemias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2180, \"last_scrape\": \"2018-12-13T16:26:16\", \"url\": \"http://www.ncpe.ie/drugs/alogliptin-vipidia/\", \"rr_start\": \"2013-09-27T00:00:00\", \"rr_end\": \"2013-10-30T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-09-27, 2013-10-30\", \"rr_multiple\": 0, \"drug_name\": \"Alogliptin (Vipidia\", \"trade_name\": \"Vipidia\", \"indication\": \"Alogliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-18T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2013-09-27T00:00:00\", \"latest\": \"2013-10-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vipidia\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2181, \"last_scrape\": \"2018-12-13T16:26:21\", \"url\": \"http://www.ncpe.ie/drugs/ambrisentan-volibris/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-05-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Ambrisentan (Volibris\", \"trade_name\": \"Volibris\", \"indication\": \"Cost Effectiveness of ambrisentan (Volibris\", \"ncpe_year\": 2014, \"eu_market\": \"2008-04-20T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 1, \"earliest\": \"2008-10-01T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/volibris\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2182, \"last_scrape\": \"2018-12-13T16:26:23\", \"url\": \"http://www.ncpe.ie/drugs/amifampridine-firdapse/\", \"rr_start\": \"2011-11-07T00:00:00\", \"rr_end\": \"2011-12-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-11-07, 2011-12-09\", \"rr_multiple\": 0, \"drug_name\": \"Amifampridine (Firdapse\", \"trade_name\": \"Firdapse\", \"indication\": \"For Lambert Eaton Myasthenic Syndrome (LEMS).  This high cost drug is likely to require a full HTA due to significant budget impact.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-11-07T00:00:00\", \"latest\": \"2011-12-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2183, \"last_scrape\": \"2018-12-13T16:26:29\", \"url\": \"http://www.ncpe.ie/drugs/amsacrine-amsidine/\", \"rr_start\": \"2017-01-10T00:00:00\", \"rr_end\": \"2017-02-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-01-10, 2017-02-15\", \"rr_multiple\": 0, \"drug_name\": \"Amsacrine (Amsidine\", \"trade_name\": \"Amsidine\", \"indication\": \"Amsidine\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2017-01-10T00:00:00\", \"latest\": \"2017-02-15T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2184, \"last_scrape\": \"2018-12-13T16:26:35\", \"url\": \"http://www.ncpe.ie/drugs/apixaban-eliquis-for-treatment-of-deep-vein-thrombosis-dvt-and-pulmonary-embolism-pe-and-prevention-of-recurrent-dvt-and-pe-in-adults/\", \"rr_start\": \"2014-07-29T00:00:00\", \"rr_end\": \"2014-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-07-29, 2014-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban (Eliquis\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban (Eliquis\", \"ncpe_year\": 2014, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-07-29T00:00:00\", \"latest\": \"2014-08-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2185, \"last_scrape\": \"2018-12-13T16:26:39\", \"url\": \"http://www.ncpe.ie/drugs/apixaban-eliquis/\", \"rr_start\": \"2011-10-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-10-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban (Eliquis\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban (Eliquis\", \"ncpe_year\": 2012, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-10-19T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2186, \"last_scrape\": \"2018-12-13T16:26:45\", \"url\": \"http://www.ncpe.ie/drugs/apremilast-otezla-for-moderate-to-severe-chronic-plaque-psoriasis/\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast (Otezla\", \"trade_name\": \"Otezla\", \"indication\": \"Indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to systemic non-biologic therapies including cyclosporine, methotrexate or psoralen and ultraviolet A light (PUVA).\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/otezla\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2187, \"last_scrape\": \"2018-12-13T16:26:47\", \"url\": \"http://www.ncpe.ie/drugs/apremilast-otezla-for-psoriatic-arthritis/\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast (Otezla\", \"trade_name\": \"Otezla\", \"indication\": \"Apremilist (Otezla\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/otezla\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2188, \"last_scrape\": \"2018-12-13T16:26:49\", \"url\": \"http://www.ncpe.ie/drugs/aripiprazole-abilify-maintena/\", \"rr_start\": \"2014-07-02T00:00:00\", \"rr_end\": \"2014-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-07-02, 2014-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Aripiprazole (Abilify Maintena\", \"trade_name\": \"Abilify Maintena\", \"indication\": \"Aripiprazole (Abilify Maintena\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-14T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2014-07-02T00:00:00\", \"latest\": \"2014-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2189, \"last_scrape\": \"2018-12-13T16:26:55\", \"url\": \"http://www.ncpe.ie/drugs/asenapine-sycrest/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-08-17, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Asenapine (Sycrest\", \"trade_name\": \"Sycrest\", \"indication\": \"Asenapine (Sycrest\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Organon\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sycrest\", \"ta_list\": \"Bipolar Disorder\", \"rr_status\": \"No HTA\"}, {\"id\": 2190, \"last_scrape\": \"2018-12-13T16:27:00\", \"url\": \"http://www.ncpe.ie/drugs/atezolizumab-tecentriq/\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-10-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-08, 2017-10-09\", \"rr_multiple\": 0, \"drug_name\": \"Atezolizumab (Tecentriq\", \"trade_name\": \"Tecentriq\", \"indication\": \"Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK?positive tumour mutations should also have received targeted therapy before receiving atezolizumab.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-21T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq\", \"ta_list\": \"Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2191, \"last_scrape\": \"2018-12-13T16:27:05\", \"url\": \"http://www.ncpe.ie/drugs/avanafil-spedra/\", \"rr_start\": \"2014-02-19T00:00:00\", \"rr_end\": \"2014-03-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-19, 2014-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Avanafil (Spedra\", \"trade_name\": \"Spedra\", \"indication\": \"Avanafil (Spedra\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2014-02-19T00:00:00\", \"latest\": \"2014-03-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/spedra\", \"ta_list\": \"Erectile Dysfunction\", \"rr_status\": \"No HTA\"}, {\"id\": 2192, \"last_scrape\": \"2018-12-13T16:27:06\", \"url\": \"http://www.ncpe.ie/drugs/avelumab-bavencio/\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-10-17, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Avelumab (Bavencio\", \"trade_name\": \"Bavencio\", \"indication\": \"Avelumab (Bavencio\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2018-10-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2193, \"last_scrape\": \"2018-12-13T16:27:08\", \"url\": \"http://www.ncpe.ie/drugs/axanum-aspirin-81mgesomeprazole-20mg/\", \"rr_start\": \"2012-04-12T00:00:00\", \"rr_end\": \"2012-04-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-04-12, 2012-04-20\", \"rr_multiple\": 0, \"drug_name\": \"Aspirin 81mg/Esomeprazole 20mg (Axanum\", \"trade_name\": \"Axanum\", \"indication\": \"Prevention of thrombotic cardiovascular and cerebrovascular events in patients requiring continuous low-dose acetylsalicylic acid treatment, and who are in need of prophylaxis against acetylsalicylic acid associated gastric and /or duodenal ulcers.\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-04-12T00:00:00\", \"latest\": \"2012-04-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2194, \"last_scrape\": \"2018-12-13T16:27:14\", \"url\": \"http://www.ncpe.ie/drugs/axicabtagene-ciloleucel-yescarta/\", \"rr_start\": \"2018-09-10T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF  AXI-CEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-10, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Axicabtagene Ciloleucel (Yescarta\", \"trade_name\": \"Yescarta\", \"indication\": \"Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Kite\", \"orphan\": 1, \"earliest\": \"2018-09-10T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta\", \"ta_list\": \"Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2195, \"last_scrape\": \"2018-12-13T16:27:23\", \"url\": \"http://www.ncpe.ie/drugs/axitinib-inlyta/\", \"rr_start\": \"2012-11-07T00:00:00\", \"rr_end\": \"2012-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-07, 2012-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Axitinib (Inlyta\", \"trade_name\": \"Inlyta\", \"indication\": \"For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-03T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-11-07T00:00:00\", \"latest\": \"2012-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2196, \"last_scrape\": \"2018-12-13T16:27:24\", \"url\": \"http://www.ncpe.ie/drugs/azelastine-hydrochloride-and-fluticasone-propionate-nasal-spray-dymista/\", \"rr_start\": \"2013-02-12T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2013-02-12, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Azelastine hydrochloride and fluticasone propionate (nasal spray) (Dymista\", \"trade_name\": \"Dymista\", \"indication\": \"Indicated for symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-02-12T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2197, \"last_scrape\": \"2018-12-13T16:27:25\", \"url\": \"http://www.ncpe.ie/drugs/azilsartan-edarbi/\", \"rr_start\": \"2012-01-10T00:00:00\", \"rr_end\": \"2012-01-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-01-10, 2012-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Azilsartan (Edarbi\", \"trade_name\": \"Edarbi\", \"indication\": \"Edarbi is indicated for the treatment of essential hypertension in adults.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-12-07T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2012-01-10T00:00:00\", \"latest\": \"2012-01-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/edarbi\", \"ta_list\": \"Hypertension\", \"rr_status\": \"No HTA\"}, {\"id\": 2198, \"last_scrape\": \"2018-12-13T16:27:27\", \"url\": \"http://www.ncpe.ie/drugs/baricitinib-olumiant/\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-06-14, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Baricitinib (Olumiant\", \"trade_name\": \"Olumiant\", \"indication\": \"Baricitinib (Olumiant\", \"ncpe_year\": 2017, \"eu_market\": \"2017-02-12T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2199, \"last_scrape\": \"2018-12-13T16:27:33\", \"url\": \"http://www.ncpe.ie/drugs/bazedoxifene-conbriza/\", \"rr_start\": \"2011-09-20T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-09-20, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Bazedoxifene (Conbriza\", \"trade_name\": \"Conbriza\", \"indication\": \"Bazedoxifene (Conbriza\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-17T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-09-20T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza\", \"ta_list\": \"Osteoporosis, Postmenopausal\", \"rr_status\": \"No HTA\"}, {\"id\": 2200, \"last_scrape\": \"2018-12-13T16:27:36\", \"url\": \"http://www.ncpe.ie/drugs/bedaquiline-sirturo/\", \"rr_start\": \"2015-01-23T00:00:00\", \"rr_end\": \"2015-02-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-01-23, 2015-02-20\", \"rr_multiple\": 0, \"drug_name\": \"Bedaquiline (Sirturo\", \"trade_name\": \"Sirturo\", \"indication\": \"Bedaquiline (Sirturo\", \"ncpe_year\": 2015, \"eu_market\": \"2014-03-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2015-01-23T00:00:00\", \"latest\": \"2015-02-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo\", \"ta_list\": \"Tuberculosis, Multidrug-Resistant\", \"rr_status\": \"No HTA\"}, {\"id\": 2201, \"last_scrape\": \"2018-12-13T16:27:37\", \"url\": \"http://www.ncpe.ie/drugs/belatacept-nulojix/\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2012-01-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-11-15, 2012-01-23\", \"rr_multiple\": 0, \"drug_name\": \"Belatacept (Nulojix\", \"trade_name\": \"Nulojix\", \"indication\": \"Belatacept, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen.\\n\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2012-01-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nulojix\", \"ta_list\": \"Graft Rejection; Kidney Transplantation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2202, \"last_scrape\": \"2018-12-13T16:27:40\", \"url\": \"http://www.ncpe.ie/drugs/belimumab-benlysta/\", \"rr_start\": \"2011-08-11T00:00:00\", \"rr_end\": \"2011-08-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-11, 2011-08-11\", \"rr_multiple\": 0, \"drug_name\": \"Belimumab (Benlysta\", \"trade_name\": \"Benlysta\", \"indication\": \"Cost-effectiveness of Belimumab (Benlysta\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-08-01T00:00:00\", \"latest\": \"2011-08-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta\", \"ta_list\": \"Lupus Erythematosus, Systemic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2203, \"last_scrape\": \"2018-12-13T16:27:46\", \"url\": \"http://www.ncpe.ie/drugs/bendamustine-levact/\", \"rr_start\": \"2011-03-21T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-03-21, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Bendamustine (Levact\", \"trade_name\": \"Levact\", \"indication\": \"Bendamustine (Levact\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2012-11-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2204, \"last_scrape\": \"2018-12-13T16:27:50\", \"url\": \"http://www.ncpe.ie/drugs/benralizumab-fasenra/\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-14T00:00:00\", \"rr_outcome\": \"FULL PHARAMCOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2018-01-15, 2018-02-14\", \"rr_multiple\": 0, \"drug_name\": \"Benralizumab (Fasenra\", \"trade_name\": \"Fasenra\", \"indication\": \"Benralizumab (Fasenra\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fasenra\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2205, \"last_scrape\": \"2018-12-13T16:27:56\", \"url\": \"http://www.ncpe.ie/drugs/bezlotoxumab-zinplava/\", \"rr_start\": \"2017-05-11T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-05-11, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Bezlotoxumab (Zinplava\", \"trade_name\": \"Zinplava\", \"indication\": \"Bezlotoxumab (Zinplava\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-05-11T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinplava\", \"ta_list\": \"Enterocolitis, Pseudomembranous\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2206, \"last_scrape\": \"2018-12-13T16:27:58\", \"url\": \"http://www.ncpe.ie/drugs/bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy/\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT BIKTARVY\", \"rr_dates\": \"2018-04-30, 2018-06-07\", \"rr_multiple\": 0, \"drug_name\": \"Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy\", \"trade_name\": \"Biktarvy\", \"indication\": \"Biktarvy\", \"ncpe_year\": 2018, \"eu_market\": \"2018-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2207, \"last_scrape\": \"2018-12-13T16:28:01\", \"url\": \"http://www.ncpe.ie/drugs/bilastine-drynol/\", \"rr_start\": \"2011-03-10T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-10, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Bilastine (Drynol\", \"trade_name\": \"Drynol\", \"indication\": \" Bilastine (Drynol\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-03-10T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2208, \"last_scrape\": \"2018-12-13T16:28:05\", \"url\": \"http://www.ncpe.ie/drugs/blinatumomab-blincyto/\", \"rr_start\": \"2015-12-08T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.  THE NCPE CANNOT RECOMMEND REIMBURSEMENT OF BLINCTYO\", \"rr_dates\": \"2015-12-08, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Blinatumomab (Blincyto\", \"trade_name\": \"Blincyto\", \"indication\": \"Blincyto\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-23T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-08T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2209, \"last_scrape\": \"2018-12-13T16:28:11\", \"url\": \"http://www.ncpe.ie/drugs/boceprevir-victrelis/\", \"rr_start\": \"\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Boceprevir (Victrelis\", \"trade_name\": \"Victrelis\", \"indication\": \"Economic evaluation of Boceprevir (Victrelis\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2011-08-19T00:00:00\", \"latest\": \"2012-01-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2210, \"last_scrape\": \"2018-12-13T16:28:16\", \"url\": \"http://www.ncpe.ie/drugs/bosentan-tracleer/\", \"rr_start\": \"2014-06-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-06-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Bosentan (Tracleer\", \"trade_name\": \"Tracleer\", \"indication\": \"Bosentan (Tracleer\", \"ncpe_year\": 2014, \"eu_market\": \"2002-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-06-27T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tracleer\", \"ta_list\": \"Scleroderma, Systemic; Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2211, \"last_scrape\": \"2018-12-13T16:28:18\", \"url\": \"http://www.ncpe.ie/drugs/bosutinib-bosulif/\", \"rr_start\": \"2013-08-09T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"AT THE CURRENT PRICE A FULL HTA WOULD BE REQUIRED.\", \"rr_dates\": \"2013-08-09, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Bosutinib (Bosulif\", \"trade_name\": \"Bosulif\", \"indication\": \"Bosutinib is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-26T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2212, \"last_scrape\": \"2018-12-13T16:28:19\", \"url\": \"http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris-for-cd30-cutaneous-t-cell-lymphoma-ctcl/\", \"rr_start\": \"2018-02-07T00:00:00\", \"rr_end\": \"2018-03-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-02-07, 2018-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin (Adcetris\", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin (Adcetris\", \"ncpe_year\": 2018, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-02-07T00:00:00\", \"latest\": \"2018-03-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2213, \"last_scrape\": \"2018-12-13T16:28:23\", \"url\": \"http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris/\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin (Adcetris\", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin (Adcetris\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2214, \"last_scrape\": \"2018-12-13T16:28:29\", \"url\": \"http://www.ncpe.ie/drugs/brigatinib-alunbrig/\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF BRIGATINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-11-19, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Brigatinib (Alunbrig\", \"trade_name\": \"Alunbrig\", \"indication\": \"Brigatinib (Alunbrig \", \"ncpe_year\": 2018, \"eu_market\": \"2018-11-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2215, \"last_scrape\": \"2018-12-13T16:28:30\", \"url\": \"http://www.ncpe.ie/drugs/brimonidine-3-3-mgg-gel-mirvaso/\", \"rr_start\": \"2014-04-09T00:00:00\", \"rr_end\": \"2014-04-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-09\", \"rr_multiple\": 0, \"drug_name\": \"Brimonidine 3.3 mg/g gel (Mirvaso\", \"trade_name\": \"Mirvaso\", \"indication\": \"Brimonidine 3.3 mg/g gel (Mirvaso\", \"ncpe_year\": 2014, \"eu_market\": \"2014-02-20T00:00:00\", \"company\": \"Galderma\", \"orphan\": 0, \"earliest\": \"2014-04-09T00:00:00\", \"latest\": \"2014-04-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mirvaso\", \"ta_list\": \"Skin Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2216, \"last_scrape\": \"2018-12-13T16:28:36\", \"url\": \"http://www.ncpe.ie/drugs/brivaracetam-briviact/\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-02-15, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Brivaracetam (Briviact\", \"trade_name\": \"Briviact\", \"indication\": \"Brivaracetam (Briviact\", \"ncpe_year\": 2016, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2217, \"last_scrape\": \"2018-12-13T16:28:40\", \"url\": \"http://www.ncpe.ie/drugs/brodalumab-kyntheum/\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-07-25, 2017-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Brodalumab (Kyntheum\", \"trade_name\": \"Kyntheum\", \"indication\": \"Brodalumab (Kyntheum\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-17T00:00:00\", \"company\": \"LEO\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2218, \"last_scrape\": \"2018-12-13T16:28:44\", \"url\": \"http://www.ncpe.ie/drugs/bronchitol/\", \"rr_start\": \"2012-09-11T00:00:00\", \"rr_end\": \"2012-09-21T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2012-09-11, 2012-09-21\", \"rr_multiple\": 0, \"drug_name\": \"Mannitol Dry Powder (Bronchitol\", \"trade_name\": \"Bronchitol\", \"indication\": \"Bronchitol\", \"ncpe_year\": 2014, \"eu_market\": \"2012-04-13T00:00:00\", \"company\": \"Pharmaxis\", \"orphan\": 1, \"earliest\": \"2012-09-11T00:00:00\", \"latest\": \"2014-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bronchitol\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2219, \"last_scrape\": \"2018-12-13T16:28:46\", \"url\": \"http://www.ncpe.ie/drugs/c-drugs/calcipotriol-and-betamethasone-dipropionate-cutaneous-foam-enstilar/\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-06-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-05-17, 2016-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Calcipotriol and betamethasone dipropionate cutaneous foam (Enstilar \", \"trade_name\": \"Enstilar\", \"indication\": \"Calcipotriol and betamethasone dipropionate cutaneous foam is indicated for the topical treatment of psoriasis vulgaris in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-06-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2220, \"last_scrape\": \"2018-12-13T16:28:53\", \"url\": \"http://www.ncpe.ie/drugs/c1inhibitor-human-cinryze/\", \"rr_start\": \"2012-10-22T00:00:00\", \"rr_end\": \"2012-11-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-22, 2012-11-14\", \"rr_multiple\": 0, \"drug_name\": \"C1inhibitor (human) (Cinryze\", \"trade_name\": \"Cinryze\", \"indication\": \"C1inhibitor (human) (Cinryze\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-15T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2012-10-22T00:00:00\", \"latest\": \"2012-11-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"id\": 2221, \"last_scrape\": \"2018-12-13T16:28:55\", \"url\": \"http://www.ncpe.ie/drugs/cabozantinib-cabometyx/\", \"rr_start\": \"2017-03-20T00:00:00\", \"rr_end\": \"2017-04-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT\\nRECOMMENDED\", \"rr_dates\": \"2017-03-20, 2017-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib (Cabometyx\", \"trade_name\": \"Cabometyx\", \"indication\": \"Cabozantinib (Cabometyx\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-03-20T00:00:00\", \"latest\": \"2018-07-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2222, \"last_scrape\": \"2018-12-13T16:28:58\", \"url\": \"http://www.ncpe.ie/drugs/cabozantinib-cometriq/\", \"rr_start\": \"2014-07-10T00:00:00\", \"rr_end\": \"2014-08-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2014-07-10, 2014-08-12\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib (Cometriq\", \"trade_name\": \"Cometriq\", \"indication\": \"Cabozantinib (COMETRIQ\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-21T00:00:00\", \"company\": \"Ipsen\", \"orphan\": 1, \"earliest\": \"2014-07-10T00:00:00\", \"latest\": \"2014-08-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2223, \"last_scrape\": \"2018-12-13T16:29:01\", \"url\": \"http://www.ncpe.ie/drugs/camellia-sinensis-folium-green-tea-leaf-catephen-10/\", \"rr_start\": \"2015-05-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-05-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Camellia sinensis, folium (green tea leaf) (Catephen 10%\", \"trade_name\": \"Catephen 10%\", \"indication\": \"Catephen 10%\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-05-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2224, \"last_scrape\": \"2018-12-13T16:29:04\", \"url\": \"http://www.ncpe.ie/drugs/canagliflozin-invokana/\", \"rr_start\": \"2013-11-25T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-11-25, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Canagliflozin (Invokana\", \"trade_name\": \"Invokana\", \"indication\": \"Canagliflozin (Invokana\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-11-25T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/invokana\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2225, \"last_scrape\": \"2018-12-13T16:29:09\", \"url\": \"http://www.ncpe.ie/drugs/capsaicin-8ww-patch-qutenza/\", \"rr_start\": \"2012-06-15T00:00:00\", \"rr_end\": \"2012-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-06-15, 2012-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Capsaicin 8%w/w patch (Qutenza\", \"trade_name\": \"Qutenza\", \"indication\": \"Capsaicin 8% w/w patch (Qutenza\", \"ncpe_year\": 2012, \"eu_market\": \"2009-05-15T00:00:00\", \"company\": \"Grunenthal\", \"orphan\": 0, \"earliest\": \"2012-06-15T00:00:00\", \"latest\": \"2012-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza\", \"ta_list\": \"Neuralgia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2226, \"last_scrape\": \"2018-12-13T16:29:11\", \"url\": \"http://www.ncpe.ie/drugs/carbazitaxel-jevtana-for-prostate-cancer/\", \"rr_start\": \"2011-06-02T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-06-02, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Cabazitaxel (Jevtana\", \"trade_name\": \"Jevtana\", \"indication\": \"Economic Evaluation of cabazitaxel (Jevtana\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2011-06-02T00:00:00\", \"latest\": \"2014-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jevtana\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2227, \"last_scrape\": \"2018-12-13T16:29:16\", \"url\": \"http://www.ncpe.ie/drugs/carfilzomib-kyprolis/\", \"rr_start\": \"2015-12-07T00:00:00\", \"rr_end\": \"2016-01-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-12-07, 2016-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Carfilzomib (Kyprolis\", \"trade_name\": \"Kyprolis\", \"indication\": \"Kyprolis\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-07T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2228, \"last_scrape\": \"2018-12-13T16:29:22\", \"url\": \"http://www.ncpe.ie/drugs/catumaxomab-removab/\", \"rr_start\": \"2011-08-05T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-08-05, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Catumaxomab (Removab\", \"trade_name\": \"Removab\", \"indication\": \"Catumazomab (Removab\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-20T00:00:00\", \"company\": \"Neovii\", \"orphan\": 0, \"earliest\": \"2011-08-05T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/removab\", \"ta_list\": \"Ascites; Cancer\", \"rr_status\": \"No HTA\"}, {\"id\": 2229, \"last_scrape\": \"2018-12-13T16:29:25\", \"url\": \"http://www.ncpe.ie/drugs/ceftaroline-zinforo/\", \"rr_start\": \"2012-10-08T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-08, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Ceftaroline (Zinforo\", \"trade_name\": \"Zinforo\", \"indication\": \"For the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP).\", \"ncpe_year\": 2012, \"eu_market\": \"2012-08-22T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-10-08T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinforo\", \"ta_list\": \"Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia\", \"rr_status\": \"No HTA\"}, {\"id\": 2230, \"last_scrape\": \"2018-12-13T16:29:29\", \"url\": \"http://www.ncpe.ie/drugs/ceftazidime-avibactam-cef-avizavicefta/\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-17, 2017-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Ceftazidime-avibactam (CEF-AVI)(Zavicefta\", \"trade_name\": \"Zavicefta\", \"indication\": \"Ceftazidime-avibactam (CEF-AVI)(Zavicefta\", \"ncpe_year\": 2017, \"eu_market\": \"2016-06-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta\", \"ta_list\": \"Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2231, \"last_scrape\": \"2018-12-13T16:29:34\", \"url\": \"http://www.ncpe.ie/drugs/ceftolozanetazobactam-zerbaxa/\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-03-03, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Ceftolozane/tazobactam (Zerbaxa\", \"trade_name\": \"Zerbaxa\", \"indication\": \"Zerbaxa\", \"ncpe_year\": 2016, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa\", \"ta_list\": \"Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2232, \"last_scrape\": \"2018-12-13T16:29:36\", \"url\": \"http://www.ncpe.ie/drugs/ceritinib-zykadia/\", \"rr_start\": \"2015-05-29T00:00:00\", \"rr_end\": \"2015-07-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2015-05-29, 2015-07-22\", \"rr_multiple\": 0, \"drug_name\": \"Ceritinib (Zykadia\", \"trade_name\": \"Zykadia\", \"indication\": \"Zykadia\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-06T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-05-29T00:00:00\", \"latest\": \"2015-07-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2233, \"last_scrape\": \"2018-12-13T16:29:40\", \"url\": \"http://www.ncpe.ie/drugs/cerliponase-alfa-brineura/\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2017-10-11, 2017-11-27\", \"rr_multiple\": 0, \"drug_name\": \"Cerliponase alfa (Brineura\", \"trade_name\": \"Brineura\", \"indication\": \"Cerliponase alfa (Brineura\", \"ncpe_year\": 2018, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-08-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brineura\", \"ta_list\": \"Neuronal Ceroid-Lipofuscinoses\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2234, \"last_scrape\": \"2018-12-13T16:29:44\", \"url\": \"http://www.ncpe.ie/drugs/certolizumab-pegol-cimzia/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Certolizumab pegol (Cimzia\", \"trade_name\": \"Cimzia\", \"indication\": \"Cost-effectiveness of certolizumab pegol (Cimzia\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2010-03-13T00:00:00\", \"latest\": \"2010-09-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia-0\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2235, \"last_scrape\": \"2018-12-13T16:29:49\", \"url\": \"http://www.ncpe.ie/drugs/ciclosporin-1mgml-eye-drops-ikervis/\", \"rr_start\": \"2015-01-07T00:00:00\", \"rr_end\": \"2016-01-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-01-07, 2016-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Ciclosporin 1mg/ml eye drops (Ikervis\", \"trade_name\": \"Ikervis\", \"indication\": \"Ikervis\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-19T00:00:00\", \"company\": \"Santen\", \"orphan\": 0, \"earliest\": \"2015-01-07T00:00:00\", \"latest\": \"2016-01-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis\", \"ta_list\": \"Corneal Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2236, \"last_scrape\": \"2018-12-13T16:29:54\", \"url\": \"http://www.ncpe.ie/drugs/cladribine-mavenclad/\", \"rr_start\": \"2017-08-22T00:00:00\", \"rr_end\": \"2017-09-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-22, 2017-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Cladribine (Mavenclad\", \"trade_name\": \"Mavenclad\", \"indication\": \"Cladribine (Mavenclad\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-08-22T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2237, \"last_scrape\": \"2018-12-13T16:29:58\", \"url\": \"http://www.ncpe.ie/drugs/clindamycin-1-with-tretinoin-0-025-treclinac/\", \"rr_start\": \"2014-04-08T00:00:00\", \"rr_end\": \"2014-05-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-08, 2014-05-06\", \"rr_multiple\": 0, \"drug_name\": \"Clindamycin 1% with tretinoin 0.025% (Treclinac\", \"trade_name\": \"Treclinac\", \"indication\": \"Clindamycin 1% with tretinoin 0.025% (Treclinac\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-04-08T00:00:00\", \"latest\": \"2014-05-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2238, \"last_scrape\": \"2018-12-13T16:30:02\", \"url\": \"http://www.ncpe.ie/drugs/cobimetinib-cotellic/\", \"rr_start\": \"2016-04-19T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-04-19, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Cobimetinib (Cotellic\", \"trade_name\": \"Cotellic\", \"indication\": \"Cotellic\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2016-04-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2239, \"last_scrape\": \"2018-12-13T16:30:03\", \"url\": \"http://www.ncpe.ie/drugs/colesevelam-cholestagel/\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Colesevelam (Cholestagel\", \"trade_name\": \"Cholestagel\", \"indication\": \"Cost-effectiveness of Colesevelam (Cholestagel\", \"ncpe_year\": 2010, \"eu_market\": \"2004-03-09T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cholestagel\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"No HTA\"}, {\"id\": 2240, \"last_scrape\": \"2018-12-13T16:30:06\", \"url\": \"http://www.ncpe.ie/drugs/colistimethate-sodium-colobreathe/\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Colistimethate sodium (Colobreathe\", \"trade_name\": \"Colobreathe\", \"indication\": \"Colistimethate sodium (colobreathe\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-13T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/colobreathe\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2241, \"last_scrape\": \"2018-12-13T16:30:17\", \"url\": \"http://www.ncpe.ie/drugs/collagenase-clostridium-histolyticum-xiapex/\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-20, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Collagenase Clostridium Histolyticum (Xiapex\", \"trade_name\": \"Xiapex\", \"indication\": \" Collagenase Clostridium Histolyticum (Xiapex\", \"ncpe_year\": 2011, \"eu_market\": \"2011-02-28T00:00:00\", \"company\": \"Swedish\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xiapex\", \"ta_list\": \"Dupuytren Contracture\", \"rr_status\": \"No HTA\"}, {\"id\": 2242, \"last_scrape\": \"2018-12-13T16:30:20\", \"url\": \"http://www.ncpe.ie/drugs/corifollitropin-alfa-elonva/\", \"rr_start\": \"2010-10-22T00:00:00\", \"rr_end\": \"2010-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-10-22, 2010-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Corifollitropin alfa (Elonva\", \"trade_name\": \"Elonva\", \"indication\": \"Cost-effectiveness of Corifollitropin alfa (Elonva\", \"ncpe_year\": 2010, \"eu_market\": \"2010-01-25T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2010-09-01T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/elonva\", \"ta_list\": \"Reproductive Techniques, Assisted; Ovulation Induction\", \"rr_status\": \"No HTA\"}, {\"id\": 2243, \"last_scrape\": \"2018-12-13T16:30:24\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori-for-first-line-alk-nsclc/\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2244, \"last_scrape\": \"2018-12-13T16:30:29\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori-for-ros1-nsclc/\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2245, \"last_scrape\": \"2018-12-13T16:30:34\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori/\", \"rr_start\": \"2013-01-09T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-01-09, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"For the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-01-09T00:00:00\", \"latest\": \"2015-08-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2246, \"last_scrape\": \"2018-12-13T16:30:37\", \"url\": \"http://www.ncpe.ie/drugs/cysteamine-bitartrate-procysbi/\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2015-12-01, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Cysteamine bitartrate delayed-release (Procysbi\", \"trade_name\": \"Procysbi\", \"indication\": \"Procysbi\", \"ncpe_year\": 2017, \"eu_market\": \"2013-09-05T00:00:00\", \"company\": \"Chiesi\", \"orphan\": 1, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/procysbi\", \"ta_list\": \"Cystinosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2247, \"last_scrape\": \"2018-12-13T16:30:43\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-2/\", \"rr_start\": \"2014-05-09T00:00:00\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-09, 2014-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate (Pradaxa\", \"ncpe_year\": 2014, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-09T00:00:00\", \"latest\": \"2014-06-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2248, \"last_scrape\": \"2018-12-13T16:30:51\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-for-the-prevention-of-stroke-and-systematic-embolisom-in-atrial-fibrillation/\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate (Pradaxa\", \"ncpe_year\": 2012, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2010-11-02T00:00:00\", \"latest\": \"2012-10-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2249, \"last_scrape\": \"2018-12-13T16:30:57\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-vte-prevention/\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Economic Evaluation of the Cost Effectiveness of Dabigatran Etexilate (Pradaxa\", \"ncpe_year\": 2008, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2008-07-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2250, \"last_scrape\": \"2018-12-13T16:30:59\", \"url\": \"http://www.ncpe.ie/drugs/dabrafenib-tafinlar/\", \"rr_start\": \"2013-09-11T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-11, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Dabrafenib (Tafinlar\", \"trade_name\": \"Tafinlar\", \"indication\": \"Dabrafenib (Tafinlar\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2013-09-11T00:00:00\", \"latest\": \"2014-06-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2251, \"last_scrape\": \"2018-12-13T16:31:02\", \"url\": \"http://www.ncpe.ie/drugs/daclatasvir-daklinza/\", \"rr_start\": \"2014-08-05T00:00:00\", \"rr_end\": \"2014-09-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-08-05, 2014-09-12\", \"rr_multiple\": 0, \"drug_name\": \"Daclatasvir (Daklinza\", \"trade_name\": \"Daklinza\", \"indication\": \"Daclatasvir (Daklinza\", \"ncpe_year\": 2015, \"eu_market\": \"2014-08-22T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-08-05T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/daklinza\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2252, \"last_scrape\": \"2018-12-13T16:31:08\", \"url\": \"http://www.ncpe.ie/drugs/daclizumab-zinbryta/\", \"rr_start\": \"2016-09-26T00:00:00\", \"rr_end\": \"2016-11-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-09-26, 2016-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Daclizumab (Zinbryta\", \"trade_name\": \"Zinbryta\", \"indication\": \"Daclizumab is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-07-01T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2016-09-26T00:00:00\", \"latest\": \"2018-03-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinbryta\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2253, \"last_scrape\": \"2018-12-13T16:31:12\", \"url\": \"http://www.ncpe.ie/drugs/dalbavancin-xydalba/\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-07, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Dalbavancin (Xydalba\", \"trade_name\": \"Xydalba\", \"indication\": \"Dalbavancin (Xydalba\", \"ncpe_year\": 2017, \"eu_market\": \"2015-02-19T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xydalba\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2254, \"last_scrape\": \"2018-12-13T16:31:18\", \"url\": \"http://www.ncpe.ie/drugs/dapagliflozin-forxiga/\", \"rr_start\": \"2012-10-10T00:00:00\", \"rr_end\": \"2012-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-10-10, 2012-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Dapagliflozin (Forxiga\", \"trade_name\": \"Forxiga\", \"indication\": \"Dapagliflozin (Forxiga\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-11T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-10T00:00:00\", \"latest\": \"2013-12-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2255, \"last_scrape\": \"2018-12-13T16:31:21\", \"url\": \"http://www.ncpe.ie/drugs/daratumumab-darzalex/\", \"rr_start\": \"2016-05-31T00:00:00\", \"rr_end\": \"2016-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-05-31, 2016-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Daratumumab (Darzalex\", \"trade_name\": \"Darzalex\", \"indication\": \"Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-04-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-05-31T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2256, \"last_scrape\": \"2018-12-13T16:31:25\", \"url\": \"http://www.ncpe.ie/drugs/darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-symtuza/\", \"rr_start\": \"2017-09-27T00:00:00\", \"rr_end\": \"2017-10-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-27, 2017-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza\", \"trade_name\": \"Symtuza\", \"indication\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza\", \"ncpe_year\": 2017, \"eu_market\": \"2017-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-09-27T00:00:00\", \"latest\": \"2017-10-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/symtuza\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2257, \"last_scrape\": \"2018-12-13T16:31:30\", \"url\": \"http://www.ncpe.ie/drugs/darunavir-cobicistat-rezolsta/\", \"rr_start\": \"2014-12-02T00:00:00\", \"rr_end\": \"2015-01-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-12-02, 2015-01-08\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir & cobicistat (Rezolsta\", \"trade_name\": \"Rezolsta\", \"indication\": \"Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-12-02T00:00:00\", \"latest\": \"2015-01-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2258, \"last_scrape\": \"2018-12-13T16:31:35\", \"url\": \"http://www.ncpe.ie/drugs/darvadstrocel-alofisel/\", \"rr_start\": \"2018-06-14T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF DARVADSTROCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-14, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Darvadstrocel (Alofisel\", \"trade_name\": \"Alofisel\", \"indication\": \"Darvadstrocel (Alofisel\", \"ncpe_year\": 2018, \"eu_market\": \"2018-03-23T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-06-14T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel\", \"ta_list\": \"Rectal Fistula\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2259, \"last_scrape\": \"2018-12-13T16:31:40\", \"url\": \"http://www.ncpe.ie/drugs/decitabine-dacogen/\", \"rr_start\": \"2012-11-08T00:00:00\", \"rr_end\": \"2012-12-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-08, 2012-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Decitabine (Dacogen\", \"trade_name\": \"Dacogen\", \"indication\": \"Decitabine (Dacogen\", \"ncpe_year\": 2013, \"eu_market\": \"2012-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2012-11-08T00:00:00\", \"latest\": \"2013-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2260, \"last_scrape\": \"2018-12-13T16:31:44\", \"url\": \"http://www.ncpe.ie/drugs/defibrotide-defitelio/\", \"rr_start\": \"2014-05-12T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2014-05-12, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Defibrotide (Defitelio\", \"trade_name\": \"Defitelio\", \"indication\": \"Defibrotide (Defitelio\", \"ncpe_year\": 2014, \"eu_market\": \"2013-10-18T00:00:00\", \"company\": \"Gentium\", \"orphan\": 1, \"earliest\": \"2014-05-12T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio\", \"ta_list\": \"Hepatic Veno-Occlusive Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2261, \"last_scrape\": \"2018-12-13T16:31:47\", \"url\": \"http://www.ncpe.ie/drugs/degarelix-firmagon/\", \"rr_start\": \"2009-10-15T00:00:00\", \"rr_end\": \"2009-10-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-10-15\", \"rr_multiple\": 0, \"drug_name\": \"Degarelix (Firmagon\", \"trade_name\": \"Firmagon\", \"indication\": \"Cost-effectiveness of Degarelix (Firmagon\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-17T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2009-10-15T00:00:00\", \"latest\": \"2009-10-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2262, \"last_scrape\": \"2018-12-13T16:31:52\", \"url\": \"http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-cannabidiol-thc-cbd-sativex/\", \"rr_start\": \"2018-02-12T00:00:00\", \"rr_end\": \"2018-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF SATIVEX\", \"rr_dates\": \"2018-02-12, 2018-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex\", \"trade_name\": \"Sativex\", \"indication\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-02-12T00:00:00\", \"latest\": \"2018-04-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2263, \"last_scrape\": \"2018-12-13T16:31:59\", \"url\": \"http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-thccannabidiol-cbd-sativex/\", \"rr_start\": \"2012-12-05T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-05, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol (THC) /Cannabidiol (CBD) (Sativex\", \"trade_name\": \"Sativex\", \"indication\": \"For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-12-05T00:00:00\", \"latest\": \"2014-09-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2264, \"last_scrape\": \"2018-12-13T16:32:04\", \"url\": \"http://www.ncpe.ie/drugs/denosumab-prolia/\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab (Prolia\", \"trade_name\": \"Prolia\", \"indication\": \"The Cost-effectiveness of Denosumab (Prolia\", \"ncpe_year\": 2010, \"eu_market\": \"2010-05-26T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2010-05-27T00:00:00\", \"latest\": \"2010-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prolia\", \"ta_list\": \"Bone Resorption; Osteoporosis, Postmenopausal\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2265, \"last_scrape\": \"2018-12-13T16:32:08\", \"url\": \"http://www.ncpe.ie/drugs/denosumab-xgeva-3/\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab (Xgeva\", \"trade_name\": \"Xgeva\", \"indication\": \"Cost-effectiveness of denosumab (Xgeva\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2011-08-15T00:00:00\", \"latest\": \"2011-12-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva\", \"ta_list\": \"Fractures, Bone; Neoplasm Metastasis\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2266, \"last_scrape\": \"2018-12-13T16:32:12\", \"url\": \"http://www.ncpe.ie/drugs/dexamethasone-intravitreal-implant-ozurdex/\", \"rr_start\": \"2010-11-12T00:00:00\", \"rr_end\": \"2010-12-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-11-12, 2010-12-16\", \"rr_multiple\": 0, \"drug_name\": \"Dexamethasone Intravitreal Implant (Ozurdex\", \"trade_name\": \"Ozurdex\", \"indication\": \"Cost-effectiveness of Ozurdex\", \"ncpe_year\": 2012, \"eu_market\": \"2010-07-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2010-11-12T00:00:00\", \"latest\": \"2012-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ozurdex\", \"ta_list\": \"Macular Edema; Uveitis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2267, \"last_scrape\": \"2018-12-13T16:32:15\", \"url\": \"http://www.ncpe.ie/drugs/dexmedetomidine-dexdor/\", \"rr_start\": \"2011-07-08T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-07-08, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Dexmedetomidine (Dexdor\", \"trade_name\": \"Dexdor\", \"indication\": \"Dexmedetomidine (Dexdor\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-15T00:00:00\", \"company\": \"Orion\", \"orphan\": 0, \"earliest\": \"2011-07-08T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dexdor\", \"ta_list\": \"Conscious Sedation\", \"rr_status\": \"No HTA\"}, {\"id\": 2268, \"last_scrape\": \"2018-12-13T16:32:21\", \"url\": \"http://www.ncpe.ie/drugs/dienogest-visanne/\", \"rr_start\": \"2010-09-17T00:00:00\", \"rr_end\": \"2010-10-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-09-17, 2010-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Dienogest (Visanne\", \"trade_name\": \"Visanne\", \"indication\": \"Dienogest (Visanne\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-09-17T00:00:00\", \"latest\": \"2010-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2269, \"last_scrape\": \"2018-12-13T16:32:24\", \"url\": \"http://www.ncpe.ie/drugs/dimethyl-fumarate-skilarence/\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-01-15, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate (Skilarence\", \"trade_name\": \"Skilarence\", \"indication\": \"Dimethyl fumarate (Skilarence\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"Almirall\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/skilarence\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2270, \"last_scrape\": \"2018-12-13T16:32:26\", \"url\": \"http://www.ncpe.ie/drugs/dimethyl-fumarate-tecfidera/\", \"rr_start\": \"2014-02-04T00:00:00\", \"rr_end\": \"2014-03-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-02-04, 2014-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate (Tecfidera\", \"trade_name\": \"Tecfidera\", \"indication\": \"Dimethyl fumarate (Tecfidera\", \"ncpe_year\": 2015, \"eu_market\": \"2014-01-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-02-04T00:00:00\", \"latest\": \"2015-04-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2271, \"last_scrape\": \"2018-12-13T16:32:29\", \"url\": \"http://www.ncpe.ie/drugs/dinutuximab-beta-dinutuximab-beta-eusa/\", \"rr_start\": \"2017-10-19T00:00:00\", \"rr_end\": \"2017-11-23T00:00:00\", \"rr_outcome\": \"FOLLOWING ASSESSMENT OF THE APPLICANT\", \"rr_dates\": \"2017-10-19, 2017-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Dinutuximab beta (Qarziba\", \"trade_name\": \"Qarziba\", \"indication\": \"Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients ? 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-10-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2272, \"last_scrape\": \"2018-12-13T16:32:34\", \"url\": \"http://www.ncpe.ie/drugs/dolutegravir-rilpivirine-juluca/\", \"rr_start\": \"2018-06-08T00:00:00\", \"rr_end\": \"2018-07-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT JULUCA\", \"rr_dates\": \"2018-06-08, 2018-07-12\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir/Rilpivirine (Juluca\", \"trade_name\": \"Juluca\", \"indication\": \"Dolutegravir/rilpivirine (Juluca\", \"ncpe_year\": 2018, \"eu_market\": \"2018-05-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2018-06-08T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/juluca\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2273, \"last_scrape\": \"2018-12-13T16:32:36\", \"url\": \"http://www.ncpe.ie/drugs/dolutegravir-tivicay/\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-10, 2014-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir (Tivicay\", \"trade_name\": \"Tivicay\", \"indication\": \"Dolutegravir (Tivicay\", \"ncpe_year\": 2014, \"eu_market\": \"2014-01-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2274, \"last_scrape\": \"2018-12-13T16:32:39\", \"url\": \"http://www.ncpe.ie/drugs/dronedarone-multaq/\", \"rr_start\": \"2010-01-12T00:00:00\", \"rr_end\": \"2010-01-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-01-12, 2010-01-01\", \"rr_multiple\": 0, \"drug_name\": \"Dronedarone (Multaq\", \"trade_name\": \"Multaq\", \"indication\": \"Rapid Review\", \"ncpe_year\": 2010, \"eu_market\": \"2009-11-25T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2010-01-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"No HTA\"}, {\"id\": 2275, \"last_scrape\": \"2018-12-13T16:32:42\", \"url\": \"http://www.ncpe.ie/drugs/dulaglutide-trulicity/\", \"rr_start\": \"2015-03-04T00:00:00\", \"rr_end\": \"2015-04-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-03-04, 2015-04-29\", \"rr_multiple\": 0, \"drug_name\": \"Dulaglutide (Trulicity\", \"trade_name\": \"Trulicity\", \"indication\": \"Dulaglutide is indicated as monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2015-03-04T00:00:00\", \"latest\": \"2015-04-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2276, \"last_scrape\": \"2018-12-13T16:32:46\", \"url\": \"http://www.ncpe.ie/drugs/dupilumab-dupixent/\", \"rr_start\": \"2017-11-13T00:00:00\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-13, 2017-11-24\", \"rr_multiple\": 0, \"drug_name\": \"Dupilumab (Dupixent\", \"trade_name\": \"Dupixent\", \"indication\": \"Dupilumab (Dupixent\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-27T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-11-13T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent\", \"ta_list\": \"Dermatitis, Atopic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2277, \"last_scrape\": \"2018-12-13T16:32:53\", \"url\": \"http://www.ncpe.ie/drugs/eculizumab-soliris/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Eculizumab (Soliris\", \"trade_name\": \"Soliris\", \"indication\": \"An Economic Evaluation of Eculizumab (Soliris\", \"ncpe_year\": 2013, \"eu_market\": \"2007-06-20T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2013-10-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/soliris\", \"ta_list\": \"Hemoglobinuria, Paroxysmal\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2278, \"last_scrape\": \"2018-12-13T16:32:55\", \"url\": \"http://www.ncpe.ie/drugs/edoxaban-lixiana/\", \"rr_start\": \"2015-06-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-06-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Edoxaban (Lixiana\", \"trade_name\": \"Lixiana\", \"indication\": \"Edoxaban is indicated for the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2015-06-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana\", \"ta_list\": \"Stroke; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2279, \"last_scrape\": \"2018-12-13T16:33:00\", \"url\": \"http://www.ncpe.ie/drugs/elbasvirgrazoprevir-zepatier-2/\", \"rr_start\": \"2016-08-10T00:00:00\", \"rr_end\": \"2016-10-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-08-10, 2016-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Elbasvir/Grazoprevir (Zepatier\", \"trade_name\": \"Zepatier\", \"indication\": \"Elbasvir 50mg/100mg grazoprevir (EBR/GZR)(Zepatier\", \"ncpe_year\": 2016, \"eu_market\": \"2016-07-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-10T00:00:00\", \"latest\": \"2016-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2280, \"last_scrape\": \"2018-12-13T16:33:03\", \"url\": \"http://www.ncpe.ie/drugs/eliglustat-cerdelga/\", \"rr_start\": \"2016-03-21T00:00:00\", \"rr_end\": \"2016-05-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-03-21, 2016-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Eliglustat (Cerdelga\", \"trade_name\": \"Cerdelga\", \"indication\": \"Eliglustat (Cerdelga\", \"ncpe_year\": 2018, \"eu_market\": \"2015-01-19T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 1, \"earliest\": \"2016-03-21T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga\", \"ta_list\": \"Gaucher Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2281, \"last_scrape\": \"2018-12-13T16:33:05\", \"url\": \"http://www.ncpe.ie/drugs/elosulfase-alfa-vimizim/\", \"rr_start\": \"2015-03-30T00:00:00\", \"rr_end\": \"2015-05-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-03-30, 2015-05-08\", \"rr_multiple\": 0, \"drug_name\": \"Elosulfase alfa (Vimizim\", \"trade_name\": \"Vimizim\", \"indication\": \"Elosulfase alfa (Vimzim\", \"ncpe_year\": 2018, \"eu_market\": \"2014-04-27T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2015-03-30T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vimizim\", \"ta_list\": \"Mucopolysaccharidosis IV\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2282, \"last_scrape\": \"2018-12-13T16:33:12\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade-2/\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-02-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-01-10, 2014-02-13\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Eltrombopag (Revolade\", \"ncpe_year\": 2014, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-02-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"id\": 2283, \"last_scrape\": \"2018-12-13T16:33:17\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade-3/\", \"rr_start\": \"2016-02-05T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-02-05, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Revolade\", \"ncpe_year\": 2016, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-02-05T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"id\": 2284, \"last_scrape\": \"2018-12-13T16:33:23\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade/\", \"rr_start\": \"2017-12-04T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, WHICH IS NOT COMPARABLE WITH CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2017-12-04, 2018-04-16, 2017-12-01\", \"rr_multiple\": 1, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Cost-effectiveness of eltrombopag (Revolade\", \"ncpe_year\": 2018, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-07-30T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2285, \"last_scrape\": \"2018-12-13T16:33:26\", \"url\": \"http://www.ncpe.ie/drugs/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya/\", \"rr_start\": \"2015-11-24T00:00:00\", \"rr_end\": \"2016-01-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-11-24, 2016-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide (Genvoya\", \"trade_name\": \"Genvoya\", \"indication\": \"Genvoya\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2015-11-24T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2286, \"last_scrape\": \"2018-12-13T16:33:32\", \"url\": \"http://www.ncpe.ie/drugs/empagliflozin-jardiance/\", \"rr_start\": \"2014-05-22T00:00:00\", \"rr_end\": \"2014-06-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-22, 2014-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Empagliflozin (Jardiance\", \"trade_name\": \"Jardiance\", \"indication\": \"Add-on combination therapy \", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-22T00:00:00\", \"latest\": \"2014-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2287, \"last_scrape\": \"2018-12-13T16:33:37\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabine-tenofovir-disoproxil-fumarate-truvada/\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-07-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-12, 2017-07-18\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine / tenofovir disoproxil fumarate (Truvada\", \"trade_name\": \"Truvada\", \"indication\": \"Truvada\", \"ncpe_year\": 2017, \"eu_market\": \"2005-02-20T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-07-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/truvada\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2288, \"last_scrape\": \"2018-12-13T16:33:43\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabine-tenovir-disoproxil-teva/\", \"rr_start\": \"2017-12-11T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-12-11, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir disoproxil (TEVA\", \"trade_name\": \"TEVA\", \"indication\": \"Emtricitabine/tenofovir disoproxil (TEVA\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-12-11T00:00:00\", \"latest\": \"2017-12-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2289, \"last_scrape\": \"2018-12-13T16:33:48\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabinetenofovir-alafenamide-descovy/\", \"rr_start\": \"2016-04-26T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-04-26, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir alafenamide (Descovy\", \"trade_name\": \"Descovy\", \"indication\": \"Descovy\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-04-26T00:00:00\", \"latest\": \"2016-04-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/descovy\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2290, \"last_scrape\": \"2018-12-13T16:33:52\", \"url\": \"http://www.ncpe.ie/drugs/enzalutamide-xtandi/\", \"rr_start\": \"2013-06-28T00:00:00\", \"rr_end\": \"2013-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-28, 2013-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Enzalutamide (Xtandi\", \"trade_name\": \"Xtandi\", \"indication\": \"Enzalutamide (Xtandi\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2013-06-28T00:00:00\", \"latest\": \"2014-04-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2291, \"last_scrape\": \"2018-12-13T16:33:59\", \"url\": \"http://www.ncpe.ie/drugs/epoprostenol-veletri/\", \"rr_start\": \"2016-12-13T00:00:00\", \"rr_end\": \"2017-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-12-13, 2017-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Epoprostenol (Veletri\", \"trade_name\": \"Veletri\", \"indication\": \"Veletri\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-12-13T00:00:00\", \"latest\": \"2017-02-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2292, \"last_scrape\": \"2018-12-13T16:34:03\", \"url\": \"http://www.ncpe.ie/drugs/erenumab-aimovig/\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-15T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF ERENUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-19, 2018-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Erenumab (Aimovig\", \"trade_name\": \"Aimovig\", \"indication\": \"Erenumab (Aimovig\", \"ncpe_year\": 2018, \"eu_market\": \"2018-07-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig\", \"ta_list\": \"Migraine Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2293, \"last_scrape\": \"2018-12-13T16:34:07\", \"url\": \"http://www.ncpe.ie/drugs/eribulin-halaven/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-03-11, 2011-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Eribulin (Halaven\", \"trade_name\": \"Halaven\", \"indication\": \"Eribulin (Halaven\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2011-02-09T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/halaven\", \"ta_list\": \"Breast Neoplasms; Liposarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2294, \"last_scrape\": \"2018-12-13T16:34:09\", \"url\": \"http://www.ncpe.ie/drugs/eslicarbazepine-zebinix/\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-08-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2009-09-01, 2009-08-01\", \"rr_multiple\": 0, \"drug_name\": \"Eslicarbazepine (Zebinix\", \"trade_name\": \"Zebinix\", \"indication\": \"Eslicarbazepine (Zebinix\", \"ncpe_year\": 2009, \"eu_market\": \"2009-04-21T00:00:00\", \"company\": \"BIAL\", \"orphan\": 0, \"earliest\": \"2009-08-01T00:00:00\", \"latest\": \"2009-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2295, \"last_scrape\": \"2018-12-13T16:34:12\", \"url\": \"http://www.ncpe.ie/drugs/etanercept-benepali/\", \"rr_start\": \"2016-03-22T00:00:00\", \"rr_end\": \"2016-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-03-22, 2016-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Etanercept (Benepali\", \"trade_name\": \"Benepali\", \"indication\": \"Benepali\", \"ncpe_year\": 2016, \"eu_market\": \"2016-01-13T00:00:00\", \"company\": \"Samsung\", \"orphan\": 0, \"earliest\": \"2016-03-22T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/benepali\", \"ta_list\": \"Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis\", \"rr_status\": \"No HTA\"}, {\"id\": 2296, \"last_scrape\": \"2018-12-13T16:34:15\", \"url\": \"http://www.ncpe.ie/drugs/etelcalcetide-parsabiv/\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-06-14, 2017-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Etelcalcetide (Parsabiv\", \"trade_name\": \"Parsabiv\", \"indication\": \"Etelcalcitide (Parsabiv\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-11T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/parsabiv\", \"ta_list\": \"Hyperparathyroidism, Secondary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2297, \"last_scrape\": \"2018-12-13T16:34:21\", \"url\": \"http://www.ncpe.ie/drugs/eurartesim-piperaquine-tetraphosphatedihidroartemisinin/\", \"rr_start\": \"2012-05-22T00:00:00\", \"rr_end\": \"2012-05-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-05-22, 2012-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Piperaquine tetraphosphate/dihidroartemisinin (Eurartesim\", \"trade_name\": \"Eurartesim\", \"indication\": \"Eurartesim\", \"ncpe_year\": 2012, \"eu_market\": \"2011-10-27T00:00:00\", \"company\": \"Alfasigma\", \"orphan\": 0, \"earliest\": \"2012-05-22T00:00:00\", \"latest\": \"2012-05-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eurartesim\", \"ta_list\": \"Malaria\", \"rr_status\": \"No HTA\"}, {\"id\": 2298, \"last_scrape\": \"2018-12-13T16:34:24\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-afinitor/\", \"rr_start\": \"2012-09-21T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-09-21, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Afinitor\", \"trade_name\": \"Afinitor\", \"indication\": \"Treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor\", \"ncpe_year\": 2012, \"eu_market\": \"2009-08-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-09-21T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/afinitor\", \"ta_list\": \"Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2299, \"last_scrape\": \"2018-12-13T16:34:26\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-votubia-for-refractory-seizures-associated-with-tuberous-sclerosis-complex-tsc/\", \"rr_start\": \"2017-04-19T00:00:00\", \"rr_end\": \"2017-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-04-19, 2017-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Votubia \", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus (Votubia\", \"ncpe_year\": 2017, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2017-04-19T00:00:00\", \"latest\": \"2017-04-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/votubia\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2300, \"last_scrape\": \"2018-12-13T16:34:29\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-votubia/\", \"rr_start\": \"2011-09-30T00:00:00\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-09-30, 2011-10-14\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Votubia\", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus (Votubia\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2011-09-30T00:00:00\", \"latest\": \"2011-10-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/votubia\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2301, \"last_scrape\": \"2018-12-13T16:34:36\", \"url\": \"http://www.ncpe.ie/drugs/evolocumab-repatha/\", \"rr_start\": \"\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Evolocumab (Repatha\", \"trade_name\": \"Repatha\", \"indication\": \"Evolocumab (Repatha\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-17T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-01-01T00:00:00\", \"latest\": \"2018-05-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/repatha\", \"ta_list\": \"Dyslipidemias; Hypercholesterolemia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2302, \"last_scrape\": \"2018-12-13T16:34:41\", \"url\": \"http://www.ncpe.ie/drugs/exenatide-bydureon/\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Exenatide (Bydureon\", \"trade_name\": \"Bydureon\", \"indication\": \"Exenatide (Bydureon\", \"ncpe_year\": 2011, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2303, \"last_scrape\": \"2018-12-13T16:34:44\", \"url\": \"http://www.ncpe.ie/drugs/fampridine-fampyra/\", \"rr_start\": \"2011-09-11T00:00:00\", \"rr_end\": \"2011-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-09-11, 2011-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Fampridine (Fampyra\", \"trade_name\": \"Fampyra\", \"indication\": \"Fampridine (Fampyra\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-20T00:00:00\", \"company\": \"Blogen\", \"orphan\": 0, \"earliest\": \"2011-09-01T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fampyra\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2304, \"last_scrape\": \"2018-12-13T16:34:48\", \"url\": \"http://www.ncpe.ie/drugs/ferric-maltol-feraccru_/\", \"rr_start\": \"2016-08-12T00:00:00\", \"rr_end\": \"2016-09-06T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-08-12, 2016-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Ferric maltol (Feraccru\", \"trade_name\": \"Feraccru\", \"indication\": \"Ferric maltol indicated for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) in adult patients.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Shield\", \"orphan\": 0, \"earliest\": \"2016-08-12T00:00:00\", \"latest\": \"2016-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/feraccru\", \"ta_list\": \"Anemia, Iron-Deficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2305, \"last_scrape\": \"2018-12-13T16:34:51\", \"url\": \"http://www.ncpe.ie/drugs/fidaxomicin-dificlir/\", \"rr_start\": \"2012-03-09T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2012-03-09, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Fidaxomicin (Dificlir\", \"trade_name\": \"Dificlir\", \"indication\": \"Fidaxomicin is indicated for the treatment of CDI also known as CDAD in adult patients.\", \"ncpe_year\": 2013, \"eu_market\": \"2011-12-05T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-03-09T00:00:00\", \"latest\": \"2013-02-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dificlir\", \"ta_list\": \"Clostridium Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2306, \"last_scrape\": \"2018-12-13T16:34:56\", \"url\": \"http://www.ncpe.ie/drugs/fingolimod-gilenya-4/\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2010-12-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-01-10, 2010-12-03\", \"rr_multiple\": 0, \"drug_name\": \"Fingolimod (Gilenya\", \"trade_name\": \"Gilenya\", \"indication\": \"Cost effectiveness of Fingolimod (Gilenya\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2010-12-03T00:00:00\", \"latest\": \"2011-09-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2307, \"last_scrape\": \"2018-12-13T16:35:01\", \"url\": \"http://www.ncpe.ie/drugs/fluocinolone-acetonide-iluvien/\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-02-15, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Fluocinolone acetonide (Iluvien\", \"trade_name\": \"Iluvien\", \"indication\": \"Iluvien\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2308, \"last_scrape\": \"2018-12-13T16:35:05\", \"url\": \"http://www.ncpe.ie/drugs/fluticasone-furoate-umeclidinium-vilantero-trelegy-ellipta/\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT TRELEGY\", \"rr_dates\": \"2018-04-30, 2018-06-18\", \"rr_multiple\": 0, \"drug_name\": \"Fluticasone furoate/ umeclidinium/ vilantero (Trelegy\", \"trade_name\": \"Trelegy Ellipta\", \"indication\": \"Trelegy\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-15T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"Reimbursement without HTA\"}, {\"id\": 2309, \"last_scrape\": \"2018-12-13T16:35:09\", \"url\": \"http://www.ncpe.ie/drugs/follitropin-delta-rekovelle/\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-07-25, 2017-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Follitropin delta (Rekovelle\", \"trade_name\": \"Rekovelle\", \"indication\": \"Follitropin delta (Rekovelle \", \"ncpe_year\": 2019, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2019-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rekovelle\", \"ta_list\": \"Anovulation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2310, \"last_scrape\": \"2018-12-13T16:35:12\", \"url\": \"http://www.ncpe.ie/drugs/gefitinib-iressa/\", \"rr_start\": \"\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Gefitinib (Iressa\", \"trade_name\": \"Iressa\", \"indication\": \"A review of the economic evaluation of oral gefitinib (Iressa\", \"ncpe_year\": 2010, \"eu_market\": \"2009-06-24T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-16T00:00:00\", \"latest\": \"2010-11-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/iressa\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2311, \"last_scrape\": \"2018-12-13T16:35:15\", \"url\": \"http://www.ncpe.ie/drugs/gemtuzumab-ozogamicin-mylotarg/\", \"rr_start\": \"2018-06-21T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF GEMTUZUMAB OZOGAMICIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-21, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Gemtuzumab ozogamicin (Mylotarg\", \"trade_name\": \"Mylotarg\", \"indication\": \"Gemtuzumab ozogamicin (Mylotarg\", \"ncpe_year\": 2018, \"eu_market\": \"2018-04-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-06-21T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2312, \"last_scrape\": \"2018-12-13T16:35:19\", \"url\": \"http://www.ncpe.ie/drugs/glecaprevirpibrentasvir-maviret/\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-07-11, 2017-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glecaprevir/Pibrentasvir (Maviret\", \"trade_name\": \"Maviret\", \"indication\": \"Glecaprevir/pibrentasvir (Maviret\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/maviret\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2313, \"last_scrape\": \"2018-12-13T16:35:25\", \"url\": \"http://www.ncpe.ie/drugs/glucosamine-sulfate-dona/\", \"rr_start\": \"\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Glucosamine sulfate (Dona\", \"trade_name\": \"Dona\", \"indication\": \"Economic evalution of glucosamine sulfate (Dona\", \"ncpe_year\": 2009, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2009-04-01T00:00:00\", \"latest\": \"2009-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2314, \"last_scrape\": \"2018-12-13T16:35:32\", \"url\": \"http://www.ncpe.ie/drugs/glycerol-phenylbutyrate-ravicti/\", \"rr_start\": \"2018-03-26T00:00:00\", \"rr_end\": \"2018-06-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT GLYCEROL PHENYLBUTYRATE (RAVICTI\", \"rr_dates\": \"2018-03-26, 2018-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Glycerol Phenylbutyrate (Ravicti\", \"trade_name\": \"Ravicti\", \"indication\": \"Glycerol phenylbutyrate (Ravicti\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-26T00:00:00\", \"company\": \"Horizon\", \"orphan\": 1, \"earliest\": \"2018-03-26T00:00:00\", \"latest\": \"2018-06-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti\", \"ta_list\": \"Urea Cycle Disorders, Inborn\", \"rr_status\": \"Reimbursement without HTA\"}, {\"id\": 2315, \"last_scrape\": \"2018-12-13T16:35:38\", \"url\": \"http://www.ncpe.ie/drugs/glycopyrronium-bromide-seebri-breezhaler/\", \"rr_start\": \"2012-08-12T00:00:00\", \"rr_end\": \"2012-08-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-08-12, 2012-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide (Seebri Breezhaler\", \"trade_name\": \"Seebri Breezhaler\", \"indication\": \"Seebri Breezhaler\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-08-12T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"id\": 2316, \"last_scrape\": \"2018-12-13T16:35:40\", \"url\": \"http://www.ncpe.ie/drugs/glypyrronium-bromide-sialanar/\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-07, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide (Sialanar\", \"trade_name\": \"Sialanar\", \"indication\": \"Glycopyrronium bromide (Sialanar\", \"ncpe_year\": 2017, \"eu_market\": \"2016-09-15T00:00:00\", \"company\": \"Proveca\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar\", \"ta_list\": \"Sialorrhea\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2317, \"last_scrape\": \"2018-12-13T16:35:47\", \"url\": \"http://www.ncpe.ie/drugs/golimumab-simponi-2/\", \"rr_start\": \"2013-10-11T00:00:00\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-10-11, 2013-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab (Simponi\", \"trade_name\": \"Simponi\", \"indication\": \"Golimumab is indicated for the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments.\", \"ncpe_year\": 2013, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2013-10-11T00:00:00\", \"latest\": \"2013-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/simponi\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"id\": 2318, \"last_scrape\": \"2018-12-13T16:35:54\", \"url\": \"http://www.ncpe.ie/drugs/golimumab-simponi/\", \"rr_start\": \"\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab (Simponi\", \"trade_name\": \"Simponi\", \"indication\": \"Cost-effectiveness of golimumab (Simponi\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2009-11-20T00:00:00\", \"latest\": \"2010-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/simponi\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2319, \"last_scrape\": \"2018-12-13T16:35:56\", \"url\": \"http://www.ncpe.ie/drugs/grass-pollen-allergen-extract-oralair/\", \"rr_start\": \"2011-10-11T00:00:00\", \"rr_end\": \"2011-09-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-10-11, 2011-09-26\", \"rr_multiple\": 0, \"drug_name\": \"Grass pollen allergen extract (Oralair\", \"trade_name\": \"Oralair\", \"indication\": \" Grass pollen allegen extract (Oralair\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-09-26T00:00:00\", \"latest\": \"2011-10-01T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2320, \"last_scrape\": \"2018-12-13T16:36:00\", \"url\": \"http://www.ncpe.ie/drugs/guanfacine-hydrochloride-intuniv/\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-01, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Guanfacine hydrochloride (Intuniv\", \"trade_name\": \"Intuniv\", \"indication\": \"Intuniv\", \"ncpe_year\": 2015, \"eu_market\": \"2015-09-17T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/intuniv\", \"ta_list\": \"Attention Deficit Disorder with Hyperactivity\", \"rr_status\": \"No HTA\"}, {\"id\": 2321, \"last_scrape\": \"2018-12-13T16:36:02\", \"url\": \"http://www.ncpe.ie/drugs/guselkumab-tremfya/\", \"rr_start\": \"2017-12-01T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-12-01, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Guselkumab (Tremfya\", \"trade_name\": \"Tremfya\", \"indication\": \"Guselkumab (Tremfya\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-10T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-12-01T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2322, \"last_scrape\": \"2018-12-13T16:36:07\", \"url\": \"http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-a1pi-prolastin/\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-06-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-05, 2017-06-08\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor (A1PI) (Prolastin\", \"trade_name\": \"Prolastin\", \"indication\": \"Human A1PI (Prolastin \", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-06-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2323, \"last_scrape\": \"2018-12-13T16:36:14\", \"url\": \"http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-respreeza/\", \"rr_start\": \"2016-01-20T00:00:00\", \"rr_end\": \"2016-02-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-20, 2016-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor (Respreeza\", \"trade_name\": \"Respreeza\", \"indication\": \"Respreeza\", \"ncpe_year\": 2017, \"eu_market\": \"2015-08-20T00:00:00\", \"company\": \"CSL\", \"orphan\": 0, \"earliest\": \"2016-01-20T00:00:00\", \"latest\": \"2017-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza\", \"ta_list\": \"Genetic Diseases, Inborn; Lung Diseases\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2324, \"last_scrape\": \"2018-12-13T16:36:17\", \"url\": \"http://www.ncpe.ie/drugs/hyaluronic-acid-and-co-enzyme-q10-visuxl/\", \"rr_start\": \"2017-11-06T00:00:00\", \"rr_end\": \"2017-11-30T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-11-06, 2017-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Hyaluronic acid and co enzyme Q10 (VisuXL\", \"trade_name\": \"VisuXL\", \"indication\": \"Cross linked hyaluronic acid and co enzyme Q10 (VisuXL\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-11-06T00:00:00\", \"latest\": \"2017-11-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2325, \"last_scrape\": \"2018-12-13T16:36:22\", \"url\": \"http://www.ncpe.ie/drugs/hydrocortisone-plenadren/\", \"rr_start\": \"2017-11-08T00:00:00\", \"rr_end\": \"2017-11-01T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-11-08, 2018-01-11, 2017-11-01\", \"rr_multiple\": 1, \"drug_name\": \"Modified Release Hydrocortisone  (Plenadren\", \"trade_name\": \"Plenadren\", \"indication\": \"Modified release hydrocortisone (Plenadren\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-03T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2018-01-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/plenadren\", \"ta_list\": \"Adrenal Insufficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2326, \"last_scrape\": \"2018-12-13T16:36:27\", \"url\": \"http://www.ncpe.ie/drugs/hydroxcarbamide-siklos/\", \"rr_start\": \"2011-08-22T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-08-22, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Hydroxycarbamide (Siklos\", \"trade_name\": \"Siklos\", \"indication\": \" Hydroxycarbamide (Siklos\", \"ncpe_year\": 2011, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"Addmedica\", \"orphan\": 1, \"earliest\": \"2011-08-22T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/siklos\", \"ta_list\": \"Anemia, Sickle Cell\", \"rr_status\": \"No HTA\"}, {\"id\": 2327, \"last_scrape\": \"2018-12-13T16:36:32\", \"url\": \"http://www.ncpe.ie/drugs/ibrutinib-imbruivca-for-previously-untreated-cll/\", \"rr_start\": \"2016-08-02T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-08-02, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib (Imbruvica\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib (Imbruvica\", \"ncpe_year\": 2016, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-08-02T00:00:00\", \"latest\": \"2016-08-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2328, \"last_scrape\": \"2018-12-13T16:36:36\", \"url\": \"http://www.ncpe.ie/drugs/ibrutinib-imbruvica-for-mcl/\", \"rr_start\": \"2014-11-07T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-11-07, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib (Imbruvica\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib (Imbruvica\", \"ncpe_year\": 2015, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-11-07T00:00:00\", \"latest\": \"2015-10-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2329, \"last_scrape\": \"2018-12-13T16:36:40\", \"url\": \"http://www.ncpe.ie/drugs/icatibant-firazyr/\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Icatibant (Firazyr\", \"trade_name\": \"Firazyr\", \"indication\": \"Icatibant (Firazyr\", \"ncpe_year\": 2013, \"eu_market\": \"2008-07-11T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"id\": 2330, \"last_scrape\": \"2018-12-13T16:36:43\", \"url\": \"http://www.ncpe.ie/drugs/idarucizumab-praxbind/\", \"rr_start\": \"2015-12-11T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-11, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Idarucizumab (Praxbind\", \"trade_name\": \"Praxbind\", \"indication\": \"Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required:\", \"ncpe_year\": 2015, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-12-11T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/praxbind\", \"ta_list\": \"Hemorrhage\", \"rr_status\": \"No HTA\"}, {\"id\": 2331, \"last_scrape\": \"2018-12-13T16:36:50\", \"url\": \"http://www.ncpe.ie/drugs/idebenone-raxone/\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-04-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-10, 2016-04-14\", \"rr_multiple\": 0, \"drug_name\": \"Idebenone (Raxone\", \"trade_name\": \"Raxone\", \"indication\": \"Raxone\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-08T00:00:00\", \"company\": \"Santhera\", \"orphan\": 1, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2018-08-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/raxone\", \"ta_list\": \"Optic Atrophy, Hereditary, Leber\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2332, \"last_scrape\": \"2018-12-13T16:36:56\", \"url\": \"http://www.ncpe.ie/drugs/idelalisib-zydelig/\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2014-12-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-08, 2014-12-30\", \"rr_multiple\": 0, \"drug_name\": \"Idelalisib (Zydelig\", \"trade_name\": \"Zydelig\", \"indication\": \"Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2016-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2333, \"last_scrape\": \"2018-12-13T16:36:59\", \"url\": \"http://www.ncpe.ie/drugs/imiquimod-zyclara/\", \"rr_start\": \"2013-09-10T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-09-10, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Imiquimod 3.75% (Zyclara\", \"trade_name\": \"Zyclara\", \"indication\": \"Imiquimod 3.75%(Zyclara\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Meda\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara\", \"ta_list\": \"Keratosis; Keratosis, Actinic\", \"rr_status\": \"No HTA\"}, {\"id\": 2334, \"last_scrape\": \"2018-12-13T16:37:01\", \"url\": \"http://www.ncpe.ie/drugs/incobotulinum-toxin-type-a-xeomin/\", \"rr_start\": \"2014-02-07T00:00:00\", \"rr_end\": \"2014-03-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-07, 2014-03-05\", \"rr_multiple\": 0, \"drug_name\": \"Incobotulinum Toxin Type A (Xeomin\", \"trade_name\": \"Xeomin\", \"indication\": \"Incobotulinum Toxin Type A (Xeomin\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-02-07T00:00:00\", \"latest\": \"2014-03-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2335, \"last_scrape\": \"2018-12-13T16:37:04\", \"url\": \"http://www.ncpe.ie/drugs/indacaterol-onbrez/\", \"rr_start\": \"2010-01-15T00:00:00\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-01-15\", \"rr_multiple\": 0, \"drug_name\": \"Indacaterol (Onbrez\", \"trade_name\": \"Onbrez\", \"indication\": \"Review of Indacaterol (Onbrez\", \"ncpe_year\": 2010, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-01-15T00:00:00\", \"latest\": \"2010-01-15T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2336, \"last_scrape\": \"2018-12-13T16:37:07\", \"url\": \"http://www.ncpe.ie/drugs/infliximab-inflectra/\", \"rr_start\": \"\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Infliximab (Inflectra\", \"trade_name\": \"Inflectra\", \"indication\": \"Inflectra\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2337, \"last_scrape\": \"2018-12-13T16:37:09\", \"url\": \"http://www.ncpe.ie/drugs/inotuzumab-ozogamicin-besponsa/\", \"rr_start\": \"2017-07-03T00:00:00\", \"rr_end\": \"2017-09-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-03, 2017-09-08\", \"rr_multiple\": 0, \"drug_name\": \"Inotuzumab ozogamicin (Besponsa\", \"trade_name\": \"Besponsa\", \"indication\": \"Inotuzumab ozogamicin (Besponsa\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2017-07-03T00:00:00\", \"latest\": \"2018-09-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2338, \"last_scrape\": \"2018-12-13T16:37:16\", \"url\": \"http://www.ncpe.ie/drugs/insulin-aspart-fiasp/\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-05-17, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart (Fiasp\", \"trade_name\": \"Fiasp\", \"indication\": \"Insulin aspart (Fiasp\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-09T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fiasp\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"No HTA\"}, {\"id\": 2339, \"last_scrape\": \"2018-12-13T16:37:21\", \"url\": \"http://www.ncpe.ie/drugs/insulin-aspart-novorapid-flextouch/\", \"rr_start\": \"2014-07-22T00:00:00\", \"rr_end\": \"2014-08-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2014-07-22, 2014-08-28\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart (NovoRapid\", \"trade_name\": \"NovoRapid FlexTouch\", \"indication\": \"Insulin aspart (NovoRapid\", \"ncpe_year\": 2014, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2014-07-22T00:00:00\", \"latest\": \"2014-08-28T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2340, \"last_scrape\": \"2018-12-13T16:37:25\", \"url\": \"http://www.ncpe.ie/drugs/insulin-degludec-tresiba/\", \"rr_start\": \"2012-12-17T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-17, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Degludec (Tresiba\", \"trade_name\": \"Tresiba\", \"indication\": \"Treatment of diabetes mellitus\", \"ncpe_year\": 2015, \"eu_market\": \"2013-01-20T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2012-12-17T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2341, \"last_scrape\": \"2018-12-13T16:37:30\", \"url\": \"http://www.ncpe.ie/drugs/insulin-degludecliraglutide-ideglira-xultophy/\", \"rr_start\": \"2016-09-19T00:00:00\", \"rr_end\": \"2016-10-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-09-19, 2016-10-17\", \"rr_multiple\": 0, \"drug_name\": \"Insulin degludec/liraglutide (IDegLira) (Xultophy\", \"trade_name\": \"Xultophy\", \"indication\": \"IDegLira is indicated for the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2016-09-19T00:00:00\", \"latest\": \"2016-10-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xultophy\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2342, \"last_scrape\": \"2018-12-13T16:37:36\", \"url\": \"http://www.ncpe.ie/drugs/insulin-glargine-abasaglar/\", \"rr_start\": \"2015-09-04T00:00:00\", \"rr_end\": \"2015-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-09-04, 2015-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine (Abasaglar\", \"trade_name\": \"Abasaglar\", \"indication\": \"Abasaglar\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-09-04T00:00:00\", \"latest\": \"2015-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2343, \"last_scrape\": \"2018-12-13T16:37:40\", \"url\": \"http://www.ncpe.ie/drugs/insulin-glargine-u300-toujeo/\", \"rr_start\": \"2015-05-14T00:00:00\", \"rr_end\": \"2015-07-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2015-05-14, 2015-07-02\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine U300 (Toujeo\", \"trade_name\": \"Toujeo\", \"indication\": \"Toujeo\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-05-14T00:00:00\", \"latest\": \"2015-07-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2344, \"last_scrape\": \"2018-12-13T16:37:43\", \"url\": \"http://www.ncpe.ie/drugs/ipilimumab-yervoy/\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Ipilimumab (Yervoy\", \"trade_name\": \"Yervoy\", \"indication\": \"Pharmacoeconomic evaluation of Ipilimumab (Yervoy\", \"ncpe_year\": 2013, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2013-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2345, \"last_scrape\": \"2018-12-13T16:37:49\", \"url\": \"http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-diafer/\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron (III) isomaltoside 1000 (Diafer\", \"trade_name\": \"Diafer\", \"indication\": \"Diafer\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2346, \"last_scrape\": \"2018-12-13T16:37:52\", \"url\": \"http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-monover/\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron (III) isomaltoside 1000 (Monover\", \"trade_name\": \"Monover\", \"indication\": \"Monover\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2347, \"last_scrape\": \"2018-12-13T16:38:02\", \"url\": \"http://www.ncpe.ie/drugs/iron-isomaltoside-1000-monover/\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2011-02-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-01-10, 2011-02-02\", \"rr_multiple\": 0, \"drug_name\": \"Iron isomaltoside 1000 (MonoVer\", \"trade_name\": \"MonoVer\", \"indication\": \"MonoVer is indicated for the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-01-10T00:00:00\", \"latest\": \"2011-02-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2348, \"last_scrape\": \"2018-12-13T16:38:07\", \"url\": \"http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-invasive-aspergillosis/\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole (Cresemba\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole (Cresemba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2349, \"last_scrape\": \"2018-12-13T16:38:09\", \"url\": \"http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-mucormycosis/\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole (Cresemba\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole (Cresemba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2350, \"last_scrape\": \"2018-12-13T16:38:15\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kaldeco/\", \"rr_start\": \"2012-08-13T00:00:00\", \"rr_end\": \"2012-08-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-08-13, 2012-08-22\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2012-08-13T00:00:00\", \"latest\": \"2013-01-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2351, \"last_scrape\": \"2018-12-13T16:38:21\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-patients-with-cf-2-years/\", \"rr_start\": \"2015-11-19T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMAOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-19, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\", \"ncpe_year\": 2016, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2015-11-19T00:00:00\", \"latest\": \"2016-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2352, \"last_scrape\": \"2018-12-13T16:38:24\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-the-treatment-of-cf-patients-with-the-r117h-mutation/\", \"rr_start\": \"2016-01-14T00:00:00\", \"rr_end\": \"2016-02-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-14, 2016-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\", \"ncpe_year\": 2017, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2016-01-14T00:00:00\", \"latest\": \"2017-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2353, \"last_scrape\": \"2018-12-13T16:38:29\", \"url\": \"http://www.ncpe.ie/drugs/ixazomib-ninlaro/\", \"rr_start\": \"2016-11-23T00:00:00\", \"rr_end\": \"2017-01-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-23, 2017-01-16\", \"rr_multiple\": 0, \"drug_name\": \"Ixazomib (Ninlaro\", \"trade_name\": \"Ninlaro\", \"indication\": \"Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-21T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2016-11-23T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2354, \"last_scrape\": \"2018-12-13T16:38:34\", \"url\": \"http://www.ncpe.ie/drugs/ixekizumab-taltz-for-psoriatic-arthritis/\", \"rr_start\": \"2018-10-16T00:00:00\", \"rr_end\": \"2018-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT IXEKIZUMAB NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE. THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013\", \"rr_dates\": \"2018-10-16, 2018-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab (Taltz\", \"trade_name\": \"Taltz\", \"indication\": \"Ixekizumab (Taltz\", \"ncpe_year\": 2018, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2018-10-16T00:00:00\", \"latest\": \"2018-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/taltz\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2355, \"last_scrape\": \"2018-12-13T16:38:37\", \"url\": \"http://www.ncpe.ie/drugs/ixekizumab-taltz/\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-06-28, 2016-07-26\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab (Taltz\", \"trade_name\": \"Taltz\", \"indication\": \"Taltz\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/taltz\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2356, \"last_scrape\": \"2018-12-13T16:38:39\", \"url\": \"http://www.ncpe.ie/drugs/l/lisdexamfetamine-dimesylate-tyvense/\", \"rr_start\": \"2013-02-09T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-02-09, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Lisdexamfetamine dimesylate (Tyvense\", \"trade_name\": \"Tyvense\", \"indication\": \"Lisdexamfetamine dimesylate (Tyvense\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-02-09T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2357, \"last_scrape\": \"2018-12-13T16:38:44\", \"url\": \"http://www.ncpe.ie/drugs/lacosamide-vimpat/\", \"rr_start\": \"2017-09-11T00:00:00\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-09-11, 2017-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Lacosamide (Vimpat \", \"trade_name\": \"Vimpat\", \"indication\": \"Vimpat \", \"ncpe_year\": 2017, \"eu_market\": \"2008-08-29T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2017-09-11T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2358, \"last_scrape\": \"2018-12-13T16:38:50\", \"url\": \"http://www.ncpe.ie/drugs/lapatinib-tyverb/\", \"rr_start\": \"\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Lapatinib (Tyverb\", \"trade_name\": \"Tyverb\", \"indication\": \"Cost-effectiveness of Lapatinib (Tyverb\", \"ncpe_year\": 2008, \"eu_market\": \"2008-06-10T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2359, \"last_scrape\": \"2018-12-13T16:38:56\", \"url\": \"http://www.ncpe.ie/drugs/ledipasvirsofosbuvir-harvoni/\", \"rr_start\": \"2014-11-14T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-11-14, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ledipasvir/sofosbuvir (Harvoni\", \"trade_name\": \"Harvoni\", \"indication\": \"Ledipasvir/sofosbuvir (Harvoni\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-17T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-11-14T00:00:00\", \"latest\": \"2015-11-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2360, \"last_scrape\": \"2018-12-13T16:39:05\", \"url\": \"http://www.ncpe.ie/drugs/lenalidomide-revlimid/\", \"rr_start\": \"2015-10-05T00:00:00\", \"rr_end\": \"2015-11-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE.\", \"rr_dates\": \"2015-10-05, 2015-11-20\", \"rr_multiple\": 0, \"drug_name\": \"Lenalidomide (Revlimid\", \"trade_name\": \"Revlimid\", \"indication\": \"Revlimid\", \"ncpe_year\": 2018, \"eu_market\": \"2007-06-14T00:00:00\", \"company\": \"Celgene\", \"orphan\": 1, \"earliest\": \"2015-10-05T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid\", \"ta_list\": \"Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2361, \"last_scrape\": \"2018-12-13T16:39:07\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-kisplyx/\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-05-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-05-05, 2017-05-18\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Kisplyx\", \"trade_name\": \"Kisplyx\", \"indication\": \"Lenvatinib (Kisplyx\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-25T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-05-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2362, \"last_scrape\": \"2018-12-13T16:39:11\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-lenvima-2/\", \"rr_start\": \"2018-08-07T00:00:00\", \"rr_end\": \"2018-08-16T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF LENVATINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-08-07, 2018-08-16\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Lenvima\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib (Lenvima\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2018-08-07T00:00:00\", \"latest\": \"2018-08-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2363, \"last_scrape\": \"2018-12-13T16:39:15\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-lenvima/\", \"rr_start\": \"2015-05-05T00:00:00\", \"rr_end\": \"2015-07-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2015-05-05, 2015-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Lenvima\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/H\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2015-05-05T00:00:00\", \"latest\": \"2015-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2364, \"last_scrape\": \"2018-12-13T16:39:20\", \"url\": \"http://www.ncpe.ie/drugs/lesinurad-zurampic/\", \"rr_start\": \"2017-03-15T00:00:00\", \"rr_end\": \"2017-03-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-15, 2017-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Lesinurad (Zurampic\", \"trade_name\": \"Zurampic\", \"indication\": \"Lesinurad (Zurampic\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Gr\", \"orphan\": 0, \"earliest\": \"2017-03-15T00:00:00\", \"latest\": \"2018-12-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zurampic\", \"ta_list\": \"Hyperuricemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2365, \"last_scrape\": \"2018-12-13T16:39:25\", \"url\": \"http://www.ncpe.ie/drugs/letermovir-prevymis/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Letermovir (Prevymis\", \"trade_name\": \"Prevymis\", \"indication\": \"Letermovir for the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevymis\", \"ta_list\": \"Cytomegalovirus Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2366, \"last_scrape\": \"2018-12-13T16:39:28\", \"url\": \"http://www.ncpe.ie/drugs/levodopa-20mgml-carbidopa-monohydrate-5mg-intestinal-gel-duodopa/\", \"rr_start\": \"2013-03-13T00:00:00\", \"rr_end\": \"2013-04-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-03-13, 2013-04-16\", \"rr_multiple\": 0, \"drug_name\": \"Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel (Duodopa\", \"trade_name\": \"Duodopa\", \"indication\": \"For the treatment of advanced levodopa-responsive Parkinson\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-13T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2367, \"last_scrape\": \"2018-12-13T16:39:34\", \"url\": \"http://www.ncpe.ie/drugs/levofloxacin-quinsair/\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-02-10, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Levofloxacin (Quinsair\", \"trade_name\": \"Quinsair\", \"indication\": \"Levofloxacin (Quinsair\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-25T00:00:00\", \"company\": \"Horizon\", \"orphan\": 0, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/quinsair\", \"ta_list\": \"Cystic Fibrosis; Respiratory Tract Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2368, \"last_scrape\": \"2018-12-13T16:39:39\", \"url\": \"http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-delivery-system-lng-ius-12-kyleena/\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-02-08, 2017-03-16\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine delivery system LNG IUS 12 (Kyleena\", \"trade_name\": \"Kyleena\", \"indication\": \"Kyleena\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2017-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2369, \"last_scrape\": \"2018-12-13T16:39:44\", \"url\": \"http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-system-lng-ius-jaydess/\", \"rr_start\": \"2013-03-07T00:00:00\", \"rr_end\": \"2013-03-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-03-07, 2013-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine system LNG-IUS (Jaydess\", \"trade_name\": \"Jaydess\", \"indication\": \"Levonorgestrel Intrauterine System LNG-IUS (Jaydess\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-07T00:00:00\", \"latest\": \"2013-03-25T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2370, \"last_scrape\": \"2018-12-13T16:39:46\", \"url\": \"http://www.ncpe.ie/drugs/lidocaine-5-plasters-versatis/\", \"rr_start\": \"2010-09-09T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2010-09-09, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Lidocaine 5% plasters (Versatis\", \"trade_name\": \"Versatis\", \"indication\": \"Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN).\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-09-09T00:00:00\", \"latest\": \"2015-09-24T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2371, \"last_scrape\": \"2018-12-13T16:39:51\", \"url\": \"http://www.ncpe.ie/drugs/linaclotide-clonstella/\", \"rr_start\": \"2013-05-28T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-05-28, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Linaclotide (Constella\", \"trade_name\": \"Constella\", \"indication\": \"Linaclotide (Constella\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2013-05-28T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/constella\", \"ta_list\": \"Irritable Bowel Syndrome\", \"rr_status\": \"No HTA\"}, {\"id\": 2372, \"last_scrape\": \"2018-12-13T16:39:54\", \"url\": \"http://www.ncpe.ie/drugs/linagliptin-trajenta/\", \"rr_start\": \"2011-08-18T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-08-18, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Linagliptin (Trajenta\", \"trade_name\": \"Trajenta\", \"indication\": \"Lingagliptin (Trajenta\", \"ncpe_year\": 2011, \"eu_market\": \"2011-08-23T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2011-08-18T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2373, \"last_scrape\": \"2018-12-13T16:39:57\", \"url\": \"http://www.ncpe.ie/drugs/lipegfilgrastim-lonquex/\", \"rr_start\": \"2013-08-20T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-08-20, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Lipegfilgrastim (Lonquex\", \"trade_name\": \"Lonquex\", \"indication\": \"Lonquex\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-25T00:00:00\", \"company\": \"Sicor\", \"orphan\": 0, \"earliest\": \"2013-08-20T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex\", \"ta_list\": \"Neutropenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2374, \"last_scrape\": \"2018-12-13T16:40:00\", \"url\": \"http://www.ncpe.ie/drugs/liposomal-daunorubicin-and-cytarabine-cpx-351vyxeos/\", \"rr_start\": \"2018-09-28T00:00:00\", \"rr_end\": \"2018-11-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-09-28, 2018-11-08\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos\", \"trade_name\": \"Vyxeos\", \"indication\": \"Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Jazz\", \"orphan\": 1, \"earliest\": \"2018-09-28T00:00:00\", \"latest\": \"2018-11-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2375, \"last_scrape\": \"2018-12-13T16:40:06\", \"url\": \"http://www.ncpe.ie/drugs/liposomal-irinotecan-nal-iri-onivyde/\", \"rr_start\": \"2017-06-13T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-13, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal irinotecan (Onivyde\", \"trade_name\": \"Onivyde\", \"indication\": \"Liposomal irinotecan (Onivyde\", \"ncpe_year\": 2017, \"eu_market\": \"2016-10-14T00:00:00\", \"company\": \"Baxalta\", \"orphan\": 1, \"earliest\": \"2017-06-13T00:00:00\", \"latest\": \"2017-07-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-0\", \"ta_list\": \"Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2376, \"last_scrape\": \"2018-12-13T16:40:09\", \"url\": \"http://www.ncpe.ie/drugs/liquid-paraffin-ointment-vita-pos-opthalmic/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Liquid Paraffin Ointment (VitA-POS Opthalmic\", \"trade_name\": \"VitA-POS Opthalmic\", \"indication\": \"Liquid Paraffin Ointment (VitA-POS Opthalmic\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2377, \"last_scrape\": \"2018-12-13T16:40:13\", \"url\": \"http://www.ncpe.ie/drugs/liraglutide-victoza/\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-10-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-09-01, 2009-10-07\", \"rr_multiple\": 0, \"drug_name\": \"Liraglutide (Victoza\", \"trade_name\": \"Victoza\", \"indication\": \"Victoza\", \"ncpe_year\": 2018, \"eu_market\": \"2009-06-30T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2009-09-01T00:00:00\", \"latest\": \"2018-10-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/victoza\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2378, \"last_scrape\": \"2018-12-13T16:40:17\", \"url\": \"http://www.ncpe.ie/drugs/lixisenatide-lyxumia/\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Lixisenatide (Lyxumia\", \"trade_name\": \"Lyxumia\", \"indication\": \"Lixisenatide (Lyxumia\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-08-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2379, \"last_scrape\": \"2018-12-13T16:40:19\", \"url\": \"http://www.ncpe.ie/drugs/lomitapide-lojuxta/\", \"rr_start\": \"2014-09-09T00:00:00\", \"rr_end\": \"2014-09-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-09-09, 2014-09-15\", \"rr_multiple\": 0, \"drug_name\": \"Lomitapide (Lojuxta\", \"trade_name\": \"Lojuxta\", \"indication\": \"Lojuxta\", \"ncpe_year\": 2014, \"eu_market\": \"2013-07-31T00:00:00\", \"company\": \"Amryt\", \"orphan\": 0, \"earliest\": \"2014-09-09T00:00:00\", \"latest\": \"2014-09-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2380, \"last_scrape\": \"2018-12-13T16:40:22\", \"url\": \"http://www.ncpe.ie/drugs/lornoxicam-xefo/\", \"rr_start\": \"2011-06-23T00:00:00\", \"rr_end\": \"2011-07-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-06-23, 2011-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Lornoxicam (Xefo\", \"trade_name\": \"Xefo\", \"indication\": \" Lornoxicam (Xefo\", \"ncpe_year\": 2011, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-06-23T00:00:00\", \"latest\": \"2011-07-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA\"}, {\"id\": 2381, \"last_scrape\": \"2018-12-13T16:40:24\", \"url\": \"http://www.ncpe.ie/drugs/lotemax-0-5-eye-drops-suspension-loteprednol/\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2011-12-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-11-15, 2011-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Lotemax 0.5% eye drops suspension (Loteprednol)\", \"trade_name\": \"Loteprednol\", \"indication\": \" Indicated for treatment of post-operative inflammation following ocular surgery.\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2011-12-05T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2382, \"last_scrape\": \"2018-12-13T16:40:30\", \"url\": \"http://www.ncpe.ie/drugs/loxapine-inhalation-powder-adasuve/\", \"rr_start\": \"2016-06-21T00:00:00\", \"rr_end\": \"2016-07-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-06-21, 2016-07-28\", \"rr_multiple\": 0, \"drug_name\": \"Loxapine inhalation powder (Adasuve\", \"trade_name\": \"Adasuve\", \"indication\": \"Inhaled loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-02-20T00:00:00\", \"company\": \"Ferrer\", \"orphan\": 0, \"earliest\": \"2016-06-21T00:00:00\", \"latest\": \"2016-07-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve\", \"ta_list\": \"Schizophrenia; Bipolar Disorder\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2383, \"last_scrape\": \"2018-12-13T16:40:34\", \"url\": \"http://www.ncpe.ie/drugs/lumacaftorivacaftor-orkambi/\", \"rr_start\": \"2015-11-26T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-26, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Lumacaftor/ivacaftor (Orkambi\", \"trade_name\": \"Orkambi\", \"indication\": \"Orkambi\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Vertex\", \"orphan\": 0, \"earliest\": \"2015-11-26T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/orkambi\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2384, \"last_scrape\": \"2018-12-13T16:40:36\", \"url\": \"http://www.ncpe.ie/drugs/lutetium-177lu-oxodotreotide-lutathera/\", \"rr_start\": \"2018-10-23T00:00:00\", \"rr_end\": \"2018-11-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-10-23, 2018-11-16\", \"rr_multiple\": 0, \"drug_name\": \"Lutetium (177Lu) Oxodotreotide (Lutathera\", \"trade_name\": \"Lutathera\", \"indication\": \"Lutetium (177Lu) Oxodotreotide (Lutathera\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-26T00:00:00\", \"company\": \"Advanced\", \"orphan\": 1, \"earliest\": \"2018-10-23T00:00:00\", \"latest\": \"2018-11-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2385, \"last_scrape\": \"2018-12-13T16:40:41\", \"url\": \"http://www.ncpe.ie/drugs/macitentan-opsumit/\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-10, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Macitentan (Opsumit\", \"trade_name\": \"Opsumit\", \"indication\": \"Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-12-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2386, \"last_scrape\": \"2018-12-13T16:40:43\", \"url\": \"http://www.ncpe.ie/drugs/melatonin-circadin/\", \"rr_start\": \"\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Melatonin (Circadin\", \"trade_name\": \"Circadin\", \"indication\": \"A Review of the Economic Evaluation of Prolonged Release Melatonin (Circadin\", \"ncpe_year\": 2008, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"RAD\", \"orphan\": 0, \"earliest\": \"2008-08-01T00:00:00\", \"latest\": \"2008-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/circadin\", \"ta_list\": \"Sleep Initiation and Maintenance Disorders\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2387, \"last_scrape\": \"2018-12-13T16:40:45\", \"url\": \"http://www.ncpe.ie/drugs/mepolizumab-nucala/\", \"rr_start\": \"2016-03-16T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-03-16, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Mepolizumab (Nucala\", \"trade_name\": \"Nucala\", \"indication\": \"Mepolizumab (Nucala\", \"ncpe_year\": 2018, \"eu_market\": \"2015-12-01T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-03-16T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nucala\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2388, \"last_scrape\": \"2018-12-13T16:40:51\", \"url\": \"http://www.ncpe.ie/drugs/methoxyflurane-penthrox/\", \"rr_start\": \"2015-11-23T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-11-23, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Methoxyflurane (Penthrox\", \"trade_name\": \"Penthrox\", \"indication\": \"Penthrox\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2015-11-23T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2389, \"last_scrape\": \"2018-12-13T16:40:56\", \"url\": \"http://www.ncpe.ie/drugs/midostaurin-rydapt-for-aml/\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF MIDOSTAURIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin (Rydapt\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin (Rydapt\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2390, \"last_scrape\": \"2018-12-13T16:41:02\", \"url\": \"http://www.ncpe.ie/drugs/midostaurin-rydapt-for-asm/\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF MIDOSTAURIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin (Rydapt\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin (Rydapt\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2391, \"last_scrape\": \"2018-12-13T16:41:04\", \"url\": \"http://www.ncpe.ie/drugs/mifamurtide-mepact/\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-06-22, 2010-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Mifamurtide (Mepact\", \"trade_name\": \"Mepact\", \"indication\": \"Mifamurtide (Meptact\", \"ncpe_year\": 2010, \"eu_market\": \"2009-03-06T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2010-06-22T00:00:00\", \"latest\": \"2010-07-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mepact\", \"ta_list\": \"Osteosarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2392, \"last_scrape\": \"2018-12-13T16:41:06\", \"url\": \"http://www.ncpe.ie/drugs/migalastat-galafold/\", \"rr_start\": \"2016-07-14T00:00:00\", \"rr_end\": \"2016-08-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-07-14, 2016-08-18\", \"rr_multiple\": 0, \"drug_name\": \"Migalastat (Galafold\", \"trade_name\": \"Galafold\", \"indication\": \"Migalastat is indicated for the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-05-25T00:00:00\", \"company\": \"Amicus\", \"orphan\": 1, \"earliest\": \"2016-07-14T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/galafold\", \"ta_list\": \"Fabry Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2393, \"last_scrape\": \"2018-12-13T16:41:13\", \"url\": \"http://www.ncpe.ie/drugs/mirabegron-betmiga/\", \"rr_start\": \"2012-12-19T00:00:00\", \"rr_end\": \"2013-03-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-12-19, 2013-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Mirabegron (Betmiga\", \"trade_name\": \"Betmiga\", \"indication\": \"Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome\", \"ncpe_year\": 2013, \"eu_market\": \"2012-12-20T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-12-19T00:00:00\", \"latest\": \"2013-03-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga\", \"ta_list\": \"Urinary Bladder, Overactive\", \"rr_status\": \"No HTA\"}, {\"id\": 2394, \"last_scrape\": \"2018-12-13T16:41:15\", \"url\": \"http://www.ncpe.ie/drugs/nab-paclitaxel-abraxane/\", \"rr_start\": \"2014-01-23T00:00:00\", \"rr_end\": \"2014-03-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-01-23, 2014-03-02\", \"rr_multiple\": 0, \"drug_name\": \"Nab-paclitaxel (Abraxane\", \"trade_name\": \"Abraxane\", \"indication\": \"Nab-paclitaxel (Abraxane\", \"ncpe_year\": 2015, \"eu_market\": \"2008-01-10T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2014-01-23T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane\", \"ta_list\": \"Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2395, \"last_scrape\": \"2018-12-13T16:41:18\", \"url\": \"http://www.ncpe.ie/drugs/nalmefene-selincro/\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Nalmefene (Selincro\", \"trade_name\": \"Selincro\", \"indication\": \"Nalmefene (Selincro\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-24T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2014-04-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/selincro\", \"ta_list\": \"Alcohol-Related Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2396, \"last_scrape\": \"2018-12-13T16:41:24\", \"url\": \"http://www.ncpe.ie/drugs/naloxegel-moventig/\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-04-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-02-10, 2015-04-13\", \"rr_multiple\": 0, \"drug_name\": \"Naloxegel (Moventig\", \"trade_name\": \"Moventig\", \"indication\": \"Naloxegel (Moventiq\", \"ncpe_year\": 2015, \"eu_market\": \"2014-12-07T00:00:00\", \"company\": \"Kyowa\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-04-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/moventig\", \"ta_list\": \"Constipation; Opioid-Related Disorders\", \"rr_status\": \"No HTA\"}, {\"id\": 2397, \"last_scrape\": \"2018-12-13T16:41:26\", \"url\": \"http://www.ncpe.ie/drugs/naltrexone-bupropion-mysimba/\", \"rr_start\": \"2017-03-12T00:00:00\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-12, 2017-03-28\", \"rr_multiple\": 0, \"drug_name\": \"Naltrexone / bupropion (Mysimba\", \"trade_name\": \"Mysimba\", \"indication\": \"Naltrexone / bupropion (Mysimba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-03-26T00:00:00\", \"company\": \"Orexigen\", \"orphan\": 0, \"earliest\": \"2017-03-12T00:00:00\", \"latest\": \"2018-05-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba\", \"ta_list\": \"Obesity; Overweight\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2398, \"last_scrape\": \"2018-12-13T16:41:30\", \"url\": \"http://www.ncpe.ie/drugs/natalizumab-tysabri/\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Natalizumab (Tysabri\", \"trade_name\": \"Tysabri\", \"indication\": \" Economic Evaluation of Natalizumab (Tysabri\", \"ncpe_year\": 2007, \"eu_market\": \"2006-06-27T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2007-01-01T00:00:00\", \"latest\": \"2007-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2399, \"last_scrape\": \"2018-12-13T16:41:35\", \"url\": \"http://www.ncpe.ie/drugs/ncpe-inhaled-insulin-exubera-assessment/\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Inhaled insulin (Exubera\", \"trade_name\": \"Exubera\", \"indication\": \"In April 2006, Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin (Exubera\", \"ncpe_year\": 2006, \"eu_market\": \"2006-01-24T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-03-01T00:00:00\", \"latest\": \"2006-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/exubera\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2400, \"last_scrape\": \"2018-12-13T16:41:38\", \"url\": \"http://www.ncpe.ie/drugs/nepafenac-nevanac-2/\", \"rr_start\": \"2011-06-14T00:00:00\", \"rr_end\": \"2011-06-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-06-14, 2011-06-27\", \"rr_multiple\": 0, \"drug_name\": \"Nepafenac (Nevanac\", \"trade_name\": \"Nevanac\", \"indication\": \"Nepafenac (Nevanac\", \"ncpe_year\": 2011, \"eu_market\": \"2007-12-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2011-06-14T00:00:00\", \"latest\": \"2011-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac\", \"ta_list\": \"Pain, Postoperative; Ophthalmologic Surgical Procedures\", \"rr_status\": \"No HTA\"}, {\"id\": 2401, \"last_scrape\": \"2018-12-13T16:41:41\", \"url\": \"http://www.ncpe.ie/drugs/netupitantpalonosetron-akynzeo/\", \"rr_start\": \"2015-08-26T00:00:00\", \"rr_end\": \"2015-10-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-08-26, 2015-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Netupitant/palonosetron (Akynzeo\", \"trade_name\": \"Akynzeo\", \"indication\": \"Akynzeo\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Helsinn\", \"orphan\": 0, \"earliest\": \"2015-08-26T00:00:00\", \"latest\": \"2015-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo\", \"ta_list\": \"Vomiting; Cancer; Nausea\", \"rr_status\": \"No HTA\"}, {\"id\": 2402, \"last_scrape\": \"2018-12-13T16:41:44\", \"url\": \"http://www.ncpe.ie/drugs/nilotinib-tasigna-newly-diagnosed-cml/\", \"rr_start\": \"2010-10-06T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2010-10-06, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib (Tasigna\", \"trade_name\": \"Tasigna\", \"indication\": \"Nilotinib (Tasigna\", \"ncpe_year\": 2010, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-10-06T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2403, \"last_scrape\": \"2018-12-13T16:41:51\", \"url\": \"http://www.ncpe.ie/drugs/nilotinib-tasigna/\", \"rr_start\": \"\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib (Tasigna\", \"trade_name\": \"Tasigna\", \"indication\": \"Cost-effectiveness of Nilotinib (Tasigna\", \"ncpe_year\": 2008, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2404, \"last_scrape\": \"2018-12-13T16:41:53\", \"url\": \"http://www.ncpe.ie/drugs/nintedanib-ofev/\", \"rr_start\": \"2015-01-30T00:00:00\", \"rr_end\": \"2015-02-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-30, 2015-02-18\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib (Ofev\", \"trade_name\": \"Ofev\", \"indication\": \"Nintedanib (Ofev\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 1, \"earliest\": \"2015-01-30T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ofev\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2405, \"last_scrape\": \"2018-12-13T16:41:56\", \"url\": \"http://www.ncpe.ie/drugs/nintedanib-vargatef/\", \"rr_start\": \"2015-01-02T00:00:00\", \"rr_end\": \"2015-02-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-02, 2015-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib (Vargatef\", \"trade_name\": \"Vargatef\", \"indication\": \"Nintedanib (Vargatef\", \"ncpe_year\": 2017, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-01-02T00:00:00\", \"latest\": \"2017-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2406, \"last_scrape\": \"2018-12-13T16:42:00\", \"url\": \"http://www.ncpe.ie/drugs/niraparib-zejula/\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF NIRAPARIB COMPARED WITH THE CURRENT STANDARD OF CARE\", \"rr_dates\": \"2018-06-01, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Niraparib (Zejula\", \"trade_name\": \"Zejula\", \"indication\": \"Niraparib (Zejula\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-16T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 1, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zejula\", \"ta_list\": \"Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2407, \"last_scrape\": \"2018-12-13T16:42:06\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-melanoma/\", \"rr_start\": \"2015-05-28T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-05-28, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-05-28T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2408, \"last_scrape\": \"2018-12-13T16:42:13\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-non-squamous-nsclc/\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-03-03, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2409, \"last_scrape\": \"2018-12-13T16:42:20\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-nsclc/\", \"rr_start\": \"2015-07-02T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-07-02, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-07-02T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2410, \"last_scrape\": \"2018-12-13T16:42:26\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-as-monotherapy-for-the-adjuvant-treatment-of-adults-with-melanoma/\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF NIVOLUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-09, 2018-07-27\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-11-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2411, \"last_scrape\": \"2018-12-13T16:42:31\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-advanced-renal-cell-carcinoma/\", \"rr_start\": \"2016-04-27T00:00:00\", \"rr_end\": \"2016-05-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-04-27, 2016-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-04-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2412, \"last_scrape\": \"2018-12-13T16:42:33\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-classical-hodgkin-lymphoma/\", \"rr_start\": \"2016-11-22T00:00:00\", \"rr_end\": \"2017-01-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-11-22, 2017-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-11-22T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2413, \"last_scrape\": \"2018-12-13T16:42:36\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-head-and-neck-cancer/\", \"rr_start\": \"2017-05-03T00:00:00\", \"rr_end\": \"2017-05-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-03, 2017-05-30\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-05-03T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2414, \"last_scrape\": \"2018-12-13T16:42:41\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-urothelial-carcinoma/\", \"rr_start\": \"2017-06-28T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-28, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-06-28T00:00:00\", \"latest\": \"2018-09-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2415, \"last_scrape\": \"2018-12-13T16:42:46\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-in-combination-with-ipilimumab-yervoy/\", \"rr_start\": \"2018-11-28T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-11-28, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Yervoy\", \"indication\": \"Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).\", \"ncpe_year\": 2018, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-11-28T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy\", \"ta_list\": \"Melanoma\", \"rr_status\": \"Unknown\"}, {\"id\": 2416, \"last_scrape\": \"2018-12-13T16:42:51\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-plus-ipilimumab-opdivio-plus-yervoy/\", \"rr_start\": \"\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab plus ipilimumab (Opdivo\", \"trade_name\": \"Opdivo plus Yervoy\", \"indication\": \"Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-06-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2417, \"last_scrape\": \"2018-12-13T16:42:56\", \"url\": \"http://www.ncpe.ie/drugs/nomace2-zoely/\", \"rr_start\": \"2011-12-08T00:00:00\", \"rr_end\": \"2012-01-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-12-08, 2012-01-03\", \"rr_multiple\": 0, \"drug_name\": \"Nomegestrol acetate/estradiol (Zoely\", \"trade_name\": \"Zoely\", \"indication\": \"Nomegestrol acetate/estradiol (Zoely\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-26T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2011-12-08T00:00:00\", \"latest\": \"2012-01-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zoely\", \"ta_list\": \"Contraception\", \"rr_status\": \"No HTA\"}, {\"id\": 2418, \"last_scrape\": \"2018-12-13T16:43:02\", \"url\": \"http://www.ncpe.ie/drugs/nusinersin-spinraza/\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-11, 2017-08-02\", \"rr_multiple\": 0, \"drug_name\": \"Nusinersin (Spinraza\", \"trade_name\": \"Spinraza\", \"indication\": \"Nusinersen (Spinraza\", \"ncpe_year\": 2017, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 1, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-12-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza\", \"ta_list\": \"Muscular Atrophy, Spinal\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2419, \"last_scrape\": \"2018-12-13T16:43:07\", \"url\": \"http://www.ncpe.ie/drugs/obeticholic-acid-ocaliva/\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-18, 2016-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Obeticholic acid (Ocaliva\", \"trade_name\": \"Ocaliva\", \"indication\": \"Obeticholic acid is indicated for the treatment of primary biliary cirrhosis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Intercept\", \"orphan\": 1, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocaliva\", \"ta_list\": \"Liver Cirrhosis, Biliary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2420, \"last_scrape\": \"2018-12-13T16:43:10\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-follicular-lymphoma/\", \"rr_start\": \"2016-05-11T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-05-11, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (in combination with bendamustine) followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2016-05-11T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2421, \"last_scrape\": \"2018-12-13T16:43:15\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-previously-untreated-advanced-follicular-lymphoma/\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-09-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-08, 2017-09-13\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (Gazyvaro\", \"ncpe_year\": 2018, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2422, \"last_scrape\": \"2018-12-13T16:43:21\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro/\", \"rr_start\": \"2014-08-08T00:00:00\", \"rr_end\": \"2014-09-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-08-08, 2014-09-11\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (Gazyvaro\", \"ncpe_year\": 2015, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2014-08-08T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2423, \"last_scrape\": \"2018-12-13T16:43:24\", \"url\": \"http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-ppms/\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab (Ocrevus\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab (Ocrevus\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2424, \"last_scrape\": \"2018-12-13T16:43:30\", \"url\": \"http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-rms/\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab (Ocrevus\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab (Ocrevus\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2425, \"last_scrape\": \"2018-12-13T16:43:34\", \"url\": \"http://www.ncpe.ie/drugs/ocriplasmin-jetrea/\", \"rr_start\": \"2013-06-12T00:00:00\", \"rr_end\": \"2013-07-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-06-12, 2013-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Ocriplasmin (Jetrea\", \"trade_name\": \"Jetrea\", \"indication\": \"Ocriplasmin (Jetrea\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-13T00:00:00\", \"company\": \"ThromboGenics\", \"orphan\": 0, \"earliest\": \"2013-06-12T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea\", \"ta_list\": \"Retinal Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2426, \"last_scrape\": \"2018-12-13T16:43:39\", \"url\": \"http://www.ncpe.ie/drugs/ofatumumab-arzerra-previously-untreated-chronic-lymphocytic-leukaemia/\", \"rr_start\": \"2014-10-13T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2014-10-13, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab (Arzerra\", \"trade_name\": \"Arzerra\", \"indication\": \"Ofatumumab (Arzerra\", \"ncpe_year\": 2014, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-10-13T00:00:00\", \"latest\": \"2014-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2427, \"last_scrape\": \"2018-12-13T16:43:46\", \"url\": \"http://www.ncpe.ie/drugs/ofatumumab-arzerra/\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-06-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-06-22, 2010-06-01\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab (Arzerra\", \"trade_name\": \"Arzerra\", \"indication\": \"Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-06-01T00:00:00\", \"latest\": \"2010-06-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2428, \"last_scrape\": \"2018-12-13T16:43:52\", \"url\": \"http://www.ncpe.ie/drugs/oladaterol-striverdi-respimat/\", \"rr_start\": \"2014-04-07T00:00:00\", \"rr_end\": \"2014-05-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-07, 2014-05-02\", \"rr_multiple\": 0, \"drug_name\": \"Oladaterol (Striverdi\", \"trade_name\": \"Striverdi, Respimat\", \"indication\": \"Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-04-07T00:00:00\", \"latest\": \"2014-05-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2429, \"last_scrape\": \"2018-12-13T16:43:57\", \"url\": \"http://www.ncpe.ie/drugs/olaparib-lynparza-2/\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-05, 2015-02-19\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib (Lynparza\", \"trade_name\": \"Lynparza\", \"indication\": \"Lynparza\", \"ncpe_year\": 2017, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2430, \"last_scrape\": \"2018-12-13T16:44:03\", \"url\": \"http://www.ncpe.ie/drugs/olaparib-lynparza-for-platinum-sensitive-relapsed-ovarian-cancer/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"THE NCPE RECOMMEND  A FULL HTA TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF OLAPARIB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib (Lynparza\", \"trade_name\": \"Lynparza\", \"indication\": \"Olaparib (Lynparza\", \"ncpe_year\": 2018, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2431, \"last_scrape\": \"2018-12-13T16:44:08\", \"url\": \"http://www.ncpe.ie/drugs/omalizumab-xolair-for-the-treatment-of-severe-allergic-asthma/\", \"rr_start\": \"\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab (Xolair\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab is indicated as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1<80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.\", \"ncpe_year\": 2015, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-08-22T00:00:00\", \"latest\": \"2015-06-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xolair\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2432, \"last_scrape\": \"2018-12-13T16:44:14\", \"url\": \"http://www.ncpe.ie/drugs/omalizumab-xolair/\", \"rr_start\": \"2014-03-25T00:00:00\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED FOR THIS INDICATION.\", \"rr_dates\": \"2014-03-25, 2014-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab (Xolair\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab (Xolair\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-03-25T00:00:00\", \"latest\": \"2014-04-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xolair\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"No HTA\"}, {\"id\": 2433, \"last_scrape\": \"2018-12-13T16:44:19\", \"url\": \"http://www.ncpe.ie/drugs/oral-oxycodonenaloxone-targin/\", \"rr_start\": \"\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Oxycodone/naloxone (Targin\", \"trade_name\": \"Targin\", \"indication\": \"Cost-effectiveness of oral oxycodone/naloxone prolonged release tablet (Targin\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-05-05T00:00:00\", \"latest\": \"2010-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2434, \"last_scrape\": \"2018-12-13T16:44:22\", \"url\": \"http://www.ncpe.ie/drugs/osimertinib-tagrisso-for-the-first-line-treatment-of-metastatic-nsclc/\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-07T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF OSIMERTINIB FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WITH ACTIVATING EGFR MUTATIONS COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-19, 2018-08-07\", \"rr_multiple\": 0, \"drug_name\": \"Osimertinib (Tagrisso\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib (Tagrisso\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2435, \"last_scrape\": \"2018-12-13T16:44:39\", \"url\": \"http://www.ncpe.ie/drugs/osimertinib-tagrisso/\", \"rr_start\": \"2016-02-26T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-26, 2016-03-22, 2017-01-10\", \"rr_multiple\": 1, \"drug_name\": \"Osimertinib (Tagrisso\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib (Tagrisso\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-26T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2436, \"last_scrape\": \"2018-12-13T16:44:40\", \"url\": \"http://www.ncpe.ie/drugs/ozenoxacin-dubine/\", \"rr_start\": \"2018-11-12T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"FULL HTA IS NOT RECOMMENDED. THE NCPE RECOMMENDS THAT OZENOXACIN CREAM NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE.  THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013.\", \"rr_dates\": \"2018-11-12, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ozenoxacin (Dubine\", \"trade_name\": \"Dubine\", \"indication\": \"Ozenoxacin (Dubine\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-12T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"id\": 2437, \"last_scrape\": \"2018-12-13T16:44:43\", \"url\": \"http://www.ncpe.ie/drugs/p-drugs/pegylated-interferon-b-1a-plegridy/\", \"rr_start\": \"2014-11-25T00:00:00\", \"rr_end\": \"2014-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-11-25, 2014-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Pegylated Interferon beta-1a (Plegridy \", \"trade_name\": \"Plegridy\", \"indication\": \"Treatment of adult patients with relapsing remitting multiple sclerosis\", \"ncpe_year\": 2014, \"eu_market\": \"2014-07-17T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-11-25T00:00:00\", \"latest\": \"2014-12-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2438, \"last_scrape\": \"2018-12-13T16:44:47\", \"url\": \"http://www.ncpe.ie/drugs/palbociclib-ibrance/\", \"rr_start\": \"2016-09-10T00:00:00\", \"rr_end\": \"2016-09-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-09-10, 2016-09-28\", \"rr_multiple\": 0, \"drug_name\": \"Palbociclib (Ibrance\", \"trade_name\": \"Ibrance\", \"indication\": \"Palbociclib is indicated for the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-11-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2016-09-10T00:00:00\", \"latest\": \"2017-07-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2439, \"last_scrape\": \"2018-12-13T16:44:53\", \"url\": \"http://www.ncpe.ie/drugs/paliperidone-palmitate-xeplion/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Paliperidone palmitate (Xeplion\", \"trade_name\": \"Xeplion\", \"indication\": \"Paliperidone palmitate (Xeplion\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-04T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeplion\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2440, \"last_scrape\": \"2018-12-13T16:44:57\", \"url\": \"http://www.ncpe.ie/drugs/panobinostat-farydak/\", \"rr_start\": \"2016-01-26T00:00:00\", \"rr_end\": \"2016-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-26, 2016-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Panobinostat (Farydak\", \"trade_name\": \"Farydak\", \"indication\": \"Panobinostat in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-01-26T00:00:00\", \"latest\": \"2016-02-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/farydak\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2441, \"last_scrape\": \"2018-12-13T16:45:01\", \"url\": \"http://www.ncpe.ie/drugs/paritaprevir-boosted-with-ritonavir-and-ombitasvir-vierkirax-with-or-without-dasabuvir-exviera/\", \"rr_start\": \"2014-12-21T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-21, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Paritaprevir boosted with ritonavir and ombitasvir (Vierkirax\", \"trade_name\": \"Exviera\", \"indication\": \"Exviera\", \"ncpe_year\": 2016, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2014-12-21T00:00:00\", \"latest\": \"2016-02-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/exviera\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2442, \"last_scrape\": \"2018-12-13T16:45:07\", \"url\": \"http://www.ncpe.ie/drugs/patiromer-veltassa/\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT\\nRECOMMENDED\", \"rr_dates\": \"2017-10-11, 2017-11-17\", \"rr_multiple\": 0, \"drug_name\": \"Patiromer (Veltassa\", \"trade_name\": \"Veltassa\", \"indication\": \"Patiromer (Veltassa\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-19T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-11-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/veltassa\", \"ta_list\": \"Hyperkalemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2443, \"last_scrape\": \"2018-12-13T16:45:10\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-1l-nsclc-with-chemotherapy/\", \"rr_start\": \"2018-08-14T00:00:00\", \"rr_end\": \"2018-08-29T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-14, 2018-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-08-14T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2444, \"last_scrape\": \"2018-12-13T16:45:15\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-adjuvant-melanoma/\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-07T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-11-19, 2018-12-07\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizuma (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2445, \"last_scrape\": \"2018-12-13T16:45:18\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-classical-hodgkin-lymphoma/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2446, \"last_scrape\": \"2018-12-13T16:45:23\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-first-line-nsclc/\", \"rr_start\": \"2016-12-19T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-12-19, 2017-01-10\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-12-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2447, \"last_scrape\": \"2018-12-13T16:45:28\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-nsclc/\", \"rr_start\": \"2016-08-03T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-08-03, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-03T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2448, \"last_scrape\": \"2018-12-13T16:45:31\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-the-treatment-of-unresectable-or-advanced-metastatic-melanoma-in-adults-refractory-to-ipilimumab/\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2449, \"last_scrape\": \"2018-12-13T16:45:36\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-uc-1l/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES\", \"rr_dates\": \"2017-12-06, 2017-12-21, 2018-06-21, 2018-07-10, 2018-07-27\", \"rr_multiple\": 1, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-07-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2450, \"last_scrape\": \"2018-12-13T16:45:38\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-urothelial-carcinoma-2l/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda \", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2451, \"last_scrape\": \"2018-12-13T16:45:45\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda/\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-02-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2452, \"last_scrape\": \"2018-12-13T16:45:50\", \"url\": \"http://www.ncpe.ie/drugs/perampanel-fycompa/\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Perampanel (Fycompa\", \"trade_name\": \"Fycompa\", \"indication\": \"Perampanel (Fycompa\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-23T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa\", \"ta_list\": \"Epilepsies, Partial\", \"rr_status\": \"No HTA\"}, {\"id\": 2453, \"last_scrape\": \"2018-12-13T16:45:56\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta-for-her2-positive-breast-cancer/\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PERTUZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-01, 2018-06-22\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab  (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.\", \"ncpe_year\": 2018, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-12-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2454, \"last_scrape\": \"2018-12-13T16:46:02\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta-in-neoadjuvant-her2-positive-breast-cancer/\", \"rr_start\": \"2015-08-10T00:00:00\", \"rr_end\": \"2015-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-10, 2015-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"Perjeta (pertuzumab) is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2015-08-10T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2455, \"last_scrape\": \"2018-12-13T16:46:04\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta/\", \"rr_start\": \"2013-01-14T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-01-14, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"The proposed licensed indication is for use (in combination with trastuzumab and docetaxel) in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. \", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-01-14T00:00:00\", \"latest\": \"2013-08-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2456, \"last_scrape\": \"2018-12-13T16:46:09\", \"url\": \"http://www.ncpe.ie/drugs/phenylephrine-hydrochloride-tropicamide-lidocaine-hydrochloride-fydrane/\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-19T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-11-18, 2016-12-19\", \"rr_multiple\": 0, \"drug_name\": \"Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride (Fydrane\", \"trade_name\": \"Fydrane\", \"indication\": \"Fydrane\", \"ncpe_year\": 2016, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2016-12-19T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2457, \"last_scrape\": \"2018-12-13T16:46:11\", \"url\": \"http://www.ncpe.ie/drugs/pirfenidone-esbriet/\", \"rr_start\": \"2011-12-15T00:00:00\", \"rr_end\": \"2012-01-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-12-15, 2012-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Pirfenidone (Esbriet\", \"trade_name\": \"Esbriet\", \"indication\": \"Pirfenidone has been licensed by the European Medicines Agency (EMA) for the treatment of mild to moderate idiopathic pulmonary fibrosis.\", \"ncpe_year\": 2015, \"eu_market\": \"2011-02-27T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2011-12-15T00:00:00\", \"latest\": \"2015-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esbriet\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2458, \"last_scrape\": \"2018-12-13T16:46:14\", \"url\": \"http://www.ncpe.ie/drugs/pitavastatin-livazo/\", \"rr_start\": \"2010-12-22T00:00:00\", \"rr_end\": \"2010-12-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-12-22, 2010-12-24\", \"rr_multiple\": 0, \"drug_name\": \"Pitavastatin (Livazo\", \"trade_name\": \"Livazo\", \"indication\": \"Pitavastatin is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined (mixed) dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-12-22T00:00:00\", \"latest\": \"2010-12-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2459, \"last_scrape\": \"2018-12-13T16:46:20\", \"url\": \"http://www.ncpe.ie/drugs/pitolisant-wakix/\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-06-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-06-12, 2017-06-15\", \"rr_multiple\": 0, \"drug_name\": \"Pitolisant hydrochloride (Wakix\", \"trade_name\": \"Wakix\", \"indication\": \"Pitolisant hydrochloride (Wakix\", \"ncpe_year\": 2017, \"eu_market\": \"2016-03-31T00:00:00\", \"company\": \"Bioprojet\", \"orphan\": 1, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-06-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/wakix\", \"ta_list\": \"Narcolepsy\", \"rr_status\": \"No HTA\"}, {\"id\": 2460, \"last_scrape\": \"2018-12-13T16:46:24\", \"url\": \"http://www.ncpe.ie/drugs/pixantrone-pixuvri/\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-03-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-02-10, 2015-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Pixantrone (Pixuvri\", \"trade_name\": \"Pixuvri\", \"indication\": \"Pixurvi\", \"ncpe_year\": 2015, \"eu_market\": \"2012-05-10T00:00:00\", \"company\": \"CTI\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-03-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri\", \"ta_list\": \"Lymphoma, Non-Hodgkin\", \"rr_status\": \"No HTA\"}, {\"id\": 2461, \"last_scrape\": \"2018-12-13T16:46:27\", \"url\": \"http://www.ncpe.ie/drugs/polynuclear-ironiii-oxyhydroxide-pn-feooh-velphoro/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-09-12, 2014-10-08\", \"rr_multiple\": 0, \"drug_name\": \"Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro\", \"trade_name\": \"Velphoro\", \"indication\": \"Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro\", \"ncpe_year\": 2014, \"eu_market\": \"2014-08-26T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-10-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/velphoro\", \"ta_list\": \"Hyperphosphatemia; Renal Dialysis\", \"rr_status\": \"No HTA\"}, {\"id\": 2462, \"last_scrape\": \"2018-12-13T16:46:30\", \"url\": \"http://www.ncpe.ie/drugs/pomalidomide-imnovid/\", \"rr_start\": \"2013-09-20T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-20, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Pomalidomide (Imnovid\", \"trade_name\": \"Imnovid\", \"indication\": \"Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-09-20T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2463, \"last_scrape\": \"2018-12-13T16:46:32\", \"url\": \"http://www.ncpe.ie/drugs/ponatinib-iclusig/\", \"rr_start\": \"2013-10-02T00:00:00\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-10-02, 2013-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Ponatinib (Iclusig\", \"trade_name\": \"Iclusig\", \"indication\": \"Ponatinib (Iclusig\", \"ncpe_year\": 2016, \"eu_market\": \"2013-07-01T00:00:00\", \"company\": \"Incyte\", \"orphan\": 1, \"earliest\": \"2013-10-02T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig\", \"ta_list\": \"Leukemia, Myeloid; Leukemia, Lymphoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2464, \"last_scrape\": \"2018-12-13T16:46:38\", \"url\": \"http://www.ncpe.ie/drugs/prasugrel-efient/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Prasugrel (Efient\", \"trade_name\": \"Efient\", \"indication\": \"Economic Evaluation of Prasugrel (Efient\", \"ncpe_year\": 2010, \"eu_market\": \"2009-02-24T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2010-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/efient\", \"ta_list\": \"Acute Coronary Syndrome; Angina, Unstable; Myocardial Infarction\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2465, \"last_scrape\": \"2018-12-13T16:46:46\", \"url\": \"http://www.ncpe.ie/drugs/pregabalin-lyrica-2/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin (Lyrica\", \"trade_name\": \"Lyrica\", \"indication\": \"Lyrica\", \"ncpe_year\": 2015, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-30T00:00:00\", \"latest\": \"2015-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2466, \"last_scrape\": \"2018-12-13T16:46:52\", \"url\": \"http://www.ncpe.ie/drugs/pregabalin-lyrica-for-the-treatment-of-generalised-anxiety-disorder/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin (Lyrica\", \"trade_name\": \"Lyrica\", \"indication\": \"Pregabalin (Lyrica\", \"ncpe_year\": 2014, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-12-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2467, \"last_scrape\": \"2018-12-13T16:46:58\", \"url\": \"http://www.ncpe.ie/drugs/prucalopride-resolor/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-01-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-01-17\", \"rr_multiple\": 0, \"drug_name\": \"Prucalopride (Resolor\", \"trade_name\": \"Resolor\", \"indication\": \"Prucalopride (Resolor\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-14T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2011-01-17T00:00:00\", \"latest\": \"2011-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/resolor\", \"ta_list\": \"Constipation\", \"rr_status\": \"No HTA\"}, {\"id\": 2468, \"last_scrape\": \"2018-12-13T16:47:00\", \"url\": \"http://www.ncpe.ie/drugs/radium-223-xofigo/\", \"rr_start\": \"2013-11-28T00:00:00\", \"rr_end\": \"2013-12-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-11-28, 2013-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Radium-223 (Xofigo\", \"trade_name\": \"Xofigo\", \"indication\": \"Radium-223 (Xofigo\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-13T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2469, \"last_scrape\": \"2018-12-13T16:47:03\", \"url\": \"http://www.ncpe.ie/drugs/ramucirumab-cyramza/\", \"rr_start\": \"2014-12-20T00:00:00\", \"rr_end\": \"2014-12-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-20, 2014-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Ramucirumab (Cyramza\", \"trade_name\": \"Cyramza\", \"indication\": \"Indicated in combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction (GEJ) adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-12-19T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2014-12-20T00:00:00\", \"latest\": \"2016-07-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2470, \"last_scrape\": \"2018-12-13T16:47:06\", \"url\": \"http://www.ncpe.ie/drugs/ranolazine-ranexa/\", \"rr_start\": \"2009-11-19T00:00:00\", \"rr_end\": \"2009-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ranolazine (Ranexa\", \"trade_name\": \"Ranexa\", \"indication\": \"Cost-effectiveness of Ranolazine (Ranexa\", \"ncpe_year\": 2009, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2009-11-19T00:00:00\", \"latest\": \"2009-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2471, \"last_scrape\": \"2018-12-13T16:47:13\", \"url\": \"http://www.ncpe.ie/drugs/regadenoson-rapiscan/\", \"rr_start\": \"2011-09-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-09-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Regadenoson (Rapiscan\", \"trade_name\": \"Rapiscan\", \"indication\": \"Cost-effectiveness of Regadenoson (Rapiscan\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-06T00:00:00\", \"company\": \"GE\", \"orphan\": 0, \"earliest\": \"2011-09-19T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rapiscan\", \"ta_list\": \"Myocardial Perfusion Imaging\", \"rr_status\": \"No HTA\"}, {\"id\": 2472, \"last_scrape\": \"2018-12-13T16:47:17\", \"url\": \"http://www.ncpe.ie/drugs/regorafenib-stivarga-for-gist/\", \"rr_start\": \"2014-09-18T00:00:00\", \"rr_end\": \"2014-10-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-09-18, 2014-10-06\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib (Stivarga\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib (Stivarga\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2014-09-18T00:00:00\", \"latest\": \"2014-10-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2473, \"last_scrape\": \"2018-12-13T16:47:23\", \"url\": \"http://www.ncpe.ie/drugs/reslizumab-cinqaero/\", \"rr_start\": \"2017-01-23T00:00:00\", \"rr_end\": \"2017-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-01-23, 2017-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Reslizumab (Cinqaero\", \"trade_name\": \"Cinqaero\", \"indication\": \"Cinqaero\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-15T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2017-01-23T00:00:00\", \"latest\": \"2017-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cinqaero\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2474, \"last_scrape\": \"2018-12-13T16:47:27\", \"url\": \"http://www.ncpe.ie/drugs/retigabine-trobalt/\", \"rr_start\": \"2011-04-06T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-04-06, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Retigabine (Trobalt\", \"trade_name\": \"Trobalt\", \"indication\": \"Cost-effectiveness of Retigabine (Trobalt\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-27T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-04-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"No HTA\"}, {\"id\": 2475, \"last_scrape\": \"2018-12-13T16:47:29\", \"url\": \"http://www.ncpe.ie/drugs/ribociclib-kisqali/\", \"rr_start\": \"2017-09-04T00:00:00\", \"rr_end\": \"2017-09-19T00:00:00\", \"rr_outcome\": \"FOLLOWING NCPE ASSESSMENT OF THE COMPANY SUBMISSION, THE NCPE RECOMMENDS THAT RIBOCICLIB (IN COMBINATION WITH AN AROMATASE INHIBITOR) FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR+/HER2- LOCALLY ADVANCED OR METASTATIC BC AS INITIAL ENDOCRINE-BASED THERAPY, NOT BE CONSIDERED FOR REIMBURSEMENT UNLESS COST EFFECTIVENESS CAN BE IMPROVED RELATIVE TO EXISTING TREATMENTS. THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2017-09-04, 2017-09-19\", \"rr_multiple\": 0, \"drug_name\": \"Ribociclib (Kisqali\", \"trade_name\": \"Kisqali\", \"indication\": \"Ribociclib (Kisqali\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2017-09-04T00:00:00\", \"latest\": \"2018-08-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2476, \"last_scrape\": \"2018-12-13T16:47:35\", \"url\": \"http://www.ncpe.ie/drugs/rifaximin-targaxan-2/\", \"rr_start\": \"2013-07-09T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-09, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Rifaximin (Targaxan\", \"trade_name\": \"Targaxan\", \"indication\": \"Rifaximin (Targaxan\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-07-09T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2477, \"last_scrape\": \"2018-12-13T16:47:38\", \"url\": \"http://www.ncpe.ie/drugs/rigorafenib-stivarga/\", \"rr_start\": \"2013-09-12T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-12, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib (Stivarga\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib (Stivarga\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-09-12T00:00:00\", \"latest\": \"2014-06-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2478, \"last_scrape\": \"2018-12-13T16:47:42\", \"url\": \"http://www.ncpe.ie/drugs/rilpivirine-edurant/\", \"rr_start\": \"2011-12-14T00:00:00\", \"rr_end\": \"2012-01-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-12-14, 2012-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine (Edurant\", \"trade_name\": \"Edurant\", \"indication\": \"Rilpivirine in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ? 100,000 HIV-1 RNA copies/ml.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-11-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-12-14T00:00:00\", \"latest\": \"2012-01-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/edurant\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2479, \"last_scrape\": \"2018-12-13T16:47:45\", \"url\": \"http://www.ncpe.ie/drugs/rilpivirine-r-emtricitabine-f-tenofovir-alafenamide-taf-odefsey/\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMEDED\", \"rr_dates\": \"2016-06-28, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) (Odefsey\", \"trade_name\": \"Odefsey\", \"indication\": \"Odefsey\", \"ncpe_year\": 2016, \"eu_market\": \"2016-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2480, \"last_scrape\": \"2018-12-13T16:47:48\", \"url\": \"http://www.ncpe.ie/drugs/rimonabant-acomplia-2/\", \"rr_start\": \"\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rimonabant (Acomplia\", \"trade_name\": \"Acomplia\", \"indication\": \"In June 2006, Sanofi-Aventis submitted an evaluation of the cost-effectiveness of rimonabant (in addition to diet and exercise) in the management of multiple cardiovascular risks in overweight or obese patients in Ireland, to support its application for reimbursement of rimonabant under the Community Drugs Schemes. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-06-19T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2006-06-01T00:00:00\", \"latest\": \"2006-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/acomplia\", \"ta_list\": \"Obesity\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2481, \"last_scrape\": \"2018-12-13T16:47:53\", \"url\": \"http://www.ncpe.ie/drugs/riociguat-adempas/\", \"rr_start\": \"2014-04-11T00:00:00\", \"rr_end\": \"2014-05-16T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED AT THE CURRENT PRICE.\", \"rr_dates\": \"2014-04-11, 2014-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Riociguat (Adempas\", \"trade_name\": \"Adempas\", \"indication\": \"Riociguat (Adempas\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-27T00:00:00\", \"company\": \"Bayer\", \"orphan\": 1, \"earliest\": \"2014-04-11T00:00:00\", \"latest\": \"2014-05-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adempas\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2482, \"last_scrape\": \"2018-12-13T16:47:59\", \"url\": \"http://www.ncpe.ie/drugs/rituximab-mabthera/\", \"rr_start\": \"2014-05-26T00:00:00\", \"rr_end\": \"2014-09-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-26, 2014-09-22\", \"rr_multiple\": 0, \"drug_name\": \"Rituximab (MabThera\", \"trade_name\": \"MabThera\", \"indication\": \"Rituximab (MabThera\", \"ncpe_year\": 2014, \"eu_market\": \"1998-06-02T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-05-26T00:00:00\", \"latest\": \"2014-09-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"No HTA\"}, {\"id\": 2483, \"last_scrape\": \"2018-12-13T16:48:05\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-atrial-fibrillation-patients-undergoing-pci/\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2484, \"last_scrape\": \"2018-12-13T16:48:10\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-dvt/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Economic evaluation of Rivaroxaban (Xarelto\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-02-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2485, \"last_scrape\": \"2018-12-13T16:48:15\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-spaf-2/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban (Xarelto\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2486, \"last_scrape\": \"2018-12-13T16:48:18\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-the-prevention-of-atherothrombotic-events/\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-11T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF RIVAROXABAN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-26, 2018-10-11\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban (Xarelto\", \"ncpe_year\": 2018, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2487, \"last_scrape\": \"2018-12-13T16:48:25\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-low-dose-for-prevention-of-recurrent-venous-thromboembolism/\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2488, \"last_scrape\": \"2018-12-13T16:48:30\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban (Xarelto\", \"ncpe_year\": 2008, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2008-04-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2489, \"last_scrape\": \"2018-12-13T16:48:33\", \"url\": \"http://www.ncpe.ie/drugs/roflumilast-daxas/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Roflumilast (Daxas\", \"trade_name\": \"Daxas\", \"indication\": \"Cost Effectiveness of Roflumilast (Daxas\", \"ncpe_year\": 2010, \"eu_market\": \"2010-07-05T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-11T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/daxas\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2490, \"last_scrape\": \"2018-12-13T16:48:40\", \"url\": \"http://www.ncpe.ie/drugs/rolapitant-varuby/\", \"rr_start\": \"2017-05-15T00:00:00\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-05-15, 2017-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Rolapitant (Varuby\", \"trade_name\": \"Varuby\", \"indication\": \"Rolapitant (Varuby\", \"ncpe_year\": 2017, \"eu_market\": \"2017-04-19T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 0, \"earliest\": \"2017-05-15T00:00:00\", \"latest\": \"2017-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/varuby\", \"ta_list\": \"Vomiting; Nausea; Cancer\", \"rr_status\": \"No HTA\"}, {\"id\": 2491, \"last_scrape\": \"2018-12-13T16:48:43\", \"url\": \"http://www.ncpe.ie/drugs/romiplostim-nplate/\", \"rr_start\": \"\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Romiplostim (Nplate\", \"trade_name\": \"Nplate\", \"indication\": \"Romiplostim (Nplate\", \"ncpe_year\": 2015, \"eu_market\": \"2009-02-04T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-04-02T00:00:00\", \"latest\": \"2015-05-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nplate\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2492, \"last_scrape\": \"2018-12-13T16:48:47\", \"url\": \"http://www.ncpe.ie/drugs/ropivacaine-readyfusor/\", \"rr_start\": \"2018-11-09T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"FULL HTA IS NOT RECOMMENDED. THE NCPE RECOMMENDS THAT ROPIVICAINE READYFUSOR NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE.  THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013.\", \"rr_dates\": \"2018-11-09, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ropivacaine Readyfusor\", \"trade_name\": \"Ropivacaine Readyfusor\", \"indication\": \"Ropivacaine Readyfusor for acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block (CPNB) via a continuous infusion.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-09T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"id\": 2493, \"last_scrape\": \"2018-12-13T16:48:50\", \"url\": \"http://www.ncpe.ie/drugs/ruxolitinib-jakavi-for-polycythaemia-vera/\", \"rr_start\": \"2015-04-15T00:00:00\", \"rr_end\": \"2015-05-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-04-15, 2015-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib (Jakavi\", \"trade_name\": \"Jakavi\", \"indication\": \"Jakavi\", \"ncpe_year\": 2016, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2015-04-15T00:00:00\", \"latest\": \"2016-08-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2494, \"last_scrape\": \"2018-12-13T16:48:55\", \"url\": \"http://www.ncpe.ie/drugs/ruxolitinib-jakavi/\", \"rr_start\": \"2012-08-01T00:00:00\", \"rr_end\": \"2012-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-08-01, 2012-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib (Jakavi\", \"trade_name\": \"Jakavi\", \"indication\": \"Ruxolitinib (Jakavi\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2012-08-01T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2495, \"last_scrape\": \"2018-12-13T16:48:58\", \"url\": \"http://www.ncpe.ie/drugs/sacubitrilvalsartan-entresto/\", \"rr_start\": \"2015-11-06T00:00:00\", \"rr_end\": \"2015-11-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-06, 2015-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Sacubitril/valsartan (Entresto\", \"trade_name\": \"Entresto\", \"indication\": \"Entresto\", \"ncpe_year\": 2017, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-06T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entresto\", \"ta_list\": \"Heart Failure\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2496, \"last_scrape\": \"2018-12-13T16:49:04\", \"url\": \"http://www.ncpe.ie/drugs/safinamide-methansulfonate-xadago/\", \"rr_start\": \"2016-06-14T00:00:00\", \"rr_end\": \"2016-07-06T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED.\", \"rr_dates\": \"2016-06-14, 2016-07-06\", \"rr_multiple\": 0, \"drug_name\": \"Safinamide methansulfonate (Xadago\", \"trade_name\": \"Xadago\", \"indication\": \"Xadago\", \"ncpe_year\": 2016, \"eu_market\": \"2015-02-23T00:00:00\", \"company\": \"Zambon\", \"orphan\": 0, \"earliest\": \"2016-06-14T00:00:00\", \"latest\": \"2016-07-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xadago\", \"ta_list\": \"Parkinson Disease\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2497, \"last_scrape\": \"2018-12-13T16:49:07\", \"url\": \"http://www.ncpe.ie/drugs/sapropterin-kuvan/\", \"rr_start\": \"2015-07-14T00:00:00\", \"rr_end\": \"2015-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-07-14, 2015-08-14, 2015-07-01\", \"rr_multiple\": 1, \"drug_name\": \"Sapropterin (Kuvan\", \"trade_name\": \"Kuvan\", \"indication\": \"Sapropterin (Kuvan\", \"ncpe_year\": 2017, \"eu_market\": \"2008-12-02T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2009-01-01T00:00:00\", \"latest\": \"2017-09-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kuvan\", \"ta_list\": \"Phenylketonurias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2498, \"last_scrape\": \"2018-12-13T16:49:11\", \"url\": \"http://www.ncpe.ie/drugs/sarilumab-kevzara/\", \"rr_start\": \"2017-08-18T00:00:00\", \"rr_end\": \"2017-10-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-08-18, 2017-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Sarilumab (Kevzara\", \"trade_name\": \"Kevzara\", \"indication\": \"Sarilumab (Kevzara\", \"ncpe_year\": 2017, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-08-18T00:00:00\", \"latest\": \"2017-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2499, \"last_scrape\": \"2018-12-13T16:49:16\", \"url\": \"http://www.ncpe.ie/drugs/sebelipase-alfa-kanuma/\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-02-08, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Sebelipase alfa (Kanuma\", \"trade_name\": \"Kanuma\", \"indication\": \"Sebelipase alfa is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2018-06-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kanuma\", \"ta_list\": \"Lipid Metabolism, Inborn Errors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2500, \"last_scrape\": \"2018-12-13T16:49:20\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-ankylosing-spondylitis/\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-02, 2015-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"id\": 2501, \"last_scrape\": \"2018-12-13T16:49:25\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-psoriatic-arthritis/\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-02, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"id\": 2502, \"last_scrape\": \"2018-12-13T16:49:31\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx/\", \"rr_start\": \"2014-12-19T00:00:00\", \"rr_end\": \"2015-02-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-19, 2015-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-12-19T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2503, \"last_scrape\": \"2018-12-13T16:49:34\", \"url\": \"http://www.ncpe.ie/drugs/selexipag-uptravi/\", \"rr_start\": \"2016-11-01T00:00:00\", \"rr_end\": \"2016-12-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-01, 2016-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Selexipag (Uptravi\", \"trade_name\": \"Uptravi\", \"indication\": \"Selexipag (Uptravi\", \"ncpe_year\": 2018, \"eu_market\": \"2016-05-12T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2016-11-01T00:00:00\", \"latest\": \"2018-05-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2504, \"last_scrape\": \"2018-12-13T16:49:39\", \"url\": \"http://www.ncpe.ie/drugs/semaglutide-ozempic/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-03-12, 2018-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Semaglutide (Ozempic\", \"trade_name\": \"Ozempic\", \"indication\": \"Semaglutide (Ozempic\", \"ncpe_year\": 2018, \"eu_market\": \"2018-02-08T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-04-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2505, \"last_scrape\": \"2018-12-13T16:49:44\", \"url\": \"http://www.ncpe.ie/drugs/sildenafil-revatio/\", \"rr_start\": \"2014-04-16T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-04-16, 2014-05-23\", \"rr_multiple\": 0, \"drug_name\": \"Sildenafil (Revatio\", \"trade_name\": \"Revatio\", \"indication\": \"Sildenafil (Revatio\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2014-04-16T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revatio\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2506, \"last_scrape\": \"2018-12-13T16:49:49\", \"url\": \"http://www.ncpe.ie/drugs/simeprevir-olysio-in-combination-with-sofosbuvir/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir (Olysio\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir (Olysio\", \"ncpe_year\": 2015, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2015-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olysio\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2507, \"last_scrape\": \"2018-12-13T16:49:53\", \"url\": \"http://www.ncpe.ie/drugs/simeprevir-olysio/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED WHEN USED IN TRIPLE THERAPY WITH PEG-INTERFERON AND RIBAVIRIN.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir (Olysio\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir (Olysio\", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2014-07-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olysio\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2508, \"last_scrape\": \"2018-12-13T16:50:00\", \"url\": \"http://www.ncpe.ie/drugs/sodium-chloride-70mgml-sodium-hyaluronate-1mgml-hyaneb/\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-10, 2014-03-19\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml (Hyaneb\", \"trade_name\": \"Hyaneb\", \"indication\": \"Hyaneb\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2509, \"last_scrape\": \"2018-12-13T16:50:06\", \"url\": \"http://www.ncpe.ie/drugs/sodium-hyaluronate-hyloforte-0-2/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate (Hyloforte\", \"trade_name\": \"Hyloforte 0.2%\", \"indication\": \"Sodium Hyaluronate (Hyloforte\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2510, \"last_scrape\": \"2018-12-13T16:50:09\", \"url\": \"http://www.ncpe.ie/drugs/sodium-hyaluronate-hylotear-0-1/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate (Hylotear\", \"trade_name\": \"Hylotear 0.1%\", \"indication\": \"Sodium Hyaluronate (Hylotear\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2511, \"last_scrape\": \"2018-12-13T16:50:15\", \"url\": \"http://www.ncpe.ie/drugs/sodium-phenylbutyrate-pheburane/\", \"rr_start\": \"2013-07-17T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-17, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Sodium phenylbutyrate (Pheburane\", \"trade_name\": \"Pheburane\", \"indication\": \"Sodium phenylbutyrate (Pheburane\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-30T00:00:00\", \"company\": \"Lucane\", \"orphan\": 0, \"earliest\": \"2013-07-17T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pheburane\", \"ta_list\": \"Carbamoyl-Phosphate Synthase I Deficiency Disease\", \"rr_status\": \"No HTA\"}, {\"id\": 2512, \"last_scrape\": \"2018-12-13T16:50:18\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvir-solvaldi/\", \"rr_start\": \"2014-02-12T00:00:00\", \"rr_end\": \"2014-03-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-02-12, 2014-03-10\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir (Solvaldi\", \"trade_name\": \"Solvaldi\", \"indication\": \"Sofosbuvir (Solvaldi\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-02-12T00:00:00\", \"latest\": \"2014-10-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2513, \"last_scrape\": \"2018-12-13T16:50:22\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvirvelpatasvir-epclusa-chronic-hepatitis-c-virus-hcv-pangenotypic/\", \"rr_start\": \"2017-09-05T00:00:00\", \"rr_end\": \"2017-10-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-05, 2017-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir (Epclusa\", \"trade_name\": \"Epclusa\", \"indication\": \"Sofosbuvir/velpatasvir (Epclusa\", \"ncpe_year\": 2017, \"eu_market\": \"2016-07-06T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-05T00:00:00\", \"latest\": \"2017-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2514, \"last_scrape\": \"2018-12-13T16:50:26\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvirvelpatasvirvoxilaprevir-vosevi/\", \"rr_start\": \"2017-09-19T00:00:00\", \"rr_end\": \"2017-11-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-19, 2017-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi\", \"trade_name\": \"Vosevi\", \"indication\": \"Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-19T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vosevi\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2515, \"last_scrape\": \"2018-12-13T16:50:32\", \"url\": \"http://www.ncpe.ie/drugs/st-johns-wort-pafica/\", \"rr_start\": \"2015-04-14T00:00:00\", \"rr_end\": \"2015-05-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-04-14, 2015-05-29\", \"rr_multiple\": 0, \"drug_name\": \"St Johns Wort (Pacifa\", \"trade_name\": \"Pacifa\", \"indication\": \"Pacifa\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-04-14T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2516, \"last_scrape\": \"2018-12-13T16:50:38\", \"url\": \"http://www.ncpe.ie/drugs/stiripentol-diacomit/\", \"rr_start\": \"2017-07-06T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-06, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Stiripentol (Diacomit\", \"trade_name\": \"Diacomit\", \"indication\": \"Stiripentol (Diacomit\", \"ncpe_year\": 2018, \"eu_market\": \"2007-01-03T00:00:00\", \"company\": \"Biocodex\", \"orphan\": 1, \"earliest\": \"2017-07-06T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/diacomit\", \"ta_list\": \"Myoclonic Epilepsy, Juvenile\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2517, \"last_scrape\": \"2018-12-13T16:50:43\", \"url\": \"http://www.ncpe.ie/drugs/stribild-elvitegravircobicistatemtricitabinetenofovir-disoproxil-as-fumarate/\", \"rr_start\": \"2013-04-28T00:00:00\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-04-28, 2013-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumarate)(Stribild\", \"trade_name\": \"Stribild\", \"indication\": \"Indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-na\", \"ncpe_year\": 2013, \"eu_market\": \"2013-05-24T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2013-04-28T00:00:00\", \"latest\": \"2013-12-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stribild\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2518, \"last_scrape\": \"2018-12-13T16:50:49\", \"url\": \"http://www.ncpe.ie/drugs/sublingual-immunotherapy-grazax/\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sublingual Immunotherapy (Grazax\", \"trade_name\": \"Grazax\", \"indication\": \"A Review of the Cost-Effectiveness of Sublingual Immunotherapy (Grazax\", \"ncpe_year\": 2007, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2007-09-01T00:00:00\", \"latest\": \"2007-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2519, \"last_scrape\": \"2018-12-13T16:50:50\", \"url\": \"http://www.ncpe.ie/drugs/suboxone-buprenorphinenaloxone/\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Buprenorphine/naloxone (Suboxone\", \"trade_name\": \"Suboxone\", \"indication\": \"An economic evaluation of suboxone for the management of opiate addiction.\", \"ncpe_year\": 2014, \"eu_market\": \"2006-09-26T00:00:00\", \"company\": \"Indivior\", \"orphan\": 0, \"earliest\": \"2007-11-01T00:00:00\", \"latest\": \"2014-05-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/suboxone\", \"ta_list\": \"Opioid-Related Disorders\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2520, \"last_scrape\": \"2018-12-13T16:50:54\", \"url\": \"http://www.ncpe.ie/drugs/sufentanil-zalviso/\", \"rr_start\": \"2016-03-14T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-03-14, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Sufentanil (Zalviso\", \"trade_name\": \"Zalviso\", \"indication\": \"Sufentanil (Zalviso\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Gr\", \"orphan\": 0, \"earliest\": \"2016-03-14T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zalviso\", \"ta_list\": \"Pain, Postoperative\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2521, \"last_scrape\": \"2018-12-13T16:50:59\", \"url\": \"http://www.ncpe.ie/drugs/sunitinib-sutent/\", \"rr_start\": \"\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sunitinib (Sutent\", \"trade_name\": \"Sutent\", \"indication\": \"In September 2006, Pfizer Healthcare Ireland submitted an evaluation of the cost-effectiveness and budget impact of sunitinib as second-line treatment of patients with gastro-intestinal stromal tumours (GIST). Data on the cost-effectiveness and budget impact of sutinitinib as second line treatment for patients with metastatic renal cell carcinoma (mRCC) was also presented. The purpose of the submission was to support an application for reimbursement under the High Tech Drug Scheme. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-07-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-09-01T00:00:00\", \"latest\": \"2006-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sutent\", \"ta_list\": \"Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2522, \"last_scrape\": \"2018-12-13T16:51:04\", \"url\": \"http://www.ncpe.ie/drugs/tadalafil-adcirca-2/\", \"rr_start\": \"2011-07-13T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-07-13, 2011-09-21, 2014-05-09, 2014-05-23\", \"rr_multiple\": 1, \"drug_name\": \"Tadalafil (Adcirca\", \"trade_name\": \"Adcirca\", \"indication\": \"Tadalafil (Adcirca\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-07-13T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2523, \"last_scrape\": \"2018-12-13T16:51:09\", \"url\": \"http://www.ncpe.ie/drugs/tafamadis-meglumine-vyndaqel/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED UNTIL ADDITIONAL EFFICACY AND/OR SAFETY DATA IS SUBMITTED. ON THE BASIS OF CURRENT EVIDENCE, THE NCPE RECOMMENDS THAT TAFAMIDIS NOT BE CONSIDERED FOR REIMBURSEMENT IN ACCORDANCE WITH THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Tafamadis meglumine (Vyndaqel\", \"trade_name\": \"Vyndaqel\", \"indication\": \"Tafamadis meglumine (Vyndaqel\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-16T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel\", \"ta_list\": \"Amyloidosis\", \"rr_status\": \"No HTA until more evidence\"}, {\"id\": 2524, \"last_scrape\": \"2018-12-13T16:51:15\", \"url\": \"http://www.ncpe.ie/drugs/tafluprost-saflutan/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Tafluprost (Saflutan\", \"trade_name\": \"Saflutan\", \"indication\": \"Tafluoprost (Salflutan\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2525, \"last_scrape\": \"2018-12-13T16:51:24\", \"url\": \"http://www.ncpe.ie/drugs/talimogene-laherparepvec-imlygic/\", \"rr_start\": \"2016-02-16T00:00:00\", \"rr_end\": \"2016-03-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-02-16, 2016-03-14\", \"rr_multiple\": 0, \"drug_name\": \"Talimogene Laherparepvec (Imlygic\", \"trade_name\": \"Imlygic\", \"indication\": \"Talimogene laherparepvec (Imlygic\", \"ncpe_year\": 2016, \"eu_market\": \"2015-12-16T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-02-16T00:00:00\", \"latest\": \"2016-03-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2526, \"last_scrape\": \"2018-12-13T16:51:28\", \"url\": \"http://www.ncpe.ie/drugs/tapentadol-palexia/\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Tapentadol (Palexia\", \"trade_name\": \"Palexia\", \"indication\": \"Economic evaluation of oral tapentadol (Palexia\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2011-04-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2527, \"last_scrape\": \"2018-12-13T16:51:34\", \"url\": \"http://www.ncpe.ie/drugs/tedizolid-phosphate-sivextro/\", \"rr_start\": \"2015-05-07T00:00:00\", \"rr_end\": \"2015-07-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-05-07, 2015-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Tedizolid phosphate (Sivextro\", \"trade_name\": \"Sivextro\", \"indication\": \"Tedizolid phosphate (Sivextro\", \"ncpe_year\": 2015, \"eu_market\": \"2015-03-23T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-05-07T00:00:00\", \"latest\": \"2015-07-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sivextro\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"No HTA\"}, {\"id\": 2528, \"last_scrape\": \"2018-12-13T16:51:38\", \"url\": \"http://www.ncpe.ie/drugs/teduglutide-revestive/\", \"rr_start\": \"2017-03-13T00:00:00\", \"rr_end\": \"2017-04-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-13, 2017-04-12\", \"rr_multiple\": 0, \"drug_name\": \"Teduglutide (Revestive\", \"trade_name\": \"Revestive\", \"indication\": \"Teduglutide (Revestive\", \"ncpe_year\": 2018, \"eu_market\": \"2012-08-30T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2017-03-13T00:00:00\", \"latest\": \"2018-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revestive\", \"ta_list\": \"Malabsorption Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2529, \"last_scrape\": \"2018-12-13T16:51:44\", \"url\": \"http://www.ncpe.ie/drugs/tegafurgimeraciloteracil-teysuno/\", \"rr_start\": \"2012-02-27T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-02-27, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Tegafur/Gimeracil/Oteracil (Teysuno\", \"trade_name\": \"Teysuno\", \"indication\": \"Teysuno is indicated in adults for the treatment of advanced gastric cancer.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-03-14T00:00:00\", \"company\": \"Nordic\", \"orphan\": 0, \"earliest\": \"2012-02-27T00:00:00\", \"latest\": \"2012-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2530, \"last_scrape\": \"2018-12-13T16:51:48\", \"url\": \"http://www.ncpe.ie/drugs/telapravir/\", \"rr_start\": \"2011-10-28T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-10-28, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Telaprevir (Incivo\", \"trade_name\": \"Incivo\", \"indication\": \"Economic evaluation of Telaprevir (Incivo\", \"ncpe_year\": 2012, \"eu_market\": \"2011-09-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-28T00:00:00\", \"latest\": \"2012-01-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/incivo\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2531, \"last_scrape\": \"2018-12-13T16:51:52\", \"url\": \"http://www.ncpe.ie/drugs/telavancin-vibativ/\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-12-08, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Telavancin (Vibativ\", \"trade_name\": \"Vibativ\", \"indication\": \"Indicated for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumomia, known or suspended to be caused by methicillin-resistant Staphylococcus aureas (MRSA).  Vabitiv\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Theravance\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2015-01-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vibativ-0\", \"ta_list\": \"Pneumonia, Bacterial; Cross Infection\", \"rr_status\": \"No HTA\"}, {\"id\": 2532, \"last_scrape\": \"2018-12-13T16:51:56\", \"url\": \"http://www.ncpe.ie/drugs/teriflunomide-aubagio/\", \"rr_start\": \"2013-08-27T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-08-27, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Teriflunomide (Aubagio\", \"trade_name\": \"Aubagio\", \"indication\": \"Aubagio\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2013-08-27T00:00:00\", \"latest\": \"2014-09-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2533, \"last_scrape\": \"2018-12-13T16:51:58\", \"url\": \"http://www.ncpe.ie/drugs/ticagrelor-brilique-2/\", \"rr_start\": \"2016-02-29T00:00:00\", \"rr_end\": \"2016-05-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-29, 2016-05-04\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor (Brilique\", \"trade_name\": \"Brilique\", \"indication\": \"Ticagrelor (Brilique\", \"ncpe_year\": 2016, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-29T00:00:00\", \"latest\": \"2016-05-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brilique\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2534, \"last_scrape\": \"2018-12-13T16:52:01\", \"url\": \"http://www.ncpe.ie/drugs/ticagrelor-brilique/\", \"rr_start\": \"2010-11-25T00:00:00\", \"rr_end\": \"2011-01-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-11-25, 2011-01-20\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor (Brilique\", \"trade_name\": \"Brilique\", \"indication\": \"Economic Evaluation of Ticagrelor (Brilique\", \"ncpe_year\": 2011, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-11-25T00:00:00\", \"latest\": \"2011-10-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brilique\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2535, \"last_scrape\": \"2018-12-13T16:52:07\", \"url\": \"http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-all/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-19T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TISAGENLECLEUCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel (Kymriah\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel (Kymriah\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2536, \"last_scrape\": \"2018-12-13T16:52:13\", \"url\": \"http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-dlbcl/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TISAGENLECLEUCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel (Kymriah\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel (Kymriah\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2537, \"last_scrape\": \"2018-12-13T16:52:19\", \"url\": \"http://www.ncpe.ie/drugs/tobramycin-tobi-podhaler/\", \"rr_start\": \"2010-11-10T00:00:00\", \"rr_end\": \"2010-11-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2010-11-10, 2010-11-03\", \"rr_multiple\": 0, \"drug_name\": \"Tobramycin (TOBI Podhaler\", \"trade_name\": \"TOBI Podhaler\", \"indication\": \"Tobramycin (TOBI Podhaler\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-11-01T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2538, \"last_scrape\": \"2018-12-13T16:52:24\", \"url\": \"http://www.ncpe.ie/drugs/tocilizumab-sc-roactemra/\", \"rr_start\": \"2014-04-28T00:00:00\", \"rr_end\": \"2014-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THESUBMITTED PRICE.\", \"rr_dates\": \"2014-04-28, 2014-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Tocilizumab SC (RoActemra\", \"trade_name\": \"RoActemra\", \"indication\": \"It is licensed for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.  It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-04-28T00:00:00\", \"latest\": \"2014-07-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra\", \"ta_list\": \"Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2539, \"last_scrape\": \"2018-12-13T16:52:30\", \"url\": \"http://www.ncpe.ie/drugs/tofacitinib-xeljanz-for-ulcerative-colitis/\", \"rr_start\": \"2018-07-16T00:00:00\", \"rr_end\": \"2018-09-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TOFACITINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-07-16, 2018-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib (Xeljanz\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy (i.e. corticosteroids, azathioprine, 6-mercaptopurine) or a biologic agent (i.e. TNF inhibitor).\", \"ncpe_year\": 2018, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2018-07-16T00:00:00\", \"latest\": \"2018-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2540, \"last_scrape\": \"2018-12-13T16:52:35\", \"url\": \"http://www.ncpe.ie/drugs/tofacitinib-xeljanz/\", \"rr_start\": \"2017-03-08T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-08, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib (Xeljanz\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib (Xeljanz\", \"ncpe_year\": 2017, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-03-08T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2541, \"last_scrape\": \"2018-12-13T16:52:40\", \"url\": \"http://www.ncpe.ie/drugs/tolvaptan-jinarc/\", \"rr_start\": \"2016-01-04T00:00:00\", \"rr_end\": \"2016-01-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-04, 2016-01-12\", \"rr_multiple\": 0, \"drug_name\": \"Tolvaptan (Jinarc\", \"trade_name\": \"Jinarc\", \"indication\": \"Jinarc\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2016-01-04T00:00:00\", \"latest\": \"2018-09-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc\", \"ta_list\": \"Polycystic Kidney, Autosomal Dominant\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2542, \"last_scrape\": \"2018-12-13T16:52:45\", \"url\": \"http://www.ncpe.ie/drugs/tramadol-hydrochloridedexketoprofen-skudexa/\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"REIMURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-10-17, 2017-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Tramadol hydrochloride/dexketoprofen (Skudexa\", \"trade_name\": \"Skudexa\", \"indication\": \"Tramadol hydrochloride/dexketoprofen (Skudexa \", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2017-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2543, \"last_scrape\": \"2018-12-13T16:52:51\", \"url\": \"http://www.ncpe.ie/drugs/trametinib-mekinist/\", \"rr_start\": \"2015-11-27T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-27, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Trametinib (Mekinist\", \"trade_name\": \"Mekinist\", \"indication\": \"Mekinist\", \"ncpe_year\": 2018, \"eu_market\": \"2014-06-30T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-27T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2544, \"last_scrape\": \"2018-12-13T16:52:56\", \"url\": \"http://www.ncpe.ie/drugs/trastuzumab-emtansine-kadcyla/\", \"rr_start\": \"2013-09-25T00:00:00\", \"rr_end\": \"2013-10-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-25, 2013-10-24\", \"rr_multiple\": 0, \"drug_name\": \"Trastuzumab emtansine (Kadcyla\", \"trade_name\": \"Kadcyla\", \"indication\": \"Trastuzumab emtansine (Kadcyla\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-09-25T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2545, \"last_scrape\": \"2018-12-13T16:53:00\", \"url\": \"http://www.ncpe.ie/drugs/trifluridinetipiracil-lonsurf/\", \"rr_start\": \"2016-06-10T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-06-10, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Trifluridine/tipiracil (Lonsurf\", \"trade_name\": \"Lonsurf\", \"indication\": \"Trifluridine/tipiracil (Lonsurf\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2016-06-10T00:00:00\", \"latest\": \"2016-07-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2546, \"last_scrape\": \"2018-12-13T16:53:04\", \"url\": \"http://www.ncpe.ie/drugs/ulipristal-acetate-esmya-2/\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-05-17, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate (Esmya \", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate is indicated for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-05-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esmya\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2547, \"last_scrape\": \"2018-12-13T16:53:08\", \"url\": \"http://www.ncpe.ie/drugs/ulipristal-acetate-esmya/\", \"rr_start\": \"2013-09-03T00:00:00\", \"rr_end\": \"2013-10-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-09-03, 2013-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate (Esmya\", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate (Esmya\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2013-09-03T00:00:00\", \"latest\": \"2013-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esmya\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2548, \"last_scrape\": \"2018-12-13T16:53:10\", \"url\": \"http://www.ncpe.ie/drugs/umeclidiniumvilanterol-anoro/\", \"rr_start\": \"2014-06-11T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-06-11, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Umeclidinium/vilanterol (Anoro\", \"trade_name\": \"Anoro\", \"indication\": \"Umeclidinium/vilanterol (Anoro\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-06-11T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2549, \"last_scrape\": \"2018-12-13T16:53:12\", \"url\": \"http://www.ncpe.ie/drugs/urea-glucorx-allpresan/\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT GLUCORX ALLPRESAN DIABETIC FOAM CREAM NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE IN ACCORDANCE WITH THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2018-07-09, 2018-07-24\", \"rr_multiple\": 0, \"drug_name\": \"Urea (GlucoRx Allpresan\", \"trade_name\": \"GlucoRx Allpresan\", \"indication\": \"GlucoRx Allpresan\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-07-24T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2550, \"last_scrape\": \"2018-12-13T16:53:17\", \"url\": \"http://www.ncpe.ie/drugs/ustekinumab-stelara-2/\", \"rr_start\": \"2016-11-28T00:00:00\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-11-28, 2017-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab (Stelara\", \"trade_name\": \"Stelara\", \"indication\": \"Ustekinumab is indicated for the treatment of adult patients with moderately to severely active Crohn\", \"ncpe_year\": 2017, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2016-11-28T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stelara\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2551, \"last_scrape\": \"2018-12-13T16:53:23\", \"url\": \"http://www.ncpe.ie/drugs/ustekinumab-stelara/\", \"rr_start\": \"\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab (Stelara\", \"trade_name\": \"Stelara\", \"indication\": \"Cost-effectiveness of Ustekinumab (Stelara\", \"ncpe_year\": 2009, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2009-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stelara\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2552, \"last_scrape\": \"2018-12-13T16:53:29\", \"url\": \"http://www.ncpe.ie/drugs/vandetanib-caprelsa/\", \"rr_start\": \"2013-06-06T00:00:00\", \"rr_end\": \"2013-07-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-06, 2013-07-03\", \"rr_multiple\": 0, \"drug_name\": \"Vandetanib (Caprelsa\", \"trade_name\": \"Caprelsa\", \"indication\": \"Vandetanib (Caprelsa\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-16T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2013-06-06T00:00:00\", \"latest\": \"2013-07-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2553, \"last_scrape\": \"2018-12-13T16:53:32\", \"url\": \"http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-crohns-disease/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab (Entyvio\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab (Entyvio\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2554, \"last_scrape\": \"2018-12-13T16:53:39\", \"url\": \"http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-ulcerative-colitis/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab (Entyvio\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab (Entyvio\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2555, \"last_scrape\": \"2018-12-13T16:53:45\", \"url\": \"http://www.ncpe.ie/drugs/velaglucerase-alfa-vpriv-2/\", \"rr_start\": \"2011-04-26T00:00:00\", \"rr_end\": \"2011-06-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-04-26, 2011-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Velaglucerase Alfa (VPRIV\", \"trade_name\": \"VPRIV\", \"indication\": \"VPRIV is indicated for long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-04-26T00:00:00\", \"latest\": \"2011-06-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2556, \"last_scrape\": \"2018-12-13T16:53:49\", \"url\": \"http://www.ncpe.ie/drugs/venetoclax-venclyxto-in-combination-with-rituximab/\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF VENETOCLAX COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-26, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax (Venclyxto\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax (Venclyxto\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2557, \"last_scrape\": \"2018-12-13T16:53:52\", \"url\": \"http://www.ncpe.ie/drugs/venetoclax-venclyxto/\", \"rr_start\": \"2018-05-08T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"FOLLOWING A RESUBMISSION OF THE RAPID REVIEW A FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, WHICH IS NOT COMPARABLE WITH CURRENT AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-05-08, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax (Venclyxto\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL)\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2558, \"last_scrape\": \"2018-12-13T16:53:58\", \"url\": \"http://www.ncpe.ie/drugs/vermurafenib-zelboraf/\", \"rr_start\": \"2011-12-23T00:00:00\", \"rr_end\": \"2012-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-12-23, 2012-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Vemurafenib (Zelboraf\", \"trade_name\": \"Zelboraf\", \"indication\": \"Vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\", \"ncpe_year\": 2014, \"eu_market\": \"2012-02-17T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2011-12-23T00:00:00\", \"latest\": \"2014-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2559, \"last_scrape\": \"2018-12-13T16:54:00\", \"url\": \"http://www.ncpe.ie/drugs/vernakalant-brinavess/\", \"rr_start\": \"2010-10-26T00:00:00\", \"rr_end\": \"2010-11-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-10-26, 2010-11-04\", \"rr_multiple\": 0, \"drug_name\": \"Vernakalant (Brinavess\", \"trade_name\": \"Brinavess\", \"indication\": \"Economic evaluation of Vernakalant (Brinavess\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Cardiome\", \"orphan\": 0, \"earliest\": \"2010-10-26T00:00:00\", \"latest\": \"2011-05-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2560, \"last_scrape\": \"2018-12-13T16:54:04\", \"url\": \"http://www.ncpe.ie/drugs/vismodegib-erivedge/\", \"rr_start\": \"2013-05-02T00:00:00\", \"rr_end\": \"2013-05-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-05-02, 2013-05-20\", \"rr_multiple\": 0, \"drug_name\": \"Vismodegib (Erivedge\", \"trade_name\": \"Erivedge\", \"indication\": \"Vismodegib (Erivedge\", \"ncpe_year\": 2017, \"eu_market\": \"2013-07-12T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-05-02T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge\", \"ta_list\": \"Carcinoma, Basal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2561, \"last_scrape\": \"2018-12-13T16:54:11\", \"url\": \"http://www.ncpe.ie/drugs/vortioxetine-brintellix/\", \"rr_start\": \"2014-10-01T00:00:00\", \"rr_end\": \"2014-11-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-10-01, 2014-11-14\", \"rr_multiple\": 0, \"drug_name\": \"Vortioxetine (Brintellix\", \"trade_name\": \"Brintellix\", \"indication\": \"Vortioxetine (Brintellix\", \"ncpe_year\": 2017, \"eu_market\": \"2013-12-18T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2014-10-01T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"HTA recommended at submitted price\"}]}};\n",
       "var opt = {};\n",
       "var type = \"vega-lite\";\n",
       "var id = \"f56a6c79-1d80-4459-aef4-ad31c6ee001c\";\n",
       "\n",
       "var output_area = this;\n",
       "\n",
       "require([\"nbextensions/jupyter-vega/index\"], function(vega) {\n",
       "  var target = document.createElement(\"div\");\n",
       "  target.id = id;\n",
       "  target.className = \"vega-embed\";\n",
       "\n",
       "  var style = document.createElement(\"style\");\n",
       "  style.textContent = [\n",
       "    \".vega-embed .error p {\",\n",
       "    \"  color: firebrick;\",\n",
       "    \"  font-size: 14px;\",\n",
       "    \"}\",\n",
       "  ].join(\"\\\\n\");\n",
       "\n",
       "  // element is a jQuery wrapped DOM element inside the output area\n",
       "  // see http://ipython.readthedocs.io/en/stable/api/generated/\\\n",
       "  // IPython.display.html#IPython.display.Javascript.__init__\n",
       "  element[0].appendChild(target);\n",
       "  element[0].appendChild(style);\n",
       "\n",
       "  vega.render(\"#\" + id, spec, type, opt, output_area);\n",
       "}, function (err) {\n",
       "  if (err.requireType !== \"scripterror\") {\n",
       "    throw(err);\n",
       "  }\n",
       "});\n"
      ],
      "text/plain": [
       "<vega.vegalite.VegaLite at 0x245818811d0>"
      ]
     },
     "metadata": {
      "jupyter-vega": "#f56a6c79-1d80-4459-aef4-ad31c6ee001c"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": []
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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"
     },
     "metadata": {
      "jupyter-vega": "#f56a6c79-1d80-4459-aef4-ad31c6ee001c"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "alt.Chart(drugs,title=\"Count Drugs By Company\").mark_bar(color='lightblue').encode(\n",
    "    alt.Y('company', sort=alt.EncodingSortField(field=\"company\", op=\"count\", order='descending'),\n",
    "          axis=alt.Axis(title='Drug Company')),\n",
    "    alt.X('count(rr_status)',\n",
    "          axis=alt.Axis(title='Records'))).properties(width=700,height=3000)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 2.4 Count: Drugs by Company with NCPE Year \n",
    "Year is highlighted with colour gradient, more recent drugs are darker."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "var spec = {\"config\": {\"view\": {\"width\": 400, \"height\": 300}}, \"data\": {\"name\": \"data-1fb11c1b30e9c74b6a5173f2568cb7ab\"}, \"mark\": \"bar\", \"encoding\": {\"color\": {\"type\": \"quantitative\", \"field\": \"ncpe_year\", \"sort\": \"descending\", \"title\": \"NCPE Year\"}, \"x\": {\"type\": \"nominal\", \"axis\": {\"title\": \"Drug Company\"}, \"field\": \"company\", \"sort\": {\"op\": \"count\", \"field\": \"company\", \"order\": \"descending\"}}, \"y\": {\"type\": \"nominal\", \"aggregate\": \"count\", \"axis\": {\"title\": \"Count\"}, \"field\": \"rr_status\"}}, \"height\": 300, \"title\": \"Drugs By Company with NCPE Year\", \"width\": 4000, \"$schema\": \"https://vega.github.io/schema/vega-lite/v2.6.0.json\", \"datasets\": {\"data-1fb11c1b30e9c74b6a5173f2568cb7ab\": [{\"id\": 2164, \"last_scrape\": \"2018-12-13T16:24:32\", \"url\": \"http://www.ncpe.ie/drugs/abatacept-orencia/\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Abatacept (Orencia\", \"trade_name\": \"Orencia\", \"indication\": \"Subcutaneous Abatacept (Orencia\", \"ncpe_year\": 2015, \"eu_market\": \"2007-05-21T00:00:00\", \"company\": \"\", \"orphan\": 0, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/orencia\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2165, \"last_scrape\": \"2018-12-13T16:24:36\", \"url\": \"http://www.ncpe.ie/drugs/abiraterone-acetate-zytiga-for-mhspc/\", \"rr_start\": \"2018-10-03T00:00:00\", \"rr_end\": \"2018-11-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-10-03, 2018-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Abiraterone acetate (Zytiga\", \"ncpe_year\": 2018, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2018-10-03T00:00:00\", \"latest\": \"2018-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2166, \"last_scrape\": \"2018-12-13T16:24:41\", \"url\": \"http://www.ncpe.ie/drugs/abiratone-acetate-zytiga-for-mcrpc-post-adt/\", \"rr_start\": \"2013-01-03T00:00:00\", \"rr_end\": \"2013-02-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-01-03, 2013-02-01\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation of Abiratone acetate (Zytiga\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-01-03T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2167, \"last_scrape\": \"2018-12-13T16:24:46\", \"url\": \"http://www.ncpe.ie/drugs/abiratone-acetate-zytiga/\", \"rr_start\": \"2011-10-21T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-10-21, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone Acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation and resource implications of Zytiga \", \"ncpe_year\": 2014, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-21T00:00:00\", \"latest\": \"2014-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2168, \"last_scrape\": \"2018-12-13T16:24:49\", \"url\": \"http://www.ncpe.ie/drugs/aceclofenac-vitafen/\", \"rr_start\": \"2016-12-21T00:00:00\", \"rr_end\": \"2017-01-24T00:00:00\", \"rr_outcome\": \"FOLLOWING A RESUBMISSION OF THE RAPID REVIEW A FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-12-21, 2017-01-24\", \"rr_multiple\": 0, \"drug_name\": \"Aceclofenac (Vitafen\", \"trade_name\": \"Vitafen\", \"indication\": \"Aceclofenac (Vitafen\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-07-22T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2169, \"last_scrape\": \"2018-12-13T16:24:56\", \"url\": \"http://www.ncpe.ie/drugs/aclidinium-bromide-eklira-genuair/\", \"rr_start\": \"2012-10-23T00:00:00\", \"rr_end\": \"2012-10-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-23, 2012-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide (Eklira Genuair\", \"trade_name\": \"Eklira Genuair\", \"indication\": \"Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)\", \"ncpe_year\": 2012, \"eu_market\": \"2012-07-20T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-23T00:00:00\", \"latest\": \"2012-10-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"id\": 2170, \"last_scrape\": \"2018-12-13T16:25:00\", \"url\": \"http://www.ncpe.ie/drugs/aclidinium-bromide-formoterol-fumarate-dihydrate-brimica-genuair/\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE.\", \"rr_dates\": \"2015-01-05, 2015-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide / formoterol fumarate dihydrate (Brimica\", \"trade_name\": \"Brimica Genuair\", \"indication\": \"Brimica\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2015-02-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brimica-genuair\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2171, \"last_scrape\": \"2018-12-13T16:25:37\", \"url\": \"http://www.ncpe.ie/drugs/adalimumab-humira/\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-20, 2011-06-02\", \"rr_multiple\": 0, \"drug_name\": \"Adalimumab (Humira\", \"trade_name\": \"Humira\", \"indication\": \"Economic evaluation of Adalimumab (Humira\", \"ncpe_year\": 2011, \"eu_market\": \"2003-09-07T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/humira\", \"ta_list\": \"Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"id\": 2172, \"last_scrape\": \"2018-12-13T16:25:40\", \"url\": \"http://www.ncpe.ie/drugs/adenuric-febuxostat/\", \"rr_start\": \"2009-12-08T00:00:00\", \"rr_end\": \"2009-12-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-12-08\", \"rr_multiple\": 0, \"drug_name\": \"Adenuric (Febuxostat\", \"trade_name\": \"Febuxostat\", \"indication\": \"NCPE review of Adenuric (Febuxostat\", \"ncpe_year\": 2009, \"eu_market\": \"2008-04-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2009-12-08T00:00:00\", \"latest\": \"2009-12-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adenuric\", \"ta_list\": \"Gout\", \"rr_status\": \"No HTA\"}, {\"id\": 2173, \"last_scrape\": \"2018-12-13T16:25:45\", \"url\": \"http://www.ncpe.ie/drugs/afatinib-giotrif/\", \"rr_start\": \"2013-10-01T00:00:00\", \"rr_end\": \"2013-10-13T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-10-01, 2013-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Afatinib (Giotrif\", \"trade_name\": \"Giotrif\", \"indication\": \"GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-na\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-25T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2013-10-01T00:00:00\", \"latest\": \"2013-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2174, \"last_scrape\": \"2018-12-13T16:25:49\", \"url\": \"http://www.ncpe.ie/drugs/aflibercept-eylea/\", \"rr_start\": \"2012-12-10T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-10, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept (Eylea\", \"trade_name\": \"Eylea\", \"indication\": \"Aflibercept (Eylea\", \"ncpe_year\": 2012, \"eu_market\": \"2012-11-21T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2012-12-10T00:00:00\", \"latest\": \"2012-12-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eylea\", \"ta_list\": \"Wet Macular Degeneration; Macular Edema; Diabetes Complications\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2175, \"last_scrape\": \"2018-12-13T16:25:52\", \"url\": \"http://www.ncpe.ie/drugs/aflibercept-zaltrap/\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept (Zaltrap\", \"trade_name\": \"Zaltrap\", \"indication\": \"Aflibercept for the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-01T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-02-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zaltrap\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2176, \"last_scrape\": \"2018-12-13T16:25:58\", \"url\": \"http://www.ncpe.ie/drugs/agomelatine-valdoxan-4/\", \"rr_start\": \"\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Agomelatine (Valdoxan\", \"trade_name\": \"Valdoxan\", \"indication\": \"Economic evaluation of Agomelatine (Valdoxan\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-19T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2009-09-03T00:00:00\", \"latest\": \"2009-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/valdoxan\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2177, \"last_scrape\": \"2018-12-13T16:26:06\", \"url\": \"http://www.ncpe.ie/drugs/alectinib-alecensa/\", \"rr_start\": \"2017-01-03T00:00:00\", \"rr_end\": \"2017-12-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-01-03, 2017-02-27, 2017-11-08, 2017-12-04\", \"rr_multiple\": 1, \"drug_name\": \"Alectinib (Alecensa\", \"trade_name\": \"Alecensa\", \"indication\": \"Alectinib (Alecensa \", \"ncpe_year\": 2018, \"eu_market\": \"2017-02-16T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2178, \"last_scrape\": \"2018-12-13T16:26:12\", \"url\": \"http://www.ncpe.ie/drugs/alemtuzumab-lemtrada/\", \"rr_start\": \"2013-11-08T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-11-08, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Alemtuzumab (Lemtrada\", \"trade_name\": \"Lemtrada\", \"indication\": \"Alemtuzumab (Lemtrada\", \"ncpe_year\": 2014, \"eu_market\": \"2013-09-12T00:00:00\", \"company\": \"Sanofi\", \"orphan\": 0, \"earliest\": \"2013-11-08T00:00:00\", \"latest\": \"2014-06-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2179, \"last_scrape\": \"2018-12-13T16:26:14\", \"url\": \"http://www.ncpe.ie/drugs/alirocumab-praluent/\", \"rr_start\": \"2015-10-13T00:00:00\", \"rr_end\": \"2015-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-10-13, 2015-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Alirocumab (Praluent\", \"trade_name\": \"Praluent\", \"indication\": \"Praluent\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2015-10-13T00:00:00\", \"latest\": \"2018-03-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/praluent\", \"ta_list\": \"Dyslipidemias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2180, \"last_scrape\": \"2018-12-13T16:26:16\", \"url\": \"http://www.ncpe.ie/drugs/alogliptin-vipidia/\", \"rr_start\": \"2013-09-27T00:00:00\", \"rr_end\": \"2013-10-30T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-09-27, 2013-10-30\", \"rr_multiple\": 0, \"drug_name\": \"Alogliptin (Vipidia\", \"trade_name\": \"Vipidia\", \"indication\": \"Alogliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-18T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2013-09-27T00:00:00\", \"latest\": \"2013-10-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vipidia\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2181, \"last_scrape\": \"2018-12-13T16:26:21\", \"url\": \"http://www.ncpe.ie/drugs/ambrisentan-volibris/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-05-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Ambrisentan (Volibris\", \"trade_name\": \"Volibris\", \"indication\": \"Cost Effectiveness of ambrisentan (Volibris\", \"ncpe_year\": 2014, \"eu_market\": \"2008-04-20T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 1, \"earliest\": \"2008-10-01T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/volibris\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2182, \"last_scrape\": \"2018-12-13T16:26:23\", \"url\": \"http://www.ncpe.ie/drugs/amifampridine-firdapse/\", \"rr_start\": \"2011-11-07T00:00:00\", \"rr_end\": \"2011-12-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-11-07, 2011-12-09\", \"rr_multiple\": 0, \"drug_name\": \"Amifampridine (Firdapse\", \"trade_name\": \"Firdapse\", \"indication\": \"For Lambert Eaton Myasthenic Syndrome (LEMS).  This high cost drug is likely to require a full HTA due to significant budget impact.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-11-07T00:00:00\", \"latest\": \"2011-12-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2183, \"last_scrape\": \"2018-12-13T16:26:29\", \"url\": \"http://www.ncpe.ie/drugs/amsacrine-amsidine/\", \"rr_start\": \"2017-01-10T00:00:00\", \"rr_end\": \"2017-02-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-01-10, 2017-02-15\", \"rr_multiple\": 0, \"drug_name\": \"Amsacrine (Amsidine\", \"trade_name\": \"Amsidine\", \"indication\": \"Amsidine\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2017-01-10T00:00:00\", \"latest\": \"2017-02-15T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2184, \"last_scrape\": \"2018-12-13T16:26:35\", \"url\": \"http://www.ncpe.ie/drugs/apixaban-eliquis-for-treatment-of-deep-vein-thrombosis-dvt-and-pulmonary-embolism-pe-and-prevention-of-recurrent-dvt-and-pe-in-adults/\", \"rr_start\": \"2014-07-29T00:00:00\", \"rr_end\": \"2014-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-07-29, 2014-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban (Eliquis\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban (Eliquis\", \"ncpe_year\": 2014, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-07-29T00:00:00\", \"latest\": \"2014-08-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2185, \"last_scrape\": \"2018-12-13T16:26:39\", \"url\": \"http://www.ncpe.ie/drugs/apixaban-eliquis/\", \"rr_start\": \"2011-10-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-10-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban (Eliquis\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban (Eliquis\", \"ncpe_year\": 2012, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-10-19T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2186, \"last_scrape\": \"2018-12-13T16:26:45\", \"url\": \"http://www.ncpe.ie/drugs/apremilast-otezla-for-moderate-to-severe-chronic-plaque-psoriasis/\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast (Otezla\", \"trade_name\": \"Otezla\", \"indication\": \"Indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to systemic non-biologic therapies including cyclosporine, methotrexate or psoralen and ultraviolet A light (PUVA).\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/otezla\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2187, \"last_scrape\": \"2018-12-13T16:26:47\", \"url\": \"http://www.ncpe.ie/drugs/apremilast-otezla-for-psoriatic-arthritis/\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast (Otezla\", \"trade_name\": \"Otezla\", \"indication\": \"Apremilist (Otezla\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/otezla\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2188, \"last_scrape\": \"2018-12-13T16:26:49\", \"url\": \"http://www.ncpe.ie/drugs/aripiprazole-abilify-maintena/\", \"rr_start\": \"2014-07-02T00:00:00\", \"rr_end\": \"2014-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-07-02, 2014-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Aripiprazole (Abilify Maintena\", \"trade_name\": \"Abilify Maintena\", \"indication\": \"Aripiprazole (Abilify Maintena\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-14T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2014-07-02T00:00:00\", \"latest\": \"2014-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2189, \"last_scrape\": \"2018-12-13T16:26:55\", \"url\": \"http://www.ncpe.ie/drugs/asenapine-sycrest/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-08-17, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Asenapine (Sycrest\", \"trade_name\": \"Sycrest\", \"indication\": \"Asenapine (Sycrest\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Organon\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sycrest\", \"ta_list\": \"Bipolar Disorder\", \"rr_status\": \"No HTA\"}, {\"id\": 2190, \"last_scrape\": \"2018-12-13T16:27:00\", \"url\": \"http://www.ncpe.ie/drugs/atezolizumab-tecentriq/\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-10-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-08, 2017-10-09\", \"rr_multiple\": 0, \"drug_name\": \"Atezolizumab (Tecentriq\", \"trade_name\": \"Tecentriq\", \"indication\": \"Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK?positive tumour mutations should also have received targeted therapy before receiving atezolizumab.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-21T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq\", \"ta_list\": \"Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2191, \"last_scrape\": \"2018-12-13T16:27:05\", \"url\": \"http://www.ncpe.ie/drugs/avanafil-spedra/\", \"rr_start\": \"2014-02-19T00:00:00\", \"rr_end\": \"2014-03-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-19, 2014-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Avanafil (Spedra\", \"trade_name\": \"Spedra\", \"indication\": \"Avanafil (Spedra\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2014-02-19T00:00:00\", \"latest\": \"2014-03-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/spedra\", \"ta_list\": \"Erectile Dysfunction\", \"rr_status\": \"No HTA\"}, {\"id\": 2192, \"last_scrape\": \"2018-12-13T16:27:06\", \"url\": \"http://www.ncpe.ie/drugs/avelumab-bavencio/\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-10-17, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Avelumab (Bavencio\", \"trade_name\": \"Bavencio\", \"indication\": \"Avelumab (Bavencio\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2018-10-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2193, \"last_scrape\": \"2018-12-13T16:27:08\", \"url\": \"http://www.ncpe.ie/drugs/axanum-aspirin-81mgesomeprazole-20mg/\", \"rr_start\": \"2012-04-12T00:00:00\", \"rr_end\": \"2012-04-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-04-12, 2012-04-20\", \"rr_multiple\": 0, \"drug_name\": \"Aspirin 81mg/Esomeprazole 20mg (Axanum\", \"trade_name\": \"Axanum\", \"indication\": \"Prevention of thrombotic cardiovascular and cerebrovascular events in patients requiring continuous low-dose acetylsalicylic acid treatment, and who are in need of prophylaxis against acetylsalicylic acid associated gastric and /or duodenal ulcers.\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-04-12T00:00:00\", \"latest\": \"2012-04-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2194, \"last_scrape\": \"2018-12-13T16:27:14\", \"url\": \"http://www.ncpe.ie/drugs/axicabtagene-ciloleucel-yescarta/\", \"rr_start\": \"2018-09-10T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF  AXI-CEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-10, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Axicabtagene Ciloleucel (Yescarta\", \"trade_name\": \"Yescarta\", \"indication\": \"Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Kite\", \"orphan\": 1, \"earliest\": \"2018-09-10T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta\", \"ta_list\": \"Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2195, \"last_scrape\": \"2018-12-13T16:27:23\", \"url\": \"http://www.ncpe.ie/drugs/axitinib-inlyta/\", \"rr_start\": \"2012-11-07T00:00:00\", \"rr_end\": \"2012-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-07, 2012-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Axitinib (Inlyta\", \"trade_name\": \"Inlyta\", \"indication\": \"For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-03T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-11-07T00:00:00\", \"latest\": \"2012-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2196, \"last_scrape\": \"2018-12-13T16:27:24\", \"url\": \"http://www.ncpe.ie/drugs/azelastine-hydrochloride-and-fluticasone-propionate-nasal-spray-dymista/\", \"rr_start\": \"2013-02-12T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2013-02-12, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Azelastine hydrochloride and fluticasone propionate (nasal spray) (Dymista\", \"trade_name\": \"Dymista\", \"indication\": \"Indicated for symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-02-12T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2197, \"last_scrape\": \"2018-12-13T16:27:25\", \"url\": \"http://www.ncpe.ie/drugs/azilsartan-edarbi/\", \"rr_start\": \"2012-01-10T00:00:00\", \"rr_end\": \"2012-01-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-01-10, 2012-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Azilsartan (Edarbi\", \"trade_name\": \"Edarbi\", \"indication\": \"Edarbi is indicated for the treatment of essential hypertension in adults.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-12-07T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2012-01-10T00:00:00\", \"latest\": \"2012-01-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/edarbi\", \"ta_list\": \"Hypertension\", \"rr_status\": \"No HTA\"}, {\"id\": 2198, \"last_scrape\": \"2018-12-13T16:27:27\", \"url\": \"http://www.ncpe.ie/drugs/baricitinib-olumiant/\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-06-14, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Baricitinib (Olumiant\", \"trade_name\": \"Olumiant\", \"indication\": \"Baricitinib (Olumiant\", \"ncpe_year\": 2017, \"eu_market\": \"2017-02-12T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2199, \"last_scrape\": \"2018-12-13T16:27:33\", \"url\": \"http://www.ncpe.ie/drugs/bazedoxifene-conbriza/\", \"rr_start\": \"2011-09-20T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-09-20, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Bazedoxifene (Conbriza\", \"trade_name\": \"Conbriza\", \"indication\": \"Bazedoxifene (Conbriza\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-17T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-09-20T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza\", \"ta_list\": \"Osteoporosis, Postmenopausal\", \"rr_status\": \"No HTA\"}, {\"id\": 2200, \"last_scrape\": \"2018-12-13T16:27:36\", \"url\": \"http://www.ncpe.ie/drugs/bedaquiline-sirturo/\", \"rr_start\": \"2015-01-23T00:00:00\", \"rr_end\": \"2015-02-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-01-23, 2015-02-20\", \"rr_multiple\": 0, \"drug_name\": \"Bedaquiline (Sirturo\", \"trade_name\": \"Sirturo\", \"indication\": \"Bedaquiline (Sirturo\", \"ncpe_year\": 2015, \"eu_market\": \"2014-03-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2015-01-23T00:00:00\", \"latest\": \"2015-02-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo\", \"ta_list\": \"Tuberculosis, Multidrug-Resistant\", \"rr_status\": \"No HTA\"}, {\"id\": 2201, \"last_scrape\": \"2018-12-13T16:27:37\", \"url\": \"http://www.ncpe.ie/drugs/belatacept-nulojix/\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2012-01-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-11-15, 2012-01-23\", \"rr_multiple\": 0, \"drug_name\": \"Belatacept (Nulojix\", \"trade_name\": \"Nulojix\", \"indication\": \"Belatacept, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen.\\n\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2012-01-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nulojix\", \"ta_list\": \"Graft Rejection; Kidney Transplantation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2202, \"last_scrape\": \"2018-12-13T16:27:40\", \"url\": \"http://www.ncpe.ie/drugs/belimumab-benlysta/\", \"rr_start\": \"2011-08-11T00:00:00\", \"rr_end\": \"2011-08-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-11, 2011-08-11\", \"rr_multiple\": 0, \"drug_name\": \"Belimumab (Benlysta\", \"trade_name\": \"Benlysta\", \"indication\": \"Cost-effectiveness of Belimumab (Benlysta\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-08-01T00:00:00\", \"latest\": \"2011-08-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta\", \"ta_list\": \"Lupus Erythematosus, Systemic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2203, \"last_scrape\": \"2018-12-13T16:27:46\", \"url\": \"http://www.ncpe.ie/drugs/bendamustine-levact/\", \"rr_start\": \"2011-03-21T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-03-21, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Bendamustine (Levact\", \"trade_name\": \"Levact\", \"indication\": \"Bendamustine (Levact\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2012-11-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2204, \"last_scrape\": \"2018-12-13T16:27:50\", \"url\": \"http://www.ncpe.ie/drugs/benralizumab-fasenra/\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-14T00:00:00\", \"rr_outcome\": \"FULL PHARAMCOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2018-01-15, 2018-02-14\", \"rr_multiple\": 0, \"drug_name\": \"Benralizumab (Fasenra\", \"trade_name\": \"Fasenra\", \"indication\": \"Benralizumab (Fasenra\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fasenra\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2205, \"last_scrape\": \"2018-12-13T16:27:56\", \"url\": \"http://www.ncpe.ie/drugs/bezlotoxumab-zinplava/\", \"rr_start\": \"2017-05-11T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-05-11, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Bezlotoxumab (Zinplava\", \"trade_name\": \"Zinplava\", \"indication\": \"Bezlotoxumab (Zinplava\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-05-11T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinplava\", \"ta_list\": \"Enterocolitis, Pseudomembranous\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2206, \"last_scrape\": \"2018-12-13T16:27:58\", \"url\": \"http://www.ncpe.ie/drugs/bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy/\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT BIKTARVY\", \"rr_dates\": \"2018-04-30, 2018-06-07\", \"rr_multiple\": 0, \"drug_name\": \"Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy\", \"trade_name\": \"Biktarvy\", \"indication\": \"Biktarvy\", \"ncpe_year\": 2018, \"eu_market\": \"2018-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2207, \"last_scrape\": \"2018-12-13T16:28:01\", \"url\": \"http://www.ncpe.ie/drugs/bilastine-drynol/\", \"rr_start\": \"2011-03-10T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-10, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Bilastine (Drynol\", \"trade_name\": \"Drynol\", \"indication\": \" Bilastine (Drynol\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-03-10T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2208, \"last_scrape\": \"2018-12-13T16:28:05\", \"url\": \"http://www.ncpe.ie/drugs/blinatumomab-blincyto/\", \"rr_start\": \"2015-12-08T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.  THE NCPE CANNOT RECOMMEND REIMBURSEMENT OF BLINCTYO\", \"rr_dates\": \"2015-12-08, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Blinatumomab (Blincyto\", \"trade_name\": \"Blincyto\", \"indication\": \"Blincyto\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-23T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-08T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2209, \"last_scrape\": \"2018-12-13T16:28:11\", \"url\": \"http://www.ncpe.ie/drugs/boceprevir-victrelis/\", \"rr_start\": \"\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Boceprevir (Victrelis\", \"trade_name\": \"Victrelis\", \"indication\": \"Economic evaluation of Boceprevir (Victrelis\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2011-08-19T00:00:00\", \"latest\": \"2012-01-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2210, \"last_scrape\": \"2018-12-13T16:28:16\", \"url\": \"http://www.ncpe.ie/drugs/bosentan-tracleer/\", \"rr_start\": \"2014-06-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-06-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Bosentan (Tracleer\", \"trade_name\": \"Tracleer\", \"indication\": \"Bosentan (Tracleer\", \"ncpe_year\": 2014, \"eu_market\": \"2002-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-06-27T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tracleer\", \"ta_list\": \"Scleroderma, Systemic; Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2211, \"last_scrape\": \"2018-12-13T16:28:18\", \"url\": \"http://www.ncpe.ie/drugs/bosutinib-bosulif/\", \"rr_start\": \"2013-08-09T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"AT THE CURRENT PRICE A FULL HTA WOULD BE REQUIRED.\", \"rr_dates\": \"2013-08-09, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Bosutinib (Bosulif\", \"trade_name\": \"Bosulif\", \"indication\": \"Bosutinib is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-26T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2212, \"last_scrape\": \"2018-12-13T16:28:19\", \"url\": \"http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris-for-cd30-cutaneous-t-cell-lymphoma-ctcl/\", \"rr_start\": \"2018-02-07T00:00:00\", \"rr_end\": \"2018-03-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-02-07, 2018-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin (Adcetris\", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin (Adcetris\", \"ncpe_year\": 2018, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-02-07T00:00:00\", \"latest\": \"2018-03-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2213, \"last_scrape\": \"2018-12-13T16:28:23\", \"url\": \"http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris/\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin (Adcetris\", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin (Adcetris\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2214, \"last_scrape\": \"2018-12-13T16:28:29\", \"url\": \"http://www.ncpe.ie/drugs/brigatinib-alunbrig/\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF BRIGATINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-11-19, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Brigatinib (Alunbrig\", \"trade_name\": \"Alunbrig\", \"indication\": \"Brigatinib (Alunbrig \", \"ncpe_year\": 2018, \"eu_market\": \"2018-11-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2215, \"last_scrape\": \"2018-12-13T16:28:30\", \"url\": \"http://www.ncpe.ie/drugs/brimonidine-3-3-mgg-gel-mirvaso/\", \"rr_start\": \"2014-04-09T00:00:00\", \"rr_end\": \"2014-04-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-09\", \"rr_multiple\": 0, \"drug_name\": \"Brimonidine 3.3 mg/g gel (Mirvaso\", \"trade_name\": \"Mirvaso\", \"indication\": \"Brimonidine 3.3 mg/g gel (Mirvaso\", \"ncpe_year\": 2014, \"eu_market\": \"2014-02-20T00:00:00\", \"company\": \"Galderma\", \"orphan\": 0, \"earliest\": \"2014-04-09T00:00:00\", \"latest\": \"2014-04-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mirvaso\", \"ta_list\": \"Skin Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2216, \"last_scrape\": \"2018-12-13T16:28:36\", \"url\": \"http://www.ncpe.ie/drugs/brivaracetam-briviact/\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-02-15, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Brivaracetam (Briviact\", \"trade_name\": \"Briviact\", \"indication\": \"Brivaracetam (Briviact\", \"ncpe_year\": 2016, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2217, \"last_scrape\": \"2018-12-13T16:28:40\", \"url\": \"http://www.ncpe.ie/drugs/brodalumab-kyntheum/\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-07-25, 2017-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Brodalumab (Kyntheum\", \"trade_name\": \"Kyntheum\", \"indication\": \"Brodalumab (Kyntheum\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-17T00:00:00\", \"company\": \"LEO\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2218, \"last_scrape\": \"2018-12-13T16:28:44\", \"url\": \"http://www.ncpe.ie/drugs/bronchitol/\", \"rr_start\": \"2012-09-11T00:00:00\", \"rr_end\": \"2012-09-21T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2012-09-11, 2012-09-21\", \"rr_multiple\": 0, \"drug_name\": \"Mannitol Dry Powder (Bronchitol\", \"trade_name\": \"Bronchitol\", \"indication\": \"Bronchitol\", \"ncpe_year\": 2014, \"eu_market\": \"2012-04-13T00:00:00\", \"company\": \"Pharmaxis\", \"orphan\": 1, \"earliest\": \"2012-09-11T00:00:00\", \"latest\": \"2014-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bronchitol\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2219, \"last_scrape\": \"2018-12-13T16:28:46\", \"url\": \"http://www.ncpe.ie/drugs/c-drugs/calcipotriol-and-betamethasone-dipropionate-cutaneous-foam-enstilar/\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-06-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-05-17, 2016-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Calcipotriol and betamethasone dipropionate cutaneous foam (Enstilar \", \"trade_name\": \"Enstilar\", \"indication\": \"Calcipotriol and betamethasone dipropionate cutaneous foam is indicated for the topical treatment of psoriasis vulgaris in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-06-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2220, \"last_scrape\": \"2018-12-13T16:28:53\", \"url\": \"http://www.ncpe.ie/drugs/c1inhibitor-human-cinryze/\", \"rr_start\": \"2012-10-22T00:00:00\", \"rr_end\": \"2012-11-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-22, 2012-11-14\", \"rr_multiple\": 0, \"drug_name\": \"C1inhibitor (human) (Cinryze\", \"trade_name\": \"Cinryze\", \"indication\": \"C1inhibitor (human) (Cinryze\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-15T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2012-10-22T00:00:00\", \"latest\": \"2012-11-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"id\": 2221, \"last_scrape\": \"2018-12-13T16:28:55\", \"url\": \"http://www.ncpe.ie/drugs/cabozantinib-cabometyx/\", \"rr_start\": \"2017-03-20T00:00:00\", \"rr_end\": \"2017-04-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT\\nRECOMMENDED\", \"rr_dates\": \"2017-03-20, 2017-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib (Cabometyx\", \"trade_name\": \"Cabometyx\", \"indication\": \"Cabozantinib (Cabometyx\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-03-20T00:00:00\", \"latest\": \"2018-07-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2222, \"last_scrape\": \"2018-12-13T16:28:58\", \"url\": \"http://www.ncpe.ie/drugs/cabozantinib-cometriq/\", \"rr_start\": \"2014-07-10T00:00:00\", \"rr_end\": \"2014-08-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2014-07-10, 2014-08-12\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib (Cometriq\", \"trade_name\": \"Cometriq\", \"indication\": \"Cabozantinib (COMETRIQ\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-21T00:00:00\", \"company\": \"Ipsen\", \"orphan\": 1, \"earliest\": \"2014-07-10T00:00:00\", \"latest\": \"2014-08-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2223, \"last_scrape\": \"2018-12-13T16:29:01\", \"url\": \"http://www.ncpe.ie/drugs/camellia-sinensis-folium-green-tea-leaf-catephen-10/\", \"rr_start\": \"2015-05-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-05-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Camellia sinensis, folium (green tea leaf) (Catephen 10%\", \"trade_name\": \"Catephen 10%\", \"indication\": \"Catephen 10%\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-05-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2224, \"last_scrape\": \"2018-12-13T16:29:04\", \"url\": \"http://www.ncpe.ie/drugs/canagliflozin-invokana/\", \"rr_start\": \"2013-11-25T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-11-25, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Canagliflozin (Invokana\", \"trade_name\": \"Invokana\", \"indication\": \"Canagliflozin (Invokana\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-11-25T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/invokana\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2225, \"last_scrape\": \"2018-12-13T16:29:09\", \"url\": \"http://www.ncpe.ie/drugs/capsaicin-8ww-patch-qutenza/\", \"rr_start\": \"2012-06-15T00:00:00\", \"rr_end\": \"2012-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-06-15, 2012-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Capsaicin 8%w/w patch (Qutenza\", \"trade_name\": \"Qutenza\", \"indication\": \"Capsaicin 8% w/w patch (Qutenza\", \"ncpe_year\": 2012, \"eu_market\": \"2009-05-15T00:00:00\", \"company\": \"Grunenthal\", \"orphan\": 0, \"earliest\": \"2012-06-15T00:00:00\", \"latest\": \"2012-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza\", \"ta_list\": \"Neuralgia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2226, \"last_scrape\": \"2018-12-13T16:29:11\", \"url\": \"http://www.ncpe.ie/drugs/carbazitaxel-jevtana-for-prostate-cancer/\", \"rr_start\": \"2011-06-02T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-06-02, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Cabazitaxel (Jevtana\", \"trade_name\": \"Jevtana\", \"indication\": \"Economic Evaluation of cabazitaxel (Jevtana\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2011-06-02T00:00:00\", \"latest\": \"2014-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jevtana\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2227, \"last_scrape\": \"2018-12-13T16:29:16\", \"url\": \"http://www.ncpe.ie/drugs/carfilzomib-kyprolis/\", \"rr_start\": \"2015-12-07T00:00:00\", \"rr_end\": \"2016-01-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-12-07, 2016-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Carfilzomib (Kyprolis\", \"trade_name\": \"Kyprolis\", \"indication\": \"Kyprolis\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-07T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2228, \"last_scrape\": \"2018-12-13T16:29:22\", \"url\": \"http://www.ncpe.ie/drugs/catumaxomab-removab/\", \"rr_start\": \"2011-08-05T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-08-05, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Catumaxomab (Removab\", \"trade_name\": \"Removab\", \"indication\": \"Catumazomab (Removab\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-20T00:00:00\", \"company\": \"Neovii\", \"orphan\": 0, \"earliest\": \"2011-08-05T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/removab\", \"ta_list\": \"Ascites; Cancer\", \"rr_status\": \"No HTA\"}, {\"id\": 2229, \"last_scrape\": \"2018-12-13T16:29:25\", \"url\": \"http://www.ncpe.ie/drugs/ceftaroline-zinforo/\", \"rr_start\": \"2012-10-08T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-08, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Ceftaroline (Zinforo\", \"trade_name\": \"Zinforo\", \"indication\": \"For the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP).\", \"ncpe_year\": 2012, \"eu_market\": \"2012-08-22T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-10-08T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinforo\", \"ta_list\": \"Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia\", \"rr_status\": \"No HTA\"}, {\"id\": 2230, \"last_scrape\": \"2018-12-13T16:29:29\", \"url\": \"http://www.ncpe.ie/drugs/ceftazidime-avibactam-cef-avizavicefta/\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-17, 2017-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Ceftazidime-avibactam (CEF-AVI)(Zavicefta\", \"trade_name\": \"Zavicefta\", \"indication\": \"Ceftazidime-avibactam (CEF-AVI)(Zavicefta\", \"ncpe_year\": 2017, \"eu_market\": \"2016-06-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta\", \"ta_list\": \"Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2231, \"last_scrape\": \"2018-12-13T16:29:34\", \"url\": \"http://www.ncpe.ie/drugs/ceftolozanetazobactam-zerbaxa/\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-03-03, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Ceftolozane/tazobactam (Zerbaxa\", \"trade_name\": \"Zerbaxa\", \"indication\": \"Zerbaxa\", \"ncpe_year\": 2016, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa\", \"ta_list\": \"Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2232, \"last_scrape\": \"2018-12-13T16:29:36\", \"url\": \"http://www.ncpe.ie/drugs/ceritinib-zykadia/\", \"rr_start\": \"2015-05-29T00:00:00\", \"rr_end\": \"2015-07-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2015-05-29, 2015-07-22\", \"rr_multiple\": 0, \"drug_name\": \"Ceritinib (Zykadia\", \"trade_name\": \"Zykadia\", \"indication\": \"Zykadia\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-06T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-05-29T00:00:00\", \"latest\": \"2015-07-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2233, \"last_scrape\": \"2018-12-13T16:29:40\", \"url\": \"http://www.ncpe.ie/drugs/cerliponase-alfa-brineura/\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2017-10-11, 2017-11-27\", \"rr_multiple\": 0, \"drug_name\": \"Cerliponase alfa (Brineura\", \"trade_name\": \"Brineura\", \"indication\": \"Cerliponase alfa (Brineura\", \"ncpe_year\": 2018, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-08-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brineura\", \"ta_list\": \"Neuronal Ceroid-Lipofuscinoses\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2234, \"last_scrape\": \"2018-12-13T16:29:44\", \"url\": \"http://www.ncpe.ie/drugs/certolizumab-pegol-cimzia/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Certolizumab pegol (Cimzia\", \"trade_name\": \"Cimzia\", \"indication\": \"Cost-effectiveness of certolizumab pegol (Cimzia\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2010-03-13T00:00:00\", \"latest\": \"2010-09-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia-0\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2235, \"last_scrape\": \"2018-12-13T16:29:49\", \"url\": \"http://www.ncpe.ie/drugs/ciclosporin-1mgml-eye-drops-ikervis/\", \"rr_start\": \"2015-01-07T00:00:00\", \"rr_end\": \"2016-01-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-01-07, 2016-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Ciclosporin 1mg/ml eye drops (Ikervis\", \"trade_name\": \"Ikervis\", \"indication\": \"Ikervis\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-19T00:00:00\", \"company\": \"Santen\", \"orphan\": 0, \"earliest\": \"2015-01-07T00:00:00\", \"latest\": \"2016-01-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis\", \"ta_list\": \"Corneal Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2236, \"last_scrape\": \"2018-12-13T16:29:54\", \"url\": \"http://www.ncpe.ie/drugs/cladribine-mavenclad/\", \"rr_start\": \"2017-08-22T00:00:00\", \"rr_end\": \"2017-09-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-22, 2017-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Cladribine (Mavenclad\", \"trade_name\": \"Mavenclad\", \"indication\": \"Cladribine (Mavenclad\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-08-22T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2237, \"last_scrape\": \"2018-12-13T16:29:58\", \"url\": \"http://www.ncpe.ie/drugs/clindamycin-1-with-tretinoin-0-025-treclinac/\", \"rr_start\": \"2014-04-08T00:00:00\", \"rr_end\": \"2014-05-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-08, 2014-05-06\", \"rr_multiple\": 0, \"drug_name\": \"Clindamycin 1% with tretinoin 0.025% (Treclinac\", \"trade_name\": \"Treclinac\", \"indication\": \"Clindamycin 1% with tretinoin 0.025% (Treclinac\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-04-08T00:00:00\", \"latest\": \"2014-05-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2238, \"last_scrape\": \"2018-12-13T16:30:02\", \"url\": \"http://www.ncpe.ie/drugs/cobimetinib-cotellic/\", \"rr_start\": \"2016-04-19T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-04-19, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Cobimetinib (Cotellic\", \"trade_name\": \"Cotellic\", \"indication\": \"Cotellic\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2016-04-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2239, \"last_scrape\": \"2018-12-13T16:30:03\", \"url\": \"http://www.ncpe.ie/drugs/colesevelam-cholestagel/\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Colesevelam (Cholestagel\", \"trade_name\": \"Cholestagel\", \"indication\": \"Cost-effectiveness of Colesevelam (Cholestagel\", \"ncpe_year\": 2010, \"eu_market\": \"2004-03-09T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cholestagel\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"No HTA\"}, {\"id\": 2240, \"last_scrape\": \"2018-12-13T16:30:06\", \"url\": \"http://www.ncpe.ie/drugs/colistimethate-sodium-colobreathe/\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Colistimethate sodium (Colobreathe\", \"trade_name\": \"Colobreathe\", \"indication\": \"Colistimethate sodium (colobreathe\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-13T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/colobreathe\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2241, \"last_scrape\": \"2018-12-13T16:30:17\", \"url\": \"http://www.ncpe.ie/drugs/collagenase-clostridium-histolyticum-xiapex/\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-20, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Collagenase Clostridium Histolyticum (Xiapex\", \"trade_name\": \"Xiapex\", \"indication\": \" Collagenase Clostridium Histolyticum (Xiapex\", \"ncpe_year\": 2011, \"eu_market\": \"2011-02-28T00:00:00\", \"company\": \"Swedish\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xiapex\", \"ta_list\": \"Dupuytren Contracture\", \"rr_status\": \"No HTA\"}, {\"id\": 2242, \"last_scrape\": \"2018-12-13T16:30:20\", \"url\": \"http://www.ncpe.ie/drugs/corifollitropin-alfa-elonva/\", \"rr_start\": \"2010-10-22T00:00:00\", \"rr_end\": \"2010-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-10-22, 2010-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Corifollitropin alfa (Elonva\", \"trade_name\": \"Elonva\", \"indication\": \"Cost-effectiveness of Corifollitropin alfa (Elonva\", \"ncpe_year\": 2010, \"eu_market\": \"2010-01-25T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2010-09-01T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/elonva\", \"ta_list\": \"Reproductive Techniques, Assisted; Ovulation Induction\", \"rr_status\": \"No HTA\"}, {\"id\": 2243, \"last_scrape\": \"2018-12-13T16:30:24\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori-for-first-line-alk-nsclc/\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2244, \"last_scrape\": \"2018-12-13T16:30:29\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori-for-ros1-nsclc/\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2245, \"last_scrape\": \"2018-12-13T16:30:34\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori/\", \"rr_start\": \"2013-01-09T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-01-09, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"For the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-01-09T00:00:00\", \"latest\": \"2015-08-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2246, \"last_scrape\": \"2018-12-13T16:30:37\", \"url\": \"http://www.ncpe.ie/drugs/cysteamine-bitartrate-procysbi/\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2015-12-01, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Cysteamine bitartrate delayed-release (Procysbi\", \"trade_name\": \"Procysbi\", \"indication\": \"Procysbi\", \"ncpe_year\": 2017, \"eu_market\": \"2013-09-05T00:00:00\", \"company\": \"Chiesi\", \"orphan\": 1, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/procysbi\", \"ta_list\": \"Cystinosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2247, \"last_scrape\": \"2018-12-13T16:30:43\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-2/\", \"rr_start\": \"2014-05-09T00:00:00\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-09, 2014-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate (Pradaxa\", \"ncpe_year\": 2014, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-09T00:00:00\", \"latest\": \"2014-06-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2248, \"last_scrape\": \"2018-12-13T16:30:51\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-for-the-prevention-of-stroke-and-systematic-embolisom-in-atrial-fibrillation/\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate (Pradaxa\", \"ncpe_year\": 2012, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2010-11-02T00:00:00\", \"latest\": \"2012-10-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2249, \"last_scrape\": \"2018-12-13T16:30:57\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-vte-prevention/\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Economic Evaluation of the Cost Effectiveness of Dabigatran Etexilate (Pradaxa\", \"ncpe_year\": 2008, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2008-07-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2250, \"last_scrape\": \"2018-12-13T16:30:59\", \"url\": \"http://www.ncpe.ie/drugs/dabrafenib-tafinlar/\", \"rr_start\": \"2013-09-11T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-11, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Dabrafenib (Tafinlar\", \"trade_name\": \"Tafinlar\", \"indication\": \"Dabrafenib (Tafinlar\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2013-09-11T00:00:00\", \"latest\": \"2014-06-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2251, \"last_scrape\": \"2018-12-13T16:31:02\", \"url\": \"http://www.ncpe.ie/drugs/daclatasvir-daklinza/\", \"rr_start\": \"2014-08-05T00:00:00\", \"rr_end\": \"2014-09-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-08-05, 2014-09-12\", \"rr_multiple\": 0, \"drug_name\": \"Daclatasvir (Daklinza\", \"trade_name\": \"Daklinza\", \"indication\": \"Daclatasvir (Daklinza\", \"ncpe_year\": 2015, \"eu_market\": \"2014-08-22T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-08-05T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/daklinza\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2252, \"last_scrape\": \"2018-12-13T16:31:08\", \"url\": \"http://www.ncpe.ie/drugs/daclizumab-zinbryta/\", \"rr_start\": \"2016-09-26T00:00:00\", \"rr_end\": \"2016-11-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-09-26, 2016-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Daclizumab (Zinbryta\", \"trade_name\": \"Zinbryta\", \"indication\": \"Daclizumab is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-07-01T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2016-09-26T00:00:00\", \"latest\": \"2018-03-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinbryta\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2253, \"last_scrape\": \"2018-12-13T16:31:12\", \"url\": \"http://www.ncpe.ie/drugs/dalbavancin-xydalba/\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-07, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Dalbavancin (Xydalba\", \"trade_name\": \"Xydalba\", \"indication\": \"Dalbavancin (Xydalba\", \"ncpe_year\": 2017, \"eu_market\": \"2015-02-19T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xydalba\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2254, \"last_scrape\": \"2018-12-13T16:31:18\", \"url\": \"http://www.ncpe.ie/drugs/dapagliflozin-forxiga/\", \"rr_start\": \"2012-10-10T00:00:00\", \"rr_end\": \"2012-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-10-10, 2012-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Dapagliflozin (Forxiga\", \"trade_name\": \"Forxiga\", \"indication\": \"Dapagliflozin (Forxiga\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-11T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-10T00:00:00\", \"latest\": \"2013-12-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2255, \"last_scrape\": \"2018-12-13T16:31:21\", \"url\": \"http://www.ncpe.ie/drugs/daratumumab-darzalex/\", \"rr_start\": \"2016-05-31T00:00:00\", \"rr_end\": \"2016-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-05-31, 2016-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Daratumumab (Darzalex\", \"trade_name\": \"Darzalex\", \"indication\": \"Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-04-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-05-31T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2256, \"last_scrape\": \"2018-12-13T16:31:25\", \"url\": \"http://www.ncpe.ie/drugs/darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-symtuza/\", \"rr_start\": \"2017-09-27T00:00:00\", \"rr_end\": \"2017-10-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-27, 2017-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza\", \"trade_name\": \"Symtuza\", \"indication\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza\", \"ncpe_year\": 2017, \"eu_market\": \"2017-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-09-27T00:00:00\", \"latest\": \"2017-10-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/symtuza\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2257, \"last_scrape\": \"2018-12-13T16:31:30\", \"url\": \"http://www.ncpe.ie/drugs/darunavir-cobicistat-rezolsta/\", \"rr_start\": \"2014-12-02T00:00:00\", \"rr_end\": \"2015-01-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-12-02, 2015-01-08\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir & cobicistat (Rezolsta\", \"trade_name\": \"Rezolsta\", \"indication\": \"Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-12-02T00:00:00\", \"latest\": \"2015-01-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2258, \"last_scrape\": \"2018-12-13T16:31:35\", \"url\": \"http://www.ncpe.ie/drugs/darvadstrocel-alofisel/\", \"rr_start\": \"2018-06-14T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF DARVADSTROCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-14, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Darvadstrocel (Alofisel\", \"trade_name\": \"Alofisel\", \"indication\": \"Darvadstrocel (Alofisel\", \"ncpe_year\": 2018, \"eu_market\": \"2018-03-23T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-06-14T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel\", \"ta_list\": \"Rectal Fistula\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2259, \"last_scrape\": \"2018-12-13T16:31:40\", \"url\": \"http://www.ncpe.ie/drugs/decitabine-dacogen/\", \"rr_start\": \"2012-11-08T00:00:00\", \"rr_end\": \"2012-12-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-08, 2012-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Decitabine (Dacogen\", \"trade_name\": \"Dacogen\", \"indication\": \"Decitabine (Dacogen\", \"ncpe_year\": 2013, \"eu_market\": \"2012-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2012-11-08T00:00:00\", \"latest\": \"2013-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2260, \"last_scrape\": \"2018-12-13T16:31:44\", \"url\": \"http://www.ncpe.ie/drugs/defibrotide-defitelio/\", \"rr_start\": \"2014-05-12T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2014-05-12, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Defibrotide (Defitelio\", \"trade_name\": \"Defitelio\", \"indication\": \"Defibrotide (Defitelio\", \"ncpe_year\": 2014, \"eu_market\": \"2013-10-18T00:00:00\", \"company\": \"Gentium\", \"orphan\": 1, \"earliest\": \"2014-05-12T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio\", \"ta_list\": \"Hepatic Veno-Occlusive Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2261, \"last_scrape\": \"2018-12-13T16:31:47\", \"url\": \"http://www.ncpe.ie/drugs/degarelix-firmagon/\", \"rr_start\": \"2009-10-15T00:00:00\", \"rr_end\": \"2009-10-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-10-15\", \"rr_multiple\": 0, \"drug_name\": \"Degarelix (Firmagon\", \"trade_name\": \"Firmagon\", \"indication\": \"Cost-effectiveness of Degarelix (Firmagon\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-17T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2009-10-15T00:00:00\", \"latest\": \"2009-10-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2262, \"last_scrape\": \"2018-12-13T16:31:52\", \"url\": \"http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-cannabidiol-thc-cbd-sativex/\", \"rr_start\": \"2018-02-12T00:00:00\", \"rr_end\": \"2018-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF SATIVEX\", \"rr_dates\": \"2018-02-12, 2018-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex\", \"trade_name\": \"Sativex\", \"indication\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-02-12T00:00:00\", \"latest\": \"2018-04-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2263, \"last_scrape\": \"2018-12-13T16:31:59\", \"url\": \"http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-thccannabidiol-cbd-sativex/\", \"rr_start\": \"2012-12-05T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-05, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol (THC) /Cannabidiol (CBD) (Sativex\", \"trade_name\": \"Sativex\", \"indication\": \"For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-12-05T00:00:00\", \"latest\": \"2014-09-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2264, \"last_scrape\": \"2018-12-13T16:32:04\", \"url\": \"http://www.ncpe.ie/drugs/denosumab-prolia/\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab (Prolia\", \"trade_name\": \"Prolia\", \"indication\": \"The Cost-effectiveness of Denosumab (Prolia\", \"ncpe_year\": 2010, \"eu_market\": \"2010-05-26T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2010-05-27T00:00:00\", \"latest\": \"2010-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prolia\", \"ta_list\": \"Bone Resorption; Osteoporosis, Postmenopausal\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2265, \"last_scrape\": \"2018-12-13T16:32:08\", \"url\": \"http://www.ncpe.ie/drugs/denosumab-xgeva-3/\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab (Xgeva\", \"trade_name\": \"Xgeva\", \"indication\": \"Cost-effectiveness of denosumab (Xgeva\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2011-08-15T00:00:00\", \"latest\": \"2011-12-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva\", \"ta_list\": \"Fractures, Bone; Neoplasm Metastasis\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2266, \"last_scrape\": \"2018-12-13T16:32:12\", \"url\": \"http://www.ncpe.ie/drugs/dexamethasone-intravitreal-implant-ozurdex/\", \"rr_start\": \"2010-11-12T00:00:00\", \"rr_end\": \"2010-12-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-11-12, 2010-12-16\", \"rr_multiple\": 0, \"drug_name\": \"Dexamethasone Intravitreal Implant (Ozurdex\", \"trade_name\": \"Ozurdex\", \"indication\": \"Cost-effectiveness of Ozurdex\", \"ncpe_year\": 2012, \"eu_market\": \"2010-07-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2010-11-12T00:00:00\", \"latest\": \"2012-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ozurdex\", \"ta_list\": \"Macular Edema; Uveitis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2267, \"last_scrape\": \"2018-12-13T16:32:15\", \"url\": \"http://www.ncpe.ie/drugs/dexmedetomidine-dexdor/\", \"rr_start\": \"2011-07-08T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-07-08, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Dexmedetomidine (Dexdor\", \"trade_name\": \"Dexdor\", \"indication\": \"Dexmedetomidine (Dexdor\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-15T00:00:00\", \"company\": \"Orion\", \"orphan\": 0, \"earliest\": \"2011-07-08T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dexdor\", \"ta_list\": \"Conscious Sedation\", \"rr_status\": \"No HTA\"}, {\"id\": 2268, \"last_scrape\": \"2018-12-13T16:32:21\", \"url\": \"http://www.ncpe.ie/drugs/dienogest-visanne/\", \"rr_start\": \"2010-09-17T00:00:00\", \"rr_end\": \"2010-10-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-09-17, 2010-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Dienogest (Visanne\", \"trade_name\": \"Visanne\", \"indication\": \"Dienogest (Visanne\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-09-17T00:00:00\", \"latest\": \"2010-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2269, \"last_scrape\": \"2018-12-13T16:32:24\", \"url\": \"http://www.ncpe.ie/drugs/dimethyl-fumarate-skilarence/\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-01-15, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate (Skilarence\", \"trade_name\": \"Skilarence\", \"indication\": \"Dimethyl fumarate (Skilarence\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"Almirall\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/skilarence\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2270, \"last_scrape\": \"2018-12-13T16:32:26\", \"url\": \"http://www.ncpe.ie/drugs/dimethyl-fumarate-tecfidera/\", \"rr_start\": \"2014-02-04T00:00:00\", \"rr_end\": \"2014-03-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-02-04, 2014-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate (Tecfidera\", \"trade_name\": \"Tecfidera\", \"indication\": \"Dimethyl fumarate (Tecfidera\", \"ncpe_year\": 2015, \"eu_market\": \"2014-01-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-02-04T00:00:00\", \"latest\": \"2015-04-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2271, \"last_scrape\": \"2018-12-13T16:32:29\", \"url\": \"http://www.ncpe.ie/drugs/dinutuximab-beta-dinutuximab-beta-eusa/\", \"rr_start\": \"2017-10-19T00:00:00\", \"rr_end\": \"2017-11-23T00:00:00\", \"rr_outcome\": \"FOLLOWING ASSESSMENT OF THE APPLICANT\", \"rr_dates\": \"2017-10-19, 2017-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Dinutuximab beta (Qarziba\", \"trade_name\": \"Qarziba\", \"indication\": \"Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients ? 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-10-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2272, \"last_scrape\": \"2018-12-13T16:32:34\", \"url\": \"http://www.ncpe.ie/drugs/dolutegravir-rilpivirine-juluca/\", \"rr_start\": \"2018-06-08T00:00:00\", \"rr_end\": \"2018-07-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT JULUCA\", \"rr_dates\": \"2018-06-08, 2018-07-12\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir/Rilpivirine (Juluca\", \"trade_name\": \"Juluca\", \"indication\": \"Dolutegravir/rilpivirine (Juluca\", \"ncpe_year\": 2018, \"eu_market\": \"2018-05-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2018-06-08T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/juluca\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2273, \"last_scrape\": \"2018-12-13T16:32:36\", \"url\": \"http://www.ncpe.ie/drugs/dolutegravir-tivicay/\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-10, 2014-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir (Tivicay\", \"trade_name\": \"Tivicay\", \"indication\": \"Dolutegravir (Tivicay\", \"ncpe_year\": 2014, \"eu_market\": \"2014-01-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2274, \"last_scrape\": \"2018-12-13T16:32:39\", \"url\": \"http://www.ncpe.ie/drugs/dronedarone-multaq/\", \"rr_start\": \"2010-01-12T00:00:00\", \"rr_end\": \"2010-01-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-01-12, 2010-01-01\", \"rr_multiple\": 0, \"drug_name\": \"Dronedarone (Multaq\", \"trade_name\": \"Multaq\", \"indication\": \"Rapid Review\", \"ncpe_year\": 2010, \"eu_market\": \"2009-11-25T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2010-01-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"No HTA\"}, {\"id\": 2275, \"last_scrape\": \"2018-12-13T16:32:42\", \"url\": \"http://www.ncpe.ie/drugs/dulaglutide-trulicity/\", \"rr_start\": \"2015-03-04T00:00:00\", \"rr_end\": \"2015-04-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-03-04, 2015-04-29\", \"rr_multiple\": 0, \"drug_name\": \"Dulaglutide (Trulicity\", \"trade_name\": \"Trulicity\", \"indication\": \"Dulaglutide is indicated as monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2015-03-04T00:00:00\", \"latest\": \"2015-04-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2276, \"last_scrape\": \"2018-12-13T16:32:46\", \"url\": \"http://www.ncpe.ie/drugs/dupilumab-dupixent/\", \"rr_start\": \"2017-11-13T00:00:00\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-13, 2017-11-24\", \"rr_multiple\": 0, \"drug_name\": \"Dupilumab (Dupixent\", \"trade_name\": \"Dupixent\", \"indication\": \"Dupilumab (Dupixent\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-27T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-11-13T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent\", \"ta_list\": \"Dermatitis, Atopic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2277, \"last_scrape\": \"2018-12-13T16:32:53\", \"url\": \"http://www.ncpe.ie/drugs/eculizumab-soliris/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Eculizumab (Soliris\", \"trade_name\": \"Soliris\", \"indication\": \"An Economic Evaluation of Eculizumab (Soliris\", \"ncpe_year\": 2013, \"eu_market\": \"2007-06-20T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2013-10-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/soliris\", \"ta_list\": \"Hemoglobinuria, Paroxysmal\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2278, \"last_scrape\": \"2018-12-13T16:32:55\", \"url\": \"http://www.ncpe.ie/drugs/edoxaban-lixiana/\", \"rr_start\": \"2015-06-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-06-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Edoxaban (Lixiana\", \"trade_name\": \"Lixiana\", \"indication\": \"Edoxaban is indicated for the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2015-06-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana\", \"ta_list\": \"Stroke; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2279, \"last_scrape\": \"2018-12-13T16:33:00\", \"url\": \"http://www.ncpe.ie/drugs/elbasvirgrazoprevir-zepatier-2/\", \"rr_start\": \"2016-08-10T00:00:00\", \"rr_end\": \"2016-10-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-08-10, 2016-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Elbasvir/Grazoprevir (Zepatier\", \"trade_name\": \"Zepatier\", \"indication\": \"Elbasvir 50mg/100mg grazoprevir (EBR/GZR)(Zepatier\", \"ncpe_year\": 2016, \"eu_market\": \"2016-07-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-10T00:00:00\", \"latest\": \"2016-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2280, \"last_scrape\": \"2018-12-13T16:33:03\", \"url\": \"http://www.ncpe.ie/drugs/eliglustat-cerdelga/\", \"rr_start\": \"2016-03-21T00:00:00\", \"rr_end\": \"2016-05-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-03-21, 2016-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Eliglustat (Cerdelga\", \"trade_name\": \"Cerdelga\", \"indication\": \"Eliglustat (Cerdelga\", \"ncpe_year\": 2018, \"eu_market\": \"2015-01-19T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 1, \"earliest\": \"2016-03-21T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga\", \"ta_list\": \"Gaucher Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2281, \"last_scrape\": \"2018-12-13T16:33:05\", \"url\": \"http://www.ncpe.ie/drugs/elosulfase-alfa-vimizim/\", \"rr_start\": \"2015-03-30T00:00:00\", \"rr_end\": \"2015-05-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-03-30, 2015-05-08\", \"rr_multiple\": 0, \"drug_name\": \"Elosulfase alfa (Vimizim\", \"trade_name\": \"Vimizim\", \"indication\": \"Elosulfase alfa (Vimzim\", \"ncpe_year\": 2018, \"eu_market\": \"2014-04-27T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2015-03-30T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vimizim\", \"ta_list\": \"Mucopolysaccharidosis IV\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2282, \"last_scrape\": \"2018-12-13T16:33:12\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade-2/\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-02-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-01-10, 2014-02-13\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Eltrombopag (Revolade\", \"ncpe_year\": 2014, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-02-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"id\": 2283, \"last_scrape\": \"2018-12-13T16:33:17\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade-3/\", \"rr_start\": \"2016-02-05T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-02-05, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Revolade\", \"ncpe_year\": 2016, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-02-05T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"id\": 2284, \"last_scrape\": \"2018-12-13T16:33:23\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade/\", \"rr_start\": \"2017-12-04T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, WHICH IS NOT COMPARABLE WITH CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2017-12-04, 2018-04-16, 2017-12-01\", \"rr_multiple\": 1, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Cost-effectiveness of eltrombopag (Revolade\", \"ncpe_year\": 2018, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-07-30T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2285, \"last_scrape\": \"2018-12-13T16:33:26\", \"url\": \"http://www.ncpe.ie/drugs/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya/\", \"rr_start\": \"2015-11-24T00:00:00\", \"rr_end\": \"2016-01-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-11-24, 2016-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide (Genvoya\", \"trade_name\": \"Genvoya\", \"indication\": \"Genvoya\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2015-11-24T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2286, \"last_scrape\": \"2018-12-13T16:33:32\", \"url\": \"http://www.ncpe.ie/drugs/empagliflozin-jardiance/\", \"rr_start\": \"2014-05-22T00:00:00\", \"rr_end\": \"2014-06-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-22, 2014-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Empagliflozin (Jardiance\", \"trade_name\": \"Jardiance\", \"indication\": \"Add-on combination therapy \", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-22T00:00:00\", \"latest\": \"2014-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2287, \"last_scrape\": \"2018-12-13T16:33:37\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabine-tenofovir-disoproxil-fumarate-truvada/\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-07-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-12, 2017-07-18\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine / tenofovir disoproxil fumarate (Truvada\", \"trade_name\": \"Truvada\", \"indication\": \"Truvada\", \"ncpe_year\": 2017, \"eu_market\": \"2005-02-20T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-07-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/truvada\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2288, \"last_scrape\": \"2018-12-13T16:33:43\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabine-tenovir-disoproxil-teva/\", \"rr_start\": \"2017-12-11T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-12-11, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir disoproxil (TEVA\", \"trade_name\": \"TEVA\", \"indication\": \"Emtricitabine/tenofovir disoproxil (TEVA\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-12-11T00:00:00\", \"latest\": \"2017-12-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2289, \"last_scrape\": \"2018-12-13T16:33:48\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabinetenofovir-alafenamide-descovy/\", \"rr_start\": \"2016-04-26T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-04-26, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir alafenamide (Descovy\", \"trade_name\": \"Descovy\", \"indication\": \"Descovy\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-04-26T00:00:00\", \"latest\": \"2016-04-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/descovy\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2290, \"last_scrape\": \"2018-12-13T16:33:52\", \"url\": \"http://www.ncpe.ie/drugs/enzalutamide-xtandi/\", \"rr_start\": \"2013-06-28T00:00:00\", \"rr_end\": \"2013-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-28, 2013-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Enzalutamide (Xtandi\", \"trade_name\": \"Xtandi\", \"indication\": \"Enzalutamide (Xtandi\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2013-06-28T00:00:00\", \"latest\": \"2014-04-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2291, \"last_scrape\": \"2018-12-13T16:33:59\", \"url\": \"http://www.ncpe.ie/drugs/epoprostenol-veletri/\", \"rr_start\": \"2016-12-13T00:00:00\", \"rr_end\": \"2017-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-12-13, 2017-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Epoprostenol (Veletri\", \"trade_name\": \"Veletri\", \"indication\": \"Veletri\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-12-13T00:00:00\", \"latest\": \"2017-02-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2292, \"last_scrape\": \"2018-12-13T16:34:03\", \"url\": \"http://www.ncpe.ie/drugs/erenumab-aimovig/\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-15T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF ERENUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-19, 2018-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Erenumab (Aimovig\", \"trade_name\": \"Aimovig\", \"indication\": \"Erenumab (Aimovig\", \"ncpe_year\": 2018, \"eu_market\": \"2018-07-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig\", \"ta_list\": \"Migraine Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2293, \"last_scrape\": \"2018-12-13T16:34:07\", \"url\": \"http://www.ncpe.ie/drugs/eribulin-halaven/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-03-11, 2011-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Eribulin (Halaven\", \"trade_name\": \"Halaven\", \"indication\": \"Eribulin (Halaven\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2011-02-09T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/halaven\", \"ta_list\": \"Breast Neoplasms; Liposarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2294, \"last_scrape\": \"2018-12-13T16:34:09\", \"url\": \"http://www.ncpe.ie/drugs/eslicarbazepine-zebinix/\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-08-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2009-09-01, 2009-08-01\", \"rr_multiple\": 0, \"drug_name\": \"Eslicarbazepine (Zebinix\", \"trade_name\": \"Zebinix\", \"indication\": \"Eslicarbazepine (Zebinix\", \"ncpe_year\": 2009, \"eu_market\": \"2009-04-21T00:00:00\", \"company\": \"BIAL\", \"orphan\": 0, \"earliest\": \"2009-08-01T00:00:00\", \"latest\": \"2009-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2295, \"last_scrape\": \"2018-12-13T16:34:12\", \"url\": \"http://www.ncpe.ie/drugs/etanercept-benepali/\", \"rr_start\": \"2016-03-22T00:00:00\", \"rr_end\": \"2016-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-03-22, 2016-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Etanercept (Benepali\", \"trade_name\": \"Benepali\", \"indication\": \"Benepali\", \"ncpe_year\": 2016, \"eu_market\": \"2016-01-13T00:00:00\", \"company\": \"Samsung\", \"orphan\": 0, \"earliest\": \"2016-03-22T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/benepali\", \"ta_list\": \"Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis\", \"rr_status\": \"No HTA\"}, {\"id\": 2296, \"last_scrape\": \"2018-12-13T16:34:15\", \"url\": \"http://www.ncpe.ie/drugs/etelcalcetide-parsabiv/\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-06-14, 2017-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Etelcalcetide (Parsabiv\", \"trade_name\": \"Parsabiv\", \"indication\": \"Etelcalcitide (Parsabiv\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-11T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/parsabiv\", \"ta_list\": \"Hyperparathyroidism, Secondary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2297, \"last_scrape\": \"2018-12-13T16:34:21\", \"url\": \"http://www.ncpe.ie/drugs/eurartesim-piperaquine-tetraphosphatedihidroartemisinin/\", \"rr_start\": \"2012-05-22T00:00:00\", \"rr_end\": \"2012-05-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-05-22, 2012-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Piperaquine tetraphosphate/dihidroartemisinin (Eurartesim\", \"trade_name\": \"Eurartesim\", \"indication\": \"Eurartesim\", \"ncpe_year\": 2012, \"eu_market\": \"2011-10-27T00:00:00\", \"company\": \"Alfasigma\", \"orphan\": 0, \"earliest\": \"2012-05-22T00:00:00\", \"latest\": \"2012-05-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eurartesim\", \"ta_list\": \"Malaria\", \"rr_status\": \"No HTA\"}, {\"id\": 2298, \"last_scrape\": \"2018-12-13T16:34:24\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-afinitor/\", \"rr_start\": \"2012-09-21T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-09-21, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Afinitor\", \"trade_name\": \"Afinitor\", \"indication\": \"Treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor\", \"ncpe_year\": 2012, \"eu_market\": \"2009-08-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-09-21T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/afinitor\", \"ta_list\": \"Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2299, \"last_scrape\": \"2018-12-13T16:34:26\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-votubia-for-refractory-seizures-associated-with-tuberous-sclerosis-complex-tsc/\", \"rr_start\": \"2017-04-19T00:00:00\", \"rr_end\": \"2017-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-04-19, 2017-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Votubia \", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus (Votubia\", \"ncpe_year\": 2017, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2017-04-19T00:00:00\", \"latest\": \"2017-04-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/votubia\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2300, \"last_scrape\": \"2018-12-13T16:34:29\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-votubia/\", \"rr_start\": \"2011-09-30T00:00:00\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-09-30, 2011-10-14\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Votubia\", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus (Votubia\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2011-09-30T00:00:00\", \"latest\": \"2011-10-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/votubia\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2301, \"last_scrape\": \"2018-12-13T16:34:36\", \"url\": \"http://www.ncpe.ie/drugs/evolocumab-repatha/\", \"rr_start\": \"\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Evolocumab (Repatha\", \"trade_name\": \"Repatha\", \"indication\": \"Evolocumab (Repatha\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-17T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-01-01T00:00:00\", \"latest\": \"2018-05-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/repatha\", \"ta_list\": \"Dyslipidemias; Hypercholesterolemia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2302, \"last_scrape\": \"2018-12-13T16:34:41\", \"url\": \"http://www.ncpe.ie/drugs/exenatide-bydureon/\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Exenatide (Bydureon\", \"trade_name\": \"Bydureon\", \"indication\": \"Exenatide (Bydureon\", \"ncpe_year\": 2011, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2303, \"last_scrape\": \"2018-12-13T16:34:44\", \"url\": \"http://www.ncpe.ie/drugs/fampridine-fampyra/\", \"rr_start\": \"2011-09-11T00:00:00\", \"rr_end\": \"2011-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-09-11, 2011-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Fampridine (Fampyra\", \"trade_name\": \"Fampyra\", \"indication\": \"Fampridine (Fampyra\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-20T00:00:00\", \"company\": \"Blogen\", \"orphan\": 0, \"earliest\": \"2011-09-01T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fampyra\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2304, \"last_scrape\": \"2018-12-13T16:34:48\", \"url\": \"http://www.ncpe.ie/drugs/ferric-maltol-feraccru_/\", \"rr_start\": \"2016-08-12T00:00:00\", \"rr_end\": \"2016-09-06T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-08-12, 2016-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Ferric maltol (Feraccru\", \"trade_name\": \"Feraccru\", \"indication\": \"Ferric maltol indicated for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) in adult patients.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Shield\", \"orphan\": 0, \"earliest\": \"2016-08-12T00:00:00\", \"latest\": \"2016-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/feraccru\", \"ta_list\": \"Anemia, Iron-Deficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2305, \"last_scrape\": \"2018-12-13T16:34:51\", \"url\": \"http://www.ncpe.ie/drugs/fidaxomicin-dificlir/\", \"rr_start\": \"2012-03-09T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2012-03-09, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Fidaxomicin (Dificlir\", \"trade_name\": \"Dificlir\", \"indication\": \"Fidaxomicin is indicated for the treatment of CDI also known as CDAD in adult patients.\", \"ncpe_year\": 2013, \"eu_market\": \"2011-12-05T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-03-09T00:00:00\", \"latest\": \"2013-02-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dificlir\", \"ta_list\": \"Clostridium Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2306, \"last_scrape\": \"2018-12-13T16:34:56\", \"url\": \"http://www.ncpe.ie/drugs/fingolimod-gilenya-4/\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2010-12-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-01-10, 2010-12-03\", \"rr_multiple\": 0, \"drug_name\": \"Fingolimod (Gilenya\", \"trade_name\": \"Gilenya\", \"indication\": \"Cost effectiveness of Fingolimod (Gilenya\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2010-12-03T00:00:00\", \"latest\": \"2011-09-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2307, \"last_scrape\": \"2018-12-13T16:35:01\", \"url\": \"http://www.ncpe.ie/drugs/fluocinolone-acetonide-iluvien/\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-02-15, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Fluocinolone acetonide (Iluvien\", \"trade_name\": \"Iluvien\", \"indication\": \"Iluvien\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2308, \"last_scrape\": \"2018-12-13T16:35:05\", \"url\": \"http://www.ncpe.ie/drugs/fluticasone-furoate-umeclidinium-vilantero-trelegy-ellipta/\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT TRELEGY\", \"rr_dates\": \"2018-04-30, 2018-06-18\", \"rr_multiple\": 0, \"drug_name\": \"Fluticasone furoate/ umeclidinium/ vilantero (Trelegy\", \"trade_name\": \"Trelegy Ellipta\", \"indication\": \"Trelegy\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-15T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"Reimbursement without HTA\"}, {\"id\": 2309, \"last_scrape\": \"2018-12-13T16:35:09\", \"url\": \"http://www.ncpe.ie/drugs/follitropin-delta-rekovelle/\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-07-25, 2017-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Follitropin delta (Rekovelle\", \"trade_name\": \"Rekovelle\", \"indication\": \"Follitropin delta (Rekovelle \", \"ncpe_year\": 2019, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2019-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rekovelle\", \"ta_list\": \"Anovulation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2310, \"last_scrape\": \"2018-12-13T16:35:12\", \"url\": \"http://www.ncpe.ie/drugs/gefitinib-iressa/\", \"rr_start\": \"\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Gefitinib (Iressa\", \"trade_name\": \"Iressa\", \"indication\": \"A review of the economic evaluation of oral gefitinib (Iressa\", \"ncpe_year\": 2010, \"eu_market\": \"2009-06-24T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-16T00:00:00\", \"latest\": \"2010-11-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/iressa\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2311, \"last_scrape\": \"2018-12-13T16:35:15\", \"url\": \"http://www.ncpe.ie/drugs/gemtuzumab-ozogamicin-mylotarg/\", \"rr_start\": \"2018-06-21T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF GEMTUZUMAB OZOGAMICIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-21, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Gemtuzumab ozogamicin (Mylotarg\", \"trade_name\": \"Mylotarg\", \"indication\": \"Gemtuzumab ozogamicin (Mylotarg\", \"ncpe_year\": 2018, \"eu_market\": \"2018-04-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-06-21T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2312, \"last_scrape\": \"2018-12-13T16:35:19\", \"url\": \"http://www.ncpe.ie/drugs/glecaprevirpibrentasvir-maviret/\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-07-11, 2017-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glecaprevir/Pibrentasvir (Maviret\", \"trade_name\": \"Maviret\", \"indication\": \"Glecaprevir/pibrentasvir (Maviret\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/maviret\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2313, \"last_scrape\": \"2018-12-13T16:35:25\", \"url\": \"http://www.ncpe.ie/drugs/glucosamine-sulfate-dona/\", \"rr_start\": \"\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Glucosamine sulfate (Dona\", \"trade_name\": \"Dona\", \"indication\": \"Economic evalution of glucosamine sulfate (Dona\", \"ncpe_year\": 2009, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2009-04-01T00:00:00\", \"latest\": \"2009-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2314, \"last_scrape\": \"2018-12-13T16:35:32\", \"url\": \"http://www.ncpe.ie/drugs/glycerol-phenylbutyrate-ravicti/\", \"rr_start\": \"2018-03-26T00:00:00\", \"rr_end\": \"2018-06-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT GLYCEROL PHENYLBUTYRATE (RAVICTI\", \"rr_dates\": \"2018-03-26, 2018-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Glycerol Phenylbutyrate (Ravicti\", \"trade_name\": \"Ravicti\", \"indication\": \"Glycerol phenylbutyrate (Ravicti\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-26T00:00:00\", \"company\": \"Horizon\", \"orphan\": 1, \"earliest\": \"2018-03-26T00:00:00\", \"latest\": \"2018-06-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti\", \"ta_list\": \"Urea Cycle Disorders, Inborn\", \"rr_status\": \"Reimbursement without HTA\"}, {\"id\": 2315, \"last_scrape\": \"2018-12-13T16:35:38\", \"url\": \"http://www.ncpe.ie/drugs/glycopyrronium-bromide-seebri-breezhaler/\", \"rr_start\": \"2012-08-12T00:00:00\", \"rr_end\": \"2012-08-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-08-12, 2012-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide (Seebri Breezhaler\", \"trade_name\": \"Seebri Breezhaler\", \"indication\": \"Seebri Breezhaler\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-08-12T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"id\": 2316, \"last_scrape\": \"2018-12-13T16:35:40\", \"url\": \"http://www.ncpe.ie/drugs/glypyrronium-bromide-sialanar/\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-07, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide (Sialanar\", \"trade_name\": \"Sialanar\", \"indication\": \"Glycopyrronium bromide (Sialanar\", \"ncpe_year\": 2017, \"eu_market\": \"2016-09-15T00:00:00\", \"company\": \"Proveca\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar\", \"ta_list\": \"Sialorrhea\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2317, \"last_scrape\": \"2018-12-13T16:35:47\", \"url\": \"http://www.ncpe.ie/drugs/golimumab-simponi-2/\", \"rr_start\": \"2013-10-11T00:00:00\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-10-11, 2013-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab (Simponi\", \"trade_name\": \"Simponi\", \"indication\": \"Golimumab is indicated for the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments.\", \"ncpe_year\": 2013, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2013-10-11T00:00:00\", \"latest\": \"2013-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/simponi\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"id\": 2318, \"last_scrape\": \"2018-12-13T16:35:54\", \"url\": \"http://www.ncpe.ie/drugs/golimumab-simponi/\", \"rr_start\": \"\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab (Simponi\", \"trade_name\": \"Simponi\", \"indication\": \"Cost-effectiveness of golimumab (Simponi\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2009-11-20T00:00:00\", \"latest\": \"2010-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/simponi\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2319, \"last_scrape\": \"2018-12-13T16:35:56\", \"url\": \"http://www.ncpe.ie/drugs/grass-pollen-allergen-extract-oralair/\", \"rr_start\": \"2011-10-11T00:00:00\", \"rr_end\": \"2011-09-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-10-11, 2011-09-26\", \"rr_multiple\": 0, \"drug_name\": \"Grass pollen allergen extract (Oralair\", \"trade_name\": \"Oralair\", \"indication\": \" Grass pollen allegen extract (Oralair\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-09-26T00:00:00\", \"latest\": \"2011-10-01T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2320, \"last_scrape\": \"2018-12-13T16:36:00\", \"url\": \"http://www.ncpe.ie/drugs/guanfacine-hydrochloride-intuniv/\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-01, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Guanfacine hydrochloride (Intuniv\", \"trade_name\": \"Intuniv\", \"indication\": \"Intuniv\", \"ncpe_year\": 2015, \"eu_market\": \"2015-09-17T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/intuniv\", \"ta_list\": \"Attention Deficit Disorder with Hyperactivity\", \"rr_status\": \"No HTA\"}, {\"id\": 2321, \"last_scrape\": \"2018-12-13T16:36:02\", \"url\": \"http://www.ncpe.ie/drugs/guselkumab-tremfya/\", \"rr_start\": \"2017-12-01T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-12-01, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Guselkumab (Tremfya\", \"trade_name\": \"Tremfya\", \"indication\": \"Guselkumab (Tremfya\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-10T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-12-01T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2322, \"last_scrape\": \"2018-12-13T16:36:07\", \"url\": \"http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-a1pi-prolastin/\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-06-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-05, 2017-06-08\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor (A1PI) (Prolastin\", \"trade_name\": \"Prolastin\", \"indication\": \"Human A1PI (Prolastin \", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-06-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2323, \"last_scrape\": \"2018-12-13T16:36:14\", \"url\": \"http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-respreeza/\", \"rr_start\": \"2016-01-20T00:00:00\", \"rr_end\": \"2016-02-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-20, 2016-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor (Respreeza\", \"trade_name\": \"Respreeza\", \"indication\": \"Respreeza\", \"ncpe_year\": 2017, \"eu_market\": \"2015-08-20T00:00:00\", \"company\": \"CSL\", \"orphan\": 0, \"earliest\": \"2016-01-20T00:00:00\", \"latest\": \"2017-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza\", \"ta_list\": \"Genetic Diseases, Inborn; Lung Diseases\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2324, \"last_scrape\": \"2018-12-13T16:36:17\", \"url\": \"http://www.ncpe.ie/drugs/hyaluronic-acid-and-co-enzyme-q10-visuxl/\", \"rr_start\": \"2017-11-06T00:00:00\", \"rr_end\": \"2017-11-30T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-11-06, 2017-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Hyaluronic acid and co enzyme Q10 (VisuXL\", \"trade_name\": \"VisuXL\", \"indication\": \"Cross linked hyaluronic acid and co enzyme Q10 (VisuXL\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-11-06T00:00:00\", \"latest\": \"2017-11-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2325, \"last_scrape\": \"2018-12-13T16:36:22\", \"url\": \"http://www.ncpe.ie/drugs/hydrocortisone-plenadren/\", \"rr_start\": \"2017-11-08T00:00:00\", \"rr_end\": \"2017-11-01T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-11-08, 2018-01-11, 2017-11-01\", \"rr_multiple\": 1, \"drug_name\": \"Modified Release Hydrocortisone  (Plenadren\", \"trade_name\": \"Plenadren\", \"indication\": \"Modified release hydrocortisone (Plenadren\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-03T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2018-01-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/plenadren\", \"ta_list\": \"Adrenal Insufficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2326, \"last_scrape\": \"2018-12-13T16:36:27\", \"url\": \"http://www.ncpe.ie/drugs/hydroxcarbamide-siklos/\", \"rr_start\": \"2011-08-22T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-08-22, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Hydroxycarbamide (Siklos\", \"trade_name\": \"Siklos\", \"indication\": \" Hydroxycarbamide (Siklos\", \"ncpe_year\": 2011, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"Addmedica\", \"orphan\": 1, \"earliest\": \"2011-08-22T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/siklos\", \"ta_list\": \"Anemia, Sickle Cell\", \"rr_status\": \"No HTA\"}, {\"id\": 2327, \"last_scrape\": \"2018-12-13T16:36:32\", \"url\": \"http://www.ncpe.ie/drugs/ibrutinib-imbruivca-for-previously-untreated-cll/\", \"rr_start\": \"2016-08-02T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-08-02, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib (Imbruvica\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib (Imbruvica\", \"ncpe_year\": 2016, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-08-02T00:00:00\", \"latest\": \"2016-08-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2328, \"last_scrape\": \"2018-12-13T16:36:36\", \"url\": \"http://www.ncpe.ie/drugs/ibrutinib-imbruvica-for-mcl/\", \"rr_start\": \"2014-11-07T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-11-07, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib (Imbruvica\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib (Imbruvica\", \"ncpe_year\": 2015, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-11-07T00:00:00\", \"latest\": \"2015-10-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2329, \"last_scrape\": \"2018-12-13T16:36:40\", \"url\": \"http://www.ncpe.ie/drugs/icatibant-firazyr/\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Icatibant (Firazyr\", \"trade_name\": \"Firazyr\", \"indication\": \"Icatibant (Firazyr\", \"ncpe_year\": 2013, \"eu_market\": \"2008-07-11T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"id\": 2330, \"last_scrape\": \"2018-12-13T16:36:43\", \"url\": \"http://www.ncpe.ie/drugs/idarucizumab-praxbind/\", \"rr_start\": \"2015-12-11T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-11, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Idarucizumab (Praxbind\", \"trade_name\": \"Praxbind\", \"indication\": \"Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required:\", \"ncpe_year\": 2015, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-12-11T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/praxbind\", \"ta_list\": \"Hemorrhage\", \"rr_status\": \"No HTA\"}, {\"id\": 2331, \"last_scrape\": \"2018-12-13T16:36:50\", \"url\": \"http://www.ncpe.ie/drugs/idebenone-raxone/\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-04-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-10, 2016-04-14\", \"rr_multiple\": 0, \"drug_name\": \"Idebenone (Raxone\", \"trade_name\": \"Raxone\", \"indication\": \"Raxone\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-08T00:00:00\", \"company\": \"Santhera\", \"orphan\": 1, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2018-08-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/raxone\", \"ta_list\": \"Optic Atrophy, Hereditary, Leber\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2332, \"last_scrape\": \"2018-12-13T16:36:56\", \"url\": \"http://www.ncpe.ie/drugs/idelalisib-zydelig/\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2014-12-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-08, 2014-12-30\", \"rr_multiple\": 0, \"drug_name\": \"Idelalisib (Zydelig\", \"trade_name\": \"Zydelig\", \"indication\": \"Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2016-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2333, \"last_scrape\": \"2018-12-13T16:36:59\", \"url\": \"http://www.ncpe.ie/drugs/imiquimod-zyclara/\", \"rr_start\": \"2013-09-10T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-09-10, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Imiquimod 3.75% (Zyclara\", \"trade_name\": \"Zyclara\", \"indication\": \"Imiquimod 3.75%(Zyclara\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Meda\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara\", \"ta_list\": \"Keratosis; Keratosis, Actinic\", \"rr_status\": \"No HTA\"}, {\"id\": 2334, \"last_scrape\": \"2018-12-13T16:37:01\", \"url\": \"http://www.ncpe.ie/drugs/incobotulinum-toxin-type-a-xeomin/\", \"rr_start\": \"2014-02-07T00:00:00\", \"rr_end\": \"2014-03-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-07, 2014-03-05\", \"rr_multiple\": 0, \"drug_name\": \"Incobotulinum Toxin Type A (Xeomin\", \"trade_name\": \"Xeomin\", \"indication\": \"Incobotulinum Toxin Type A (Xeomin\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-02-07T00:00:00\", \"latest\": \"2014-03-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2335, \"last_scrape\": \"2018-12-13T16:37:04\", \"url\": \"http://www.ncpe.ie/drugs/indacaterol-onbrez/\", \"rr_start\": \"2010-01-15T00:00:00\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-01-15\", \"rr_multiple\": 0, \"drug_name\": \"Indacaterol (Onbrez\", \"trade_name\": \"Onbrez\", \"indication\": \"Review of Indacaterol (Onbrez\", \"ncpe_year\": 2010, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-01-15T00:00:00\", \"latest\": \"2010-01-15T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2336, \"last_scrape\": \"2018-12-13T16:37:07\", \"url\": \"http://www.ncpe.ie/drugs/infliximab-inflectra/\", \"rr_start\": \"\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Infliximab (Inflectra\", \"trade_name\": \"Inflectra\", \"indication\": \"Inflectra\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2337, \"last_scrape\": \"2018-12-13T16:37:09\", \"url\": \"http://www.ncpe.ie/drugs/inotuzumab-ozogamicin-besponsa/\", \"rr_start\": \"2017-07-03T00:00:00\", \"rr_end\": \"2017-09-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-03, 2017-09-08\", \"rr_multiple\": 0, \"drug_name\": \"Inotuzumab ozogamicin (Besponsa\", \"trade_name\": \"Besponsa\", \"indication\": \"Inotuzumab ozogamicin (Besponsa\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2017-07-03T00:00:00\", \"latest\": \"2018-09-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2338, \"last_scrape\": \"2018-12-13T16:37:16\", \"url\": \"http://www.ncpe.ie/drugs/insulin-aspart-fiasp/\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-05-17, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart (Fiasp\", \"trade_name\": \"Fiasp\", \"indication\": \"Insulin aspart (Fiasp\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-09T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fiasp\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"No HTA\"}, {\"id\": 2339, \"last_scrape\": \"2018-12-13T16:37:21\", \"url\": \"http://www.ncpe.ie/drugs/insulin-aspart-novorapid-flextouch/\", \"rr_start\": \"2014-07-22T00:00:00\", \"rr_end\": \"2014-08-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2014-07-22, 2014-08-28\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart (NovoRapid\", \"trade_name\": \"NovoRapid FlexTouch\", \"indication\": \"Insulin aspart (NovoRapid\", \"ncpe_year\": 2014, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2014-07-22T00:00:00\", \"latest\": \"2014-08-28T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2340, \"last_scrape\": \"2018-12-13T16:37:25\", \"url\": \"http://www.ncpe.ie/drugs/insulin-degludec-tresiba/\", \"rr_start\": \"2012-12-17T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-17, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Degludec (Tresiba\", \"trade_name\": \"Tresiba\", \"indication\": \"Treatment of diabetes mellitus\", \"ncpe_year\": 2015, \"eu_market\": \"2013-01-20T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2012-12-17T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2341, \"last_scrape\": \"2018-12-13T16:37:30\", \"url\": \"http://www.ncpe.ie/drugs/insulin-degludecliraglutide-ideglira-xultophy/\", \"rr_start\": \"2016-09-19T00:00:00\", \"rr_end\": \"2016-10-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-09-19, 2016-10-17\", \"rr_multiple\": 0, \"drug_name\": \"Insulin degludec/liraglutide (IDegLira) (Xultophy\", \"trade_name\": \"Xultophy\", \"indication\": \"IDegLira is indicated for the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2016-09-19T00:00:00\", \"latest\": \"2016-10-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xultophy\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2342, \"last_scrape\": \"2018-12-13T16:37:36\", \"url\": \"http://www.ncpe.ie/drugs/insulin-glargine-abasaglar/\", \"rr_start\": \"2015-09-04T00:00:00\", \"rr_end\": \"2015-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-09-04, 2015-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine (Abasaglar\", \"trade_name\": \"Abasaglar\", \"indication\": \"Abasaglar\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-09-04T00:00:00\", \"latest\": \"2015-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2343, \"last_scrape\": \"2018-12-13T16:37:40\", \"url\": \"http://www.ncpe.ie/drugs/insulin-glargine-u300-toujeo/\", \"rr_start\": \"2015-05-14T00:00:00\", \"rr_end\": \"2015-07-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2015-05-14, 2015-07-02\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine U300 (Toujeo\", \"trade_name\": \"Toujeo\", \"indication\": \"Toujeo\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-05-14T00:00:00\", \"latest\": \"2015-07-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2344, \"last_scrape\": \"2018-12-13T16:37:43\", \"url\": \"http://www.ncpe.ie/drugs/ipilimumab-yervoy/\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Ipilimumab (Yervoy\", \"trade_name\": \"Yervoy\", \"indication\": \"Pharmacoeconomic evaluation of Ipilimumab (Yervoy\", \"ncpe_year\": 2013, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2013-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2345, \"last_scrape\": \"2018-12-13T16:37:49\", \"url\": \"http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-diafer/\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron (III) isomaltoside 1000 (Diafer\", \"trade_name\": \"Diafer\", \"indication\": \"Diafer\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2346, \"last_scrape\": \"2018-12-13T16:37:52\", \"url\": \"http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-monover/\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron (III) isomaltoside 1000 (Monover\", \"trade_name\": \"Monover\", \"indication\": \"Monover\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2347, \"last_scrape\": \"2018-12-13T16:38:02\", \"url\": \"http://www.ncpe.ie/drugs/iron-isomaltoside-1000-monover/\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2011-02-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-01-10, 2011-02-02\", \"rr_multiple\": 0, \"drug_name\": \"Iron isomaltoside 1000 (MonoVer\", \"trade_name\": \"MonoVer\", \"indication\": \"MonoVer is indicated for the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-01-10T00:00:00\", \"latest\": \"2011-02-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2348, \"last_scrape\": \"2018-12-13T16:38:07\", \"url\": \"http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-invasive-aspergillosis/\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole (Cresemba\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole (Cresemba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2349, \"last_scrape\": \"2018-12-13T16:38:09\", \"url\": \"http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-mucormycosis/\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole (Cresemba\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole (Cresemba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2350, \"last_scrape\": \"2018-12-13T16:38:15\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kaldeco/\", \"rr_start\": \"2012-08-13T00:00:00\", \"rr_end\": \"2012-08-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-08-13, 2012-08-22\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2012-08-13T00:00:00\", \"latest\": \"2013-01-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2351, \"last_scrape\": \"2018-12-13T16:38:21\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-patients-with-cf-2-years/\", \"rr_start\": \"2015-11-19T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMAOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-19, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\", \"ncpe_year\": 2016, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2015-11-19T00:00:00\", \"latest\": \"2016-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2352, \"last_scrape\": \"2018-12-13T16:38:24\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-the-treatment-of-cf-patients-with-the-r117h-mutation/\", \"rr_start\": \"2016-01-14T00:00:00\", \"rr_end\": \"2016-02-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-14, 2016-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\", \"ncpe_year\": 2017, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2016-01-14T00:00:00\", \"latest\": \"2017-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2353, \"last_scrape\": \"2018-12-13T16:38:29\", \"url\": \"http://www.ncpe.ie/drugs/ixazomib-ninlaro/\", \"rr_start\": \"2016-11-23T00:00:00\", \"rr_end\": \"2017-01-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-23, 2017-01-16\", \"rr_multiple\": 0, \"drug_name\": \"Ixazomib (Ninlaro\", \"trade_name\": \"Ninlaro\", \"indication\": \"Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-21T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2016-11-23T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2354, \"last_scrape\": \"2018-12-13T16:38:34\", \"url\": \"http://www.ncpe.ie/drugs/ixekizumab-taltz-for-psoriatic-arthritis/\", \"rr_start\": \"2018-10-16T00:00:00\", \"rr_end\": \"2018-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT IXEKIZUMAB NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE. THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013\", \"rr_dates\": \"2018-10-16, 2018-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab (Taltz\", \"trade_name\": \"Taltz\", \"indication\": \"Ixekizumab (Taltz\", \"ncpe_year\": 2018, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2018-10-16T00:00:00\", \"latest\": \"2018-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/taltz\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2355, \"last_scrape\": \"2018-12-13T16:38:37\", \"url\": \"http://www.ncpe.ie/drugs/ixekizumab-taltz/\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-06-28, 2016-07-26\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab (Taltz\", \"trade_name\": \"Taltz\", \"indication\": \"Taltz\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/taltz\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2356, \"last_scrape\": \"2018-12-13T16:38:39\", \"url\": \"http://www.ncpe.ie/drugs/l/lisdexamfetamine-dimesylate-tyvense/\", \"rr_start\": \"2013-02-09T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-02-09, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Lisdexamfetamine dimesylate (Tyvense\", \"trade_name\": \"Tyvense\", \"indication\": \"Lisdexamfetamine dimesylate (Tyvense\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-02-09T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2357, \"last_scrape\": \"2018-12-13T16:38:44\", \"url\": \"http://www.ncpe.ie/drugs/lacosamide-vimpat/\", \"rr_start\": \"2017-09-11T00:00:00\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-09-11, 2017-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Lacosamide (Vimpat \", \"trade_name\": \"Vimpat\", \"indication\": \"Vimpat \", \"ncpe_year\": 2017, \"eu_market\": \"2008-08-29T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2017-09-11T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2358, \"last_scrape\": \"2018-12-13T16:38:50\", \"url\": \"http://www.ncpe.ie/drugs/lapatinib-tyverb/\", \"rr_start\": \"\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Lapatinib (Tyverb\", \"trade_name\": \"Tyverb\", \"indication\": \"Cost-effectiveness of Lapatinib (Tyverb\", \"ncpe_year\": 2008, \"eu_market\": \"2008-06-10T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2359, \"last_scrape\": \"2018-12-13T16:38:56\", \"url\": \"http://www.ncpe.ie/drugs/ledipasvirsofosbuvir-harvoni/\", \"rr_start\": \"2014-11-14T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-11-14, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ledipasvir/sofosbuvir (Harvoni\", \"trade_name\": \"Harvoni\", \"indication\": \"Ledipasvir/sofosbuvir (Harvoni\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-17T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-11-14T00:00:00\", \"latest\": \"2015-11-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2360, \"last_scrape\": \"2018-12-13T16:39:05\", \"url\": \"http://www.ncpe.ie/drugs/lenalidomide-revlimid/\", \"rr_start\": \"2015-10-05T00:00:00\", \"rr_end\": \"2015-11-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE.\", \"rr_dates\": \"2015-10-05, 2015-11-20\", \"rr_multiple\": 0, \"drug_name\": \"Lenalidomide (Revlimid\", \"trade_name\": \"Revlimid\", \"indication\": \"Revlimid\", \"ncpe_year\": 2018, \"eu_market\": \"2007-06-14T00:00:00\", \"company\": \"Celgene\", \"orphan\": 1, \"earliest\": \"2015-10-05T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid\", \"ta_list\": \"Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2361, \"last_scrape\": \"2018-12-13T16:39:07\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-kisplyx/\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-05-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-05-05, 2017-05-18\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Kisplyx\", \"trade_name\": \"Kisplyx\", \"indication\": \"Lenvatinib (Kisplyx\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-25T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-05-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2362, \"last_scrape\": \"2018-12-13T16:39:11\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-lenvima-2/\", \"rr_start\": \"2018-08-07T00:00:00\", \"rr_end\": \"2018-08-16T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF LENVATINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-08-07, 2018-08-16\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Lenvima\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib (Lenvima\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2018-08-07T00:00:00\", \"latest\": \"2018-08-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2363, \"last_scrape\": \"2018-12-13T16:39:15\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-lenvima/\", \"rr_start\": \"2015-05-05T00:00:00\", \"rr_end\": \"2015-07-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2015-05-05, 2015-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Lenvima\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/H\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2015-05-05T00:00:00\", \"latest\": \"2015-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2364, \"last_scrape\": \"2018-12-13T16:39:20\", \"url\": \"http://www.ncpe.ie/drugs/lesinurad-zurampic/\", \"rr_start\": \"2017-03-15T00:00:00\", \"rr_end\": \"2017-03-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-15, 2017-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Lesinurad (Zurampic\", \"trade_name\": \"Zurampic\", \"indication\": \"Lesinurad (Zurampic\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Gr\", \"orphan\": 0, \"earliest\": \"2017-03-15T00:00:00\", \"latest\": \"2018-12-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zurampic\", \"ta_list\": \"Hyperuricemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2365, \"last_scrape\": \"2018-12-13T16:39:25\", \"url\": \"http://www.ncpe.ie/drugs/letermovir-prevymis/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Letermovir (Prevymis\", \"trade_name\": \"Prevymis\", \"indication\": \"Letermovir for the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevymis\", \"ta_list\": \"Cytomegalovirus Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2366, \"last_scrape\": \"2018-12-13T16:39:28\", \"url\": \"http://www.ncpe.ie/drugs/levodopa-20mgml-carbidopa-monohydrate-5mg-intestinal-gel-duodopa/\", \"rr_start\": \"2013-03-13T00:00:00\", \"rr_end\": \"2013-04-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-03-13, 2013-04-16\", \"rr_multiple\": 0, \"drug_name\": \"Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel (Duodopa\", \"trade_name\": \"Duodopa\", \"indication\": \"For the treatment of advanced levodopa-responsive Parkinson\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-13T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2367, \"last_scrape\": \"2018-12-13T16:39:34\", \"url\": \"http://www.ncpe.ie/drugs/levofloxacin-quinsair/\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-02-10, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Levofloxacin (Quinsair\", \"trade_name\": \"Quinsair\", \"indication\": \"Levofloxacin (Quinsair\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-25T00:00:00\", \"company\": \"Horizon\", \"orphan\": 0, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/quinsair\", \"ta_list\": \"Cystic Fibrosis; Respiratory Tract Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2368, \"last_scrape\": \"2018-12-13T16:39:39\", \"url\": \"http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-delivery-system-lng-ius-12-kyleena/\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-02-08, 2017-03-16\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine delivery system LNG IUS 12 (Kyleena\", \"trade_name\": \"Kyleena\", \"indication\": \"Kyleena\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2017-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2369, \"last_scrape\": \"2018-12-13T16:39:44\", \"url\": \"http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-system-lng-ius-jaydess/\", \"rr_start\": \"2013-03-07T00:00:00\", \"rr_end\": \"2013-03-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-03-07, 2013-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine system LNG-IUS (Jaydess\", \"trade_name\": \"Jaydess\", \"indication\": \"Levonorgestrel Intrauterine System LNG-IUS (Jaydess\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-07T00:00:00\", \"latest\": \"2013-03-25T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2370, \"last_scrape\": \"2018-12-13T16:39:46\", \"url\": \"http://www.ncpe.ie/drugs/lidocaine-5-plasters-versatis/\", \"rr_start\": \"2010-09-09T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2010-09-09, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Lidocaine 5% plasters (Versatis\", \"trade_name\": \"Versatis\", \"indication\": \"Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN).\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-09-09T00:00:00\", \"latest\": \"2015-09-24T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2371, \"last_scrape\": \"2018-12-13T16:39:51\", \"url\": \"http://www.ncpe.ie/drugs/linaclotide-clonstella/\", \"rr_start\": \"2013-05-28T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-05-28, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Linaclotide (Constella\", \"trade_name\": \"Constella\", \"indication\": \"Linaclotide (Constella\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2013-05-28T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/constella\", \"ta_list\": \"Irritable Bowel Syndrome\", \"rr_status\": \"No HTA\"}, {\"id\": 2372, \"last_scrape\": \"2018-12-13T16:39:54\", \"url\": \"http://www.ncpe.ie/drugs/linagliptin-trajenta/\", \"rr_start\": \"2011-08-18T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-08-18, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Linagliptin (Trajenta\", \"trade_name\": \"Trajenta\", \"indication\": \"Lingagliptin (Trajenta\", \"ncpe_year\": 2011, \"eu_market\": \"2011-08-23T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2011-08-18T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2373, \"last_scrape\": \"2018-12-13T16:39:57\", \"url\": \"http://www.ncpe.ie/drugs/lipegfilgrastim-lonquex/\", \"rr_start\": \"2013-08-20T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-08-20, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Lipegfilgrastim (Lonquex\", \"trade_name\": \"Lonquex\", \"indication\": \"Lonquex\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-25T00:00:00\", \"company\": \"Sicor\", \"orphan\": 0, \"earliest\": \"2013-08-20T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex\", \"ta_list\": \"Neutropenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2374, \"last_scrape\": \"2018-12-13T16:40:00\", \"url\": \"http://www.ncpe.ie/drugs/liposomal-daunorubicin-and-cytarabine-cpx-351vyxeos/\", \"rr_start\": \"2018-09-28T00:00:00\", \"rr_end\": \"2018-11-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-09-28, 2018-11-08\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos\", \"trade_name\": \"Vyxeos\", \"indication\": \"Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Jazz\", \"orphan\": 1, \"earliest\": \"2018-09-28T00:00:00\", \"latest\": \"2018-11-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2375, \"last_scrape\": \"2018-12-13T16:40:06\", \"url\": \"http://www.ncpe.ie/drugs/liposomal-irinotecan-nal-iri-onivyde/\", \"rr_start\": \"2017-06-13T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-13, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal irinotecan (Onivyde\", \"trade_name\": \"Onivyde\", \"indication\": \"Liposomal irinotecan (Onivyde\", \"ncpe_year\": 2017, \"eu_market\": \"2016-10-14T00:00:00\", \"company\": \"Baxalta\", \"orphan\": 1, \"earliest\": \"2017-06-13T00:00:00\", \"latest\": \"2017-07-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-0\", \"ta_list\": \"Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2376, \"last_scrape\": \"2018-12-13T16:40:09\", \"url\": \"http://www.ncpe.ie/drugs/liquid-paraffin-ointment-vita-pos-opthalmic/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Liquid Paraffin Ointment (VitA-POS Opthalmic\", \"trade_name\": \"VitA-POS Opthalmic\", \"indication\": \"Liquid Paraffin Ointment (VitA-POS Opthalmic\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2377, \"last_scrape\": \"2018-12-13T16:40:13\", \"url\": \"http://www.ncpe.ie/drugs/liraglutide-victoza/\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-10-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-09-01, 2009-10-07\", \"rr_multiple\": 0, \"drug_name\": \"Liraglutide (Victoza\", \"trade_name\": \"Victoza\", \"indication\": \"Victoza\", \"ncpe_year\": 2018, \"eu_market\": \"2009-06-30T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2009-09-01T00:00:00\", \"latest\": \"2018-10-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/victoza\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2378, \"last_scrape\": \"2018-12-13T16:40:17\", \"url\": \"http://www.ncpe.ie/drugs/lixisenatide-lyxumia/\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Lixisenatide (Lyxumia\", \"trade_name\": \"Lyxumia\", \"indication\": \"Lixisenatide (Lyxumia\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-08-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2379, \"last_scrape\": \"2018-12-13T16:40:19\", \"url\": \"http://www.ncpe.ie/drugs/lomitapide-lojuxta/\", \"rr_start\": \"2014-09-09T00:00:00\", \"rr_end\": \"2014-09-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-09-09, 2014-09-15\", \"rr_multiple\": 0, \"drug_name\": \"Lomitapide (Lojuxta\", \"trade_name\": \"Lojuxta\", \"indication\": \"Lojuxta\", \"ncpe_year\": 2014, \"eu_market\": \"2013-07-31T00:00:00\", \"company\": \"Amryt\", \"orphan\": 0, \"earliest\": \"2014-09-09T00:00:00\", \"latest\": \"2014-09-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2380, \"last_scrape\": \"2018-12-13T16:40:22\", \"url\": \"http://www.ncpe.ie/drugs/lornoxicam-xefo/\", \"rr_start\": \"2011-06-23T00:00:00\", \"rr_end\": \"2011-07-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-06-23, 2011-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Lornoxicam (Xefo\", \"trade_name\": \"Xefo\", \"indication\": \" Lornoxicam (Xefo\", \"ncpe_year\": 2011, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-06-23T00:00:00\", \"latest\": \"2011-07-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA\"}, {\"id\": 2381, \"last_scrape\": \"2018-12-13T16:40:24\", \"url\": \"http://www.ncpe.ie/drugs/lotemax-0-5-eye-drops-suspension-loteprednol/\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2011-12-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-11-15, 2011-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Lotemax 0.5% eye drops suspension (Loteprednol)\", \"trade_name\": \"Loteprednol\", \"indication\": \" Indicated for treatment of post-operative inflammation following ocular surgery.\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2011-12-05T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2382, \"last_scrape\": \"2018-12-13T16:40:30\", \"url\": \"http://www.ncpe.ie/drugs/loxapine-inhalation-powder-adasuve/\", \"rr_start\": \"2016-06-21T00:00:00\", \"rr_end\": \"2016-07-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-06-21, 2016-07-28\", \"rr_multiple\": 0, \"drug_name\": \"Loxapine inhalation powder (Adasuve\", \"trade_name\": \"Adasuve\", \"indication\": \"Inhaled loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-02-20T00:00:00\", \"company\": \"Ferrer\", \"orphan\": 0, \"earliest\": \"2016-06-21T00:00:00\", \"latest\": \"2016-07-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve\", \"ta_list\": \"Schizophrenia; Bipolar Disorder\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2383, \"last_scrape\": \"2018-12-13T16:40:34\", \"url\": \"http://www.ncpe.ie/drugs/lumacaftorivacaftor-orkambi/\", \"rr_start\": \"2015-11-26T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-26, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Lumacaftor/ivacaftor (Orkambi\", \"trade_name\": \"Orkambi\", \"indication\": \"Orkambi\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Vertex\", \"orphan\": 0, \"earliest\": \"2015-11-26T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/orkambi\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2384, \"last_scrape\": \"2018-12-13T16:40:36\", \"url\": \"http://www.ncpe.ie/drugs/lutetium-177lu-oxodotreotide-lutathera/\", \"rr_start\": \"2018-10-23T00:00:00\", \"rr_end\": \"2018-11-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-10-23, 2018-11-16\", \"rr_multiple\": 0, \"drug_name\": \"Lutetium (177Lu) Oxodotreotide (Lutathera\", \"trade_name\": \"Lutathera\", \"indication\": \"Lutetium (177Lu) Oxodotreotide (Lutathera\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-26T00:00:00\", \"company\": \"Advanced\", \"orphan\": 1, \"earliest\": \"2018-10-23T00:00:00\", \"latest\": \"2018-11-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2385, \"last_scrape\": \"2018-12-13T16:40:41\", \"url\": \"http://www.ncpe.ie/drugs/macitentan-opsumit/\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-10, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Macitentan (Opsumit\", \"trade_name\": \"Opsumit\", \"indication\": \"Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-12-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2386, \"last_scrape\": \"2018-12-13T16:40:43\", \"url\": \"http://www.ncpe.ie/drugs/melatonin-circadin/\", \"rr_start\": \"\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Melatonin (Circadin\", \"trade_name\": \"Circadin\", \"indication\": \"A Review of the Economic Evaluation of Prolonged Release Melatonin (Circadin\", \"ncpe_year\": 2008, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"RAD\", \"orphan\": 0, \"earliest\": \"2008-08-01T00:00:00\", \"latest\": \"2008-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/circadin\", \"ta_list\": \"Sleep Initiation and Maintenance Disorders\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2387, \"last_scrape\": \"2018-12-13T16:40:45\", \"url\": \"http://www.ncpe.ie/drugs/mepolizumab-nucala/\", \"rr_start\": \"2016-03-16T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-03-16, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Mepolizumab (Nucala\", \"trade_name\": \"Nucala\", \"indication\": \"Mepolizumab (Nucala\", \"ncpe_year\": 2018, \"eu_market\": \"2015-12-01T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-03-16T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nucala\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2388, \"last_scrape\": \"2018-12-13T16:40:51\", \"url\": \"http://www.ncpe.ie/drugs/methoxyflurane-penthrox/\", \"rr_start\": \"2015-11-23T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-11-23, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Methoxyflurane (Penthrox\", \"trade_name\": \"Penthrox\", \"indication\": \"Penthrox\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2015-11-23T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2389, \"last_scrape\": \"2018-12-13T16:40:56\", \"url\": \"http://www.ncpe.ie/drugs/midostaurin-rydapt-for-aml/\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF MIDOSTAURIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin (Rydapt\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin (Rydapt\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2390, \"last_scrape\": \"2018-12-13T16:41:02\", \"url\": \"http://www.ncpe.ie/drugs/midostaurin-rydapt-for-asm/\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF MIDOSTAURIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin (Rydapt\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin (Rydapt\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2391, \"last_scrape\": \"2018-12-13T16:41:04\", \"url\": \"http://www.ncpe.ie/drugs/mifamurtide-mepact/\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-06-22, 2010-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Mifamurtide (Mepact\", \"trade_name\": \"Mepact\", \"indication\": \"Mifamurtide (Meptact\", \"ncpe_year\": 2010, \"eu_market\": \"2009-03-06T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2010-06-22T00:00:00\", \"latest\": \"2010-07-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mepact\", \"ta_list\": \"Osteosarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2392, \"last_scrape\": \"2018-12-13T16:41:06\", \"url\": \"http://www.ncpe.ie/drugs/migalastat-galafold/\", \"rr_start\": \"2016-07-14T00:00:00\", \"rr_end\": \"2016-08-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-07-14, 2016-08-18\", \"rr_multiple\": 0, \"drug_name\": \"Migalastat (Galafold\", \"trade_name\": \"Galafold\", \"indication\": \"Migalastat is indicated for the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-05-25T00:00:00\", \"company\": \"Amicus\", \"orphan\": 1, \"earliest\": \"2016-07-14T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/galafold\", \"ta_list\": \"Fabry Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2393, \"last_scrape\": \"2018-12-13T16:41:13\", \"url\": \"http://www.ncpe.ie/drugs/mirabegron-betmiga/\", \"rr_start\": \"2012-12-19T00:00:00\", \"rr_end\": \"2013-03-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-12-19, 2013-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Mirabegron (Betmiga\", \"trade_name\": \"Betmiga\", \"indication\": \"Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome\", \"ncpe_year\": 2013, \"eu_market\": \"2012-12-20T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-12-19T00:00:00\", \"latest\": \"2013-03-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga\", \"ta_list\": \"Urinary Bladder, Overactive\", \"rr_status\": \"No HTA\"}, {\"id\": 2394, \"last_scrape\": \"2018-12-13T16:41:15\", \"url\": \"http://www.ncpe.ie/drugs/nab-paclitaxel-abraxane/\", \"rr_start\": \"2014-01-23T00:00:00\", \"rr_end\": \"2014-03-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-01-23, 2014-03-02\", \"rr_multiple\": 0, \"drug_name\": \"Nab-paclitaxel (Abraxane\", \"trade_name\": \"Abraxane\", \"indication\": \"Nab-paclitaxel (Abraxane\", \"ncpe_year\": 2015, \"eu_market\": \"2008-01-10T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2014-01-23T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane\", \"ta_list\": \"Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2395, \"last_scrape\": \"2018-12-13T16:41:18\", \"url\": \"http://www.ncpe.ie/drugs/nalmefene-selincro/\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Nalmefene (Selincro\", \"trade_name\": \"Selincro\", \"indication\": \"Nalmefene (Selincro\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-24T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2014-04-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/selincro\", \"ta_list\": \"Alcohol-Related Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2396, \"last_scrape\": \"2018-12-13T16:41:24\", \"url\": \"http://www.ncpe.ie/drugs/naloxegel-moventig/\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-04-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-02-10, 2015-04-13\", \"rr_multiple\": 0, \"drug_name\": \"Naloxegel (Moventig\", \"trade_name\": \"Moventig\", \"indication\": \"Naloxegel (Moventiq\", \"ncpe_year\": 2015, \"eu_market\": \"2014-12-07T00:00:00\", \"company\": \"Kyowa\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-04-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/moventig\", \"ta_list\": \"Constipation; Opioid-Related Disorders\", \"rr_status\": \"No HTA\"}, {\"id\": 2397, \"last_scrape\": \"2018-12-13T16:41:26\", \"url\": \"http://www.ncpe.ie/drugs/naltrexone-bupropion-mysimba/\", \"rr_start\": \"2017-03-12T00:00:00\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-12, 2017-03-28\", \"rr_multiple\": 0, \"drug_name\": \"Naltrexone / bupropion (Mysimba\", \"trade_name\": \"Mysimba\", \"indication\": \"Naltrexone / bupropion (Mysimba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-03-26T00:00:00\", \"company\": \"Orexigen\", \"orphan\": 0, \"earliest\": \"2017-03-12T00:00:00\", \"latest\": \"2018-05-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba\", \"ta_list\": \"Obesity; Overweight\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2398, \"last_scrape\": \"2018-12-13T16:41:30\", \"url\": \"http://www.ncpe.ie/drugs/natalizumab-tysabri/\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Natalizumab (Tysabri\", \"trade_name\": \"Tysabri\", \"indication\": \" Economic Evaluation of Natalizumab (Tysabri\", \"ncpe_year\": 2007, \"eu_market\": \"2006-06-27T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2007-01-01T00:00:00\", \"latest\": \"2007-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2399, \"last_scrape\": \"2018-12-13T16:41:35\", \"url\": \"http://www.ncpe.ie/drugs/ncpe-inhaled-insulin-exubera-assessment/\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Inhaled insulin (Exubera\", \"trade_name\": \"Exubera\", \"indication\": \"In April 2006, Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin (Exubera\", \"ncpe_year\": 2006, \"eu_market\": \"2006-01-24T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-03-01T00:00:00\", \"latest\": \"2006-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/exubera\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2400, \"last_scrape\": \"2018-12-13T16:41:38\", \"url\": \"http://www.ncpe.ie/drugs/nepafenac-nevanac-2/\", \"rr_start\": \"2011-06-14T00:00:00\", \"rr_end\": \"2011-06-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-06-14, 2011-06-27\", \"rr_multiple\": 0, \"drug_name\": \"Nepafenac (Nevanac\", \"trade_name\": \"Nevanac\", \"indication\": \"Nepafenac (Nevanac\", \"ncpe_year\": 2011, \"eu_market\": \"2007-12-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2011-06-14T00:00:00\", \"latest\": \"2011-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac\", \"ta_list\": \"Pain, Postoperative; Ophthalmologic Surgical Procedures\", \"rr_status\": \"No HTA\"}, {\"id\": 2401, \"last_scrape\": \"2018-12-13T16:41:41\", \"url\": \"http://www.ncpe.ie/drugs/netupitantpalonosetron-akynzeo/\", \"rr_start\": \"2015-08-26T00:00:00\", \"rr_end\": \"2015-10-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-08-26, 2015-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Netupitant/palonosetron (Akynzeo\", \"trade_name\": \"Akynzeo\", \"indication\": \"Akynzeo\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Helsinn\", \"orphan\": 0, \"earliest\": \"2015-08-26T00:00:00\", \"latest\": \"2015-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo\", \"ta_list\": \"Vomiting; Cancer; Nausea\", \"rr_status\": \"No HTA\"}, {\"id\": 2402, \"last_scrape\": \"2018-12-13T16:41:44\", \"url\": \"http://www.ncpe.ie/drugs/nilotinib-tasigna-newly-diagnosed-cml/\", \"rr_start\": \"2010-10-06T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2010-10-06, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib (Tasigna\", \"trade_name\": \"Tasigna\", \"indication\": \"Nilotinib (Tasigna\", \"ncpe_year\": 2010, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-10-06T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2403, \"last_scrape\": \"2018-12-13T16:41:51\", \"url\": \"http://www.ncpe.ie/drugs/nilotinib-tasigna/\", \"rr_start\": \"\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib (Tasigna\", \"trade_name\": \"Tasigna\", \"indication\": \"Cost-effectiveness of Nilotinib (Tasigna\", \"ncpe_year\": 2008, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2404, \"last_scrape\": \"2018-12-13T16:41:53\", \"url\": \"http://www.ncpe.ie/drugs/nintedanib-ofev/\", \"rr_start\": \"2015-01-30T00:00:00\", \"rr_end\": \"2015-02-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-30, 2015-02-18\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib (Ofev\", \"trade_name\": \"Ofev\", \"indication\": \"Nintedanib (Ofev\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 1, \"earliest\": \"2015-01-30T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ofev\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2405, \"last_scrape\": \"2018-12-13T16:41:56\", \"url\": \"http://www.ncpe.ie/drugs/nintedanib-vargatef/\", \"rr_start\": \"2015-01-02T00:00:00\", \"rr_end\": \"2015-02-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-02, 2015-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib (Vargatef\", \"trade_name\": \"Vargatef\", \"indication\": \"Nintedanib (Vargatef\", \"ncpe_year\": 2017, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-01-02T00:00:00\", \"latest\": \"2017-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2406, \"last_scrape\": \"2018-12-13T16:42:00\", \"url\": \"http://www.ncpe.ie/drugs/niraparib-zejula/\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF NIRAPARIB COMPARED WITH THE CURRENT STANDARD OF CARE\", \"rr_dates\": \"2018-06-01, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Niraparib (Zejula\", \"trade_name\": \"Zejula\", \"indication\": \"Niraparib (Zejula\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-16T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 1, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zejula\", \"ta_list\": \"Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2407, \"last_scrape\": \"2018-12-13T16:42:06\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-melanoma/\", \"rr_start\": \"2015-05-28T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-05-28, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-05-28T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2408, \"last_scrape\": \"2018-12-13T16:42:13\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-non-squamous-nsclc/\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-03-03, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2409, \"last_scrape\": \"2018-12-13T16:42:20\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-nsclc/\", \"rr_start\": \"2015-07-02T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-07-02, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-07-02T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2410, \"last_scrape\": \"2018-12-13T16:42:26\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-as-monotherapy-for-the-adjuvant-treatment-of-adults-with-melanoma/\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF NIVOLUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-09, 2018-07-27\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-11-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2411, \"last_scrape\": \"2018-12-13T16:42:31\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-advanced-renal-cell-carcinoma/\", \"rr_start\": \"2016-04-27T00:00:00\", \"rr_end\": \"2016-05-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-04-27, 2016-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-04-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2412, \"last_scrape\": \"2018-12-13T16:42:33\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-classical-hodgkin-lymphoma/\", \"rr_start\": \"2016-11-22T00:00:00\", \"rr_end\": \"2017-01-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-11-22, 2017-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-11-22T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2413, \"last_scrape\": \"2018-12-13T16:42:36\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-head-and-neck-cancer/\", \"rr_start\": \"2017-05-03T00:00:00\", \"rr_end\": \"2017-05-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-03, 2017-05-30\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-05-03T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2414, \"last_scrape\": \"2018-12-13T16:42:41\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-urothelial-carcinoma/\", \"rr_start\": \"2017-06-28T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-28, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-06-28T00:00:00\", \"latest\": \"2018-09-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2415, \"last_scrape\": \"2018-12-13T16:42:46\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-in-combination-with-ipilimumab-yervoy/\", \"rr_start\": \"2018-11-28T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-11-28, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Yervoy\", \"indication\": \"Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).\", \"ncpe_year\": 2018, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-11-28T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy\", \"ta_list\": \"Melanoma\", \"rr_status\": \"Unknown\"}, {\"id\": 2416, \"last_scrape\": \"2018-12-13T16:42:51\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-plus-ipilimumab-opdivio-plus-yervoy/\", \"rr_start\": \"\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab plus ipilimumab (Opdivo\", \"trade_name\": \"Opdivo plus Yervoy\", \"indication\": \"Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-06-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2417, \"last_scrape\": \"2018-12-13T16:42:56\", \"url\": \"http://www.ncpe.ie/drugs/nomace2-zoely/\", \"rr_start\": \"2011-12-08T00:00:00\", \"rr_end\": \"2012-01-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-12-08, 2012-01-03\", \"rr_multiple\": 0, \"drug_name\": \"Nomegestrol acetate/estradiol (Zoely\", \"trade_name\": \"Zoely\", \"indication\": \"Nomegestrol acetate/estradiol (Zoely\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-26T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2011-12-08T00:00:00\", \"latest\": \"2012-01-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zoely\", \"ta_list\": \"Contraception\", \"rr_status\": \"No HTA\"}, {\"id\": 2418, \"last_scrape\": \"2018-12-13T16:43:02\", \"url\": \"http://www.ncpe.ie/drugs/nusinersin-spinraza/\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-11, 2017-08-02\", \"rr_multiple\": 0, \"drug_name\": \"Nusinersin (Spinraza\", \"trade_name\": \"Spinraza\", \"indication\": \"Nusinersen (Spinraza\", \"ncpe_year\": 2017, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 1, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-12-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza\", \"ta_list\": \"Muscular Atrophy, Spinal\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2419, \"last_scrape\": \"2018-12-13T16:43:07\", \"url\": \"http://www.ncpe.ie/drugs/obeticholic-acid-ocaliva/\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-18, 2016-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Obeticholic acid (Ocaliva\", \"trade_name\": \"Ocaliva\", \"indication\": \"Obeticholic acid is indicated for the treatment of primary biliary cirrhosis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Intercept\", \"orphan\": 1, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocaliva\", \"ta_list\": \"Liver Cirrhosis, Biliary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2420, \"last_scrape\": \"2018-12-13T16:43:10\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-follicular-lymphoma/\", \"rr_start\": \"2016-05-11T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-05-11, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (in combination with bendamustine) followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2016-05-11T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2421, \"last_scrape\": \"2018-12-13T16:43:15\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-previously-untreated-advanced-follicular-lymphoma/\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-09-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-08, 2017-09-13\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (Gazyvaro\", \"ncpe_year\": 2018, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2422, \"last_scrape\": \"2018-12-13T16:43:21\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro/\", \"rr_start\": \"2014-08-08T00:00:00\", \"rr_end\": \"2014-09-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-08-08, 2014-09-11\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (Gazyvaro\", \"ncpe_year\": 2015, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2014-08-08T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2423, \"last_scrape\": \"2018-12-13T16:43:24\", \"url\": \"http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-ppms/\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab (Ocrevus\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab (Ocrevus\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2424, \"last_scrape\": \"2018-12-13T16:43:30\", \"url\": \"http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-rms/\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab (Ocrevus\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab (Ocrevus\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2425, \"last_scrape\": \"2018-12-13T16:43:34\", \"url\": \"http://www.ncpe.ie/drugs/ocriplasmin-jetrea/\", \"rr_start\": \"2013-06-12T00:00:00\", \"rr_end\": \"2013-07-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-06-12, 2013-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Ocriplasmin (Jetrea\", \"trade_name\": \"Jetrea\", \"indication\": \"Ocriplasmin (Jetrea\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-13T00:00:00\", \"company\": \"ThromboGenics\", \"orphan\": 0, \"earliest\": \"2013-06-12T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea\", \"ta_list\": \"Retinal Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2426, \"last_scrape\": \"2018-12-13T16:43:39\", \"url\": \"http://www.ncpe.ie/drugs/ofatumumab-arzerra-previously-untreated-chronic-lymphocytic-leukaemia/\", \"rr_start\": \"2014-10-13T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2014-10-13, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab (Arzerra\", \"trade_name\": \"Arzerra\", \"indication\": \"Ofatumumab (Arzerra\", \"ncpe_year\": 2014, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-10-13T00:00:00\", \"latest\": \"2014-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2427, \"last_scrape\": \"2018-12-13T16:43:46\", \"url\": \"http://www.ncpe.ie/drugs/ofatumumab-arzerra/\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-06-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-06-22, 2010-06-01\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab (Arzerra\", \"trade_name\": \"Arzerra\", \"indication\": \"Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-06-01T00:00:00\", \"latest\": \"2010-06-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2428, \"last_scrape\": \"2018-12-13T16:43:52\", \"url\": \"http://www.ncpe.ie/drugs/oladaterol-striverdi-respimat/\", \"rr_start\": \"2014-04-07T00:00:00\", \"rr_end\": \"2014-05-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-07, 2014-05-02\", \"rr_multiple\": 0, \"drug_name\": \"Oladaterol (Striverdi\", \"trade_name\": \"Striverdi, Respimat\", \"indication\": \"Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-04-07T00:00:00\", \"latest\": \"2014-05-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2429, \"last_scrape\": \"2018-12-13T16:43:57\", \"url\": \"http://www.ncpe.ie/drugs/olaparib-lynparza-2/\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-05, 2015-02-19\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib (Lynparza\", \"trade_name\": \"Lynparza\", \"indication\": \"Lynparza\", \"ncpe_year\": 2017, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2430, \"last_scrape\": \"2018-12-13T16:44:03\", \"url\": \"http://www.ncpe.ie/drugs/olaparib-lynparza-for-platinum-sensitive-relapsed-ovarian-cancer/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"THE NCPE RECOMMEND  A FULL HTA TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF OLAPARIB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib (Lynparza\", \"trade_name\": \"Lynparza\", \"indication\": \"Olaparib (Lynparza\", \"ncpe_year\": 2018, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2431, \"last_scrape\": \"2018-12-13T16:44:08\", \"url\": \"http://www.ncpe.ie/drugs/omalizumab-xolair-for-the-treatment-of-severe-allergic-asthma/\", \"rr_start\": \"\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab (Xolair\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab is indicated as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1<80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.\", \"ncpe_year\": 2015, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-08-22T00:00:00\", \"latest\": \"2015-06-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xolair\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2432, \"last_scrape\": \"2018-12-13T16:44:14\", \"url\": \"http://www.ncpe.ie/drugs/omalizumab-xolair/\", \"rr_start\": \"2014-03-25T00:00:00\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED FOR THIS INDICATION.\", \"rr_dates\": \"2014-03-25, 2014-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab (Xolair\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab (Xolair\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-03-25T00:00:00\", \"latest\": \"2014-04-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xolair\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"No HTA\"}, {\"id\": 2433, \"last_scrape\": \"2018-12-13T16:44:19\", \"url\": \"http://www.ncpe.ie/drugs/oral-oxycodonenaloxone-targin/\", \"rr_start\": \"\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Oxycodone/naloxone (Targin\", \"trade_name\": \"Targin\", \"indication\": \"Cost-effectiveness of oral oxycodone/naloxone prolonged release tablet (Targin\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-05-05T00:00:00\", \"latest\": \"2010-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2434, \"last_scrape\": \"2018-12-13T16:44:22\", \"url\": \"http://www.ncpe.ie/drugs/osimertinib-tagrisso-for-the-first-line-treatment-of-metastatic-nsclc/\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-07T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF OSIMERTINIB FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WITH ACTIVATING EGFR MUTATIONS COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-19, 2018-08-07\", \"rr_multiple\": 0, \"drug_name\": \"Osimertinib (Tagrisso\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib (Tagrisso\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2435, \"last_scrape\": \"2018-12-13T16:44:39\", \"url\": \"http://www.ncpe.ie/drugs/osimertinib-tagrisso/\", \"rr_start\": \"2016-02-26T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-26, 2016-03-22, 2017-01-10\", \"rr_multiple\": 1, \"drug_name\": \"Osimertinib (Tagrisso\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib (Tagrisso\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-26T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2436, \"last_scrape\": \"2018-12-13T16:44:40\", \"url\": \"http://www.ncpe.ie/drugs/ozenoxacin-dubine/\", \"rr_start\": \"2018-11-12T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"FULL HTA IS NOT RECOMMENDED. THE NCPE RECOMMENDS THAT OZENOXACIN CREAM NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE.  THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013.\", \"rr_dates\": \"2018-11-12, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ozenoxacin (Dubine\", \"trade_name\": \"Dubine\", \"indication\": \"Ozenoxacin (Dubine\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-12T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"id\": 2437, \"last_scrape\": \"2018-12-13T16:44:43\", \"url\": \"http://www.ncpe.ie/drugs/p-drugs/pegylated-interferon-b-1a-plegridy/\", \"rr_start\": \"2014-11-25T00:00:00\", \"rr_end\": \"2014-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-11-25, 2014-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Pegylated Interferon beta-1a (Plegridy \", \"trade_name\": \"Plegridy\", \"indication\": \"Treatment of adult patients with relapsing remitting multiple sclerosis\", \"ncpe_year\": 2014, \"eu_market\": \"2014-07-17T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-11-25T00:00:00\", \"latest\": \"2014-12-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2438, \"last_scrape\": \"2018-12-13T16:44:47\", \"url\": \"http://www.ncpe.ie/drugs/palbociclib-ibrance/\", \"rr_start\": \"2016-09-10T00:00:00\", \"rr_end\": \"2016-09-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-09-10, 2016-09-28\", \"rr_multiple\": 0, \"drug_name\": \"Palbociclib (Ibrance\", \"trade_name\": \"Ibrance\", \"indication\": \"Palbociclib is indicated for the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-11-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2016-09-10T00:00:00\", \"latest\": \"2017-07-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2439, \"last_scrape\": \"2018-12-13T16:44:53\", \"url\": \"http://www.ncpe.ie/drugs/paliperidone-palmitate-xeplion/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Paliperidone palmitate (Xeplion\", \"trade_name\": \"Xeplion\", \"indication\": \"Paliperidone palmitate (Xeplion\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-04T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeplion\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2440, \"last_scrape\": \"2018-12-13T16:44:57\", \"url\": \"http://www.ncpe.ie/drugs/panobinostat-farydak/\", \"rr_start\": \"2016-01-26T00:00:00\", \"rr_end\": \"2016-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-26, 2016-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Panobinostat (Farydak\", \"trade_name\": \"Farydak\", \"indication\": \"Panobinostat in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-01-26T00:00:00\", \"latest\": \"2016-02-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/farydak\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2441, \"last_scrape\": \"2018-12-13T16:45:01\", \"url\": \"http://www.ncpe.ie/drugs/paritaprevir-boosted-with-ritonavir-and-ombitasvir-vierkirax-with-or-without-dasabuvir-exviera/\", \"rr_start\": \"2014-12-21T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-21, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Paritaprevir boosted with ritonavir and ombitasvir (Vierkirax\", \"trade_name\": \"Exviera\", \"indication\": \"Exviera\", \"ncpe_year\": 2016, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2014-12-21T00:00:00\", \"latest\": \"2016-02-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/exviera\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2442, \"last_scrape\": \"2018-12-13T16:45:07\", \"url\": \"http://www.ncpe.ie/drugs/patiromer-veltassa/\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT\\nRECOMMENDED\", \"rr_dates\": \"2017-10-11, 2017-11-17\", \"rr_multiple\": 0, \"drug_name\": \"Patiromer (Veltassa\", \"trade_name\": \"Veltassa\", \"indication\": \"Patiromer (Veltassa\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-19T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-11-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/veltassa\", \"ta_list\": \"Hyperkalemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2443, \"last_scrape\": \"2018-12-13T16:45:10\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-1l-nsclc-with-chemotherapy/\", \"rr_start\": \"2018-08-14T00:00:00\", \"rr_end\": \"2018-08-29T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-14, 2018-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-08-14T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2444, \"last_scrape\": \"2018-12-13T16:45:15\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-adjuvant-melanoma/\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-07T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-11-19, 2018-12-07\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizuma (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2445, \"last_scrape\": \"2018-12-13T16:45:18\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-classical-hodgkin-lymphoma/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2446, \"last_scrape\": \"2018-12-13T16:45:23\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-first-line-nsclc/\", \"rr_start\": \"2016-12-19T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-12-19, 2017-01-10\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-12-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2447, \"last_scrape\": \"2018-12-13T16:45:28\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-nsclc/\", \"rr_start\": \"2016-08-03T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-08-03, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-03T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2448, \"last_scrape\": \"2018-12-13T16:45:31\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-the-treatment-of-unresectable-or-advanced-metastatic-melanoma-in-adults-refractory-to-ipilimumab/\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2449, \"last_scrape\": \"2018-12-13T16:45:36\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-uc-1l/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES\", \"rr_dates\": \"2017-12-06, 2017-12-21, 2018-06-21, 2018-07-10, 2018-07-27\", \"rr_multiple\": 1, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-07-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2450, \"last_scrape\": \"2018-12-13T16:45:38\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-urothelial-carcinoma-2l/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda \", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2451, \"last_scrape\": \"2018-12-13T16:45:45\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda/\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-02-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2452, \"last_scrape\": \"2018-12-13T16:45:50\", \"url\": \"http://www.ncpe.ie/drugs/perampanel-fycompa/\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Perampanel (Fycompa\", \"trade_name\": \"Fycompa\", \"indication\": \"Perampanel (Fycompa\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-23T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa\", \"ta_list\": \"Epilepsies, Partial\", \"rr_status\": \"No HTA\"}, {\"id\": 2453, \"last_scrape\": \"2018-12-13T16:45:56\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta-for-her2-positive-breast-cancer/\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PERTUZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-01, 2018-06-22\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab  (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.\", \"ncpe_year\": 2018, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-12-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2454, \"last_scrape\": \"2018-12-13T16:46:02\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta-in-neoadjuvant-her2-positive-breast-cancer/\", \"rr_start\": \"2015-08-10T00:00:00\", \"rr_end\": \"2015-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-10, 2015-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"Perjeta (pertuzumab) is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2015-08-10T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2455, \"last_scrape\": \"2018-12-13T16:46:04\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta/\", \"rr_start\": \"2013-01-14T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-01-14, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"The proposed licensed indication is for use (in combination with trastuzumab and docetaxel) in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. \", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-01-14T00:00:00\", \"latest\": \"2013-08-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2456, \"last_scrape\": \"2018-12-13T16:46:09\", \"url\": \"http://www.ncpe.ie/drugs/phenylephrine-hydrochloride-tropicamide-lidocaine-hydrochloride-fydrane/\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-19T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-11-18, 2016-12-19\", \"rr_multiple\": 0, \"drug_name\": \"Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride (Fydrane\", \"trade_name\": \"Fydrane\", \"indication\": \"Fydrane\", \"ncpe_year\": 2016, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2016-12-19T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2457, \"last_scrape\": \"2018-12-13T16:46:11\", \"url\": \"http://www.ncpe.ie/drugs/pirfenidone-esbriet/\", \"rr_start\": \"2011-12-15T00:00:00\", \"rr_end\": \"2012-01-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-12-15, 2012-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Pirfenidone (Esbriet\", \"trade_name\": \"Esbriet\", \"indication\": \"Pirfenidone has been licensed by the European Medicines Agency (EMA) for the treatment of mild to moderate idiopathic pulmonary fibrosis.\", \"ncpe_year\": 2015, \"eu_market\": \"2011-02-27T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2011-12-15T00:00:00\", \"latest\": \"2015-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esbriet\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2458, \"last_scrape\": \"2018-12-13T16:46:14\", \"url\": \"http://www.ncpe.ie/drugs/pitavastatin-livazo/\", \"rr_start\": \"2010-12-22T00:00:00\", \"rr_end\": \"2010-12-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-12-22, 2010-12-24\", \"rr_multiple\": 0, \"drug_name\": \"Pitavastatin (Livazo\", \"trade_name\": \"Livazo\", \"indication\": \"Pitavastatin is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined (mixed) dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-12-22T00:00:00\", \"latest\": \"2010-12-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2459, \"last_scrape\": \"2018-12-13T16:46:20\", \"url\": \"http://www.ncpe.ie/drugs/pitolisant-wakix/\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-06-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-06-12, 2017-06-15\", \"rr_multiple\": 0, \"drug_name\": \"Pitolisant hydrochloride (Wakix\", \"trade_name\": \"Wakix\", \"indication\": \"Pitolisant hydrochloride (Wakix\", \"ncpe_year\": 2017, \"eu_market\": \"2016-03-31T00:00:00\", \"company\": \"Bioprojet\", \"orphan\": 1, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-06-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/wakix\", \"ta_list\": \"Narcolepsy\", \"rr_status\": \"No HTA\"}, {\"id\": 2460, \"last_scrape\": \"2018-12-13T16:46:24\", \"url\": \"http://www.ncpe.ie/drugs/pixantrone-pixuvri/\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-03-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-02-10, 2015-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Pixantrone (Pixuvri\", \"trade_name\": \"Pixuvri\", \"indication\": \"Pixurvi\", \"ncpe_year\": 2015, \"eu_market\": \"2012-05-10T00:00:00\", \"company\": \"CTI\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-03-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri\", \"ta_list\": \"Lymphoma, Non-Hodgkin\", \"rr_status\": \"No HTA\"}, {\"id\": 2461, \"last_scrape\": \"2018-12-13T16:46:27\", \"url\": \"http://www.ncpe.ie/drugs/polynuclear-ironiii-oxyhydroxide-pn-feooh-velphoro/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-09-12, 2014-10-08\", \"rr_multiple\": 0, \"drug_name\": \"Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro\", \"trade_name\": \"Velphoro\", \"indication\": \"Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro\", \"ncpe_year\": 2014, \"eu_market\": \"2014-08-26T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-10-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/velphoro\", \"ta_list\": \"Hyperphosphatemia; Renal Dialysis\", \"rr_status\": \"No HTA\"}, {\"id\": 2462, \"last_scrape\": \"2018-12-13T16:46:30\", \"url\": \"http://www.ncpe.ie/drugs/pomalidomide-imnovid/\", \"rr_start\": \"2013-09-20T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-20, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Pomalidomide (Imnovid\", \"trade_name\": \"Imnovid\", \"indication\": \"Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-09-20T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2463, \"last_scrape\": \"2018-12-13T16:46:32\", \"url\": \"http://www.ncpe.ie/drugs/ponatinib-iclusig/\", \"rr_start\": \"2013-10-02T00:00:00\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-10-02, 2013-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Ponatinib (Iclusig\", \"trade_name\": \"Iclusig\", \"indication\": \"Ponatinib (Iclusig\", \"ncpe_year\": 2016, \"eu_market\": \"2013-07-01T00:00:00\", \"company\": \"Incyte\", \"orphan\": 1, \"earliest\": \"2013-10-02T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig\", \"ta_list\": \"Leukemia, Myeloid; Leukemia, Lymphoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2464, \"last_scrape\": \"2018-12-13T16:46:38\", \"url\": \"http://www.ncpe.ie/drugs/prasugrel-efient/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Prasugrel (Efient\", \"trade_name\": \"Efient\", \"indication\": \"Economic Evaluation of Prasugrel (Efient\", \"ncpe_year\": 2010, \"eu_market\": \"2009-02-24T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2010-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/efient\", \"ta_list\": \"Acute Coronary Syndrome; Angina, Unstable; Myocardial Infarction\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2465, \"last_scrape\": \"2018-12-13T16:46:46\", \"url\": \"http://www.ncpe.ie/drugs/pregabalin-lyrica-2/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin (Lyrica\", \"trade_name\": \"Lyrica\", \"indication\": \"Lyrica\", \"ncpe_year\": 2015, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-30T00:00:00\", \"latest\": \"2015-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2466, \"last_scrape\": \"2018-12-13T16:46:52\", \"url\": \"http://www.ncpe.ie/drugs/pregabalin-lyrica-for-the-treatment-of-generalised-anxiety-disorder/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin (Lyrica\", \"trade_name\": \"Lyrica\", \"indication\": \"Pregabalin (Lyrica\", \"ncpe_year\": 2014, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-12-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2467, \"last_scrape\": \"2018-12-13T16:46:58\", \"url\": \"http://www.ncpe.ie/drugs/prucalopride-resolor/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-01-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-01-17\", \"rr_multiple\": 0, \"drug_name\": \"Prucalopride (Resolor\", \"trade_name\": \"Resolor\", \"indication\": \"Prucalopride (Resolor\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-14T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2011-01-17T00:00:00\", \"latest\": \"2011-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/resolor\", \"ta_list\": \"Constipation\", \"rr_status\": \"No HTA\"}, {\"id\": 2468, \"last_scrape\": \"2018-12-13T16:47:00\", \"url\": \"http://www.ncpe.ie/drugs/radium-223-xofigo/\", \"rr_start\": \"2013-11-28T00:00:00\", \"rr_end\": \"2013-12-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-11-28, 2013-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Radium-223 (Xofigo\", \"trade_name\": \"Xofigo\", \"indication\": \"Radium-223 (Xofigo\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-13T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2469, \"last_scrape\": \"2018-12-13T16:47:03\", \"url\": \"http://www.ncpe.ie/drugs/ramucirumab-cyramza/\", \"rr_start\": \"2014-12-20T00:00:00\", \"rr_end\": \"2014-12-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-20, 2014-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Ramucirumab (Cyramza\", \"trade_name\": \"Cyramza\", \"indication\": \"Indicated in combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction (GEJ) adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-12-19T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2014-12-20T00:00:00\", \"latest\": \"2016-07-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2470, \"last_scrape\": \"2018-12-13T16:47:06\", \"url\": \"http://www.ncpe.ie/drugs/ranolazine-ranexa/\", \"rr_start\": \"2009-11-19T00:00:00\", \"rr_end\": \"2009-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ranolazine (Ranexa\", \"trade_name\": \"Ranexa\", \"indication\": \"Cost-effectiveness of Ranolazine (Ranexa\", \"ncpe_year\": 2009, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2009-11-19T00:00:00\", \"latest\": \"2009-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2471, \"last_scrape\": \"2018-12-13T16:47:13\", \"url\": \"http://www.ncpe.ie/drugs/regadenoson-rapiscan/\", \"rr_start\": \"2011-09-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-09-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Regadenoson (Rapiscan\", \"trade_name\": \"Rapiscan\", \"indication\": \"Cost-effectiveness of Regadenoson (Rapiscan\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-06T00:00:00\", \"company\": \"GE\", \"orphan\": 0, \"earliest\": \"2011-09-19T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rapiscan\", \"ta_list\": \"Myocardial Perfusion Imaging\", \"rr_status\": \"No HTA\"}, {\"id\": 2472, \"last_scrape\": \"2018-12-13T16:47:17\", \"url\": \"http://www.ncpe.ie/drugs/regorafenib-stivarga-for-gist/\", \"rr_start\": \"2014-09-18T00:00:00\", \"rr_end\": \"2014-10-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-09-18, 2014-10-06\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib (Stivarga\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib (Stivarga\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2014-09-18T00:00:00\", \"latest\": \"2014-10-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2473, \"last_scrape\": \"2018-12-13T16:47:23\", \"url\": \"http://www.ncpe.ie/drugs/reslizumab-cinqaero/\", \"rr_start\": \"2017-01-23T00:00:00\", \"rr_end\": \"2017-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-01-23, 2017-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Reslizumab (Cinqaero\", \"trade_name\": \"Cinqaero\", \"indication\": \"Cinqaero\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-15T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2017-01-23T00:00:00\", \"latest\": \"2017-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cinqaero\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2474, \"last_scrape\": \"2018-12-13T16:47:27\", \"url\": \"http://www.ncpe.ie/drugs/retigabine-trobalt/\", \"rr_start\": \"2011-04-06T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-04-06, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Retigabine (Trobalt\", \"trade_name\": \"Trobalt\", \"indication\": \"Cost-effectiveness of Retigabine (Trobalt\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-27T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-04-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"No HTA\"}, {\"id\": 2475, \"last_scrape\": \"2018-12-13T16:47:29\", \"url\": \"http://www.ncpe.ie/drugs/ribociclib-kisqali/\", \"rr_start\": \"2017-09-04T00:00:00\", \"rr_end\": \"2017-09-19T00:00:00\", \"rr_outcome\": \"FOLLOWING NCPE ASSESSMENT OF THE COMPANY SUBMISSION, THE NCPE RECOMMENDS THAT RIBOCICLIB (IN COMBINATION WITH AN AROMATASE INHIBITOR) FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR+/HER2- LOCALLY ADVANCED OR METASTATIC BC AS INITIAL ENDOCRINE-BASED THERAPY, NOT BE CONSIDERED FOR REIMBURSEMENT UNLESS COST EFFECTIVENESS CAN BE IMPROVED RELATIVE TO EXISTING TREATMENTS. THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2017-09-04, 2017-09-19\", \"rr_multiple\": 0, \"drug_name\": \"Ribociclib (Kisqali\", \"trade_name\": \"Kisqali\", \"indication\": \"Ribociclib (Kisqali\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2017-09-04T00:00:00\", \"latest\": \"2018-08-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2476, \"last_scrape\": \"2018-12-13T16:47:35\", \"url\": \"http://www.ncpe.ie/drugs/rifaximin-targaxan-2/\", \"rr_start\": \"2013-07-09T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-09, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Rifaximin (Targaxan\", \"trade_name\": \"Targaxan\", \"indication\": \"Rifaximin (Targaxan\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-07-09T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2477, \"last_scrape\": \"2018-12-13T16:47:38\", \"url\": \"http://www.ncpe.ie/drugs/rigorafenib-stivarga/\", \"rr_start\": \"2013-09-12T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-12, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib (Stivarga\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib (Stivarga\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-09-12T00:00:00\", \"latest\": \"2014-06-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2478, \"last_scrape\": \"2018-12-13T16:47:42\", \"url\": \"http://www.ncpe.ie/drugs/rilpivirine-edurant/\", \"rr_start\": \"2011-12-14T00:00:00\", \"rr_end\": \"2012-01-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-12-14, 2012-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine (Edurant\", \"trade_name\": \"Edurant\", \"indication\": \"Rilpivirine in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ? 100,000 HIV-1 RNA copies/ml.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-11-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-12-14T00:00:00\", \"latest\": \"2012-01-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/edurant\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2479, \"last_scrape\": \"2018-12-13T16:47:45\", \"url\": \"http://www.ncpe.ie/drugs/rilpivirine-r-emtricitabine-f-tenofovir-alafenamide-taf-odefsey/\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMEDED\", \"rr_dates\": \"2016-06-28, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) (Odefsey\", \"trade_name\": \"Odefsey\", \"indication\": \"Odefsey\", \"ncpe_year\": 2016, \"eu_market\": \"2016-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2480, \"last_scrape\": \"2018-12-13T16:47:48\", \"url\": \"http://www.ncpe.ie/drugs/rimonabant-acomplia-2/\", \"rr_start\": \"\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rimonabant (Acomplia\", \"trade_name\": \"Acomplia\", \"indication\": \"In June 2006, Sanofi-Aventis submitted an evaluation of the cost-effectiveness of rimonabant (in addition to diet and exercise) in the management of multiple cardiovascular risks in overweight or obese patients in Ireland, to support its application for reimbursement of rimonabant under the Community Drugs Schemes. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-06-19T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2006-06-01T00:00:00\", \"latest\": \"2006-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/acomplia\", \"ta_list\": \"Obesity\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2481, \"last_scrape\": \"2018-12-13T16:47:53\", \"url\": \"http://www.ncpe.ie/drugs/riociguat-adempas/\", \"rr_start\": \"2014-04-11T00:00:00\", \"rr_end\": \"2014-05-16T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED AT THE CURRENT PRICE.\", \"rr_dates\": \"2014-04-11, 2014-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Riociguat (Adempas\", \"trade_name\": \"Adempas\", \"indication\": \"Riociguat (Adempas\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-27T00:00:00\", \"company\": \"Bayer\", \"orphan\": 1, \"earliest\": \"2014-04-11T00:00:00\", \"latest\": \"2014-05-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adempas\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2482, \"last_scrape\": \"2018-12-13T16:47:59\", \"url\": \"http://www.ncpe.ie/drugs/rituximab-mabthera/\", \"rr_start\": \"2014-05-26T00:00:00\", \"rr_end\": \"2014-09-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-26, 2014-09-22\", \"rr_multiple\": 0, \"drug_name\": \"Rituximab (MabThera\", \"trade_name\": \"MabThera\", \"indication\": \"Rituximab (MabThera\", \"ncpe_year\": 2014, \"eu_market\": \"1998-06-02T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-05-26T00:00:00\", \"latest\": \"2014-09-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"No HTA\"}, {\"id\": 2483, \"last_scrape\": \"2018-12-13T16:48:05\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-atrial-fibrillation-patients-undergoing-pci/\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2484, \"last_scrape\": \"2018-12-13T16:48:10\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-dvt/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Economic evaluation of Rivaroxaban (Xarelto\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-02-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2485, \"last_scrape\": \"2018-12-13T16:48:15\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-spaf-2/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban (Xarelto\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2486, \"last_scrape\": \"2018-12-13T16:48:18\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-the-prevention-of-atherothrombotic-events/\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-11T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF RIVAROXABAN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-26, 2018-10-11\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban (Xarelto\", \"ncpe_year\": 2018, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2487, \"last_scrape\": \"2018-12-13T16:48:25\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-low-dose-for-prevention-of-recurrent-venous-thromboembolism/\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2488, \"last_scrape\": \"2018-12-13T16:48:30\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban (Xarelto\", \"ncpe_year\": 2008, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2008-04-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2489, \"last_scrape\": \"2018-12-13T16:48:33\", \"url\": \"http://www.ncpe.ie/drugs/roflumilast-daxas/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Roflumilast (Daxas\", \"trade_name\": \"Daxas\", \"indication\": \"Cost Effectiveness of Roflumilast (Daxas\", \"ncpe_year\": 2010, \"eu_market\": \"2010-07-05T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-11T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/daxas\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2490, \"last_scrape\": \"2018-12-13T16:48:40\", \"url\": \"http://www.ncpe.ie/drugs/rolapitant-varuby/\", \"rr_start\": \"2017-05-15T00:00:00\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-05-15, 2017-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Rolapitant (Varuby\", \"trade_name\": \"Varuby\", \"indication\": \"Rolapitant (Varuby\", \"ncpe_year\": 2017, \"eu_market\": \"2017-04-19T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 0, \"earliest\": \"2017-05-15T00:00:00\", \"latest\": \"2017-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/varuby\", \"ta_list\": \"Vomiting; Nausea; Cancer\", \"rr_status\": \"No HTA\"}, {\"id\": 2491, \"last_scrape\": \"2018-12-13T16:48:43\", \"url\": \"http://www.ncpe.ie/drugs/romiplostim-nplate/\", \"rr_start\": \"\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Romiplostim (Nplate\", \"trade_name\": \"Nplate\", \"indication\": \"Romiplostim (Nplate\", \"ncpe_year\": 2015, \"eu_market\": \"2009-02-04T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-04-02T00:00:00\", \"latest\": \"2015-05-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nplate\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2492, \"last_scrape\": \"2018-12-13T16:48:47\", \"url\": \"http://www.ncpe.ie/drugs/ropivacaine-readyfusor/\", \"rr_start\": \"2018-11-09T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"FULL HTA IS NOT RECOMMENDED. THE NCPE RECOMMENDS THAT ROPIVICAINE READYFUSOR NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE.  THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013.\", \"rr_dates\": \"2018-11-09, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ropivacaine Readyfusor\", \"trade_name\": \"Ropivacaine Readyfusor\", \"indication\": \"Ropivacaine Readyfusor for acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block (CPNB) via a continuous infusion.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-09T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"id\": 2493, \"last_scrape\": \"2018-12-13T16:48:50\", \"url\": \"http://www.ncpe.ie/drugs/ruxolitinib-jakavi-for-polycythaemia-vera/\", \"rr_start\": \"2015-04-15T00:00:00\", \"rr_end\": \"2015-05-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-04-15, 2015-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib (Jakavi\", \"trade_name\": \"Jakavi\", \"indication\": \"Jakavi\", \"ncpe_year\": 2016, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2015-04-15T00:00:00\", \"latest\": \"2016-08-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2494, \"last_scrape\": \"2018-12-13T16:48:55\", \"url\": \"http://www.ncpe.ie/drugs/ruxolitinib-jakavi/\", \"rr_start\": \"2012-08-01T00:00:00\", \"rr_end\": \"2012-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-08-01, 2012-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib (Jakavi\", \"trade_name\": \"Jakavi\", \"indication\": \"Ruxolitinib (Jakavi\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2012-08-01T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2495, \"last_scrape\": \"2018-12-13T16:48:58\", \"url\": \"http://www.ncpe.ie/drugs/sacubitrilvalsartan-entresto/\", \"rr_start\": \"2015-11-06T00:00:00\", \"rr_end\": \"2015-11-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-06, 2015-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Sacubitril/valsartan (Entresto\", \"trade_name\": \"Entresto\", \"indication\": \"Entresto\", \"ncpe_year\": 2017, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-06T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entresto\", \"ta_list\": \"Heart Failure\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2496, \"last_scrape\": \"2018-12-13T16:49:04\", \"url\": \"http://www.ncpe.ie/drugs/safinamide-methansulfonate-xadago/\", \"rr_start\": \"2016-06-14T00:00:00\", \"rr_end\": \"2016-07-06T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED.\", \"rr_dates\": \"2016-06-14, 2016-07-06\", \"rr_multiple\": 0, \"drug_name\": \"Safinamide methansulfonate (Xadago\", \"trade_name\": \"Xadago\", \"indication\": \"Xadago\", \"ncpe_year\": 2016, \"eu_market\": \"2015-02-23T00:00:00\", \"company\": \"Zambon\", \"orphan\": 0, \"earliest\": \"2016-06-14T00:00:00\", \"latest\": \"2016-07-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xadago\", \"ta_list\": \"Parkinson Disease\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2497, \"last_scrape\": \"2018-12-13T16:49:07\", \"url\": \"http://www.ncpe.ie/drugs/sapropterin-kuvan/\", \"rr_start\": \"2015-07-14T00:00:00\", \"rr_end\": \"2015-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-07-14, 2015-08-14, 2015-07-01\", \"rr_multiple\": 1, \"drug_name\": \"Sapropterin (Kuvan\", \"trade_name\": \"Kuvan\", \"indication\": \"Sapropterin (Kuvan\", \"ncpe_year\": 2017, \"eu_market\": \"2008-12-02T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2009-01-01T00:00:00\", \"latest\": \"2017-09-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kuvan\", \"ta_list\": \"Phenylketonurias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2498, \"last_scrape\": \"2018-12-13T16:49:11\", \"url\": \"http://www.ncpe.ie/drugs/sarilumab-kevzara/\", \"rr_start\": \"2017-08-18T00:00:00\", \"rr_end\": \"2017-10-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-08-18, 2017-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Sarilumab (Kevzara\", \"trade_name\": \"Kevzara\", \"indication\": \"Sarilumab (Kevzara\", \"ncpe_year\": 2017, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-08-18T00:00:00\", \"latest\": \"2017-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2499, \"last_scrape\": \"2018-12-13T16:49:16\", \"url\": \"http://www.ncpe.ie/drugs/sebelipase-alfa-kanuma/\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-02-08, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Sebelipase alfa (Kanuma\", \"trade_name\": \"Kanuma\", \"indication\": \"Sebelipase alfa is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2018-06-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kanuma\", \"ta_list\": \"Lipid Metabolism, Inborn Errors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2500, \"last_scrape\": \"2018-12-13T16:49:20\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-ankylosing-spondylitis/\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-02, 2015-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"id\": 2501, \"last_scrape\": \"2018-12-13T16:49:25\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-psoriatic-arthritis/\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-02, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"id\": 2502, \"last_scrape\": \"2018-12-13T16:49:31\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx/\", \"rr_start\": \"2014-12-19T00:00:00\", \"rr_end\": \"2015-02-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-19, 2015-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-12-19T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2503, \"last_scrape\": \"2018-12-13T16:49:34\", \"url\": \"http://www.ncpe.ie/drugs/selexipag-uptravi/\", \"rr_start\": \"2016-11-01T00:00:00\", \"rr_end\": \"2016-12-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-01, 2016-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Selexipag (Uptravi\", \"trade_name\": \"Uptravi\", \"indication\": \"Selexipag (Uptravi\", \"ncpe_year\": 2018, \"eu_market\": \"2016-05-12T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2016-11-01T00:00:00\", \"latest\": \"2018-05-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2504, \"last_scrape\": \"2018-12-13T16:49:39\", \"url\": \"http://www.ncpe.ie/drugs/semaglutide-ozempic/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-03-12, 2018-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Semaglutide (Ozempic\", \"trade_name\": \"Ozempic\", \"indication\": \"Semaglutide (Ozempic\", \"ncpe_year\": 2018, \"eu_market\": \"2018-02-08T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-04-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2505, \"last_scrape\": \"2018-12-13T16:49:44\", \"url\": \"http://www.ncpe.ie/drugs/sildenafil-revatio/\", \"rr_start\": \"2014-04-16T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-04-16, 2014-05-23\", \"rr_multiple\": 0, \"drug_name\": \"Sildenafil (Revatio\", \"trade_name\": \"Revatio\", \"indication\": \"Sildenafil (Revatio\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2014-04-16T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revatio\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2506, \"last_scrape\": \"2018-12-13T16:49:49\", \"url\": \"http://www.ncpe.ie/drugs/simeprevir-olysio-in-combination-with-sofosbuvir/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir (Olysio\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir (Olysio\", \"ncpe_year\": 2015, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2015-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olysio\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2507, \"last_scrape\": \"2018-12-13T16:49:53\", \"url\": \"http://www.ncpe.ie/drugs/simeprevir-olysio/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED WHEN USED IN TRIPLE THERAPY WITH PEG-INTERFERON AND RIBAVIRIN.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir (Olysio\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir (Olysio\", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2014-07-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olysio\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2508, \"last_scrape\": \"2018-12-13T16:50:00\", \"url\": \"http://www.ncpe.ie/drugs/sodium-chloride-70mgml-sodium-hyaluronate-1mgml-hyaneb/\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-10, 2014-03-19\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml (Hyaneb\", \"trade_name\": \"Hyaneb\", \"indication\": \"Hyaneb\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2509, \"last_scrape\": \"2018-12-13T16:50:06\", \"url\": \"http://www.ncpe.ie/drugs/sodium-hyaluronate-hyloforte-0-2/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate (Hyloforte\", \"trade_name\": \"Hyloforte 0.2%\", \"indication\": \"Sodium Hyaluronate (Hyloforte\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2510, \"last_scrape\": \"2018-12-13T16:50:09\", \"url\": \"http://www.ncpe.ie/drugs/sodium-hyaluronate-hylotear-0-1/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate (Hylotear\", \"trade_name\": \"Hylotear 0.1%\", \"indication\": \"Sodium Hyaluronate (Hylotear\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2511, \"last_scrape\": \"2018-12-13T16:50:15\", \"url\": \"http://www.ncpe.ie/drugs/sodium-phenylbutyrate-pheburane/\", \"rr_start\": \"2013-07-17T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-17, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Sodium phenylbutyrate (Pheburane\", \"trade_name\": \"Pheburane\", \"indication\": \"Sodium phenylbutyrate (Pheburane\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-30T00:00:00\", \"company\": \"Lucane\", \"orphan\": 0, \"earliest\": \"2013-07-17T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pheburane\", \"ta_list\": \"Carbamoyl-Phosphate Synthase I Deficiency Disease\", \"rr_status\": \"No HTA\"}, {\"id\": 2512, \"last_scrape\": \"2018-12-13T16:50:18\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvir-solvaldi/\", \"rr_start\": \"2014-02-12T00:00:00\", \"rr_end\": \"2014-03-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-02-12, 2014-03-10\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir (Solvaldi\", \"trade_name\": \"Solvaldi\", \"indication\": \"Sofosbuvir (Solvaldi\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-02-12T00:00:00\", \"latest\": \"2014-10-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2513, \"last_scrape\": \"2018-12-13T16:50:22\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvirvelpatasvir-epclusa-chronic-hepatitis-c-virus-hcv-pangenotypic/\", \"rr_start\": \"2017-09-05T00:00:00\", \"rr_end\": \"2017-10-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-05, 2017-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir (Epclusa\", \"trade_name\": \"Epclusa\", \"indication\": \"Sofosbuvir/velpatasvir (Epclusa\", \"ncpe_year\": 2017, \"eu_market\": \"2016-07-06T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-05T00:00:00\", \"latest\": \"2017-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2514, \"last_scrape\": \"2018-12-13T16:50:26\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvirvelpatasvirvoxilaprevir-vosevi/\", \"rr_start\": \"2017-09-19T00:00:00\", \"rr_end\": \"2017-11-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-19, 2017-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi\", \"trade_name\": \"Vosevi\", \"indication\": \"Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-19T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vosevi\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2515, \"last_scrape\": \"2018-12-13T16:50:32\", \"url\": \"http://www.ncpe.ie/drugs/st-johns-wort-pafica/\", \"rr_start\": \"2015-04-14T00:00:00\", \"rr_end\": \"2015-05-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-04-14, 2015-05-29\", \"rr_multiple\": 0, \"drug_name\": \"St Johns Wort (Pacifa\", \"trade_name\": \"Pacifa\", \"indication\": \"Pacifa\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-04-14T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2516, \"last_scrape\": \"2018-12-13T16:50:38\", \"url\": \"http://www.ncpe.ie/drugs/stiripentol-diacomit/\", \"rr_start\": \"2017-07-06T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-06, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Stiripentol (Diacomit\", \"trade_name\": \"Diacomit\", \"indication\": \"Stiripentol (Diacomit\", \"ncpe_year\": 2018, \"eu_market\": \"2007-01-03T00:00:00\", \"company\": \"Biocodex\", \"orphan\": 1, \"earliest\": \"2017-07-06T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/diacomit\", \"ta_list\": \"Myoclonic Epilepsy, Juvenile\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2517, \"last_scrape\": \"2018-12-13T16:50:43\", \"url\": \"http://www.ncpe.ie/drugs/stribild-elvitegravircobicistatemtricitabinetenofovir-disoproxil-as-fumarate/\", \"rr_start\": \"2013-04-28T00:00:00\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-04-28, 2013-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumarate)(Stribild\", \"trade_name\": \"Stribild\", \"indication\": \"Indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-na\", \"ncpe_year\": 2013, \"eu_market\": \"2013-05-24T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2013-04-28T00:00:00\", \"latest\": \"2013-12-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stribild\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2518, \"last_scrape\": \"2018-12-13T16:50:49\", \"url\": \"http://www.ncpe.ie/drugs/sublingual-immunotherapy-grazax/\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sublingual Immunotherapy (Grazax\", \"trade_name\": \"Grazax\", \"indication\": \"A Review of the Cost-Effectiveness of Sublingual Immunotherapy (Grazax\", \"ncpe_year\": 2007, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2007-09-01T00:00:00\", \"latest\": \"2007-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2519, \"last_scrape\": \"2018-12-13T16:50:50\", \"url\": \"http://www.ncpe.ie/drugs/suboxone-buprenorphinenaloxone/\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Buprenorphine/naloxone (Suboxone\", \"trade_name\": \"Suboxone\", \"indication\": \"An economic evaluation of suboxone for the management of opiate addiction.\", \"ncpe_year\": 2014, \"eu_market\": \"2006-09-26T00:00:00\", \"company\": \"Indivior\", \"orphan\": 0, \"earliest\": \"2007-11-01T00:00:00\", \"latest\": \"2014-05-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/suboxone\", \"ta_list\": \"Opioid-Related Disorders\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2520, \"last_scrape\": \"2018-12-13T16:50:54\", \"url\": \"http://www.ncpe.ie/drugs/sufentanil-zalviso/\", \"rr_start\": \"2016-03-14T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-03-14, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Sufentanil (Zalviso\", \"trade_name\": \"Zalviso\", \"indication\": \"Sufentanil (Zalviso\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Gr\", \"orphan\": 0, \"earliest\": \"2016-03-14T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zalviso\", \"ta_list\": \"Pain, Postoperative\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2521, \"last_scrape\": \"2018-12-13T16:50:59\", \"url\": \"http://www.ncpe.ie/drugs/sunitinib-sutent/\", \"rr_start\": \"\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sunitinib (Sutent\", \"trade_name\": \"Sutent\", \"indication\": \"In September 2006, Pfizer Healthcare Ireland submitted an evaluation of the cost-effectiveness and budget impact of sunitinib as second-line treatment of patients with gastro-intestinal stromal tumours (GIST). Data on the cost-effectiveness and budget impact of sutinitinib as second line treatment for patients with metastatic renal cell carcinoma (mRCC) was also presented. The purpose of the submission was to support an application for reimbursement under the High Tech Drug Scheme. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-07-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-09-01T00:00:00\", \"latest\": \"2006-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sutent\", \"ta_list\": \"Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2522, \"last_scrape\": \"2018-12-13T16:51:04\", \"url\": \"http://www.ncpe.ie/drugs/tadalafil-adcirca-2/\", \"rr_start\": \"2011-07-13T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-07-13, 2011-09-21, 2014-05-09, 2014-05-23\", \"rr_multiple\": 1, \"drug_name\": \"Tadalafil (Adcirca\", \"trade_name\": \"Adcirca\", \"indication\": \"Tadalafil (Adcirca\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-07-13T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2523, \"last_scrape\": \"2018-12-13T16:51:09\", \"url\": \"http://www.ncpe.ie/drugs/tafamadis-meglumine-vyndaqel/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED UNTIL ADDITIONAL EFFICACY AND/OR SAFETY DATA IS SUBMITTED. ON THE BASIS OF CURRENT EVIDENCE, THE NCPE RECOMMENDS THAT TAFAMIDIS NOT BE CONSIDERED FOR REIMBURSEMENT IN ACCORDANCE WITH THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Tafamadis meglumine (Vyndaqel\", \"trade_name\": \"Vyndaqel\", \"indication\": \"Tafamadis meglumine (Vyndaqel\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-16T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel\", \"ta_list\": \"Amyloidosis\", \"rr_status\": \"No HTA until more evidence\"}, {\"id\": 2524, \"last_scrape\": \"2018-12-13T16:51:15\", \"url\": \"http://www.ncpe.ie/drugs/tafluprost-saflutan/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Tafluprost (Saflutan\", \"trade_name\": \"Saflutan\", \"indication\": \"Tafluoprost (Salflutan\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2525, \"last_scrape\": \"2018-12-13T16:51:24\", \"url\": \"http://www.ncpe.ie/drugs/talimogene-laherparepvec-imlygic/\", \"rr_start\": \"2016-02-16T00:00:00\", \"rr_end\": \"2016-03-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-02-16, 2016-03-14\", \"rr_multiple\": 0, \"drug_name\": \"Talimogene Laherparepvec (Imlygic\", \"trade_name\": \"Imlygic\", \"indication\": \"Talimogene laherparepvec (Imlygic\", \"ncpe_year\": 2016, \"eu_market\": \"2015-12-16T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-02-16T00:00:00\", \"latest\": \"2016-03-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2526, \"last_scrape\": \"2018-12-13T16:51:28\", \"url\": \"http://www.ncpe.ie/drugs/tapentadol-palexia/\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Tapentadol (Palexia\", \"trade_name\": \"Palexia\", \"indication\": \"Economic evaluation of oral tapentadol (Palexia\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2011-04-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2527, \"last_scrape\": \"2018-12-13T16:51:34\", \"url\": \"http://www.ncpe.ie/drugs/tedizolid-phosphate-sivextro/\", \"rr_start\": \"2015-05-07T00:00:00\", \"rr_end\": \"2015-07-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-05-07, 2015-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Tedizolid phosphate (Sivextro\", \"trade_name\": \"Sivextro\", \"indication\": \"Tedizolid phosphate (Sivextro\", \"ncpe_year\": 2015, \"eu_market\": \"2015-03-23T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-05-07T00:00:00\", \"latest\": \"2015-07-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sivextro\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"No HTA\"}, {\"id\": 2528, \"last_scrape\": \"2018-12-13T16:51:38\", \"url\": \"http://www.ncpe.ie/drugs/teduglutide-revestive/\", \"rr_start\": \"2017-03-13T00:00:00\", \"rr_end\": \"2017-04-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-13, 2017-04-12\", \"rr_multiple\": 0, \"drug_name\": \"Teduglutide (Revestive\", \"trade_name\": \"Revestive\", \"indication\": \"Teduglutide (Revestive\", \"ncpe_year\": 2018, \"eu_market\": \"2012-08-30T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2017-03-13T00:00:00\", \"latest\": \"2018-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revestive\", \"ta_list\": \"Malabsorption Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2529, \"last_scrape\": \"2018-12-13T16:51:44\", \"url\": \"http://www.ncpe.ie/drugs/tegafurgimeraciloteracil-teysuno/\", \"rr_start\": \"2012-02-27T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-02-27, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Tegafur/Gimeracil/Oteracil (Teysuno\", \"trade_name\": \"Teysuno\", \"indication\": \"Teysuno is indicated in adults for the treatment of advanced gastric cancer.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-03-14T00:00:00\", \"company\": \"Nordic\", \"orphan\": 0, \"earliest\": \"2012-02-27T00:00:00\", \"latest\": \"2012-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2530, \"last_scrape\": \"2018-12-13T16:51:48\", \"url\": \"http://www.ncpe.ie/drugs/telapravir/\", \"rr_start\": \"2011-10-28T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-10-28, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Telaprevir (Incivo\", \"trade_name\": \"Incivo\", \"indication\": \"Economic evaluation of Telaprevir (Incivo\", \"ncpe_year\": 2012, \"eu_market\": \"2011-09-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-28T00:00:00\", \"latest\": \"2012-01-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/incivo\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2531, \"last_scrape\": \"2018-12-13T16:51:52\", \"url\": \"http://www.ncpe.ie/drugs/telavancin-vibativ/\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-12-08, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Telavancin (Vibativ\", \"trade_name\": \"Vibativ\", \"indication\": \"Indicated for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumomia, known or suspended to be caused by methicillin-resistant Staphylococcus aureas (MRSA).  Vabitiv\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Theravance\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2015-01-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vibativ-0\", \"ta_list\": \"Pneumonia, Bacterial; Cross Infection\", \"rr_status\": \"No HTA\"}, {\"id\": 2532, \"last_scrape\": \"2018-12-13T16:51:56\", \"url\": \"http://www.ncpe.ie/drugs/teriflunomide-aubagio/\", \"rr_start\": \"2013-08-27T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-08-27, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Teriflunomide (Aubagio\", \"trade_name\": \"Aubagio\", \"indication\": \"Aubagio\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2013-08-27T00:00:00\", \"latest\": \"2014-09-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2533, \"last_scrape\": \"2018-12-13T16:51:58\", \"url\": \"http://www.ncpe.ie/drugs/ticagrelor-brilique-2/\", \"rr_start\": \"2016-02-29T00:00:00\", \"rr_end\": \"2016-05-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-29, 2016-05-04\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor (Brilique\", \"trade_name\": \"Brilique\", \"indication\": \"Ticagrelor (Brilique\", \"ncpe_year\": 2016, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-29T00:00:00\", \"latest\": \"2016-05-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brilique\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2534, \"last_scrape\": \"2018-12-13T16:52:01\", \"url\": \"http://www.ncpe.ie/drugs/ticagrelor-brilique/\", \"rr_start\": \"2010-11-25T00:00:00\", \"rr_end\": \"2011-01-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-11-25, 2011-01-20\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor (Brilique\", \"trade_name\": \"Brilique\", \"indication\": \"Economic Evaluation of Ticagrelor (Brilique\", \"ncpe_year\": 2011, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-11-25T00:00:00\", \"latest\": \"2011-10-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brilique\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2535, \"last_scrape\": \"2018-12-13T16:52:07\", \"url\": \"http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-all/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-19T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TISAGENLECLEUCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel (Kymriah\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel (Kymriah\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2536, \"last_scrape\": \"2018-12-13T16:52:13\", \"url\": \"http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-dlbcl/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TISAGENLECLEUCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel (Kymriah\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel (Kymriah\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2537, \"last_scrape\": \"2018-12-13T16:52:19\", \"url\": \"http://www.ncpe.ie/drugs/tobramycin-tobi-podhaler/\", \"rr_start\": \"2010-11-10T00:00:00\", \"rr_end\": \"2010-11-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2010-11-10, 2010-11-03\", \"rr_multiple\": 0, \"drug_name\": \"Tobramycin (TOBI Podhaler\", \"trade_name\": \"TOBI Podhaler\", \"indication\": \"Tobramycin (TOBI Podhaler\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-11-01T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2538, \"last_scrape\": \"2018-12-13T16:52:24\", \"url\": \"http://www.ncpe.ie/drugs/tocilizumab-sc-roactemra/\", \"rr_start\": \"2014-04-28T00:00:00\", \"rr_end\": \"2014-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THESUBMITTED PRICE.\", \"rr_dates\": \"2014-04-28, 2014-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Tocilizumab SC (RoActemra\", \"trade_name\": \"RoActemra\", \"indication\": \"It is licensed for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.  It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-04-28T00:00:00\", \"latest\": \"2014-07-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra\", \"ta_list\": \"Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2539, \"last_scrape\": \"2018-12-13T16:52:30\", \"url\": \"http://www.ncpe.ie/drugs/tofacitinib-xeljanz-for-ulcerative-colitis/\", \"rr_start\": \"2018-07-16T00:00:00\", \"rr_end\": \"2018-09-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TOFACITINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-07-16, 2018-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib (Xeljanz\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy (i.e. corticosteroids, azathioprine, 6-mercaptopurine) or a biologic agent (i.e. TNF inhibitor).\", \"ncpe_year\": 2018, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2018-07-16T00:00:00\", \"latest\": \"2018-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2540, \"last_scrape\": \"2018-12-13T16:52:35\", \"url\": \"http://www.ncpe.ie/drugs/tofacitinib-xeljanz/\", \"rr_start\": \"2017-03-08T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-08, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib (Xeljanz\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib (Xeljanz\", \"ncpe_year\": 2017, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-03-08T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2541, \"last_scrape\": \"2018-12-13T16:52:40\", \"url\": \"http://www.ncpe.ie/drugs/tolvaptan-jinarc/\", \"rr_start\": \"2016-01-04T00:00:00\", \"rr_end\": \"2016-01-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-04, 2016-01-12\", \"rr_multiple\": 0, \"drug_name\": \"Tolvaptan (Jinarc\", \"trade_name\": \"Jinarc\", \"indication\": \"Jinarc\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2016-01-04T00:00:00\", \"latest\": \"2018-09-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc\", \"ta_list\": \"Polycystic Kidney, Autosomal Dominant\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2542, \"last_scrape\": \"2018-12-13T16:52:45\", \"url\": \"http://www.ncpe.ie/drugs/tramadol-hydrochloridedexketoprofen-skudexa/\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"REIMURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-10-17, 2017-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Tramadol hydrochloride/dexketoprofen (Skudexa\", \"trade_name\": \"Skudexa\", \"indication\": \"Tramadol hydrochloride/dexketoprofen (Skudexa \", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2017-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2543, \"last_scrape\": \"2018-12-13T16:52:51\", \"url\": \"http://www.ncpe.ie/drugs/trametinib-mekinist/\", \"rr_start\": \"2015-11-27T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-27, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Trametinib (Mekinist\", \"trade_name\": \"Mekinist\", \"indication\": \"Mekinist\", \"ncpe_year\": 2018, \"eu_market\": \"2014-06-30T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-27T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2544, \"last_scrape\": \"2018-12-13T16:52:56\", \"url\": \"http://www.ncpe.ie/drugs/trastuzumab-emtansine-kadcyla/\", \"rr_start\": \"2013-09-25T00:00:00\", \"rr_end\": \"2013-10-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-25, 2013-10-24\", \"rr_multiple\": 0, \"drug_name\": \"Trastuzumab emtansine (Kadcyla\", \"trade_name\": \"Kadcyla\", \"indication\": \"Trastuzumab emtansine (Kadcyla\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-09-25T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2545, \"last_scrape\": \"2018-12-13T16:53:00\", \"url\": \"http://www.ncpe.ie/drugs/trifluridinetipiracil-lonsurf/\", \"rr_start\": \"2016-06-10T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-06-10, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Trifluridine/tipiracil (Lonsurf\", \"trade_name\": \"Lonsurf\", \"indication\": \"Trifluridine/tipiracil (Lonsurf\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2016-06-10T00:00:00\", \"latest\": \"2016-07-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2546, \"last_scrape\": \"2018-12-13T16:53:04\", \"url\": \"http://www.ncpe.ie/drugs/ulipristal-acetate-esmya-2/\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-05-17, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate (Esmya \", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate is indicated for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-05-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esmya\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2547, \"last_scrape\": \"2018-12-13T16:53:08\", \"url\": \"http://www.ncpe.ie/drugs/ulipristal-acetate-esmya/\", \"rr_start\": \"2013-09-03T00:00:00\", \"rr_end\": \"2013-10-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-09-03, 2013-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate (Esmya\", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate (Esmya\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2013-09-03T00:00:00\", \"latest\": \"2013-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esmya\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2548, \"last_scrape\": \"2018-12-13T16:53:10\", \"url\": \"http://www.ncpe.ie/drugs/umeclidiniumvilanterol-anoro/\", \"rr_start\": \"2014-06-11T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-06-11, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Umeclidinium/vilanterol (Anoro\", \"trade_name\": \"Anoro\", \"indication\": \"Umeclidinium/vilanterol (Anoro\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-06-11T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2549, \"last_scrape\": \"2018-12-13T16:53:12\", \"url\": \"http://www.ncpe.ie/drugs/urea-glucorx-allpresan/\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT GLUCORX ALLPRESAN DIABETIC FOAM CREAM NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE IN ACCORDANCE WITH THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2018-07-09, 2018-07-24\", \"rr_multiple\": 0, \"drug_name\": \"Urea (GlucoRx Allpresan\", \"trade_name\": \"GlucoRx Allpresan\", \"indication\": \"GlucoRx Allpresan\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-07-24T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2550, \"last_scrape\": \"2018-12-13T16:53:17\", \"url\": \"http://www.ncpe.ie/drugs/ustekinumab-stelara-2/\", \"rr_start\": \"2016-11-28T00:00:00\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-11-28, 2017-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab (Stelara\", \"trade_name\": \"Stelara\", \"indication\": \"Ustekinumab is indicated for the treatment of adult patients with moderately to severely active Crohn\", \"ncpe_year\": 2017, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2016-11-28T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stelara\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2551, \"last_scrape\": \"2018-12-13T16:53:23\", \"url\": \"http://www.ncpe.ie/drugs/ustekinumab-stelara/\", \"rr_start\": \"\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab (Stelara\", \"trade_name\": \"Stelara\", \"indication\": \"Cost-effectiveness of Ustekinumab (Stelara\", \"ncpe_year\": 2009, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2009-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stelara\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2552, \"last_scrape\": \"2018-12-13T16:53:29\", \"url\": \"http://www.ncpe.ie/drugs/vandetanib-caprelsa/\", \"rr_start\": \"2013-06-06T00:00:00\", \"rr_end\": \"2013-07-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-06, 2013-07-03\", \"rr_multiple\": 0, \"drug_name\": \"Vandetanib (Caprelsa\", \"trade_name\": \"Caprelsa\", \"indication\": \"Vandetanib (Caprelsa\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-16T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2013-06-06T00:00:00\", \"latest\": \"2013-07-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2553, \"last_scrape\": \"2018-12-13T16:53:32\", \"url\": \"http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-crohns-disease/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab (Entyvio\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab (Entyvio\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2554, \"last_scrape\": \"2018-12-13T16:53:39\", \"url\": \"http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-ulcerative-colitis/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab (Entyvio\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab (Entyvio\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2555, \"last_scrape\": \"2018-12-13T16:53:45\", \"url\": \"http://www.ncpe.ie/drugs/velaglucerase-alfa-vpriv-2/\", \"rr_start\": \"2011-04-26T00:00:00\", \"rr_end\": \"2011-06-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-04-26, 2011-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Velaglucerase Alfa (VPRIV\", \"trade_name\": \"VPRIV\", \"indication\": \"VPRIV is indicated for long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-04-26T00:00:00\", \"latest\": \"2011-06-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2556, \"last_scrape\": \"2018-12-13T16:53:49\", \"url\": \"http://www.ncpe.ie/drugs/venetoclax-venclyxto-in-combination-with-rituximab/\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF VENETOCLAX COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-26, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax (Venclyxto\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax (Venclyxto\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2557, \"last_scrape\": \"2018-12-13T16:53:52\", \"url\": \"http://www.ncpe.ie/drugs/venetoclax-venclyxto/\", \"rr_start\": \"2018-05-08T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"FOLLOWING A RESUBMISSION OF THE RAPID REVIEW A FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, WHICH IS NOT COMPARABLE WITH CURRENT AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-05-08, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax (Venclyxto\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL)\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2558, \"last_scrape\": \"2018-12-13T16:53:58\", \"url\": \"http://www.ncpe.ie/drugs/vermurafenib-zelboraf/\", \"rr_start\": \"2011-12-23T00:00:00\", \"rr_end\": \"2012-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-12-23, 2012-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Vemurafenib (Zelboraf\", \"trade_name\": \"Zelboraf\", \"indication\": \"Vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\", \"ncpe_year\": 2014, \"eu_market\": \"2012-02-17T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2011-12-23T00:00:00\", \"latest\": \"2014-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2559, \"last_scrape\": \"2018-12-13T16:54:00\", \"url\": \"http://www.ncpe.ie/drugs/vernakalant-brinavess/\", \"rr_start\": \"2010-10-26T00:00:00\", \"rr_end\": \"2010-11-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-10-26, 2010-11-04\", \"rr_multiple\": 0, \"drug_name\": \"Vernakalant (Brinavess\", \"trade_name\": \"Brinavess\", \"indication\": \"Economic evaluation of Vernakalant (Brinavess\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Cardiome\", \"orphan\": 0, \"earliest\": \"2010-10-26T00:00:00\", \"latest\": \"2011-05-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2560, \"last_scrape\": \"2018-12-13T16:54:04\", \"url\": \"http://www.ncpe.ie/drugs/vismodegib-erivedge/\", \"rr_start\": \"2013-05-02T00:00:00\", \"rr_end\": \"2013-05-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-05-02, 2013-05-20\", \"rr_multiple\": 0, \"drug_name\": \"Vismodegib (Erivedge\", \"trade_name\": \"Erivedge\", \"indication\": \"Vismodegib (Erivedge\", \"ncpe_year\": 2017, \"eu_market\": \"2013-07-12T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-05-02T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge\", \"ta_list\": \"Carcinoma, Basal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2561, \"last_scrape\": \"2018-12-13T16:54:11\", \"url\": \"http://www.ncpe.ie/drugs/vortioxetine-brintellix/\", \"rr_start\": \"2014-10-01T00:00:00\", \"rr_end\": \"2014-11-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-10-01, 2014-11-14\", \"rr_multiple\": 0, \"drug_name\": \"Vortioxetine (Brintellix\", \"trade_name\": \"Brintellix\", \"indication\": \"Vortioxetine (Brintellix\", \"ncpe_year\": 2017, \"eu_market\": \"2013-12-18T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2014-10-01T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"HTA recommended at submitted price\"}]}};\n",
       "var opt = {};\n",
       "var type = \"vega-lite\";\n",
       "var id = \"bdd6dc6a-b30e-4cd3-9acf-7256d2696bca\";\n",
       "\n",
       "var output_area = this;\n",
       "\n",
       "require([\"nbextensions/jupyter-vega/index\"], function(vega) {\n",
       "  var target = document.createElement(\"div\");\n",
       "  target.id = id;\n",
       "  target.className = \"vega-embed\";\n",
       "\n",
       "  var style = document.createElement(\"style\");\n",
       "  style.textContent = [\n",
       "    \".vega-embed .error p {\",\n",
       "    \"  color: firebrick;\",\n",
       "    \"  font-size: 14px;\",\n",
       "    \"}\",\n",
       "  ].join(\"\\\\n\");\n",
       "\n",
       "  // element is a jQuery wrapped DOM element inside the output area\n",
       "  // see http://ipython.readthedocs.io/en/stable/api/generated/\\\n",
       "  // IPython.display.html#IPython.display.Javascript.__init__\n",
       "  element[0].appendChild(target);\n",
       "  element[0].appendChild(style);\n",
       "\n",
       "  vega.render(\"#\" + id, spec, type, opt, output_area);\n",
       "}, function (err) {\n",
       "  if (err.requireType !== \"scripterror\") {\n",
       "    throw(err);\n",
       "  }\n",
       "});\n"
      ],
      "text/plain": [
       "<vega.vegalite.VegaLite at 0x24582118dd8>"
      ]
     },
     "metadata": {
      "jupyter-vega": "#bdd6dc6a-b30e-4cd3-9acf-7256d2696bca"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": []
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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"
     },
     "metadata": {
      "jupyter-vega": "#bdd6dc6a-b30e-4cd3-9acf-7256d2696bca"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "alt.Chart(drugs,title=\"Drugs By Company with NCPE Year\").mark_bar().encode(\n",
    "    alt.X('company', sort=alt.EncodingSortField(field=\"company\", op=\"count\", order='descending'),\n",
    "          axis=alt.Axis(title='Drug Company')),\n",
    "    alt.Y('count(rr_status)',\n",
    "          axis=alt.Axis(title='Count')),\n",
    "    alt.Color('ncpe_year',title=\"NCPE Year\",sort='descending')).properties(width=4000,height=300)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Axes flipped."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "var spec = {\"config\": {\"view\": {\"width\": 400, \"height\": 300}}, \"data\": {\"name\": \"data-1fb11c1b30e9c74b6a5173f2568cb7ab\"}, \"mark\": \"bar\", \"encoding\": {\"color\": {\"type\": \"quantitative\", \"field\": \"ncpe_year\", \"sort\": \"descending\", \"title\": \"NCPE Year\"}, \"x\": {\"type\": \"nominal\", \"aggregate\": \"count\", \"axis\": {\"title\": \"Count\"}, \"field\": \"rr_status\"}, \"y\": {\"type\": \"nominal\", \"axis\": {\"title\": \"Drug Company\"}, \"field\": \"company\", \"sort\": {\"op\": \"count\", \"field\": \"company\", \"order\": \"descending\"}}}, \"height\": 3000, \"title\": \"Count Drugs By Company\", \"width\": 700, \"$schema\": \"https://vega.github.io/schema/vega-lite/v2.6.0.json\", \"datasets\": {\"data-1fb11c1b30e9c74b6a5173f2568cb7ab\": [{\"id\": 2164, \"last_scrape\": \"2018-12-13T16:24:32\", \"url\": \"http://www.ncpe.ie/drugs/abatacept-orencia/\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Abatacept (Orencia\", \"trade_name\": \"Orencia\", \"indication\": \"Subcutaneous Abatacept (Orencia\", \"ncpe_year\": 2015, \"eu_market\": \"2007-05-21T00:00:00\", \"company\": \"\", \"orphan\": 0, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/orencia\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2165, \"last_scrape\": \"2018-12-13T16:24:36\", \"url\": \"http://www.ncpe.ie/drugs/abiraterone-acetate-zytiga-for-mhspc/\", \"rr_start\": \"2018-10-03T00:00:00\", \"rr_end\": \"2018-11-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-10-03, 2018-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Abiraterone acetate (Zytiga\", \"ncpe_year\": 2018, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2018-10-03T00:00:00\", \"latest\": \"2018-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2166, \"last_scrape\": \"2018-12-13T16:24:41\", \"url\": \"http://www.ncpe.ie/drugs/abiratone-acetate-zytiga-for-mcrpc-post-adt/\", \"rr_start\": \"2013-01-03T00:00:00\", \"rr_end\": \"2013-02-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-01-03, 2013-02-01\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation of Abiratone acetate (Zytiga\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-01-03T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2167, \"last_scrape\": \"2018-12-13T16:24:46\", \"url\": \"http://www.ncpe.ie/drugs/abiratone-acetate-zytiga/\", \"rr_start\": \"2011-10-21T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-10-21, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone Acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation and resource implications of Zytiga \", \"ncpe_year\": 2014, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-21T00:00:00\", \"latest\": \"2014-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2168, \"last_scrape\": \"2018-12-13T16:24:49\", \"url\": \"http://www.ncpe.ie/drugs/aceclofenac-vitafen/\", \"rr_start\": \"2016-12-21T00:00:00\", \"rr_end\": \"2017-01-24T00:00:00\", \"rr_outcome\": \"FOLLOWING A RESUBMISSION OF THE RAPID REVIEW A FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-12-21, 2017-01-24\", \"rr_multiple\": 0, \"drug_name\": \"Aceclofenac (Vitafen\", \"trade_name\": \"Vitafen\", \"indication\": \"Aceclofenac (Vitafen\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-07-22T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2169, \"last_scrape\": \"2018-12-13T16:24:56\", \"url\": \"http://www.ncpe.ie/drugs/aclidinium-bromide-eklira-genuair/\", \"rr_start\": \"2012-10-23T00:00:00\", \"rr_end\": \"2012-10-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-23, 2012-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide (Eklira Genuair\", \"trade_name\": \"Eklira Genuair\", \"indication\": \"Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)\", \"ncpe_year\": 2012, \"eu_market\": \"2012-07-20T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-23T00:00:00\", \"latest\": \"2012-10-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"id\": 2170, \"last_scrape\": \"2018-12-13T16:25:00\", \"url\": \"http://www.ncpe.ie/drugs/aclidinium-bromide-formoterol-fumarate-dihydrate-brimica-genuair/\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE.\", \"rr_dates\": \"2015-01-05, 2015-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide / formoterol fumarate dihydrate (Brimica\", \"trade_name\": \"Brimica Genuair\", \"indication\": \"Brimica\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2015-02-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brimica-genuair\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2171, \"last_scrape\": \"2018-12-13T16:25:37\", \"url\": \"http://www.ncpe.ie/drugs/adalimumab-humira/\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-20, 2011-06-02\", \"rr_multiple\": 0, \"drug_name\": \"Adalimumab (Humira\", \"trade_name\": \"Humira\", \"indication\": \"Economic evaluation of Adalimumab (Humira\", \"ncpe_year\": 2011, \"eu_market\": \"2003-09-07T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/humira\", \"ta_list\": \"Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"id\": 2172, \"last_scrape\": \"2018-12-13T16:25:40\", \"url\": \"http://www.ncpe.ie/drugs/adenuric-febuxostat/\", \"rr_start\": \"2009-12-08T00:00:00\", \"rr_end\": \"2009-12-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-12-08\", \"rr_multiple\": 0, \"drug_name\": \"Adenuric (Febuxostat\", \"trade_name\": \"Febuxostat\", \"indication\": \"NCPE review of Adenuric (Febuxostat\", \"ncpe_year\": 2009, \"eu_market\": \"2008-04-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2009-12-08T00:00:00\", \"latest\": \"2009-12-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adenuric\", \"ta_list\": \"Gout\", \"rr_status\": \"No HTA\"}, {\"id\": 2173, \"last_scrape\": \"2018-12-13T16:25:45\", \"url\": \"http://www.ncpe.ie/drugs/afatinib-giotrif/\", \"rr_start\": \"2013-10-01T00:00:00\", \"rr_end\": \"2013-10-13T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-10-01, 2013-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Afatinib (Giotrif\", \"trade_name\": \"Giotrif\", \"indication\": \"GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-na\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-25T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2013-10-01T00:00:00\", \"latest\": \"2013-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2174, \"last_scrape\": \"2018-12-13T16:25:49\", \"url\": \"http://www.ncpe.ie/drugs/aflibercept-eylea/\", \"rr_start\": \"2012-12-10T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-10, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept (Eylea\", \"trade_name\": \"Eylea\", \"indication\": \"Aflibercept (Eylea\", \"ncpe_year\": 2012, \"eu_market\": \"2012-11-21T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2012-12-10T00:00:00\", \"latest\": \"2012-12-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eylea\", \"ta_list\": \"Wet Macular Degeneration; Macular Edema; Diabetes Complications\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2175, \"last_scrape\": \"2018-12-13T16:25:52\", \"url\": \"http://www.ncpe.ie/drugs/aflibercept-zaltrap/\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept (Zaltrap\", \"trade_name\": \"Zaltrap\", \"indication\": \"Aflibercept for the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-01T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-02-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zaltrap\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2176, \"last_scrape\": \"2018-12-13T16:25:58\", \"url\": \"http://www.ncpe.ie/drugs/agomelatine-valdoxan-4/\", \"rr_start\": \"\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Agomelatine (Valdoxan\", \"trade_name\": \"Valdoxan\", \"indication\": \"Economic evaluation of Agomelatine (Valdoxan\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-19T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2009-09-03T00:00:00\", \"latest\": \"2009-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/valdoxan\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2177, \"last_scrape\": \"2018-12-13T16:26:06\", \"url\": \"http://www.ncpe.ie/drugs/alectinib-alecensa/\", \"rr_start\": \"2017-01-03T00:00:00\", \"rr_end\": \"2017-12-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-01-03, 2017-02-27, 2017-11-08, 2017-12-04\", \"rr_multiple\": 1, \"drug_name\": \"Alectinib (Alecensa\", \"trade_name\": \"Alecensa\", \"indication\": \"Alectinib (Alecensa \", \"ncpe_year\": 2018, \"eu_market\": \"2017-02-16T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2178, \"last_scrape\": \"2018-12-13T16:26:12\", \"url\": \"http://www.ncpe.ie/drugs/alemtuzumab-lemtrada/\", \"rr_start\": \"2013-11-08T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-11-08, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Alemtuzumab (Lemtrada\", \"trade_name\": \"Lemtrada\", \"indication\": \"Alemtuzumab (Lemtrada\", \"ncpe_year\": 2014, \"eu_market\": \"2013-09-12T00:00:00\", \"company\": \"Sanofi\", \"orphan\": 0, \"earliest\": \"2013-11-08T00:00:00\", \"latest\": \"2014-06-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2179, \"last_scrape\": \"2018-12-13T16:26:14\", \"url\": \"http://www.ncpe.ie/drugs/alirocumab-praluent/\", \"rr_start\": \"2015-10-13T00:00:00\", \"rr_end\": \"2015-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-10-13, 2015-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Alirocumab (Praluent\", \"trade_name\": \"Praluent\", \"indication\": \"Praluent\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2015-10-13T00:00:00\", \"latest\": \"2018-03-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/praluent\", \"ta_list\": \"Dyslipidemias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2180, \"last_scrape\": \"2018-12-13T16:26:16\", \"url\": \"http://www.ncpe.ie/drugs/alogliptin-vipidia/\", \"rr_start\": \"2013-09-27T00:00:00\", \"rr_end\": \"2013-10-30T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-09-27, 2013-10-30\", \"rr_multiple\": 0, \"drug_name\": \"Alogliptin (Vipidia\", \"trade_name\": \"Vipidia\", \"indication\": \"Alogliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-18T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2013-09-27T00:00:00\", \"latest\": \"2013-10-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vipidia\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2181, \"last_scrape\": \"2018-12-13T16:26:21\", \"url\": \"http://www.ncpe.ie/drugs/ambrisentan-volibris/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-05-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Ambrisentan (Volibris\", \"trade_name\": \"Volibris\", \"indication\": \"Cost Effectiveness of ambrisentan (Volibris\", \"ncpe_year\": 2014, \"eu_market\": \"2008-04-20T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 1, \"earliest\": \"2008-10-01T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/volibris\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2182, \"last_scrape\": \"2018-12-13T16:26:23\", \"url\": \"http://www.ncpe.ie/drugs/amifampridine-firdapse/\", \"rr_start\": \"2011-11-07T00:00:00\", \"rr_end\": \"2011-12-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-11-07, 2011-12-09\", \"rr_multiple\": 0, \"drug_name\": \"Amifampridine (Firdapse\", \"trade_name\": \"Firdapse\", \"indication\": \"For Lambert Eaton Myasthenic Syndrome (LEMS).  This high cost drug is likely to require a full HTA due to significant budget impact.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-11-07T00:00:00\", \"latest\": \"2011-12-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2183, \"last_scrape\": \"2018-12-13T16:26:29\", \"url\": \"http://www.ncpe.ie/drugs/amsacrine-amsidine/\", \"rr_start\": \"2017-01-10T00:00:00\", \"rr_end\": \"2017-02-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-01-10, 2017-02-15\", \"rr_multiple\": 0, \"drug_name\": \"Amsacrine (Amsidine\", \"trade_name\": \"Amsidine\", \"indication\": \"Amsidine\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2017-01-10T00:00:00\", \"latest\": \"2017-02-15T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2184, \"last_scrape\": \"2018-12-13T16:26:35\", \"url\": \"http://www.ncpe.ie/drugs/apixaban-eliquis-for-treatment-of-deep-vein-thrombosis-dvt-and-pulmonary-embolism-pe-and-prevention-of-recurrent-dvt-and-pe-in-adults/\", \"rr_start\": \"2014-07-29T00:00:00\", \"rr_end\": \"2014-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-07-29, 2014-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban (Eliquis\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban (Eliquis\", \"ncpe_year\": 2014, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-07-29T00:00:00\", \"latest\": \"2014-08-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2185, \"last_scrape\": \"2018-12-13T16:26:39\", \"url\": \"http://www.ncpe.ie/drugs/apixaban-eliquis/\", \"rr_start\": \"2011-10-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-10-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban (Eliquis\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban (Eliquis\", \"ncpe_year\": 2012, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-10-19T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2186, \"last_scrape\": \"2018-12-13T16:26:45\", \"url\": \"http://www.ncpe.ie/drugs/apremilast-otezla-for-moderate-to-severe-chronic-plaque-psoriasis/\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast (Otezla\", \"trade_name\": \"Otezla\", \"indication\": \"Indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to systemic non-biologic therapies including cyclosporine, methotrexate or psoralen and ultraviolet A light (PUVA).\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/otezla\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2187, \"last_scrape\": \"2018-12-13T16:26:47\", \"url\": \"http://www.ncpe.ie/drugs/apremilast-otezla-for-psoriatic-arthritis/\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast (Otezla\", \"trade_name\": \"Otezla\", \"indication\": \"Apremilist (Otezla\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/otezla\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2188, \"last_scrape\": \"2018-12-13T16:26:49\", \"url\": \"http://www.ncpe.ie/drugs/aripiprazole-abilify-maintena/\", \"rr_start\": \"2014-07-02T00:00:00\", \"rr_end\": \"2014-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-07-02, 2014-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Aripiprazole (Abilify Maintena\", \"trade_name\": \"Abilify Maintena\", \"indication\": \"Aripiprazole (Abilify Maintena\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-14T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2014-07-02T00:00:00\", \"latest\": \"2014-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2189, \"last_scrape\": \"2018-12-13T16:26:55\", \"url\": \"http://www.ncpe.ie/drugs/asenapine-sycrest/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-08-17, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Asenapine (Sycrest\", \"trade_name\": \"Sycrest\", \"indication\": \"Asenapine (Sycrest\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Organon\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sycrest\", \"ta_list\": \"Bipolar Disorder\", \"rr_status\": \"No HTA\"}, {\"id\": 2190, \"last_scrape\": \"2018-12-13T16:27:00\", \"url\": \"http://www.ncpe.ie/drugs/atezolizumab-tecentriq/\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-10-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-08, 2017-10-09\", \"rr_multiple\": 0, \"drug_name\": \"Atezolizumab (Tecentriq\", \"trade_name\": \"Tecentriq\", \"indication\": \"Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK?positive tumour mutations should also have received targeted therapy before receiving atezolizumab.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-21T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq\", \"ta_list\": \"Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2191, \"last_scrape\": \"2018-12-13T16:27:05\", \"url\": \"http://www.ncpe.ie/drugs/avanafil-spedra/\", \"rr_start\": \"2014-02-19T00:00:00\", \"rr_end\": \"2014-03-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-19, 2014-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Avanafil (Spedra\", \"trade_name\": \"Spedra\", \"indication\": \"Avanafil (Spedra\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2014-02-19T00:00:00\", \"latest\": \"2014-03-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/spedra\", \"ta_list\": \"Erectile Dysfunction\", \"rr_status\": \"No HTA\"}, {\"id\": 2192, \"last_scrape\": \"2018-12-13T16:27:06\", \"url\": \"http://www.ncpe.ie/drugs/avelumab-bavencio/\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-10-17, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Avelumab (Bavencio\", \"trade_name\": \"Bavencio\", \"indication\": \"Avelumab (Bavencio\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2018-10-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2193, \"last_scrape\": \"2018-12-13T16:27:08\", \"url\": \"http://www.ncpe.ie/drugs/axanum-aspirin-81mgesomeprazole-20mg/\", \"rr_start\": \"2012-04-12T00:00:00\", \"rr_end\": \"2012-04-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-04-12, 2012-04-20\", \"rr_multiple\": 0, \"drug_name\": \"Aspirin 81mg/Esomeprazole 20mg (Axanum\", \"trade_name\": \"Axanum\", \"indication\": \"Prevention of thrombotic cardiovascular and cerebrovascular events in patients requiring continuous low-dose acetylsalicylic acid treatment, and who are in need of prophylaxis against acetylsalicylic acid associated gastric and /or duodenal ulcers.\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-04-12T00:00:00\", \"latest\": \"2012-04-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2194, \"last_scrape\": \"2018-12-13T16:27:14\", \"url\": \"http://www.ncpe.ie/drugs/axicabtagene-ciloleucel-yescarta/\", \"rr_start\": \"2018-09-10T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF  AXI-CEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-10, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Axicabtagene Ciloleucel (Yescarta\", \"trade_name\": \"Yescarta\", \"indication\": \"Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Kite\", \"orphan\": 1, \"earliest\": \"2018-09-10T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta\", \"ta_list\": \"Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2195, \"last_scrape\": \"2018-12-13T16:27:23\", \"url\": \"http://www.ncpe.ie/drugs/axitinib-inlyta/\", \"rr_start\": \"2012-11-07T00:00:00\", \"rr_end\": \"2012-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-07, 2012-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Axitinib (Inlyta\", \"trade_name\": \"Inlyta\", \"indication\": \"For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-03T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-11-07T00:00:00\", \"latest\": \"2012-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2196, \"last_scrape\": \"2018-12-13T16:27:24\", \"url\": \"http://www.ncpe.ie/drugs/azelastine-hydrochloride-and-fluticasone-propionate-nasal-spray-dymista/\", \"rr_start\": \"2013-02-12T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2013-02-12, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Azelastine hydrochloride and fluticasone propionate (nasal spray) (Dymista\", \"trade_name\": \"Dymista\", \"indication\": \"Indicated for symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-02-12T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2197, \"last_scrape\": \"2018-12-13T16:27:25\", \"url\": \"http://www.ncpe.ie/drugs/azilsartan-edarbi/\", \"rr_start\": \"2012-01-10T00:00:00\", \"rr_end\": \"2012-01-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-01-10, 2012-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Azilsartan (Edarbi\", \"trade_name\": \"Edarbi\", \"indication\": \"Edarbi is indicated for the treatment of essential hypertension in adults.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-12-07T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2012-01-10T00:00:00\", \"latest\": \"2012-01-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/edarbi\", \"ta_list\": \"Hypertension\", \"rr_status\": \"No HTA\"}, {\"id\": 2198, \"last_scrape\": \"2018-12-13T16:27:27\", \"url\": \"http://www.ncpe.ie/drugs/baricitinib-olumiant/\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-06-14, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Baricitinib (Olumiant\", \"trade_name\": \"Olumiant\", \"indication\": \"Baricitinib (Olumiant\", \"ncpe_year\": 2017, \"eu_market\": \"2017-02-12T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2199, \"last_scrape\": \"2018-12-13T16:27:33\", \"url\": \"http://www.ncpe.ie/drugs/bazedoxifene-conbriza/\", \"rr_start\": \"2011-09-20T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-09-20, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Bazedoxifene (Conbriza\", \"trade_name\": \"Conbriza\", \"indication\": \"Bazedoxifene (Conbriza\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-17T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-09-20T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza\", \"ta_list\": \"Osteoporosis, Postmenopausal\", \"rr_status\": \"No HTA\"}, {\"id\": 2200, \"last_scrape\": \"2018-12-13T16:27:36\", \"url\": \"http://www.ncpe.ie/drugs/bedaquiline-sirturo/\", \"rr_start\": \"2015-01-23T00:00:00\", \"rr_end\": \"2015-02-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-01-23, 2015-02-20\", \"rr_multiple\": 0, \"drug_name\": \"Bedaquiline (Sirturo\", \"trade_name\": \"Sirturo\", \"indication\": \"Bedaquiline (Sirturo\", \"ncpe_year\": 2015, \"eu_market\": \"2014-03-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2015-01-23T00:00:00\", \"latest\": \"2015-02-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo\", \"ta_list\": \"Tuberculosis, Multidrug-Resistant\", \"rr_status\": \"No HTA\"}, {\"id\": 2201, \"last_scrape\": \"2018-12-13T16:27:37\", \"url\": \"http://www.ncpe.ie/drugs/belatacept-nulojix/\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2012-01-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-11-15, 2012-01-23\", \"rr_multiple\": 0, \"drug_name\": \"Belatacept (Nulojix\", \"trade_name\": \"Nulojix\", \"indication\": \"Belatacept, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen.\\n\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2012-01-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nulojix\", \"ta_list\": \"Graft Rejection; Kidney Transplantation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2202, \"last_scrape\": \"2018-12-13T16:27:40\", \"url\": \"http://www.ncpe.ie/drugs/belimumab-benlysta/\", \"rr_start\": \"2011-08-11T00:00:00\", \"rr_end\": \"2011-08-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-11, 2011-08-11\", \"rr_multiple\": 0, \"drug_name\": \"Belimumab (Benlysta\", \"trade_name\": \"Benlysta\", \"indication\": \"Cost-effectiveness of Belimumab (Benlysta\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-08-01T00:00:00\", \"latest\": \"2011-08-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta\", \"ta_list\": \"Lupus Erythematosus, Systemic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2203, \"last_scrape\": \"2018-12-13T16:27:46\", \"url\": \"http://www.ncpe.ie/drugs/bendamustine-levact/\", \"rr_start\": \"2011-03-21T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-03-21, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Bendamustine (Levact\", \"trade_name\": \"Levact\", \"indication\": \"Bendamustine (Levact\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2012-11-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2204, \"last_scrape\": \"2018-12-13T16:27:50\", \"url\": \"http://www.ncpe.ie/drugs/benralizumab-fasenra/\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-14T00:00:00\", \"rr_outcome\": \"FULL PHARAMCOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2018-01-15, 2018-02-14\", \"rr_multiple\": 0, \"drug_name\": \"Benralizumab (Fasenra\", \"trade_name\": \"Fasenra\", \"indication\": \"Benralizumab (Fasenra\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fasenra\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2205, \"last_scrape\": \"2018-12-13T16:27:56\", \"url\": \"http://www.ncpe.ie/drugs/bezlotoxumab-zinplava/\", \"rr_start\": \"2017-05-11T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-05-11, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Bezlotoxumab (Zinplava\", \"trade_name\": \"Zinplava\", \"indication\": \"Bezlotoxumab (Zinplava\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-05-11T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinplava\", \"ta_list\": \"Enterocolitis, Pseudomembranous\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2206, \"last_scrape\": \"2018-12-13T16:27:58\", \"url\": \"http://www.ncpe.ie/drugs/bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy/\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT BIKTARVY\", \"rr_dates\": \"2018-04-30, 2018-06-07\", \"rr_multiple\": 0, \"drug_name\": \"Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy\", \"trade_name\": \"Biktarvy\", \"indication\": \"Biktarvy\", \"ncpe_year\": 2018, \"eu_market\": \"2018-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2207, \"last_scrape\": \"2018-12-13T16:28:01\", \"url\": \"http://www.ncpe.ie/drugs/bilastine-drynol/\", \"rr_start\": \"2011-03-10T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-10, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Bilastine (Drynol\", \"trade_name\": \"Drynol\", \"indication\": \" Bilastine (Drynol\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-03-10T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2208, \"last_scrape\": \"2018-12-13T16:28:05\", \"url\": \"http://www.ncpe.ie/drugs/blinatumomab-blincyto/\", \"rr_start\": \"2015-12-08T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.  THE NCPE CANNOT RECOMMEND REIMBURSEMENT OF BLINCTYO\", \"rr_dates\": \"2015-12-08, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Blinatumomab (Blincyto\", \"trade_name\": \"Blincyto\", \"indication\": \"Blincyto\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-23T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-08T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2209, \"last_scrape\": \"2018-12-13T16:28:11\", \"url\": \"http://www.ncpe.ie/drugs/boceprevir-victrelis/\", \"rr_start\": \"\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Boceprevir (Victrelis\", \"trade_name\": \"Victrelis\", \"indication\": \"Economic evaluation of Boceprevir (Victrelis\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2011-08-19T00:00:00\", \"latest\": \"2012-01-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2210, \"last_scrape\": \"2018-12-13T16:28:16\", \"url\": \"http://www.ncpe.ie/drugs/bosentan-tracleer/\", \"rr_start\": \"2014-06-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-06-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Bosentan (Tracleer\", \"trade_name\": \"Tracleer\", \"indication\": \"Bosentan (Tracleer\", \"ncpe_year\": 2014, \"eu_market\": \"2002-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-06-27T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tracleer\", \"ta_list\": \"Scleroderma, Systemic; Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2211, \"last_scrape\": \"2018-12-13T16:28:18\", \"url\": \"http://www.ncpe.ie/drugs/bosutinib-bosulif/\", \"rr_start\": \"2013-08-09T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"AT THE CURRENT PRICE A FULL HTA WOULD BE REQUIRED.\", \"rr_dates\": \"2013-08-09, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Bosutinib (Bosulif\", \"trade_name\": \"Bosulif\", \"indication\": \"Bosutinib is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-26T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2212, \"last_scrape\": \"2018-12-13T16:28:19\", \"url\": \"http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris-for-cd30-cutaneous-t-cell-lymphoma-ctcl/\", \"rr_start\": \"2018-02-07T00:00:00\", \"rr_end\": \"2018-03-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-02-07, 2018-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin (Adcetris\", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin (Adcetris\", \"ncpe_year\": 2018, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-02-07T00:00:00\", \"latest\": \"2018-03-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2213, \"last_scrape\": \"2018-12-13T16:28:23\", \"url\": \"http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris/\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin (Adcetris\", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin (Adcetris\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2214, \"last_scrape\": \"2018-12-13T16:28:29\", \"url\": \"http://www.ncpe.ie/drugs/brigatinib-alunbrig/\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF BRIGATINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-11-19, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Brigatinib (Alunbrig\", \"trade_name\": \"Alunbrig\", \"indication\": \"Brigatinib (Alunbrig \", \"ncpe_year\": 2018, \"eu_market\": \"2018-11-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2215, \"last_scrape\": \"2018-12-13T16:28:30\", \"url\": \"http://www.ncpe.ie/drugs/brimonidine-3-3-mgg-gel-mirvaso/\", \"rr_start\": \"2014-04-09T00:00:00\", \"rr_end\": \"2014-04-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-09\", \"rr_multiple\": 0, \"drug_name\": \"Brimonidine 3.3 mg/g gel (Mirvaso\", \"trade_name\": \"Mirvaso\", \"indication\": \"Brimonidine 3.3 mg/g gel (Mirvaso\", \"ncpe_year\": 2014, \"eu_market\": \"2014-02-20T00:00:00\", \"company\": \"Galderma\", \"orphan\": 0, \"earliest\": \"2014-04-09T00:00:00\", \"latest\": \"2014-04-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mirvaso\", \"ta_list\": \"Skin Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2216, \"last_scrape\": \"2018-12-13T16:28:36\", \"url\": \"http://www.ncpe.ie/drugs/brivaracetam-briviact/\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-02-15, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Brivaracetam (Briviact\", \"trade_name\": \"Briviact\", \"indication\": \"Brivaracetam (Briviact\", \"ncpe_year\": 2016, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2217, \"last_scrape\": \"2018-12-13T16:28:40\", \"url\": \"http://www.ncpe.ie/drugs/brodalumab-kyntheum/\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-07-25, 2017-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Brodalumab (Kyntheum\", \"trade_name\": \"Kyntheum\", \"indication\": \"Brodalumab (Kyntheum\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-17T00:00:00\", \"company\": \"LEO\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2218, \"last_scrape\": \"2018-12-13T16:28:44\", \"url\": \"http://www.ncpe.ie/drugs/bronchitol/\", \"rr_start\": \"2012-09-11T00:00:00\", \"rr_end\": \"2012-09-21T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2012-09-11, 2012-09-21\", \"rr_multiple\": 0, \"drug_name\": \"Mannitol Dry Powder (Bronchitol\", \"trade_name\": \"Bronchitol\", \"indication\": \"Bronchitol\", \"ncpe_year\": 2014, \"eu_market\": \"2012-04-13T00:00:00\", \"company\": \"Pharmaxis\", \"orphan\": 1, \"earliest\": \"2012-09-11T00:00:00\", \"latest\": \"2014-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bronchitol\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2219, \"last_scrape\": \"2018-12-13T16:28:46\", \"url\": \"http://www.ncpe.ie/drugs/c-drugs/calcipotriol-and-betamethasone-dipropionate-cutaneous-foam-enstilar/\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-06-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-05-17, 2016-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Calcipotriol and betamethasone dipropionate cutaneous foam (Enstilar \", \"trade_name\": \"Enstilar\", \"indication\": \"Calcipotriol and betamethasone dipropionate cutaneous foam is indicated for the topical treatment of psoriasis vulgaris in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-06-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2220, \"last_scrape\": \"2018-12-13T16:28:53\", \"url\": \"http://www.ncpe.ie/drugs/c1inhibitor-human-cinryze/\", \"rr_start\": \"2012-10-22T00:00:00\", \"rr_end\": \"2012-11-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-22, 2012-11-14\", \"rr_multiple\": 0, \"drug_name\": \"C1inhibitor (human) (Cinryze\", \"trade_name\": \"Cinryze\", \"indication\": \"C1inhibitor (human) (Cinryze\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-15T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2012-10-22T00:00:00\", \"latest\": \"2012-11-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"id\": 2221, \"last_scrape\": \"2018-12-13T16:28:55\", \"url\": \"http://www.ncpe.ie/drugs/cabozantinib-cabometyx/\", \"rr_start\": \"2017-03-20T00:00:00\", \"rr_end\": \"2017-04-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT\\nRECOMMENDED\", \"rr_dates\": \"2017-03-20, 2017-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib (Cabometyx\", \"trade_name\": \"Cabometyx\", \"indication\": \"Cabozantinib (Cabometyx\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-03-20T00:00:00\", \"latest\": \"2018-07-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2222, \"last_scrape\": \"2018-12-13T16:28:58\", \"url\": \"http://www.ncpe.ie/drugs/cabozantinib-cometriq/\", \"rr_start\": \"2014-07-10T00:00:00\", \"rr_end\": \"2014-08-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2014-07-10, 2014-08-12\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib (Cometriq\", \"trade_name\": \"Cometriq\", \"indication\": \"Cabozantinib (COMETRIQ\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-21T00:00:00\", \"company\": \"Ipsen\", \"orphan\": 1, \"earliest\": \"2014-07-10T00:00:00\", \"latest\": \"2014-08-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2223, \"last_scrape\": \"2018-12-13T16:29:01\", \"url\": \"http://www.ncpe.ie/drugs/camellia-sinensis-folium-green-tea-leaf-catephen-10/\", \"rr_start\": \"2015-05-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-05-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Camellia sinensis, folium (green tea leaf) (Catephen 10%\", \"trade_name\": \"Catephen 10%\", \"indication\": \"Catephen 10%\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-05-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2224, \"last_scrape\": \"2018-12-13T16:29:04\", \"url\": \"http://www.ncpe.ie/drugs/canagliflozin-invokana/\", \"rr_start\": \"2013-11-25T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-11-25, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Canagliflozin (Invokana\", \"trade_name\": \"Invokana\", \"indication\": \"Canagliflozin (Invokana\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-11-25T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/invokana\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2225, \"last_scrape\": \"2018-12-13T16:29:09\", \"url\": \"http://www.ncpe.ie/drugs/capsaicin-8ww-patch-qutenza/\", \"rr_start\": \"2012-06-15T00:00:00\", \"rr_end\": \"2012-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-06-15, 2012-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Capsaicin 8%w/w patch (Qutenza\", \"trade_name\": \"Qutenza\", \"indication\": \"Capsaicin 8% w/w patch (Qutenza\", \"ncpe_year\": 2012, \"eu_market\": \"2009-05-15T00:00:00\", \"company\": \"Grunenthal\", \"orphan\": 0, \"earliest\": \"2012-06-15T00:00:00\", \"latest\": \"2012-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza\", \"ta_list\": \"Neuralgia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2226, \"last_scrape\": \"2018-12-13T16:29:11\", \"url\": \"http://www.ncpe.ie/drugs/carbazitaxel-jevtana-for-prostate-cancer/\", \"rr_start\": \"2011-06-02T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-06-02, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Cabazitaxel (Jevtana\", \"trade_name\": \"Jevtana\", \"indication\": \"Economic Evaluation of cabazitaxel (Jevtana\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2011-06-02T00:00:00\", \"latest\": \"2014-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jevtana\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2227, \"last_scrape\": \"2018-12-13T16:29:16\", \"url\": \"http://www.ncpe.ie/drugs/carfilzomib-kyprolis/\", \"rr_start\": \"2015-12-07T00:00:00\", \"rr_end\": \"2016-01-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-12-07, 2016-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Carfilzomib (Kyprolis\", \"trade_name\": \"Kyprolis\", \"indication\": \"Kyprolis\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-07T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2228, \"last_scrape\": \"2018-12-13T16:29:22\", \"url\": \"http://www.ncpe.ie/drugs/catumaxomab-removab/\", \"rr_start\": \"2011-08-05T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-08-05, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Catumaxomab (Removab\", \"trade_name\": \"Removab\", \"indication\": \"Catumazomab (Removab\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-20T00:00:00\", \"company\": \"Neovii\", \"orphan\": 0, \"earliest\": \"2011-08-05T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/removab\", \"ta_list\": \"Ascites; Cancer\", \"rr_status\": \"No HTA\"}, {\"id\": 2229, \"last_scrape\": \"2018-12-13T16:29:25\", \"url\": \"http://www.ncpe.ie/drugs/ceftaroline-zinforo/\", \"rr_start\": \"2012-10-08T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-08, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Ceftaroline (Zinforo\", \"trade_name\": \"Zinforo\", \"indication\": \"For the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP).\", \"ncpe_year\": 2012, \"eu_market\": \"2012-08-22T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-10-08T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinforo\", \"ta_list\": \"Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia\", \"rr_status\": \"No HTA\"}, {\"id\": 2230, \"last_scrape\": \"2018-12-13T16:29:29\", \"url\": \"http://www.ncpe.ie/drugs/ceftazidime-avibactam-cef-avizavicefta/\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-17, 2017-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Ceftazidime-avibactam (CEF-AVI)(Zavicefta\", \"trade_name\": \"Zavicefta\", \"indication\": \"Ceftazidime-avibactam (CEF-AVI)(Zavicefta\", \"ncpe_year\": 2017, \"eu_market\": \"2016-06-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta\", \"ta_list\": \"Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2231, \"last_scrape\": \"2018-12-13T16:29:34\", \"url\": \"http://www.ncpe.ie/drugs/ceftolozanetazobactam-zerbaxa/\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-03-03, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Ceftolozane/tazobactam (Zerbaxa\", \"trade_name\": \"Zerbaxa\", \"indication\": \"Zerbaxa\", \"ncpe_year\": 2016, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa\", \"ta_list\": \"Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2232, \"last_scrape\": \"2018-12-13T16:29:36\", \"url\": \"http://www.ncpe.ie/drugs/ceritinib-zykadia/\", \"rr_start\": \"2015-05-29T00:00:00\", \"rr_end\": \"2015-07-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2015-05-29, 2015-07-22\", \"rr_multiple\": 0, \"drug_name\": \"Ceritinib (Zykadia\", \"trade_name\": \"Zykadia\", \"indication\": \"Zykadia\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-06T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-05-29T00:00:00\", \"latest\": \"2015-07-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2233, \"last_scrape\": \"2018-12-13T16:29:40\", \"url\": \"http://www.ncpe.ie/drugs/cerliponase-alfa-brineura/\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2017-10-11, 2017-11-27\", \"rr_multiple\": 0, \"drug_name\": \"Cerliponase alfa (Brineura\", \"trade_name\": \"Brineura\", \"indication\": \"Cerliponase alfa (Brineura\", \"ncpe_year\": 2018, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-08-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brineura\", \"ta_list\": \"Neuronal Ceroid-Lipofuscinoses\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2234, \"last_scrape\": \"2018-12-13T16:29:44\", \"url\": \"http://www.ncpe.ie/drugs/certolizumab-pegol-cimzia/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Certolizumab pegol (Cimzia\", \"trade_name\": \"Cimzia\", \"indication\": \"Cost-effectiveness of certolizumab pegol (Cimzia\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2010-03-13T00:00:00\", \"latest\": \"2010-09-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia-0\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2235, \"last_scrape\": \"2018-12-13T16:29:49\", \"url\": \"http://www.ncpe.ie/drugs/ciclosporin-1mgml-eye-drops-ikervis/\", \"rr_start\": \"2015-01-07T00:00:00\", \"rr_end\": \"2016-01-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-01-07, 2016-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Ciclosporin 1mg/ml eye drops (Ikervis\", \"trade_name\": \"Ikervis\", \"indication\": \"Ikervis\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-19T00:00:00\", \"company\": \"Santen\", \"orphan\": 0, \"earliest\": \"2015-01-07T00:00:00\", \"latest\": \"2016-01-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis\", \"ta_list\": \"Corneal Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2236, \"last_scrape\": \"2018-12-13T16:29:54\", \"url\": \"http://www.ncpe.ie/drugs/cladribine-mavenclad/\", \"rr_start\": \"2017-08-22T00:00:00\", \"rr_end\": \"2017-09-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-22, 2017-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Cladribine (Mavenclad\", \"trade_name\": \"Mavenclad\", \"indication\": \"Cladribine (Mavenclad\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-08-22T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2237, \"last_scrape\": \"2018-12-13T16:29:58\", \"url\": \"http://www.ncpe.ie/drugs/clindamycin-1-with-tretinoin-0-025-treclinac/\", \"rr_start\": \"2014-04-08T00:00:00\", \"rr_end\": \"2014-05-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-08, 2014-05-06\", \"rr_multiple\": 0, \"drug_name\": \"Clindamycin 1% with tretinoin 0.025% (Treclinac\", \"trade_name\": \"Treclinac\", \"indication\": \"Clindamycin 1% with tretinoin 0.025% (Treclinac\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-04-08T00:00:00\", \"latest\": \"2014-05-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2238, \"last_scrape\": \"2018-12-13T16:30:02\", \"url\": \"http://www.ncpe.ie/drugs/cobimetinib-cotellic/\", \"rr_start\": \"2016-04-19T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-04-19, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Cobimetinib (Cotellic\", \"trade_name\": \"Cotellic\", \"indication\": \"Cotellic\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2016-04-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2239, \"last_scrape\": \"2018-12-13T16:30:03\", \"url\": \"http://www.ncpe.ie/drugs/colesevelam-cholestagel/\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Colesevelam (Cholestagel\", \"trade_name\": \"Cholestagel\", \"indication\": \"Cost-effectiveness of Colesevelam (Cholestagel\", \"ncpe_year\": 2010, \"eu_market\": \"2004-03-09T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cholestagel\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"No HTA\"}, {\"id\": 2240, \"last_scrape\": \"2018-12-13T16:30:06\", \"url\": \"http://www.ncpe.ie/drugs/colistimethate-sodium-colobreathe/\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Colistimethate sodium (Colobreathe\", \"trade_name\": \"Colobreathe\", \"indication\": \"Colistimethate sodium (colobreathe\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-13T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/colobreathe\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2241, \"last_scrape\": \"2018-12-13T16:30:17\", \"url\": \"http://www.ncpe.ie/drugs/collagenase-clostridium-histolyticum-xiapex/\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-20, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Collagenase Clostridium Histolyticum (Xiapex\", \"trade_name\": \"Xiapex\", \"indication\": \" Collagenase Clostridium Histolyticum (Xiapex\", \"ncpe_year\": 2011, \"eu_market\": \"2011-02-28T00:00:00\", \"company\": \"Swedish\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xiapex\", \"ta_list\": \"Dupuytren Contracture\", \"rr_status\": \"No HTA\"}, {\"id\": 2242, \"last_scrape\": \"2018-12-13T16:30:20\", \"url\": \"http://www.ncpe.ie/drugs/corifollitropin-alfa-elonva/\", \"rr_start\": \"2010-10-22T00:00:00\", \"rr_end\": \"2010-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-10-22, 2010-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Corifollitropin alfa (Elonva\", \"trade_name\": \"Elonva\", \"indication\": \"Cost-effectiveness of Corifollitropin alfa (Elonva\", \"ncpe_year\": 2010, \"eu_market\": \"2010-01-25T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2010-09-01T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/elonva\", \"ta_list\": \"Reproductive Techniques, Assisted; Ovulation Induction\", \"rr_status\": \"No HTA\"}, {\"id\": 2243, \"last_scrape\": \"2018-12-13T16:30:24\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori-for-first-line-alk-nsclc/\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2244, \"last_scrape\": \"2018-12-13T16:30:29\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori-for-ros1-nsclc/\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2245, \"last_scrape\": \"2018-12-13T16:30:34\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori/\", \"rr_start\": \"2013-01-09T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-01-09, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"For the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-01-09T00:00:00\", \"latest\": \"2015-08-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2246, \"last_scrape\": \"2018-12-13T16:30:37\", \"url\": \"http://www.ncpe.ie/drugs/cysteamine-bitartrate-procysbi/\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2015-12-01, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Cysteamine bitartrate delayed-release (Procysbi\", \"trade_name\": \"Procysbi\", \"indication\": \"Procysbi\", \"ncpe_year\": 2017, \"eu_market\": \"2013-09-05T00:00:00\", \"company\": \"Chiesi\", \"orphan\": 1, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/procysbi\", \"ta_list\": \"Cystinosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2247, \"last_scrape\": \"2018-12-13T16:30:43\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-2/\", \"rr_start\": \"2014-05-09T00:00:00\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-09, 2014-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate (Pradaxa\", \"ncpe_year\": 2014, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-09T00:00:00\", \"latest\": \"2014-06-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2248, \"last_scrape\": \"2018-12-13T16:30:51\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-for-the-prevention-of-stroke-and-systematic-embolisom-in-atrial-fibrillation/\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate (Pradaxa\", \"ncpe_year\": 2012, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2010-11-02T00:00:00\", \"latest\": \"2012-10-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2249, \"last_scrape\": \"2018-12-13T16:30:57\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-vte-prevention/\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Economic Evaluation of the Cost Effectiveness of Dabigatran Etexilate (Pradaxa\", \"ncpe_year\": 2008, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2008-07-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2250, \"last_scrape\": \"2018-12-13T16:30:59\", \"url\": \"http://www.ncpe.ie/drugs/dabrafenib-tafinlar/\", \"rr_start\": \"2013-09-11T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-11, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Dabrafenib (Tafinlar\", \"trade_name\": \"Tafinlar\", \"indication\": \"Dabrafenib (Tafinlar\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2013-09-11T00:00:00\", \"latest\": \"2014-06-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2251, \"last_scrape\": \"2018-12-13T16:31:02\", \"url\": \"http://www.ncpe.ie/drugs/daclatasvir-daklinza/\", \"rr_start\": \"2014-08-05T00:00:00\", \"rr_end\": \"2014-09-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-08-05, 2014-09-12\", \"rr_multiple\": 0, \"drug_name\": \"Daclatasvir (Daklinza\", \"trade_name\": \"Daklinza\", \"indication\": \"Daclatasvir (Daklinza\", \"ncpe_year\": 2015, \"eu_market\": \"2014-08-22T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-08-05T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/daklinza\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2252, \"last_scrape\": \"2018-12-13T16:31:08\", \"url\": \"http://www.ncpe.ie/drugs/daclizumab-zinbryta/\", \"rr_start\": \"2016-09-26T00:00:00\", \"rr_end\": \"2016-11-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-09-26, 2016-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Daclizumab (Zinbryta\", \"trade_name\": \"Zinbryta\", \"indication\": \"Daclizumab is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-07-01T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2016-09-26T00:00:00\", \"latest\": \"2018-03-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinbryta\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2253, \"last_scrape\": \"2018-12-13T16:31:12\", \"url\": \"http://www.ncpe.ie/drugs/dalbavancin-xydalba/\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-07, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Dalbavancin (Xydalba\", \"trade_name\": \"Xydalba\", \"indication\": \"Dalbavancin (Xydalba\", \"ncpe_year\": 2017, \"eu_market\": \"2015-02-19T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xydalba\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2254, \"last_scrape\": \"2018-12-13T16:31:18\", \"url\": \"http://www.ncpe.ie/drugs/dapagliflozin-forxiga/\", \"rr_start\": \"2012-10-10T00:00:00\", \"rr_end\": \"2012-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-10-10, 2012-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Dapagliflozin (Forxiga\", \"trade_name\": \"Forxiga\", \"indication\": \"Dapagliflozin (Forxiga\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-11T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-10T00:00:00\", \"latest\": \"2013-12-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2255, \"last_scrape\": \"2018-12-13T16:31:21\", \"url\": \"http://www.ncpe.ie/drugs/daratumumab-darzalex/\", \"rr_start\": \"2016-05-31T00:00:00\", \"rr_end\": \"2016-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-05-31, 2016-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Daratumumab (Darzalex\", \"trade_name\": \"Darzalex\", \"indication\": \"Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-04-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-05-31T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2256, \"last_scrape\": \"2018-12-13T16:31:25\", \"url\": \"http://www.ncpe.ie/drugs/darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-symtuza/\", \"rr_start\": \"2017-09-27T00:00:00\", \"rr_end\": \"2017-10-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-27, 2017-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza\", \"trade_name\": \"Symtuza\", \"indication\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza\", \"ncpe_year\": 2017, \"eu_market\": \"2017-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-09-27T00:00:00\", \"latest\": \"2017-10-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/symtuza\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2257, \"last_scrape\": \"2018-12-13T16:31:30\", \"url\": \"http://www.ncpe.ie/drugs/darunavir-cobicistat-rezolsta/\", \"rr_start\": \"2014-12-02T00:00:00\", \"rr_end\": \"2015-01-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-12-02, 2015-01-08\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir & cobicistat (Rezolsta\", \"trade_name\": \"Rezolsta\", \"indication\": \"Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-12-02T00:00:00\", \"latest\": \"2015-01-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2258, \"last_scrape\": \"2018-12-13T16:31:35\", \"url\": \"http://www.ncpe.ie/drugs/darvadstrocel-alofisel/\", \"rr_start\": \"2018-06-14T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF DARVADSTROCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-14, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Darvadstrocel (Alofisel\", \"trade_name\": \"Alofisel\", \"indication\": \"Darvadstrocel (Alofisel\", \"ncpe_year\": 2018, \"eu_market\": \"2018-03-23T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-06-14T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel\", \"ta_list\": \"Rectal Fistula\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2259, \"last_scrape\": \"2018-12-13T16:31:40\", \"url\": \"http://www.ncpe.ie/drugs/decitabine-dacogen/\", \"rr_start\": \"2012-11-08T00:00:00\", \"rr_end\": \"2012-12-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-08, 2012-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Decitabine (Dacogen\", \"trade_name\": \"Dacogen\", \"indication\": \"Decitabine (Dacogen\", \"ncpe_year\": 2013, \"eu_market\": \"2012-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2012-11-08T00:00:00\", \"latest\": \"2013-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2260, \"last_scrape\": \"2018-12-13T16:31:44\", \"url\": \"http://www.ncpe.ie/drugs/defibrotide-defitelio/\", \"rr_start\": \"2014-05-12T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2014-05-12, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Defibrotide (Defitelio\", \"trade_name\": \"Defitelio\", \"indication\": \"Defibrotide (Defitelio\", \"ncpe_year\": 2014, \"eu_market\": \"2013-10-18T00:00:00\", \"company\": \"Gentium\", \"orphan\": 1, \"earliest\": \"2014-05-12T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio\", \"ta_list\": \"Hepatic Veno-Occlusive Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2261, \"last_scrape\": \"2018-12-13T16:31:47\", \"url\": \"http://www.ncpe.ie/drugs/degarelix-firmagon/\", \"rr_start\": \"2009-10-15T00:00:00\", \"rr_end\": \"2009-10-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-10-15\", \"rr_multiple\": 0, \"drug_name\": \"Degarelix (Firmagon\", \"trade_name\": \"Firmagon\", \"indication\": \"Cost-effectiveness of Degarelix (Firmagon\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-17T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2009-10-15T00:00:00\", \"latest\": \"2009-10-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2262, \"last_scrape\": \"2018-12-13T16:31:52\", \"url\": \"http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-cannabidiol-thc-cbd-sativex/\", \"rr_start\": \"2018-02-12T00:00:00\", \"rr_end\": \"2018-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF SATIVEX\", \"rr_dates\": \"2018-02-12, 2018-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex\", \"trade_name\": \"Sativex\", \"indication\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-02-12T00:00:00\", \"latest\": \"2018-04-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2263, \"last_scrape\": \"2018-12-13T16:31:59\", \"url\": \"http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-thccannabidiol-cbd-sativex/\", \"rr_start\": \"2012-12-05T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-05, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol (THC) /Cannabidiol (CBD) (Sativex\", \"trade_name\": \"Sativex\", \"indication\": \"For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-12-05T00:00:00\", \"latest\": \"2014-09-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2264, \"last_scrape\": \"2018-12-13T16:32:04\", \"url\": \"http://www.ncpe.ie/drugs/denosumab-prolia/\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab (Prolia\", \"trade_name\": \"Prolia\", \"indication\": \"The Cost-effectiveness of Denosumab (Prolia\", \"ncpe_year\": 2010, \"eu_market\": \"2010-05-26T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2010-05-27T00:00:00\", \"latest\": \"2010-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prolia\", \"ta_list\": \"Bone Resorption; Osteoporosis, Postmenopausal\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2265, \"last_scrape\": \"2018-12-13T16:32:08\", \"url\": \"http://www.ncpe.ie/drugs/denosumab-xgeva-3/\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab (Xgeva\", \"trade_name\": \"Xgeva\", \"indication\": \"Cost-effectiveness of denosumab (Xgeva\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2011-08-15T00:00:00\", \"latest\": \"2011-12-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva\", \"ta_list\": \"Fractures, Bone; Neoplasm Metastasis\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2266, \"last_scrape\": \"2018-12-13T16:32:12\", \"url\": \"http://www.ncpe.ie/drugs/dexamethasone-intravitreal-implant-ozurdex/\", \"rr_start\": \"2010-11-12T00:00:00\", \"rr_end\": \"2010-12-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-11-12, 2010-12-16\", \"rr_multiple\": 0, \"drug_name\": \"Dexamethasone Intravitreal Implant (Ozurdex\", \"trade_name\": \"Ozurdex\", \"indication\": \"Cost-effectiveness of Ozurdex\", \"ncpe_year\": 2012, \"eu_market\": \"2010-07-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2010-11-12T00:00:00\", \"latest\": \"2012-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ozurdex\", \"ta_list\": \"Macular Edema; Uveitis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2267, \"last_scrape\": \"2018-12-13T16:32:15\", \"url\": \"http://www.ncpe.ie/drugs/dexmedetomidine-dexdor/\", \"rr_start\": \"2011-07-08T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-07-08, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Dexmedetomidine (Dexdor\", \"trade_name\": \"Dexdor\", \"indication\": \"Dexmedetomidine (Dexdor\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-15T00:00:00\", \"company\": \"Orion\", \"orphan\": 0, \"earliest\": \"2011-07-08T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dexdor\", \"ta_list\": \"Conscious Sedation\", \"rr_status\": \"No HTA\"}, {\"id\": 2268, \"last_scrape\": \"2018-12-13T16:32:21\", \"url\": \"http://www.ncpe.ie/drugs/dienogest-visanne/\", \"rr_start\": \"2010-09-17T00:00:00\", \"rr_end\": \"2010-10-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-09-17, 2010-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Dienogest (Visanne\", \"trade_name\": \"Visanne\", \"indication\": \"Dienogest (Visanne\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-09-17T00:00:00\", \"latest\": \"2010-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2269, \"last_scrape\": \"2018-12-13T16:32:24\", \"url\": \"http://www.ncpe.ie/drugs/dimethyl-fumarate-skilarence/\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-01-15, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate (Skilarence\", \"trade_name\": \"Skilarence\", \"indication\": \"Dimethyl fumarate (Skilarence\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"Almirall\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/skilarence\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2270, \"last_scrape\": \"2018-12-13T16:32:26\", \"url\": \"http://www.ncpe.ie/drugs/dimethyl-fumarate-tecfidera/\", \"rr_start\": \"2014-02-04T00:00:00\", \"rr_end\": \"2014-03-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-02-04, 2014-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate (Tecfidera\", \"trade_name\": \"Tecfidera\", \"indication\": \"Dimethyl fumarate (Tecfidera\", \"ncpe_year\": 2015, \"eu_market\": \"2014-01-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-02-04T00:00:00\", \"latest\": \"2015-04-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2271, \"last_scrape\": \"2018-12-13T16:32:29\", \"url\": \"http://www.ncpe.ie/drugs/dinutuximab-beta-dinutuximab-beta-eusa/\", \"rr_start\": \"2017-10-19T00:00:00\", \"rr_end\": \"2017-11-23T00:00:00\", \"rr_outcome\": \"FOLLOWING ASSESSMENT OF THE APPLICANT\", \"rr_dates\": \"2017-10-19, 2017-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Dinutuximab beta (Qarziba\", \"trade_name\": \"Qarziba\", \"indication\": \"Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients ? 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-10-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2272, \"last_scrape\": \"2018-12-13T16:32:34\", \"url\": \"http://www.ncpe.ie/drugs/dolutegravir-rilpivirine-juluca/\", \"rr_start\": \"2018-06-08T00:00:00\", \"rr_end\": \"2018-07-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT JULUCA\", \"rr_dates\": \"2018-06-08, 2018-07-12\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir/Rilpivirine (Juluca\", \"trade_name\": \"Juluca\", \"indication\": \"Dolutegravir/rilpivirine (Juluca\", \"ncpe_year\": 2018, \"eu_market\": \"2018-05-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2018-06-08T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/juluca\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2273, \"last_scrape\": \"2018-12-13T16:32:36\", \"url\": \"http://www.ncpe.ie/drugs/dolutegravir-tivicay/\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-10, 2014-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir (Tivicay\", \"trade_name\": \"Tivicay\", \"indication\": \"Dolutegravir (Tivicay\", \"ncpe_year\": 2014, \"eu_market\": \"2014-01-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2274, \"last_scrape\": \"2018-12-13T16:32:39\", \"url\": \"http://www.ncpe.ie/drugs/dronedarone-multaq/\", \"rr_start\": \"2010-01-12T00:00:00\", \"rr_end\": \"2010-01-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-01-12, 2010-01-01\", \"rr_multiple\": 0, \"drug_name\": \"Dronedarone (Multaq\", \"trade_name\": \"Multaq\", \"indication\": \"Rapid Review\", \"ncpe_year\": 2010, \"eu_market\": \"2009-11-25T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2010-01-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"No HTA\"}, {\"id\": 2275, \"last_scrape\": \"2018-12-13T16:32:42\", \"url\": \"http://www.ncpe.ie/drugs/dulaglutide-trulicity/\", \"rr_start\": \"2015-03-04T00:00:00\", \"rr_end\": \"2015-04-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-03-04, 2015-04-29\", \"rr_multiple\": 0, \"drug_name\": \"Dulaglutide (Trulicity\", \"trade_name\": \"Trulicity\", \"indication\": \"Dulaglutide is indicated as monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2015-03-04T00:00:00\", \"latest\": \"2015-04-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2276, \"last_scrape\": \"2018-12-13T16:32:46\", \"url\": \"http://www.ncpe.ie/drugs/dupilumab-dupixent/\", \"rr_start\": \"2017-11-13T00:00:00\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-13, 2017-11-24\", \"rr_multiple\": 0, \"drug_name\": \"Dupilumab (Dupixent\", \"trade_name\": \"Dupixent\", \"indication\": \"Dupilumab (Dupixent\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-27T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-11-13T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent\", \"ta_list\": \"Dermatitis, Atopic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2277, \"last_scrape\": \"2018-12-13T16:32:53\", \"url\": \"http://www.ncpe.ie/drugs/eculizumab-soliris/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Eculizumab (Soliris\", \"trade_name\": \"Soliris\", \"indication\": \"An Economic Evaluation of Eculizumab (Soliris\", \"ncpe_year\": 2013, \"eu_market\": \"2007-06-20T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2013-10-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/soliris\", \"ta_list\": \"Hemoglobinuria, Paroxysmal\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2278, \"last_scrape\": \"2018-12-13T16:32:55\", \"url\": \"http://www.ncpe.ie/drugs/edoxaban-lixiana/\", \"rr_start\": \"2015-06-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-06-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Edoxaban (Lixiana\", \"trade_name\": \"Lixiana\", \"indication\": \"Edoxaban is indicated for the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2015-06-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana\", \"ta_list\": \"Stroke; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2279, \"last_scrape\": \"2018-12-13T16:33:00\", \"url\": \"http://www.ncpe.ie/drugs/elbasvirgrazoprevir-zepatier-2/\", \"rr_start\": \"2016-08-10T00:00:00\", \"rr_end\": \"2016-10-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-08-10, 2016-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Elbasvir/Grazoprevir (Zepatier\", \"trade_name\": \"Zepatier\", \"indication\": \"Elbasvir 50mg/100mg grazoprevir (EBR/GZR)(Zepatier\", \"ncpe_year\": 2016, \"eu_market\": \"2016-07-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-10T00:00:00\", \"latest\": \"2016-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2280, \"last_scrape\": \"2018-12-13T16:33:03\", \"url\": \"http://www.ncpe.ie/drugs/eliglustat-cerdelga/\", \"rr_start\": \"2016-03-21T00:00:00\", \"rr_end\": \"2016-05-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-03-21, 2016-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Eliglustat (Cerdelga\", \"trade_name\": \"Cerdelga\", \"indication\": \"Eliglustat (Cerdelga\", \"ncpe_year\": 2018, \"eu_market\": \"2015-01-19T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 1, \"earliest\": \"2016-03-21T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga\", \"ta_list\": \"Gaucher Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2281, \"last_scrape\": \"2018-12-13T16:33:05\", \"url\": \"http://www.ncpe.ie/drugs/elosulfase-alfa-vimizim/\", \"rr_start\": \"2015-03-30T00:00:00\", \"rr_end\": \"2015-05-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-03-30, 2015-05-08\", \"rr_multiple\": 0, \"drug_name\": \"Elosulfase alfa (Vimizim\", \"trade_name\": \"Vimizim\", \"indication\": \"Elosulfase alfa (Vimzim\", \"ncpe_year\": 2018, \"eu_market\": \"2014-04-27T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2015-03-30T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vimizim\", \"ta_list\": \"Mucopolysaccharidosis IV\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2282, \"last_scrape\": \"2018-12-13T16:33:12\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade-2/\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-02-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-01-10, 2014-02-13\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Eltrombopag (Revolade\", \"ncpe_year\": 2014, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-02-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"id\": 2283, \"last_scrape\": \"2018-12-13T16:33:17\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade-3/\", \"rr_start\": \"2016-02-05T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-02-05, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Revolade\", \"ncpe_year\": 2016, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-02-05T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"id\": 2284, \"last_scrape\": \"2018-12-13T16:33:23\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade/\", \"rr_start\": \"2017-12-04T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, WHICH IS NOT COMPARABLE WITH CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2017-12-04, 2018-04-16, 2017-12-01\", \"rr_multiple\": 1, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Cost-effectiveness of eltrombopag (Revolade\", \"ncpe_year\": 2018, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-07-30T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2285, \"last_scrape\": \"2018-12-13T16:33:26\", \"url\": \"http://www.ncpe.ie/drugs/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya/\", \"rr_start\": \"2015-11-24T00:00:00\", \"rr_end\": \"2016-01-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-11-24, 2016-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide (Genvoya\", \"trade_name\": \"Genvoya\", \"indication\": \"Genvoya\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2015-11-24T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2286, \"last_scrape\": \"2018-12-13T16:33:32\", \"url\": \"http://www.ncpe.ie/drugs/empagliflozin-jardiance/\", \"rr_start\": \"2014-05-22T00:00:00\", \"rr_end\": \"2014-06-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-22, 2014-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Empagliflozin (Jardiance\", \"trade_name\": \"Jardiance\", \"indication\": \"Add-on combination therapy \", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-22T00:00:00\", \"latest\": \"2014-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2287, \"last_scrape\": \"2018-12-13T16:33:37\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabine-tenofovir-disoproxil-fumarate-truvada/\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-07-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-12, 2017-07-18\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine / tenofovir disoproxil fumarate (Truvada\", \"trade_name\": \"Truvada\", \"indication\": \"Truvada\", \"ncpe_year\": 2017, \"eu_market\": \"2005-02-20T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-07-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/truvada\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2288, \"last_scrape\": \"2018-12-13T16:33:43\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabine-tenovir-disoproxil-teva/\", \"rr_start\": \"2017-12-11T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-12-11, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir disoproxil (TEVA\", \"trade_name\": \"TEVA\", \"indication\": \"Emtricitabine/tenofovir disoproxil (TEVA\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-12-11T00:00:00\", \"latest\": \"2017-12-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2289, \"last_scrape\": \"2018-12-13T16:33:48\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabinetenofovir-alafenamide-descovy/\", \"rr_start\": \"2016-04-26T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-04-26, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir alafenamide (Descovy\", \"trade_name\": \"Descovy\", \"indication\": \"Descovy\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-04-26T00:00:00\", \"latest\": \"2016-04-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/descovy\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2290, \"last_scrape\": \"2018-12-13T16:33:52\", \"url\": \"http://www.ncpe.ie/drugs/enzalutamide-xtandi/\", \"rr_start\": \"2013-06-28T00:00:00\", \"rr_end\": \"2013-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-28, 2013-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Enzalutamide (Xtandi\", \"trade_name\": \"Xtandi\", \"indication\": \"Enzalutamide (Xtandi\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2013-06-28T00:00:00\", \"latest\": \"2014-04-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2291, \"last_scrape\": \"2018-12-13T16:33:59\", \"url\": \"http://www.ncpe.ie/drugs/epoprostenol-veletri/\", \"rr_start\": \"2016-12-13T00:00:00\", \"rr_end\": \"2017-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-12-13, 2017-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Epoprostenol (Veletri\", \"trade_name\": \"Veletri\", \"indication\": \"Veletri\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-12-13T00:00:00\", \"latest\": \"2017-02-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2292, \"last_scrape\": \"2018-12-13T16:34:03\", \"url\": \"http://www.ncpe.ie/drugs/erenumab-aimovig/\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-15T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF ERENUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-19, 2018-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Erenumab (Aimovig\", \"trade_name\": \"Aimovig\", \"indication\": \"Erenumab (Aimovig\", \"ncpe_year\": 2018, \"eu_market\": \"2018-07-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig\", \"ta_list\": \"Migraine Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2293, \"last_scrape\": \"2018-12-13T16:34:07\", \"url\": \"http://www.ncpe.ie/drugs/eribulin-halaven/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-03-11, 2011-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Eribulin (Halaven\", \"trade_name\": \"Halaven\", \"indication\": \"Eribulin (Halaven\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2011-02-09T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/halaven\", \"ta_list\": \"Breast Neoplasms; Liposarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2294, \"last_scrape\": \"2018-12-13T16:34:09\", \"url\": \"http://www.ncpe.ie/drugs/eslicarbazepine-zebinix/\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-08-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2009-09-01, 2009-08-01\", \"rr_multiple\": 0, \"drug_name\": \"Eslicarbazepine (Zebinix\", \"trade_name\": \"Zebinix\", \"indication\": \"Eslicarbazepine (Zebinix\", \"ncpe_year\": 2009, \"eu_market\": \"2009-04-21T00:00:00\", \"company\": \"BIAL\", \"orphan\": 0, \"earliest\": \"2009-08-01T00:00:00\", \"latest\": \"2009-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2295, \"last_scrape\": \"2018-12-13T16:34:12\", \"url\": \"http://www.ncpe.ie/drugs/etanercept-benepali/\", \"rr_start\": \"2016-03-22T00:00:00\", \"rr_end\": \"2016-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-03-22, 2016-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Etanercept (Benepali\", \"trade_name\": \"Benepali\", \"indication\": \"Benepali\", \"ncpe_year\": 2016, \"eu_market\": \"2016-01-13T00:00:00\", \"company\": \"Samsung\", \"orphan\": 0, \"earliest\": \"2016-03-22T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/benepali\", \"ta_list\": \"Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis\", \"rr_status\": \"No HTA\"}, {\"id\": 2296, \"last_scrape\": \"2018-12-13T16:34:15\", \"url\": \"http://www.ncpe.ie/drugs/etelcalcetide-parsabiv/\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-06-14, 2017-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Etelcalcetide (Parsabiv\", \"trade_name\": \"Parsabiv\", \"indication\": \"Etelcalcitide (Parsabiv\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-11T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/parsabiv\", \"ta_list\": \"Hyperparathyroidism, Secondary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2297, \"last_scrape\": \"2018-12-13T16:34:21\", \"url\": \"http://www.ncpe.ie/drugs/eurartesim-piperaquine-tetraphosphatedihidroartemisinin/\", \"rr_start\": \"2012-05-22T00:00:00\", \"rr_end\": \"2012-05-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-05-22, 2012-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Piperaquine tetraphosphate/dihidroartemisinin (Eurartesim\", \"trade_name\": \"Eurartesim\", \"indication\": \"Eurartesim\", \"ncpe_year\": 2012, \"eu_market\": \"2011-10-27T00:00:00\", \"company\": \"Alfasigma\", \"orphan\": 0, \"earliest\": \"2012-05-22T00:00:00\", \"latest\": \"2012-05-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eurartesim\", \"ta_list\": \"Malaria\", \"rr_status\": \"No HTA\"}, {\"id\": 2298, \"last_scrape\": \"2018-12-13T16:34:24\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-afinitor/\", \"rr_start\": \"2012-09-21T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-09-21, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Afinitor\", \"trade_name\": \"Afinitor\", \"indication\": \"Treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor\", \"ncpe_year\": 2012, \"eu_market\": \"2009-08-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-09-21T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/afinitor\", \"ta_list\": \"Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2299, \"last_scrape\": \"2018-12-13T16:34:26\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-votubia-for-refractory-seizures-associated-with-tuberous-sclerosis-complex-tsc/\", \"rr_start\": \"2017-04-19T00:00:00\", \"rr_end\": \"2017-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-04-19, 2017-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Votubia \", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus (Votubia\", \"ncpe_year\": 2017, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2017-04-19T00:00:00\", \"latest\": \"2017-04-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/votubia\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2300, \"last_scrape\": \"2018-12-13T16:34:29\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-votubia/\", \"rr_start\": \"2011-09-30T00:00:00\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-09-30, 2011-10-14\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Votubia\", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus (Votubia\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2011-09-30T00:00:00\", \"latest\": \"2011-10-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/votubia\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2301, \"last_scrape\": \"2018-12-13T16:34:36\", \"url\": \"http://www.ncpe.ie/drugs/evolocumab-repatha/\", \"rr_start\": \"\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Evolocumab (Repatha\", \"trade_name\": \"Repatha\", \"indication\": \"Evolocumab (Repatha\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-17T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-01-01T00:00:00\", \"latest\": \"2018-05-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/repatha\", \"ta_list\": \"Dyslipidemias; Hypercholesterolemia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2302, \"last_scrape\": \"2018-12-13T16:34:41\", \"url\": \"http://www.ncpe.ie/drugs/exenatide-bydureon/\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Exenatide (Bydureon\", \"trade_name\": \"Bydureon\", \"indication\": \"Exenatide (Bydureon\", \"ncpe_year\": 2011, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2303, \"last_scrape\": \"2018-12-13T16:34:44\", \"url\": \"http://www.ncpe.ie/drugs/fampridine-fampyra/\", \"rr_start\": \"2011-09-11T00:00:00\", \"rr_end\": \"2011-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-09-11, 2011-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Fampridine (Fampyra\", \"trade_name\": \"Fampyra\", \"indication\": \"Fampridine (Fampyra\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-20T00:00:00\", \"company\": \"Blogen\", \"orphan\": 0, \"earliest\": \"2011-09-01T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fampyra\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2304, \"last_scrape\": \"2018-12-13T16:34:48\", \"url\": \"http://www.ncpe.ie/drugs/ferric-maltol-feraccru_/\", \"rr_start\": \"2016-08-12T00:00:00\", \"rr_end\": \"2016-09-06T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-08-12, 2016-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Ferric maltol (Feraccru\", \"trade_name\": \"Feraccru\", \"indication\": \"Ferric maltol indicated for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) in adult patients.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Shield\", \"orphan\": 0, \"earliest\": \"2016-08-12T00:00:00\", \"latest\": \"2016-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/feraccru\", \"ta_list\": \"Anemia, Iron-Deficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2305, \"last_scrape\": \"2018-12-13T16:34:51\", \"url\": \"http://www.ncpe.ie/drugs/fidaxomicin-dificlir/\", \"rr_start\": \"2012-03-09T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2012-03-09, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Fidaxomicin (Dificlir\", \"trade_name\": \"Dificlir\", \"indication\": \"Fidaxomicin is indicated for the treatment of CDI also known as CDAD in adult patients.\", \"ncpe_year\": 2013, \"eu_market\": \"2011-12-05T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-03-09T00:00:00\", \"latest\": \"2013-02-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dificlir\", \"ta_list\": \"Clostridium Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2306, \"last_scrape\": \"2018-12-13T16:34:56\", \"url\": \"http://www.ncpe.ie/drugs/fingolimod-gilenya-4/\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2010-12-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-01-10, 2010-12-03\", \"rr_multiple\": 0, \"drug_name\": \"Fingolimod (Gilenya\", \"trade_name\": \"Gilenya\", \"indication\": \"Cost effectiveness of Fingolimod (Gilenya\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2010-12-03T00:00:00\", \"latest\": \"2011-09-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2307, \"last_scrape\": \"2018-12-13T16:35:01\", \"url\": \"http://www.ncpe.ie/drugs/fluocinolone-acetonide-iluvien/\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-02-15, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Fluocinolone acetonide (Iluvien\", \"trade_name\": \"Iluvien\", \"indication\": \"Iluvien\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2308, \"last_scrape\": \"2018-12-13T16:35:05\", \"url\": \"http://www.ncpe.ie/drugs/fluticasone-furoate-umeclidinium-vilantero-trelegy-ellipta/\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT TRELEGY\", \"rr_dates\": \"2018-04-30, 2018-06-18\", \"rr_multiple\": 0, \"drug_name\": \"Fluticasone furoate/ umeclidinium/ vilantero (Trelegy\", \"trade_name\": \"Trelegy Ellipta\", \"indication\": \"Trelegy\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-15T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"Reimbursement without HTA\"}, {\"id\": 2309, \"last_scrape\": \"2018-12-13T16:35:09\", \"url\": \"http://www.ncpe.ie/drugs/follitropin-delta-rekovelle/\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-07-25, 2017-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Follitropin delta (Rekovelle\", \"trade_name\": \"Rekovelle\", \"indication\": \"Follitropin delta (Rekovelle \", \"ncpe_year\": 2019, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2019-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rekovelle\", \"ta_list\": \"Anovulation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2310, \"last_scrape\": \"2018-12-13T16:35:12\", \"url\": \"http://www.ncpe.ie/drugs/gefitinib-iressa/\", \"rr_start\": \"\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Gefitinib (Iressa\", \"trade_name\": \"Iressa\", \"indication\": \"A review of the economic evaluation of oral gefitinib (Iressa\", \"ncpe_year\": 2010, \"eu_market\": \"2009-06-24T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-16T00:00:00\", \"latest\": \"2010-11-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/iressa\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2311, \"last_scrape\": \"2018-12-13T16:35:15\", \"url\": \"http://www.ncpe.ie/drugs/gemtuzumab-ozogamicin-mylotarg/\", \"rr_start\": \"2018-06-21T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF GEMTUZUMAB OZOGAMICIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-21, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Gemtuzumab ozogamicin (Mylotarg\", \"trade_name\": \"Mylotarg\", \"indication\": \"Gemtuzumab ozogamicin (Mylotarg\", \"ncpe_year\": 2018, \"eu_market\": \"2018-04-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-06-21T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2312, \"last_scrape\": \"2018-12-13T16:35:19\", \"url\": \"http://www.ncpe.ie/drugs/glecaprevirpibrentasvir-maviret/\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-07-11, 2017-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glecaprevir/Pibrentasvir (Maviret\", \"trade_name\": \"Maviret\", \"indication\": \"Glecaprevir/pibrentasvir (Maviret\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/maviret\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2313, \"last_scrape\": \"2018-12-13T16:35:25\", \"url\": \"http://www.ncpe.ie/drugs/glucosamine-sulfate-dona/\", \"rr_start\": \"\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Glucosamine sulfate (Dona\", \"trade_name\": \"Dona\", \"indication\": \"Economic evalution of glucosamine sulfate (Dona\", \"ncpe_year\": 2009, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2009-04-01T00:00:00\", \"latest\": \"2009-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2314, \"last_scrape\": \"2018-12-13T16:35:32\", \"url\": \"http://www.ncpe.ie/drugs/glycerol-phenylbutyrate-ravicti/\", \"rr_start\": \"2018-03-26T00:00:00\", \"rr_end\": \"2018-06-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT GLYCEROL PHENYLBUTYRATE (RAVICTI\", \"rr_dates\": \"2018-03-26, 2018-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Glycerol Phenylbutyrate (Ravicti\", \"trade_name\": \"Ravicti\", \"indication\": \"Glycerol phenylbutyrate (Ravicti\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-26T00:00:00\", \"company\": \"Horizon\", \"orphan\": 1, \"earliest\": \"2018-03-26T00:00:00\", \"latest\": \"2018-06-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti\", \"ta_list\": \"Urea Cycle Disorders, Inborn\", \"rr_status\": \"Reimbursement without HTA\"}, {\"id\": 2315, \"last_scrape\": \"2018-12-13T16:35:38\", \"url\": \"http://www.ncpe.ie/drugs/glycopyrronium-bromide-seebri-breezhaler/\", \"rr_start\": \"2012-08-12T00:00:00\", \"rr_end\": \"2012-08-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-08-12, 2012-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide (Seebri Breezhaler\", \"trade_name\": \"Seebri Breezhaler\", \"indication\": \"Seebri Breezhaler\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-08-12T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"id\": 2316, \"last_scrape\": \"2018-12-13T16:35:40\", \"url\": \"http://www.ncpe.ie/drugs/glypyrronium-bromide-sialanar/\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-07, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide (Sialanar\", \"trade_name\": \"Sialanar\", \"indication\": \"Glycopyrronium bromide (Sialanar\", \"ncpe_year\": 2017, \"eu_market\": \"2016-09-15T00:00:00\", \"company\": \"Proveca\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar\", \"ta_list\": \"Sialorrhea\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2317, \"last_scrape\": \"2018-12-13T16:35:47\", \"url\": \"http://www.ncpe.ie/drugs/golimumab-simponi-2/\", \"rr_start\": \"2013-10-11T00:00:00\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-10-11, 2013-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab (Simponi\", \"trade_name\": \"Simponi\", \"indication\": \"Golimumab is indicated for the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments.\", \"ncpe_year\": 2013, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2013-10-11T00:00:00\", \"latest\": \"2013-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/simponi\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"id\": 2318, \"last_scrape\": \"2018-12-13T16:35:54\", \"url\": \"http://www.ncpe.ie/drugs/golimumab-simponi/\", \"rr_start\": \"\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab (Simponi\", \"trade_name\": \"Simponi\", \"indication\": \"Cost-effectiveness of golimumab (Simponi\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2009-11-20T00:00:00\", \"latest\": \"2010-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/simponi\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2319, \"last_scrape\": \"2018-12-13T16:35:56\", \"url\": \"http://www.ncpe.ie/drugs/grass-pollen-allergen-extract-oralair/\", \"rr_start\": \"2011-10-11T00:00:00\", \"rr_end\": \"2011-09-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-10-11, 2011-09-26\", \"rr_multiple\": 0, \"drug_name\": \"Grass pollen allergen extract (Oralair\", \"trade_name\": \"Oralair\", \"indication\": \" Grass pollen allegen extract (Oralair\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-09-26T00:00:00\", \"latest\": \"2011-10-01T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2320, \"last_scrape\": \"2018-12-13T16:36:00\", \"url\": \"http://www.ncpe.ie/drugs/guanfacine-hydrochloride-intuniv/\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-01, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Guanfacine hydrochloride (Intuniv\", \"trade_name\": \"Intuniv\", \"indication\": \"Intuniv\", \"ncpe_year\": 2015, \"eu_market\": \"2015-09-17T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/intuniv\", \"ta_list\": \"Attention Deficit Disorder with Hyperactivity\", \"rr_status\": \"No HTA\"}, {\"id\": 2321, \"last_scrape\": \"2018-12-13T16:36:02\", \"url\": \"http://www.ncpe.ie/drugs/guselkumab-tremfya/\", \"rr_start\": \"2017-12-01T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-12-01, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Guselkumab (Tremfya\", \"trade_name\": \"Tremfya\", \"indication\": \"Guselkumab (Tremfya\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-10T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-12-01T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2322, \"last_scrape\": \"2018-12-13T16:36:07\", \"url\": \"http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-a1pi-prolastin/\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-06-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-05, 2017-06-08\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor (A1PI) (Prolastin\", \"trade_name\": \"Prolastin\", \"indication\": \"Human A1PI (Prolastin \", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-06-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2323, \"last_scrape\": \"2018-12-13T16:36:14\", \"url\": \"http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-respreeza/\", \"rr_start\": \"2016-01-20T00:00:00\", \"rr_end\": \"2016-02-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-20, 2016-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor (Respreeza\", \"trade_name\": \"Respreeza\", \"indication\": \"Respreeza\", \"ncpe_year\": 2017, \"eu_market\": \"2015-08-20T00:00:00\", \"company\": \"CSL\", \"orphan\": 0, \"earliest\": \"2016-01-20T00:00:00\", \"latest\": \"2017-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza\", \"ta_list\": \"Genetic Diseases, Inborn; Lung Diseases\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2324, \"last_scrape\": \"2018-12-13T16:36:17\", \"url\": \"http://www.ncpe.ie/drugs/hyaluronic-acid-and-co-enzyme-q10-visuxl/\", \"rr_start\": \"2017-11-06T00:00:00\", \"rr_end\": \"2017-11-30T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-11-06, 2017-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Hyaluronic acid and co enzyme Q10 (VisuXL\", \"trade_name\": \"VisuXL\", \"indication\": \"Cross linked hyaluronic acid and co enzyme Q10 (VisuXL\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-11-06T00:00:00\", \"latest\": \"2017-11-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2325, \"last_scrape\": \"2018-12-13T16:36:22\", \"url\": \"http://www.ncpe.ie/drugs/hydrocortisone-plenadren/\", \"rr_start\": \"2017-11-08T00:00:00\", \"rr_end\": \"2017-11-01T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-11-08, 2018-01-11, 2017-11-01\", \"rr_multiple\": 1, \"drug_name\": \"Modified Release Hydrocortisone  (Plenadren\", \"trade_name\": \"Plenadren\", \"indication\": \"Modified release hydrocortisone (Plenadren\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-03T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2018-01-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/plenadren\", \"ta_list\": \"Adrenal Insufficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2326, \"last_scrape\": \"2018-12-13T16:36:27\", \"url\": \"http://www.ncpe.ie/drugs/hydroxcarbamide-siklos/\", \"rr_start\": \"2011-08-22T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-08-22, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Hydroxycarbamide (Siklos\", \"trade_name\": \"Siklos\", \"indication\": \" Hydroxycarbamide (Siklos\", \"ncpe_year\": 2011, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"Addmedica\", \"orphan\": 1, \"earliest\": \"2011-08-22T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/siklos\", \"ta_list\": \"Anemia, Sickle Cell\", \"rr_status\": \"No HTA\"}, {\"id\": 2327, \"last_scrape\": \"2018-12-13T16:36:32\", \"url\": \"http://www.ncpe.ie/drugs/ibrutinib-imbruivca-for-previously-untreated-cll/\", \"rr_start\": \"2016-08-02T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-08-02, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib (Imbruvica\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib (Imbruvica\", \"ncpe_year\": 2016, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-08-02T00:00:00\", \"latest\": \"2016-08-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2328, \"last_scrape\": \"2018-12-13T16:36:36\", \"url\": \"http://www.ncpe.ie/drugs/ibrutinib-imbruvica-for-mcl/\", \"rr_start\": \"2014-11-07T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-11-07, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib (Imbruvica\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib (Imbruvica\", \"ncpe_year\": 2015, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-11-07T00:00:00\", \"latest\": \"2015-10-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2329, \"last_scrape\": \"2018-12-13T16:36:40\", \"url\": \"http://www.ncpe.ie/drugs/icatibant-firazyr/\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Icatibant (Firazyr\", \"trade_name\": \"Firazyr\", \"indication\": \"Icatibant (Firazyr\", \"ncpe_year\": 2013, \"eu_market\": \"2008-07-11T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"id\": 2330, \"last_scrape\": \"2018-12-13T16:36:43\", \"url\": \"http://www.ncpe.ie/drugs/idarucizumab-praxbind/\", \"rr_start\": \"2015-12-11T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-11, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Idarucizumab (Praxbind\", \"trade_name\": \"Praxbind\", \"indication\": \"Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required:\", \"ncpe_year\": 2015, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-12-11T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/praxbind\", \"ta_list\": \"Hemorrhage\", \"rr_status\": \"No HTA\"}, {\"id\": 2331, \"last_scrape\": \"2018-12-13T16:36:50\", \"url\": \"http://www.ncpe.ie/drugs/idebenone-raxone/\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-04-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-10, 2016-04-14\", \"rr_multiple\": 0, \"drug_name\": \"Idebenone (Raxone\", \"trade_name\": \"Raxone\", \"indication\": \"Raxone\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-08T00:00:00\", \"company\": \"Santhera\", \"orphan\": 1, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2018-08-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/raxone\", \"ta_list\": \"Optic Atrophy, Hereditary, Leber\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2332, \"last_scrape\": \"2018-12-13T16:36:56\", \"url\": \"http://www.ncpe.ie/drugs/idelalisib-zydelig/\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2014-12-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-08, 2014-12-30\", \"rr_multiple\": 0, \"drug_name\": \"Idelalisib (Zydelig\", \"trade_name\": \"Zydelig\", \"indication\": \"Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2016-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2333, \"last_scrape\": \"2018-12-13T16:36:59\", \"url\": \"http://www.ncpe.ie/drugs/imiquimod-zyclara/\", \"rr_start\": \"2013-09-10T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-09-10, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Imiquimod 3.75% (Zyclara\", \"trade_name\": \"Zyclara\", \"indication\": \"Imiquimod 3.75%(Zyclara\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Meda\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara\", \"ta_list\": \"Keratosis; Keratosis, Actinic\", \"rr_status\": \"No HTA\"}, {\"id\": 2334, \"last_scrape\": \"2018-12-13T16:37:01\", \"url\": \"http://www.ncpe.ie/drugs/incobotulinum-toxin-type-a-xeomin/\", \"rr_start\": \"2014-02-07T00:00:00\", \"rr_end\": \"2014-03-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-07, 2014-03-05\", \"rr_multiple\": 0, \"drug_name\": \"Incobotulinum Toxin Type A (Xeomin\", \"trade_name\": \"Xeomin\", \"indication\": \"Incobotulinum Toxin Type A (Xeomin\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-02-07T00:00:00\", \"latest\": \"2014-03-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2335, \"last_scrape\": \"2018-12-13T16:37:04\", \"url\": \"http://www.ncpe.ie/drugs/indacaterol-onbrez/\", \"rr_start\": \"2010-01-15T00:00:00\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-01-15\", \"rr_multiple\": 0, \"drug_name\": \"Indacaterol (Onbrez\", \"trade_name\": \"Onbrez\", \"indication\": \"Review of Indacaterol (Onbrez\", \"ncpe_year\": 2010, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-01-15T00:00:00\", \"latest\": \"2010-01-15T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2336, \"last_scrape\": \"2018-12-13T16:37:07\", \"url\": \"http://www.ncpe.ie/drugs/infliximab-inflectra/\", \"rr_start\": \"\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Infliximab (Inflectra\", \"trade_name\": \"Inflectra\", \"indication\": \"Inflectra\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2337, \"last_scrape\": \"2018-12-13T16:37:09\", \"url\": \"http://www.ncpe.ie/drugs/inotuzumab-ozogamicin-besponsa/\", \"rr_start\": \"2017-07-03T00:00:00\", \"rr_end\": \"2017-09-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-03, 2017-09-08\", \"rr_multiple\": 0, \"drug_name\": \"Inotuzumab ozogamicin (Besponsa\", \"trade_name\": \"Besponsa\", \"indication\": \"Inotuzumab ozogamicin (Besponsa\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2017-07-03T00:00:00\", \"latest\": \"2018-09-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2338, \"last_scrape\": \"2018-12-13T16:37:16\", \"url\": \"http://www.ncpe.ie/drugs/insulin-aspart-fiasp/\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-05-17, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart (Fiasp\", \"trade_name\": \"Fiasp\", \"indication\": \"Insulin aspart (Fiasp\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-09T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fiasp\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"No HTA\"}, {\"id\": 2339, \"last_scrape\": \"2018-12-13T16:37:21\", \"url\": \"http://www.ncpe.ie/drugs/insulin-aspart-novorapid-flextouch/\", \"rr_start\": \"2014-07-22T00:00:00\", \"rr_end\": \"2014-08-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2014-07-22, 2014-08-28\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart (NovoRapid\", \"trade_name\": \"NovoRapid FlexTouch\", \"indication\": \"Insulin aspart (NovoRapid\", \"ncpe_year\": 2014, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2014-07-22T00:00:00\", \"latest\": \"2014-08-28T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2340, \"last_scrape\": \"2018-12-13T16:37:25\", \"url\": \"http://www.ncpe.ie/drugs/insulin-degludec-tresiba/\", \"rr_start\": \"2012-12-17T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-17, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Degludec (Tresiba\", \"trade_name\": \"Tresiba\", \"indication\": \"Treatment of diabetes mellitus\", \"ncpe_year\": 2015, \"eu_market\": \"2013-01-20T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2012-12-17T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2341, \"last_scrape\": \"2018-12-13T16:37:30\", \"url\": \"http://www.ncpe.ie/drugs/insulin-degludecliraglutide-ideglira-xultophy/\", \"rr_start\": \"2016-09-19T00:00:00\", \"rr_end\": \"2016-10-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-09-19, 2016-10-17\", \"rr_multiple\": 0, \"drug_name\": \"Insulin degludec/liraglutide (IDegLira) (Xultophy\", \"trade_name\": \"Xultophy\", \"indication\": \"IDegLira is indicated for the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2016-09-19T00:00:00\", \"latest\": \"2016-10-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xultophy\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2342, \"last_scrape\": \"2018-12-13T16:37:36\", \"url\": \"http://www.ncpe.ie/drugs/insulin-glargine-abasaglar/\", \"rr_start\": \"2015-09-04T00:00:00\", \"rr_end\": \"2015-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-09-04, 2015-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine (Abasaglar\", \"trade_name\": \"Abasaglar\", \"indication\": \"Abasaglar\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-09-04T00:00:00\", \"latest\": \"2015-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2343, \"last_scrape\": \"2018-12-13T16:37:40\", \"url\": \"http://www.ncpe.ie/drugs/insulin-glargine-u300-toujeo/\", \"rr_start\": \"2015-05-14T00:00:00\", \"rr_end\": \"2015-07-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2015-05-14, 2015-07-02\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine U300 (Toujeo\", \"trade_name\": \"Toujeo\", \"indication\": \"Toujeo\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-05-14T00:00:00\", \"latest\": \"2015-07-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2344, \"last_scrape\": \"2018-12-13T16:37:43\", \"url\": \"http://www.ncpe.ie/drugs/ipilimumab-yervoy/\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Ipilimumab (Yervoy\", \"trade_name\": \"Yervoy\", \"indication\": \"Pharmacoeconomic evaluation of Ipilimumab (Yervoy\", \"ncpe_year\": 2013, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2013-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2345, \"last_scrape\": \"2018-12-13T16:37:49\", \"url\": \"http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-diafer/\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron (III) isomaltoside 1000 (Diafer\", \"trade_name\": \"Diafer\", \"indication\": \"Diafer\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2346, \"last_scrape\": \"2018-12-13T16:37:52\", \"url\": \"http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-monover/\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron (III) isomaltoside 1000 (Monover\", \"trade_name\": \"Monover\", \"indication\": \"Monover\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2347, \"last_scrape\": \"2018-12-13T16:38:02\", \"url\": \"http://www.ncpe.ie/drugs/iron-isomaltoside-1000-monover/\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2011-02-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-01-10, 2011-02-02\", \"rr_multiple\": 0, \"drug_name\": \"Iron isomaltoside 1000 (MonoVer\", \"trade_name\": \"MonoVer\", \"indication\": \"MonoVer is indicated for the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-01-10T00:00:00\", \"latest\": \"2011-02-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2348, \"last_scrape\": \"2018-12-13T16:38:07\", \"url\": \"http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-invasive-aspergillosis/\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole (Cresemba\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole (Cresemba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2349, \"last_scrape\": \"2018-12-13T16:38:09\", \"url\": \"http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-mucormycosis/\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole (Cresemba\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole (Cresemba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2350, \"last_scrape\": \"2018-12-13T16:38:15\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kaldeco/\", \"rr_start\": \"2012-08-13T00:00:00\", \"rr_end\": \"2012-08-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-08-13, 2012-08-22\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2012-08-13T00:00:00\", \"latest\": \"2013-01-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2351, \"last_scrape\": \"2018-12-13T16:38:21\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-patients-with-cf-2-years/\", \"rr_start\": \"2015-11-19T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMAOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-19, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\", \"ncpe_year\": 2016, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2015-11-19T00:00:00\", \"latest\": \"2016-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2352, \"last_scrape\": \"2018-12-13T16:38:24\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-the-treatment-of-cf-patients-with-the-r117h-mutation/\", \"rr_start\": \"2016-01-14T00:00:00\", \"rr_end\": \"2016-02-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-14, 2016-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\", \"ncpe_year\": 2017, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2016-01-14T00:00:00\", \"latest\": \"2017-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2353, \"last_scrape\": \"2018-12-13T16:38:29\", \"url\": \"http://www.ncpe.ie/drugs/ixazomib-ninlaro/\", \"rr_start\": \"2016-11-23T00:00:00\", \"rr_end\": \"2017-01-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-23, 2017-01-16\", \"rr_multiple\": 0, \"drug_name\": \"Ixazomib (Ninlaro\", \"trade_name\": \"Ninlaro\", \"indication\": \"Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-21T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2016-11-23T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2354, \"last_scrape\": \"2018-12-13T16:38:34\", \"url\": \"http://www.ncpe.ie/drugs/ixekizumab-taltz-for-psoriatic-arthritis/\", \"rr_start\": \"2018-10-16T00:00:00\", \"rr_end\": \"2018-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT IXEKIZUMAB NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE. THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013\", \"rr_dates\": \"2018-10-16, 2018-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab (Taltz\", \"trade_name\": \"Taltz\", \"indication\": \"Ixekizumab (Taltz\", \"ncpe_year\": 2018, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2018-10-16T00:00:00\", \"latest\": \"2018-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/taltz\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2355, \"last_scrape\": \"2018-12-13T16:38:37\", \"url\": \"http://www.ncpe.ie/drugs/ixekizumab-taltz/\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-06-28, 2016-07-26\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab (Taltz\", \"trade_name\": \"Taltz\", \"indication\": \"Taltz\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/taltz\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2356, \"last_scrape\": \"2018-12-13T16:38:39\", \"url\": \"http://www.ncpe.ie/drugs/l/lisdexamfetamine-dimesylate-tyvense/\", \"rr_start\": \"2013-02-09T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-02-09, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Lisdexamfetamine dimesylate (Tyvense\", \"trade_name\": \"Tyvense\", \"indication\": \"Lisdexamfetamine dimesylate (Tyvense\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-02-09T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2357, \"last_scrape\": \"2018-12-13T16:38:44\", \"url\": \"http://www.ncpe.ie/drugs/lacosamide-vimpat/\", \"rr_start\": \"2017-09-11T00:00:00\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-09-11, 2017-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Lacosamide (Vimpat \", \"trade_name\": \"Vimpat\", \"indication\": \"Vimpat \", \"ncpe_year\": 2017, \"eu_market\": \"2008-08-29T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2017-09-11T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2358, \"last_scrape\": \"2018-12-13T16:38:50\", \"url\": \"http://www.ncpe.ie/drugs/lapatinib-tyverb/\", \"rr_start\": \"\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Lapatinib (Tyverb\", \"trade_name\": \"Tyverb\", \"indication\": \"Cost-effectiveness of Lapatinib (Tyverb\", \"ncpe_year\": 2008, \"eu_market\": \"2008-06-10T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2359, \"last_scrape\": \"2018-12-13T16:38:56\", \"url\": \"http://www.ncpe.ie/drugs/ledipasvirsofosbuvir-harvoni/\", \"rr_start\": \"2014-11-14T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-11-14, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ledipasvir/sofosbuvir (Harvoni\", \"trade_name\": \"Harvoni\", \"indication\": \"Ledipasvir/sofosbuvir (Harvoni\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-17T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-11-14T00:00:00\", \"latest\": \"2015-11-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2360, \"last_scrape\": \"2018-12-13T16:39:05\", \"url\": \"http://www.ncpe.ie/drugs/lenalidomide-revlimid/\", \"rr_start\": \"2015-10-05T00:00:00\", \"rr_end\": \"2015-11-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE.\", \"rr_dates\": \"2015-10-05, 2015-11-20\", \"rr_multiple\": 0, \"drug_name\": \"Lenalidomide (Revlimid\", \"trade_name\": \"Revlimid\", \"indication\": \"Revlimid\", \"ncpe_year\": 2018, \"eu_market\": \"2007-06-14T00:00:00\", \"company\": \"Celgene\", \"orphan\": 1, \"earliest\": \"2015-10-05T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid\", \"ta_list\": \"Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2361, \"last_scrape\": \"2018-12-13T16:39:07\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-kisplyx/\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-05-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-05-05, 2017-05-18\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Kisplyx\", \"trade_name\": \"Kisplyx\", \"indication\": \"Lenvatinib (Kisplyx\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-25T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-05-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2362, \"last_scrape\": \"2018-12-13T16:39:11\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-lenvima-2/\", \"rr_start\": \"2018-08-07T00:00:00\", \"rr_end\": \"2018-08-16T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF LENVATINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-08-07, 2018-08-16\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Lenvima\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib (Lenvima\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2018-08-07T00:00:00\", \"latest\": \"2018-08-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2363, \"last_scrape\": \"2018-12-13T16:39:15\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-lenvima/\", \"rr_start\": \"2015-05-05T00:00:00\", \"rr_end\": \"2015-07-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2015-05-05, 2015-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Lenvima\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/H\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2015-05-05T00:00:00\", \"latest\": \"2015-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2364, \"last_scrape\": \"2018-12-13T16:39:20\", \"url\": \"http://www.ncpe.ie/drugs/lesinurad-zurampic/\", \"rr_start\": \"2017-03-15T00:00:00\", \"rr_end\": \"2017-03-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-15, 2017-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Lesinurad (Zurampic\", \"trade_name\": \"Zurampic\", \"indication\": \"Lesinurad (Zurampic\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Gr\", \"orphan\": 0, \"earliest\": \"2017-03-15T00:00:00\", \"latest\": \"2018-12-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zurampic\", \"ta_list\": \"Hyperuricemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2365, \"last_scrape\": \"2018-12-13T16:39:25\", \"url\": \"http://www.ncpe.ie/drugs/letermovir-prevymis/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Letermovir (Prevymis\", \"trade_name\": \"Prevymis\", \"indication\": \"Letermovir for the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevymis\", \"ta_list\": \"Cytomegalovirus Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2366, \"last_scrape\": \"2018-12-13T16:39:28\", \"url\": \"http://www.ncpe.ie/drugs/levodopa-20mgml-carbidopa-monohydrate-5mg-intestinal-gel-duodopa/\", \"rr_start\": \"2013-03-13T00:00:00\", \"rr_end\": \"2013-04-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-03-13, 2013-04-16\", \"rr_multiple\": 0, \"drug_name\": \"Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel (Duodopa\", \"trade_name\": \"Duodopa\", \"indication\": \"For the treatment of advanced levodopa-responsive Parkinson\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-13T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2367, \"last_scrape\": \"2018-12-13T16:39:34\", \"url\": \"http://www.ncpe.ie/drugs/levofloxacin-quinsair/\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-02-10, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Levofloxacin (Quinsair\", \"trade_name\": \"Quinsair\", \"indication\": \"Levofloxacin (Quinsair\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-25T00:00:00\", \"company\": \"Horizon\", \"orphan\": 0, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/quinsair\", \"ta_list\": \"Cystic Fibrosis; Respiratory Tract Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2368, \"last_scrape\": \"2018-12-13T16:39:39\", \"url\": \"http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-delivery-system-lng-ius-12-kyleena/\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-02-08, 2017-03-16\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine delivery system LNG IUS 12 (Kyleena\", \"trade_name\": \"Kyleena\", \"indication\": \"Kyleena\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2017-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2369, \"last_scrape\": \"2018-12-13T16:39:44\", \"url\": \"http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-system-lng-ius-jaydess/\", \"rr_start\": \"2013-03-07T00:00:00\", \"rr_end\": \"2013-03-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-03-07, 2013-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine system LNG-IUS (Jaydess\", \"trade_name\": \"Jaydess\", \"indication\": \"Levonorgestrel Intrauterine System LNG-IUS (Jaydess\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-07T00:00:00\", \"latest\": \"2013-03-25T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2370, \"last_scrape\": \"2018-12-13T16:39:46\", \"url\": \"http://www.ncpe.ie/drugs/lidocaine-5-plasters-versatis/\", \"rr_start\": \"2010-09-09T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2010-09-09, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Lidocaine 5% plasters (Versatis\", \"trade_name\": \"Versatis\", \"indication\": \"Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN).\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-09-09T00:00:00\", \"latest\": \"2015-09-24T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2371, \"last_scrape\": \"2018-12-13T16:39:51\", \"url\": \"http://www.ncpe.ie/drugs/linaclotide-clonstella/\", \"rr_start\": \"2013-05-28T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-05-28, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Linaclotide (Constella\", \"trade_name\": \"Constella\", \"indication\": \"Linaclotide (Constella\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2013-05-28T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/constella\", \"ta_list\": \"Irritable Bowel Syndrome\", \"rr_status\": \"No HTA\"}, {\"id\": 2372, \"last_scrape\": \"2018-12-13T16:39:54\", \"url\": \"http://www.ncpe.ie/drugs/linagliptin-trajenta/\", \"rr_start\": \"2011-08-18T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-08-18, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Linagliptin (Trajenta\", \"trade_name\": \"Trajenta\", \"indication\": \"Lingagliptin (Trajenta\", \"ncpe_year\": 2011, \"eu_market\": \"2011-08-23T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2011-08-18T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2373, \"last_scrape\": \"2018-12-13T16:39:57\", \"url\": \"http://www.ncpe.ie/drugs/lipegfilgrastim-lonquex/\", \"rr_start\": \"2013-08-20T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-08-20, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Lipegfilgrastim (Lonquex\", \"trade_name\": \"Lonquex\", \"indication\": \"Lonquex\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-25T00:00:00\", \"company\": \"Sicor\", \"orphan\": 0, \"earliest\": \"2013-08-20T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex\", \"ta_list\": \"Neutropenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2374, \"last_scrape\": \"2018-12-13T16:40:00\", \"url\": \"http://www.ncpe.ie/drugs/liposomal-daunorubicin-and-cytarabine-cpx-351vyxeos/\", \"rr_start\": \"2018-09-28T00:00:00\", \"rr_end\": \"2018-11-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-09-28, 2018-11-08\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos\", \"trade_name\": \"Vyxeos\", \"indication\": \"Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Jazz\", \"orphan\": 1, \"earliest\": \"2018-09-28T00:00:00\", \"latest\": \"2018-11-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2375, \"last_scrape\": \"2018-12-13T16:40:06\", \"url\": \"http://www.ncpe.ie/drugs/liposomal-irinotecan-nal-iri-onivyde/\", \"rr_start\": \"2017-06-13T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-13, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal irinotecan (Onivyde\", \"trade_name\": \"Onivyde\", \"indication\": \"Liposomal irinotecan (Onivyde\", \"ncpe_year\": 2017, \"eu_market\": \"2016-10-14T00:00:00\", \"company\": \"Baxalta\", \"orphan\": 1, \"earliest\": \"2017-06-13T00:00:00\", \"latest\": \"2017-07-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-0\", \"ta_list\": \"Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2376, \"last_scrape\": \"2018-12-13T16:40:09\", \"url\": \"http://www.ncpe.ie/drugs/liquid-paraffin-ointment-vita-pos-opthalmic/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Liquid Paraffin Ointment (VitA-POS Opthalmic\", \"trade_name\": \"VitA-POS Opthalmic\", \"indication\": \"Liquid Paraffin Ointment (VitA-POS Opthalmic\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2377, \"last_scrape\": \"2018-12-13T16:40:13\", \"url\": \"http://www.ncpe.ie/drugs/liraglutide-victoza/\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-10-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-09-01, 2009-10-07\", \"rr_multiple\": 0, \"drug_name\": \"Liraglutide (Victoza\", \"trade_name\": \"Victoza\", \"indication\": \"Victoza\", \"ncpe_year\": 2018, \"eu_market\": \"2009-06-30T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2009-09-01T00:00:00\", \"latest\": \"2018-10-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/victoza\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2378, \"last_scrape\": \"2018-12-13T16:40:17\", \"url\": \"http://www.ncpe.ie/drugs/lixisenatide-lyxumia/\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Lixisenatide (Lyxumia\", \"trade_name\": \"Lyxumia\", \"indication\": \"Lixisenatide (Lyxumia\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-08-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2379, \"last_scrape\": \"2018-12-13T16:40:19\", \"url\": \"http://www.ncpe.ie/drugs/lomitapide-lojuxta/\", \"rr_start\": \"2014-09-09T00:00:00\", \"rr_end\": \"2014-09-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-09-09, 2014-09-15\", \"rr_multiple\": 0, \"drug_name\": \"Lomitapide (Lojuxta\", \"trade_name\": \"Lojuxta\", \"indication\": \"Lojuxta\", \"ncpe_year\": 2014, \"eu_market\": \"2013-07-31T00:00:00\", \"company\": \"Amryt\", \"orphan\": 0, \"earliest\": \"2014-09-09T00:00:00\", \"latest\": \"2014-09-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2380, \"last_scrape\": \"2018-12-13T16:40:22\", \"url\": \"http://www.ncpe.ie/drugs/lornoxicam-xefo/\", \"rr_start\": \"2011-06-23T00:00:00\", \"rr_end\": \"2011-07-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-06-23, 2011-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Lornoxicam (Xefo\", \"trade_name\": \"Xefo\", \"indication\": \" Lornoxicam (Xefo\", \"ncpe_year\": 2011, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-06-23T00:00:00\", \"latest\": \"2011-07-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA\"}, {\"id\": 2381, \"last_scrape\": \"2018-12-13T16:40:24\", \"url\": \"http://www.ncpe.ie/drugs/lotemax-0-5-eye-drops-suspension-loteprednol/\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2011-12-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-11-15, 2011-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Lotemax 0.5% eye drops suspension (Loteprednol)\", \"trade_name\": \"Loteprednol\", \"indication\": \" Indicated for treatment of post-operative inflammation following ocular surgery.\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2011-12-05T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2382, \"last_scrape\": \"2018-12-13T16:40:30\", \"url\": \"http://www.ncpe.ie/drugs/loxapine-inhalation-powder-adasuve/\", \"rr_start\": \"2016-06-21T00:00:00\", \"rr_end\": \"2016-07-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-06-21, 2016-07-28\", \"rr_multiple\": 0, \"drug_name\": \"Loxapine inhalation powder (Adasuve\", \"trade_name\": \"Adasuve\", \"indication\": \"Inhaled loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-02-20T00:00:00\", \"company\": \"Ferrer\", \"orphan\": 0, \"earliest\": \"2016-06-21T00:00:00\", \"latest\": \"2016-07-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve\", \"ta_list\": \"Schizophrenia; Bipolar Disorder\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2383, \"last_scrape\": \"2018-12-13T16:40:34\", \"url\": \"http://www.ncpe.ie/drugs/lumacaftorivacaftor-orkambi/\", \"rr_start\": \"2015-11-26T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-26, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Lumacaftor/ivacaftor (Orkambi\", \"trade_name\": \"Orkambi\", \"indication\": \"Orkambi\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Vertex\", \"orphan\": 0, \"earliest\": \"2015-11-26T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/orkambi\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2384, \"last_scrape\": \"2018-12-13T16:40:36\", \"url\": \"http://www.ncpe.ie/drugs/lutetium-177lu-oxodotreotide-lutathera/\", \"rr_start\": \"2018-10-23T00:00:00\", \"rr_end\": \"2018-11-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-10-23, 2018-11-16\", \"rr_multiple\": 0, \"drug_name\": \"Lutetium (177Lu) Oxodotreotide (Lutathera\", \"trade_name\": \"Lutathera\", \"indication\": \"Lutetium (177Lu) Oxodotreotide (Lutathera\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-26T00:00:00\", \"company\": \"Advanced\", \"orphan\": 1, \"earliest\": \"2018-10-23T00:00:00\", \"latest\": \"2018-11-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2385, \"last_scrape\": \"2018-12-13T16:40:41\", \"url\": \"http://www.ncpe.ie/drugs/macitentan-opsumit/\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-10, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Macitentan (Opsumit\", \"trade_name\": \"Opsumit\", \"indication\": \"Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-12-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2386, \"last_scrape\": \"2018-12-13T16:40:43\", \"url\": \"http://www.ncpe.ie/drugs/melatonin-circadin/\", \"rr_start\": \"\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Melatonin (Circadin\", \"trade_name\": \"Circadin\", \"indication\": \"A Review of the Economic Evaluation of Prolonged Release Melatonin (Circadin\", \"ncpe_year\": 2008, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"RAD\", \"orphan\": 0, \"earliest\": \"2008-08-01T00:00:00\", \"latest\": \"2008-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/circadin\", \"ta_list\": \"Sleep Initiation and Maintenance Disorders\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2387, \"last_scrape\": \"2018-12-13T16:40:45\", \"url\": \"http://www.ncpe.ie/drugs/mepolizumab-nucala/\", \"rr_start\": \"2016-03-16T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-03-16, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Mepolizumab (Nucala\", \"trade_name\": \"Nucala\", \"indication\": \"Mepolizumab (Nucala\", \"ncpe_year\": 2018, \"eu_market\": \"2015-12-01T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-03-16T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nucala\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2388, \"last_scrape\": \"2018-12-13T16:40:51\", \"url\": \"http://www.ncpe.ie/drugs/methoxyflurane-penthrox/\", \"rr_start\": \"2015-11-23T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-11-23, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Methoxyflurane (Penthrox\", \"trade_name\": \"Penthrox\", \"indication\": \"Penthrox\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2015-11-23T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2389, \"last_scrape\": \"2018-12-13T16:40:56\", \"url\": \"http://www.ncpe.ie/drugs/midostaurin-rydapt-for-aml/\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF MIDOSTAURIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin (Rydapt\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin (Rydapt\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2390, \"last_scrape\": \"2018-12-13T16:41:02\", \"url\": \"http://www.ncpe.ie/drugs/midostaurin-rydapt-for-asm/\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF MIDOSTAURIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin (Rydapt\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin (Rydapt\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2391, \"last_scrape\": \"2018-12-13T16:41:04\", \"url\": \"http://www.ncpe.ie/drugs/mifamurtide-mepact/\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-06-22, 2010-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Mifamurtide (Mepact\", \"trade_name\": \"Mepact\", \"indication\": \"Mifamurtide (Meptact\", \"ncpe_year\": 2010, \"eu_market\": \"2009-03-06T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2010-06-22T00:00:00\", \"latest\": \"2010-07-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mepact\", \"ta_list\": \"Osteosarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2392, \"last_scrape\": \"2018-12-13T16:41:06\", \"url\": \"http://www.ncpe.ie/drugs/migalastat-galafold/\", \"rr_start\": \"2016-07-14T00:00:00\", \"rr_end\": \"2016-08-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-07-14, 2016-08-18\", \"rr_multiple\": 0, \"drug_name\": \"Migalastat (Galafold\", \"trade_name\": \"Galafold\", \"indication\": \"Migalastat is indicated for the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-05-25T00:00:00\", \"company\": \"Amicus\", \"orphan\": 1, \"earliest\": \"2016-07-14T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/galafold\", \"ta_list\": \"Fabry Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2393, \"last_scrape\": \"2018-12-13T16:41:13\", \"url\": \"http://www.ncpe.ie/drugs/mirabegron-betmiga/\", \"rr_start\": \"2012-12-19T00:00:00\", \"rr_end\": \"2013-03-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-12-19, 2013-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Mirabegron (Betmiga\", \"trade_name\": \"Betmiga\", \"indication\": \"Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome\", \"ncpe_year\": 2013, \"eu_market\": \"2012-12-20T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-12-19T00:00:00\", \"latest\": \"2013-03-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga\", \"ta_list\": \"Urinary Bladder, Overactive\", \"rr_status\": \"No HTA\"}, {\"id\": 2394, \"last_scrape\": \"2018-12-13T16:41:15\", \"url\": \"http://www.ncpe.ie/drugs/nab-paclitaxel-abraxane/\", \"rr_start\": \"2014-01-23T00:00:00\", \"rr_end\": \"2014-03-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-01-23, 2014-03-02\", \"rr_multiple\": 0, \"drug_name\": \"Nab-paclitaxel (Abraxane\", \"trade_name\": \"Abraxane\", \"indication\": \"Nab-paclitaxel (Abraxane\", \"ncpe_year\": 2015, \"eu_market\": \"2008-01-10T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2014-01-23T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane\", \"ta_list\": \"Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2395, \"last_scrape\": \"2018-12-13T16:41:18\", \"url\": \"http://www.ncpe.ie/drugs/nalmefene-selincro/\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Nalmefene (Selincro\", \"trade_name\": \"Selincro\", \"indication\": \"Nalmefene (Selincro\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-24T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2014-04-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/selincro\", \"ta_list\": \"Alcohol-Related Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2396, \"last_scrape\": \"2018-12-13T16:41:24\", \"url\": \"http://www.ncpe.ie/drugs/naloxegel-moventig/\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-04-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-02-10, 2015-04-13\", \"rr_multiple\": 0, \"drug_name\": \"Naloxegel (Moventig\", \"trade_name\": \"Moventig\", \"indication\": \"Naloxegel (Moventiq\", \"ncpe_year\": 2015, \"eu_market\": \"2014-12-07T00:00:00\", \"company\": \"Kyowa\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-04-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/moventig\", \"ta_list\": \"Constipation; Opioid-Related Disorders\", \"rr_status\": \"No HTA\"}, {\"id\": 2397, \"last_scrape\": \"2018-12-13T16:41:26\", \"url\": \"http://www.ncpe.ie/drugs/naltrexone-bupropion-mysimba/\", \"rr_start\": \"2017-03-12T00:00:00\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-12, 2017-03-28\", \"rr_multiple\": 0, \"drug_name\": \"Naltrexone / bupropion (Mysimba\", \"trade_name\": \"Mysimba\", \"indication\": \"Naltrexone / bupropion (Mysimba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-03-26T00:00:00\", \"company\": \"Orexigen\", \"orphan\": 0, \"earliest\": \"2017-03-12T00:00:00\", \"latest\": \"2018-05-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba\", \"ta_list\": \"Obesity; Overweight\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2398, \"last_scrape\": \"2018-12-13T16:41:30\", \"url\": \"http://www.ncpe.ie/drugs/natalizumab-tysabri/\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Natalizumab (Tysabri\", \"trade_name\": \"Tysabri\", \"indication\": \" Economic Evaluation of Natalizumab (Tysabri\", \"ncpe_year\": 2007, \"eu_market\": \"2006-06-27T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2007-01-01T00:00:00\", \"latest\": \"2007-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2399, \"last_scrape\": \"2018-12-13T16:41:35\", \"url\": \"http://www.ncpe.ie/drugs/ncpe-inhaled-insulin-exubera-assessment/\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Inhaled insulin (Exubera\", \"trade_name\": \"Exubera\", \"indication\": \"In April 2006, Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin (Exubera\", \"ncpe_year\": 2006, \"eu_market\": \"2006-01-24T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-03-01T00:00:00\", \"latest\": \"2006-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/exubera\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2400, \"last_scrape\": \"2018-12-13T16:41:38\", \"url\": \"http://www.ncpe.ie/drugs/nepafenac-nevanac-2/\", \"rr_start\": \"2011-06-14T00:00:00\", \"rr_end\": \"2011-06-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-06-14, 2011-06-27\", \"rr_multiple\": 0, \"drug_name\": \"Nepafenac (Nevanac\", \"trade_name\": \"Nevanac\", \"indication\": \"Nepafenac (Nevanac\", \"ncpe_year\": 2011, \"eu_market\": \"2007-12-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2011-06-14T00:00:00\", \"latest\": \"2011-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac\", \"ta_list\": \"Pain, Postoperative; Ophthalmologic Surgical Procedures\", \"rr_status\": \"No HTA\"}, {\"id\": 2401, \"last_scrape\": \"2018-12-13T16:41:41\", \"url\": \"http://www.ncpe.ie/drugs/netupitantpalonosetron-akynzeo/\", \"rr_start\": \"2015-08-26T00:00:00\", \"rr_end\": \"2015-10-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-08-26, 2015-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Netupitant/palonosetron (Akynzeo\", \"trade_name\": \"Akynzeo\", \"indication\": \"Akynzeo\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Helsinn\", \"orphan\": 0, \"earliest\": \"2015-08-26T00:00:00\", \"latest\": \"2015-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo\", \"ta_list\": \"Vomiting; Cancer; Nausea\", \"rr_status\": \"No HTA\"}, {\"id\": 2402, \"last_scrape\": \"2018-12-13T16:41:44\", \"url\": \"http://www.ncpe.ie/drugs/nilotinib-tasigna-newly-diagnosed-cml/\", \"rr_start\": \"2010-10-06T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2010-10-06, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib (Tasigna\", \"trade_name\": \"Tasigna\", \"indication\": \"Nilotinib (Tasigna\", \"ncpe_year\": 2010, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-10-06T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2403, \"last_scrape\": \"2018-12-13T16:41:51\", \"url\": \"http://www.ncpe.ie/drugs/nilotinib-tasigna/\", \"rr_start\": \"\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib (Tasigna\", \"trade_name\": \"Tasigna\", \"indication\": \"Cost-effectiveness of Nilotinib (Tasigna\", \"ncpe_year\": 2008, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2404, \"last_scrape\": \"2018-12-13T16:41:53\", \"url\": \"http://www.ncpe.ie/drugs/nintedanib-ofev/\", \"rr_start\": \"2015-01-30T00:00:00\", \"rr_end\": \"2015-02-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-30, 2015-02-18\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib (Ofev\", \"trade_name\": \"Ofev\", \"indication\": \"Nintedanib (Ofev\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 1, \"earliest\": \"2015-01-30T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ofev\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2405, \"last_scrape\": \"2018-12-13T16:41:56\", \"url\": \"http://www.ncpe.ie/drugs/nintedanib-vargatef/\", \"rr_start\": \"2015-01-02T00:00:00\", \"rr_end\": \"2015-02-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-02, 2015-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib (Vargatef\", \"trade_name\": \"Vargatef\", \"indication\": \"Nintedanib (Vargatef\", \"ncpe_year\": 2017, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-01-02T00:00:00\", \"latest\": \"2017-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2406, \"last_scrape\": \"2018-12-13T16:42:00\", \"url\": \"http://www.ncpe.ie/drugs/niraparib-zejula/\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF NIRAPARIB COMPARED WITH THE CURRENT STANDARD OF CARE\", \"rr_dates\": \"2018-06-01, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Niraparib (Zejula\", \"trade_name\": \"Zejula\", \"indication\": \"Niraparib (Zejula\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-16T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 1, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zejula\", \"ta_list\": \"Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2407, \"last_scrape\": \"2018-12-13T16:42:06\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-melanoma/\", \"rr_start\": \"2015-05-28T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-05-28, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-05-28T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2408, \"last_scrape\": \"2018-12-13T16:42:13\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-non-squamous-nsclc/\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-03-03, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2409, \"last_scrape\": \"2018-12-13T16:42:20\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-nsclc/\", \"rr_start\": \"2015-07-02T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-07-02, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-07-02T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2410, \"last_scrape\": \"2018-12-13T16:42:26\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-as-monotherapy-for-the-adjuvant-treatment-of-adults-with-melanoma/\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF NIVOLUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-09, 2018-07-27\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-11-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2411, \"last_scrape\": \"2018-12-13T16:42:31\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-advanced-renal-cell-carcinoma/\", \"rr_start\": \"2016-04-27T00:00:00\", \"rr_end\": \"2016-05-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-04-27, 2016-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-04-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2412, \"last_scrape\": \"2018-12-13T16:42:33\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-classical-hodgkin-lymphoma/\", \"rr_start\": \"2016-11-22T00:00:00\", \"rr_end\": \"2017-01-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-11-22, 2017-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-11-22T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2413, \"last_scrape\": \"2018-12-13T16:42:36\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-head-and-neck-cancer/\", \"rr_start\": \"2017-05-03T00:00:00\", \"rr_end\": \"2017-05-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-03, 2017-05-30\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-05-03T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2414, \"last_scrape\": \"2018-12-13T16:42:41\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-urothelial-carcinoma/\", \"rr_start\": \"2017-06-28T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-28, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-06-28T00:00:00\", \"latest\": \"2018-09-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2415, \"last_scrape\": \"2018-12-13T16:42:46\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-in-combination-with-ipilimumab-yervoy/\", \"rr_start\": \"2018-11-28T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-11-28, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Yervoy\", \"indication\": \"Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).\", \"ncpe_year\": 2018, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-11-28T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy\", \"ta_list\": \"Melanoma\", \"rr_status\": \"Unknown\"}, {\"id\": 2416, \"last_scrape\": \"2018-12-13T16:42:51\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-plus-ipilimumab-opdivio-plus-yervoy/\", \"rr_start\": \"\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab plus ipilimumab (Opdivo\", \"trade_name\": \"Opdivo plus Yervoy\", \"indication\": \"Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-06-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2417, \"last_scrape\": \"2018-12-13T16:42:56\", \"url\": \"http://www.ncpe.ie/drugs/nomace2-zoely/\", \"rr_start\": \"2011-12-08T00:00:00\", \"rr_end\": \"2012-01-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-12-08, 2012-01-03\", \"rr_multiple\": 0, \"drug_name\": \"Nomegestrol acetate/estradiol (Zoely\", \"trade_name\": \"Zoely\", \"indication\": \"Nomegestrol acetate/estradiol (Zoely\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-26T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2011-12-08T00:00:00\", \"latest\": \"2012-01-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zoely\", \"ta_list\": \"Contraception\", \"rr_status\": \"No HTA\"}, {\"id\": 2418, \"last_scrape\": \"2018-12-13T16:43:02\", \"url\": \"http://www.ncpe.ie/drugs/nusinersin-spinraza/\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-11, 2017-08-02\", \"rr_multiple\": 0, \"drug_name\": \"Nusinersin (Spinraza\", \"trade_name\": \"Spinraza\", \"indication\": \"Nusinersen (Spinraza\", \"ncpe_year\": 2017, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 1, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-12-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza\", \"ta_list\": \"Muscular Atrophy, Spinal\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2419, \"last_scrape\": \"2018-12-13T16:43:07\", \"url\": \"http://www.ncpe.ie/drugs/obeticholic-acid-ocaliva/\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-18, 2016-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Obeticholic acid (Ocaliva\", \"trade_name\": \"Ocaliva\", \"indication\": \"Obeticholic acid is indicated for the treatment of primary biliary cirrhosis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Intercept\", \"orphan\": 1, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocaliva\", \"ta_list\": \"Liver Cirrhosis, Biliary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2420, \"last_scrape\": \"2018-12-13T16:43:10\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-follicular-lymphoma/\", \"rr_start\": \"2016-05-11T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-05-11, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (in combination with bendamustine) followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2016-05-11T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2421, \"last_scrape\": \"2018-12-13T16:43:15\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-previously-untreated-advanced-follicular-lymphoma/\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-09-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-08, 2017-09-13\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (Gazyvaro\", \"ncpe_year\": 2018, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2422, \"last_scrape\": \"2018-12-13T16:43:21\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro/\", \"rr_start\": \"2014-08-08T00:00:00\", \"rr_end\": \"2014-09-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-08-08, 2014-09-11\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (Gazyvaro\", \"ncpe_year\": 2015, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2014-08-08T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2423, \"last_scrape\": \"2018-12-13T16:43:24\", \"url\": \"http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-ppms/\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab (Ocrevus\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab (Ocrevus\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2424, \"last_scrape\": \"2018-12-13T16:43:30\", \"url\": \"http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-rms/\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab (Ocrevus\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab (Ocrevus\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2425, \"last_scrape\": \"2018-12-13T16:43:34\", \"url\": \"http://www.ncpe.ie/drugs/ocriplasmin-jetrea/\", \"rr_start\": \"2013-06-12T00:00:00\", \"rr_end\": \"2013-07-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-06-12, 2013-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Ocriplasmin (Jetrea\", \"trade_name\": \"Jetrea\", \"indication\": \"Ocriplasmin (Jetrea\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-13T00:00:00\", \"company\": \"ThromboGenics\", \"orphan\": 0, \"earliest\": \"2013-06-12T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea\", \"ta_list\": \"Retinal Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2426, \"last_scrape\": \"2018-12-13T16:43:39\", \"url\": \"http://www.ncpe.ie/drugs/ofatumumab-arzerra-previously-untreated-chronic-lymphocytic-leukaemia/\", \"rr_start\": \"2014-10-13T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2014-10-13, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab (Arzerra\", \"trade_name\": \"Arzerra\", \"indication\": \"Ofatumumab (Arzerra\", \"ncpe_year\": 2014, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-10-13T00:00:00\", \"latest\": \"2014-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2427, \"last_scrape\": \"2018-12-13T16:43:46\", \"url\": \"http://www.ncpe.ie/drugs/ofatumumab-arzerra/\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-06-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-06-22, 2010-06-01\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab (Arzerra\", \"trade_name\": \"Arzerra\", \"indication\": \"Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-06-01T00:00:00\", \"latest\": \"2010-06-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2428, \"last_scrape\": \"2018-12-13T16:43:52\", \"url\": \"http://www.ncpe.ie/drugs/oladaterol-striverdi-respimat/\", \"rr_start\": \"2014-04-07T00:00:00\", \"rr_end\": \"2014-05-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-07, 2014-05-02\", \"rr_multiple\": 0, \"drug_name\": \"Oladaterol (Striverdi\", \"trade_name\": \"Striverdi, Respimat\", \"indication\": \"Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-04-07T00:00:00\", \"latest\": \"2014-05-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2429, \"last_scrape\": \"2018-12-13T16:43:57\", \"url\": \"http://www.ncpe.ie/drugs/olaparib-lynparza-2/\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-05, 2015-02-19\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib (Lynparza\", \"trade_name\": \"Lynparza\", \"indication\": \"Lynparza\", \"ncpe_year\": 2017, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2430, \"last_scrape\": \"2018-12-13T16:44:03\", \"url\": \"http://www.ncpe.ie/drugs/olaparib-lynparza-for-platinum-sensitive-relapsed-ovarian-cancer/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"THE NCPE RECOMMEND  A FULL HTA TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF OLAPARIB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib (Lynparza\", \"trade_name\": \"Lynparza\", \"indication\": \"Olaparib (Lynparza\", \"ncpe_year\": 2018, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2431, \"last_scrape\": \"2018-12-13T16:44:08\", \"url\": \"http://www.ncpe.ie/drugs/omalizumab-xolair-for-the-treatment-of-severe-allergic-asthma/\", \"rr_start\": \"\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab (Xolair\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab is indicated as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1<80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.\", \"ncpe_year\": 2015, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-08-22T00:00:00\", \"latest\": \"2015-06-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xolair\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2432, \"last_scrape\": \"2018-12-13T16:44:14\", \"url\": \"http://www.ncpe.ie/drugs/omalizumab-xolair/\", \"rr_start\": \"2014-03-25T00:00:00\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED FOR THIS INDICATION.\", \"rr_dates\": \"2014-03-25, 2014-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab (Xolair\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab (Xolair\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-03-25T00:00:00\", \"latest\": \"2014-04-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xolair\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"No HTA\"}, {\"id\": 2433, \"last_scrape\": \"2018-12-13T16:44:19\", \"url\": \"http://www.ncpe.ie/drugs/oral-oxycodonenaloxone-targin/\", \"rr_start\": \"\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Oxycodone/naloxone (Targin\", \"trade_name\": \"Targin\", \"indication\": \"Cost-effectiveness of oral oxycodone/naloxone prolonged release tablet (Targin\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-05-05T00:00:00\", \"latest\": \"2010-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2434, \"last_scrape\": \"2018-12-13T16:44:22\", \"url\": \"http://www.ncpe.ie/drugs/osimertinib-tagrisso-for-the-first-line-treatment-of-metastatic-nsclc/\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-07T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF OSIMERTINIB FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WITH ACTIVATING EGFR MUTATIONS COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-19, 2018-08-07\", \"rr_multiple\": 0, \"drug_name\": \"Osimertinib (Tagrisso\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib (Tagrisso\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2435, \"last_scrape\": \"2018-12-13T16:44:39\", \"url\": \"http://www.ncpe.ie/drugs/osimertinib-tagrisso/\", \"rr_start\": \"2016-02-26T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-26, 2016-03-22, 2017-01-10\", \"rr_multiple\": 1, \"drug_name\": \"Osimertinib (Tagrisso\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib (Tagrisso\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-26T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2436, \"last_scrape\": \"2018-12-13T16:44:40\", \"url\": \"http://www.ncpe.ie/drugs/ozenoxacin-dubine/\", \"rr_start\": \"2018-11-12T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"FULL HTA IS NOT RECOMMENDED. THE NCPE RECOMMENDS THAT OZENOXACIN CREAM NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE.  THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013.\", \"rr_dates\": \"2018-11-12, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ozenoxacin (Dubine\", \"trade_name\": \"Dubine\", \"indication\": \"Ozenoxacin (Dubine\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-12T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"id\": 2437, \"last_scrape\": \"2018-12-13T16:44:43\", \"url\": \"http://www.ncpe.ie/drugs/p-drugs/pegylated-interferon-b-1a-plegridy/\", \"rr_start\": \"2014-11-25T00:00:00\", \"rr_end\": \"2014-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-11-25, 2014-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Pegylated Interferon beta-1a (Plegridy \", \"trade_name\": \"Plegridy\", \"indication\": \"Treatment of adult patients with relapsing remitting multiple sclerosis\", \"ncpe_year\": 2014, \"eu_market\": \"2014-07-17T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-11-25T00:00:00\", \"latest\": \"2014-12-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2438, \"last_scrape\": \"2018-12-13T16:44:47\", \"url\": \"http://www.ncpe.ie/drugs/palbociclib-ibrance/\", \"rr_start\": \"2016-09-10T00:00:00\", \"rr_end\": \"2016-09-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-09-10, 2016-09-28\", \"rr_multiple\": 0, \"drug_name\": \"Palbociclib (Ibrance\", \"trade_name\": \"Ibrance\", \"indication\": \"Palbociclib is indicated for the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-11-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2016-09-10T00:00:00\", \"latest\": \"2017-07-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2439, \"last_scrape\": \"2018-12-13T16:44:53\", \"url\": \"http://www.ncpe.ie/drugs/paliperidone-palmitate-xeplion/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Paliperidone palmitate (Xeplion\", \"trade_name\": \"Xeplion\", \"indication\": \"Paliperidone palmitate (Xeplion\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-04T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeplion\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2440, \"last_scrape\": \"2018-12-13T16:44:57\", \"url\": \"http://www.ncpe.ie/drugs/panobinostat-farydak/\", \"rr_start\": \"2016-01-26T00:00:00\", \"rr_end\": \"2016-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-26, 2016-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Panobinostat (Farydak\", \"trade_name\": \"Farydak\", \"indication\": \"Panobinostat in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-01-26T00:00:00\", \"latest\": \"2016-02-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/farydak\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2441, \"last_scrape\": \"2018-12-13T16:45:01\", \"url\": \"http://www.ncpe.ie/drugs/paritaprevir-boosted-with-ritonavir-and-ombitasvir-vierkirax-with-or-without-dasabuvir-exviera/\", \"rr_start\": \"2014-12-21T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-21, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Paritaprevir boosted with ritonavir and ombitasvir (Vierkirax\", \"trade_name\": \"Exviera\", \"indication\": \"Exviera\", \"ncpe_year\": 2016, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2014-12-21T00:00:00\", \"latest\": \"2016-02-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/exviera\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2442, \"last_scrape\": \"2018-12-13T16:45:07\", \"url\": \"http://www.ncpe.ie/drugs/patiromer-veltassa/\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT\\nRECOMMENDED\", \"rr_dates\": \"2017-10-11, 2017-11-17\", \"rr_multiple\": 0, \"drug_name\": \"Patiromer (Veltassa\", \"trade_name\": \"Veltassa\", \"indication\": \"Patiromer (Veltassa\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-19T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-11-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/veltassa\", \"ta_list\": \"Hyperkalemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2443, \"last_scrape\": \"2018-12-13T16:45:10\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-1l-nsclc-with-chemotherapy/\", \"rr_start\": \"2018-08-14T00:00:00\", \"rr_end\": \"2018-08-29T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-14, 2018-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-08-14T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2444, \"last_scrape\": \"2018-12-13T16:45:15\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-adjuvant-melanoma/\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-07T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-11-19, 2018-12-07\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizuma (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2445, \"last_scrape\": \"2018-12-13T16:45:18\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-classical-hodgkin-lymphoma/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2446, \"last_scrape\": \"2018-12-13T16:45:23\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-first-line-nsclc/\", \"rr_start\": \"2016-12-19T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-12-19, 2017-01-10\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-12-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2447, \"last_scrape\": \"2018-12-13T16:45:28\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-nsclc/\", \"rr_start\": \"2016-08-03T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-08-03, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-03T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2448, \"last_scrape\": \"2018-12-13T16:45:31\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-the-treatment-of-unresectable-or-advanced-metastatic-melanoma-in-adults-refractory-to-ipilimumab/\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2449, \"last_scrape\": \"2018-12-13T16:45:36\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-uc-1l/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES\", \"rr_dates\": \"2017-12-06, 2017-12-21, 2018-06-21, 2018-07-10, 2018-07-27\", \"rr_multiple\": 1, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-07-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2450, \"last_scrape\": \"2018-12-13T16:45:38\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-urothelial-carcinoma-2l/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda \", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2451, \"last_scrape\": \"2018-12-13T16:45:45\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda/\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-02-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2452, \"last_scrape\": \"2018-12-13T16:45:50\", \"url\": \"http://www.ncpe.ie/drugs/perampanel-fycompa/\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Perampanel (Fycompa\", \"trade_name\": \"Fycompa\", \"indication\": \"Perampanel (Fycompa\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-23T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa\", \"ta_list\": \"Epilepsies, Partial\", \"rr_status\": \"No HTA\"}, {\"id\": 2453, \"last_scrape\": \"2018-12-13T16:45:56\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta-for-her2-positive-breast-cancer/\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PERTUZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-01, 2018-06-22\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab  (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.\", \"ncpe_year\": 2018, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-12-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2454, \"last_scrape\": \"2018-12-13T16:46:02\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta-in-neoadjuvant-her2-positive-breast-cancer/\", \"rr_start\": \"2015-08-10T00:00:00\", \"rr_end\": \"2015-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-10, 2015-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"Perjeta (pertuzumab) is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2015-08-10T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2455, \"last_scrape\": \"2018-12-13T16:46:04\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta/\", \"rr_start\": \"2013-01-14T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-01-14, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"The proposed licensed indication is for use (in combination with trastuzumab and docetaxel) in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. \", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-01-14T00:00:00\", \"latest\": \"2013-08-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2456, \"last_scrape\": \"2018-12-13T16:46:09\", \"url\": \"http://www.ncpe.ie/drugs/phenylephrine-hydrochloride-tropicamide-lidocaine-hydrochloride-fydrane/\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-19T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-11-18, 2016-12-19\", \"rr_multiple\": 0, \"drug_name\": \"Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride (Fydrane\", \"trade_name\": \"Fydrane\", \"indication\": \"Fydrane\", \"ncpe_year\": 2016, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2016-12-19T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2457, \"last_scrape\": \"2018-12-13T16:46:11\", \"url\": \"http://www.ncpe.ie/drugs/pirfenidone-esbriet/\", \"rr_start\": \"2011-12-15T00:00:00\", \"rr_end\": \"2012-01-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-12-15, 2012-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Pirfenidone (Esbriet\", \"trade_name\": \"Esbriet\", \"indication\": \"Pirfenidone has been licensed by the European Medicines Agency (EMA) for the treatment of mild to moderate idiopathic pulmonary fibrosis.\", \"ncpe_year\": 2015, \"eu_market\": \"2011-02-27T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2011-12-15T00:00:00\", \"latest\": \"2015-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esbriet\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2458, \"last_scrape\": \"2018-12-13T16:46:14\", \"url\": \"http://www.ncpe.ie/drugs/pitavastatin-livazo/\", \"rr_start\": \"2010-12-22T00:00:00\", \"rr_end\": \"2010-12-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-12-22, 2010-12-24\", \"rr_multiple\": 0, \"drug_name\": \"Pitavastatin (Livazo\", \"trade_name\": \"Livazo\", \"indication\": \"Pitavastatin is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined (mixed) dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-12-22T00:00:00\", \"latest\": \"2010-12-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2459, \"last_scrape\": \"2018-12-13T16:46:20\", \"url\": \"http://www.ncpe.ie/drugs/pitolisant-wakix/\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-06-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-06-12, 2017-06-15\", \"rr_multiple\": 0, \"drug_name\": \"Pitolisant hydrochloride (Wakix\", \"trade_name\": \"Wakix\", \"indication\": \"Pitolisant hydrochloride (Wakix\", \"ncpe_year\": 2017, \"eu_market\": \"2016-03-31T00:00:00\", \"company\": \"Bioprojet\", \"orphan\": 1, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-06-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/wakix\", \"ta_list\": \"Narcolepsy\", \"rr_status\": \"No HTA\"}, {\"id\": 2460, \"last_scrape\": \"2018-12-13T16:46:24\", \"url\": \"http://www.ncpe.ie/drugs/pixantrone-pixuvri/\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-03-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-02-10, 2015-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Pixantrone (Pixuvri\", \"trade_name\": \"Pixuvri\", \"indication\": \"Pixurvi\", \"ncpe_year\": 2015, \"eu_market\": \"2012-05-10T00:00:00\", \"company\": \"CTI\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-03-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri\", \"ta_list\": \"Lymphoma, Non-Hodgkin\", \"rr_status\": \"No HTA\"}, {\"id\": 2461, \"last_scrape\": \"2018-12-13T16:46:27\", \"url\": \"http://www.ncpe.ie/drugs/polynuclear-ironiii-oxyhydroxide-pn-feooh-velphoro/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-09-12, 2014-10-08\", \"rr_multiple\": 0, \"drug_name\": \"Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro\", \"trade_name\": \"Velphoro\", \"indication\": \"Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro\", \"ncpe_year\": 2014, \"eu_market\": \"2014-08-26T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-10-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/velphoro\", \"ta_list\": \"Hyperphosphatemia; Renal Dialysis\", \"rr_status\": \"No HTA\"}, {\"id\": 2462, \"last_scrape\": \"2018-12-13T16:46:30\", \"url\": \"http://www.ncpe.ie/drugs/pomalidomide-imnovid/\", \"rr_start\": \"2013-09-20T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-20, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Pomalidomide (Imnovid\", \"trade_name\": \"Imnovid\", \"indication\": \"Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-09-20T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2463, \"last_scrape\": \"2018-12-13T16:46:32\", \"url\": \"http://www.ncpe.ie/drugs/ponatinib-iclusig/\", \"rr_start\": \"2013-10-02T00:00:00\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-10-02, 2013-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Ponatinib (Iclusig\", \"trade_name\": \"Iclusig\", \"indication\": \"Ponatinib (Iclusig\", \"ncpe_year\": 2016, \"eu_market\": \"2013-07-01T00:00:00\", \"company\": \"Incyte\", \"orphan\": 1, \"earliest\": \"2013-10-02T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig\", \"ta_list\": \"Leukemia, Myeloid; Leukemia, Lymphoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2464, \"last_scrape\": \"2018-12-13T16:46:38\", \"url\": \"http://www.ncpe.ie/drugs/prasugrel-efient/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Prasugrel (Efient\", \"trade_name\": \"Efient\", \"indication\": \"Economic Evaluation of Prasugrel (Efient\", \"ncpe_year\": 2010, \"eu_market\": \"2009-02-24T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2010-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/efient\", \"ta_list\": \"Acute Coronary Syndrome; Angina, Unstable; Myocardial Infarction\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2465, \"last_scrape\": \"2018-12-13T16:46:46\", \"url\": \"http://www.ncpe.ie/drugs/pregabalin-lyrica-2/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin (Lyrica\", \"trade_name\": \"Lyrica\", \"indication\": \"Lyrica\", \"ncpe_year\": 2015, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-30T00:00:00\", \"latest\": \"2015-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2466, \"last_scrape\": \"2018-12-13T16:46:52\", \"url\": \"http://www.ncpe.ie/drugs/pregabalin-lyrica-for-the-treatment-of-generalised-anxiety-disorder/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin (Lyrica\", \"trade_name\": \"Lyrica\", \"indication\": \"Pregabalin (Lyrica\", \"ncpe_year\": 2014, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-12-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2467, \"last_scrape\": \"2018-12-13T16:46:58\", \"url\": \"http://www.ncpe.ie/drugs/prucalopride-resolor/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-01-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-01-17\", \"rr_multiple\": 0, \"drug_name\": \"Prucalopride (Resolor\", \"trade_name\": \"Resolor\", \"indication\": \"Prucalopride (Resolor\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-14T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2011-01-17T00:00:00\", \"latest\": \"2011-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/resolor\", \"ta_list\": \"Constipation\", \"rr_status\": \"No HTA\"}, {\"id\": 2468, \"last_scrape\": \"2018-12-13T16:47:00\", \"url\": \"http://www.ncpe.ie/drugs/radium-223-xofigo/\", \"rr_start\": \"2013-11-28T00:00:00\", \"rr_end\": \"2013-12-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-11-28, 2013-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Radium-223 (Xofigo\", \"trade_name\": \"Xofigo\", \"indication\": \"Radium-223 (Xofigo\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-13T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2469, \"last_scrape\": \"2018-12-13T16:47:03\", \"url\": \"http://www.ncpe.ie/drugs/ramucirumab-cyramza/\", \"rr_start\": \"2014-12-20T00:00:00\", \"rr_end\": \"2014-12-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-20, 2014-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Ramucirumab (Cyramza\", \"trade_name\": \"Cyramza\", \"indication\": \"Indicated in combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction (GEJ) adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-12-19T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2014-12-20T00:00:00\", \"latest\": \"2016-07-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2470, \"last_scrape\": \"2018-12-13T16:47:06\", \"url\": \"http://www.ncpe.ie/drugs/ranolazine-ranexa/\", \"rr_start\": \"2009-11-19T00:00:00\", \"rr_end\": \"2009-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ranolazine (Ranexa\", \"trade_name\": \"Ranexa\", \"indication\": \"Cost-effectiveness of Ranolazine (Ranexa\", \"ncpe_year\": 2009, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2009-11-19T00:00:00\", \"latest\": \"2009-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2471, \"last_scrape\": \"2018-12-13T16:47:13\", \"url\": \"http://www.ncpe.ie/drugs/regadenoson-rapiscan/\", \"rr_start\": \"2011-09-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-09-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Regadenoson (Rapiscan\", \"trade_name\": \"Rapiscan\", \"indication\": \"Cost-effectiveness of Regadenoson (Rapiscan\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-06T00:00:00\", \"company\": \"GE\", \"orphan\": 0, \"earliest\": \"2011-09-19T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rapiscan\", \"ta_list\": \"Myocardial Perfusion Imaging\", \"rr_status\": \"No HTA\"}, {\"id\": 2472, \"last_scrape\": \"2018-12-13T16:47:17\", \"url\": \"http://www.ncpe.ie/drugs/regorafenib-stivarga-for-gist/\", \"rr_start\": \"2014-09-18T00:00:00\", \"rr_end\": \"2014-10-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-09-18, 2014-10-06\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib (Stivarga\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib (Stivarga\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2014-09-18T00:00:00\", \"latest\": \"2014-10-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2473, \"last_scrape\": \"2018-12-13T16:47:23\", \"url\": \"http://www.ncpe.ie/drugs/reslizumab-cinqaero/\", \"rr_start\": \"2017-01-23T00:00:00\", \"rr_end\": \"2017-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-01-23, 2017-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Reslizumab (Cinqaero\", \"trade_name\": \"Cinqaero\", \"indication\": \"Cinqaero\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-15T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2017-01-23T00:00:00\", \"latest\": \"2017-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cinqaero\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2474, \"last_scrape\": \"2018-12-13T16:47:27\", \"url\": \"http://www.ncpe.ie/drugs/retigabine-trobalt/\", \"rr_start\": \"2011-04-06T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-04-06, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Retigabine (Trobalt\", \"trade_name\": \"Trobalt\", \"indication\": \"Cost-effectiveness of Retigabine (Trobalt\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-27T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-04-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"No HTA\"}, {\"id\": 2475, \"last_scrape\": \"2018-12-13T16:47:29\", \"url\": \"http://www.ncpe.ie/drugs/ribociclib-kisqali/\", \"rr_start\": \"2017-09-04T00:00:00\", \"rr_end\": \"2017-09-19T00:00:00\", \"rr_outcome\": \"FOLLOWING NCPE ASSESSMENT OF THE COMPANY SUBMISSION, THE NCPE RECOMMENDS THAT RIBOCICLIB (IN COMBINATION WITH AN AROMATASE INHIBITOR) FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR+/HER2- LOCALLY ADVANCED OR METASTATIC BC AS INITIAL ENDOCRINE-BASED THERAPY, NOT BE CONSIDERED FOR REIMBURSEMENT UNLESS COST EFFECTIVENESS CAN BE IMPROVED RELATIVE TO EXISTING TREATMENTS. THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2017-09-04, 2017-09-19\", \"rr_multiple\": 0, \"drug_name\": \"Ribociclib (Kisqali\", \"trade_name\": \"Kisqali\", \"indication\": \"Ribociclib (Kisqali\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2017-09-04T00:00:00\", \"latest\": \"2018-08-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2476, \"last_scrape\": \"2018-12-13T16:47:35\", \"url\": \"http://www.ncpe.ie/drugs/rifaximin-targaxan-2/\", \"rr_start\": \"2013-07-09T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-09, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Rifaximin (Targaxan\", \"trade_name\": \"Targaxan\", \"indication\": \"Rifaximin (Targaxan\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-07-09T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2477, \"last_scrape\": \"2018-12-13T16:47:38\", \"url\": \"http://www.ncpe.ie/drugs/rigorafenib-stivarga/\", \"rr_start\": \"2013-09-12T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-12, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib (Stivarga\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib (Stivarga\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-09-12T00:00:00\", \"latest\": \"2014-06-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2478, \"last_scrape\": \"2018-12-13T16:47:42\", \"url\": \"http://www.ncpe.ie/drugs/rilpivirine-edurant/\", \"rr_start\": \"2011-12-14T00:00:00\", \"rr_end\": \"2012-01-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-12-14, 2012-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine (Edurant\", \"trade_name\": \"Edurant\", \"indication\": \"Rilpivirine in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ? 100,000 HIV-1 RNA copies/ml.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-11-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-12-14T00:00:00\", \"latest\": \"2012-01-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/edurant\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2479, \"last_scrape\": \"2018-12-13T16:47:45\", \"url\": \"http://www.ncpe.ie/drugs/rilpivirine-r-emtricitabine-f-tenofovir-alafenamide-taf-odefsey/\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMEDED\", \"rr_dates\": \"2016-06-28, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) (Odefsey\", \"trade_name\": \"Odefsey\", \"indication\": \"Odefsey\", \"ncpe_year\": 2016, \"eu_market\": \"2016-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2480, \"last_scrape\": \"2018-12-13T16:47:48\", \"url\": \"http://www.ncpe.ie/drugs/rimonabant-acomplia-2/\", \"rr_start\": \"\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rimonabant (Acomplia\", \"trade_name\": \"Acomplia\", \"indication\": \"In June 2006, Sanofi-Aventis submitted an evaluation of the cost-effectiveness of rimonabant (in addition to diet and exercise) in the management of multiple cardiovascular risks in overweight or obese patients in Ireland, to support its application for reimbursement of rimonabant under the Community Drugs Schemes. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-06-19T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2006-06-01T00:00:00\", \"latest\": \"2006-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/acomplia\", \"ta_list\": \"Obesity\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2481, \"last_scrape\": \"2018-12-13T16:47:53\", \"url\": \"http://www.ncpe.ie/drugs/riociguat-adempas/\", \"rr_start\": \"2014-04-11T00:00:00\", \"rr_end\": \"2014-05-16T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED AT THE CURRENT PRICE.\", \"rr_dates\": \"2014-04-11, 2014-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Riociguat (Adempas\", \"trade_name\": \"Adempas\", \"indication\": \"Riociguat (Adempas\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-27T00:00:00\", \"company\": \"Bayer\", \"orphan\": 1, \"earliest\": \"2014-04-11T00:00:00\", \"latest\": \"2014-05-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adempas\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2482, \"last_scrape\": \"2018-12-13T16:47:59\", \"url\": \"http://www.ncpe.ie/drugs/rituximab-mabthera/\", \"rr_start\": \"2014-05-26T00:00:00\", \"rr_end\": \"2014-09-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-26, 2014-09-22\", \"rr_multiple\": 0, \"drug_name\": \"Rituximab (MabThera\", \"trade_name\": \"MabThera\", \"indication\": \"Rituximab (MabThera\", \"ncpe_year\": 2014, \"eu_market\": \"1998-06-02T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-05-26T00:00:00\", \"latest\": \"2014-09-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"No HTA\"}, {\"id\": 2483, \"last_scrape\": \"2018-12-13T16:48:05\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-atrial-fibrillation-patients-undergoing-pci/\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2484, \"last_scrape\": \"2018-12-13T16:48:10\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-dvt/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Economic evaluation of Rivaroxaban (Xarelto\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-02-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2485, \"last_scrape\": \"2018-12-13T16:48:15\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-spaf-2/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban (Xarelto\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2486, \"last_scrape\": \"2018-12-13T16:48:18\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-the-prevention-of-atherothrombotic-events/\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-11T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF RIVAROXABAN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-26, 2018-10-11\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban (Xarelto\", \"ncpe_year\": 2018, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2487, \"last_scrape\": \"2018-12-13T16:48:25\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-low-dose-for-prevention-of-recurrent-venous-thromboembolism/\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2488, \"last_scrape\": \"2018-12-13T16:48:30\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban (Xarelto\", \"ncpe_year\": 2008, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2008-04-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2489, \"last_scrape\": \"2018-12-13T16:48:33\", \"url\": \"http://www.ncpe.ie/drugs/roflumilast-daxas/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Roflumilast (Daxas\", \"trade_name\": \"Daxas\", \"indication\": \"Cost Effectiveness of Roflumilast (Daxas\", \"ncpe_year\": 2010, \"eu_market\": \"2010-07-05T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-11T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/daxas\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2490, \"last_scrape\": \"2018-12-13T16:48:40\", \"url\": \"http://www.ncpe.ie/drugs/rolapitant-varuby/\", \"rr_start\": \"2017-05-15T00:00:00\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-05-15, 2017-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Rolapitant (Varuby\", \"trade_name\": \"Varuby\", \"indication\": \"Rolapitant (Varuby\", \"ncpe_year\": 2017, \"eu_market\": \"2017-04-19T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 0, \"earliest\": \"2017-05-15T00:00:00\", \"latest\": \"2017-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/varuby\", \"ta_list\": \"Vomiting; Nausea; Cancer\", \"rr_status\": \"No HTA\"}, {\"id\": 2491, \"last_scrape\": \"2018-12-13T16:48:43\", \"url\": \"http://www.ncpe.ie/drugs/romiplostim-nplate/\", \"rr_start\": \"\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Romiplostim (Nplate\", \"trade_name\": \"Nplate\", \"indication\": \"Romiplostim (Nplate\", \"ncpe_year\": 2015, \"eu_market\": \"2009-02-04T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-04-02T00:00:00\", \"latest\": \"2015-05-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nplate\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2492, \"last_scrape\": \"2018-12-13T16:48:47\", \"url\": \"http://www.ncpe.ie/drugs/ropivacaine-readyfusor/\", \"rr_start\": \"2018-11-09T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"FULL HTA IS NOT RECOMMENDED. THE NCPE RECOMMENDS THAT ROPIVICAINE READYFUSOR NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE.  THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013.\", \"rr_dates\": \"2018-11-09, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ropivacaine Readyfusor\", \"trade_name\": \"Ropivacaine Readyfusor\", \"indication\": \"Ropivacaine Readyfusor for acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block (CPNB) via a continuous infusion.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-09T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"id\": 2493, \"last_scrape\": \"2018-12-13T16:48:50\", \"url\": \"http://www.ncpe.ie/drugs/ruxolitinib-jakavi-for-polycythaemia-vera/\", \"rr_start\": \"2015-04-15T00:00:00\", \"rr_end\": \"2015-05-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-04-15, 2015-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib (Jakavi\", \"trade_name\": \"Jakavi\", \"indication\": \"Jakavi\", \"ncpe_year\": 2016, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2015-04-15T00:00:00\", \"latest\": \"2016-08-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2494, \"last_scrape\": \"2018-12-13T16:48:55\", \"url\": \"http://www.ncpe.ie/drugs/ruxolitinib-jakavi/\", \"rr_start\": \"2012-08-01T00:00:00\", \"rr_end\": \"2012-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-08-01, 2012-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib (Jakavi\", \"trade_name\": \"Jakavi\", \"indication\": \"Ruxolitinib (Jakavi\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2012-08-01T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2495, \"last_scrape\": \"2018-12-13T16:48:58\", \"url\": \"http://www.ncpe.ie/drugs/sacubitrilvalsartan-entresto/\", \"rr_start\": \"2015-11-06T00:00:00\", \"rr_end\": \"2015-11-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-06, 2015-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Sacubitril/valsartan (Entresto\", \"trade_name\": \"Entresto\", \"indication\": \"Entresto\", \"ncpe_year\": 2017, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-06T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entresto\", \"ta_list\": \"Heart Failure\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2496, \"last_scrape\": \"2018-12-13T16:49:04\", \"url\": \"http://www.ncpe.ie/drugs/safinamide-methansulfonate-xadago/\", \"rr_start\": \"2016-06-14T00:00:00\", \"rr_end\": \"2016-07-06T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED.\", \"rr_dates\": \"2016-06-14, 2016-07-06\", \"rr_multiple\": 0, \"drug_name\": \"Safinamide methansulfonate (Xadago\", \"trade_name\": \"Xadago\", \"indication\": \"Xadago\", \"ncpe_year\": 2016, \"eu_market\": \"2015-02-23T00:00:00\", \"company\": \"Zambon\", \"orphan\": 0, \"earliest\": \"2016-06-14T00:00:00\", \"latest\": \"2016-07-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xadago\", \"ta_list\": \"Parkinson Disease\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2497, \"last_scrape\": \"2018-12-13T16:49:07\", \"url\": \"http://www.ncpe.ie/drugs/sapropterin-kuvan/\", \"rr_start\": \"2015-07-14T00:00:00\", \"rr_end\": \"2015-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-07-14, 2015-08-14, 2015-07-01\", \"rr_multiple\": 1, \"drug_name\": \"Sapropterin (Kuvan\", \"trade_name\": \"Kuvan\", \"indication\": \"Sapropterin (Kuvan\", \"ncpe_year\": 2017, \"eu_market\": \"2008-12-02T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2009-01-01T00:00:00\", \"latest\": \"2017-09-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kuvan\", \"ta_list\": \"Phenylketonurias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2498, \"last_scrape\": \"2018-12-13T16:49:11\", \"url\": \"http://www.ncpe.ie/drugs/sarilumab-kevzara/\", \"rr_start\": \"2017-08-18T00:00:00\", \"rr_end\": \"2017-10-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-08-18, 2017-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Sarilumab (Kevzara\", \"trade_name\": \"Kevzara\", \"indication\": \"Sarilumab (Kevzara\", \"ncpe_year\": 2017, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-08-18T00:00:00\", \"latest\": \"2017-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2499, \"last_scrape\": \"2018-12-13T16:49:16\", \"url\": \"http://www.ncpe.ie/drugs/sebelipase-alfa-kanuma/\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-02-08, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Sebelipase alfa (Kanuma\", \"trade_name\": \"Kanuma\", \"indication\": \"Sebelipase alfa is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2018-06-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kanuma\", \"ta_list\": \"Lipid Metabolism, Inborn Errors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2500, \"last_scrape\": \"2018-12-13T16:49:20\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-ankylosing-spondylitis/\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-02, 2015-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"id\": 2501, \"last_scrape\": \"2018-12-13T16:49:25\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-psoriatic-arthritis/\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-02, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"id\": 2502, \"last_scrape\": \"2018-12-13T16:49:31\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx/\", \"rr_start\": \"2014-12-19T00:00:00\", \"rr_end\": \"2015-02-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-19, 2015-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-12-19T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2503, \"last_scrape\": \"2018-12-13T16:49:34\", \"url\": \"http://www.ncpe.ie/drugs/selexipag-uptravi/\", \"rr_start\": \"2016-11-01T00:00:00\", \"rr_end\": \"2016-12-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-01, 2016-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Selexipag (Uptravi\", \"trade_name\": \"Uptravi\", \"indication\": \"Selexipag (Uptravi\", \"ncpe_year\": 2018, \"eu_market\": \"2016-05-12T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2016-11-01T00:00:00\", \"latest\": \"2018-05-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2504, \"last_scrape\": \"2018-12-13T16:49:39\", \"url\": \"http://www.ncpe.ie/drugs/semaglutide-ozempic/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-03-12, 2018-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Semaglutide (Ozempic\", \"trade_name\": \"Ozempic\", \"indication\": \"Semaglutide (Ozempic\", \"ncpe_year\": 2018, \"eu_market\": \"2018-02-08T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-04-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2505, \"last_scrape\": \"2018-12-13T16:49:44\", \"url\": \"http://www.ncpe.ie/drugs/sildenafil-revatio/\", \"rr_start\": \"2014-04-16T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-04-16, 2014-05-23\", \"rr_multiple\": 0, \"drug_name\": \"Sildenafil (Revatio\", \"trade_name\": \"Revatio\", \"indication\": \"Sildenafil (Revatio\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2014-04-16T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revatio\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2506, \"last_scrape\": \"2018-12-13T16:49:49\", \"url\": \"http://www.ncpe.ie/drugs/simeprevir-olysio-in-combination-with-sofosbuvir/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir (Olysio\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir (Olysio\", \"ncpe_year\": 2015, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2015-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olysio\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2507, \"last_scrape\": \"2018-12-13T16:49:53\", \"url\": \"http://www.ncpe.ie/drugs/simeprevir-olysio/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED WHEN USED IN TRIPLE THERAPY WITH PEG-INTERFERON AND RIBAVIRIN.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir (Olysio\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir (Olysio\", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2014-07-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olysio\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2508, \"last_scrape\": \"2018-12-13T16:50:00\", \"url\": \"http://www.ncpe.ie/drugs/sodium-chloride-70mgml-sodium-hyaluronate-1mgml-hyaneb/\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-10, 2014-03-19\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml (Hyaneb\", \"trade_name\": \"Hyaneb\", \"indication\": \"Hyaneb\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2509, \"last_scrape\": \"2018-12-13T16:50:06\", \"url\": \"http://www.ncpe.ie/drugs/sodium-hyaluronate-hyloforte-0-2/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate (Hyloforte\", \"trade_name\": \"Hyloforte 0.2%\", \"indication\": \"Sodium Hyaluronate (Hyloforte\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2510, \"last_scrape\": \"2018-12-13T16:50:09\", \"url\": \"http://www.ncpe.ie/drugs/sodium-hyaluronate-hylotear-0-1/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate (Hylotear\", \"trade_name\": \"Hylotear 0.1%\", \"indication\": \"Sodium Hyaluronate (Hylotear\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2511, \"last_scrape\": \"2018-12-13T16:50:15\", \"url\": \"http://www.ncpe.ie/drugs/sodium-phenylbutyrate-pheburane/\", \"rr_start\": \"2013-07-17T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-17, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Sodium phenylbutyrate (Pheburane\", \"trade_name\": \"Pheburane\", \"indication\": \"Sodium phenylbutyrate (Pheburane\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-30T00:00:00\", \"company\": \"Lucane\", \"orphan\": 0, \"earliest\": \"2013-07-17T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pheburane\", \"ta_list\": \"Carbamoyl-Phosphate Synthase I Deficiency Disease\", \"rr_status\": \"No HTA\"}, {\"id\": 2512, \"last_scrape\": \"2018-12-13T16:50:18\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvir-solvaldi/\", \"rr_start\": \"2014-02-12T00:00:00\", \"rr_end\": \"2014-03-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-02-12, 2014-03-10\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir (Solvaldi\", \"trade_name\": \"Solvaldi\", \"indication\": \"Sofosbuvir (Solvaldi\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-02-12T00:00:00\", \"latest\": \"2014-10-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2513, \"last_scrape\": \"2018-12-13T16:50:22\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvirvelpatasvir-epclusa-chronic-hepatitis-c-virus-hcv-pangenotypic/\", \"rr_start\": \"2017-09-05T00:00:00\", \"rr_end\": \"2017-10-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-05, 2017-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir (Epclusa\", \"trade_name\": \"Epclusa\", \"indication\": \"Sofosbuvir/velpatasvir (Epclusa\", \"ncpe_year\": 2017, \"eu_market\": \"2016-07-06T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-05T00:00:00\", \"latest\": \"2017-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2514, \"last_scrape\": \"2018-12-13T16:50:26\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvirvelpatasvirvoxilaprevir-vosevi/\", \"rr_start\": \"2017-09-19T00:00:00\", \"rr_end\": \"2017-11-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-19, 2017-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi\", \"trade_name\": \"Vosevi\", \"indication\": \"Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-19T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vosevi\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2515, \"last_scrape\": \"2018-12-13T16:50:32\", \"url\": \"http://www.ncpe.ie/drugs/st-johns-wort-pafica/\", \"rr_start\": \"2015-04-14T00:00:00\", \"rr_end\": \"2015-05-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-04-14, 2015-05-29\", \"rr_multiple\": 0, \"drug_name\": \"St Johns Wort (Pacifa\", \"trade_name\": \"Pacifa\", \"indication\": \"Pacifa\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-04-14T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2516, \"last_scrape\": \"2018-12-13T16:50:38\", \"url\": \"http://www.ncpe.ie/drugs/stiripentol-diacomit/\", \"rr_start\": \"2017-07-06T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-06, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Stiripentol (Diacomit\", \"trade_name\": \"Diacomit\", \"indication\": \"Stiripentol (Diacomit\", \"ncpe_year\": 2018, \"eu_market\": \"2007-01-03T00:00:00\", \"company\": \"Biocodex\", \"orphan\": 1, \"earliest\": \"2017-07-06T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/diacomit\", \"ta_list\": \"Myoclonic Epilepsy, Juvenile\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2517, \"last_scrape\": \"2018-12-13T16:50:43\", \"url\": \"http://www.ncpe.ie/drugs/stribild-elvitegravircobicistatemtricitabinetenofovir-disoproxil-as-fumarate/\", \"rr_start\": \"2013-04-28T00:00:00\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-04-28, 2013-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumarate)(Stribild\", \"trade_name\": \"Stribild\", \"indication\": \"Indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-na\", \"ncpe_year\": 2013, \"eu_market\": \"2013-05-24T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2013-04-28T00:00:00\", \"latest\": \"2013-12-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stribild\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2518, \"last_scrape\": \"2018-12-13T16:50:49\", \"url\": \"http://www.ncpe.ie/drugs/sublingual-immunotherapy-grazax/\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sublingual Immunotherapy (Grazax\", \"trade_name\": \"Grazax\", \"indication\": \"A Review of the Cost-Effectiveness of Sublingual Immunotherapy (Grazax\", \"ncpe_year\": 2007, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2007-09-01T00:00:00\", \"latest\": \"2007-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2519, \"last_scrape\": \"2018-12-13T16:50:50\", \"url\": \"http://www.ncpe.ie/drugs/suboxone-buprenorphinenaloxone/\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Buprenorphine/naloxone (Suboxone\", \"trade_name\": \"Suboxone\", \"indication\": \"An economic evaluation of suboxone for the management of opiate addiction.\", \"ncpe_year\": 2014, \"eu_market\": \"2006-09-26T00:00:00\", \"company\": \"Indivior\", \"orphan\": 0, \"earliest\": \"2007-11-01T00:00:00\", \"latest\": \"2014-05-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/suboxone\", \"ta_list\": \"Opioid-Related Disorders\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2520, \"last_scrape\": \"2018-12-13T16:50:54\", \"url\": \"http://www.ncpe.ie/drugs/sufentanil-zalviso/\", \"rr_start\": \"2016-03-14T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-03-14, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Sufentanil (Zalviso\", \"trade_name\": \"Zalviso\", \"indication\": \"Sufentanil (Zalviso\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Gr\", \"orphan\": 0, \"earliest\": \"2016-03-14T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zalviso\", \"ta_list\": \"Pain, Postoperative\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2521, \"last_scrape\": \"2018-12-13T16:50:59\", \"url\": \"http://www.ncpe.ie/drugs/sunitinib-sutent/\", \"rr_start\": \"\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sunitinib (Sutent\", \"trade_name\": \"Sutent\", \"indication\": \"In September 2006, Pfizer Healthcare Ireland submitted an evaluation of the cost-effectiveness and budget impact of sunitinib as second-line treatment of patients with gastro-intestinal stromal tumours (GIST). Data on the cost-effectiveness and budget impact of sutinitinib as second line treatment for patients with metastatic renal cell carcinoma (mRCC) was also presented. The purpose of the submission was to support an application for reimbursement under the High Tech Drug Scheme. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-07-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-09-01T00:00:00\", \"latest\": \"2006-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sutent\", \"ta_list\": \"Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2522, \"last_scrape\": \"2018-12-13T16:51:04\", \"url\": \"http://www.ncpe.ie/drugs/tadalafil-adcirca-2/\", \"rr_start\": \"2011-07-13T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-07-13, 2011-09-21, 2014-05-09, 2014-05-23\", \"rr_multiple\": 1, \"drug_name\": \"Tadalafil (Adcirca\", \"trade_name\": \"Adcirca\", \"indication\": \"Tadalafil (Adcirca\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-07-13T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2523, \"last_scrape\": \"2018-12-13T16:51:09\", \"url\": \"http://www.ncpe.ie/drugs/tafamadis-meglumine-vyndaqel/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED UNTIL ADDITIONAL EFFICACY AND/OR SAFETY DATA IS SUBMITTED. ON THE BASIS OF CURRENT EVIDENCE, THE NCPE RECOMMENDS THAT TAFAMIDIS NOT BE CONSIDERED FOR REIMBURSEMENT IN ACCORDANCE WITH THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Tafamadis meglumine (Vyndaqel\", \"trade_name\": \"Vyndaqel\", \"indication\": \"Tafamadis meglumine (Vyndaqel\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-16T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel\", \"ta_list\": \"Amyloidosis\", \"rr_status\": \"No HTA until more evidence\"}, {\"id\": 2524, \"last_scrape\": \"2018-12-13T16:51:15\", \"url\": \"http://www.ncpe.ie/drugs/tafluprost-saflutan/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Tafluprost (Saflutan\", \"trade_name\": \"Saflutan\", \"indication\": \"Tafluoprost (Salflutan\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2525, \"last_scrape\": \"2018-12-13T16:51:24\", \"url\": \"http://www.ncpe.ie/drugs/talimogene-laherparepvec-imlygic/\", \"rr_start\": \"2016-02-16T00:00:00\", \"rr_end\": \"2016-03-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-02-16, 2016-03-14\", \"rr_multiple\": 0, \"drug_name\": \"Talimogene Laherparepvec (Imlygic\", \"trade_name\": \"Imlygic\", \"indication\": \"Talimogene laherparepvec (Imlygic\", \"ncpe_year\": 2016, \"eu_market\": \"2015-12-16T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-02-16T00:00:00\", \"latest\": \"2016-03-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2526, \"last_scrape\": \"2018-12-13T16:51:28\", \"url\": \"http://www.ncpe.ie/drugs/tapentadol-palexia/\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Tapentadol (Palexia\", \"trade_name\": \"Palexia\", \"indication\": \"Economic evaluation of oral tapentadol (Palexia\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2011-04-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2527, \"last_scrape\": \"2018-12-13T16:51:34\", \"url\": \"http://www.ncpe.ie/drugs/tedizolid-phosphate-sivextro/\", \"rr_start\": \"2015-05-07T00:00:00\", \"rr_end\": \"2015-07-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-05-07, 2015-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Tedizolid phosphate (Sivextro\", \"trade_name\": \"Sivextro\", \"indication\": \"Tedizolid phosphate (Sivextro\", \"ncpe_year\": 2015, \"eu_market\": \"2015-03-23T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-05-07T00:00:00\", \"latest\": \"2015-07-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sivextro\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"No HTA\"}, {\"id\": 2528, \"last_scrape\": \"2018-12-13T16:51:38\", \"url\": \"http://www.ncpe.ie/drugs/teduglutide-revestive/\", \"rr_start\": \"2017-03-13T00:00:00\", \"rr_end\": \"2017-04-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-13, 2017-04-12\", \"rr_multiple\": 0, \"drug_name\": \"Teduglutide (Revestive\", \"trade_name\": \"Revestive\", \"indication\": \"Teduglutide (Revestive\", \"ncpe_year\": 2018, \"eu_market\": \"2012-08-30T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2017-03-13T00:00:00\", \"latest\": \"2018-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revestive\", \"ta_list\": \"Malabsorption Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2529, \"last_scrape\": \"2018-12-13T16:51:44\", \"url\": \"http://www.ncpe.ie/drugs/tegafurgimeraciloteracil-teysuno/\", \"rr_start\": \"2012-02-27T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-02-27, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Tegafur/Gimeracil/Oteracil (Teysuno\", \"trade_name\": \"Teysuno\", \"indication\": \"Teysuno is indicated in adults for the treatment of advanced gastric cancer.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-03-14T00:00:00\", \"company\": \"Nordic\", \"orphan\": 0, \"earliest\": \"2012-02-27T00:00:00\", \"latest\": \"2012-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2530, \"last_scrape\": \"2018-12-13T16:51:48\", \"url\": \"http://www.ncpe.ie/drugs/telapravir/\", \"rr_start\": \"2011-10-28T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-10-28, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Telaprevir (Incivo\", \"trade_name\": \"Incivo\", \"indication\": \"Economic evaluation of Telaprevir (Incivo\", \"ncpe_year\": 2012, \"eu_market\": \"2011-09-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-28T00:00:00\", \"latest\": \"2012-01-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/incivo\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2531, \"last_scrape\": \"2018-12-13T16:51:52\", \"url\": \"http://www.ncpe.ie/drugs/telavancin-vibativ/\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-12-08, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Telavancin (Vibativ\", \"trade_name\": \"Vibativ\", \"indication\": \"Indicated for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumomia, known or suspended to be caused by methicillin-resistant Staphylococcus aureas (MRSA).  Vabitiv\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Theravance\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2015-01-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vibativ-0\", \"ta_list\": \"Pneumonia, Bacterial; Cross Infection\", \"rr_status\": \"No HTA\"}, {\"id\": 2532, \"last_scrape\": \"2018-12-13T16:51:56\", \"url\": \"http://www.ncpe.ie/drugs/teriflunomide-aubagio/\", \"rr_start\": \"2013-08-27T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-08-27, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Teriflunomide (Aubagio\", \"trade_name\": \"Aubagio\", \"indication\": \"Aubagio\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2013-08-27T00:00:00\", \"latest\": \"2014-09-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2533, \"last_scrape\": \"2018-12-13T16:51:58\", \"url\": \"http://www.ncpe.ie/drugs/ticagrelor-brilique-2/\", \"rr_start\": \"2016-02-29T00:00:00\", \"rr_end\": \"2016-05-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-29, 2016-05-04\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor (Brilique\", \"trade_name\": \"Brilique\", \"indication\": \"Ticagrelor (Brilique\", \"ncpe_year\": 2016, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-29T00:00:00\", \"latest\": \"2016-05-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brilique\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2534, \"last_scrape\": \"2018-12-13T16:52:01\", \"url\": \"http://www.ncpe.ie/drugs/ticagrelor-brilique/\", \"rr_start\": \"2010-11-25T00:00:00\", \"rr_end\": \"2011-01-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-11-25, 2011-01-20\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor (Brilique\", \"trade_name\": \"Brilique\", \"indication\": \"Economic Evaluation of Ticagrelor (Brilique\", \"ncpe_year\": 2011, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-11-25T00:00:00\", \"latest\": \"2011-10-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brilique\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2535, \"last_scrape\": \"2018-12-13T16:52:07\", \"url\": \"http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-all/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-19T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TISAGENLECLEUCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel (Kymriah\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel (Kymriah\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2536, \"last_scrape\": \"2018-12-13T16:52:13\", \"url\": \"http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-dlbcl/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TISAGENLECLEUCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel (Kymriah\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel (Kymriah\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2537, \"last_scrape\": \"2018-12-13T16:52:19\", \"url\": \"http://www.ncpe.ie/drugs/tobramycin-tobi-podhaler/\", \"rr_start\": \"2010-11-10T00:00:00\", \"rr_end\": \"2010-11-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2010-11-10, 2010-11-03\", \"rr_multiple\": 0, \"drug_name\": \"Tobramycin (TOBI Podhaler\", \"trade_name\": \"TOBI Podhaler\", \"indication\": \"Tobramycin (TOBI Podhaler\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-11-01T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2538, \"last_scrape\": \"2018-12-13T16:52:24\", \"url\": \"http://www.ncpe.ie/drugs/tocilizumab-sc-roactemra/\", \"rr_start\": \"2014-04-28T00:00:00\", \"rr_end\": \"2014-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THESUBMITTED PRICE.\", \"rr_dates\": \"2014-04-28, 2014-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Tocilizumab SC (RoActemra\", \"trade_name\": \"RoActemra\", \"indication\": \"It is licensed for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.  It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-04-28T00:00:00\", \"latest\": \"2014-07-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra\", \"ta_list\": \"Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2539, \"last_scrape\": \"2018-12-13T16:52:30\", \"url\": \"http://www.ncpe.ie/drugs/tofacitinib-xeljanz-for-ulcerative-colitis/\", \"rr_start\": \"2018-07-16T00:00:00\", \"rr_end\": \"2018-09-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TOFACITINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-07-16, 2018-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib (Xeljanz\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy (i.e. corticosteroids, azathioprine, 6-mercaptopurine) or a biologic agent (i.e. TNF inhibitor).\", \"ncpe_year\": 2018, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2018-07-16T00:00:00\", \"latest\": \"2018-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2540, \"last_scrape\": \"2018-12-13T16:52:35\", \"url\": \"http://www.ncpe.ie/drugs/tofacitinib-xeljanz/\", \"rr_start\": \"2017-03-08T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-08, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib (Xeljanz\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib (Xeljanz\", \"ncpe_year\": 2017, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-03-08T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2541, \"last_scrape\": \"2018-12-13T16:52:40\", \"url\": \"http://www.ncpe.ie/drugs/tolvaptan-jinarc/\", \"rr_start\": \"2016-01-04T00:00:00\", \"rr_end\": \"2016-01-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-04, 2016-01-12\", \"rr_multiple\": 0, \"drug_name\": \"Tolvaptan (Jinarc\", \"trade_name\": \"Jinarc\", \"indication\": \"Jinarc\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2016-01-04T00:00:00\", \"latest\": \"2018-09-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc\", \"ta_list\": \"Polycystic Kidney, Autosomal Dominant\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2542, \"last_scrape\": \"2018-12-13T16:52:45\", \"url\": \"http://www.ncpe.ie/drugs/tramadol-hydrochloridedexketoprofen-skudexa/\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"REIMURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-10-17, 2017-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Tramadol hydrochloride/dexketoprofen (Skudexa\", \"trade_name\": \"Skudexa\", \"indication\": \"Tramadol hydrochloride/dexketoprofen (Skudexa \", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2017-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2543, \"last_scrape\": \"2018-12-13T16:52:51\", \"url\": \"http://www.ncpe.ie/drugs/trametinib-mekinist/\", \"rr_start\": \"2015-11-27T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-27, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Trametinib (Mekinist\", \"trade_name\": \"Mekinist\", \"indication\": \"Mekinist\", \"ncpe_year\": 2018, \"eu_market\": \"2014-06-30T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-27T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2544, \"last_scrape\": \"2018-12-13T16:52:56\", \"url\": \"http://www.ncpe.ie/drugs/trastuzumab-emtansine-kadcyla/\", \"rr_start\": \"2013-09-25T00:00:00\", \"rr_end\": \"2013-10-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-25, 2013-10-24\", \"rr_multiple\": 0, \"drug_name\": \"Trastuzumab emtansine (Kadcyla\", \"trade_name\": \"Kadcyla\", \"indication\": \"Trastuzumab emtansine (Kadcyla\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-09-25T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2545, \"last_scrape\": \"2018-12-13T16:53:00\", \"url\": \"http://www.ncpe.ie/drugs/trifluridinetipiracil-lonsurf/\", \"rr_start\": \"2016-06-10T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-06-10, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Trifluridine/tipiracil (Lonsurf\", \"trade_name\": \"Lonsurf\", \"indication\": \"Trifluridine/tipiracil (Lonsurf\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2016-06-10T00:00:00\", \"latest\": \"2016-07-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2546, \"last_scrape\": \"2018-12-13T16:53:04\", \"url\": \"http://www.ncpe.ie/drugs/ulipristal-acetate-esmya-2/\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-05-17, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate (Esmya \", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate is indicated for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-05-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esmya\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2547, \"last_scrape\": \"2018-12-13T16:53:08\", \"url\": \"http://www.ncpe.ie/drugs/ulipristal-acetate-esmya/\", \"rr_start\": \"2013-09-03T00:00:00\", \"rr_end\": \"2013-10-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-09-03, 2013-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate (Esmya\", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate (Esmya\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2013-09-03T00:00:00\", \"latest\": \"2013-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esmya\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2548, \"last_scrape\": \"2018-12-13T16:53:10\", \"url\": \"http://www.ncpe.ie/drugs/umeclidiniumvilanterol-anoro/\", \"rr_start\": \"2014-06-11T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-06-11, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Umeclidinium/vilanterol (Anoro\", \"trade_name\": \"Anoro\", \"indication\": \"Umeclidinium/vilanterol (Anoro\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-06-11T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2549, \"last_scrape\": \"2018-12-13T16:53:12\", \"url\": \"http://www.ncpe.ie/drugs/urea-glucorx-allpresan/\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT GLUCORX ALLPRESAN DIABETIC FOAM CREAM NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE IN ACCORDANCE WITH THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2018-07-09, 2018-07-24\", \"rr_multiple\": 0, \"drug_name\": \"Urea (GlucoRx Allpresan\", \"trade_name\": \"GlucoRx Allpresan\", \"indication\": \"GlucoRx Allpresan\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-07-24T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2550, \"last_scrape\": \"2018-12-13T16:53:17\", \"url\": \"http://www.ncpe.ie/drugs/ustekinumab-stelara-2/\", \"rr_start\": \"2016-11-28T00:00:00\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-11-28, 2017-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab (Stelara\", \"trade_name\": \"Stelara\", \"indication\": \"Ustekinumab is indicated for the treatment of adult patients with moderately to severely active Crohn\", \"ncpe_year\": 2017, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2016-11-28T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stelara\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2551, \"last_scrape\": \"2018-12-13T16:53:23\", \"url\": \"http://www.ncpe.ie/drugs/ustekinumab-stelara/\", \"rr_start\": \"\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab (Stelara\", \"trade_name\": \"Stelara\", \"indication\": \"Cost-effectiveness of Ustekinumab (Stelara\", \"ncpe_year\": 2009, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2009-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stelara\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2552, \"last_scrape\": \"2018-12-13T16:53:29\", \"url\": \"http://www.ncpe.ie/drugs/vandetanib-caprelsa/\", \"rr_start\": \"2013-06-06T00:00:00\", \"rr_end\": \"2013-07-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-06, 2013-07-03\", \"rr_multiple\": 0, \"drug_name\": \"Vandetanib (Caprelsa\", \"trade_name\": \"Caprelsa\", \"indication\": \"Vandetanib (Caprelsa\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-16T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2013-06-06T00:00:00\", \"latest\": \"2013-07-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2553, \"last_scrape\": \"2018-12-13T16:53:32\", \"url\": \"http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-crohns-disease/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab (Entyvio\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab (Entyvio\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2554, \"last_scrape\": \"2018-12-13T16:53:39\", \"url\": \"http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-ulcerative-colitis/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab (Entyvio\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab (Entyvio\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2555, \"last_scrape\": \"2018-12-13T16:53:45\", \"url\": \"http://www.ncpe.ie/drugs/velaglucerase-alfa-vpriv-2/\", \"rr_start\": \"2011-04-26T00:00:00\", \"rr_end\": \"2011-06-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-04-26, 2011-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Velaglucerase Alfa (VPRIV\", \"trade_name\": \"VPRIV\", \"indication\": \"VPRIV is indicated for long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-04-26T00:00:00\", \"latest\": \"2011-06-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2556, \"last_scrape\": \"2018-12-13T16:53:49\", \"url\": \"http://www.ncpe.ie/drugs/venetoclax-venclyxto-in-combination-with-rituximab/\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF VENETOCLAX COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-26, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax (Venclyxto\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax (Venclyxto\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2557, \"last_scrape\": \"2018-12-13T16:53:52\", \"url\": \"http://www.ncpe.ie/drugs/venetoclax-venclyxto/\", \"rr_start\": \"2018-05-08T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"FOLLOWING A RESUBMISSION OF THE RAPID REVIEW A FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, WHICH IS NOT COMPARABLE WITH CURRENT AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-05-08, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax (Venclyxto\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL)\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2558, \"last_scrape\": \"2018-12-13T16:53:58\", \"url\": \"http://www.ncpe.ie/drugs/vermurafenib-zelboraf/\", \"rr_start\": \"2011-12-23T00:00:00\", \"rr_end\": \"2012-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-12-23, 2012-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Vemurafenib (Zelboraf\", \"trade_name\": \"Zelboraf\", \"indication\": \"Vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\", \"ncpe_year\": 2014, \"eu_market\": \"2012-02-17T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2011-12-23T00:00:00\", \"latest\": \"2014-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2559, \"last_scrape\": \"2018-12-13T16:54:00\", \"url\": \"http://www.ncpe.ie/drugs/vernakalant-brinavess/\", \"rr_start\": \"2010-10-26T00:00:00\", \"rr_end\": \"2010-11-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-10-26, 2010-11-04\", \"rr_multiple\": 0, \"drug_name\": \"Vernakalant (Brinavess\", \"trade_name\": \"Brinavess\", \"indication\": \"Economic evaluation of Vernakalant (Brinavess\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Cardiome\", \"orphan\": 0, \"earliest\": \"2010-10-26T00:00:00\", \"latest\": \"2011-05-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2560, \"last_scrape\": \"2018-12-13T16:54:04\", \"url\": \"http://www.ncpe.ie/drugs/vismodegib-erivedge/\", \"rr_start\": \"2013-05-02T00:00:00\", \"rr_end\": \"2013-05-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-05-02, 2013-05-20\", \"rr_multiple\": 0, \"drug_name\": \"Vismodegib (Erivedge\", \"trade_name\": \"Erivedge\", \"indication\": \"Vismodegib (Erivedge\", \"ncpe_year\": 2017, \"eu_market\": \"2013-07-12T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-05-02T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge\", \"ta_list\": \"Carcinoma, Basal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2561, \"last_scrape\": \"2018-12-13T16:54:11\", \"url\": \"http://www.ncpe.ie/drugs/vortioxetine-brintellix/\", \"rr_start\": \"2014-10-01T00:00:00\", \"rr_end\": \"2014-11-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-10-01, 2014-11-14\", \"rr_multiple\": 0, \"drug_name\": \"Vortioxetine (Brintellix\", \"trade_name\": \"Brintellix\", \"indication\": \"Vortioxetine (Brintellix\", \"ncpe_year\": 2017, \"eu_market\": \"2013-12-18T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2014-10-01T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"HTA recommended at submitted price\"}]}};\n",
       "var opt = {};\n",
       "var type = \"vega-lite\";\n",
       "var id = \"27189485-327d-4a77-a1d3-81a2289393d0\";\n",
       "\n",
       "var output_area = this;\n",
       "\n",
       "require([\"nbextensions/jupyter-vega/index\"], function(vega) {\n",
       "  var target = document.createElement(\"div\");\n",
       "  target.id = id;\n",
       "  target.className = \"vega-embed\";\n",
       "\n",
       "  var style = document.createElement(\"style\");\n",
       "  style.textContent = [\n",
       "    \".vega-embed .error p {\",\n",
       "    \"  color: firebrick;\",\n",
       "    \"  font-size: 14px;\",\n",
       "    \"}\",\n",
       "  ].join(\"\\\\n\");\n",
       "\n",
       "  // element is a jQuery wrapped DOM element inside the output area\n",
       "  // see http://ipython.readthedocs.io/en/stable/api/generated/\\\n",
       "  // IPython.display.html#IPython.display.Javascript.__init__\n",
       "  element[0].appendChild(target);\n",
       "  element[0].appendChild(style);\n",
       "\n",
       "  vega.render(\"#\" + id, spec, type, opt, output_area);\n",
       "}, function (err) {\n",
       "  if (err.requireType !== \"scripterror\") {\n",
       "    throw(err);\n",
       "  }\n",
       "});\n"
      ],
      "text/plain": [
       "<vega.vegalite.VegaLite at 0x2458213d2b0>"
      ]
     },
     "metadata": {
      "jupyter-vega": "#27189485-327d-4a77-a1d3-81a2289393d0"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": []
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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"
     },
     "metadata": {
      "jupyter-vega": "#27189485-327d-4a77-a1d3-81a2289393d0"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "alt.Chart(drugs,title=\"Count Drugs By Company\").mark_bar().encode(\n",
    "    alt.Y('company', sort=alt.EncodingSortField(field=\"company\", op=\"count\", order='descending'),\n",
    "          axis=alt.Axis(title='Drug Company')),\n",
    "    alt.X('count(rr_status)',\n",
    "          axis=alt.Axis(title='Count')),\n",
    "    alt.Color('ncpe_year',title=\"NCPE Year\",sort='descending')).properties(width=700,height=3000)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 2.5 Count: Drugs by Company with Status\n",
    "Which Company has the most HTA recommendations at the submitted price (yellow)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "var spec = {\"config\": {\"view\": {\"width\": 400, \"height\": 300}}, \"data\": {\"name\": \"data-1fb11c1b30e9c74b6a5173f2568cb7ab\"}, \"mark\": \"bar\", \"encoding\": {\"color\": {\"type\": \"nominal\", \"field\": \"rr_status\", \"scale\": {\"domain\": [\"HTA recommended at submitted price\", \"No HTA\", \"No HTA at submitted price\", \"No HTA until more evidence\", \"RR not conducted\", \"Reimbursement not recommended\", \"Reimbursement without HTA\", \"Unknown\"], \"range\": [\"#ffd728\", \"#cd8383\", \"#83af83\", \"#8383c3\", \"#b98d1e\", \"#50b997\", \"#836491\", \"#7d6565\"]}, \"title\": \"Status\"}, \"x\": {\"type\": \"nominal\", \"axis\": {\"title\": \"Drug Company\"}, \"field\": \"company\", \"sort\": {\"op\": \"count\", \"field\": \"company\", \"order\": \"descending\"}}, \"y\": {\"type\": \"nominal\", \"aggregate\": \"count\", \"axis\": {\"title\": \"Count Drugs\"}, \"field\": \"rr_status\"}}, \"height\": 300, \"selection\": {\"selector001\": {\"type\": \"interval\", \"bind\": \"scales\", \"encodings\": [\"x\", \"y\"]}}, \"title\": \"Count Drugs by Company & Status\", \"width\": 3000, \"$schema\": \"https://vega.github.io/schema/vega-lite/v2.6.0.json\", \"datasets\": {\"data-1fb11c1b30e9c74b6a5173f2568cb7ab\": [{\"id\": 2164, \"last_scrape\": \"2018-12-13T16:24:32\", \"url\": \"http://www.ncpe.ie/drugs/abatacept-orencia/\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Abatacept (Orencia\", \"trade_name\": \"Orencia\", \"indication\": \"Subcutaneous Abatacept (Orencia\", \"ncpe_year\": 2015, \"eu_market\": \"2007-05-21T00:00:00\", \"company\": \"\", \"orphan\": 0, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/orencia\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2165, \"last_scrape\": \"2018-12-13T16:24:36\", \"url\": \"http://www.ncpe.ie/drugs/abiraterone-acetate-zytiga-for-mhspc/\", \"rr_start\": \"2018-10-03T00:00:00\", \"rr_end\": \"2018-11-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-10-03, 2018-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Abiraterone acetate (Zytiga\", \"ncpe_year\": 2018, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2018-10-03T00:00:00\", \"latest\": \"2018-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2166, \"last_scrape\": \"2018-12-13T16:24:41\", \"url\": \"http://www.ncpe.ie/drugs/abiratone-acetate-zytiga-for-mcrpc-post-adt/\", \"rr_start\": \"2013-01-03T00:00:00\", \"rr_end\": \"2013-02-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-01-03, 2013-02-01\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation of Abiratone acetate (Zytiga\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-01-03T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2167, \"last_scrape\": \"2018-12-13T16:24:46\", \"url\": \"http://www.ncpe.ie/drugs/abiratone-acetate-zytiga/\", \"rr_start\": \"2011-10-21T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-10-21, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone Acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation and resource implications of Zytiga \", \"ncpe_year\": 2014, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-21T00:00:00\", \"latest\": \"2014-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2168, \"last_scrape\": \"2018-12-13T16:24:49\", \"url\": \"http://www.ncpe.ie/drugs/aceclofenac-vitafen/\", \"rr_start\": \"2016-12-21T00:00:00\", \"rr_end\": \"2017-01-24T00:00:00\", \"rr_outcome\": \"FOLLOWING A RESUBMISSION OF THE RAPID REVIEW A FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-12-21, 2017-01-24\", \"rr_multiple\": 0, \"drug_name\": \"Aceclofenac (Vitafen\", \"trade_name\": \"Vitafen\", \"indication\": \"Aceclofenac (Vitafen\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-07-22T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2169, \"last_scrape\": \"2018-12-13T16:24:56\", \"url\": \"http://www.ncpe.ie/drugs/aclidinium-bromide-eklira-genuair/\", \"rr_start\": \"2012-10-23T00:00:00\", \"rr_end\": \"2012-10-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-23, 2012-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide (Eklira Genuair\", \"trade_name\": \"Eklira Genuair\", \"indication\": \"Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)\", \"ncpe_year\": 2012, \"eu_market\": \"2012-07-20T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-23T00:00:00\", \"latest\": \"2012-10-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"id\": 2170, \"last_scrape\": \"2018-12-13T16:25:00\", \"url\": \"http://www.ncpe.ie/drugs/aclidinium-bromide-formoterol-fumarate-dihydrate-brimica-genuair/\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE.\", \"rr_dates\": \"2015-01-05, 2015-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide / formoterol fumarate dihydrate (Brimica\", \"trade_name\": \"Brimica Genuair\", \"indication\": \"Brimica\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2015-02-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brimica-genuair\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2171, \"last_scrape\": \"2018-12-13T16:25:37\", \"url\": \"http://www.ncpe.ie/drugs/adalimumab-humira/\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-20, 2011-06-02\", \"rr_multiple\": 0, \"drug_name\": \"Adalimumab (Humira\", \"trade_name\": \"Humira\", \"indication\": \"Economic evaluation of Adalimumab (Humira\", \"ncpe_year\": 2011, \"eu_market\": \"2003-09-07T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/humira\", \"ta_list\": \"Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"id\": 2172, \"last_scrape\": \"2018-12-13T16:25:40\", \"url\": \"http://www.ncpe.ie/drugs/adenuric-febuxostat/\", \"rr_start\": \"2009-12-08T00:00:00\", \"rr_end\": \"2009-12-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-12-08\", \"rr_multiple\": 0, \"drug_name\": \"Adenuric (Febuxostat\", \"trade_name\": \"Febuxostat\", \"indication\": \"NCPE review of Adenuric (Febuxostat\", \"ncpe_year\": 2009, \"eu_market\": \"2008-04-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2009-12-08T00:00:00\", \"latest\": \"2009-12-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adenuric\", \"ta_list\": \"Gout\", \"rr_status\": \"No HTA\"}, {\"id\": 2173, \"last_scrape\": \"2018-12-13T16:25:45\", \"url\": \"http://www.ncpe.ie/drugs/afatinib-giotrif/\", \"rr_start\": \"2013-10-01T00:00:00\", \"rr_end\": \"2013-10-13T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-10-01, 2013-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Afatinib (Giotrif\", \"trade_name\": \"Giotrif\", \"indication\": \"GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-na\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-25T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2013-10-01T00:00:00\", \"latest\": \"2013-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2174, \"last_scrape\": \"2018-12-13T16:25:49\", \"url\": \"http://www.ncpe.ie/drugs/aflibercept-eylea/\", \"rr_start\": \"2012-12-10T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-10, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept (Eylea\", \"trade_name\": \"Eylea\", \"indication\": \"Aflibercept (Eylea\", \"ncpe_year\": 2012, \"eu_market\": \"2012-11-21T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2012-12-10T00:00:00\", \"latest\": \"2012-12-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eylea\", \"ta_list\": \"Wet Macular Degeneration; Macular Edema; Diabetes Complications\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2175, \"last_scrape\": \"2018-12-13T16:25:52\", \"url\": \"http://www.ncpe.ie/drugs/aflibercept-zaltrap/\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept (Zaltrap\", \"trade_name\": \"Zaltrap\", \"indication\": \"Aflibercept for the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-01T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-02-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zaltrap\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2176, \"last_scrape\": \"2018-12-13T16:25:58\", \"url\": \"http://www.ncpe.ie/drugs/agomelatine-valdoxan-4/\", \"rr_start\": \"\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Agomelatine (Valdoxan\", \"trade_name\": \"Valdoxan\", \"indication\": \"Economic evaluation of Agomelatine (Valdoxan\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-19T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2009-09-03T00:00:00\", \"latest\": \"2009-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/valdoxan\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2177, \"last_scrape\": \"2018-12-13T16:26:06\", \"url\": \"http://www.ncpe.ie/drugs/alectinib-alecensa/\", \"rr_start\": \"2017-01-03T00:00:00\", \"rr_end\": \"2017-12-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-01-03, 2017-02-27, 2017-11-08, 2017-12-04\", \"rr_multiple\": 1, \"drug_name\": \"Alectinib (Alecensa\", \"trade_name\": \"Alecensa\", \"indication\": \"Alectinib (Alecensa \", \"ncpe_year\": 2018, \"eu_market\": \"2017-02-16T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2178, \"last_scrape\": \"2018-12-13T16:26:12\", \"url\": \"http://www.ncpe.ie/drugs/alemtuzumab-lemtrada/\", \"rr_start\": \"2013-11-08T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-11-08, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Alemtuzumab (Lemtrada\", \"trade_name\": \"Lemtrada\", \"indication\": \"Alemtuzumab (Lemtrada\", \"ncpe_year\": 2014, \"eu_market\": \"2013-09-12T00:00:00\", \"company\": \"Sanofi\", \"orphan\": 0, \"earliest\": \"2013-11-08T00:00:00\", \"latest\": \"2014-06-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2179, \"last_scrape\": \"2018-12-13T16:26:14\", \"url\": \"http://www.ncpe.ie/drugs/alirocumab-praluent/\", \"rr_start\": \"2015-10-13T00:00:00\", \"rr_end\": \"2015-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-10-13, 2015-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Alirocumab (Praluent\", \"trade_name\": \"Praluent\", \"indication\": \"Praluent\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2015-10-13T00:00:00\", \"latest\": \"2018-03-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/praluent\", \"ta_list\": \"Dyslipidemias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2180, \"last_scrape\": \"2018-12-13T16:26:16\", \"url\": \"http://www.ncpe.ie/drugs/alogliptin-vipidia/\", \"rr_start\": \"2013-09-27T00:00:00\", \"rr_end\": \"2013-10-30T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-09-27, 2013-10-30\", \"rr_multiple\": 0, \"drug_name\": \"Alogliptin (Vipidia\", \"trade_name\": \"Vipidia\", \"indication\": \"Alogliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-18T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2013-09-27T00:00:00\", \"latest\": \"2013-10-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vipidia\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2181, \"last_scrape\": \"2018-12-13T16:26:21\", \"url\": \"http://www.ncpe.ie/drugs/ambrisentan-volibris/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-05-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Ambrisentan (Volibris\", \"trade_name\": \"Volibris\", \"indication\": \"Cost Effectiveness of ambrisentan (Volibris\", \"ncpe_year\": 2014, \"eu_market\": \"2008-04-20T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 1, \"earliest\": \"2008-10-01T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/volibris\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2182, \"last_scrape\": \"2018-12-13T16:26:23\", \"url\": \"http://www.ncpe.ie/drugs/amifampridine-firdapse/\", \"rr_start\": \"2011-11-07T00:00:00\", \"rr_end\": \"2011-12-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-11-07, 2011-12-09\", \"rr_multiple\": 0, \"drug_name\": \"Amifampridine (Firdapse\", \"trade_name\": \"Firdapse\", \"indication\": \"For Lambert Eaton Myasthenic Syndrome (LEMS).  This high cost drug is likely to require a full HTA due to significant budget impact.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-11-07T00:00:00\", \"latest\": \"2011-12-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2183, \"last_scrape\": \"2018-12-13T16:26:29\", \"url\": \"http://www.ncpe.ie/drugs/amsacrine-amsidine/\", \"rr_start\": \"2017-01-10T00:00:00\", \"rr_end\": \"2017-02-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-01-10, 2017-02-15\", \"rr_multiple\": 0, \"drug_name\": \"Amsacrine (Amsidine\", \"trade_name\": \"Amsidine\", \"indication\": \"Amsidine\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2017-01-10T00:00:00\", \"latest\": \"2017-02-15T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2184, \"last_scrape\": \"2018-12-13T16:26:35\", \"url\": \"http://www.ncpe.ie/drugs/apixaban-eliquis-for-treatment-of-deep-vein-thrombosis-dvt-and-pulmonary-embolism-pe-and-prevention-of-recurrent-dvt-and-pe-in-adults/\", \"rr_start\": \"2014-07-29T00:00:00\", \"rr_end\": \"2014-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-07-29, 2014-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban (Eliquis\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban (Eliquis\", \"ncpe_year\": 2014, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-07-29T00:00:00\", \"latest\": \"2014-08-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2185, \"last_scrape\": \"2018-12-13T16:26:39\", \"url\": \"http://www.ncpe.ie/drugs/apixaban-eliquis/\", \"rr_start\": \"2011-10-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-10-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban (Eliquis\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban (Eliquis\", \"ncpe_year\": 2012, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-10-19T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2186, \"last_scrape\": \"2018-12-13T16:26:45\", \"url\": \"http://www.ncpe.ie/drugs/apremilast-otezla-for-moderate-to-severe-chronic-plaque-psoriasis/\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast (Otezla\", \"trade_name\": \"Otezla\", \"indication\": \"Indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to systemic non-biologic therapies including cyclosporine, methotrexate or psoralen and ultraviolet A light (PUVA).\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/otezla\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2187, \"last_scrape\": \"2018-12-13T16:26:47\", \"url\": \"http://www.ncpe.ie/drugs/apremilast-otezla-for-psoriatic-arthritis/\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast (Otezla\", \"trade_name\": \"Otezla\", \"indication\": \"Apremilist (Otezla\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/otezla\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2188, \"last_scrape\": \"2018-12-13T16:26:49\", \"url\": \"http://www.ncpe.ie/drugs/aripiprazole-abilify-maintena/\", \"rr_start\": \"2014-07-02T00:00:00\", \"rr_end\": \"2014-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-07-02, 2014-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Aripiprazole (Abilify Maintena\", \"trade_name\": \"Abilify Maintena\", \"indication\": \"Aripiprazole (Abilify Maintena\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-14T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2014-07-02T00:00:00\", \"latest\": \"2014-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2189, \"last_scrape\": \"2018-12-13T16:26:55\", \"url\": \"http://www.ncpe.ie/drugs/asenapine-sycrest/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-08-17, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Asenapine (Sycrest\", \"trade_name\": \"Sycrest\", \"indication\": \"Asenapine (Sycrest\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Organon\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sycrest\", \"ta_list\": \"Bipolar Disorder\", \"rr_status\": \"No HTA\"}, {\"id\": 2190, \"last_scrape\": \"2018-12-13T16:27:00\", \"url\": \"http://www.ncpe.ie/drugs/atezolizumab-tecentriq/\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-10-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-08, 2017-10-09\", \"rr_multiple\": 0, \"drug_name\": \"Atezolizumab (Tecentriq\", \"trade_name\": \"Tecentriq\", \"indication\": \"Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK?positive tumour mutations should also have received targeted therapy before receiving atezolizumab.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-21T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq\", \"ta_list\": \"Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2191, \"last_scrape\": \"2018-12-13T16:27:05\", \"url\": \"http://www.ncpe.ie/drugs/avanafil-spedra/\", \"rr_start\": \"2014-02-19T00:00:00\", \"rr_end\": \"2014-03-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-19, 2014-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Avanafil (Spedra\", \"trade_name\": \"Spedra\", \"indication\": \"Avanafil (Spedra\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2014-02-19T00:00:00\", \"latest\": \"2014-03-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/spedra\", \"ta_list\": \"Erectile Dysfunction\", \"rr_status\": \"No HTA\"}, {\"id\": 2192, \"last_scrape\": \"2018-12-13T16:27:06\", \"url\": \"http://www.ncpe.ie/drugs/avelumab-bavencio/\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-10-17, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Avelumab (Bavencio\", \"trade_name\": \"Bavencio\", \"indication\": \"Avelumab (Bavencio\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2018-10-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2193, \"last_scrape\": \"2018-12-13T16:27:08\", \"url\": \"http://www.ncpe.ie/drugs/axanum-aspirin-81mgesomeprazole-20mg/\", \"rr_start\": \"2012-04-12T00:00:00\", \"rr_end\": \"2012-04-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-04-12, 2012-04-20\", \"rr_multiple\": 0, \"drug_name\": \"Aspirin 81mg/Esomeprazole 20mg (Axanum\", \"trade_name\": \"Axanum\", \"indication\": \"Prevention of thrombotic cardiovascular and cerebrovascular events in patients requiring continuous low-dose acetylsalicylic acid treatment, and who are in need of prophylaxis against acetylsalicylic acid associated gastric and /or duodenal ulcers.\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-04-12T00:00:00\", \"latest\": \"2012-04-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2194, \"last_scrape\": \"2018-12-13T16:27:14\", \"url\": \"http://www.ncpe.ie/drugs/axicabtagene-ciloleucel-yescarta/\", \"rr_start\": \"2018-09-10T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF  AXI-CEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-10, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Axicabtagene Ciloleucel (Yescarta\", \"trade_name\": \"Yescarta\", \"indication\": \"Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Kite\", \"orphan\": 1, \"earliest\": \"2018-09-10T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta\", \"ta_list\": \"Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2195, \"last_scrape\": \"2018-12-13T16:27:23\", \"url\": \"http://www.ncpe.ie/drugs/axitinib-inlyta/\", \"rr_start\": \"2012-11-07T00:00:00\", \"rr_end\": \"2012-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-07, 2012-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Axitinib (Inlyta\", \"trade_name\": \"Inlyta\", \"indication\": \"For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-03T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-11-07T00:00:00\", \"latest\": \"2012-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2196, \"last_scrape\": \"2018-12-13T16:27:24\", \"url\": \"http://www.ncpe.ie/drugs/azelastine-hydrochloride-and-fluticasone-propionate-nasal-spray-dymista/\", \"rr_start\": \"2013-02-12T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2013-02-12, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Azelastine hydrochloride and fluticasone propionate (nasal spray) (Dymista\", \"trade_name\": \"Dymista\", \"indication\": \"Indicated for symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-02-12T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2197, \"last_scrape\": \"2018-12-13T16:27:25\", \"url\": \"http://www.ncpe.ie/drugs/azilsartan-edarbi/\", \"rr_start\": \"2012-01-10T00:00:00\", \"rr_end\": \"2012-01-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-01-10, 2012-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Azilsartan (Edarbi\", \"trade_name\": \"Edarbi\", \"indication\": \"Edarbi is indicated for the treatment of essential hypertension in adults.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-12-07T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2012-01-10T00:00:00\", \"latest\": \"2012-01-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/edarbi\", \"ta_list\": \"Hypertension\", \"rr_status\": \"No HTA\"}, {\"id\": 2198, \"last_scrape\": \"2018-12-13T16:27:27\", \"url\": \"http://www.ncpe.ie/drugs/baricitinib-olumiant/\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-06-14, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Baricitinib (Olumiant\", \"trade_name\": \"Olumiant\", \"indication\": \"Baricitinib (Olumiant\", \"ncpe_year\": 2017, \"eu_market\": \"2017-02-12T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2199, \"last_scrape\": \"2018-12-13T16:27:33\", \"url\": \"http://www.ncpe.ie/drugs/bazedoxifene-conbriza/\", \"rr_start\": \"2011-09-20T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-09-20, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Bazedoxifene (Conbriza\", \"trade_name\": \"Conbriza\", \"indication\": \"Bazedoxifene (Conbriza\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-17T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-09-20T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza\", \"ta_list\": \"Osteoporosis, Postmenopausal\", \"rr_status\": \"No HTA\"}, {\"id\": 2200, \"last_scrape\": \"2018-12-13T16:27:36\", \"url\": \"http://www.ncpe.ie/drugs/bedaquiline-sirturo/\", \"rr_start\": \"2015-01-23T00:00:00\", \"rr_end\": \"2015-02-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-01-23, 2015-02-20\", \"rr_multiple\": 0, \"drug_name\": \"Bedaquiline (Sirturo\", \"trade_name\": \"Sirturo\", \"indication\": \"Bedaquiline (Sirturo\", \"ncpe_year\": 2015, \"eu_market\": \"2014-03-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2015-01-23T00:00:00\", \"latest\": \"2015-02-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo\", \"ta_list\": \"Tuberculosis, Multidrug-Resistant\", \"rr_status\": \"No HTA\"}, {\"id\": 2201, \"last_scrape\": \"2018-12-13T16:27:37\", \"url\": \"http://www.ncpe.ie/drugs/belatacept-nulojix/\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2012-01-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-11-15, 2012-01-23\", \"rr_multiple\": 0, \"drug_name\": \"Belatacept (Nulojix\", \"trade_name\": \"Nulojix\", \"indication\": \"Belatacept, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen.\\n\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2012-01-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nulojix\", \"ta_list\": \"Graft Rejection; Kidney Transplantation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2202, \"last_scrape\": \"2018-12-13T16:27:40\", \"url\": \"http://www.ncpe.ie/drugs/belimumab-benlysta/\", \"rr_start\": \"2011-08-11T00:00:00\", \"rr_end\": \"2011-08-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-11, 2011-08-11\", \"rr_multiple\": 0, \"drug_name\": \"Belimumab (Benlysta\", \"trade_name\": \"Benlysta\", \"indication\": \"Cost-effectiveness of Belimumab (Benlysta\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-08-01T00:00:00\", \"latest\": \"2011-08-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta\", \"ta_list\": \"Lupus Erythematosus, Systemic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2203, \"last_scrape\": \"2018-12-13T16:27:46\", \"url\": \"http://www.ncpe.ie/drugs/bendamustine-levact/\", \"rr_start\": \"2011-03-21T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-03-21, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Bendamustine (Levact\", \"trade_name\": \"Levact\", \"indication\": \"Bendamustine (Levact\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2012-11-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2204, \"last_scrape\": \"2018-12-13T16:27:50\", \"url\": \"http://www.ncpe.ie/drugs/benralizumab-fasenra/\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-14T00:00:00\", \"rr_outcome\": \"FULL PHARAMCOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2018-01-15, 2018-02-14\", \"rr_multiple\": 0, \"drug_name\": \"Benralizumab (Fasenra\", \"trade_name\": \"Fasenra\", \"indication\": \"Benralizumab (Fasenra\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fasenra\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2205, \"last_scrape\": \"2018-12-13T16:27:56\", \"url\": \"http://www.ncpe.ie/drugs/bezlotoxumab-zinplava/\", \"rr_start\": \"2017-05-11T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-05-11, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Bezlotoxumab (Zinplava\", \"trade_name\": \"Zinplava\", \"indication\": \"Bezlotoxumab (Zinplava\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-05-11T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinplava\", \"ta_list\": \"Enterocolitis, Pseudomembranous\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2206, \"last_scrape\": \"2018-12-13T16:27:58\", \"url\": \"http://www.ncpe.ie/drugs/bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy/\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT BIKTARVY\", \"rr_dates\": \"2018-04-30, 2018-06-07\", \"rr_multiple\": 0, \"drug_name\": \"Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy\", \"trade_name\": \"Biktarvy\", \"indication\": \"Biktarvy\", \"ncpe_year\": 2018, \"eu_market\": \"2018-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2207, \"last_scrape\": \"2018-12-13T16:28:01\", \"url\": \"http://www.ncpe.ie/drugs/bilastine-drynol/\", \"rr_start\": \"2011-03-10T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-10, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Bilastine (Drynol\", \"trade_name\": \"Drynol\", \"indication\": \" Bilastine (Drynol\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-03-10T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2208, \"last_scrape\": \"2018-12-13T16:28:05\", \"url\": \"http://www.ncpe.ie/drugs/blinatumomab-blincyto/\", \"rr_start\": \"2015-12-08T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.  THE NCPE CANNOT RECOMMEND REIMBURSEMENT OF BLINCTYO\", \"rr_dates\": \"2015-12-08, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Blinatumomab (Blincyto\", \"trade_name\": \"Blincyto\", \"indication\": \"Blincyto\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-23T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-08T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2209, \"last_scrape\": \"2018-12-13T16:28:11\", \"url\": \"http://www.ncpe.ie/drugs/boceprevir-victrelis/\", \"rr_start\": \"\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Boceprevir (Victrelis\", \"trade_name\": \"Victrelis\", \"indication\": \"Economic evaluation of Boceprevir (Victrelis\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2011-08-19T00:00:00\", \"latest\": \"2012-01-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2210, \"last_scrape\": \"2018-12-13T16:28:16\", \"url\": \"http://www.ncpe.ie/drugs/bosentan-tracleer/\", \"rr_start\": \"2014-06-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-06-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Bosentan (Tracleer\", \"trade_name\": \"Tracleer\", \"indication\": \"Bosentan (Tracleer\", \"ncpe_year\": 2014, \"eu_market\": \"2002-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-06-27T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tracleer\", \"ta_list\": \"Scleroderma, Systemic; Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2211, \"last_scrape\": \"2018-12-13T16:28:18\", \"url\": \"http://www.ncpe.ie/drugs/bosutinib-bosulif/\", \"rr_start\": \"2013-08-09T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"AT THE CURRENT PRICE A FULL HTA WOULD BE REQUIRED.\", \"rr_dates\": \"2013-08-09, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Bosutinib (Bosulif\", \"trade_name\": \"Bosulif\", \"indication\": \"Bosutinib is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-26T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2212, \"last_scrape\": \"2018-12-13T16:28:19\", \"url\": \"http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris-for-cd30-cutaneous-t-cell-lymphoma-ctcl/\", \"rr_start\": \"2018-02-07T00:00:00\", \"rr_end\": \"2018-03-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-02-07, 2018-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin (Adcetris\", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin (Adcetris\", \"ncpe_year\": 2018, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-02-07T00:00:00\", \"latest\": \"2018-03-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2213, \"last_scrape\": \"2018-12-13T16:28:23\", \"url\": \"http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris/\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin (Adcetris\", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin (Adcetris\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2214, \"last_scrape\": \"2018-12-13T16:28:29\", \"url\": \"http://www.ncpe.ie/drugs/brigatinib-alunbrig/\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF BRIGATINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-11-19, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Brigatinib (Alunbrig\", \"trade_name\": \"Alunbrig\", \"indication\": \"Brigatinib (Alunbrig \", \"ncpe_year\": 2018, \"eu_market\": \"2018-11-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2215, \"last_scrape\": \"2018-12-13T16:28:30\", \"url\": \"http://www.ncpe.ie/drugs/brimonidine-3-3-mgg-gel-mirvaso/\", \"rr_start\": \"2014-04-09T00:00:00\", \"rr_end\": \"2014-04-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-09\", \"rr_multiple\": 0, \"drug_name\": \"Brimonidine 3.3 mg/g gel (Mirvaso\", \"trade_name\": \"Mirvaso\", \"indication\": \"Brimonidine 3.3 mg/g gel (Mirvaso\", \"ncpe_year\": 2014, \"eu_market\": \"2014-02-20T00:00:00\", \"company\": \"Galderma\", \"orphan\": 0, \"earliest\": \"2014-04-09T00:00:00\", \"latest\": \"2014-04-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mirvaso\", \"ta_list\": \"Skin Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2216, \"last_scrape\": \"2018-12-13T16:28:36\", \"url\": \"http://www.ncpe.ie/drugs/brivaracetam-briviact/\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-02-15, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Brivaracetam (Briviact\", \"trade_name\": \"Briviact\", \"indication\": \"Brivaracetam (Briviact\", \"ncpe_year\": 2016, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2217, \"last_scrape\": \"2018-12-13T16:28:40\", \"url\": \"http://www.ncpe.ie/drugs/brodalumab-kyntheum/\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-07-25, 2017-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Brodalumab (Kyntheum\", \"trade_name\": \"Kyntheum\", \"indication\": \"Brodalumab (Kyntheum\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-17T00:00:00\", \"company\": \"LEO\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2218, \"last_scrape\": \"2018-12-13T16:28:44\", \"url\": \"http://www.ncpe.ie/drugs/bronchitol/\", \"rr_start\": \"2012-09-11T00:00:00\", \"rr_end\": \"2012-09-21T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2012-09-11, 2012-09-21\", \"rr_multiple\": 0, \"drug_name\": \"Mannitol Dry Powder (Bronchitol\", \"trade_name\": \"Bronchitol\", \"indication\": \"Bronchitol\", \"ncpe_year\": 2014, \"eu_market\": \"2012-04-13T00:00:00\", \"company\": \"Pharmaxis\", \"orphan\": 1, \"earliest\": \"2012-09-11T00:00:00\", \"latest\": \"2014-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bronchitol\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2219, \"last_scrape\": \"2018-12-13T16:28:46\", \"url\": \"http://www.ncpe.ie/drugs/c-drugs/calcipotriol-and-betamethasone-dipropionate-cutaneous-foam-enstilar/\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-06-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-05-17, 2016-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Calcipotriol and betamethasone dipropionate cutaneous foam (Enstilar \", \"trade_name\": \"Enstilar\", \"indication\": \"Calcipotriol and betamethasone dipropionate cutaneous foam is indicated for the topical treatment of psoriasis vulgaris in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-06-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2220, \"last_scrape\": \"2018-12-13T16:28:53\", \"url\": \"http://www.ncpe.ie/drugs/c1inhibitor-human-cinryze/\", \"rr_start\": \"2012-10-22T00:00:00\", \"rr_end\": \"2012-11-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-22, 2012-11-14\", \"rr_multiple\": 0, \"drug_name\": \"C1inhibitor (human) (Cinryze\", \"trade_name\": \"Cinryze\", \"indication\": \"C1inhibitor (human) (Cinryze\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-15T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2012-10-22T00:00:00\", \"latest\": \"2012-11-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"id\": 2221, \"last_scrape\": \"2018-12-13T16:28:55\", \"url\": \"http://www.ncpe.ie/drugs/cabozantinib-cabometyx/\", \"rr_start\": \"2017-03-20T00:00:00\", \"rr_end\": \"2017-04-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT\\nRECOMMENDED\", \"rr_dates\": \"2017-03-20, 2017-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib (Cabometyx\", \"trade_name\": \"Cabometyx\", \"indication\": \"Cabozantinib (Cabometyx\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-03-20T00:00:00\", \"latest\": \"2018-07-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2222, \"last_scrape\": \"2018-12-13T16:28:58\", \"url\": \"http://www.ncpe.ie/drugs/cabozantinib-cometriq/\", \"rr_start\": \"2014-07-10T00:00:00\", \"rr_end\": \"2014-08-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2014-07-10, 2014-08-12\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib (Cometriq\", \"trade_name\": \"Cometriq\", \"indication\": \"Cabozantinib (COMETRIQ\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-21T00:00:00\", \"company\": \"Ipsen\", \"orphan\": 1, \"earliest\": \"2014-07-10T00:00:00\", \"latest\": \"2014-08-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2223, \"last_scrape\": \"2018-12-13T16:29:01\", \"url\": \"http://www.ncpe.ie/drugs/camellia-sinensis-folium-green-tea-leaf-catephen-10/\", \"rr_start\": \"2015-05-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-05-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Camellia sinensis, folium (green tea leaf) (Catephen 10%\", \"trade_name\": \"Catephen 10%\", \"indication\": \"Catephen 10%\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-05-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2224, \"last_scrape\": \"2018-12-13T16:29:04\", \"url\": \"http://www.ncpe.ie/drugs/canagliflozin-invokana/\", \"rr_start\": \"2013-11-25T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-11-25, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Canagliflozin (Invokana\", \"trade_name\": \"Invokana\", \"indication\": \"Canagliflozin (Invokana\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-11-25T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/invokana\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2225, \"last_scrape\": \"2018-12-13T16:29:09\", \"url\": \"http://www.ncpe.ie/drugs/capsaicin-8ww-patch-qutenza/\", \"rr_start\": \"2012-06-15T00:00:00\", \"rr_end\": \"2012-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-06-15, 2012-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Capsaicin 8%w/w patch (Qutenza\", \"trade_name\": \"Qutenza\", \"indication\": \"Capsaicin 8% w/w patch (Qutenza\", \"ncpe_year\": 2012, \"eu_market\": \"2009-05-15T00:00:00\", \"company\": \"Grunenthal\", \"orphan\": 0, \"earliest\": \"2012-06-15T00:00:00\", \"latest\": \"2012-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza\", \"ta_list\": \"Neuralgia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2226, \"last_scrape\": \"2018-12-13T16:29:11\", \"url\": \"http://www.ncpe.ie/drugs/carbazitaxel-jevtana-for-prostate-cancer/\", \"rr_start\": \"2011-06-02T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-06-02, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Cabazitaxel (Jevtana\", \"trade_name\": \"Jevtana\", \"indication\": \"Economic Evaluation of cabazitaxel (Jevtana\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2011-06-02T00:00:00\", \"latest\": \"2014-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jevtana\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2227, \"last_scrape\": \"2018-12-13T16:29:16\", \"url\": \"http://www.ncpe.ie/drugs/carfilzomib-kyprolis/\", \"rr_start\": \"2015-12-07T00:00:00\", \"rr_end\": \"2016-01-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-12-07, 2016-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Carfilzomib (Kyprolis\", \"trade_name\": \"Kyprolis\", \"indication\": \"Kyprolis\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-07T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2228, \"last_scrape\": \"2018-12-13T16:29:22\", \"url\": \"http://www.ncpe.ie/drugs/catumaxomab-removab/\", \"rr_start\": \"2011-08-05T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-08-05, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Catumaxomab (Removab\", \"trade_name\": \"Removab\", \"indication\": \"Catumazomab (Removab\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-20T00:00:00\", \"company\": \"Neovii\", \"orphan\": 0, \"earliest\": \"2011-08-05T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/removab\", \"ta_list\": \"Ascites; Cancer\", \"rr_status\": \"No HTA\"}, {\"id\": 2229, \"last_scrape\": \"2018-12-13T16:29:25\", \"url\": \"http://www.ncpe.ie/drugs/ceftaroline-zinforo/\", \"rr_start\": \"2012-10-08T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-08, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Ceftaroline (Zinforo\", \"trade_name\": \"Zinforo\", \"indication\": \"For the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP).\", \"ncpe_year\": 2012, \"eu_market\": \"2012-08-22T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-10-08T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinforo\", \"ta_list\": \"Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia\", \"rr_status\": \"No HTA\"}, {\"id\": 2230, \"last_scrape\": \"2018-12-13T16:29:29\", \"url\": \"http://www.ncpe.ie/drugs/ceftazidime-avibactam-cef-avizavicefta/\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-17, 2017-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Ceftazidime-avibactam (CEF-AVI)(Zavicefta\", \"trade_name\": \"Zavicefta\", \"indication\": \"Ceftazidime-avibactam (CEF-AVI)(Zavicefta\", \"ncpe_year\": 2017, \"eu_market\": \"2016-06-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta\", \"ta_list\": \"Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2231, \"last_scrape\": \"2018-12-13T16:29:34\", \"url\": \"http://www.ncpe.ie/drugs/ceftolozanetazobactam-zerbaxa/\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-03-03, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Ceftolozane/tazobactam (Zerbaxa\", \"trade_name\": \"Zerbaxa\", \"indication\": \"Zerbaxa\", \"ncpe_year\": 2016, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa\", \"ta_list\": \"Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2232, \"last_scrape\": \"2018-12-13T16:29:36\", \"url\": \"http://www.ncpe.ie/drugs/ceritinib-zykadia/\", \"rr_start\": \"2015-05-29T00:00:00\", \"rr_end\": \"2015-07-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2015-05-29, 2015-07-22\", \"rr_multiple\": 0, \"drug_name\": \"Ceritinib (Zykadia\", \"trade_name\": \"Zykadia\", \"indication\": \"Zykadia\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-06T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-05-29T00:00:00\", \"latest\": \"2015-07-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2233, \"last_scrape\": \"2018-12-13T16:29:40\", \"url\": \"http://www.ncpe.ie/drugs/cerliponase-alfa-brineura/\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2017-10-11, 2017-11-27\", \"rr_multiple\": 0, \"drug_name\": \"Cerliponase alfa (Brineura\", \"trade_name\": \"Brineura\", \"indication\": \"Cerliponase alfa (Brineura\", \"ncpe_year\": 2018, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-08-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brineura\", \"ta_list\": \"Neuronal Ceroid-Lipofuscinoses\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2234, \"last_scrape\": \"2018-12-13T16:29:44\", \"url\": \"http://www.ncpe.ie/drugs/certolizumab-pegol-cimzia/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Certolizumab pegol (Cimzia\", \"trade_name\": \"Cimzia\", \"indication\": \"Cost-effectiveness of certolizumab pegol (Cimzia\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2010-03-13T00:00:00\", \"latest\": \"2010-09-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia-0\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2235, \"last_scrape\": \"2018-12-13T16:29:49\", \"url\": \"http://www.ncpe.ie/drugs/ciclosporin-1mgml-eye-drops-ikervis/\", \"rr_start\": \"2015-01-07T00:00:00\", \"rr_end\": \"2016-01-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-01-07, 2016-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Ciclosporin 1mg/ml eye drops (Ikervis\", \"trade_name\": \"Ikervis\", \"indication\": \"Ikervis\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-19T00:00:00\", \"company\": \"Santen\", \"orphan\": 0, \"earliest\": \"2015-01-07T00:00:00\", \"latest\": \"2016-01-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis\", \"ta_list\": \"Corneal Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2236, \"last_scrape\": \"2018-12-13T16:29:54\", \"url\": \"http://www.ncpe.ie/drugs/cladribine-mavenclad/\", \"rr_start\": \"2017-08-22T00:00:00\", \"rr_end\": \"2017-09-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-22, 2017-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Cladribine (Mavenclad\", \"trade_name\": \"Mavenclad\", \"indication\": \"Cladribine (Mavenclad\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-08-22T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2237, \"last_scrape\": \"2018-12-13T16:29:58\", \"url\": \"http://www.ncpe.ie/drugs/clindamycin-1-with-tretinoin-0-025-treclinac/\", \"rr_start\": \"2014-04-08T00:00:00\", \"rr_end\": \"2014-05-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-08, 2014-05-06\", \"rr_multiple\": 0, \"drug_name\": \"Clindamycin 1% with tretinoin 0.025% (Treclinac\", \"trade_name\": \"Treclinac\", \"indication\": \"Clindamycin 1% with tretinoin 0.025% (Treclinac\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-04-08T00:00:00\", \"latest\": \"2014-05-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2238, \"last_scrape\": \"2018-12-13T16:30:02\", \"url\": \"http://www.ncpe.ie/drugs/cobimetinib-cotellic/\", \"rr_start\": \"2016-04-19T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-04-19, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Cobimetinib (Cotellic\", \"trade_name\": \"Cotellic\", \"indication\": \"Cotellic\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2016-04-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2239, \"last_scrape\": \"2018-12-13T16:30:03\", \"url\": \"http://www.ncpe.ie/drugs/colesevelam-cholestagel/\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Colesevelam (Cholestagel\", \"trade_name\": \"Cholestagel\", \"indication\": \"Cost-effectiveness of Colesevelam (Cholestagel\", \"ncpe_year\": 2010, \"eu_market\": \"2004-03-09T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cholestagel\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"No HTA\"}, {\"id\": 2240, \"last_scrape\": \"2018-12-13T16:30:06\", \"url\": \"http://www.ncpe.ie/drugs/colistimethate-sodium-colobreathe/\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Colistimethate sodium (Colobreathe\", \"trade_name\": \"Colobreathe\", \"indication\": \"Colistimethate sodium (colobreathe\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-13T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/colobreathe\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2241, \"last_scrape\": \"2018-12-13T16:30:17\", \"url\": \"http://www.ncpe.ie/drugs/collagenase-clostridium-histolyticum-xiapex/\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-20, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Collagenase Clostridium Histolyticum (Xiapex\", \"trade_name\": \"Xiapex\", \"indication\": \" Collagenase Clostridium Histolyticum (Xiapex\", \"ncpe_year\": 2011, \"eu_market\": \"2011-02-28T00:00:00\", \"company\": \"Swedish\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xiapex\", \"ta_list\": \"Dupuytren Contracture\", \"rr_status\": \"No HTA\"}, {\"id\": 2242, \"last_scrape\": \"2018-12-13T16:30:20\", \"url\": \"http://www.ncpe.ie/drugs/corifollitropin-alfa-elonva/\", \"rr_start\": \"2010-10-22T00:00:00\", \"rr_end\": \"2010-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-10-22, 2010-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Corifollitropin alfa (Elonva\", \"trade_name\": \"Elonva\", \"indication\": \"Cost-effectiveness of Corifollitropin alfa (Elonva\", \"ncpe_year\": 2010, \"eu_market\": \"2010-01-25T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2010-09-01T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/elonva\", \"ta_list\": \"Reproductive Techniques, Assisted; Ovulation Induction\", \"rr_status\": \"No HTA\"}, {\"id\": 2243, \"last_scrape\": \"2018-12-13T16:30:24\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori-for-first-line-alk-nsclc/\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2244, \"last_scrape\": \"2018-12-13T16:30:29\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori-for-ros1-nsclc/\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2245, \"last_scrape\": \"2018-12-13T16:30:34\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori/\", \"rr_start\": \"2013-01-09T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-01-09, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"For the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-01-09T00:00:00\", \"latest\": \"2015-08-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2246, \"last_scrape\": \"2018-12-13T16:30:37\", \"url\": \"http://www.ncpe.ie/drugs/cysteamine-bitartrate-procysbi/\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2015-12-01, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Cysteamine bitartrate delayed-release (Procysbi\", \"trade_name\": \"Procysbi\", \"indication\": \"Procysbi\", \"ncpe_year\": 2017, \"eu_market\": \"2013-09-05T00:00:00\", \"company\": \"Chiesi\", \"orphan\": 1, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/procysbi\", \"ta_list\": \"Cystinosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2247, \"last_scrape\": \"2018-12-13T16:30:43\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-2/\", \"rr_start\": \"2014-05-09T00:00:00\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-09, 2014-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate (Pradaxa\", \"ncpe_year\": 2014, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-09T00:00:00\", \"latest\": \"2014-06-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2248, \"last_scrape\": \"2018-12-13T16:30:51\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-for-the-prevention-of-stroke-and-systematic-embolisom-in-atrial-fibrillation/\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate (Pradaxa\", \"ncpe_year\": 2012, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2010-11-02T00:00:00\", \"latest\": \"2012-10-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2249, \"last_scrape\": \"2018-12-13T16:30:57\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-vte-prevention/\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Economic Evaluation of the Cost Effectiveness of Dabigatran Etexilate (Pradaxa\", \"ncpe_year\": 2008, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2008-07-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2250, \"last_scrape\": \"2018-12-13T16:30:59\", \"url\": \"http://www.ncpe.ie/drugs/dabrafenib-tafinlar/\", \"rr_start\": \"2013-09-11T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-11, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Dabrafenib (Tafinlar\", \"trade_name\": \"Tafinlar\", \"indication\": \"Dabrafenib (Tafinlar\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2013-09-11T00:00:00\", \"latest\": \"2014-06-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2251, \"last_scrape\": \"2018-12-13T16:31:02\", \"url\": \"http://www.ncpe.ie/drugs/daclatasvir-daklinza/\", \"rr_start\": \"2014-08-05T00:00:00\", \"rr_end\": \"2014-09-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-08-05, 2014-09-12\", \"rr_multiple\": 0, \"drug_name\": \"Daclatasvir (Daklinza\", \"trade_name\": \"Daklinza\", \"indication\": \"Daclatasvir (Daklinza\", \"ncpe_year\": 2015, \"eu_market\": \"2014-08-22T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-08-05T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/daklinza\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2252, \"last_scrape\": \"2018-12-13T16:31:08\", \"url\": \"http://www.ncpe.ie/drugs/daclizumab-zinbryta/\", \"rr_start\": \"2016-09-26T00:00:00\", \"rr_end\": \"2016-11-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-09-26, 2016-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Daclizumab (Zinbryta\", \"trade_name\": \"Zinbryta\", \"indication\": \"Daclizumab is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-07-01T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2016-09-26T00:00:00\", \"latest\": \"2018-03-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinbryta\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2253, \"last_scrape\": \"2018-12-13T16:31:12\", \"url\": \"http://www.ncpe.ie/drugs/dalbavancin-xydalba/\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-07, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Dalbavancin (Xydalba\", \"trade_name\": \"Xydalba\", \"indication\": \"Dalbavancin (Xydalba\", \"ncpe_year\": 2017, \"eu_market\": \"2015-02-19T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xydalba\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2254, \"last_scrape\": \"2018-12-13T16:31:18\", \"url\": \"http://www.ncpe.ie/drugs/dapagliflozin-forxiga/\", \"rr_start\": \"2012-10-10T00:00:00\", \"rr_end\": \"2012-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-10-10, 2012-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Dapagliflozin (Forxiga\", \"trade_name\": \"Forxiga\", \"indication\": \"Dapagliflozin (Forxiga\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-11T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-10T00:00:00\", \"latest\": \"2013-12-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2255, \"last_scrape\": \"2018-12-13T16:31:21\", \"url\": \"http://www.ncpe.ie/drugs/daratumumab-darzalex/\", \"rr_start\": \"2016-05-31T00:00:00\", \"rr_end\": \"2016-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-05-31, 2016-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Daratumumab (Darzalex\", \"trade_name\": \"Darzalex\", \"indication\": \"Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-04-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-05-31T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2256, \"last_scrape\": \"2018-12-13T16:31:25\", \"url\": \"http://www.ncpe.ie/drugs/darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-symtuza/\", \"rr_start\": \"2017-09-27T00:00:00\", \"rr_end\": \"2017-10-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-27, 2017-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza\", \"trade_name\": \"Symtuza\", \"indication\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza\", \"ncpe_year\": 2017, \"eu_market\": \"2017-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-09-27T00:00:00\", \"latest\": \"2017-10-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/symtuza\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2257, \"last_scrape\": \"2018-12-13T16:31:30\", \"url\": \"http://www.ncpe.ie/drugs/darunavir-cobicistat-rezolsta/\", \"rr_start\": \"2014-12-02T00:00:00\", \"rr_end\": \"2015-01-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-12-02, 2015-01-08\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir & cobicistat (Rezolsta\", \"trade_name\": \"Rezolsta\", \"indication\": \"Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-12-02T00:00:00\", \"latest\": \"2015-01-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2258, \"last_scrape\": \"2018-12-13T16:31:35\", \"url\": \"http://www.ncpe.ie/drugs/darvadstrocel-alofisel/\", \"rr_start\": \"2018-06-14T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF DARVADSTROCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-14, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Darvadstrocel (Alofisel\", \"trade_name\": \"Alofisel\", \"indication\": \"Darvadstrocel (Alofisel\", \"ncpe_year\": 2018, \"eu_market\": \"2018-03-23T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-06-14T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel\", \"ta_list\": \"Rectal Fistula\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2259, \"last_scrape\": \"2018-12-13T16:31:40\", \"url\": \"http://www.ncpe.ie/drugs/decitabine-dacogen/\", \"rr_start\": \"2012-11-08T00:00:00\", \"rr_end\": \"2012-12-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-08, 2012-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Decitabine (Dacogen\", \"trade_name\": \"Dacogen\", \"indication\": \"Decitabine (Dacogen\", \"ncpe_year\": 2013, \"eu_market\": \"2012-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2012-11-08T00:00:00\", \"latest\": \"2013-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2260, \"last_scrape\": \"2018-12-13T16:31:44\", \"url\": \"http://www.ncpe.ie/drugs/defibrotide-defitelio/\", \"rr_start\": \"2014-05-12T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2014-05-12, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Defibrotide (Defitelio\", \"trade_name\": \"Defitelio\", \"indication\": \"Defibrotide (Defitelio\", \"ncpe_year\": 2014, \"eu_market\": \"2013-10-18T00:00:00\", \"company\": \"Gentium\", \"orphan\": 1, \"earliest\": \"2014-05-12T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio\", \"ta_list\": \"Hepatic Veno-Occlusive Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2261, \"last_scrape\": \"2018-12-13T16:31:47\", \"url\": \"http://www.ncpe.ie/drugs/degarelix-firmagon/\", \"rr_start\": \"2009-10-15T00:00:00\", \"rr_end\": \"2009-10-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-10-15\", \"rr_multiple\": 0, \"drug_name\": \"Degarelix (Firmagon\", \"trade_name\": \"Firmagon\", \"indication\": \"Cost-effectiveness of Degarelix (Firmagon\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-17T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2009-10-15T00:00:00\", \"latest\": \"2009-10-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2262, \"last_scrape\": \"2018-12-13T16:31:52\", \"url\": \"http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-cannabidiol-thc-cbd-sativex/\", \"rr_start\": \"2018-02-12T00:00:00\", \"rr_end\": \"2018-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF SATIVEX\", \"rr_dates\": \"2018-02-12, 2018-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex\", \"trade_name\": \"Sativex\", \"indication\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-02-12T00:00:00\", \"latest\": \"2018-04-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2263, \"last_scrape\": \"2018-12-13T16:31:59\", \"url\": \"http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-thccannabidiol-cbd-sativex/\", \"rr_start\": \"2012-12-05T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-05, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol (THC) /Cannabidiol (CBD) (Sativex\", \"trade_name\": \"Sativex\", \"indication\": \"For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-12-05T00:00:00\", \"latest\": \"2014-09-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2264, \"last_scrape\": \"2018-12-13T16:32:04\", \"url\": \"http://www.ncpe.ie/drugs/denosumab-prolia/\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab (Prolia\", \"trade_name\": \"Prolia\", \"indication\": \"The Cost-effectiveness of Denosumab (Prolia\", \"ncpe_year\": 2010, \"eu_market\": \"2010-05-26T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2010-05-27T00:00:00\", \"latest\": \"2010-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prolia\", \"ta_list\": \"Bone Resorption; Osteoporosis, Postmenopausal\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2265, \"last_scrape\": \"2018-12-13T16:32:08\", \"url\": \"http://www.ncpe.ie/drugs/denosumab-xgeva-3/\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab (Xgeva\", \"trade_name\": \"Xgeva\", \"indication\": \"Cost-effectiveness of denosumab (Xgeva\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2011-08-15T00:00:00\", \"latest\": \"2011-12-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva\", \"ta_list\": \"Fractures, Bone; Neoplasm Metastasis\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2266, \"last_scrape\": \"2018-12-13T16:32:12\", \"url\": \"http://www.ncpe.ie/drugs/dexamethasone-intravitreal-implant-ozurdex/\", \"rr_start\": \"2010-11-12T00:00:00\", \"rr_end\": \"2010-12-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-11-12, 2010-12-16\", \"rr_multiple\": 0, \"drug_name\": \"Dexamethasone Intravitreal Implant (Ozurdex\", \"trade_name\": \"Ozurdex\", \"indication\": \"Cost-effectiveness of Ozurdex\", \"ncpe_year\": 2012, \"eu_market\": \"2010-07-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2010-11-12T00:00:00\", \"latest\": \"2012-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ozurdex\", \"ta_list\": \"Macular Edema; Uveitis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2267, \"last_scrape\": \"2018-12-13T16:32:15\", \"url\": \"http://www.ncpe.ie/drugs/dexmedetomidine-dexdor/\", \"rr_start\": \"2011-07-08T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-07-08, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Dexmedetomidine (Dexdor\", \"trade_name\": \"Dexdor\", \"indication\": \"Dexmedetomidine (Dexdor\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-15T00:00:00\", \"company\": \"Orion\", \"orphan\": 0, \"earliest\": \"2011-07-08T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dexdor\", \"ta_list\": \"Conscious Sedation\", \"rr_status\": \"No HTA\"}, {\"id\": 2268, \"last_scrape\": \"2018-12-13T16:32:21\", \"url\": \"http://www.ncpe.ie/drugs/dienogest-visanne/\", \"rr_start\": \"2010-09-17T00:00:00\", \"rr_end\": \"2010-10-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-09-17, 2010-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Dienogest (Visanne\", \"trade_name\": \"Visanne\", \"indication\": \"Dienogest (Visanne\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-09-17T00:00:00\", \"latest\": \"2010-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2269, \"last_scrape\": \"2018-12-13T16:32:24\", \"url\": \"http://www.ncpe.ie/drugs/dimethyl-fumarate-skilarence/\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-01-15, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate (Skilarence\", \"trade_name\": \"Skilarence\", \"indication\": \"Dimethyl fumarate (Skilarence\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"Almirall\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/skilarence\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2270, \"last_scrape\": \"2018-12-13T16:32:26\", \"url\": \"http://www.ncpe.ie/drugs/dimethyl-fumarate-tecfidera/\", \"rr_start\": \"2014-02-04T00:00:00\", \"rr_end\": \"2014-03-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-02-04, 2014-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate (Tecfidera\", \"trade_name\": \"Tecfidera\", \"indication\": \"Dimethyl fumarate (Tecfidera\", \"ncpe_year\": 2015, \"eu_market\": \"2014-01-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-02-04T00:00:00\", \"latest\": \"2015-04-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2271, \"last_scrape\": \"2018-12-13T16:32:29\", \"url\": \"http://www.ncpe.ie/drugs/dinutuximab-beta-dinutuximab-beta-eusa/\", \"rr_start\": \"2017-10-19T00:00:00\", \"rr_end\": \"2017-11-23T00:00:00\", \"rr_outcome\": \"FOLLOWING ASSESSMENT OF THE APPLICANT\", \"rr_dates\": \"2017-10-19, 2017-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Dinutuximab beta (Qarziba\", \"trade_name\": \"Qarziba\", \"indication\": \"Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients ? 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-10-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2272, \"last_scrape\": \"2018-12-13T16:32:34\", \"url\": \"http://www.ncpe.ie/drugs/dolutegravir-rilpivirine-juluca/\", \"rr_start\": \"2018-06-08T00:00:00\", \"rr_end\": \"2018-07-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT JULUCA\", \"rr_dates\": \"2018-06-08, 2018-07-12\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir/Rilpivirine (Juluca\", \"trade_name\": \"Juluca\", \"indication\": \"Dolutegravir/rilpivirine (Juluca\", \"ncpe_year\": 2018, \"eu_market\": \"2018-05-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2018-06-08T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/juluca\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2273, \"last_scrape\": \"2018-12-13T16:32:36\", \"url\": \"http://www.ncpe.ie/drugs/dolutegravir-tivicay/\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-10, 2014-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir (Tivicay\", \"trade_name\": \"Tivicay\", \"indication\": \"Dolutegravir (Tivicay\", \"ncpe_year\": 2014, \"eu_market\": \"2014-01-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2274, \"last_scrape\": \"2018-12-13T16:32:39\", \"url\": \"http://www.ncpe.ie/drugs/dronedarone-multaq/\", \"rr_start\": \"2010-01-12T00:00:00\", \"rr_end\": \"2010-01-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-01-12, 2010-01-01\", \"rr_multiple\": 0, \"drug_name\": \"Dronedarone (Multaq\", \"trade_name\": \"Multaq\", \"indication\": \"Rapid Review\", \"ncpe_year\": 2010, \"eu_market\": \"2009-11-25T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2010-01-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"No HTA\"}, {\"id\": 2275, \"last_scrape\": \"2018-12-13T16:32:42\", \"url\": \"http://www.ncpe.ie/drugs/dulaglutide-trulicity/\", \"rr_start\": \"2015-03-04T00:00:00\", \"rr_end\": \"2015-04-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-03-04, 2015-04-29\", \"rr_multiple\": 0, \"drug_name\": \"Dulaglutide (Trulicity\", \"trade_name\": \"Trulicity\", \"indication\": \"Dulaglutide is indicated as monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2015-03-04T00:00:00\", \"latest\": \"2015-04-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2276, \"last_scrape\": \"2018-12-13T16:32:46\", \"url\": \"http://www.ncpe.ie/drugs/dupilumab-dupixent/\", \"rr_start\": \"2017-11-13T00:00:00\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-13, 2017-11-24\", \"rr_multiple\": 0, \"drug_name\": \"Dupilumab (Dupixent\", \"trade_name\": \"Dupixent\", \"indication\": \"Dupilumab (Dupixent\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-27T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-11-13T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent\", \"ta_list\": \"Dermatitis, Atopic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2277, \"last_scrape\": \"2018-12-13T16:32:53\", \"url\": \"http://www.ncpe.ie/drugs/eculizumab-soliris/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Eculizumab (Soliris\", \"trade_name\": \"Soliris\", \"indication\": \"An Economic Evaluation of Eculizumab (Soliris\", \"ncpe_year\": 2013, \"eu_market\": \"2007-06-20T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2013-10-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/soliris\", \"ta_list\": \"Hemoglobinuria, Paroxysmal\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2278, \"last_scrape\": \"2018-12-13T16:32:55\", \"url\": \"http://www.ncpe.ie/drugs/edoxaban-lixiana/\", \"rr_start\": \"2015-06-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-06-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Edoxaban (Lixiana\", \"trade_name\": \"Lixiana\", \"indication\": \"Edoxaban is indicated for the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2015-06-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana\", \"ta_list\": \"Stroke; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2279, \"last_scrape\": \"2018-12-13T16:33:00\", \"url\": \"http://www.ncpe.ie/drugs/elbasvirgrazoprevir-zepatier-2/\", \"rr_start\": \"2016-08-10T00:00:00\", \"rr_end\": \"2016-10-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-08-10, 2016-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Elbasvir/Grazoprevir (Zepatier\", \"trade_name\": \"Zepatier\", \"indication\": \"Elbasvir 50mg/100mg grazoprevir (EBR/GZR)(Zepatier\", \"ncpe_year\": 2016, \"eu_market\": \"2016-07-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-10T00:00:00\", \"latest\": \"2016-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2280, \"last_scrape\": \"2018-12-13T16:33:03\", \"url\": \"http://www.ncpe.ie/drugs/eliglustat-cerdelga/\", \"rr_start\": \"2016-03-21T00:00:00\", \"rr_end\": \"2016-05-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-03-21, 2016-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Eliglustat (Cerdelga\", \"trade_name\": \"Cerdelga\", \"indication\": \"Eliglustat (Cerdelga\", \"ncpe_year\": 2018, \"eu_market\": \"2015-01-19T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 1, \"earliest\": \"2016-03-21T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga\", \"ta_list\": \"Gaucher Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2281, \"last_scrape\": \"2018-12-13T16:33:05\", \"url\": \"http://www.ncpe.ie/drugs/elosulfase-alfa-vimizim/\", \"rr_start\": \"2015-03-30T00:00:00\", \"rr_end\": \"2015-05-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-03-30, 2015-05-08\", \"rr_multiple\": 0, \"drug_name\": \"Elosulfase alfa (Vimizim\", \"trade_name\": \"Vimizim\", \"indication\": \"Elosulfase alfa (Vimzim\", \"ncpe_year\": 2018, \"eu_market\": \"2014-04-27T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2015-03-30T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vimizim\", \"ta_list\": \"Mucopolysaccharidosis IV\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2282, \"last_scrape\": \"2018-12-13T16:33:12\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade-2/\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-02-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-01-10, 2014-02-13\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Eltrombopag (Revolade\", \"ncpe_year\": 2014, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-02-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"id\": 2283, \"last_scrape\": \"2018-12-13T16:33:17\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade-3/\", \"rr_start\": \"2016-02-05T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-02-05, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Revolade\", \"ncpe_year\": 2016, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-02-05T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"id\": 2284, \"last_scrape\": \"2018-12-13T16:33:23\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade/\", \"rr_start\": \"2017-12-04T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, WHICH IS NOT COMPARABLE WITH CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2017-12-04, 2018-04-16, 2017-12-01\", \"rr_multiple\": 1, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Cost-effectiveness of eltrombopag (Revolade\", \"ncpe_year\": 2018, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-07-30T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2285, \"last_scrape\": \"2018-12-13T16:33:26\", \"url\": \"http://www.ncpe.ie/drugs/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya/\", \"rr_start\": \"2015-11-24T00:00:00\", \"rr_end\": \"2016-01-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-11-24, 2016-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide (Genvoya\", \"trade_name\": \"Genvoya\", \"indication\": \"Genvoya\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2015-11-24T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2286, \"last_scrape\": \"2018-12-13T16:33:32\", \"url\": \"http://www.ncpe.ie/drugs/empagliflozin-jardiance/\", \"rr_start\": \"2014-05-22T00:00:00\", \"rr_end\": \"2014-06-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-22, 2014-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Empagliflozin (Jardiance\", \"trade_name\": \"Jardiance\", \"indication\": \"Add-on combination therapy \", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-22T00:00:00\", \"latest\": \"2014-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2287, \"last_scrape\": \"2018-12-13T16:33:37\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabine-tenofovir-disoproxil-fumarate-truvada/\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-07-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-12, 2017-07-18\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine / tenofovir disoproxil fumarate (Truvada\", \"trade_name\": \"Truvada\", \"indication\": \"Truvada\", \"ncpe_year\": 2017, \"eu_market\": \"2005-02-20T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-07-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/truvada\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2288, \"last_scrape\": \"2018-12-13T16:33:43\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabine-tenovir-disoproxil-teva/\", \"rr_start\": \"2017-12-11T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-12-11, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir disoproxil (TEVA\", \"trade_name\": \"TEVA\", \"indication\": \"Emtricitabine/tenofovir disoproxil (TEVA\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-12-11T00:00:00\", \"latest\": \"2017-12-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2289, \"last_scrape\": \"2018-12-13T16:33:48\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabinetenofovir-alafenamide-descovy/\", \"rr_start\": \"2016-04-26T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-04-26, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir alafenamide (Descovy\", \"trade_name\": \"Descovy\", \"indication\": \"Descovy\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-04-26T00:00:00\", \"latest\": \"2016-04-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/descovy\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2290, \"last_scrape\": \"2018-12-13T16:33:52\", \"url\": \"http://www.ncpe.ie/drugs/enzalutamide-xtandi/\", \"rr_start\": \"2013-06-28T00:00:00\", \"rr_end\": \"2013-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-28, 2013-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Enzalutamide (Xtandi\", \"trade_name\": \"Xtandi\", \"indication\": \"Enzalutamide (Xtandi\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2013-06-28T00:00:00\", \"latest\": \"2014-04-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2291, \"last_scrape\": \"2018-12-13T16:33:59\", \"url\": \"http://www.ncpe.ie/drugs/epoprostenol-veletri/\", \"rr_start\": \"2016-12-13T00:00:00\", \"rr_end\": \"2017-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-12-13, 2017-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Epoprostenol (Veletri\", \"trade_name\": \"Veletri\", \"indication\": \"Veletri\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-12-13T00:00:00\", \"latest\": \"2017-02-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2292, \"last_scrape\": \"2018-12-13T16:34:03\", \"url\": \"http://www.ncpe.ie/drugs/erenumab-aimovig/\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-15T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF ERENUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-19, 2018-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Erenumab (Aimovig\", \"trade_name\": \"Aimovig\", \"indication\": \"Erenumab (Aimovig\", \"ncpe_year\": 2018, \"eu_market\": \"2018-07-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig\", \"ta_list\": \"Migraine Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2293, \"last_scrape\": \"2018-12-13T16:34:07\", \"url\": \"http://www.ncpe.ie/drugs/eribulin-halaven/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-03-11, 2011-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Eribulin (Halaven\", \"trade_name\": \"Halaven\", \"indication\": \"Eribulin (Halaven\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2011-02-09T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/halaven\", \"ta_list\": \"Breast Neoplasms; Liposarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2294, \"last_scrape\": \"2018-12-13T16:34:09\", \"url\": \"http://www.ncpe.ie/drugs/eslicarbazepine-zebinix/\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-08-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2009-09-01, 2009-08-01\", \"rr_multiple\": 0, \"drug_name\": \"Eslicarbazepine (Zebinix\", \"trade_name\": \"Zebinix\", \"indication\": \"Eslicarbazepine (Zebinix\", \"ncpe_year\": 2009, \"eu_market\": \"2009-04-21T00:00:00\", \"company\": \"BIAL\", \"orphan\": 0, \"earliest\": \"2009-08-01T00:00:00\", \"latest\": \"2009-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2295, \"last_scrape\": \"2018-12-13T16:34:12\", \"url\": \"http://www.ncpe.ie/drugs/etanercept-benepali/\", \"rr_start\": \"2016-03-22T00:00:00\", \"rr_end\": \"2016-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-03-22, 2016-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Etanercept (Benepali\", \"trade_name\": \"Benepali\", \"indication\": \"Benepali\", \"ncpe_year\": 2016, \"eu_market\": \"2016-01-13T00:00:00\", \"company\": \"Samsung\", \"orphan\": 0, \"earliest\": \"2016-03-22T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/benepali\", \"ta_list\": \"Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis\", \"rr_status\": \"No HTA\"}, {\"id\": 2296, \"last_scrape\": \"2018-12-13T16:34:15\", \"url\": \"http://www.ncpe.ie/drugs/etelcalcetide-parsabiv/\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-06-14, 2017-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Etelcalcetide (Parsabiv\", \"trade_name\": \"Parsabiv\", \"indication\": \"Etelcalcitide (Parsabiv\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-11T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/parsabiv\", \"ta_list\": \"Hyperparathyroidism, Secondary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2297, \"last_scrape\": \"2018-12-13T16:34:21\", \"url\": \"http://www.ncpe.ie/drugs/eurartesim-piperaquine-tetraphosphatedihidroartemisinin/\", \"rr_start\": \"2012-05-22T00:00:00\", \"rr_end\": \"2012-05-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-05-22, 2012-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Piperaquine tetraphosphate/dihidroartemisinin (Eurartesim\", \"trade_name\": \"Eurartesim\", \"indication\": \"Eurartesim\", \"ncpe_year\": 2012, \"eu_market\": \"2011-10-27T00:00:00\", \"company\": \"Alfasigma\", \"orphan\": 0, \"earliest\": \"2012-05-22T00:00:00\", \"latest\": \"2012-05-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eurartesim\", \"ta_list\": \"Malaria\", \"rr_status\": \"No HTA\"}, {\"id\": 2298, \"last_scrape\": \"2018-12-13T16:34:24\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-afinitor/\", \"rr_start\": \"2012-09-21T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-09-21, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Afinitor\", \"trade_name\": \"Afinitor\", \"indication\": \"Treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor\", \"ncpe_year\": 2012, \"eu_market\": \"2009-08-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-09-21T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/afinitor\", \"ta_list\": \"Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2299, \"last_scrape\": \"2018-12-13T16:34:26\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-votubia-for-refractory-seizures-associated-with-tuberous-sclerosis-complex-tsc/\", \"rr_start\": \"2017-04-19T00:00:00\", \"rr_end\": \"2017-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-04-19, 2017-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Votubia \", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus (Votubia\", \"ncpe_year\": 2017, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2017-04-19T00:00:00\", \"latest\": \"2017-04-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/votubia\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2300, \"last_scrape\": \"2018-12-13T16:34:29\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-votubia/\", \"rr_start\": \"2011-09-30T00:00:00\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-09-30, 2011-10-14\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Votubia\", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus (Votubia\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2011-09-30T00:00:00\", \"latest\": \"2011-10-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/votubia\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2301, \"last_scrape\": \"2018-12-13T16:34:36\", \"url\": \"http://www.ncpe.ie/drugs/evolocumab-repatha/\", \"rr_start\": \"\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Evolocumab (Repatha\", \"trade_name\": \"Repatha\", \"indication\": \"Evolocumab (Repatha\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-17T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-01-01T00:00:00\", \"latest\": \"2018-05-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/repatha\", \"ta_list\": \"Dyslipidemias; Hypercholesterolemia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2302, \"last_scrape\": \"2018-12-13T16:34:41\", \"url\": \"http://www.ncpe.ie/drugs/exenatide-bydureon/\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Exenatide (Bydureon\", \"trade_name\": \"Bydureon\", \"indication\": \"Exenatide (Bydureon\", \"ncpe_year\": 2011, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2303, \"last_scrape\": \"2018-12-13T16:34:44\", \"url\": \"http://www.ncpe.ie/drugs/fampridine-fampyra/\", \"rr_start\": \"2011-09-11T00:00:00\", \"rr_end\": \"2011-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-09-11, 2011-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Fampridine (Fampyra\", \"trade_name\": \"Fampyra\", \"indication\": \"Fampridine (Fampyra\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-20T00:00:00\", \"company\": \"Blogen\", \"orphan\": 0, \"earliest\": \"2011-09-01T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fampyra\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2304, \"last_scrape\": \"2018-12-13T16:34:48\", \"url\": \"http://www.ncpe.ie/drugs/ferric-maltol-feraccru_/\", \"rr_start\": \"2016-08-12T00:00:00\", \"rr_end\": \"2016-09-06T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-08-12, 2016-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Ferric maltol (Feraccru\", \"trade_name\": \"Feraccru\", \"indication\": \"Ferric maltol indicated for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) in adult patients.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Shield\", \"orphan\": 0, \"earliest\": \"2016-08-12T00:00:00\", \"latest\": \"2016-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/feraccru\", \"ta_list\": \"Anemia, Iron-Deficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2305, \"last_scrape\": \"2018-12-13T16:34:51\", \"url\": \"http://www.ncpe.ie/drugs/fidaxomicin-dificlir/\", \"rr_start\": \"2012-03-09T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2012-03-09, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Fidaxomicin (Dificlir\", \"trade_name\": \"Dificlir\", \"indication\": \"Fidaxomicin is indicated for the treatment of CDI also known as CDAD in adult patients.\", \"ncpe_year\": 2013, \"eu_market\": \"2011-12-05T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-03-09T00:00:00\", \"latest\": \"2013-02-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dificlir\", \"ta_list\": \"Clostridium Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2306, \"last_scrape\": \"2018-12-13T16:34:56\", \"url\": \"http://www.ncpe.ie/drugs/fingolimod-gilenya-4/\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2010-12-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-01-10, 2010-12-03\", \"rr_multiple\": 0, \"drug_name\": \"Fingolimod (Gilenya\", \"trade_name\": \"Gilenya\", \"indication\": \"Cost effectiveness of Fingolimod (Gilenya\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2010-12-03T00:00:00\", \"latest\": \"2011-09-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2307, \"last_scrape\": \"2018-12-13T16:35:01\", \"url\": \"http://www.ncpe.ie/drugs/fluocinolone-acetonide-iluvien/\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-02-15, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Fluocinolone acetonide (Iluvien\", \"trade_name\": \"Iluvien\", \"indication\": \"Iluvien\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2308, \"last_scrape\": \"2018-12-13T16:35:05\", \"url\": \"http://www.ncpe.ie/drugs/fluticasone-furoate-umeclidinium-vilantero-trelegy-ellipta/\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT TRELEGY\", \"rr_dates\": \"2018-04-30, 2018-06-18\", \"rr_multiple\": 0, \"drug_name\": \"Fluticasone furoate/ umeclidinium/ vilantero (Trelegy\", \"trade_name\": \"Trelegy Ellipta\", \"indication\": \"Trelegy\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-15T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"Reimbursement without HTA\"}, {\"id\": 2309, \"last_scrape\": \"2018-12-13T16:35:09\", \"url\": \"http://www.ncpe.ie/drugs/follitropin-delta-rekovelle/\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-07-25, 2017-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Follitropin delta (Rekovelle\", \"trade_name\": \"Rekovelle\", \"indication\": \"Follitropin delta (Rekovelle \", \"ncpe_year\": 2019, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2019-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rekovelle\", \"ta_list\": \"Anovulation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2310, \"last_scrape\": \"2018-12-13T16:35:12\", \"url\": \"http://www.ncpe.ie/drugs/gefitinib-iressa/\", \"rr_start\": \"\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Gefitinib (Iressa\", \"trade_name\": \"Iressa\", \"indication\": \"A review of the economic evaluation of oral gefitinib (Iressa\", \"ncpe_year\": 2010, \"eu_market\": \"2009-06-24T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-16T00:00:00\", \"latest\": \"2010-11-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/iressa\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2311, \"last_scrape\": \"2018-12-13T16:35:15\", \"url\": \"http://www.ncpe.ie/drugs/gemtuzumab-ozogamicin-mylotarg/\", \"rr_start\": \"2018-06-21T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF GEMTUZUMAB OZOGAMICIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-21, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Gemtuzumab ozogamicin (Mylotarg\", \"trade_name\": \"Mylotarg\", \"indication\": \"Gemtuzumab ozogamicin (Mylotarg\", \"ncpe_year\": 2018, \"eu_market\": \"2018-04-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-06-21T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2312, \"last_scrape\": \"2018-12-13T16:35:19\", \"url\": \"http://www.ncpe.ie/drugs/glecaprevirpibrentasvir-maviret/\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-07-11, 2017-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glecaprevir/Pibrentasvir (Maviret\", \"trade_name\": \"Maviret\", \"indication\": \"Glecaprevir/pibrentasvir (Maviret\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/maviret\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2313, \"last_scrape\": \"2018-12-13T16:35:25\", \"url\": \"http://www.ncpe.ie/drugs/glucosamine-sulfate-dona/\", \"rr_start\": \"\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Glucosamine sulfate (Dona\", \"trade_name\": \"Dona\", \"indication\": \"Economic evalution of glucosamine sulfate (Dona\", \"ncpe_year\": 2009, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2009-04-01T00:00:00\", \"latest\": \"2009-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2314, \"last_scrape\": \"2018-12-13T16:35:32\", \"url\": \"http://www.ncpe.ie/drugs/glycerol-phenylbutyrate-ravicti/\", \"rr_start\": \"2018-03-26T00:00:00\", \"rr_end\": \"2018-06-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT GLYCEROL PHENYLBUTYRATE (RAVICTI\", \"rr_dates\": \"2018-03-26, 2018-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Glycerol Phenylbutyrate (Ravicti\", \"trade_name\": \"Ravicti\", \"indication\": \"Glycerol phenylbutyrate (Ravicti\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-26T00:00:00\", \"company\": \"Horizon\", \"orphan\": 1, \"earliest\": \"2018-03-26T00:00:00\", \"latest\": \"2018-06-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti\", \"ta_list\": \"Urea Cycle Disorders, Inborn\", \"rr_status\": \"Reimbursement without HTA\"}, {\"id\": 2315, \"last_scrape\": \"2018-12-13T16:35:38\", \"url\": \"http://www.ncpe.ie/drugs/glycopyrronium-bromide-seebri-breezhaler/\", \"rr_start\": \"2012-08-12T00:00:00\", \"rr_end\": \"2012-08-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-08-12, 2012-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide (Seebri Breezhaler\", \"trade_name\": \"Seebri Breezhaler\", \"indication\": \"Seebri Breezhaler\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-08-12T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"id\": 2316, \"last_scrape\": \"2018-12-13T16:35:40\", \"url\": \"http://www.ncpe.ie/drugs/glypyrronium-bromide-sialanar/\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-07, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide (Sialanar\", \"trade_name\": \"Sialanar\", \"indication\": \"Glycopyrronium bromide (Sialanar\", \"ncpe_year\": 2017, \"eu_market\": \"2016-09-15T00:00:00\", \"company\": \"Proveca\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar\", \"ta_list\": \"Sialorrhea\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2317, \"last_scrape\": \"2018-12-13T16:35:47\", \"url\": \"http://www.ncpe.ie/drugs/golimumab-simponi-2/\", \"rr_start\": \"2013-10-11T00:00:00\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-10-11, 2013-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab (Simponi\", \"trade_name\": \"Simponi\", \"indication\": \"Golimumab is indicated for the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments.\", \"ncpe_year\": 2013, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2013-10-11T00:00:00\", \"latest\": \"2013-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/simponi\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"id\": 2318, \"last_scrape\": \"2018-12-13T16:35:54\", \"url\": \"http://www.ncpe.ie/drugs/golimumab-simponi/\", \"rr_start\": \"\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab (Simponi\", \"trade_name\": \"Simponi\", \"indication\": \"Cost-effectiveness of golimumab (Simponi\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2009-11-20T00:00:00\", \"latest\": \"2010-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/simponi\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2319, \"last_scrape\": \"2018-12-13T16:35:56\", \"url\": \"http://www.ncpe.ie/drugs/grass-pollen-allergen-extract-oralair/\", \"rr_start\": \"2011-10-11T00:00:00\", \"rr_end\": \"2011-09-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-10-11, 2011-09-26\", \"rr_multiple\": 0, \"drug_name\": \"Grass pollen allergen extract (Oralair\", \"trade_name\": \"Oralair\", \"indication\": \" Grass pollen allegen extract (Oralair\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-09-26T00:00:00\", \"latest\": \"2011-10-01T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2320, \"last_scrape\": \"2018-12-13T16:36:00\", \"url\": \"http://www.ncpe.ie/drugs/guanfacine-hydrochloride-intuniv/\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-01, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Guanfacine hydrochloride (Intuniv\", \"trade_name\": \"Intuniv\", \"indication\": \"Intuniv\", \"ncpe_year\": 2015, \"eu_market\": \"2015-09-17T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/intuniv\", \"ta_list\": \"Attention Deficit Disorder with Hyperactivity\", \"rr_status\": \"No HTA\"}, {\"id\": 2321, \"last_scrape\": \"2018-12-13T16:36:02\", \"url\": \"http://www.ncpe.ie/drugs/guselkumab-tremfya/\", \"rr_start\": \"2017-12-01T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-12-01, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Guselkumab (Tremfya\", \"trade_name\": \"Tremfya\", \"indication\": \"Guselkumab (Tremfya\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-10T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-12-01T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2322, \"last_scrape\": \"2018-12-13T16:36:07\", \"url\": \"http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-a1pi-prolastin/\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-06-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-05, 2017-06-08\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor (A1PI) (Prolastin\", \"trade_name\": \"Prolastin\", \"indication\": \"Human A1PI (Prolastin \", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-06-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2323, \"last_scrape\": \"2018-12-13T16:36:14\", \"url\": \"http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-respreeza/\", \"rr_start\": \"2016-01-20T00:00:00\", \"rr_end\": \"2016-02-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-20, 2016-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor (Respreeza\", \"trade_name\": \"Respreeza\", \"indication\": \"Respreeza\", \"ncpe_year\": 2017, \"eu_market\": \"2015-08-20T00:00:00\", \"company\": \"CSL\", \"orphan\": 0, \"earliest\": \"2016-01-20T00:00:00\", \"latest\": \"2017-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza\", \"ta_list\": \"Genetic Diseases, Inborn; Lung Diseases\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2324, \"last_scrape\": \"2018-12-13T16:36:17\", \"url\": \"http://www.ncpe.ie/drugs/hyaluronic-acid-and-co-enzyme-q10-visuxl/\", \"rr_start\": \"2017-11-06T00:00:00\", \"rr_end\": \"2017-11-30T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-11-06, 2017-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Hyaluronic acid and co enzyme Q10 (VisuXL\", \"trade_name\": \"VisuXL\", \"indication\": \"Cross linked hyaluronic acid and co enzyme Q10 (VisuXL\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-11-06T00:00:00\", \"latest\": \"2017-11-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2325, \"last_scrape\": \"2018-12-13T16:36:22\", \"url\": \"http://www.ncpe.ie/drugs/hydrocortisone-plenadren/\", \"rr_start\": \"2017-11-08T00:00:00\", \"rr_end\": \"2017-11-01T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-11-08, 2018-01-11, 2017-11-01\", \"rr_multiple\": 1, \"drug_name\": \"Modified Release Hydrocortisone  (Plenadren\", \"trade_name\": \"Plenadren\", \"indication\": \"Modified release hydrocortisone (Plenadren\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-03T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2018-01-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/plenadren\", \"ta_list\": \"Adrenal Insufficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2326, \"last_scrape\": \"2018-12-13T16:36:27\", \"url\": \"http://www.ncpe.ie/drugs/hydroxcarbamide-siklos/\", \"rr_start\": \"2011-08-22T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-08-22, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Hydroxycarbamide (Siklos\", \"trade_name\": \"Siklos\", \"indication\": \" Hydroxycarbamide (Siklos\", \"ncpe_year\": 2011, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"Addmedica\", \"orphan\": 1, \"earliest\": \"2011-08-22T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/siklos\", \"ta_list\": \"Anemia, Sickle Cell\", \"rr_status\": \"No HTA\"}, {\"id\": 2327, \"last_scrape\": \"2018-12-13T16:36:32\", \"url\": \"http://www.ncpe.ie/drugs/ibrutinib-imbruivca-for-previously-untreated-cll/\", \"rr_start\": \"2016-08-02T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-08-02, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib (Imbruvica\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib (Imbruvica\", \"ncpe_year\": 2016, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-08-02T00:00:00\", \"latest\": \"2016-08-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2328, \"last_scrape\": \"2018-12-13T16:36:36\", \"url\": \"http://www.ncpe.ie/drugs/ibrutinib-imbruvica-for-mcl/\", \"rr_start\": \"2014-11-07T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-11-07, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib (Imbruvica\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib (Imbruvica\", \"ncpe_year\": 2015, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-11-07T00:00:00\", \"latest\": \"2015-10-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2329, \"last_scrape\": \"2018-12-13T16:36:40\", \"url\": \"http://www.ncpe.ie/drugs/icatibant-firazyr/\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Icatibant (Firazyr\", \"trade_name\": \"Firazyr\", \"indication\": \"Icatibant (Firazyr\", \"ncpe_year\": 2013, \"eu_market\": \"2008-07-11T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"id\": 2330, \"last_scrape\": \"2018-12-13T16:36:43\", \"url\": \"http://www.ncpe.ie/drugs/idarucizumab-praxbind/\", \"rr_start\": \"2015-12-11T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-11, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Idarucizumab (Praxbind\", \"trade_name\": \"Praxbind\", \"indication\": \"Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required:\", \"ncpe_year\": 2015, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-12-11T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/praxbind\", \"ta_list\": \"Hemorrhage\", \"rr_status\": \"No HTA\"}, {\"id\": 2331, \"last_scrape\": \"2018-12-13T16:36:50\", \"url\": \"http://www.ncpe.ie/drugs/idebenone-raxone/\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-04-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-10, 2016-04-14\", \"rr_multiple\": 0, \"drug_name\": \"Idebenone (Raxone\", \"trade_name\": \"Raxone\", \"indication\": \"Raxone\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-08T00:00:00\", \"company\": \"Santhera\", \"orphan\": 1, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2018-08-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/raxone\", \"ta_list\": \"Optic Atrophy, Hereditary, Leber\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2332, \"last_scrape\": \"2018-12-13T16:36:56\", \"url\": \"http://www.ncpe.ie/drugs/idelalisib-zydelig/\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2014-12-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-08, 2014-12-30\", \"rr_multiple\": 0, \"drug_name\": \"Idelalisib (Zydelig\", \"trade_name\": \"Zydelig\", \"indication\": \"Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2016-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2333, \"last_scrape\": \"2018-12-13T16:36:59\", \"url\": \"http://www.ncpe.ie/drugs/imiquimod-zyclara/\", \"rr_start\": \"2013-09-10T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-09-10, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Imiquimod 3.75% (Zyclara\", \"trade_name\": \"Zyclara\", \"indication\": \"Imiquimod 3.75%(Zyclara\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Meda\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara\", \"ta_list\": \"Keratosis; Keratosis, Actinic\", \"rr_status\": \"No HTA\"}, {\"id\": 2334, \"last_scrape\": \"2018-12-13T16:37:01\", \"url\": \"http://www.ncpe.ie/drugs/incobotulinum-toxin-type-a-xeomin/\", \"rr_start\": \"2014-02-07T00:00:00\", \"rr_end\": \"2014-03-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-07, 2014-03-05\", \"rr_multiple\": 0, \"drug_name\": \"Incobotulinum Toxin Type A (Xeomin\", \"trade_name\": \"Xeomin\", \"indication\": \"Incobotulinum Toxin Type A (Xeomin\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-02-07T00:00:00\", \"latest\": \"2014-03-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2335, \"last_scrape\": \"2018-12-13T16:37:04\", \"url\": \"http://www.ncpe.ie/drugs/indacaterol-onbrez/\", \"rr_start\": \"2010-01-15T00:00:00\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-01-15\", \"rr_multiple\": 0, \"drug_name\": \"Indacaterol (Onbrez\", \"trade_name\": \"Onbrez\", \"indication\": \"Review of Indacaterol (Onbrez\", \"ncpe_year\": 2010, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-01-15T00:00:00\", \"latest\": \"2010-01-15T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2336, \"last_scrape\": \"2018-12-13T16:37:07\", \"url\": \"http://www.ncpe.ie/drugs/infliximab-inflectra/\", \"rr_start\": \"\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Infliximab (Inflectra\", \"trade_name\": \"Inflectra\", \"indication\": \"Inflectra\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2337, \"last_scrape\": \"2018-12-13T16:37:09\", \"url\": \"http://www.ncpe.ie/drugs/inotuzumab-ozogamicin-besponsa/\", \"rr_start\": \"2017-07-03T00:00:00\", \"rr_end\": \"2017-09-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-03, 2017-09-08\", \"rr_multiple\": 0, \"drug_name\": \"Inotuzumab ozogamicin (Besponsa\", \"trade_name\": \"Besponsa\", \"indication\": \"Inotuzumab ozogamicin (Besponsa\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2017-07-03T00:00:00\", \"latest\": \"2018-09-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2338, \"last_scrape\": \"2018-12-13T16:37:16\", \"url\": \"http://www.ncpe.ie/drugs/insulin-aspart-fiasp/\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-05-17, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart (Fiasp\", \"trade_name\": \"Fiasp\", \"indication\": \"Insulin aspart (Fiasp\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-09T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fiasp\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"No HTA\"}, {\"id\": 2339, \"last_scrape\": \"2018-12-13T16:37:21\", \"url\": \"http://www.ncpe.ie/drugs/insulin-aspart-novorapid-flextouch/\", \"rr_start\": \"2014-07-22T00:00:00\", \"rr_end\": \"2014-08-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2014-07-22, 2014-08-28\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart (NovoRapid\", \"trade_name\": \"NovoRapid FlexTouch\", \"indication\": \"Insulin aspart (NovoRapid\", \"ncpe_year\": 2014, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2014-07-22T00:00:00\", \"latest\": \"2014-08-28T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2340, \"last_scrape\": \"2018-12-13T16:37:25\", \"url\": \"http://www.ncpe.ie/drugs/insulin-degludec-tresiba/\", \"rr_start\": \"2012-12-17T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-17, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Degludec (Tresiba\", \"trade_name\": \"Tresiba\", \"indication\": \"Treatment of diabetes mellitus\", \"ncpe_year\": 2015, \"eu_market\": \"2013-01-20T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2012-12-17T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2341, \"last_scrape\": \"2018-12-13T16:37:30\", \"url\": \"http://www.ncpe.ie/drugs/insulin-degludecliraglutide-ideglira-xultophy/\", \"rr_start\": \"2016-09-19T00:00:00\", \"rr_end\": \"2016-10-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-09-19, 2016-10-17\", \"rr_multiple\": 0, \"drug_name\": \"Insulin degludec/liraglutide (IDegLira) (Xultophy\", \"trade_name\": \"Xultophy\", \"indication\": \"IDegLira is indicated for the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2016-09-19T00:00:00\", \"latest\": \"2016-10-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xultophy\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2342, \"last_scrape\": \"2018-12-13T16:37:36\", \"url\": \"http://www.ncpe.ie/drugs/insulin-glargine-abasaglar/\", \"rr_start\": \"2015-09-04T00:00:00\", \"rr_end\": \"2015-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-09-04, 2015-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine (Abasaglar\", \"trade_name\": \"Abasaglar\", \"indication\": \"Abasaglar\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-09-04T00:00:00\", \"latest\": \"2015-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2343, \"last_scrape\": \"2018-12-13T16:37:40\", \"url\": \"http://www.ncpe.ie/drugs/insulin-glargine-u300-toujeo/\", \"rr_start\": \"2015-05-14T00:00:00\", \"rr_end\": \"2015-07-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2015-05-14, 2015-07-02\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine U300 (Toujeo\", \"trade_name\": \"Toujeo\", \"indication\": \"Toujeo\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-05-14T00:00:00\", \"latest\": \"2015-07-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2344, \"last_scrape\": \"2018-12-13T16:37:43\", \"url\": \"http://www.ncpe.ie/drugs/ipilimumab-yervoy/\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Ipilimumab (Yervoy\", \"trade_name\": \"Yervoy\", \"indication\": \"Pharmacoeconomic evaluation of Ipilimumab (Yervoy\", \"ncpe_year\": 2013, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2013-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2345, \"last_scrape\": \"2018-12-13T16:37:49\", \"url\": \"http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-diafer/\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron (III) isomaltoside 1000 (Diafer\", \"trade_name\": \"Diafer\", \"indication\": \"Diafer\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2346, \"last_scrape\": \"2018-12-13T16:37:52\", \"url\": \"http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-monover/\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron (III) isomaltoside 1000 (Monover\", \"trade_name\": \"Monover\", \"indication\": \"Monover\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2347, \"last_scrape\": \"2018-12-13T16:38:02\", \"url\": \"http://www.ncpe.ie/drugs/iron-isomaltoside-1000-monover/\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2011-02-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-01-10, 2011-02-02\", \"rr_multiple\": 0, \"drug_name\": \"Iron isomaltoside 1000 (MonoVer\", \"trade_name\": \"MonoVer\", \"indication\": \"MonoVer is indicated for the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-01-10T00:00:00\", \"latest\": \"2011-02-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2348, \"last_scrape\": \"2018-12-13T16:38:07\", \"url\": \"http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-invasive-aspergillosis/\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole (Cresemba\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole (Cresemba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2349, \"last_scrape\": \"2018-12-13T16:38:09\", \"url\": \"http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-mucormycosis/\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole (Cresemba\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole (Cresemba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2350, \"last_scrape\": \"2018-12-13T16:38:15\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kaldeco/\", \"rr_start\": \"2012-08-13T00:00:00\", \"rr_end\": \"2012-08-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-08-13, 2012-08-22\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2012-08-13T00:00:00\", \"latest\": \"2013-01-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2351, \"last_scrape\": \"2018-12-13T16:38:21\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-patients-with-cf-2-years/\", \"rr_start\": \"2015-11-19T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMAOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-19, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\", \"ncpe_year\": 2016, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2015-11-19T00:00:00\", \"latest\": \"2016-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2352, \"last_scrape\": \"2018-12-13T16:38:24\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-the-treatment-of-cf-patients-with-the-r117h-mutation/\", \"rr_start\": \"2016-01-14T00:00:00\", \"rr_end\": \"2016-02-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-14, 2016-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\", \"ncpe_year\": 2017, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2016-01-14T00:00:00\", \"latest\": \"2017-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2353, \"last_scrape\": \"2018-12-13T16:38:29\", \"url\": \"http://www.ncpe.ie/drugs/ixazomib-ninlaro/\", \"rr_start\": \"2016-11-23T00:00:00\", \"rr_end\": \"2017-01-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-23, 2017-01-16\", \"rr_multiple\": 0, \"drug_name\": \"Ixazomib (Ninlaro\", \"trade_name\": \"Ninlaro\", \"indication\": \"Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-21T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2016-11-23T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2354, \"last_scrape\": \"2018-12-13T16:38:34\", \"url\": \"http://www.ncpe.ie/drugs/ixekizumab-taltz-for-psoriatic-arthritis/\", \"rr_start\": \"2018-10-16T00:00:00\", \"rr_end\": \"2018-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT IXEKIZUMAB NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE. THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013\", \"rr_dates\": \"2018-10-16, 2018-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab (Taltz\", \"trade_name\": \"Taltz\", \"indication\": \"Ixekizumab (Taltz\", \"ncpe_year\": 2018, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2018-10-16T00:00:00\", \"latest\": \"2018-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/taltz\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2355, \"last_scrape\": \"2018-12-13T16:38:37\", \"url\": \"http://www.ncpe.ie/drugs/ixekizumab-taltz/\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-06-28, 2016-07-26\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab (Taltz\", \"trade_name\": \"Taltz\", \"indication\": \"Taltz\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/taltz\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2356, \"last_scrape\": \"2018-12-13T16:38:39\", \"url\": \"http://www.ncpe.ie/drugs/l/lisdexamfetamine-dimesylate-tyvense/\", \"rr_start\": \"2013-02-09T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-02-09, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Lisdexamfetamine dimesylate (Tyvense\", \"trade_name\": \"Tyvense\", \"indication\": \"Lisdexamfetamine dimesylate (Tyvense\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-02-09T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2357, \"last_scrape\": \"2018-12-13T16:38:44\", \"url\": \"http://www.ncpe.ie/drugs/lacosamide-vimpat/\", \"rr_start\": \"2017-09-11T00:00:00\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-09-11, 2017-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Lacosamide (Vimpat \", \"trade_name\": \"Vimpat\", \"indication\": \"Vimpat \", \"ncpe_year\": 2017, \"eu_market\": \"2008-08-29T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2017-09-11T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2358, \"last_scrape\": \"2018-12-13T16:38:50\", \"url\": \"http://www.ncpe.ie/drugs/lapatinib-tyverb/\", \"rr_start\": \"\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Lapatinib (Tyverb\", \"trade_name\": \"Tyverb\", \"indication\": \"Cost-effectiveness of Lapatinib (Tyverb\", \"ncpe_year\": 2008, \"eu_market\": \"2008-06-10T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2359, \"last_scrape\": \"2018-12-13T16:38:56\", \"url\": \"http://www.ncpe.ie/drugs/ledipasvirsofosbuvir-harvoni/\", \"rr_start\": \"2014-11-14T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-11-14, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ledipasvir/sofosbuvir (Harvoni\", \"trade_name\": \"Harvoni\", \"indication\": \"Ledipasvir/sofosbuvir (Harvoni\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-17T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-11-14T00:00:00\", \"latest\": \"2015-11-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2360, \"last_scrape\": \"2018-12-13T16:39:05\", \"url\": \"http://www.ncpe.ie/drugs/lenalidomide-revlimid/\", \"rr_start\": \"2015-10-05T00:00:00\", \"rr_end\": \"2015-11-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE.\", \"rr_dates\": \"2015-10-05, 2015-11-20\", \"rr_multiple\": 0, \"drug_name\": \"Lenalidomide (Revlimid\", \"trade_name\": \"Revlimid\", \"indication\": \"Revlimid\", \"ncpe_year\": 2018, \"eu_market\": \"2007-06-14T00:00:00\", \"company\": \"Celgene\", \"orphan\": 1, \"earliest\": \"2015-10-05T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid\", \"ta_list\": \"Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2361, \"last_scrape\": \"2018-12-13T16:39:07\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-kisplyx/\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-05-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-05-05, 2017-05-18\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Kisplyx\", \"trade_name\": \"Kisplyx\", \"indication\": \"Lenvatinib (Kisplyx\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-25T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-05-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2362, \"last_scrape\": \"2018-12-13T16:39:11\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-lenvima-2/\", \"rr_start\": \"2018-08-07T00:00:00\", \"rr_end\": \"2018-08-16T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF LENVATINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-08-07, 2018-08-16\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Lenvima\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib (Lenvima\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2018-08-07T00:00:00\", \"latest\": \"2018-08-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2363, \"last_scrape\": \"2018-12-13T16:39:15\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-lenvima/\", \"rr_start\": \"2015-05-05T00:00:00\", \"rr_end\": \"2015-07-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2015-05-05, 2015-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Lenvima\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/H\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2015-05-05T00:00:00\", \"latest\": \"2015-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2364, \"last_scrape\": \"2018-12-13T16:39:20\", \"url\": \"http://www.ncpe.ie/drugs/lesinurad-zurampic/\", \"rr_start\": \"2017-03-15T00:00:00\", \"rr_end\": \"2017-03-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-15, 2017-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Lesinurad (Zurampic\", \"trade_name\": \"Zurampic\", \"indication\": \"Lesinurad (Zurampic\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Gr\", \"orphan\": 0, \"earliest\": \"2017-03-15T00:00:00\", \"latest\": \"2018-12-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zurampic\", \"ta_list\": \"Hyperuricemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2365, \"last_scrape\": \"2018-12-13T16:39:25\", \"url\": \"http://www.ncpe.ie/drugs/letermovir-prevymis/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Letermovir (Prevymis\", \"trade_name\": \"Prevymis\", \"indication\": \"Letermovir for the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevymis\", \"ta_list\": \"Cytomegalovirus Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2366, \"last_scrape\": \"2018-12-13T16:39:28\", \"url\": \"http://www.ncpe.ie/drugs/levodopa-20mgml-carbidopa-monohydrate-5mg-intestinal-gel-duodopa/\", \"rr_start\": \"2013-03-13T00:00:00\", \"rr_end\": \"2013-04-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-03-13, 2013-04-16\", \"rr_multiple\": 0, \"drug_name\": \"Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel (Duodopa\", \"trade_name\": \"Duodopa\", \"indication\": \"For the treatment of advanced levodopa-responsive Parkinson\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-13T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2367, \"last_scrape\": \"2018-12-13T16:39:34\", \"url\": \"http://www.ncpe.ie/drugs/levofloxacin-quinsair/\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-02-10, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Levofloxacin (Quinsair\", \"trade_name\": \"Quinsair\", \"indication\": \"Levofloxacin (Quinsair\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-25T00:00:00\", \"company\": \"Horizon\", \"orphan\": 0, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/quinsair\", \"ta_list\": \"Cystic Fibrosis; Respiratory Tract Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2368, \"last_scrape\": \"2018-12-13T16:39:39\", \"url\": \"http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-delivery-system-lng-ius-12-kyleena/\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-02-08, 2017-03-16\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine delivery system LNG IUS 12 (Kyleena\", \"trade_name\": \"Kyleena\", \"indication\": \"Kyleena\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2017-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2369, \"last_scrape\": \"2018-12-13T16:39:44\", \"url\": \"http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-system-lng-ius-jaydess/\", \"rr_start\": \"2013-03-07T00:00:00\", \"rr_end\": \"2013-03-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-03-07, 2013-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine system LNG-IUS (Jaydess\", \"trade_name\": \"Jaydess\", \"indication\": \"Levonorgestrel Intrauterine System LNG-IUS (Jaydess\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-07T00:00:00\", \"latest\": \"2013-03-25T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2370, \"last_scrape\": \"2018-12-13T16:39:46\", \"url\": \"http://www.ncpe.ie/drugs/lidocaine-5-plasters-versatis/\", \"rr_start\": \"2010-09-09T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2010-09-09, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Lidocaine 5% plasters (Versatis\", \"trade_name\": \"Versatis\", \"indication\": \"Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN).\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-09-09T00:00:00\", \"latest\": \"2015-09-24T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2371, \"last_scrape\": \"2018-12-13T16:39:51\", \"url\": \"http://www.ncpe.ie/drugs/linaclotide-clonstella/\", \"rr_start\": \"2013-05-28T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-05-28, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Linaclotide (Constella\", \"trade_name\": \"Constella\", \"indication\": \"Linaclotide (Constella\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2013-05-28T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/constella\", \"ta_list\": \"Irritable Bowel Syndrome\", \"rr_status\": \"No HTA\"}, {\"id\": 2372, \"last_scrape\": \"2018-12-13T16:39:54\", \"url\": \"http://www.ncpe.ie/drugs/linagliptin-trajenta/\", \"rr_start\": \"2011-08-18T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-08-18, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Linagliptin (Trajenta\", \"trade_name\": \"Trajenta\", \"indication\": \"Lingagliptin (Trajenta\", \"ncpe_year\": 2011, \"eu_market\": \"2011-08-23T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2011-08-18T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2373, \"last_scrape\": \"2018-12-13T16:39:57\", \"url\": \"http://www.ncpe.ie/drugs/lipegfilgrastim-lonquex/\", \"rr_start\": \"2013-08-20T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-08-20, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Lipegfilgrastim (Lonquex\", \"trade_name\": \"Lonquex\", \"indication\": \"Lonquex\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-25T00:00:00\", \"company\": \"Sicor\", \"orphan\": 0, \"earliest\": \"2013-08-20T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex\", \"ta_list\": \"Neutropenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2374, \"last_scrape\": \"2018-12-13T16:40:00\", \"url\": \"http://www.ncpe.ie/drugs/liposomal-daunorubicin-and-cytarabine-cpx-351vyxeos/\", \"rr_start\": \"2018-09-28T00:00:00\", \"rr_end\": \"2018-11-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-09-28, 2018-11-08\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos\", \"trade_name\": \"Vyxeos\", \"indication\": \"Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Jazz\", \"orphan\": 1, \"earliest\": \"2018-09-28T00:00:00\", \"latest\": \"2018-11-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2375, \"last_scrape\": \"2018-12-13T16:40:06\", \"url\": \"http://www.ncpe.ie/drugs/liposomal-irinotecan-nal-iri-onivyde/\", \"rr_start\": \"2017-06-13T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-13, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal irinotecan (Onivyde\", \"trade_name\": \"Onivyde\", \"indication\": \"Liposomal irinotecan (Onivyde\", \"ncpe_year\": 2017, \"eu_market\": \"2016-10-14T00:00:00\", \"company\": \"Baxalta\", \"orphan\": 1, \"earliest\": \"2017-06-13T00:00:00\", \"latest\": \"2017-07-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-0\", \"ta_list\": \"Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2376, \"last_scrape\": \"2018-12-13T16:40:09\", \"url\": \"http://www.ncpe.ie/drugs/liquid-paraffin-ointment-vita-pos-opthalmic/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Liquid Paraffin Ointment (VitA-POS Opthalmic\", \"trade_name\": \"VitA-POS Opthalmic\", \"indication\": \"Liquid Paraffin Ointment (VitA-POS Opthalmic\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2377, \"last_scrape\": \"2018-12-13T16:40:13\", \"url\": \"http://www.ncpe.ie/drugs/liraglutide-victoza/\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-10-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-09-01, 2009-10-07\", \"rr_multiple\": 0, \"drug_name\": \"Liraglutide (Victoza\", \"trade_name\": \"Victoza\", \"indication\": \"Victoza\", \"ncpe_year\": 2018, \"eu_market\": \"2009-06-30T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2009-09-01T00:00:00\", \"latest\": \"2018-10-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/victoza\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2378, \"last_scrape\": \"2018-12-13T16:40:17\", \"url\": \"http://www.ncpe.ie/drugs/lixisenatide-lyxumia/\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Lixisenatide (Lyxumia\", \"trade_name\": \"Lyxumia\", \"indication\": \"Lixisenatide (Lyxumia\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-08-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2379, \"last_scrape\": \"2018-12-13T16:40:19\", \"url\": \"http://www.ncpe.ie/drugs/lomitapide-lojuxta/\", \"rr_start\": \"2014-09-09T00:00:00\", \"rr_end\": \"2014-09-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-09-09, 2014-09-15\", \"rr_multiple\": 0, \"drug_name\": \"Lomitapide (Lojuxta\", \"trade_name\": \"Lojuxta\", \"indication\": \"Lojuxta\", \"ncpe_year\": 2014, \"eu_market\": \"2013-07-31T00:00:00\", \"company\": \"Amryt\", \"orphan\": 0, \"earliest\": \"2014-09-09T00:00:00\", \"latest\": \"2014-09-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2380, \"last_scrape\": \"2018-12-13T16:40:22\", \"url\": \"http://www.ncpe.ie/drugs/lornoxicam-xefo/\", \"rr_start\": \"2011-06-23T00:00:00\", \"rr_end\": \"2011-07-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-06-23, 2011-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Lornoxicam (Xefo\", \"trade_name\": \"Xefo\", \"indication\": \" Lornoxicam (Xefo\", \"ncpe_year\": 2011, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-06-23T00:00:00\", \"latest\": \"2011-07-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA\"}, {\"id\": 2381, \"last_scrape\": \"2018-12-13T16:40:24\", \"url\": \"http://www.ncpe.ie/drugs/lotemax-0-5-eye-drops-suspension-loteprednol/\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2011-12-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-11-15, 2011-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Lotemax 0.5% eye drops suspension (Loteprednol)\", \"trade_name\": \"Loteprednol\", \"indication\": \" Indicated for treatment of post-operative inflammation following ocular surgery.\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2011-12-05T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2382, \"last_scrape\": \"2018-12-13T16:40:30\", \"url\": \"http://www.ncpe.ie/drugs/loxapine-inhalation-powder-adasuve/\", \"rr_start\": \"2016-06-21T00:00:00\", \"rr_end\": \"2016-07-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-06-21, 2016-07-28\", \"rr_multiple\": 0, \"drug_name\": \"Loxapine inhalation powder (Adasuve\", \"trade_name\": \"Adasuve\", \"indication\": \"Inhaled loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-02-20T00:00:00\", \"company\": \"Ferrer\", \"orphan\": 0, \"earliest\": \"2016-06-21T00:00:00\", \"latest\": \"2016-07-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve\", \"ta_list\": \"Schizophrenia; Bipolar Disorder\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2383, \"last_scrape\": \"2018-12-13T16:40:34\", \"url\": \"http://www.ncpe.ie/drugs/lumacaftorivacaftor-orkambi/\", \"rr_start\": \"2015-11-26T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-26, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Lumacaftor/ivacaftor (Orkambi\", \"trade_name\": \"Orkambi\", \"indication\": \"Orkambi\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Vertex\", \"orphan\": 0, \"earliest\": \"2015-11-26T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/orkambi\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2384, \"last_scrape\": \"2018-12-13T16:40:36\", \"url\": \"http://www.ncpe.ie/drugs/lutetium-177lu-oxodotreotide-lutathera/\", \"rr_start\": \"2018-10-23T00:00:00\", \"rr_end\": \"2018-11-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-10-23, 2018-11-16\", \"rr_multiple\": 0, \"drug_name\": \"Lutetium (177Lu) Oxodotreotide (Lutathera\", \"trade_name\": \"Lutathera\", \"indication\": \"Lutetium (177Lu) Oxodotreotide (Lutathera\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-26T00:00:00\", \"company\": \"Advanced\", \"orphan\": 1, \"earliest\": \"2018-10-23T00:00:00\", \"latest\": \"2018-11-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2385, \"last_scrape\": \"2018-12-13T16:40:41\", \"url\": \"http://www.ncpe.ie/drugs/macitentan-opsumit/\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-10, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Macitentan (Opsumit\", \"trade_name\": \"Opsumit\", \"indication\": \"Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-12-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2386, \"last_scrape\": \"2018-12-13T16:40:43\", \"url\": \"http://www.ncpe.ie/drugs/melatonin-circadin/\", \"rr_start\": \"\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Melatonin (Circadin\", \"trade_name\": \"Circadin\", \"indication\": \"A Review of the Economic Evaluation of Prolonged Release Melatonin (Circadin\", \"ncpe_year\": 2008, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"RAD\", \"orphan\": 0, \"earliest\": \"2008-08-01T00:00:00\", \"latest\": \"2008-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/circadin\", \"ta_list\": \"Sleep Initiation and Maintenance Disorders\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2387, \"last_scrape\": \"2018-12-13T16:40:45\", \"url\": \"http://www.ncpe.ie/drugs/mepolizumab-nucala/\", \"rr_start\": \"2016-03-16T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-03-16, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Mepolizumab (Nucala\", \"trade_name\": \"Nucala\", \"indication\": \"Mepolizumab (Nucala\", \"ncpe_year\": 2018, \"eu_market\": \"2015-12-01T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-03-16T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nucala\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2388, \"last_scrape\": \"2018-12-13T16:40:51\", \"url\": \"http://www.ncpe.ie/drugs/methoxyflurane-penthrox/\", \"rr_start\": \"2015-11-23T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-11-23, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Methoxyflurane (Penthrox\", \"trade_name\": \"Penthrox\", \"indication\": \"Penthrox\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2015-11-23T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2389, \"last_scrape\": \"2018-12-13T16:40:56\", \"url\": \"http://www.ncpe.ie/drugs/midostaurin-rydapt-for-aml/\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF MIDOSTAURIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin (Rydapt\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin (Rydapt\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2390, \"last_scrape\": \"2018-12-13T16:41:02\", \"url\": \"http://www.ncpe.ie/drugs/midostaurin-rydapt-for-asm/\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF MIDOSTAURIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin (Rydapt\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin (Rydapt\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2391, \"last_scrape\": \"2018-12-13T16:41:04\", \"url\": \"http://www.ncpe.ie/drugs/mifamurtide-mepact/\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-06-22, 2010-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Mifamurtide (Mepact\", \"trade_name\": \"Mepact\", \"indication\": \"Mifamurtide (Meptact\", \"ncpe_year\": 2010, \"eu_market\": \"2009-03-06T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2010-06-22T00:00:00\", \"latest\": \"2010-07-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mepact\", \"ta_list\": \"Osteosarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2392, \"last_scrape\": \"2018-12-13T16:41:06\", \"url\": \"http://www.ncpe.ie/drugs/migalastat-galafold/\", \"rr_start\": \"2016-07-14T00:00:00\", \"rr_end\": \"2016-08-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-07-14, 2016-08-18\", \"rr_multiple\": 0, \"drug_name\": \"Migalastat (Galafold\", \"trade_name\": \"Galafold\", \"indication\": \"Migalastat is indicated for the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-05-25T00:00:00\", \"company\": \"Amicus\", \"orphan\": 1, \"earliest\": \"2016-07-14T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/galafold\", \"ta_list\": \"Fabry Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2393, \"last_scrape\": \"2018-12-13T16:41:13\", \"url\": \"http://www.ncpe.ie/drugs/mirabegron-betmiga/\", \"rr_start\": \"2012-12-19T00:00:00\", \"rr_end\": \"2013-03-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-12-19, 2013-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Mirabegron (Betmiga\", \"trade_name\": \"Betmiga\", \"indication\": \"Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome\", \"ncpe_year\": 2013, \"eu_market\": \"2012-12-20T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-12-19T00:00:00\", \"latest\": \"2013-03-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga\", \"ta_list\": \"Urinary Bladder, Overactive\", \"rr_status\": \"No HTA\"}, {\"id\": 2394, \"last_scrape\": \"2018-12-13T16:41:15\", \"url\": \"http://www.ncpe.ie/drugs/nab-paclitaxel-abraxane/\", \"rr_start\": \"2014-01-23T00:00:00\", \"rr_end\": \"2014-03-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-01-23, 2014-03-02\", \"rr_multiple\": 0, \"drug_name\": \"Nab-paclitaxel (Abraxane\", \"trade_name\": \"Abraxane\", \"indication\": \"Nab-paclitaxel (Abraxane\", \"ncpe_year\": 2015, \"eu_market\": \"2008-01-10T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2014-01-23T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane\", \"ta_list\": \"Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2395, \"last_scrape\": \"2018-12-13T16:41:18\", \"url\": \"http://www.ncpe.ie/drugs/nalmefene-selincro/\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Nalmefene (Selincro\", \"trade_name\": \"Selincro\", \"indication\": \"Nalmefene (Selincro\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-24T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2014-04-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/selincro\", \"ta_list\": \"Alcohol-Related Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2396, \"last_scrape\": \"2018-12-13T16:41:24\", \"url\": \"http://www.ncpe.ie/drugs/naloxegel-moventig/\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-04-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-02-10, 2015-04-13\", \"rr_multiple\": 0, \"drug_name\": \"Naloxegel (Moventig\", \"trade_name\": \"Moventig\", \"indication\": \"Naloxegel (Moventiq\", \"ncpe_year\": 2015, \"eu_market\": \"2014-12-07T00:00:00\", \"company\": \"Kyowa\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-04-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/moventig\", \"ta_list\": \"Constipation; Opioid-Related Disorders\", \"rr_status\": \"No HTA\"}, {\"id\": 2397, \"last_scrape\": \"2018-12-13T16:41:26\", \"url\": \"http://www.ncpe.ie/drugs/naltrexone-bupropion-mysimba/\", \"rr_start\": \"2017-03-12T00:00:00\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-12, 2017-03-28\", \"rr_multiple\": 0, \"drug_name\": \"Naltrexone / bupropion (Mysimba\", \"trade_name\": \"Mysimba\", \"indication\": \"Naltrexone / bupropion (Mysimba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-03-26T00:00:00\", \"company\": \"Orexigen\", \"orphan\": 0, \"earliest\": \"2017-03-12T00:00:00\", \"latest\": \"2018-05-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba\", \"ta_list\": \"Obesity; Overweight\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2398, \"last_scrape\": \"2018-12-13T16:41:30\", \"url\": \"http://www.ncpe.ie/drugs/natalizumab-tysabri/\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Natalizumab (Tysabri\", \"trade_name\": \"Tysabri\", \"indication\": \" Economic Evaluation of Natalizumab (Tysabri\", \"ncpe_year\": 2007, \"eu_market\": \"2006-06-27T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2007-01-01T00:00:00\", \"latest\": \"2007-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2399, \"last_scrape\": \"2018-12-13T16:41:35\", \"url\": \"http://www.ncpe.ie/drugs/ncpe-inhaled-insulin-exubera-assessment/\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Inhaled insulin (Exubera\", \"trade_name\": \"Exubera\", \"indication\": \"In April 2006, Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin (Exubera\", \"ncpe_year\": 2006, \"eu_market\": \"2006-01-24T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-03-01T00:00:00\", \"latest\": \"2006-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/exubera\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2400, \"last_scrape\": \"2018-12-13T16:41:38\", \"url\": \"http://www.ncpe.ie/drugs/nepafenac-nevanac-2/\", \"rr_start\": \"2011-06-14T00:00:00\", \"rr_end\": \"2011-06-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-06-14, 2011-06-27\", \"rr_multiple\": 0, \"drug_name\": \"Nepafenac (Nevanac\", \"trade_name\": \"Nevanac\", \"indication\": \"Nepafenac (Nevanac\", \"ncpe_year\": 2011, \"eu_market\": \"2007-12-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2011-06-14T00:00:00\", \"latest\": \"2011-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac\", \"ta_list\": \"Pain, Postoperative; Ophthalmologic Surgical Procedures\", \"rr_status\": \"No HTA\"}, {\"id\": 2401, \"last_scrape\": \"2018-12-13T16:41:41\", \"url\": \"http://www.ncpe.ie/drugs/netupitantpalonosetron-akynzeo/\", \"rr_start\": \"2015-08-26T00:00:00\", \"rr_end\": \"2015-10-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-08-26, 2015-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Netupitant/palonosetron (Akynzeo\", \"trade_name\": \"Akynzeo\", \"indication\": \"Akynzeo\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Helsinn\", \"orphan\": 0, \"earliest\": \"2015-08-26T00:00:00\", \"latest\": \"2015-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo\", \"ta_list\": \"Vomiting; Cancer; Nausea\", \"rr_status\": \"No HTA\"}, {\"id\": 2402, \"last_scrape\": \"2018-12-13T16:41:44\", \"url\": \"http://www.ncpe.ie/drugs/nilotinib-tasigna-newly-diagnosed-cml/\", \"rr_start\": \"2010-10-06T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2010-10-06, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib (Tasigna\", \"trade_name\": \"Tasigna\", \"indication\": \"Nilotinib (Tasigna\", \"ncpe_year\": 2010, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-10-06T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2403, \"last_scrape\": \"2018-12-13T16:41:51\", \"url\": \"http://www.ncpe.ie/drugs/nilotinib-tasigna/\", \"rr_start\": \"\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib (Tasigna\", \"trade_name\": \"Tasigna\", \"indication\": \"Cost-effectiveness of Nilotinib (Tasigna\", \"ncpe_year\": 2008, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2404, \"last_scrape\": \"2018-12-13T16:41:53\", \"url\": \"http://www.ncpe.ie/drugs/nintedanib-ofev/\", \"rr_start\": \"2015-01-30T00:00:00\", \"rr_end\": \"2015-02-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-30, 2015-02-18\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib (Ofev\", \"trade_name\": \"Ofev\", \"indication\": \"Nintedanib (Ofev\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 1, \"earliest\": \"2015-01-30T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ofev\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2405, \"last_scrape\": \"2018-12-13T16:41:56\", \"url\": \"http://www.ncpe.ie/drugs/nintedanib-vargatef/\", \"rr_start\": \"2015-01-02T00:00:00\", \"rr_end\": \"2015-02-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-02, 2015-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib (Vargatef\", \"trade_name\": \"Vargatef\", \"indication\": \"Nintedanib (Vargatef\", \"ncpe_year\": 2017, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-01-02T00:00:00\", \"latest\": \"2017-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2406, \"last_scrape\": \"2018-12-13T16:42:00\", \"url\": \"http://www.ncpe.ie/drugs/niraparib-zejula/\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF NIRAPARIB COMPARED WITH THE CURRENT STANDARD OF CARE\", \"rr_dates\": \"2018-06-01, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Niraparib (Zejula\", \"trade_name\": \"Zejula\", \"indication\": \"Niraparib (Zejula\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-16T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 1, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zejula\", \"ta_list\": \"Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2407, \"last_scrape\": \"2018-12-13T16:42:06\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-melanoma/\", \"rr_start\": \"2015-05-28T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-05-28, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-05-28T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2408, \"last_scrape\": \"2018-12-13T16:42:13\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-non-squamous-nsclc/\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-03-03, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2409, \"last_scrape\": \"2018-12-13T16:42:20\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-nsclc/\", \"rr_start\": \"2015-07-02T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-07-02, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-07-02T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2410, \"last_scrape\": \"2018-12-13T16:42:26\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-as-monotherapy-for-the-adjuvant-treatment-of-adults-with-melanoma/\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF NIVOLUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-09, 2018-07-27\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-11-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2411, \"last_scrape\": \"2018-12-13T16:42:31\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-advanced-renal-cell-carcinoma/\", \"rr_start\": \"2016-04-27T00:00:00\", \"rr_end\": \"2016-05-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-04-27, 2016-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-04-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2412, \"last_scrape\": \"2018-12-13T16:42:33\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-classical-hodgkin-lymphoma/\", \"rr_start\": \"2016-11-22T00:00:00\", \"rr_end\": \"2017-01-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-11-22, 2017-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-11-22T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2413, \"last_scrape\": \"2018-12-13T16:42:36\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-head-and-neck-cancer/\", \"rr_start\": \"2017-05-03T00:00:00\", \"rr_end\": \"2017-05-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-03, 2017-05-30\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-05-03T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2414, \"last_scrape\": \"2018-12-13T16:42:41\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-urothelial-carcinoma/\", \"rr_start\": \"2017-06-28T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-28, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-06-28T00:00:00\", \"latest\": \"2018-09-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2415, \"last_scrape\": \"2018-12-13T16:42:46\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-in-combination-with-ipilimumab-yervoy/\", \"rr_start\": \"2018-11-28T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-11-28, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Yervoy\", \"indication\": \"Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).\", \"ncpe_year\": 2018, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-11-28T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy\", \"ta_list\": \"Melanoma\", \"rr_status\": \"Unknown\"}, {\"id\": 2416, \"last_scrape\": \"2018-12-13T16:42:51\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-plus-ipilimumab-opdivio-plus-yervoy/\", \"rr_start\": \"\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab plus ipilimumab (Opdivo\", \"trade_name\": \"Opdivo plus Yervoy\", \"indication\": \"Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-06-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2417, \"last_scrape\": \"2018-12-13T16:42:56\", \"url\": \"http://www.ncpe.ie/drugs/nomace2-zoely/\", \"rr_start\": \"2011-12-08T00:00:00\", \"rr_end\": \"2012-01-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-12-08, 2012-01-03\", \"rr_multiple\": 0, \"drug_name\": \"Nomegestrol acetate/estradiol (Zoely\", \"trade_name\": \"Zoely\", \"indication\": \"Nomegestrol acetate/estradiol (Zoely\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-26T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2011-12-08T00:00:00\", \"latest\": \"2012-01-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zoely\", \"ta_list\": \"Contraception\", \"rr_status\": \"No HTA\"}, {\"id\": 2418, \"last_scrape\": \"2018-12-13T16:43:02\", \"url\": \"http://www.ncpe.ie/drugs/nusinersin-spinraza/\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-11, 2017-08-02\", \"rr_multiple\": 0, \"drug_name\": \"Nusinersin (Spinraza\", \"trade_name\": \"Spinraza\", \"indication\": \"Nusinersen (Spinraza\", \"ncpe_year\": 2017, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 1, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-12-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza\", \"ta_list\": \"Muscular Atrophy, Spinal\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2419, \"last_scrape\": \"2018-12-13T16:43:07\", \"url\": \"http://www.ncpe.ie/drugs/obeticholic-acid-ocaliva/\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-18, 2016-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Obeticholic acid (Ocaliva\", \"trade_name\": \"Ocaliva\", \"indication\": \"Obeticholic acid is indicated for the treatment of primary biliary cirrhosis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Intercept\", \"orphan\": 1, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocaliva\", \"ta_list\": \"Liver Cirrhosis, Biliary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2420, \"last_scrape\": \"2018-12-13T16:43:10\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-follicular-lymphoma/\", \"rr_start\": \"2016-05-11T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-05-11, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (in combination with bendamustine) followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2016-05-11T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2421, \"last_scrape\": \"2018-12-13T16:43:15\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-previously-untreated-advanced-follicular-lymphoma/\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-09-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-08, 2017-09-13\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (Gazyvaro\", \"ncpe_year\": 2018, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2422, \"last_scrape\": \"2018-12-13T16:43:21\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro/\", \"rr_start\": \"2014-08-08T00:00:00\", \"rr_end\": \"2014-09-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-08-08, 2014-09-11\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (Gazyvaro\", \"ncpe_year\": 2015, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2014-08-08T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2423, \"last_scrape\": \"2018-12-13T16:43:24\", \"url\": \"http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-ppms/\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab (Ocrevus\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab (Ocrevus\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2424, \"last_scrape\": \"2018-12-13T16:43:30\", \"url\": \"http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-rms/\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab (Ocrevus\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab (Ocrevus\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2425, \"last_scrape\": \"2018-12-13T16:43:34\", \"url\": \"http://www.ncpe.ie/drugs/ocriplasmin-jetrea/\", \"rr_start\": \"2013-06-12T00:00:00\", \"rr_end\": \"2013-07-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-06-12, 2013-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Ocriplasmin (Jetrea\", \"trade_name\": \"Jetrea\", \"indication\": \"Ocriplasmin (Jetrea\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-13T00:00:00\", \"company\": \"ThromboGenics\", \"orphan\": 0, \"earliest\": \"2013-06-12T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea\", \"ta_list\": \"Retinal Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2426, \"last_scrape\": \"2018-12-13T16:43:39\", \"url\": \"http://www.ncpe.ie/drugs/ofatumumab-arzerra-previously-untreated-chronic-lymphocytic-leukaemia/\", \"rr_start\": \"2014-10-13T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2014-10-13, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab (Arzerra\", \"trade_name\": \"Arzerra\", \"indication\": \"Ofatumumab (Arzerra\", \"ncpe_year\": 2014, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-10-13T00:00:00\", \"latest\": \"2014-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2427, \"last_scrape\": \"2018-12-13T16:43:46\", \"url\": \"http://www.ncpe.ie/drugs/ofatumumab-arzerra/\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-06-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-06-22, 2010-06-01\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab (Arzerra\", \"trade_name\": \"Arzerra\", \"indication\": \"Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-06-01T00:00:00\", \"latest\": \"2010-06-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2428, \"last_scrape\": \"2018-12-13T16:43:52\", \"url\": \"http://www.ncpe.ie/drugs/oladaterol-striverdi-respimat/\", \"rr_start\": \"2014-04-07T00:00:00\", \"rr_end\": \"2014-05-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-07, 2014-05-02\", \"rr_multiple\": 0, \"drug_name\": \"Oladaterol (Striverdi\", \"trade_name\": \"Striverdi, Respimat\", \"indication\": \"Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-04-07T00:00:00\", \"latest\": \"2014-05-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2429, \"last_scrape\": \"2018-12-13T16:43:57\", \"url\": \"http://www.ncpe.ie/drugs/olaparib-lynparza-2/\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-05, 2015-02-19\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib (Lynparza\", \"trade_name\": \"Lynparza\", \"indication\": \"Lynparza\", \"ncpe_year\": 2017, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2430, \"last_scrape\": \"2018-12-13T16:44:03\", \"url\": \"http://www.ncpe.ie/drugs/olaparib-lynparza-for-platinum-sensitive-relapsed-ovarian-cancer/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"THE NCPE RECOMMEND  A FULL HTA TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF OLAPARIB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib (Lynparza\", \"trade_name\": \"Lynparza\", \"indication\": \"Olaparib (Lynparza\", \"ncpe_year\": 2018, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2431, \"last_scrape\": \"2018-12-13T16:44:08\", \"url\": \"http://www.ncpe.ie/drugs/omalizumab-xolair-for-the-treatment-of-severe-allergic-asthma/\", \"rr_start\": \"\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab (Xolair\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab is indicated as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1<80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.\", \"ncpe_year\": 2015, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-08-22T00:00:00\", \"latest\": \"2015-06-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xolair\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2432, \"last_scrape\": \"2018-12-13T16:44:14\", \"url\": \"http://www.ncpe.ie/drugs/omalizumab-xolair/\", \"rr_start\": \"2014-03-25T00:00:00\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED FOR THIS INDICATION.\", \"rr_dates\": \"2014-03-25, 2014-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab (Xolair\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab (Xolair\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-03-25T00:00:00\", \"latest\": \"2014-04-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xolair\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"No HTA\"}, {\"id\": 2433, \"last_scrape\": \"2018-12-13T16:44:19\", \"url\": \"http://www.ncpe.ie/drugs/oral-oxycodonenaloxone-targin/\", \"rr_start\": \"\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Oxycodone/naloxone (Targin\", \"trade_name\": \"Targin\", \"indication\": \"Cost-effectiveness of oral oxycodone/naloxone prolonged release tablet (Targin\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-05-05T00:00:00\", \"latest\": \"2010-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2434, \"last_scrape\": \"2018-12-13T16:44:22\", \"url\": \"http://www.ncpe.ie/drugs/osimertinib-tagrisso-for-the-first-line-treatment-of-metastatic-nsclc/\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-07T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF OSIMERTINIB FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WITH ACTIVATING EGFR MUTATIONS COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-19, 2018-08-07\", \"rr_multiple\": 0, \"drug_name\": \"Osimertinib (Tagrisso\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib (Tagrisso\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2435, \"last_scrape\": \"2018-12-13T16:44:39\", \"url\": \"http://www.ncpe.ie/drugs/osimertinib-tagrisso/\", \"rr_start\": \"2016-02-26T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-26, 2016-03-22, 2017-01-10\", \"rr_multiple\": 1, \"drug_name\": \"Osimertinib (Tagrisso\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib (Tagrisso\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-26T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2436, \"last_scrape\": \"2018-12-13T16:44:40\", \"url\": \"http://www.ncpe.ie/drugs/ozenoxacin-dubine/\", \"rr_start\": \"2018-11-12T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"FULL HTA IS NOT RECOMMENDED. THE NCPE RECOMMENDS THAT OZENOXACIN CREAM NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE.  THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013.\", \"rr_dates\": \"2018-11-12, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ozenoxacin (Dubine\", \"trade_name\": \"Dubine\", \"indication\": \"Ozenoxacin (Dubine\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-12T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"id\": 2437, \"last_scrape\": \"2018-12-13T16:44:43\", \"url\": \"http://www.ncpe.ie/drugs/p-drugs/pegylated-interferon-b-1a-plegridy/\", \"rr_start\": \"2014-11-25T00:00:00\", \"rr_end\": \"2014-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-11-25, 2014-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Pegylated Interferon beta-1a (Plegridy \", \"trade_name\": \"Plegridy\", \"indication\": \"Treatment of adult patients with relapsing remitting multiple sclerosis\", \"ncpe_year\": 2014, \"eu_market\": \"2014-07-17T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-11-25T00:00:00\", \"latest\": \"2014-12-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2438, \"last_scrape\": \"2018-12-13T16:44:47\", \"url\": \"http://www.ncpe.ie/drugs/palbociclib-ibrance/\", \"rr_start\": \"2016-09-10T00:00:00\", \"rr_end\": \"2016-09-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-09-10, 2016-09-28\", \"rr_multiple\": 0, \"drug_name\": \"Palbociclib (Ibrance\", \"trade_name\": \"Ibrance\", \"indication\": \"Palbociclib is indicated for the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-11-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2016-09-10T00:00:00\", \"latest\": \"2017-07-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2439, \"last_scrape\": \"2018-12-13T16:44:53\", \"url\": \"http://www.ncpe.ie/drugs/paliperidone-palmitate-xeplion/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Paliperidone palmitate (Xeplion\", \"trade_name\": \"Xeplion\", \"indication\": \"Paliperidone palmitate (Xeplion\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-04T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeplion\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2440, \"last_scrape\": \"2018-12-13T16:44:57\", \"url\": \"http://www.ncpe.ie/drugs/panobinostat-farydak/\", \"rr_start\": \"2016-01-26T00:00:00\", \"rr_end\": \"2016-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-26, 2016-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Panobinostat (Farydak\", \"trade_name\": \"Farydak\", \"indication\": \"Panobinostat in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-01-26T00:00:00\", \"latest\": \"2016-02-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/farydak\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2441, \"last_scrape\": \"2018-12-13T16:45:01\", \"url\": \"http://www.ncpe.ie/drugs/paritaprevir-boosted-with-ritonavir-and-ombitasvir-vierkirax-with-or-without-dasabuvir-exviera/\", \"rr_start\": \"2014-12-21T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-21, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Paritaprevir boosted with ritonavir and ombitasvir (Vierkirax\", \"trade_name\": \"Exviera\", \"indication\": \"Exviera\", \"ncpe_year\": 2016, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2014-12-21T00:00:00\", \"latest\": \"2016-02-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/exviera\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2442, \"last_scrape\": \"2018-12-13T16:45:07\", \"url\": \"http://www.ncpe.ie/drugs/patiromer-veltassa/\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT\\nRECOMMENDED\", \"rr_dates\": \"2017-10-11, 2017-11-17\", \"rr_multiple\": 0, \"drug_name\": \"Patiromer (Veltassa\", \"trade_name\": \"Veltassa\", \"indication\": \"Patiromer (Veltassa\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-19T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-11-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/veltassa\", \"ta_list\": \"Hyperkalemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2443, \"last_scrape\": \"2018-12-13T16:45:10\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-1l-nsclc-with-chemotherapy/\", \"rr_start\": \"2018-08-14T00:00:00\", \"rr_end\": \"2018-08-29T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-14, 2018-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-08-14T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2444, \"last_scrape\": \"2018-12-13T16:45:15\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-adjuvant-melanoma/\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-07T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-11-19, 2018-12-07\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizuma (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2445, \"last_scrape\": \"2018-12-13T16:45:18\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-classical-hodgkin-lymphoma/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2446, \"last_scrape\": \"2018-12-13T16:45:23\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-first-line-nsclc/\", \"rr_start\": \"2016-12-19T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-12-19, 2017-01-10\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-12-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2447, \"last_scrape\": \"2018-12-13T16:45:28\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-nsclc/\", \"rr_start\": \"2016-08-03T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-08-03, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-03T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2448, \"last_scrape\": \"2018-12-13T16:45:31\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-the-treatment-of-unresectable-or-advanced-metastatic-melanoma-in-adults-refractory-to-ipilimumab/\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2449, \"last_scrape\": \"2018-12-13T16:45:36\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-uc-1l/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES\", \"rr_dates\": \"2017-12-06, 2017-12-21, 2018-06-21, 2018-07-10, 2018-07-27\", \"rr_multiple\": 1, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-07-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2450, \"last_scrape\": \"2018-12-13T16:45:38\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-urothelial-carcinoma-2l/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda \", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2451, \"last_scrape\": \"2018-12-13T16:45:45\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda/\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-02-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2452, \"last_scrape\": \"2018-12-13T16:45:50\", \"url\": \"http://www.ncpe.ie/drugs/perampanel-fycompa/\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Perampanel (Fycompa\", \"trade_name\": \"Fycompa\", \"indication\": \"Perampanel (Fycompa\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-23T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa\", \"ta_list\": \"Epilepsies, Partial\", \"rr_status\": \"No HTA\"}, {\"id\": 2453, \"last_scrape\": \"2018-12-13T16:45:56\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta-for-her2-positive-breast-cancer/\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PERTUZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-01, 2018-06-22\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab  (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.\", \"ncpe_year\": 2018, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-12-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2454, \"last_scrape\": \"2018-12-13T16:46:02\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta-in-neoadjuvant-her2-positive-breast-cancer/\", \"rr_start\": \"2015-08-10T00:00:00\", \"rr_end\": \"2015-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-10, 2015-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"Perjeta (pertuzumab) is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2015-08-10T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2455, \"last_scrape\": \"2018-12-13T16:46:04\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta/\", \"rr_start\": \"2013-01-14T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-01-14, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"The proposed licensed indication is for use (in combination with trastuzumab and docetaxel) in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. \", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-01-14T00:00:00\", \"latest\": \"2013-08-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2456, \"last_scrape\": \"2018-12-13T16:46:09\", \"url\": \"http://www.ncpe.ie/drugs/phenylephrine-hydrochloride-tropicamide-lidocaine-hydrochloride-fydrane/\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-19T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-11-18, 2016-12-19\", \"rr_multiple\": 0, \"drug_name\": \"Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride (Fydrane\", \"trade_name\": \"Fydrane\", \"indication\": \"Fydrane\", \"ncpe_year\": 2016, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2016-12-19T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2457, \"last_scrape\": \"2018-12-13T16:46:11\", \"url\": \"http://www.ncpe.ie/drugs/pirfenidone-esbriet/\", \"rr_start\": \"2011-12-15T00:00:00\", \"rr_end\": \"2012-01-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-12-15, 2012-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Pirfenidone (Esbriet\", \"trade_name\": \"Esbriet\", \"indication\": \"Pirfenidone has been licensed by the European Medicines Agency (EMA) for the treatment of mild to moderate idiopathic pulmonary fibrosis.\", \"ncpe_year\": 2015, \"eu_market\": \"2011-02-27T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2011-12-15T00:00:00\", \"latest\": \"2015-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esbriet\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2458, \"last_scrape\": \"2018-12-13T16:46:14\", \"url\": \"http://www.ncpe.ie/drugs/pitavastatin-livazo/\", \"rr_start\": \"2010-12-22T00:00:00\", \"rr_end\": \"2010-12-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-12-22, 2010-12-24\", \"rr_multiple\": 0, \"drug_name\": \"Pitavastatin (Livazo\", \"trade_name\": \"Livazo\", \"indication\": \"Pitavastatin is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined (mixed) dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-12-22T00:00:00\", \"latest\": \"2010-12-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2459, \"last_scrape\": \"2018-12-13T16:46:20\", \"url\": \"http://www.ncpe.ie/drugs/pitolisant-wakix/\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-06-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-06-12, 2017-06-15\", \"rr_multiple\": 0, \"drug_name\": \"Pitolisant hydrochloride (Wakix\", \"trade_name\": \"Wakix\", \"indication\": \"Pitolisant hydrochloride (Wakix\", \"ncpe_year\": 2017, \"eu_market\": \"2016-03-31T00:00:00\", \"company\": \"Bioprojet\", \"orphan\": 1, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-06-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/wakix\", \"ta_list\": \"Narcolepsy\", \"rr_status\": \"No HTA\"}, {\"id\": 2460, \"last_scrape\": \"2018-12-13T16:46:24\", \"url\": \"http://www.ncpe.ie/drugs/pixantrone-pixuvri/\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-03-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-02-10, 2015-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Pixantrone (Pixuvri\", \"trade_name\": \"Pixuvri\", \"indication\": \"Pixurvi\", \"ncpe_year\": 2015, \"eu_market\": \"2012-05-10T00:00:00\", \"company\": \"CTI\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-03-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri\", \"ta_list\": \"Lymphoma, Non-Hodgkin\", \"rr_status\": \"No HTA\"}, {\"id\": 2461, \"last_scrape\": \"2018-12-13T16:46:27\", \"url\": \"http://www.ncpe.ie/drugs/polynuclear-ironiii-oxyhydroxide-pn-feooh-velphoro/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-09-12, 2014-10-08\", \"rr_multiple\": 0, \"drug_name\": \"Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro\", \"trade_name\": \"Velphoro\", \"indication\": \"Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro\", \"ncpe_year\": 2014, \"eu_market\": \"2014-08-26T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-10-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/velphoro\", \"ta_list\": \"Hyperphosphatemia; Renal Dialysis\", \"rr_status\": \"No HTA\"}, {\"id\": 2462, \"last_scrape\": \"2018-12-13T16:46:30\", \"url\": \"http://www.ncpe.ie/drugs/pomalidomide-imnovid/\", \"rr_start\": \"2013-09-20T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-20, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Pomalidomide (Imnovid\", \"trade_name\": \"Imnovid\", \"indication\": \"Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-09-20T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2463, \"last_scrape\": \"2018-12-13T16:46:32\", \"url\": \"http://www.ncpe.ie/drugs/ponatinib-iclusig/\", \"rr_start\": \"2013-10-02T00:00:00\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-10-02, 2013-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Ponatinib (Iclusig\", \"trade_name\": \"Iclusig\", \"indication\": \"Ponatinib (Iclusig\", \"ncpe_year\": 2016, \"eu_market\": \"2013-07-01T00:00:00\", \"company\": \"Incyte\", \"orphan\": 1, \"earliest\": \"2013-10-02T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig\", \"ta_list\": \"Leukemia, Myeloid; Leukemia, Lymphoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2464, \"last_scrape\": \"2018-12-13T16:46:38\", \"url\": \"http://www.ncpe.ie/drugs/prasugrel-efient/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Prasugrel (Efient\", \"trade_name\": \"Efient\", \"indication\": \"Economic Evaluation of Prasugrel (Efient\", \"ncpe_year\": 2010, \"eu_market\": \"2009-02-24T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2010-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/efient\", \"ta_list\": \"Acute Coronary Syndrome; Angina, Unstable; Myocardial Infarction\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2465, \"last_scrape\": \"2018-12-13T16:46:46\", \"url\": \"http://www.ncpe.ie/drugs/pregabalin-lyrica-2/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin (Lyrica\", \"trade_name\": \"Lyrica\", \"indication\": \"Lyrica\", \"ncpe_year\": 2015, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-30T00:00:00\", \"latest\": \"2015-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2466, \"last_scrape\": \"2018-12-13T16:46:52\", \"url\": \"http://www.ncpe.ie/drugs/pregabalin-lyrica-for-the-treatment-of-generalised-anxiety-disorder/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin (Lyrica\", \"trade_name\": \"Lyrica\", \"indication\": \"Pregabalin (Lyrica\", \"ncpe_year\": 2014, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-12-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2467, \"last_scrape\": \"2018-12-13T16:46:58\", \"url\": \"http://www.ncpe.ie/drugs/prucalopride-resolor/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-01-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-01-17\", \"rr_multiple\": 0, \"drug_name\": \"Prucalopride (Resolor\", \"trade_name\": \"Resolor\", \"indication\": \"Prucalopride (Resolor\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-14T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2011-01-17T00:00:00\", \"latest\": \"2011-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/resolor\", \"ta_list\": \"Constipation\", \"rr_status\": \"No HTA\"}, {\"id\": 2468, \"last_scrape\": \"2018-12-13T16:47:00\", \"url\": \"http://www.ncpe.ie/drugs/radium-223-xofigo/\", \"rr_start\": \"2013-11-28T00:00:00\", \"rr_end\": \"2013-12-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-11-28, 2013-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Radium-223 (Xofigo\", \"trade_name\": \"Xofigo\", \"indication\": \"Radium-223 (Xofigo\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-13T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2469, \"last_scrape\": \"2018-12-13T16:47:03\", \"url\": \"http://www.ncpe.ie/drugs/ramucirumab-cyramza/\", \"rr_start\": \"2014-12-20T00:00:00\", \"rr_end\": \"2014-12-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-20, 2014-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Ramucirumab (Cyramza\", \"trade_name\": \"Cyramza\", \"indication\": \"Indicated in combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction (GEJ) adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-12-19T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2014-12-20T00:00:00\", \"latest\": \"2016-07-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2470, \"last_scrape\": \"2018-12-13T16:47:06\", \"url\": \"http://www.ncpe.ie/drugs/ranolazine-ranexa/\", \"rr_start\": \"2009-11-19T00:00:00\", \"rr_end\": \"2009-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ranolazine (Ranexa\", \"trade_name\": \"Ranexa\", \"indication\": \"Cost-effectiveness of Ranolazine (Ranexa\", \"ncpe_year\": 2009, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2009-11-19T00:00:00\", \"latest\": \"2009-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2471, \"last_scrape\": \"2018-12-13T16:47:13\", \"url\": \"http://www.ncpe.ie/drugs/regadenoson-rapiscan/\", \"rr_start\": \"2011-09-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-09-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Regadenoson (Rapiscan\", \"trade_name\": \"Rapiscan\", \"indication\": \"Cost-effectiveness of Regadenoson (Rapiscan\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-06T00:00:00\", \"company\": \"GE\", \"orphan\": 0, \"earliest\": \"2011-09-19T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rapiscan\", \"ta_list\": \"Myocardial Perfusion Imaging\", \"rr_status\": \"No HTA\"}, {\"id\": 2472, \"last_scrape\": \"2018-12-13T16:47:17\", \"url\": \"http://www.ncpe.ie/drugs/regorafenib-stivarga-for-gist/\", \"rr_start\": \"2014-09-18T00:00:00\", \"rr_end\": \"2014-10-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-09-18, 2014-10-06\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib (Stivarga\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib (Stivarga\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2014-09-18T00:00:00\", \"latest\": \"2014-10-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2473, \"last_scrape\": \"2018-12-13T16:47:23\", \"url\": \"http://www.ncpe.ie/drugs/reslizumab-cinqaero/\", \"rr_start\": \"2017-01-23T00:00:00\", \"rr_end\": \"2017-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-01-23, 2017-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Reslizumab (Cinqaero\", \"trade_name\": \"Cinqaero\", \"indication\": \"Cinqaero\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-15T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2017-01-23T00:00:00\", \"latest\": \"2017-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cinqaero\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2474, \"last_scrape\": \"2018-12-13T16:47:27\", \"url\": \"http://www.ncpe.ie/drugs/retigabine-trobalt/\", \"rr_start\": \"2011-04-06T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-04-06, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Retigabine (Trobalt\", \"trade_name\": \"Trobalt\", \"indication\": \"Cost-effectiveness of Retigabine (Trobalt\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-27T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-04-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"No HTA\"}, {\"id\": 2475, \"last_scrape\": \"2018-12-13T16:47:29\", \"url\": \"http://www.ncpe.ie/drugs/ribociclib-kisqali/\", \"rr_start\": \"2017-09-04T00:00:00\", \"rr_end\": \"2017-09-19T00:00:00\", \"rr_outcome\": \"FOLLOWING NCPE ASSESSMENT OF THE COMPANY SUBMISSION, THE NCPE RECOMMENDS THAT RIBOCICLIB (IN COMBINATION WITH AN AROMATASE INHIBITOR) FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR+/HER2- LOCALLY ADVANCED OR METASTATIC BC AS INITIAL ENDOCRINE-BASED THERAPY, NOT BE CONSIDERED FOR REIMBURSEMENT UNLESS COST EFFECTIVENESS CAN BE IMPROVED RELATIVE TO EXISTING TREATMENTS. THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2017-09-04, 2017-09-19\", \"rr_multiple\": 0, \"drug_name\": \"Ribociclib (Kisqali\", \"trade_name\": \"Kisqali\", \"indication\": \"Ribociclib (Kisqali\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2017-09-04T00:00:00\", \"latest\": \"2018-08-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2476, \"last_scrape\": \"2018-12-13T16:47:35\", \"url\": \"http://www.ncpe.ie/drugs/rifaximin-targaxan-2/\", \"rr_start\": \"2013-07-09T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-09, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Rifaximin (Targaxan\", \"trade_name\": \"Targaxan\", \"indication\": \"Rifaximin (Targaxan\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-07-09T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2477, \"last_scrape\": \"2018-12-13T16:47:38\", \"url\": \"http://www.ncpe.ie/drugs/rigorafenib-stivarga/\", \"rr_start\": \"2013-09-12T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-12, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib (Stivarga\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib (Stivarga\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-09-12T00:00:00\", \"latest\": \"2014-06-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2478, \"last_scrape\": \"2018-12-13T16:47:42\", \"url\": \"http://www.ncpe.ie/drugs/rilpivirine-edurant/\", \"rr_start\": \"2011-12-14T00:00:00\", \"rr_end\": \"2012-01-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-12-14, 2012-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine (Edurant\", \"trade_name\": \"Edurant\", \"indication\": \"Rilpivirine in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ? 100,000 HIV-1 RNA copies/ml.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-11-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-12-14T00:00:00\", \"latest\": \"2012-01-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/edurant\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2479, \"last_scrape\": \"2018-12-13T16:47:45\", \"url\": \"http://www.ncpe.ie/drugs/rilpivirine-r-emtricitabine-f-tenofovir-alafenamide-taf-odefsey/\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMEDED\", \"rr_dates\": \"2016-06-28, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) (Odefsey\", \"trade_name\": \"Odefsey\", \"indication\": \"Odefsey\", \"ncpe_year\": 2016, \"eu_market\": \"2016-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2480, \"last_scrape\": \"2018-12-13T16:47:48\", \"url\": \"http://www.ncpe.ie/drugs/rimonabant-acomplia-2/\", \"rr_start\": \"\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rimonabant (Acomplia\", \"trade_name\": \"Acomplia\", \"indication\": \"In June 2006, Sanofi-Aventis submitted an evaluation of the cost-effectiveness of rimonabant (in addition to diet and exercise) in the management of multiple cardiovascular risks in overweight or obese patients in Ireland, to support its application for reimbursement of rimonabant under the Community Drugs Schemes. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-06-19T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2006-06-01T00:00:00\", \"latest\": \"2006-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/acomplia\", \"ta_list\": \"Obesity\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2481, \"last_scrape\": \"2018-12-13T16:47:53\", \"url\": \"http://www.ncpe.ie/drugs/riociguat-adempas/\", \"rr_start\": \"2014-04-11T00:00:00\", \"rr_end\": \"2014-05-16T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED AT THE CURRENT PRICE.\", \"rr_dates\": \"2014-04-11, 2014-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Riociguat (Adempas\", \"trade_name\": \"Adempas\", \"indication\": \"Riociguat (Adempas\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-27T00:00:00\", \"company\": \"Bayer\", \"orphan\": 1, \"earliest\": \"2014-04-11T00:00:00\", \"latest\": \"2014-05-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adempas\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2482, \"last_scrape\": \"2018-12-13T16:47:59\", \"url\": \"http://www.ncpe.ie/drugs/rituximab-mabthera/\", \"rr_start\": \"2014-05-26T00:00:00\", \"rr_end\": \"2014-09-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-26, 2014-09-22\", \"rr_multiple\": 0, \"drug_name\": \"Rituximab (MabThera\", \"trade_name\": \"MabThera\", \"indication\": \"Rituximab (MabThera\", \"ncpe_year\": 2014, \"eu_market\": \"1998-06-02T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-05-26T00:00:00\", \"latest\": \"2014-09-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"No HTA\"}, {\"id\": 2483, \"last_scrape\": \"2018-12-13T16:48:05\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-atrial-fibrillation-patients-undergoing-pci/\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2484, \"last_scrape\": \"2018-12-13T16:48:10\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-dvt/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Economic evaluation of Rivaroxaban (Xarelto\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-02-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2485, \"last_scrape\": \"2018-12-13T16:48:15\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-spaf-2/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban (Xarelto\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2486, \"last_scrape\": \"2018-12-13T16:48:18\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-the-prevention-of-atherothrombotic-events/\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-11T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF RIVAROXABAN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-26, 2018-10-11\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban (Xarelto\", \"ncpe_year\": 2018, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2487, \"last_scrape\": \"2018-12-13T16:48:25\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-low-dose-for-prevention-of-recurrent-venous-thromboembolism/\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2488, \"last_scrape\": \"2018-12-13T16:48:30\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban (Xarelto\", \"ncpe_year\": 2008, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2008-04-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2489, \"last_scrape\": \"2018-12-13T16:48:33\", \"url\": \"http://www.ncpe.ie/drugs/roflumilast-daxas/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Roflumilast (Daxas\", \"trade_name\": \"Daxas\", \"indication\": \"Cost Effectiveness of Roflumilast (Daxas\", \"ncpe_year\": 2010, \"eu_market\": \"2010-07-05T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-11T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/daxas\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2490, \"last_scrape\": \"2018-12-13T16:48:40\", \"url\": \"http://www.ncpe.ie/drugs/rolapitant-varuby/\", \"rr_start\": \"2017-05-15T00:00:00\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-05-15, 2017-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Rolapitant (Varuby\", \"trade_name\": \"Varuby\", \"indication\": \"Rolapitant (Varuby\", \"ncpe_year\": 2017, \"eu_market\": \"2017-04-19T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 0, \"earliest\": \"2017-05-15T00:00:00\", \"latest\": \"2017-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/varuby\", \"ta_list\": \"Vomiting; Nausea; Cancer\", \"rr_status\": \"No HTA\"}, {\"id\": 2491, \"last_scrape\": \"2018-12-13T16:48:43\", \"url\": \"http://www.ncpe.ie/drugs/romiplostim-nplate/\", \"rr_start\": \"\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Romiplostim (Nplate\", \"trade_name\": \"Nplate\", \"indication\": \"Romiplostim (Nplate\", \"ncpe_year\": 2015, \"eu_market\": \"2009-02-04T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-04-02T00:00:00\", \"latest\": \"2015-05-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nplate\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2492, \"last_scrape\": \"2018-12-13T16:48:47\", \"url\": \"http://www.ncpe.ie/drugs/ropivacaine-readyfusor/\", \"rr_start\": \"2018-11-09T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"FULL HTA IS NOT RECOMMENDED. THE NCPE RECOMMENDS THAT ROPIVICAINE READYFUSOR NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE.  THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013.\", \"rr_dates\": \"2018-11-09, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ropivacaine Readyfusor\", \"trade_name\": \"Ropivacaine Readyfusor\", \"indication\": \"Ropivacaine Readyfusor for acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block (CPNB) via a continuous infusion.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-09T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"id\": 2493, \"last_scrape\": \"2018-12-13T16:48:50\", \"url\": \"http://www.ncpe.ie/drugs/ruxolitinib-jakavi-for-polycythaemia-vera/\", \"rr_start\": \"2015-04-15T00:00:00\", \"rr_end\": \"2015-05-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-04-15, 2015-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib (Jakavi\", \"trade_name\": \"Jakavi\", \"indication\": \"Jakavi\", \"ncpe_year\": 2016, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2015-04-15T00:00:00\", \"latest\": \"2016-08-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2494, \"last_scrape\": \"2018-12-13T16:48:55\", \"url\": \"http://www.ncpe.ie/drugs/ruxolitinib-jakavi/\", \"rr_start\": \"2012-08-01T00:00:00\", \"rr_end\": \"2012-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-08-01, 2012-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib (Jakavi\", \"trade_name\": \"Jakavi\", \"indication\": \"Ruxolitinib (Jakavi\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2012-08-01T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2495, \"last_scrape\": \"2018-12-13T16:48:58\", \"url\": \"http://www.ncpe.ie/drugs/sacubitrilvalsartan-entresto/\", \"rr_start\": \"2015-11-06T00:00:00\", \"rr_end\": \"2015-11-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-06, 2015-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Sacubitril/valsartan (Entresto\", \"trade_name\": \"Entresto\", \"indication\": \"Entresto\", \"ncpe_year\": 2017, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-06T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entresto\", \"ta_list\": \"Heart Failure\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2496, \"last_scrape\": \"2018-12-13T16:49:04\", \"url\": \"http://www.ncpe.ie/drugs/safinamide-methansulfonate-xadago/\", \"rr_start\": \"2016-06-14T00:00:00\", \"rr_end\": \"2016-07-06T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED.\", \"rr_dates\": \"2016-06-14, 2016-07-06\", \"rr_multiple\": 0, \"drug_name\": \"Safinamide methansulfonate (Xadago\", \"trade_name\": \"Xadago\", \"indication\": \"Xadago\", \"ncpe_year\": 2016, \"eu_market\": \"2015-02-23T00:00:00\", \"company\": \"Zambon\", \"orphan\": 0, \"earliest\": \"2016-06-14T00:00:00\", \"latest\": \"2016-07-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xadago\", \"ta_list\": \"Parkinson Disease\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2497, \"last_scrape\": \"2018-12-13T16:49:07\", \"url\": \"http://www.ncpe.ie/drugs/sapropterin-kuvan/\", \"rr_start\": \"2015-07-14T00:00:00\", \"rr_end\": \"2015-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-07-14, 2015-08-14, 2015-07-01\", \"rr_multiple\": 1, \"drug_name\": \"Sapropterin (Kuvan\", \"trade_name\": \"Kuvan\", \"indication\": \"Sapropterin (Kuvan\", \"ncpe_year\": 2017, \"eu_market\": \"2008-12-02T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2009-01-01T00:00:00\", \"latest\": \"2017-09-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kuvan\", \"ta_list\": \"Phenylketonurias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2498, \"last_scrape\": \"2018-12-13T16:49:11\", \"url\": \"http://www.ncpe.ie/drugs/sarilumab-kevzara/\", \"rr_start\": \"2017-08-18T00:00:00\", \"rr_end\": \"2017-10-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-08-18, 2017-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Sarilumab (Kevzara\", \"trade_name\": \"Kevzara\", \"indication\": \"Sarilumab (Kevzara\", \"ncpe_year\": 2017, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-08-18T00:00:00\", \"latest\": \"2017-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2499, \"last_scrape\": \"2018-12-13T16:49:16\", \"url\": \"http://www.ncpe.ie/drugs/sebelipase-alfa-kanuma/\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-02-08, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Sebelipase alfa (Kanuma\", \"trade_name\": \"Kanuma\", \"indication\": \"Sebelipase alfa is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2018-06-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kanuma\", \"ta_list\": \"Lipid Metabolism, Inborn Errors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2500, \"last_scrape\": \"2018-12-13T16:49:20\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-ankylosing-spondylitis/\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-02, 2015-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"id\": 2501, \"last_scrape\": \"2018-12-13T16:49:25\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-psoriatic-arthritis/\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-02, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"id\": 2502, \"last_scrape\": \"2018-12-13T16:49:31\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx/\", \"rr_start\": \"2014-12-19T00:00:00\", \"rr_end\": \"2015-02-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-19, 2015-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-12-19T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2503, \"last_scrape\": \"2018-12-13T16:49:34\", \"url\": \"http://www.ncpe.ie/drugs/selexipag-uptravi/\", \"rr_start\": \"2016-11-01T00:00:00\", \"rr_end\": \"2016-12-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-01, 2016-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Selexipag (Uptravi\", \"trade_name\": \"Uptravi\", \"indication\": \"Selexipag (Uptravi\", \"ncpe_year\": 2018, \"eu_market\": \"2016-05-12T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2016-11-01T00:00:00\", \"latest\": \"2018-05-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2504, \"last_scrape\": \"2018-12-13T16:49:39\", \"url\": \"http://www.ncpe.ie/drugs/semaglutide-ozempic/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-03-12, 2018-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Semaglutide (Ozempic\", \"trade_name\": \"Ozempic\", \"indication\": \"Semaglutide (Ozempic\", \"ncpe_year\": 2018, \"eu_market\": \"2018-02-08T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-04-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2505, \"last_scrape\": \"2018-12-13T16:49:44\", \"url\": \"http://www.ncpe.ie/drugs/sildenafil-revatio/\", \"rr_start\": \"2014-04-16T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-04-16, 2014-05-23\", \"rr_multiple\": 0, \"drug_name\": \"Sildenafil (Revatio\", \"trade_name\": \"Revatio\", \"indication\": \"Sildenafil (Revatio\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2014-04-16T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revatio\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2506, \"last_scrape\": \"2018-12-13T16:49:49\", \"url\": \"http://www.ncpe.ie/drugs/simeprevir-olysio-in-combination-with-sofosbuvir/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir (Olysio\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir (Olysio\", \"ncpe_year\": 2015, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2015-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olysio\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2507, \"last_scrape\": \"2018-12-13T16:49:53\", \"url\": \"http://www.ncpe.ie/drugs/simeprevir-olysio/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED WHEN USED IN TRIPLE THERAPY WITH PEG-INTERFERON AND RIBAVIRIN.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir (Olysio\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir (Olysio\", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2014-07-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olysio\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2508, \"last_scrape\": \"2018-12-13T16:50:00\", \"url\": \"http://www.ncpe.ie/drugs/sodium-chloride-70mgml-sodium-hyaluronate-1mgml-hyaneb/\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-10, 2014-03-19\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml (Hyaneb\", \"trade_name\": \"Hyaneb\", \"indication\": \"Hyaneb\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2509, \"last_scrape\": \"2018-12-13T16:50:06\", \"url\": \"http://www.ncpe.ie/drugs/sodium-hyaluronate-hyloforte-0-2/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate (Hyloforte\", \"trade_name\": \"Hyloforte 0.2%\", \"indication\": \"Sodium Hyaluronate (Hyloforte\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2510, \"last_scrape\": \"2018-12-13T16:50:09\", \"url\": \"http://www.ncpe.ie/drugs/sodium-hyaluronate-hylotear-0-1/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate (Hylotear\", \"trade_name\": \"Hylotear 0.1%\", \"indication\": \"Sodium Hyaluronate (Hylotear\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2511, \"last_scrape\": \"2018-12-13T16:50:15\", \"url\": \"http://www.ncpe.ie/drugs/sodium-phenylbutyrate-pheburane/\", \"rr_start\": \"2013-07-17T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-17, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Sodium phenylbutyrate (Pheburane\", \"trade_name\": \"Pheburane\", \"indication\": \"Sodium phenylbutyrate (Pheburane\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-30T00:00:00\", \"company\": \"Lucane\", \"orphan\": 0, \"earliest\": \"2013-07-17T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pheburane\", \"ta_list\": \"Carbamoyl-Phosphate Synthase I Deficiency Disease\", \"rr_status\": \"No HTA\"}, {\"id\": 2512, \"last_scrape\": \"2018-12-13T16:50:18\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvir-solvaldi/\", \"rr_start\": \"2014-02-12T00:00:00\", \"rr_end\": \"2014-03-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-02-12, 2014-03-10\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir (Solvaldi\", \"trade_name\": \"Solvaldi\", \"indication\": \"Sofosbuvir (Solvaldi\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-02-12T00:00:00\", \"latest\": \"2014-10-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2513, \"last_scrape\": \"2018-12-13T16:50:22\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvirvelpatasvir-epclusa-chronic-hepatitis-c-virus-hcv-pangenotypic/\", \"rr_start\": \"2017-09-05T00:00:00\", \"rr_end\": \"2017-10-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-05, 2017-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir (Epclusa\", \"trade_name\": \"Epclusa\", \"indication\": \"Sofosbuvir/velpatasvir (Epclusa\", \"ncpe_year\": 2017, \"eu_market\": \"2016-07-06T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-05T00:00:00\", \"latest\": \"2017-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2514, \"last_scrape\": \"2018-12-13T16:50:26\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvirvelpatasvirvoxilaprevir-vosevi/\", \"rr_start\": \"2017-09-19T00:00:00\", \"rr_end\": \"2017-11-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-19, 2017-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi\", \"trade_name\": \"Vosevi\", \"indication\": \"Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-19T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vosevi\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2515, \"last_scrape\": \"2018-12-13T16:50:32\", \"url\": \"http://www.ncpe.ie/drugs/st-johns-wort-pafica/\", \"rr_start\": \"2015-04-14T00:00:00\", \"rr_end\": \"2015-05-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-04-14, 2015-05-29\", \"rr_multiple\": 0, \"drug_name\": \"St Johns Wort (Pacifa\", \"trade_name\": \"Pacifa\", \"indication\": \"Pacifa\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-04-14T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2516, \"last_scrape\": \"2018-12-13T16:50:38\", \"url\": \"http://www.ncpe.ie/drugs/stiripentol-diacomit/\", \"rr_start\": \"2017-07-06T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-06, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Stiripentol (Diacomit\", \"trade_name\": \"Diacomit\", \"indication\": \"Stiripentol (Diacomit\", \"ncpe_year\": 2018, \"eu_market\": \"2007-01-03T00:00:00\", \"company\": \"Biocodex\", \"orphan\": 1, \"earliest\": \"2017-07-06T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/diacomit\", \"ta_list\": \"Myoclonic Epilepsy, Juvenile\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2517, \"last_scrape\": \"2018-12-13T16:50:43\", \"url\": \"http://www.ncpe.ie/drugs/stribild-elvitegravircobicistatemtricitabinetenofovir-disoproxil-as-fumarate/\", \"rr_start\": \"2013-04-28T00:00:00\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-04-28, 2013-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumarate)(Stribild\", \"trade_name\": \"Stribild\", \"indication\": \"Indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-na\", \"ncpe_year\": 2013, \"eu_market\": \"2013-05-24T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2013-04-28T00:00:00\", \"latest\": \"2013-12-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stribild\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2518, \"last_scrape\": \"2018-12-13T16:50:49\", \"url\": \"http://www.ncpe.ie/drugs/sublingual-immunotherapy-grazax/\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sublingual Immunotherapy (Grazax\", \"trade_name\": \"Grazax\", \"indication\": \"A Review of the Cost-Effectiveness of Sublingual Immunotherapy (Grazax\", \"ncpe_year\": 2007, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2007-09-01T00:00:00\", \"latest\": \"2007-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2519, \"last_scrape\": \"2018-12-13T16:50:50\", \"url\": \"http://www.ncpe.ie/drugs/suboxone-buprenorphinenaloxone/\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Buprenorphine/naloxone (Suboxone\", \"trade_name\": \"Suboxone\", \"indication\": \"An economic evaluation of suboxone for the management of opiate addiction.\", \"ncpe_year\": 2014, \"eu_market\": \"2006-09-26T00:00:00\", \"company\": \"Indivior\", \"orphan\": 0, \"earliest\": \"2007-11-01T00:00:00\", \"latest\": \"2014-05-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/suboxone\", \"ta_list\": \"Opioid-Related Disorders\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2520, \"last_scrape\": \"2018-12-13T16:50:54\", \"url\": \"http://www.ncpe.ie/drugs/sufentanil-zalviso/\", \"rr_start\": \"2016-03-14T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-03-14, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Sufentanil (Zalviso\", \"trade_name\": \"Zalviso\", \"indication\": \"Sufentanil (Zalviso\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Gr\", \"orphan\": 0, \"earliest\": \"2016-03-14T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zalviso\", \"ta_list\": \"Pain, Postoperative\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2521, \"last_scrape\": \"2018-12-13T16:50:59\", \"url\": \"http://www.ncpe.ie/drugs/sunitinib-sutent/\", \"rr_start\": \"\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sunitinib (Sutent\", \"trade_name\": \"Sutent\", \"indication\": \"In September 2006, Pfizer Healthcare Ireland submitted an evaluation of the cost-effectiveness and budget impact of sunitinib as second-line treatment of patients with gastro-intestinal stromal tumours (GIST). Data on the cost-effectiveness and budget impact of sutinitinib as second line treatment for patients with metastatic renal cell carcinoma (mRCC) was also presented. The purpose of the submission was to support an application for reimbursement under the High Tech Drug Scheme. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-07-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-09-01T00:00:00\", \"latest\": \"2006-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sutent\", \"ta_list\": \"Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2522, \"last_scrape\": \"2018-12-13T16:51:04\", \"url\": \"http://www.ncpe.ie/drugs/tadalafil-adcirca-2/\", \"rr_start\": \"2011-07-13T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-07-13, 2011-09-21, 2014-05-09, 2014-05-23\", \"rr_multiple\": 1, \"drug_name\": \"Tadalafil (Adcirca\", \"trade_name\": \"Adcirca\", \"indication\": \"Tadalafil (Adcirca\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-07-13T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2523, \"last_scrape\": \"2018-12-13T16:51:09\", \"url\": \"http://www.ncpe.ie/drugs/tafamadis-meglumine-vyndaqel/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED UNTIL ADDITIONAL EFFICACY AND/OR SAFETY DATA IS SUBMITTED. ON THE BASIS OF CURRENT EVIDENCE, THE NCPE RECOMMENDS THAT TAFAMIDIS NOT BE CONSIDERED FOR REIMBURSEMENT IN ACCORDANCE WITH THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Tafamadis meglumine (Vyndaqel\", \"trade_name\": \"Vyndaqel\", \"indication\": \"Tafamadis meglumine (Vyndaqel\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-16T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel\", \"ta_list\": \"Amyloidosis\", \"rr_status\": \"No HTA until more evidence\"}, {\"id\": 2524, \"last_scrape\": \"2018-12-13T16:51:15\", \"url\": \"http://www.ncpe.ie/drugs/tafluprost-saflutan/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Tafluprost (Saflutan\", \"trade_name\": \"Saflutan\", \"indication\": \"Tafluoprost (Salflutan\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2525, \"last_scrape\": \"2018-12-13T16:51:24\", \"url\": \"http://www.ncpe.ie/drugs/talimogene-laherparepvec-imlygic/\", \"rr_start\": \"2016-02-16T00:00:00\", \"rr_end\": \"2016-03-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-02-16, 2016-03-14\", \"rr_multiple\": 0, \"drug_name\": \"Talimogene Laherparepvec (Imlygic\", \"trade_name\": \"Imlygic\", \"indication\": \"Talimogene laherparepvec (Imlygic\", \"ncpe_year\": 2016, \"eu_market\": \"2015-12-16T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-02-16T00:00:00\", \"latest\": \"2016-03-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2526, \"last_scrape\": \"2018-12-13T16:51:28\", \"url\": \"http://www.ncpe.ie/drugs/tapentadol-palexia/\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Tapentadol (Palexia\", \"trade_name\": \"Palexia\", \"indication\": \"Economic evaluation of oral tapentadol (Palexia\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2011-04-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2527, \"last_scrape\": \"2018-12-13T16:51:34\", \"url\": \"http://www.ncpe.ie/drugs/tedizolid-phosphate-sivextro/\", \"rr_start\": \"2015-05-07T00:00:00\", \"rr_end\": \"2015-07-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-05-07, 2015-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Tedizolid phosphate (Sivextro\", \"trade_name\": \"Sivextro\", \"indication\": \"Tedizolid phosphate (Sivextro\", \"ncpe_year\": 2015, \"eu_market\": \"2015-03-23T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-05-07T00:00:00\", \"latest\": \"2015-07-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sivextro\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"No HTA\"}, {\"id\": 2528, \"last_scrape\": \"2018-12-13T16:51:38\", \"url\": \"http://www.ncpe.ie/drugs/teduglutide-revestive/\", \"rr_start\": \"2017-03-13T00:00:00\", \"rr_end\": \"2017-04-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-13, 2017-04-12\", \"rr_multiple\": 0, \"drug_name\": \"Teduglutide (Revestive\", \"trade_name\": \"Revestive\", \"indication\": \"Teduglutide (Revestive\", \"ncpe_year\": 2018, \"eu_market\": \"2012-08-30T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2017-03-13T00:00:00\", \"latest\": \"2018-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revestive\", \"ta_list\": \"Malabsorption Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2529, \"last_scrape\": \"2018-12-13T16:51:44\", \"url\": \"http://www.ncpe.ie/drugs/tegafurgimeraciloteracil-teysuno/\", \"rr_start\": \"2012-02-27T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-02-27, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Tegafur/Gimeracil/Oteracil (Teysuno\", \"trade_name\": \"Teysuno\", \"indication\": \"Teysuno is indicated in adults for the treatment of advanced gastric cancer.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-03-14T00:00:00\", \"company\": \"Nordic\", \"orphan\": 0, \"earliest\": \"2012-02-27T00:00:00\", \"latest\": \"2012-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2530, \"last_scrape\": \"2018-12-13T16:51:48\", \"url\": \"http://www.ncpe.ie/drugs/telapravir/\", \"rr_start\": \"2011-10-28T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-10-28, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Telaprevir (Incivo\", \"trade_name\": \"Incivo\", \"indication\": \"Economic evaluation of Telaprevir (Incivo\", \"ncpe_year\": 2012, \"eu_market\": \"2011-09-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-28T00:00:00\", \"latest\": \"2012-01-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/incivo\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2531, \"last_scrape\": \"2018-12-13T16:51:52\", \"url\": \"http://www.ncpe.ie/drugs/telavancin-vibativ/\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-12-08, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Telavancin (Vibativ\", \"trade_name\": \"Vibativ\", \"indication\": \"Indicated for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumomia, known or suspended to be caused by methicillin-resistant Staphylococcus aureas (MRSA).  Vabitiv\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Theravance\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2015-01-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vibativ-0\", \"ta_list\": \"Pneumonia, Bacterial; Cross Infection\", \"rr_status\": \"No HTA\"}, {\"id\": 2532, \"last_scrape\": \"2018-12-13T16:51:56\", \"url\": \"http://www.ncpe.ie/drugs/teriflunomide-aubagio/\", \"rr_start\": \"2013-08-27T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-08-27, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Teriflunomide (Aubagio\", \"trade_name\": \"Aubagio\", \"indication\": \"Aubagio\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2013-08-27T00:00:00\", \"latest\": \"2014-09-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2533, \"last_scrape\": \"2018-12-13T16:51:58\", \"url\": \"http://www.ncpe.ie/drugs/ticagrelor-brilique-2/\", \"rr_start\": \"2016-02-29T00:00:00\", \"rr_end\": \"2016-05-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-29, 2016-05-04\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor (Brilique\", \"trade_name\": \"Brilique\", \"indication\": \"Ticagrelor (Brilique\", \"ncpe_year\": 2016, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-29T00:00:00\", \"latest\": \"2016-05-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brilique\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2534, \"last_scrape\": \"2018-12-13T16:52:01\", \"url\": \"http://www.ncpe.ie/drugs/ticagrelor-brilique/\", \"rr_start\": \"2010-11-25T00:00:00\", \"rr_end\": \"2011-01-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-11-25, 2011-01-20\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor (Brilique\", \"trade_name\": \"Brilique\", \"indication\": \"Economic Evaluation of Ticagrelor (Brilique\", \"ncpe_year\": 2011, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-11-25T00:00:00\", \"latest\": \"2011-10-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brilique\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2535, \"last_scrape\": \"2018-12-13T16:52:07\", \"url\": \"http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-all/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-19T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TISAGENLECLEUCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel (Kymriah\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel (Kymriah\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2536, \"last_scrape\": \"2018-12-13T16:52:13\", \"url\": \"http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-dlbcl/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TISAGENLECLEUCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel (Kymriah\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel (Kymriah\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2537, \"last_scrape\": \"2018-12-13T16:52:19\", \"url\": \"http://www.ncpe.ie/drugs/tobramycin-tobi-podhaler/\", \"rr_start\": \"2010-11-10T00:00:00\", \"rr_end\": \"2010-11-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2010-11-10, 2010-11-03\", \"rr_multiple\": 0, \"drug_name\": \"Tobramycin (TOBI Podhaler\", \"trade_name\": \"TOBI Podhaler\", \"indication\": \"Tobramycin (TOBI Podhaler\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-11-01T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2538, \"last_scrape\": \"2018-12-13T16:52:24\", \"url\": \"http://www.ncpe.ie/drugs/tocilizumab-sc-roactemra/\", \"rr_start\": \"2014-04-28T00:00:00\", \"rr_end\": \"2014-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THESUBMITTED PRICE.\", \"rr_dates\": \"2014-04-28, 2014-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Tocilizumab SC (RoActemra\", \"trade_name\": \"RoActemra\", \"indication\": \"It is licensed for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.  It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-04-28T00:00:00\", \"latest\": \"2014-07-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra\", \"ta_list\": \"Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2539, \"last_scrape\": \"2018-12-13T16:52:30\", \"url\": \"http://www.ncpe.ie/drugs/tofacitinib-xeljanz-for-ulcerative-colitis/\", \"rr_start\": \"2018-07-16T00:00:00\", \"rr_end\": \"2018-09-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TOFACITINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-07-16, 2018-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib (Xeljanz\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy (i.e. corticosteroids, azathioprine, 6-mercaptopurine) or a biologic agent (i.e. TNF inhibitor).\", \"ncpe_year\": 2018, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2018-07-16T00:00:00\", \"latest\": \"2018-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2540, \"last_scrape\": \"2018-12-13T16:52:35\", \"url\": \"http://www.ncpe.ie/drugs/tofacitinib-xeljanz/\", \"rr_start\": \"2017-03-08T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-08, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib (Xeljanz\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib (Xeljanz\", \"ncpe_year\": 2017, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-03-08T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2541, \"last_scrape\": \"2018-12-13T16:52:40\", \"url\": \"http://www.ncpe.ie/drugs/tolvaptan-jinarc/\", \"rr_start\": \"2016-01-04T00:00:00\", \"rr_end\": \"2016-01-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-04, 2016-01-12\", \"rr_multiple\": 0, \"drug_name\": \"Tolvaptan (Jinarc\", \"trade_name\": \"Jinarc\", \"indication\": \"Jinarc\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2016-01-04T00:00:00\", \"latest\": \"2018-09-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc\", \"ta_list\": \"Polycystic Kidney, Autosomal Dominant\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2542, \"last_scrape\": \"2018-12-13T16:52:45\", \"url\": \"http://www.ncpe.ie/drugs/tramadol-hydrochloridedexketoprofen-skudexa/\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"REIMURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-10-17, 2017-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Tramadol hydrochloride/dexketoprofen (Skudexa\", \"trade_name\": \"Skudexa\", \"indication\": \"Tramadol hydrochloride/dexketoprofen (Skudexa \", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2017-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2543, \"last_scrape\": \"2018-12-13T16:52:51\", \"url\": \"http://www.ncpe.ie/drugs/trametinib-mekinist/\", \"rr_start\": \"2015-11-27T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-27, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Trametinib (Mekinist\", \"trade_name\": \"Mekinist\", \"indication\": \"Mekinist\", \"ncpe_year\": 2018, \"eu_market\": \"2014-06-30T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-27T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2544, \"last_scrape\": \"2018-12-13T16:52:56\", \"url\": \"http://www.ncpe.ie/drugs/trastuzumab-emtansine-kadcyla/\", \"rr_start\": \"2013-09-25T00:00:00\", \"rr_end\": \"2013-10-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-25, 2013-10-24\", \"rr_multiple\": 0, \"drug_name\": \"Trastuzumab emtansine (Kadcyla\", \"trade_name\": \"Kadcyla\", \"indication\": \"Trastuzumab emtansine (Kadcyla\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-09-25T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2545, \"last_scrape\": \"2018-12-13T16:53:00\", \"url\": \"http://www.ncpe.ie/drugs/trifluridinetipiracil-lonsurf/\", \"rr_start\": \"2016-06-10T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-06-10, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Trifluridine/tipiracil (Lonsurf\", \"trade_name\": \"Lonsurf\", \"indication\": \"Trifluridine/tipiracil (Lonsurf\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2016-06-10T00:00:00\", \"latest\": \"2016-07-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2546, \"last_scrape\": \"2018-12-13T16:53:04\", \"url\": \"http://www.ncpe.ie/drugs/ulipristal-acetate-esmya-2/\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-05-17, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate (Esmya \", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate is indicated for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-05-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esmya\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2547, \"last_scrape\": \"2018-12-13T16:53:08\", \"url\": \"http://www.ncpe.ie/drugs/ulipristal-acetate-esmya/\", \"rr_start\": \"2013-09-03T00:00:00\", \"rr_end\": \"2013-10-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-09-03, 2013-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate (Esmya\", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate (Esmya\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2013-09-03T00:00:00\", \"latest\": \"2013-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esmya\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2548, \"last_scrape\": \"2018-12-13T16:53:10\", \"url\": \"http://www.ncpe.ie/drugs/umeclidiniumvilanterol-anoro/\", \"rr_start\": \"2014-06-11T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-06-11, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Umeclidinium/vilanterol (Anoro\", \"trade_name\": \"Anoro\", \"indication\": \"Umeclidinium/vilanterol (Anoro\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-06-11T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2549, \"last_scrape\": \"2018-12-13T16:53:12\", \"url\": \"http://www.ncpe.ie/drugs/urea-glucorx-allpresan/\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT GLUCORX ALLPRESAN DIABETIC FOAM CREAM NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE IN ACCORDANCE WITH THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2018-07-09, 2018-07-24\", \"rr_multiple\": 0, \"drug_name\": \"Urea (GlucoRx Allpresan\", \"trade_name\": \"GlucoRx Allpresan\", \"indication\": \"GlucoRx Allpresan\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-07-24T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2550, \"last_scrape\": \"2018-12-13T16:53:17\", \"url\": \"http://www.ncpe.ie/drugs/ustekinumab-stelara-2/\", \"rr_start\": \"2016-11-28T00:00:00\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-11-28, 2017-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab (Stelara\", \"trade_name\": \"Stelara\", \"indication\": \"Ustekinumab is indicated for the treatment of adult patients with moderately to severely active Crohn\", \"ncpe_year\": 2017, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2016-11-28T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stelara\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2551, \"last_scrape\": \"2018-12-13T16:53:23\", \"url\": \"http://www.ncpe.ie/drugs/ustekinumab-stelara/\", \"rr_start\": \"\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab (Stelara\", \"trade_name\": \"Stelara\", \"indication\": \"Cost-effectiveness of Ustekinumab (Stelara\", \"ncpe_year\": 2009, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2009-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stelara\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2552, \"last_scrape\": \"2018-12-13T16:53:29\", \"url\": \"http://www.ncpe.ie/drugs/vandetanib-caprelsa/\", \"rr_start\": \"2013-06-06T00:00:00\", \"rr_end\": \"2013-07-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-06, 2013-07-03\", \"rr_multiple\": 0, \"drug_name\": \"Vandetanib (Caprelsa\", \"trade_name\": \"Caprelsa\", \"indication\": \"Vandetanib (Caprelsa\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-16T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2013-06-06T00:00:00\", \"latest\": \"2013-07-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2553, \"last_scrape\": \"2018-12-13T16:53:32\", \"url\": \"http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-crohns-disease/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab (Entyvio\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab (Entyvio\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2554, \"last_scrape\": \"2018-12-13T16:53:39\", \"url\": \"http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-ulcerative-colitis/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab (Entyvio\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab (Entyvio\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2555, \"last_scrape\": \"2018-12-13T16:53:45\", \"url\": \"http://www.ncpe.ie/drugs/velaglucerase-alfa-vpriv-2/\", \"rr_start\": \"2011-04-26T00:00:00\", \"rr_end\": \"2011-06-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-04-26, 2011-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Velaglucerase Alfa (VPRIV\", \"trade_name\": \"VPRIV\", \"indication\": \"VPRIV is indicated for long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-04-26T00:00:00\", \"latest\": \"2011-06-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2556, \"last_scrape\": \"2018-12-13T16:53:49\", \"url\": \"http://www.ncpe.ie/drugs/venetoclax-venclyxto-in-combination-with-rituximab/\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF VENETOCLAX COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-26, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax (Venclyxto\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax (Venclyxto\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2557, \"last_scrape\": \"2018-12-13T16:53:52\", \"url\": \"http://www.ncpe.ie/drugs/venetoclax-venclyxto/\", \"rr_start\": \"2018-05-08T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"FOLLOWING A RESUBMISSION OF THE RAPID REVIEW A FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, WHICH IS NOT COMPARABLE WITH CURRENT AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-05-08, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax (Venclyxto\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL)\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2558, \"last_scrape\": \"2018-12-13T16:53:58\", \"url\": \"http://www.ncpe.ie/drugs/vermurafenib-zelboraf/\", \"rr_start\": \"2011-12-23T00:00:00\", \"rr_end\": \"2012-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-12-23, 2012-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Vemurafenib (Zelboraf\", \"trade_name\": \"Zelboraf\", \"indication\": \"Vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\", \"ncpe_year\": 2014, \"eu_market\": \"2012-02-17T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2011-12-23T00:00:00\", \"latest\": \"2014-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2559, \"last_scrape\": \"2018-12-13T16:54:00\", \"url\": \"http://www.ncpe.ie/drugs/vernakalant-brinavess/\", \"rr_start\": \"2010-10-26T00:00:00\", \"rr_end\": \"2010-11-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-10-26, 2010-11-04\", \"rr_multiple\": 0, \"drug_name\": \"Vernakalant (Brinavess\", \"trade_name\": \"Brinavess\", \"indication\": \"Economic evaluation of Vernakalant (Brinavess\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Cardiome\", \"orphan\": 0, \"earliest\": \"2010-10-26T00:00:00\", \"latest\": \"2011-05-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2560, \"last_scrape\": \"2018-12-13T16:54:04\", \"url\": \"http://www.ncpe.ie/drugs/vismodegib-erivedge/\", \"rr_start\": \"2013-05-02T00:00:00\", \"rr_end\": \"2013-05-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-05-02, 2013-05-20\", \"rr_multiple\": 0, \"drug_name\": \"Vismodegib (Erivedge\", \"trade_name\": \"Erivedge\", \"indication\": \"Vismodegib (Erivedge\", \"ncpe_year\": 2017, \"eu_market\": \"2013-07-12T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-05-02T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge\", \"ta_list\": \"Carcinoma, Basal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2561, \"last_scrape\": \"2018-12-13T16:54:11\", \"url\": \"http://www.ncpe.ie/drugs/vortioxetine-brintellix/\", \"rr_start\": \"2014-10-01T00:00:00\", \"rr_end\": \"2014-11-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-10-01, 2014-11-14\", \"rr_multiple\": 0, \"drug_name\": \"Vortioxetine (Brintellix\", \"trade_name\": \"Brintellix\", \"indication\": \"Vortioxetine (Brintellix\", \"ncpe_year\": 2017, \"eu_market\": \"2013-12-18T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2014-10-01T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"HTA recommended at submitted price\"}]}};\n",
       "var opt = {};\n",
       "var type = \"vega-lite\";\n",
       "var id = \"8420f947-0b69-4434-9463-ab58e9dcb041\";\n",
       "\n",
       "var output_area = this;\n",
       "\n",
       "require([\"nbextensions/jupyter-vega/index\"], function(vega) {\n",
       "  var target = document.createElement(\"div\");\n",
       "  target.id = id;\n",
       "  target.className = \"vega-embed\";\n",
       "\n",
       "  var style = document.createElement(\"style\");\n",
       "  style.textContent = [\n",
       "    \".vega-embed .error p {\",\n",
       "    \"  color: firebrick;\",\n",
       "    \"  font-size: 14px;\",\n",
       "    \"}\",\n",
       "  ].join(\"\\\\n\");\n",
       "\n",
       "  // element is a jQuery wrapped DOM element inside the output area\n",
       "  // see http://ipython.readthedocs.io/en/stable/api/generated/\\\n",
       "  // IPython.display.html#IPython.display.Javascript.__init__\n",
       "  element[0].appendChild(target);\n",
       "  element[0].appendChild(style);\n",
       "\n",
       "  vega.render(\"#\" + id, spec, type, opt, output_area);\n",
       "}, function (err) {\n",
       "  if (err.requireType !== \"scripterror\") {\n",
       "    throw(err);\n",
       "  }\n",
       "});\n"
      ],
      "text/plain": [
       "<vega.vegalite.VegaLite at 0x24582179b00>"
      ]
     },
     "metadata": {
      "jupyter-vega": "#8420f947-0b69-4434-9463-ab58e9dcb041"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": []
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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"
     },
     "metadata": {
      "jupyter-vega": "#8420f947-0b69-4434-9463-ab58e9dcb041"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "alt.Chart(drugs,title=\"Count Drugs by Company & Status\").mark_bar().encode(\n",
    "    alt.X('company', sort=alt.EncodingSortField(field=\"company\", op=\"count\", order='descending'),\n",
    "          axis=alt.Axis(title='Drug Company')),\n",
    "    alt.Y('count(rr_status)',\n",
    "          axis=alt.Axis(title='Count Drugs')),\n",
    "    alt.Color(\"rr_status\",title=\"Status\",\n",
    "          scale=Scale(domain=['HTA recommended at submitted price','No HTA','No HTA at submitted price','No HTA until more evidence','RR not conducted','Reimbursement not recommended','Reimbursement without HTA','Unknown'],\n",
    "                      range=[rgb_to_hex((255,215,40)),rgb_to_hex((205,131,131)),rgb_to_hex((131,175,131)),rgb_to_hex((131,131,195)),rgb_to_hex((185,141,30)),rgb_to_hex((80,185,151)),rgb_to_hex((131,100,145)),rgb_to_hex((125,101,101))]))).properties(width=3000,height=300).interactive()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Axes flipped."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "var spec = {\"config\": {\"view\": {\"width\": 400, \"height\": 300}}, \"data\": {\"name\": \"data-1fb11c1b30e9c74b6a5173f2568cb7ab\"}, \"mark\": \"bar\", \"encoding\": {\"color\": {\"type\": \"nominal\", \"field\": \"rr_status\", \"scale\": {\"domain\": [\"HTA recommended at submitted price\", \"No HTA\", \"No HTA at submitted price\", \"No HTA until more evidence\", \"RR not conducted\", \"Reimbursement not recommended\", \"Reimbursement without HTA\", \"Unknown\"], \"range\": [\"#ffd728\", \"#cd8383\", \"#83af83\", \"#8383c3\", \"#b98d1e\", \"#50b997\", \"#836491\", \"#7d6565\"]}, \"title\": \"Status\"}, \"x\": {\"type\": \"nominal\", \"aggregate\": \"count\", \"axis\": {\"title\": \"Count Drugs\"}, \"field\": \"rr_status\"}, \"y\": {\"type\": \"nominal\", \"axis\": {\"title\": \"Drug Company\"}, \"field\": \"company\", \"sort\": {\"op\": \"count\", \"field\": \"company\", \"order\": \"descending\"}}}, \"height\": 3000, \"selection\": {\"selector002\": {\"type\": \"interval\", \"bind\": \"scales\", \"encodings\": [\"x\", \"y\"]}}, \"title\": \"Count Drugs by Company & Status\", \"width\": 650, \"$schema\": \"https://vega.github.io/schema/vega-lite/v2.6.0.json\", \"datasets\": {\"data-1fb11c1b30e9c74b6a5173f2568cb7ab\": [{\"id\": 2164, \"last_scrape\": \"2018-12-13T16:24:32\", \"url\": \"http://www.ncpe.ie/drugs/abatacept-orencia/\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Abatacept (Orencia\", \"trade_name\": \"Orencia\", \"indication\": \"Subcutaneous Abatacept (Orencia\", \"ncpe_year\": 2015, \"eu_market\": \"2007-05-21T00:00:00\", \"company\": \"\", \"orphan\": 0, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/orencia\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2165, \"last_scrape\": \"2018-12-13T16:24:36\", \"url\": \"http://www.ncpe.ie/drugs/abiraterone-acetate-zytiga-for-mhspc/\", \"rr_start\": \"2018-10-03T00:00:00\", \"rr_end\": \"2018-11-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-10-03, 2018-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Abiraterone acetate (Zytiga\", \"ncpe_year\": 2018, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2018-10-03T00:00:00\", \"latest\": \"2018-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2166, \"last_scrape\": \"2018-12-13T16:24:41\", \"url\": \"http://www.ncpe.ie/drugs/abiratone-acetate-zytiga-for-mcrpc-post-adt/\", \"rr_start\": \"2013-01-03T00:00:00\", \"rr_end\": \"2013-02-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-01-03, 2013-02-01\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation of Abiratone acetate (Zytiga\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-01-03T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2167, \"last_scrape\": \"2018-12-13T16:24:46\", \"url\": \"http://www.ncpe.ie/drugs/abiratone-acetate-zytiga/\", \"rr_start\": \"2011-10-21T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-10-21, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone Acetate (Zytiga\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation and resource implications of Zytiga \", \"ncpe_year\": 2014, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-21T00:00:00\", \"latest\": \"2014-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2168, \"last_scrape\": \"2018-12-13T16:24:49\", \"url\": \"http://www.ncpe.ie/drugs/aceclofenac-vitafen/\", \"rr_start\": \"2016-12-21T00:00:00\", \"rr_end\": \"2017-01-24T00:00:00\", \"rr_outcome\": \"FOLLOWING A RESUBMISSION OF THE RAPID REVIEW A FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-12-21, 2017-01-24\", \"rr_multiple\": 0, \"drug_name\": \"Aceclofenac (Vitafen\", \"trade_name\": \"Vitafen\", \"indication\": \"Aceclofenac (Vitafen\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-07-22T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2169, \"last_scrape\": \"2018-12-13T16:24:56\", \"url\": \"http://www.ncpe.ie/drugs/aclidinium-bromide-eklira-genuair/\", \"rr_start\": \"2012-10-23T00:00:00\", \"rr_end\": \"2012-10-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-23, 2012-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide (Eklira Genuair\", \"trade_name\": \"Eklira Genuair\", \"indication\": \"Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)\", \"ncpe_year\": 2012, \"eu_market\": \"2012-07-20T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-23T00:00:00\", \"latest\": \"2012-10-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"id\": 2170, \"last_scrape\": \"2018-12-13T16:25:00\", \"url\": \"http://www.ncpe.ie/drugs/aclidinium-bromide-formoterol-fumarate-dihydrate-brimica-genuair/\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE.\", \"rr_dates\": \"2015-01-05, 2015-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide / formoterol fumarate dihydrate (Brimica\", \"trade_name\": \"Brimica Genuair\", \"indication\": \"Brimica\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2015-02-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brimica-genuair\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2171, \"last_scrape\": \"2018-12-13T16:25:37\", \"url\": \"http://www.ncpe.ie/drugs/adalimumab-humira/\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-20, 2011-06-02\", \"rr_multiple\": 0, \"drug_name\": \"Adalimumab (Humira\", \"trade_name\": \"Humira\", \"indication\": \"Economic evaluation of Adalimumab (Humira\", \"ncpe_year\": 2011, \"eu_market\": \"2003-09-07T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/humira\", \"ta_list\": \"Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"id\": 2172, \"last_scrape\": \"2018-12-13T16:25:40\", \"url\": \"http://www.ncpe.ie/drugs/adenuric-febuxostat/\", \"rr_start\": \"2009-12-08T00:00:00\", \"rr_end\": \"2009-12-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-12-08\", \"rr_multiple\": 0, \"drug_name\": \"Adenuric (Febuxostat\", \"trade_name\": \"Febuxostat\", \"indication\": \"NCPE review of Adenuric (Febuxostat\", \"ncpe_year\": 2009, \"eu_market\": \"2008-04-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2009-12-08T00:00:00\", \"latest\": \"2009-12-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adenuric\", \"ta_list\": \"Gout\", \"rr_status\": \"No HTA\"}, {\"id\": 2173, \"last_scrape\": \"2018-12-13T16:25:45\", \"url\": \"http://www.ncpe.ie/drugs/afatinib-giotrif/\", \"rr_start\": \"2013-10-01T00:00:00\", \"rr_end\": \"2013-10-13T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-10-01, 2013-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Afatinib (Giotrif\", \"trade_name\": \"Giotrif\", \"indication\": \"GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-na\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-25T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2013-10-01T00:00:00\", \"latest\": \"2013-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2174, \"last_scrape\": \"2018-12-13T16:25:49\", \"url\": \"http://www.ncpe.ie/drugs/aflibercept-eylea/\", \"rr_start\": \"2012-12-10T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-10, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept (Eylea\", \"trade_name\": \"Eylea\", \"indication\": \"Aflibercept (Eylea\", \"ncpe_year\": 2012, \"eu_market\": \"2012-11-21T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2012-12-10T00:00:00\", \"latest\": \"2012-12-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eylea\", \"ta_list\": \"Wet Macular Degeneration; Macular Edema; Diabetes Complications\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2175, \"last_scrape\": \"2018-12-13T16:25:52\", \"url\": \"http://www.ncpe.ie/drugs/aflibercept-zaltrap/\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept (Zaltrap\", \"trade_name\": \"Zaltrap\", \"indication\": \"Aflibercept for the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-01T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-02-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zaltrap\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2176, \"last_scrape\": \"2018-12-13T16:25:58\", \"url\": \"http://www.ncpe.ie/drugs/agomelatine-valdoxan-4/\", \"rr_start\": \"\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Agomelatine (Valdoxan\", \"trade_name\": \"Valdoxan\", \"indication\": \"Economic evaluation of Agomelatine (Valdoxan\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-19T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2009-09-03T00:00:00\", \"latest\": \"2009-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/valdoxan\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2177, \"last_scrape\": \"2018-12-13T16:26:06\", \"url\": \"http://www.ncpe.ie/drugs/alectinib-alecensa/\", \"rr_start\": \"2017-01-03T00:00:00\", \"rr_end\": \"2017-12-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-01-03, 2017-02-27, 2017-11-08, 2017-12-04\", \"rr_multiple\": 1, \"drug_name\": \"Alectinib (Alecensa\", \"trade_name\": \"Alecensa\", \"indication\": \"Alectinib (Alecensa \", \"ncpe_year\": 2018, \"eu_market\": \"2017-02-16T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2178, \"last_scrape\": \"2018-12-13T16:26:12\", \"url\": \"http://www.ncpe.ie/drugs/alemtuzumab-lemtrada/\", \"rr_start\": \"2013-11-08T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-11-08, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Alemtuzumab (Lemtrada\", \"trade_name\": \"Lemtrada\", \"indication\": \"Alemtuzumab (Lemtrada\", \"ncpe_year\": 2014, \"eu_market\": \"2013-09-12T00:00:00\", \"company\": \"Sanofi\", \"orphan\": 0, \"earliest\": \"2013-11-08T00:00:00\", \"latest\": \"2014-06-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2179, \"last_scrape\": \"2018-12-13T16:26:14\", \"url\": \"http://www.ncpe.ie/drugs/alirocumab-praluent/\", \"rr_start\": \"2015-10-13T00:00:00\", \"rr_end\": \"2015-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-10-13, 2015-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Alirocumab (Praluent\", \"trade_name\": \"Praluent\", \"indication\": \"Praluent\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2015-10-13T00:00:00\", \"latest\": \"2018-03-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/praluent\", \"ta_list\": \"Dyslipidemias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2180, \"last_scrape\": \"2018-12-13T16:26:16\", \"url\": \"http://www.ncpe.ie/drugs/alogliptin-vipidia/\", \"rr_start\": \"2013-09-27T00:00:00\", \"rr_end\": \"2013-10-30T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-09-27, 2013-10-30\", \"rr_multiple\": 0, \"drug_name\": \"Alogliptin (Vipidia\", \"trade_name\": \"Vipidia\", \"indication\": \"Alogliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-18T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2013-09-27T00:00:00\", \"latest\": \"2013-10-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vipidia\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2181, \"last_scrape\": \"2018-12-13T16:26:21\", \"url\": \"http://www.ncpe.ie/drugs/ambrisentan-volibris/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-05-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Ambrisentan (Volibris\", \"trade_name\": \"Volibris\", \"indication\": \"Cost Effectiveness of ambrisentan (Volibris\", \"ncpe_year\": 2014, \"eu_market\": \"2008-04-20T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 1, \"earliest\": \"2008-10-01T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/volibris\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2182, \"last_scrape\": \"2018-12-13T16:26:23\", \"url\": \"http://www.ncpe.ie/drugs/amifampridine-firdapse/\", \"rr_start\": \"2011-11-07T00:00:00\", \"rr_end\": \"2011-12-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-11-07, 2011-12-09\", \"rr_multiple\": 0, \"drug_name\": \"Amifampridine (Firdapse\", \"trade_name\": \"Firdapse\", \"indication\": \"For Lambert Eaton Myasthenic Syndrome (LEMS).  This high cost drug is likely to require a full HTA due to significant budget impact.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-11-07T00:00:00\", \"latest\": \"2011-12-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2183, \"last_scrape\": \"2018-12-13T16:26:29\", \"url\": \"http://www.ncpe.ie/drugs/amsacrine-amsidine/\", \"rr_start\": \"2017-01-10T00:00:00\", \"rr_end\": \"2017-02-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-01-10, 2017-02-15\", \"rr_multiple\": 0, \"drug_name\": \"Amsacrine (Amsidine\", \"trade_name\": \"Amsidine\", \"indication\": \"Amsidine\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2017-01-10T00:00:00\", \"latest\": \"2017-02-15T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2184, \"last_scrape\": \"2018-12-13T16:26:35\", \"url\": \"http://www.ncpe.ie/drugs/apixaban-eliquis-for-treatment-of-deep-vein-thrombosis-dvt-and-pulmonary-embolism-pe-and-prevention-of-recurrent-dvt-and-pe-in-adults/\", \"rr_start\": \"2014-07-29T00:00:00\", \"rr_end\": \"2014-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-07-29, 2014-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban (Eliquis\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban (Eliquis\", \"ncpe_year\": 2014, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-07-29T00:00:00\", \"latest\": \"2014-08-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2185, \"last_scrape\": \"2018-12-13T16:26:39\", \"url\": \"http://www.ncpe.ie/drugs/apixaban-eliquis/\", \"rr_start\": \"2011-10-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-10-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban (Eliquis\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban (Eliquis\", \"ncpe_year\": 2012, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-10-19T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2186, \"last_scrape\": \"2018-12-13T16:26:45\", \"url\": \"http://www.ncpe.ie/drugs/apremilast-otezla-for-moderate-to-severe-chronic-plaque-psoriasis/\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast (Otezla\", \"trade_name\": \"Otezla\", \"indication\": \"Indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to systemic non-biologic therapies including cyclosporine, methotrexate or psoralen and ultraviolet A light (PUVA).\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/otezla\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2187, \"last_scrape\": \"2018-12-13T16:26:47\", \"url\": \"http://www.ncpe.ie/drugs/apremilast-otezla-for-psoriatic-arthritis/\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast (Otezla\", \"trade_name\": \"Otezla\", \"indication\": \"Apremilist (Otezla\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/otezla\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2188, \"last_scrape\": \"2018-12-13T16:26:49\", \"url\": \"http://www.ncpe.ie/drugs/aripiprazole-abilify-maintena/\", \"rr_start\": \"2014-07-02T00:00:00\", \"rr_end\": \"2014-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-07-02, 2014-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Aripiprazole (Abilify Maintena\", \"trade_name\": \"Abilify Maintena\", \"indication\": \"Aripiprazole (Abilify Maintena\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-14T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2014-07-02T00:00:00\", \"latest\": \"2014-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2189, \"last_scrape\": \"2018-12-13T16:26:55\", \"url\": \"http://www.ncpe.ie/drugs/asenapine-sycrest/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-08-17, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Asenapine (Sycrest\", \"trade_name\": \"Sycrest\", \"indication\": \"Asenapine (Sycrest\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Organon\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sycrest\", \"ta_list\": \"Bipolar Disorder\", \"rr_status\": \"No HTA\"}, {\"id\": 2190, \"last_scrape\": \"2018-12-13T16:27:00\", \"url\": \"http://www.ncpe.ie/drugs/atezolizumab-tecentriq/\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-10-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-08, 2017-10-09\", \"rr_multiple\": 0, \"drug_name\": \"Atezolizumab (Tecentriq\", \"trade_name\": \"Tecentriq\", \"indication\": \"Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK?positive tumour mutations should also have received targeted therapy before receiving atezolizumab.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-21T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq\", \"ta_list\": \"Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2191, \"last_scrape\": \"2018-12-13T16:27:05\", \"url\": \"http://www.ncpe.ie/drugs/avanafil-spedra/\", \"rr_start\": \"2014-02-19T00:00:00\", \"rr_end\": \"2014-03-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-19, 2014-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Avanafil (Spedra\", \"trade_name\": \"Spedra\", \"indication\": \"Avanafil (Spedra\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2014-02-19T00:00:00\", \"latest\": \"2014-03-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/spedra\", \"ta_list\": \"Erectile Dysfunction\", \"rr_status\": \"No HTA\"}, {\"id\": 2192, \"last_scrape\": \"2018-12-13T16:27:06\", \"url\": \"http://www.ncpe.ie/drugs/avelumab-bavencio/\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-10-17, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Avelumab (Bavencio\", \"trade_name\": \"Bavencio\", \"indication\": \"Avelumab (Bavencio\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2018-10-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2193, \"last_scrape\": \"2018-12-13T16:27:08\", \"url\": \"http://www.ncpe.ie/drugs/axanum-aspirin-81mgesomeprazole-20mg/\", \"rr_start\": \"2012-04-12T00:00:00\", \"rr_end\": \"2012-04-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-04-12, 2012-04-20\", \"rr_multiple\": 0, \"drug_name\": \"Aspirin 81mg/Esomeprazole 20mg (Axanum\", \"trade_name\": \"Axanum\", \"indication\": \"Prevention of thrombotic cardiovascular and cerebrovascular events in patients requiring continuous low-dose acetylsalicylic acid treatment, and who are in need of prophylaxis against acetylsalicylic acid associated gastric and /or duodenal ulcers.\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-04-12T00:00:00\", \"latest\": \"2012-04-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2194, \"last_scrape\": \"2018-12-13T16:27:14\", \"url\": \"http://www.ncpe.ie/drugs/axicabtagene-ciloleucel-yescarta/\", \"rr_start\": \"2018-09-10T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF  AXI-CEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-10, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Axicabtagene Ciloleucel (Yescarta\", \"trade_name\": \"Yescarta\", \"indication\": \"Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Kite\", \"orphan\": 1, \"earliest\": \"2018-09-10T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta\", \"ta_list\": \"Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2195, \"last_scrape\": \"2018-12-13T16:27:23\", \"url\": \"http://www.ncpe.ie/drugs/axitinib-inlyta/\", \"rr_start\": \"2012-11-07T00:00:00\", \"rr_end\": \"2012-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-07, 2012-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Axitinib (Inlyta\", \"trade_name\": \"Inlyta\", \"indication\": \"For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-03T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-11-07T00:00:00\", \"latest\": \"2012-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2196, \"last_scrape\": \"2018-12-13T16:27:24\", \"url\": \"http://www.ncpe.ie/drugs/azelastine-hydrochloride-and-fluticasone-propionate-nasal-spray-dymista/\", \"rr_start\": \"2013-02-12T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2013-02-12, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Azelastine hydrochloride and fluticasone propionate (nasal spray) (Dymista\", \"trade_name\": \"Dymista\", \"indication\": \"Indicated for symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-02-12T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2197, \"last_scrape\": \"2018-12-13T16:27:25\", \"url\": \"http://www.ncpe.ie/drugs/azilsartan-edarbi/\", \"rr_start\": \"2012-01-10T00:00:00\", \"rr_end\": \"2012-01-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-01-10, 2012-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Azilsartan (Edarbi\", \"trade_name\": \"Edarbi\", \"indication\": \"Edarbi is indicated for the treatment of essential hypertension in adults.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-12-07T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2012-01-10T00:00:00\", \"latest\": \"2012-01-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/edarbi\", \"ta_list\": \"Hypertension\", \"rr_status\": \"No HTA\"}, {\"id\": 2198, \"last_scrape\": \"2018-12-13T16:27:27\", \"url\": \"http://www.ncpe.ie/drugs/baricitinib-olumiant/\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-06-14, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Baricitinib (Olumiant\", \"trade_name\": \"Olumiant\", \"indication\": \"Baricitinib (Olumiant\", \"ncpe_year\": 2017, \"eu_market\": \"2017-02-12T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2199, \"last_scrape\": \"2018-12-13T16:27:33\", \"url\": \"http://www.ncpe.ie/drugs/bazedoxifene-conbriza/\", \"rr_start\": \"2011-09-20T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-09-20, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Bazedoxifene (Conbriza\", \"trade_name\": \"Conbriza\", \"indication\": \"Bazedoxifene (Conbriza\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-17T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-09-20T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza\", \"ta_list\": \"Osteoporosis, Postmenopausal\", \"rr_status\": \"No HTA\"}, {\"id\": 2200, \"last_scrape\": \"2018-12-13T16:27:36\", \"url\": \"http://www.ncpe.ie/drugs/bedaquiline-sirturo/\", \"rr_start\": \"2015-01-23T00:00:00\", \"rr_end\": \"2015-02-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-01-23, 2015-02-20\", \"rr_multiple\": 0, \"drug_name\": \"Bedaquiline (Sirturo\", \"trade_name\": \"Sirturo\", \"indication\": \"Bedaquiline (Sirturo\", \"ncpe_year\": 2015, \"eu_market\": \"2014-03-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2015-01-23T00:00:00\", \"latest\": \"2015-02-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo\", \"ta_list\": \"Tuberculosis, Multidrug-Resistant\", \"rr_status\": \"No HTA\"}, {\"id\": 2201, \"last_scrape\": \"2018-12-13T16:27:37\", \"url\": \"http://www.ncpe.ie/drugs/belatacept-nulojix/\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2012-01-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-11-15, 2012-01-23\", \"rr_multiple\": 0, \"drug_name\": \"Belatacept (Nulojix\", \"trade_name\": \"Nulojix\", \"indication\": \"Belatacept, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen.\\n\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2012-01-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nulojix\", \"ta_list\": \"Graft Rejection; Kidney Transplantation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2202, \"last_scrape\": \"2018-12-13T16:27:40\", \"url\": \"http://www.ncpe.ie/drugs/belimumab-benlysta/\", \"rr_start\": \"2011-08-11T00:00:00\", \"rr_end\": \"2011-08-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-11, 2011-08-11\", \"rr_multiple\": 0, \"drug_name\": \"Belimumab (Benlysta\", \"trade_name\": \"Benlysta\", \"indication\": \"Cost-effectiveness of Belimumab (Benlysta\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-08-01T00:00:00\", \"latest\": \"2011-08-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta\", \"ta_list\": \"Lupus Erythematosus, Systemic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2203, \"last_scrape\": \"2018-12-13T16:27:46\", \"url\": \"http://www.ncpe.ie/drugs/bendamustine-levact/\", \"rr_start\": \"2011-03-21T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-03-21, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Bendamustine (Levact\", \"trade_name\": \"Levact\", \"indication\": \"Bendamustine (Levact\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2012-11-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2204, \"last_scrape\": \"2018-12-13T16:27:50\", \"url\": \"http://www.ncpe.ie/drugs/benralizumab-fasenra/\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-14T00:00:00\", \"rr_outcome\": \"FULL PHARAMCOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2018-01-15, 2018-02-14\", \"rr_multiple\": 0, \"drug_name\": \"Benralizumab (Fasenra\", \"trade_name\": \"Fasenra\", \"indication\": \"Benralizumab (Fasenra\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fasenra\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2205, \"last_scrape\": \"2018-12-13T16:27:56\", \"url\": \"http://www.ncpe.ie/drugs/bezlotoxumab-zinplava/\", \"rr_start\": \"2017-05-11T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-05-11, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Bezlotoxumab (Zinplava\", \"trade_name\": \"Zinplava\", \"indication\": \"Bezlotoxumab (Zinplava\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-05-11T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinplava\", \"ta_list\": \"Enterocolitis, Pseudomembranous\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2206, \"last_scrape\": \"2018-12-13T16:27:58\", \"url\": \"http://www.ncpe.ie/drugs/bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy/\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT BIKTARVY\", \"rr_dates\": \"2018-04-30, 2018-06-07\", \"rr_multiple\": 0, \"drug_name\": \"Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy\", \"trade_name\": \"Biktarvy\", \"indication\": \"Biktarvy\", \"ncpe_year\": 2018, \"eu_market\": \"2018-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2207, \"last_scrape\": \"2018-12-13T16:28:01\", \"url\": \"http://www.ncpe.ie/drugs/bilastine-drynol/\", \"rr_start\": \"2011-03-10T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-10, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Bilastine (Drynol\", \"trade_name\": \"Drynol\", \"indication\": \" Bilastine (Drynol\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-03-10T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2208, \"last_scrape\": \"2018-12-13T16:28:05\", \"url\": \"http://www.ncpe.ie/drugs/blinatumomab-blincyto/\", \"rr_start\": \"2015-12-08T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.  THE NCPE CANNOT RECOMMEND REIMBURSEMENT OF BLINCTYO\", \"rr_dates\": \"2015-12-08, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Blinatumomab (Blincyto\", \"trade_name\": \"Blincyto\", \"indication\": \"Blincyto\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-23T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-08T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2209, \"last_scrape\": \"2018-12-13T16:28:11\", \"url\": \"http://www.ncpe.ie/drugs/boceprevir-victrelis/\", \"rr_start\": \"\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Boceprevir (Victrelis\", \"trade_name\": \"Victrelis\", \"indication\": \"Economic evaluation of Boceprevir (Victrelis\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2011-08-19T00:00:00\", \"latest\": \"2012-01-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2210, \"last_scrape\": \"2018-12-13T16:28:16\", \"url\": \"http://www.ncpe.ie/drugs/bosentan-tracleer/\", \"rr_start\": \"2014-06-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-06-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Bosentan (Tracleer\", \"trade_name\": \"Tracleer\", \"indication\": \"Bosentan (Tracleer\", \"ncpe_year\": 2014, \"eu_market\": \"2002-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-06-27T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tracleer\", \"ta_list\": \"Scleroderma, Systemic; Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2211, \"last_scrape\": \"2018-12-13T16:28:18\", \"url\": \"http://www.ncpe.ie/drugs/bosutinib-bosulif/\", \"rr_start\": \"2013-08-09T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"AT THE CURRENT PRICE A FULL HTA WOULD BE REQUIRED.\", \"rr_dates\": \"2013-08-09, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Bosutinib (Bosulif\", \"trade_name\": \"Bosulif\", \"indication\": \"Bosutinib is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-26T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2212, \"last_scrape\": \"2018-12-13T16:28:19\", \"url\": \"http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris-for-cd30-cutaneous-t-cell-lymphoma-ctcl/\", \"rr_start\": \"2018-02-07T00:00:00\", \"rr_end\": \"2018-03-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-02-07, 2018-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin (Adcetris\", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin (Adcetris\", \"ncpe_year\": 2018, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-02-07T00:00:00\", \"latest\": \"2018-03-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2213, \"last_scrape\": \"2018-12-13T16:28:23\", \"url\": \"http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris/\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin (Adcetris\", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin (Adcetris\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2214, \"last_scrape\": \"2018-12-13T16:28:29\", \"url\": \"http://www.ncpe.ie/drugs/brigatinib-alunbrig/\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF BRIGATINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-11-19, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Brigatinib (Alunbrig\", \"trade_name\": \"Alunbrig\", \"indication\": \"Brigatinib (Alunbrig \", \"ncpe_year\": 2018, \"eu_market\": \"2018-11-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2215, \"last_scrape\": \"2018-12-13T16:28:30\", \"url\": \"http://www.ncpe.ie/drugs/brimonidine-3-3-mgg-gel-mirvaso/\", \"rr_start\": \"2014-04-09T00:00:00\", \"rr_end\": \"2014-04-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-09\", \"rr_multiple\": 0, \"drug_name\": \"Brimonidine 3.3 mg/g gel (Mirvaso\", \"trade_name\": \"Mirvaso\", \"indication\": \"Brimonidine 3.3 mg/g gel (Mirvaso\", \"ncpe_year\": 2014, \"eu_market\": \"2014-02-20T00:00:00\", \"company\": \"Galderma\", \"orphan\": 0, \"earliest\": \"2014-04-09T00:00:00\", \"latest\": \"2014-04-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mirvaso\", \"ta_list\": \"Skin Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2216, \"last_scrape\": \"2018-12-13T16:28:36\", \"url\": \"http://www.ncpe.ie/drugs/brivaracetam-briviact/\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-02-15, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Brivaracetam (Briviact\", \"trade_name\": \"Briviact\", \"indication\": \"Brivaracetam (Briviact\", \"ncpe_year\": 2016, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2217, \"last_scrape\": \"2018-12-13T16:28:40\", \"url\": \"http://www.ncpe.ie/drugs/brodalumab-kyntheum/\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-07-25, 2017-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Brodalumab (Kyntheum\", \"trade_name\": \"Kyntheum\", \"indication\": \"Brodalumab (Kyntheum\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-17T00:00:00\", \"company\": \"LEO\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2218, \"last_scrape\": \"2018-12-13T16:28:44\", \"url\": \"http://www.ncpe.ie/drugs/bronchitol/\", \"rr_start\": \"2012-09-11T00:00:00\", \"rr_end\": \"2012-09-21T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2012-09-11, 2012-09-21\", \"rr_multiple\": 0, \"drug_name\": \"Mannitol Dry Powder (Bronchitol\", \"trade_name\": \"Bronchitol\", \"indication\": \"Bronchitol\", \"ncpe_year\": 2014, \"eu_market\": \"2012-04-13T00:00:00\", \"company\": \"Pharmaxis\", \"orphan\": 1, \"earliest\": \"2012-09-11T00:00:00\", \"latest\": \"2014-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bronchitol\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2219, \"last_scrape\": \"2018-12-13T16:28:46\", \"url\": \"http://www.ncpe.ie/drugs/c-drugs/calcipotriol-and-betamethasone-dipropionate-cutaneous-foam-enstilar/\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-06-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-05-17, 2016-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Calcipotriol and betamethasone dipropionate cutaneous foam (Enstilar \", \"trade_name\": \"Enstilar\", \"indication\": \"Calcipotriol and betamethasone dipropionate cutaneous foam is indicated for the topical treatment of psoriasis vulgaris in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-06-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2220, \"last_scrape\": \"2018-12-13T16:28:53\", \"url\": \"http://www.ncpe.ie/drugs/c1inhibitor-human-cinryze/\", \"rr_start\": \"2012-10-22T00:00:00\", \"rr_end\": \"2012-11-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-22, 2012-11-14\", \"rr_multiple\": 0, \"drug_name\": \"C1inhibitor (human) (Cinryze\", \"trade_name\": \"Cinryze\", \"indication\": \"C1inhibitor (human) (Cinryze\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-15T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2012-10-22T00:00:00\", \"latest\": \"2012-11-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"id\": 2221, \"last_scrape\": \"2018-12-13T16:28:55\", \"url\": \"http://www.ncpe.ie/drugs/cabozantinib-cabometyx/\", \"rr_start\": \"2017-03-20T00:00:00\", \"rr_end\": \"2017-04-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT\\nRECOMMENDED\", \"rr_dates\": \"2017-03-20, 2017-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib (Cabometyx\", \"trade_name\": \"Cabometyx\", \"indication\": \"Cabozantinib (Cabometyx\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-03-20T00:00:00\", \"latest\": \"2018-07-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2222, \"last_scrape\": \"2018-12-13T16:28:58\", \"url\": \"http://www.ncpe.ie/drugs/cabozantinib-cometriq/\", \"rr_start\": \"2014-07-10T00:00:00\", \"rr_end\": \"2014-08-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2014-07-10, 2014-08-12\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib (Cometriq\", \"trade_name\": \"Cometriq\", \"indication\": \"Cabozantinib (COMETRIQ\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-21T00:00:00\", \"company\": \"Ipsen\", \"orphan\": 1, \"earliest\": \"2014-07-10T00:00:00\", \"latest\": \"2014-08-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2223, \"last_scrape\": \"2018-12-13T16:29:01\", \"url\": \"http://www.ncpe.ie/drugs/camellia-sinensis-folium-green-tea-leaf-catephen-10/\", \"rr_start\": \"2015-05-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-05-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Camellia sinensis, folium (green tea leaf) (Catephen 10%\", \"trade_name\": \"Catephen 10%\", \"indication\": \"Catephen 10%\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-05-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2224, \"last_scrape\": \"2018-12-13T16:29:04\", \"url\": \"http://www.ncpe.ie/drugs/canagliflozin-invokana/\", \"rr_start\": \"2013-11-25T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-11-25, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Canagliflozin (Invokana\", \"trade_name\": \"Invokana\", \"indication\": \"Canagliflozin (Invokana\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-11-25T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/invokana\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2225, \"last_scrape\": \"2018-12-13T16:29:09\", \"url\": \"http://www.ncpe.ie/drugs/capsaicin-8ww-patch-qutenza/\", \"rr_start\": \"2012-06-15T00:00:00\", \"rr_end\": \"2012-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-06-15, 2012-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Capsaicin 8%w/w patch (Qutenza\", \"trade_name\": \"Qutenza\", \"indication\": \"Capsaicin 8% w/w patch (Qutenza\", \"ncpe_year\": 2012, \"eu_market\": \"2009-05-15T00:00:00\", \"company\": \"Grunenthal\", \"orphan\": 0, \"earliest\": \"2012-06-15T00:00:00\", \"latest\": \"2012-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza\", \"ta_list\": \"Neuralgia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2226, \"last_scrape\": \"2018-12-13T16:29:11\", \"url\": \"http://www.ncpe.ie/drugs/carbazitaxel-jevtana-for-prostate-cancer/\", \"rr_start\": \"2011-06-02T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-06-02, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Cabazitaxel (Jevtana\", \"trade_name\": \"Jevtana\", \"indication\": \"Economic Evaluation of cabazitaxel (Jevtana\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2011-06-02T00:00:00\", \"latest\": \"2014-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jevtana\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2227, \"last_scrape\": \"2018-12-13T16:29:16\", \"url\": \"http://www.ncpe.ie/drugs/carfilzomib-kyprolis/\", \"rr_start\": \"2015-12-07T00:00:00\", \"rr_end\": \"2016-01-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-12-07, 2016-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Carfilzomib (Kyprolis\", \"trade_name\": \"Kyprolis\", \"indication\": \"Kyprolis\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-07T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2228, \"last_scrape\": \"2018-12-13T16:29:22\", \"url\": \"http://www.ncpe.ie/drugs/catumaxomab-removab/\", \"rr_start\": \"2011-08-05T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-08-05, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Catumaxomab (Removab\", \"trade_name\": \"Removab\", \"indication\": \"Catumazomab (Removab\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-20T00:00:00\", \"company\": \"Neovii\", \"orphan\": 0, \"earliest\": \"2011-08-05T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/removab\", \"ta_list\": \"Ascites; Cancer\", \"rr_status\": \"No HTA\"}, {\"id\": 2229, \"last_scrape\": \"2018-12-13T16:29:25\", \"url\": \"http://www.ncpe.ie/drugs/ceftaroline-zinforo/\", \"rr_start\": \"2012-10-08T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-10-08, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Ceftaroline (Zinforo\", \"trade_name\": \"Zinforo\", \"indication\": \"For the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP).\", \"ncpe_year\": 2012, \"eu_market\": \"2012-08-22T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-10-08T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinforo\", \"ta_list\": \"Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia\", \"rr_status\": \"No HTA\"}, {\"id\": 2230, \"last_scrape\": \"2018-12-13T16:29:29\", \"url\": \"http://www.ncpe.ie/drugs/ceftazidime-avibactam-cef-avizavicefta/\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-17, 2017-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Ceftazidime-avibactam (CEF-AVI)(Zavicefta\", \"trade_name\": \"Zavicefta\", \"indication\": \"Ceftazidime-avibactam (CEF-AVI)(Zavicefta\", \"ncpe_year\": 2017, \"eu_market\": \"2016-06-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta\", \"ta_list\": \"Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2231, \"last_scrape\": \"2018-12-13T16:29:34\", \"url\": \"http://www.ncpe.ie/drugs/ceftolozanetazobactam-zerbaxa/\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-03-03, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Ceftolozane/tazobactam (Zerbaxa\", \"trade_name\": \"Zerbaxa\", \"indication\": \"Zerbaxa\", \"ncpe_year\": 2016, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa\", \"ta_list\": \"Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2232, \"last_scrape\": \"2018-12-13T16:29:36\", \"url\": \"http://www.ncpe.ie/drugs/ceritinib-zykadia/\", \"rr_start\": \"2015-05-29T00:00:00\", \"rr_end\": \"2015-07-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2015-05-29, 2015-07-22\", \"rr_multiple\": 0, \"drug_name\": \"Ceritinib (Zykadia\", \"trade_name\": \"Zykadia\", \"indication\": \"Zykadia\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-06T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-05-29T00:00:00\", \"latest\": \"2015-07-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2233, \"last_scrape\": \"2018-12-13T16:29:40\", \"url\": \"http://www.ncpe.ie/drugs/cerliponase-alfa-brineura/\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2017-10-11, 2017-11-27\", \"rr_multiple\": 0, \"drug_name\": \"Cerliponase alfa (Brineura\", \"trade_name\": \"Brineura\", \"indication\": \"Cerliponase alfa (Brineura\", \"ncpe_year\": 2018, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-08-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brineura\", \"ta_list\": \"Neuronal Ceroid-Lipofuscinoses\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2234, \"last_scrape\": \"2018-12-13T16:29:44\", \"url\": \"http://www.ncpe.ie/drugs/certolizumab-pegol-cimzia/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Certolizumab pegol (Cimzia\", \"trade_name\": \"Cimzia\", \"indication\": \"Cost-effectiveness of certolizumab pegol (Cimzia\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2010-03-13T00:00:00\", \"latest\": \"2010-09-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia-0\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2235, \"last_scrape\": \"2018-12-13T16:29:49\", \"url\": \"http://www.ncpe.ie/drugs/ciclosporin-1mgml-eye-drops-ikervis/\", \"rr_start\": \"2015-01-07T00:00:00\", \"rr_end\": \"2016-01-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-01-07, 2016-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Ciclosporin 1mg/ml eye drops (Ikervis\", \"trade_name\": \"Ikervis\", \"indication\": \"Ikervis\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-19T00:00:00\", \"company\": \"Santen\", \"orphan\": 0, \"earliest\": \"2015-01-07T00:00:00\", \"latest\": \"2016-01-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis\", \"ta_list\": \"Corneal Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2236, \"last_scrape\": \"2018-12-13T16:29:54\", \"url\": \"http://www.ncpe.ie/drugs/cladribine-mavenclad/\", \"rr_start\": \"2017-08-22T00:00:00\", \"rr_end\": \"2017-09-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-22, 2017-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Cladribine (Mavenclad\", \"trade_name\": \"Mavenclad\", \"indication\": \"Cladribine (Mavenclad\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-08-22T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2237, \"last_scrape\": \"2018-12-13T16:29:58\", \"url\": \"http://www.ncpe.ie/drugs/clindamycin-1-with-tretinoin-0-025-treclinac/\", \"rr_start\": \"2014-04-08T00:00:00\", \"rr_end\": \"2014-05-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-08, 2014-05-06\", \"rr_multiple\": 0, \"drug_name\": \"Clindamycin 1% with tretinoin 0.025% (Treclinac\", \"trade_name\": \"Treclinac\", \"indication\": \"Clindamycin 1% with tretinoin 0.025% (Treclinac\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-04-08T00:00:00\", \"latest\": \"2014-05-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2238, \"last_scrape\": \"2018-12-13T16:30:02\", \"url\": \"http://www.ncpe.ie/drugs/cobimetinib-cotellic/\", \"rr_start\": \"2016-04-19T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-04-19, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Cobimetinib (Cotellic\", \"trade_name\": \"Cotellic\", \"indication\": \"Cotellic\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2016-04-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2239, \"last_scrape\": \"2018-12-13T16:30:03\", \"url\": \"http://www.ncpe.ie/drugs/colesevelam-cholestagel/\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Colesevelam (Cholestagel\", \"trade_name\": \"Cholestagel\", \"indication\": \"Cost-effectiveness of Colesevelam (Cholestagel\", \"ncpe_year\": 2010, \"eu_market\": \"2004-03-09T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cholestagel\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"No HTA\"}, {\"id\": 2240, \"last_scrape\": \"2018-12-13T16:30:06\", \"url\": \"http://www.ncpe.ie/drugs/colistimethate-sodium-colobreathe/\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Colistimethate sodium (Colobreathe\", \"trade_name\": \"Colobreathe\", \"indication\": \"Colistimethate sodium (colobreathe\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-13T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/colobreathe\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2241, \"last_scrape\": \"2018-12-13T16:30:17\", \"url\": \"http://www.ncpe.ie/drugs/collagenase-clostridium-histolyticum-xiapex/\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-20, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Collagenase Clostridium Histolyticum (Xiapex\", \"trade_name\": \"Xiapex\", \"indication\": \" Collagenase Clostridium Histolyticum (Xiapex\", \"ncpe_year\": 2011, \"eu_market\": \"2011-02-28T00:00:00\", \"company\": \"Swedish\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xiapex\", \"ta_list\": \"Dupuytren Contracture\", \"rr_status\": \"No HTA\"}, {\"id\": 2242, \"last_scrape\": \"2018-12-13T16:30:20\", \"url\": \"http://www.ncpe.ie/drugs/corifollitropin-alfa-elonva/\", \"rr_start\": \"2010-10-22T00:00:00\", \"rr_end\": \"2010-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-10-22, 2010-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Corifollitropin alfa (Elonva\", \"trade_name\": \"Elonva\", \"indication\": \"Cost-effectiveness of Corifollitropin alfa (Elonva\", \"ncpe_year\": 2010, \"eu_market\": \"2010-01-25T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2010-09-01T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/elonva\", \"ta_list\": \"Reproductive Techniques, Assisted; Ovulation Induction\", \"rr_status\": \"No HTA\"}, {\"id\": 2243, \"last_scrape\": \"2018-12-13T16:30:24\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori-for-first-line-alk-nsclc/\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2244, \"last_scrape\": \"2018-12-13T16:30:29\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori-for-ros1-nsclc/\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"id\": 2245, \"last_scrape\": \"2018-12-13T16:30:34\", \"url\": \"http://www.ncpe.ie/drugs/crizotinib-xalkori/\", \"rr_start\": \"2013-01-09T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-01-09, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib (Xalkori\", \"trade_name\": \"Xalkori\", \"indication\": \"For the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-01-09T00:00:00\", \"latest\": \"2015-08-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2246, \"last_scrape\": \"2018-12-13T16:30:37\", \"url\": \"http://www.ncpe.ie/drugs/cysteamine-bitartrate-procysbi/\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2015-12-01, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Cysteamine bitartrate delayed-release (Procysbi\", \"trade_name\": \"Procysbi\", \"indication\": \"Procysbi\", \"ncpe_year\": 2017, \"eu_market\": \"2013-09-05T00:00:00\", \"company\": \"Chiesi\", \"orphan\": 1, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/procysbi\", \"ta_list\": \"Cystinosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2247, \"last_scrape\": \"2018-12-13T16:30:43\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-2/\", \"rr_start\": \"2014-05-09T00:00:00\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-09, 2014-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate (Pradaxa\", \"ncpe_year\": 2014, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-09T00:00:00\", \"latest\": \"2014-06-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2248, \"last_scrape\": \"2018-12-13T16:30:51\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-for-the-prevention-of-stroke-and-systematic-embolisom-in-atrial-fibrillation/\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate (Pradaxa\", \"ncpe_year\": 2012, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2010-11-02T00:00:00\", \"latest\": \"2012-10-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2249, \"last_scrape\": \"2018-12-13T16:30:57\", \"url\": \"http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-vte-prevention/\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate (Pradaxa\", \"trade_name\": \"Pradaxa\", \"indication\": \"Economic Evaluation of the Cost Effectiveness of Dabigatran Etexilate (Pradaxa\", \"ncpe_year\": 2008, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2008-07-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2250, \"last_scrape\": \"2018-12-13T16:30:59\", \"url\": \"http://www.ncpe.ie/drugs/dabrafenib-tafinlar/\", \"rr_start\": \"2013-09-11T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-11, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Dabrafenib (Tafinlar\", \"trade_name\": \"Tafinlar\", \"indication\": \"Dabrafenib (Tafinlar\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2013-09-11T00:00:00\", \"latest\": \"2014-06-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2251, \"last_scrape\": \"2018-12-13T16:31:02\", \"url\": \"http://www.ncpe.ie/drugs/daclatasvir-daklinza/\", \"rr_start\": \"2014-08-05T00:00:00\", \"rr_end\": \"2014-09-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-08-05, 2014-09-12\", \"rr_multiple\": 0, \"drug_name\": \"Daclatasvir (Daklinza\", \"trade_name\": \"Daklinza\", \"indication\": \"Daclatasvir (Daklinza\", \"ncpe_year\": 2015, \"eu_market\": \"2014-08-22T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-08-05T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/daklinza\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2252, \"last_scrape\": \"2018-12-13T16:31:08\", \"url\": \"http://www.ncpe.ie/drugs/daclizumab-zinbryta/\", \"rr_start\": \"2016-09-26T00:00:00\", \"rr_end\": \"2016-11-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-09-26, 2016-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Daclizumab (Zinbryta\", \"trade_name\": \"Zinbryta\", \"indication\": \"Daclizumab is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-07-01T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2016-09-26T00:00:00\", \"latest\": \"2018-03-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zinbryta\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2253, \"last_scrape\": \"2018-12-13T16:31:12\", \"url\": \"http://www.ncpe.ie/drugs/dalbavancin-xydalba/\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-07, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Dalbavancin (Xydalba\", \"trade_name\": \"Xydalba\", \"indication\": \"Dalbavancin (Xydalba\", \"ncpe_year\": 2017, \"eu_market\": \"2015-02-19T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xydalba\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2254, \"last_scrape\": \"2018-12-13T16:31:18\", \"url\": \"http://www.ncpe.ie/drugs/dapagliflozin-forxiga/\", \"rr_start\": \"2012-10-10T00:00:00\", \"rr_end\": \"2012-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-10-10, 2012-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Dapagliflozin (Forxiga\", \"trade_name\": \"Forxiga\", \"indication\": \"Dapagliflozin (Forxiga\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-11T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-10T00:00:00\", \"latest\": \"2013-12-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2255, \"last_scrape\": \"2018-12-13T16:31:21\", \"url\": \"http://www.ncpe.ie/drugs/daratumumab-darzalex/\", \"rr_start\": \"2016-05-31T00:00:00\", \"rr_end\": \"2016-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-05-31, 2016-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Daratumumab (Darzalex\", \"trade_name\": \"Darzalex\", \"indication\": \"Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-04-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-05-31T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2256, \"last_scrape\": \"2018-12-13T16:31:25\", \"url\": \"http://www.ncpe.ie/drugs/darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-symtuza/\", \"rr_start\": \"2017-09-27T00:00:00\", \"rr_end\": \"2017-10-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-27, 2017-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza\", \"trade_name\": \"Symtuza\", \"indication\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza\", \"ncpe_year\": 2017, \"eu_market\": \"2017-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-09-27T00:00:00\", \"latest\": \"2017-10-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/symtuza\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2257, \"last_scrape\": \"2018-12-13T16:31:30\", \"url\": \"http://www.ncpe.ie/drugs/darunavir-cobicistat-rezolsta/\", \"rr_start\": \"2014-12-02T00:00:00\", \"rr_end\": \"2015-01-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-12-02, 2015-01-08\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir & cobicistat (Rezolsta\", \"trade_name\": \"Rezolsta\", \"indication\": \"Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-12-02T00:00:00\", \"latest\": \"2015-01-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2258, \"last_scrape\": \"2018-12-13T16:31:35\", \"url\": \"http://www.ncpe.ie/drugs/darvadstrocel-alofisel/\", \"rr_start\": \"2018-06-14T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF DARVADSTROCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-14, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Darvadstrocel (Alofisel\", \"trade_name\": \"Alofisel\", \"indication\": \"Darvadstrocel (Alofisel\", \"ncpe_year\": 2018, \"eu_market\": \"2018-03-23T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-06-14T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel\", \"ta_list\": \"Rectal Fistula\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2259, \"last_scrape\": \"2018-12-13T16:31:40\", \"url\": \"http://www.ncpe.ie/drugs/decitabine-dacogen/\", \"rr_start\": \"2012-11-08T00:00:00\", \"rr_end\": \"2012-12-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-11-08, 2012-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Decitabine (Dacogen\", \"trade_name\": \"Dacogen\", \"indication\": \"Decitabine (Dacogen\", \"ncpe_year\": 2013, \"eu_market\": \"2012-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2012-11-08T00:00:00\", \"latest\": \"2013-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2260, \"last_scrape\": \"2018-12-13T16:31:44\", \"url\": \"http://www.ncpe.ie/drugs/defibrotide-defitelio/\", \"rr_start\": \"2014-05-12T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2014-05-12, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Defibrotide (Defitelio\", \"trade_name\": \"Defitelio\", \"indication\": \"Defibrotide (Defitelio\", \"ncpe_year\": 2014, \"eu_market\": \"2013-10-18T00:00:00\", \"company\": \"Gentium\", \"orphan\": 1, \"earliest\": \"2014-05-12T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio\", \"ta_list\": \"Hepatic Veno-Occlusive Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2261, \"last_scrape\": \"2018-12-13T16:31:47\", \"url\": \"http://www.ncpe.ie/drugs/degarelix-firmagon/\", \"rr_start\": \"2009-10-15T00:00:00\", \"rr_end\": \"2009-10-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-10-15\", \"rr_multiple\": 0, \"drug_name\": \"Degarelix (Firmagon\", \"trade_name\": \"Firmagon\", \"indication\": \"Cost-effectiveness of Degarelix (Firmagon\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-17T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2009-10-15T00:00:00\", \"latest\": \"2009-10-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2262, \"last_scrape\": \"2018-12-13T16:31:52\", \"url\": \"http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-cannabidiol-thc-cbd-sativex/\", \"rr_start\": \"2018-02-12T00:00:00\", \"rr_end\": \"2018-04-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF SATIVEX\", \"rr_dates\": \"2018-02-12, 2018-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex\", \"trade_name\": \"Sativex\", \"indication\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-02-12T00:00:00\", \"latest\": \"2018-04-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2263, \"last_scrape\": \"2018-12-13T16:31:59\", \"url\": \"http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-thccannabidiol-cbd-sativex/\", \"rr_start\": \"2012-12-05T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-05, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol (THC) /Cannabidiol (CBD) (Sativex\", \"trade_name\": \"Sativex\", \"indication\": \"For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-12-05T00:00:00\", \"latest\": \"2014-09-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2264, \"last_scrape\": \"2018-12-13T16:32:04\", \"url\": \"http://www.ncpe.ie/drugs/denosumab-prolia/\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab (Prolia\", \"trade_name\": \"Prolia\", \"indication\": \"The Cost-effectiveness of Denosumab (Prolia\", \"ncpe_year\": 2010, \"eu_market\": \"2010-05-26T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2010-05-27T00:00:00\", \"latest\": \"2010-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prolia\", \"ta_list\": \"Bone Resorption; Osteoporosis, Postmenopausal\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2265, \"last_scrape\": \"2018-12-13T16:32:08\", \"url\": \"http://www.ncpe.ie/drugs/denosumab-xgeva-3/\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab (Xgeva\", \"trade_name\": \"Xgeva\", \"indication\": \"Cost-effectiveness of denosumab (Xgeva\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2011-08-15T00:00:00\", \"latest\": \"2011-12-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva\", \"ta_list\": \"Fractures, Bone; Neoplasm Metastasis\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2266, \"last_scrape\": \"2018-12-13T16:32:12\", \"url\": \"http://www.ncpe.ie/drugs/dexamethasone-intravitreal-implant-ozurdex/\", \"rr_start\": \"2010-11-12T00:00:00\", \"rr_end\": \"2010-12-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-11-12, 2010-12-16\", \"rr_multiple\": 0, \"drug_name\": \"Dexamethasone Intravitreal Implant (Ozurdex\", \"trade_name\": \"Ozurdex\", \"indication\": \"Cost-effectiveness of Ozurdex\", \"ncpe_year\": 2012, \"eu_market\": \"2010-07-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2010-11-12T00:00:00\", \"latest\": \"2012-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ozurdex\", \"ta_list\": \"Macular Edema; Uveitis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2267, \"last_scrape\": \"2018-12-13T16:32:15\", \"url\": \"http://www.ncpe.ie/drugs/dexmedetomidine-dexdor/\", \"rr_start\": \"2011-07-08T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-07-08, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Dexmedetomidine (Dexdor\", \"trade_name\": \"Dexdor\", \"indication\": \"Dexmedetomidine (Dexdor\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-15T00:00:00\", \"company\": \"Orion\", \"orphan\": 0, \"earliest\": \"2011-07-08T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dexdor\", \"ta_list\": \"Conscious Sedation\", \"rr_status\": \"No HTA\"}, {\"id\": 2268, \"last_scrape\": \"2018-12-13T16:32:21\", \"url\": \"http://www.ncpe.ie/drugs/dienogest-visanne/\", \"rr_start\": \"2010-09-17T00:00:00\", \"rr_end\": \"2010-10-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-09-17, 2010-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Dienogest (Visanne\", \"trade_name\": \"Visanne\", \"indication\": \"Dienogest (Visanne\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-09-17T00:00:00\", \"latest\": \"2010-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2269, \"last_scrape\": \"2018-12-13T16:32:24\", \"url\": \"http://www.ncpe.ie/drugs/dimethyl-fumarate-skilarence/\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-01-15, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate (Skilarence\", \"trade_name\": \"Skilarence\", \"indication\": \"Dimethyl fumarate (Skilarence\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"Almirall\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/skilarence\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2270, \"last_scrape\": \"2018-12-13T16:32:26\", \"url\": \"http://www.ncpe.ie/drugs/dimethyl-fumarate-tecfidera/\", \"rr_start\": \"2014-02-04T00:00:00\", \"rr_end\": \"2014-03-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-02-04, 2014-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate (Tecfidera\", \"trade_name\": \"Tecfidera\", \"indication\": \"Dimethyl fumarate (Tecfidera\", \"ncpe_year\": 2015, \"eu_market\": \"2014-01-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-02-04T00:00:00\", \"latest\": \"2015-04-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2271, \"last_scrape\": \"2018-12-13T16:32:29\", \"url\": \"http://www.ncpe.ie/drugs/dinutuximab-beta-dinutuximab-beta-eusa/\", \"rr_start\": \"2017-10-19T00:00:00\", \"rr_end\": \"2017-11-23T00:00:00\", \"rr_outcome\": \"FOLLOWING ASSESSMENT OF THE APPLICANT\", \"rr_dates\": \"2017-10-19, 2017-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Dinutuximab beta (Qarziba\", \"trade_name\": \"Qarziba\", \"indication\": \"Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients ? 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-10-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2272, \"last_scrape\": \"2018-12-13T16:32:34\", \"url\": \"http://www.ncpe.ie/drugs/dolutegravir-rilpivirine-juluca/\", \"rr_start\": \"2018-06-08T00:00:00\", \"rr_end\": \"2018-07-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT JULUCA\", \"rr_dates\": \"2018-06-08, 2018-07-12\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir/Rilpivirine (Juluca\", \"trade_name\": \"Juluca\", \"indication\": \"Dolutegravir/rilpivirine (Juluca\", \"ncpe_year\": 2018, \"eu_market\": \"2018-05-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2018-06-08T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/juluca\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2273, \"last_scrape\": \"2018-12-13T16:32:36\", \"url\": \"http://www.ncpe.ie/drugs/dolutegravir-tivicay/\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-10, 2014-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir (Tivicay\", \"trade_name\": \"Tivicay\", \"indication\": \"Dolutegravir (Tivicay\", \"ncpe_year\": 2014, \"eu_market\": \"2014-01-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2274, \"last_scrape\": \"2018-12-13T16:32:39\", \"url\": \"http://www.ncpe.ie/drugs/dronedarone-multaq/\", \"rr_start\": \"2010-01-12T00:00:00\", \"rr_end\": \"2010-01-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-01-12, 2010-01-01\", \"rr_multiple\": 0, \"drug_name\": \"Dronedarone (Multaq\", \"trade_name\": \"Multaq\", \"indication\": \"Rapid Review\", \"ncpe_year\": 2010, \"eu_market\": \"2009-11-25T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2010-01-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"No HTA\"}, {\"id\": 2275, \"last_scrape\": \"2018-12-13T16:32:42\", \"url\": \"http://www.ncpe.ie/drugs/dulaglutide-trulicity/\", \"rr_start\": \"2015-03-04T00:00:00\", \"rr_end\": \"2015-04-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-03-04, 2015-04-29\", \"rr_multiple\": 0, \"drug_name\": \"Dulaglutide (Trulicity\", \"trade_name\": \"Trulicity\", \"indication\": \"Dulaglutide is indicated as monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2015-03-04T00:00:00\", \"latest\": \"2015-04-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2276, \"last_scrape\": \"2018-12-13T16:32:46\", \"url\": \"http://www.ncpe.ie/drugs/dupilumab-dupixent/\", \"rr_start\": \"2017-11-13T00:00:00\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-13, 2017-11-24\", \"rr_multiple\": 0, \"drug_name\": \"Dupilumab (Dupixent\", \"trade_name\": \"Dupixent\", \"indication\": \"Dupilumab (Dupixent\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-27T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-11-13T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent\", \"ta_list\": \"Dermatitis, Atopic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2277, \"last_scrape\": \"2018-12-13T16:32:53\", \"url\": \"http://www.ncpe.ie/drugs/eculizumab-soliris/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Eculizumab (Soliris\", \"trade_name\": \"Soliris\", \"indication\": \"An Economic Evaluation of Eculizumab (Soliris\", \"ncpe_year\": 2013, \"eu_market\": \"2007-06-20T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2013-10-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/soliris\", \"ta_list\": \"Hemoglobinuria, Paroxysmal\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2278, \"last_scrape\": \"2018-12-13T16:32:55\", \"url\": \"http://www.ncpe.ie/drugs/edoxaban-lixiana/\", \"rr_start\": \"2015-06-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-06-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Edoxaban (Lixiana\", \"trade_name\": \"Lixiana\", \"indication\": \"Edoxaban is indicated for the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2015-06-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana\", \"ta_list\": \"Stroke; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"id\": 2279, \"last_scrape\": \"2018-12-13T16:33:00\", \"url\": \"http://www.ncpe.ie/drugs/elbasvirgrazoprevir-zepatier-2/\", \"rr_start\": \"2016-08-10T00:00:00\", \"rr_end\": \"2016-10-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-08-10, 2016-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Elbasvir/Grazoprevir (Zepatier\", \"trade_name\": \"Zepatier\", \"indication\": \"Elbasvir 50mg/100mg grazoprevir (EBR/GZR)(Zepatier\", \"ncpe_year\": 2016, \"eu_market\": \"2016-07-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-10T00:00:00\", \"latest\": \"2016-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2280, \"last_scrape\": \"2018-12-13T16:33:03\", \"url\": \"http://www.ncpe.ie/drugs/eliglustat-cerdelga/\", \"rr_start\": \"2016-03-21T00:00:00\", \"rr_end\": \"2016-05-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-03-21, 2016-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Eliglustat (Cerdelga\", \"trade_name\": \"Cerdelga\", \"indication\": \"Eliglustat (Cerdelga\", \"ncpe_year\": 2018, \"eu_market\": \"2015-01-19T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 1, \"earliest\": \"2016-03-21T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga\", \"ta_list\": \"Gaucher Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2281, \"last_scrape\": \"2018-12-13T16:33:05\", \"url\": \"http://www.ncpe.ie/drugs/elosulfase-alfa-vimizim/\", \"rr_start\": \"2015-03-30T00:00:00\", \"rr_end\": \"2015-05-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-03-30, 2015-05-08\", \"rr_multiple\": 0, \"drug_name\": \"Elosulfase alfa (Vimizim\", \"trade_name\": \"Vimizim\", \"indication\": \"Elosulfase alfa (Vimzim\", \"ncpe_year\": 2018, \"eu_market\": \"2014-04-27T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2015-03-30T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vimizim\", \"ta_list\": \"Mucopolysaccharidosis IV\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2282, \"last_scrape\": \"2018-12-13T16:33:12\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade-2/\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-02-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-01-10, 2014-02-13\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Eltrombopag (Revolade\", \"ncpe_year\": 2014, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-02-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"id\": 2283, \"last_scrape\": \"2018-12-13T16:33:17\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade-3/\", \"rr_start\": \"2016-02-05T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-02-05, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Revolade\", \"ncpe_year\": 2016, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-02-05T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"id\": 2284, \"last_scrape\": \"2018-12-13T16:33:23\", \"url\": \"http://www.ncpe.ie/drugs/eltrombopag-revolade/\", \"rr_start\": \"2017-12-04T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, WHICH IS NOT COMPARABLE WITH CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2017-12-04, 2018-04-16, 2017-12-01\", \"rr_multiple\": 1, \"drug_name\": \"Eltrombopag (Revolade\", \"trade_name\": \"Revolade\", \"indication\": \"Cost-effectiveness of eltrombopag (Revolade\", \"ncpe_year\": 2018, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-07-30T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revolade\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2285, \"last_scrape\": \"2018-12-13T16:33:26\", \"url\": \"http://www.ncpe.ie/drugs/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya/\", \"rr_start\": \"2015-11-24T00:00:00\", \"rr_end\": \"2016-01-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-11-24, 2016-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide (Genvoya\", \"trade_name\": \"Genvoya\", \"indication\": \"Genvoya\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2015-11-24T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2286, \"last_scrape\": \"2018-12-13T16:33:32\", \"url\": \"http://www.ncpe.ie/drugs/empagliflozin-jardiance/\", \"rr_start\": \"2014-05-22T00:00:00\", \"rr_end\": \"2014-06-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-22, 2014-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Empagliflozin (Jardiance\", \"trade_name\": \"Jardiance\", \"indication\": \"Add-on combination therapy \", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-22T00:00:00\", \"latest\": \"2014-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2287, \"last_scrape\": \"2018-12-13T16:33:37\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabine-tenofovir-disoproxil-fumarate-truvada/\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-07-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-12, 2017-07-18\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine / tenofovir disoproxil fumarate (Truvada\", \"trade_name\": \"Truvada\", \"indication\": \"Truvada\", \"ncpe_year\": 2017, \"eu_market\": \"2005-02-20T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-07-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/truvada\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2288, \"last_scrape\": \"2018-12-13T16:33:43\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabine-tenovir-disoproxil-teva/\", \"rr_start\": \"2017-12-11T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-12-11, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir disoproxil (TEVA\", \"trade_name\": \"TEVA\", \"indication\": \"Emtricitabine/tenofovir disoproxil (TEVA\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-12-11T00:00:00\", \"latest\": \"2017-12-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2289, \"last_scrape\": \"2018-12-13T16:33:48\", \"url\": \"http://www.ncpe.ie/drugs/emtricitabinetenofovir-alafenamide-descovy/\", \"rr_start\": \"2016-04-26T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-04-26, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir alafenamide (Descovy\", \"trade_name\": \"Descovy\", \"indication\": \"Descovy\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-04-26T00:00:00\", \"latest\": \"2016-04-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/descovy\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2290, \"last_scrape\": \"2018-12-13T16:33:52\", \"url\": \"http://www.ncpe.ie/drugs/enzalutamide-xtandi/\", \"rr_start\": \"2013-06-28T00:00:00\", \"rr_end\": \"2013-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-28, 2013-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Enzalutamide (Xtandi\", \"trade_name\": \"Xtandi\", \"indication\": \"Enzalutamide (Xtandi\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2013-06-28T00:00:00\", \"latest\": \"2014-04-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2291, \"last_scrape\": \"2018-12-13T16:33:59\", \"url\": \"http://www.ncpe.ie/drugs/epoprostenol-veletri/\", \"rr_start\": \"2016-12-13T00:00:00\", \"rr_end\": \"2017-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-12-13, 2017-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Epoprostenol (Veletri\", \"trade_name\": \"Veletri\", \"indication\": \"Veletri\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-12-13T00:00:00\", \"latest\": \"2017-02-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2292, \"last_scrape\": \"2018-12-13T16:34:03\", \"url\": \"http://www.ncpe.ie/drugs/erenumab-aimovig/\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-15T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF ERENUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-19, 2018-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Erenumab (Aimovig\", \"trade_name\": \"Aimovig\", \"indication\": \"Erenumab (Aimovig\", \"ncpe_year\": 2018, \"eu_market\": \"2018-07-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig\", \"ta_list\": \"Migraine Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2293, \"last_scrape\": \"2018-12-13T16:34:07\", \"url\": \"http://www.ncpe.ie/drugs/eribulin-halaven/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-03-11, 2011-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Eribulin (Halaven\", \"trade_name\": \"Halaven\", \"indication\": \"Eribulin (Halaven\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2011-02-09T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/halaven\", \"ta_list\": \"Breast Neoplasms; Liposarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2294, \"last_scrape\": \"2018-12-13T16:34:09\", \"url\": \"http://www.ncpe.ie/drugs/eslicarbazepine-zebinix/\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-08-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2009-09-01, 2009-08-01\", \"rr_multiple\": 0, \"drug_name\": \"Eslicarbazepine (Zebinix\", \"trade_name\": \"Zebinix\", \"indication\": \"Eslicarbazepine (Zebinix\", \"ncpe_year\": 2009, \"eu_market\": \"2009-04-21T00:00:00\", \"company\": \"BIAL\", \"orphan\": 0, \"earliest\": \"2009-08-01T00:00:00\", \"latest\": \"2009-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2295, \"last_scrape\": \"2018-12-13T16:34:12\", \"url\": \"http://www.ncpe.ie/drugs/etanercept-benepali/\", \"rr_start\": \"2016-03-22T00:00:00\", \"rr_end\": \"2016-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-03-22, 2016-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Etanercept (Benepali\", \"trade_name\": \"Benepali\", \"indication\": \"Benepali\", \"ncpe_year\": 2016, \"eu_market\": \"2016-01-13T00:00:00\", \"company\": \"Samsung\", \"orphan\": 0, \"earliest\": \"2016-03-22T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/benepali\", \"ta_list\": \"Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis\", \"rr_status\": \"No HTA\"}, {\"id\": 2296, \"last_scrape\": \"2018-12-13T16:34:15\", \"url\": \"http://www.ncpe.ie/drugs/etelcalcetide-parsabiv/\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-06-14, 2017-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Etelcalcetide (Parsabiv\", \"trade_name\": \"Parsabiv\", \"indication\": \"Etelcalcitide (Parsabiv\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-11T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/parsabiv\", \"ta_list\": \"Hyperparathyroidism, Secondary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2297, \"last_scrape\": \"2018-12-13T16:34:21\", \"url\": \"http://www.ncpe.ie/drugs/eurartesim-piperaquine-tetraphosphatedihidroartemisinin/\", \"rr_start\": \"2012-05-22T00:00:00\", \"rr_end\": \"2012-05-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-05-22, 2012-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Piperaquine tetraphosphate/dihidroartemisinin (Eurartesim\", \"trade_name\": \"Eurartesim\", \"indication\": \"Eurartesim\", \"ncpe_year\": 2012, \"eu_market\": \"2011-10-27T00:00:00\", \"company\": \"Alfasigma\", \"orphan\": 0, \"earliest\": \"2012-05-22T00:00:00\", \"latest\": \"2012-05-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/eurartesim\", \"ta_list\": \"Malaria\", \"rr_status\": \"No HTA\"}, {\"id\": 2298, \"last_scrape\": \"2018-12-13T16:34:24\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-afinitor/\", \"rr_start\": \"2012-09-21T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-09-21, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Afinitor\", \"trade_name\": \"Afinitor\", \"indication\": \"Treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor\", \"ncpe_year\": 2012, \"eu_market\": \"2009-08-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-09-21T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/afinitor\", \"ta_list\": \"Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2299, \"last_scrape\": \"2018-12-13T16:34:26\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-votubia-for-refractory-seizures-associated-with-tuberous-sclerosis-complex-tsc/\", \"rr_start\": \"2017-04-19T00:00:00\", \"rr_end\": \"2017-04-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-04-19, 2017-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Votubia \", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus (Votubia\", \"ncpe_year\": 2017, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2017-04-19T00:00:00\", \"latest\": \"2017-04-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/votubia\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2300, \"last_scrape\": \"2018-12-13T16:34:29\", \"url\": \"http://www.ncpe.ie/drugs/everolimus-votubia/\", \"rr_start\": \"2011-09-30T00:00:00\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-09-30, 2011-10-14\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus (Votubia\", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus (Votubia\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2011-09-30T00:00:00\", \"latest\": \"2011-10-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/votubia\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2301, \"last_scrape\": \"2018-12-13T16:34:36\", \"url\": \"http://www.ncpe.ie/drugs/evolocumab-repatha/\", \"rr_start\": \"\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Evolocumab (Repatha\", \"trade_name\": \"Repatha\", \"indication\": \"Evolocumab (Repatha\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-17T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-01-01T00:00:00\", \"latest\": \"2018-05-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/repatha\", \"ta_list\": \"Dyslipidemias; Hypercholesterolemia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2302, \"last_scrape\": \"2018-12-13T16:34:41\", \"url\": \"http://www.ncpe.ie/drugs/exenatide-bydureon/\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Exenatide (Bydureon\", \"trade_name\": \"Bydureon\", \"indication\": \"Exenatide (Bydureon\", \"ncpe_year\": 2011, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2303, \"last_scrape\": \"2018-12-13T16:34:44\", \"url\": \"http://www.ncpe.ie/drugs/fampridine-fampyra/\", \"rr_start\": \"2011-09-11T00:00:00\", \"rr_end\": \"2011-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-09-11, 2011-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Fampridine (Fampyra\", \"trade_name\": \"Fampyra\", \"indication\": \"Fampridine (Fampyra\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-20T00:00:00\", \"company\": \"Blogen\", \"orphan\": 0, \"earliest\": \"2011-09-01T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fampyra\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2304, \"last_scrape\": \"2018-12-13T16:34:48\", \"url\": \"http://www.ncpe.ie/drugs/ferric-maltol-feraccru_/\", \"rr_start\": \"2016-08-12T00:00:00\", \"rr_end\": \"2016-09-06T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-08-12, 2016-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Ferric maltol (Feraccru\", \"trade_name\": \"Feraccru\", \"indication\": \"Ferric maltol indicated for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) in adult patients.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Shield\", \"orphan\": 0, \"earliest\": \"2016-08-12T00:00:00\", \"latest\": \"2016-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/feraccru\", \"ta_list\": \"Anemia, Iron-Deficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2305, \"last_scrape\": \"2018-12-13T16:34:51\", \"url\": \"http://www.ncpe.ie/drugs/fidaxomicin-dificlir/\", \"rr_start\": \"2012-03-09T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2012-03-09, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Fidaxomicin (Dificlir\", \"trade_name\": \"Dificlir\", \"indication\": \"Fidaxomicin is indicated for the treatment of CDI also known as CDAD in adult patients.\", \"ncpe_year\": 2013, \"eu_market\": \"2011-12-05T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-03-09T00:00:00\", \"latest\": \"2013-02-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/dificlir\", \"ta_list\": \"Clostridium Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2306, \"last_scrape\": \"2018-12-13T16:34:56\", \"url\": \"http://www.ncpe.ie/drugs/fingolimod-gilenya-4/\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2010-12-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-01-10, 2010-12-03\", \"rr_multiple\": 0, \"drug_name\": \"Fingolimod (Gilenya\", \"trade_name\": \"Gilenya\", \"indication\": \"Cost effectiveness of Fingolimod (Gilenya\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2010-12-03T00:00:00\", \"latest\": \"2011-09-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2307, \"last_scrape\": \"2018-12-13T16:35:01\", \"url\": \"http://www.ncpe.ie/drugs/fluocinolone-acetonide-iluvien/\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-02-15, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Fluocinolone acetonide (Iluvien\", \"trade_name\": \"Iluvien\", \"indication\": \"Iluvien\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2308, \"last_scrape\": \"2018-12-13T16:35:05\", \"url\": \"http://www.ncpe.ie/drugs/fluticasone-furoate-umeclidinium-vilantero-trelegy-ellipta/\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT TRELEGY\", \"rr_dates\": \"2018-04-30, 2018-06-18\", \"rr_multiple\": 0, \"drug_name\": \"Fluticasone furoate/ umeclidinium/ vilantero (Trelegy\", \"trade_name\": \"Trelegy Ellipta\", \"indication\": \"Trelegy\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-15T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"Reimbursement without HTA\"}, {\"id\": 2309, \"last_scrape\": \"2018-12-13T16:35:09\", \"url\": \"http://www.ncpe.ie/drugs/follitropin-delta-rekovelle/\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-07-25, 2017-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Follitropin delta (Rekovelle\", \"trade_name\": \"Rekovelle\", \"indication\": \"Follitropin delta (Rekovelle \", \"ncpe_year\": 2019, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2019-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rekovelle\", \"ta_list\": \"Anovulation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2310, \"last_scrape\": \"2018-12-13T16:35:12\", \"url\": \"http://www.ncpe.ie/drugs/gefitinib-iressa/\", \"rr_start\": \"\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Gefitinib (Iressa\", \"trade_name\": \"Iressa\", \"indication\": \"A review of the economic evaluation of oral gefitinib (Iressa\", \"ncpe_year\": 2010, \"eu_market\": \"2009-06-24T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-16T00:00:00\", \"latest\": \"2010-11-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/iressa\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2311, \"last_scrape\": \"2018-12-13T16:35:15\", \"url\": \"http://www.ncpe.ie/drugs/gemtuzumab-ozogamicin-mylotarg/\", \"rr_start\": \"2018-06-21T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF GEMTUZUMAB OZOGAMICIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-21, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Gemtuzumab ozogamicin (Mylotarg\", \"trade_name\": \"Mylotarg\", \"indication\": \"Gemtuzumab ozogamicin (Mylotarg\", \"ncpe_year\": 2018, \"eu_market\": \"2018-04-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-06-21T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2312, \"last_scrape\": \"2018-12-13T16:35:19\", \"url\": \"http://www.ncpe.ie/drugs/glecaprevirpibrentasvir-maviret/\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-07-11, 2017-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glecaprevir/Pibrentasvir (Maviret\", \"trade_name\": \"Maviret\", \"indication\": \"Glecaprevir/pibrentasvir (Maviret\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/maviret\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2313, \"last_scrape\": \"2018-12-13T16:35:25\", \"url\": \"http://www.ncpe.ie/drugs/glucosamine-sulfate-dona/\", \"rr_start\": \"\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Glucosamine sulfate (Dona\", \"trade_name\": \"Dona\", \"indication\": \"Economic evalution of glucosamine sulfate (Dona\", \"ncpe_year\": 2009, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2009-04-01T00:00:00\", \"latest\": \"2009-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2314, \"last_scrape\": \"2018-12-13T16:35:32\", \"url\": \"http://www.ncpe.ie/drugs/glycerol-phenylbutyrate-ravicti/\", \"rr_start\": \"2018-03-26T00:00:00\", \"rr_end\": \"2018-06-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT GLYCEROL PHENYLBUTYRATE (RAVICTI\", \"rr_dates\": \"2018-03-26, 2018-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Glycerol Phenylbutyrate (Ravicti\", \"trade_name\": \"Ravicti\", \"indication\": \"Glycerol phenylbutyrate (Ravicti\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-26T00:00:00\", \"company\": \"Horizon\", \"orphan\": 1, \"earliest\": \"2018-03-26T00:00:00\", \"latest\": \"2018-06-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti\", \"ta_list\": \"Urea Cycle Disorders, Inborn\", \"rr_status\": \"Reimbursement without HTA\"}, {\"id\": 2315, \"last_scrape\": \"2018-12-13T16:35:38\", \"url\": \"http://www.ncpe.ie/drugs/glycopyrronium-bromide-seebri-breezhaler/\", \"rr_start\": \"2012-08-12T00:00:00\", \"rr_end\": \"2012-08-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-08-12, 2012-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide (Seebri Breezhaler\", \"trade_name\": \"Seebri Breezhaler\", \"indication\": \"Seebri Breezhaler\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-08-12T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"id\": 2316, \"last_scrape\": \"2018-12-13T16:35:40\", \"url\": \"http://www.ncpe.ie/drugs/glypyrronium-bromide-sialanar/\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-07, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide (Sialanar\", \"trade_name\": \"Sialanar\", \"indication\": \"Glycopyrronium bromide (Sialanar\", \"ncpe_year\": 2017, \"eu_market\": \"2016-09-15T00:00:00\", \"company\": \"Proveca\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar\", \"ta_list\": \"Sialorrhea\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2317, \"last_scrape\": \"2018-12-13T16:35:47\", \"url\": \"http://www.ncpe.ie/drugs/golimumab-simponi-2/\", \"rr_start\": \"2013-10-11T00:00:00\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"FULL HTA NOT RECOMMENDED\", \"rr_dates\": \"2013-10-11, 2013-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab (Simponi\", \"trade_name\": \"Simponi\", \"indication\": \"Golimumab is indicated for the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments.\", \"ncpe_year\": 2013, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2013-10-11T00:00:00\", \"latest\": \"2013-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/simponi\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"id\": 2318, \"last_scrape\": \"2018-12-13T16:35:54\", \"url\": \"http://www.ncpe.ie/drugs/golimumab-simponi/\", \"rr_start\": \"\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab (Simponi\", \"trade_name\": \"Simponi\", \"indication\": \"Cost-effectiveness of golimumab (Simponi\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2009-11-20T00:00:00\", \"latest\": \"2010-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/simponi\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2319, \"last_scrape\": \"2018-12-13T16:35:56\", \"url\": \"http://www.ncpe.ie/drugs/grass-pollen-allergen-extract-oralair/\", \"rr_start\": \"2011-10-11T00:00:00\", \"rr_end\": \"2011-09-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-10-11, 2011-09-26\", \"rr_multiple\": 0, \"drug_name\": \"Grass pollen allergen extract (Oralair\", \"trade_name\": \"Oralair\", \"indication\": \" Grass pollen allegen extract (Oralair\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-09-26T00:00:00\", \"latest\": \"2011-10-01T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2320, \"last_scrape\": \"2018-12-13T16:36:00\", \"url\": \"http://www.ncpe.ie/drugs/guanfacine-hydrochloride-intuniv/\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-01, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Guanfacine hydrochloride (Intuniv\", \"trade_name\": \"Intuniv\", \"indication\": \"Intuniv\", \"ncpe_year\": 2015, \"eu_market\": \"2015-09-17T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/intuniv\", \"ta_list\": \"Attention Deficit Disorder with Hyperactivity\", \"rr_status\": \"No HTA\"}, {\"id\": 2321, \"last_scrape\": \"2018-12-13T16:36:02\", \"url\": \"http://www.ncpe.ie/drugs/guselkumab-tremfya/\", \"rr_start\": \"2017-12-01T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-12-01, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Guselkumab (Tremfya\", \"trade_name\": \"Tremfya\", \"indication\": \"Guselkumab (Tremfya\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-10T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-12-01T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2322, \"last_scrape\": \"2018-12-13T16:36:07\", \"url\": \"http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-a1pi-prolastin/\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-06-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-05, 2017-06-08\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor (A1PI) (Prolastin\", \"trade_name\": \"Prolastin\", \"indication\": \"Human A1PI (Prolastin \", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-06-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2323, \"last_scrape\": \"2018-12-13T16:36:14\", \"url\": \"http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-respreeza/\", \"rr_start\": \"2016-01-20T00:00:00\", \"rr_end\": \"2016-02-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-20, 2016-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor (Respreeza\", \"trade_name\": \"Respreeza\", \"indication\": \"Respreeza\", \"ncpe_year\": 2017, \"eu_market\": \"2015-08-20T00:00:00\", \"company\": \"CSL\", \"orphan\": 0, \"earliest\": \"2016-01-20T00:00:00\", \"latest\": \"2017-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza\", \"ta_list\": \"Genetic Diseases, Inborn; Lung Diseases\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2324, \"last_scrape\": \"2018-12-13T16:36:17\", \"url\": \"http://www.ncpe.ie/drugs/hyaluronic-acid-and-co-enzyme-q10-visuxl/\", \"rr_start\": \"2017-11-06T00:00:00\", \"rr_end\": \"2017-11-30T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-11-06, 2017-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Hyaluronic acid and co enzyme Q10 (VisuXL\", \"trade_name\": \"VisuXL\", \"indication\": \"Cross linked hyaluronic acid and co enzyme Q10 (VisuXL\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-11-06T00:00:00\", \"latest\": \"2017-11-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2325, \"last_scrape\": \"2018-12-13T16:36:22\", \"url\": \"http://www.ncpe.ie/drugs/hydrocortisone-plenadren/\", \"rr_start\": \"2017-11-08T00:00:00\", \"rr_end\": \"2017-11-01T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-11-08, 2018-01-11, 2017-11-01\", \"rr_multiple\": 1, \"drug_name\": \"Modified Release Hydrocortisone  (Plenadren\", \"trade_name\": \"Plenadren\", \"indication\": \"Modified release hydrocortisone (Plenadren\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-03T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2018-01-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/plenadren\", \"ta_list\": \"Adrenal Insufficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2326, \"last_scrape\": \"2018-12-13T16:36:27\", \"url\": \"http://www.ncpe.ie/drugs/hydroxcarbamide-siklos/\", \"rr_start\": \"2011-08-22T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-08-22, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Hydroxycarbamide (Siklos\", \"trade_name\": \"Siklos\", \"indication\": \" Hydroxycarbamide (Siklos\", \"ncpe_year\": 2011, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"Addmedica\", \"orphan\": 1, \"earliest\": \"2011-08-22T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/siklos\", \"ta_list\": \"Anemia, Sickle Cell\", \"rr_status\": \"No HTA\"}, {\"id\": 2327, \"last_scrape\": \"2018-12-13T16:36:32\", \"url\": \"http://www.ncpe.ie/drugs/ibrutinib-imbruivca-for-previously-untreated-cll/\", \"rr_start\": \"2016-08-02T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-08-02, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib (Imbruvica\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib (Imbruvica\", \"ncpe_year\": 2016, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-08-02T00:00:00\", \"latest\": \"2016-08-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2328, \"last_scrape\": \"2018-12-13T16:36:36\", \"url\": \"http://www.ncpe.ie/drugs/ibrutinib-imbruvica-for-mcl/\", \"rr_start\": \"2014-11-07T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-11-07, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib (Imbruvica\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib (Imbruvica\", \"ncpe_year\": 2015, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-11-07T00:00:00\", \"latest\": \"2015-10-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2329, \"last_scrape\": \"2018-12-13T16:36:40\", \"url\": \"http://www.ncpe.ie/drugs/icatibant-firazyr/\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Icatibant (Firazyr\", \"trade_name\": \"Firazyr\", \"indication\": \"Icatibant (Firazyr\", \"ncpe_year\": 2013, \"eu_market\": \"2008-07-11T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"id\": 2330, \"last_scrape\": \"2018-12-13T16:36:43\", \"url\": \"http://www.ncpe.ie/drugs/idarucizumab-praxbind/\", \"rr_start\": \"2015-12-11T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-11, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Idarucizumab (Praxbind\", \"trade_name\": \"Praxbind\", \"indication\": \"Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required:\", \"ncpe_year\": 2015, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-12-11T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/praxbind\", \"ta_list\": \"Hemorrhage\", \"rr_status\": \"No HTA\"}, {\"id\": 2331, \"last_scrape\": \"2018-12-13T16:36:50\", \"url\": \"http://www.ncpe.ie/drugs/idebenone-raxone/\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-04-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-10, 2016-04-14\", \"rr_multiple\": 0, \"drug_name\": \"Idebenone (Raxone\", \"trade_name\": \"Raxone\", \"indication\": \"Raxone\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-08T00:00:00\", \"company\": \"Santhera\", \"orphan\": 1, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2018-08-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/raxone\", \"ta_list\": \"Optic Atrophy, Hereditary, Leber\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2332, \"last_scrape\": \"2018-12-13T16:36:56\", \"url\": \"http://www.ncpe.ie/drugs/idelalisib-zydelig/\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2014-12-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-08, 2014-12-30\", \"rr_multiple\": 0, \"drug_name\": \"Idelalisib (Zydelig\", \"trade_name\": \"Zydelig\", \"indication\": \"Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2016-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2333, \"last_scrape\": \"2018-12-13T16:36:59\", \"url\": \"http://www.ncpe.ie/drugs/imiquimod-zyclara/\", \"rr_start\": \"2013-09-10T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-09-10, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Imiquimod 3.75% (Zyclara\", \"trade_name\": \"Zyclara\", \"indication\": \"Imiquimod 3.75%(Zyclara\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Meda\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara\", \"ta_list\": \"Keratosis; Keratosis, Actinic\", \"rr_status\": \"No HTA\"}, {\"id\": 2334, \"last_scrape\": \"2018-12-13T16:37:01\", \"url\": \"http://www.ncpe.ie/drugs/incobotulinum-toxin-type-a-xeomin/\", \"rr_start\": \"2014-02-07T00:00:00\", \"rr_end\": \"2014-03-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-07, 2014-03-05\", \"rr_multiple\": 0, \"drug_name\": \"Incobotulinum Toxin Type A (Xeomin\", \"trade_name\": \"Xeomin\", \"indication\": \"Incobotulinum Toxin Type A (Xeomin\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-02-07T00:00:00\", \"latest\": \"2014-03-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2335, \"last_scrape\": \"2018-12-13T16:37:04\", \"url\": \"http://www.ncpe.ie/drugs/indacaterol-onbrez/\", \"rr_start\": \"2010-01-15T00:00:00\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-01-15\", \"rr_multiple\": 0, \"drug_name\": \"Indacaterol (Onbrez\", \"trade_name\": \"Onbrez\", \"indication\": \"Review of Indacaterol (Onbrez\", \"ncpe_year\": 2010, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-01-15T00:00:00\", \"latest\": \"2010-01-15T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2336, \"last_scrape\": \"2018-12-13T16:37:07\", \"url\": \"http://www.ncpe.ie/drugs/infliximab-inflectra/\", \"rr_start\": \"\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Infliximab (Inflectra\", \"trade_name\": \"Inflectra\", \"indication\": \"Inflectra\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2337, \"last_scrape\": \"2018-12-13T16:37:09\", \"url\": \"http://www.ncpe.ie/drugs/inotuzumab-ozogamicin-besponsa/\", \"rr_start\": \"2017-07-03T00:00:00\", \"rr_end\": \"2017-09-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-03, 2017-09-08\", \"rr_multiple\": 0, \"drug_name\": \"Inotuzumab ozogamicin (Besponsa\", \"trade_name\": \"Besponsa\", \"indication\": \"Inotuzumab ozogamicin (Besponsa\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2017-07-03T00:00:00\", \"latest\": \"2018-09-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2338, \"last_scrape\": \"2018-12-13T16:37:16\", \"url\": \"http://www.ncpe.ie/drugs/insulin-aspart-fiasp/\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-05-17, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart (Fiasp\", \"trade_name\": \"Fiasp\", \"indication\": \"Insulin aspart (Fiasp\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-09T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fiasp\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"No HTA\"}, {\"id\": 2339, \"last_scrape\": \"2018-12-13T16:37:21\", \"url\": \"http://www.ncpe.ie/drugs/insulin-aspart-novorapid-flextouch/\", \"rr_start\": \"2014-07-22T00:00:00\", \"rr_end\": \"2014-08-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2014-07-22, 2014-08-28\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart (NovoRapid\", \"trade_name\": \"NovoRapid FlexTouch\", \"indication\": \"Insulin aspart (NovoRapid\", \"ncpe_year\": 2014, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2014-07-22T00:00:00\", \"latest\": \"2014-08-28T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2340, \"last_scrape\": \"2018-12-13T16:37:25\", \"url\": \"http://www.ncpe.ie/drugs/insulin-degludec-tresiba/\", \"rr_start\": \"2012-12-17T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-12-17, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Degludec (Tresiba\", \"trade_name\": \"Tresiba\", \"indication\": \"Treatment of diabetes mellitus\", \"ncpe_year\": 2015, \"eu_market\": \"2013-01-20T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2012-12-17T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2341, \"last_scrape\": \"2018-12-13T16:37:30\", \"url\": \"http://www.ncpe.ie/drugs/insulin-degludecliraglutide-ideglira-xultophy/\", \"rr_start\": \"2016-09-19T00:00:00\", \"rr_end\": \"2016-10-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-09-19, 2016-10-17\", \"rr_multiple\": 0, \"drug_name\": \"Insulin degludec/liraglutide (IDegLira) (Xultophy\", \"trade_name\": \"Xultophy\", \"indication\": \"IDegLira is indicated for the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2016-09-19T00:00:00\", \"latest\": \"2016-10-17T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xultophy\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2342, \"last_scrape\": \"2018-12-13T16:37:36\", \"url\": \"http://www.ncpe.ie/drugs/insulin-glargine-abasaglar/\", \"rr_start\": \"2015-09-04T00:00:00\", \"rr_end\": \"2015-10-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-09-04, 2015-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine (Abasaglar\", \"trade_name\": \"Abasaglar\", \"indication\": \"Abasaglar\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-09-04T00:00:00\", \"latest\": \"2015-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2343, \"last_scrape\": \"2018-12-13T16:37:40\", \"url\": \"http://www.ncpe.ie/drugs/insulin-glargine-u300-toujeo/\", \"rr_start\": \"2015-05-14T00:00:00\", \"rr_end\": \"2015-07-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2015-05-14, 2015-07-02\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine U300 (Toujeo\", \"trade_name\": \"Toujeo\", \"indication\": \"Toujeo\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-05-14T00:00:00\", \"latest\": \"2015-07-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2344, \"last_scrape\": \"2018-12-13T16:37:43\", \"url\": \"http://www.ncpe.ie/drugs/ipilimumab-yervoy/\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Ipilimumab (Yervoy\", \"trade_name\": \"Yervoy\", \"indication\": \"Pharmacoeconomic evaluation of Ipilimumab (Yervoy\", \"ncpe_year\": 2013, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2013-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2345, \"last_scrape\": \"2018-12-13T16:37:49\", \"url\": \"http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-diafer/\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron (III) isomaltoside 1000 (Diafer\", \"trade_name\": \"Diafer\", \"indication\": \"Diafer\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2346, \"last_scrape\": \"2018-12-13T16:37:52\", \"url\": \"http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-monover/\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron (III) isomaltoside 1000 (Monover\", \"trade_name\": \"Monover\", \"indication\": \"Monover\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2347, \"last_scrape\": \"2018-12-13T16:38:02\", \"url\": \"http://www.ncpe.ie/drugs/iron-isomaltoside-1000-monover/\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2011-02-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-01-10, 2011-02-02\", \"rr_multiple\": 0, \"drug_name\": \"Iron isomaltoside 1000 (MonoVer\", \"trade_name\": \"MonoVer\", \"indication\": \"MonoVer is indicated for the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-01-10T00:00:00\", \"latest\": \"2011-02-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2348, \"last_scrape\": \"2018-12-13T16:38:07\", \"url\": \"http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-invasive-aspergillosis/\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole (Cresemba\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole (Cresemba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2349, \"last_scrape\": \"2018-12-13T16:38:09\", \"url\": \"http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-mucormycosis/\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole (Cresemba\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole (Cresemba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2350, \"last_scrape\": \"2018-12-13T16:38:15\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kaldeco/\", \"rr_start\": \"2012-08-13T00:00:00\", \"rr_end\": \"2012-08-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-08-13, 2012-08-22\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2012-08-13T00:00:00\", \"latest\": \"2013-01-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2351, \"last_scrape\": \"2018-12-13T16:38:21\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-patients-with-cf-2-years/\", \"rr_start\": \"2015-11-19T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMAOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-19, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\", \"ncpe_year\": 2016, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2015-11-19T00:00:00\", \"latest\": \"2016-10-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2352, \"last_scrape\": \"2018-12-13T16:38:24\", \"url\": \"http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-the-treatment-of-cf-patients-with-the-r117h-mutation/\", \"rr_start\": \"2016-01-14T00:00:00\", \"rr_end\": \"2016-02-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-14, 2016-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor (Kalydeco\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\", \"ncpe_year\": 2017, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2016-01-14T00:00:00\", \"latest\": \"2017-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2353, \"last_scrape\": \"2018-12-13T16:38:29\", \"url\": \"http://www.ncpe.ie/drugs/ixazomib-ninlaro/\", \"rr_start\": \"2016-11-23T00:00:00\", \"rr_end\": \"2017-01-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-23, 2017-01-16\", \"rr_multiple\": 0, \"drug_name\": \"Ixazomib (Ninlaro\", \"trade_name\": \"Ninlaro\", \"indication\": \"Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-21T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2016-11-23T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2354, \"last_scrape\": \"2018-12-13T16:38:34\", \"url\": \"http://www.ncpe.ie/drugs/ixekizumab-taltz-for-psoriatic-arthritis/\", \"rr_start\": \"2018-10-16T00:00:00\", \"rr_end\": \"2018-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT IXEKIZUMAB NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE. THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013\", \"rr_dates\": \"2018-10-16, 2018-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab (Taltz\", \"trade_name\": \"Taltz\", \"indication\": \"Ixekizumab (Taltz\", \"ncpe_year\": 2018, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2018-10-16T00:00:00\", \"latest\": \"2018-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/taltz\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2355, \"last_scrape\": \"2018-12-13T16:38:37\", \"url\": \"http://www.ncpe.ie/drugs/ixekizumab-taltz/\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-26T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-06-28, 2016-07-26\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab (Taltz\", \"trade_name\": \"Taltz\", \"indication\": \"Taltz\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/taltz\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2356, \"last_scrape\": \"2018-12-13T16:38:39\", \"url\": \"http://www.ncpe.ie/drugs/l/lisdexamfetamine-dimesylate-tyvense/\", \"rr_start\": \"2013-02-09T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-02-09, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Lisdexamfetamine dimesylate (Tyvense\", \"trade_name\": \"Tyvense\", \"indication\": \"Lisdexamfetamine dimesylate (Tyvense\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-02-09T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2357, \"last_scrape\": \"2018-12-13T16:38:44\", \"url\": \"http://www.ncpe.ie/drugs/lacosamide-vimpat/\", \"rr_start\": \"2017-09-11T00:00:00\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-09-11, 2017-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Lacosamide (Vimpat \", \"trade_name\": \"Vimpat\", \"indication\": \"Vimpat \", \"ncpe_year\": 2017, \"eu_market\": \"2008-08-29T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2017-09-11T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2358, \"last_scrape\": \"2018-12-13T16:38:50\", \"url\": \"http://www.ncpe.ie/drugs/lapatinib-tyverb/\", \"rr_start\": \"\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Lapatinib (Tyverb\", \"trade_name\": \"Tyverb\", \"indication\": \"Cost-effectiveness of Lapatinib (Tyverb\", \"ncpe_year\": 2008, \"eu_market\": \"2008-06-10T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2359, \"last_scrape\": \"2018-12-13T16:38:56\", \"url\": \"http://www.ncpe.ie/drugs/ledipasvirsofosbuvir-harvoni/\", \"rr_start\": \"2014-11-14T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-11-14, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ledipasvir/sofosbuvir (Harvoni\", \"trade_name\": \"Harvoni\", \"indication\": \"Ledipasvir/sofosbuvir (Harvoni\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-17T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-11-14T00:00:00\", \"latest\": \"2015-11-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2360, \"last_scrape\": \"2018-12-13T16:39:05\", \"url\": \"http://www.ncpe.ie/drugs/lenalidomide-revlimid/\", \"rr_start\": \"2015-10-05T00:00:00\", \"rr_end\": \"2015-11-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE.\", \"rr_dates\": \"2015-10-05, 2015-11-20\", \"rr_multiple\": 0, \"drug_name\": \"Lenalidomide (Revlimid\", \"trade_name\": \"Revlimid\", \"indication\": \"Revlimid\", \"ncpe_year\": 2018, \"eu_market\": \"2007-06-14T00:00:00\", \"company\": \"Celgene\", \"orphan\": 1, \"earliest\": \"2015-10-05T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid\", \"ta_list\": \"Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2361, \"last_scrape\": \"2018-12-13T16:39:07\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-kisplyx/\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-05-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-05-05, 2017-05-18\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Kisplyx\", \"trade_name\": \"Kisplyx\", \"indication\": \"Lenvatinib (Kisplyx\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-25T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-05-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2362, \"last_scrape\": \"2018-12-13T16:39:11\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-lenvima-2/\", \"rr_start\": \"2018-08-07T00:00:00\", \"rr_end\": \"2018-08-16T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF LENVATINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-08-07, 2018-08-16\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Lenvima\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib (Lenvima\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2018-08-07T00:00:00\", \"latest\": \"2018-08-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2363, \"last_scrape\": \"2018-12-13T16:39:15\", \"url\": \"http://www.ncpe.ie/drugs/lenvatinib-lenvima/\", \"rr_start\": \"2015-05-05T00:00:00\", \"rr_end\": \"2015-07-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2015-05-05, 2015-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib (Lenvima\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/H\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2015-05-05T00:00:00\", \"latest\": \"2015-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2364, \"last_scrape\": \"2018-12-13T16:39:20\", \"url\": \"http://www.ncpe.ie/drugs/lesinurad-zurampic/\", \"rr_start\": \"2017-03-15T00:00:00\", \"rr_end\": \"2017-03-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-15, 2017-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Lesinurad (Zurampic\", \"trade_name\": \"Zurampic\", \"indication\": \"Lesinurad (Zurampic\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Gr\", \"orphan\": 0, \"earliest\": \"2017-03-15T00:00:00\", \"latest\": \"2018-12-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zurampic\", \"ta_list\": \"Hyperuricemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2365, \"last_scrape\": \"2018-12-13T16:39:25\", \"url\": \"http://www.ncpe.ie/drugs/letermovir-prevymis/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Letermovir (Prevymis\", \"trade_name\": \"Prevymis\", \"indication\": \"Letermovir for the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevymis\", \"ta_list\": \"Cytomegalovirus Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2366, \"last_scrape\": \"2018-12-13T16:39:28\", \"url\": \"http://www.ncpe.ie/drugs/levodopa-20mgml-carbidopa-monohydrate-5mg-intestinal-gel-duodopa/\", \"rr_start\": \"2013-03-13T00:00:00\", \"rr_end\": \"2013-04-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-03-13, 2013-04-16\", \"rr_multiple\": 0, \"drug_name\": \"Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel (Duodopa\", \"trade_name\": \"Duodopa\", \"indication\": \"For the treatment of advanced levodopa-responsive Parkinson\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-13T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2367, \"last_scrape\": \"2018-12-13T16:39:34\", \"url\": \"http://www.ncpe.ie/drugs/levofloxacin-quinsair/\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-02-10, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Levofloxacin (Quinsair\", \"trade_name\": \"Quinsair\", \"indication\": \"Levofloxacin (Quinsair\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-25T00:00:00\", \"company\": \"Horizon\", \"orphan\": 0, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/quinsair\", \"ta_list\": \"Cystic Fibrosis; Respiratory Tract Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2368, \"last_scrape\": \"2018-12-13T16:39:39\", \"url\": \"http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-delivery-system-lng-ius-12-kyleena/\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-02-08, 2017-03-16\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine delivery system LNG IUS 12 (Kyleena\", \"trade_name\": \"Kyleena\", \"indication\": \"Kyleena\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2017-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2369, \"last_scrape\": \"2018-12-13T16:39:44\", \"url\": \"http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-system-lng-ius-jaydess/\", \"rr_start\": \"2013-03-07T00:00:00\", \"rr_end\": \"2013-03-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-03-07, 2013-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine system LNG-IUS (Jaydess\", \"trade_name\": \"Jaydess\", \"indication\": \"Levonorgestrel Intrauterine System LNG-IUS (Jaydess\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-07T00:00:00\", \"latest\": \"2013-03-25T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2370, \"last_scrape\": \"2018-12-13T16:39:46\", \"url\": \"http://www.ncpe.ie/drugs/lidocaine-5-plasters-versatis/\", \"rr_start\": \"2010-09-09T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2010-09-09, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Lidocaine 5% plasters (Versatis\", \"trade_name\": \"Versatis\", \"indication\": \"Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN).\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-09-09T00:00:00\", \"latest\": \"2015-09-24T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2371, \"last_scrape\": \"2018-12-13T16:39:51\", \"url\": \"http://www.ncpe.ie/drugs/linaclotide-clonstella/\", \"rr_start\": \"2013-05-28T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-05-28, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Linaclotide (Constella\", \"trade_name\": \"Constella\", \"indication\": \"Linaclotide (Constella\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2013-05-28T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/constella\", \"ta_list\": \"Irritable Bowel Syndrome\", \"rr_status\": \"No HTA\"}, {\"id\": 2372, \"last_scrape\": \"2018-12-13T16:39:54\", \"url\": \"http://www.ncpe.ie/drugs/linagliptin-trajenta/\", \"rr_start\": \"2011-08-18T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-08-18, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Linagliptin (Trajenta\", \"trade_name\": \"Trajenta\", \"indication\": \"Lingagliptin (Trajenta\", \"ncpe_year\": 2011, \"eu_market\": \"2011-08-23T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2011-08-18T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2373, \"last_scrape\": \"2018-12-13T16:39:57\", \"url\": \"http://www.ncpe.ie/drugs/lipegfilgrastim-lonquex/\", \"rr_start\": \"2013-08-20T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-08-20, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Lipegfilgrastim (Lonquex\", \"trade_name\": \"Lonquex\", \"indication\": \"Lonquex\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-25T00:00:00\", \"company\": \"Sicor\", \"orphan\": 0, \"earliest\": \"2013-08-20T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex\", \"ta_list\": \"Neutropenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2374, \"last_scrape\": \"2018-12-13T16:40:00\", \"url\": \"http://www.ncpe.ie/drugs/liposomal-daunorubicin-and-cytarabine-cpx-351vyxeos/\", \"rr_start\": \"2018-09-28T00:00:00\", \"rr_end\": \"2018-11-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-09-28, 2018-11-08\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos\", \"trade_name\": \"Vyxeos\", \"indication\": \"Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Jazz\", \"orphan\": 1, \"earliest\": \"2018-09-28T00:00:00\", \"latest\": \"2018-11-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2375, \"last_scrape\": \"2018-12-13T16:40:06\", \"url\": \"http://www.ncpe.ie/drugs/liposomal-irinotecan-nal-iri-onivyde/\", \"rr_start\": \"2017-06-13T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-13, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal irinotecan (Onivyde\", \"trade_name\": \"Onivyde\", \"indication\": \"Liposomal irinotecan (Onivyde\", \"ncpe_year\": 2017, \"eu_market\": \"2016-10-14T00:00:00\", \"company\": \"Baxalta\", \"orphan\": 1, \"earliest\": \"2017-06-13T00:00:00\", \"latest\": \"2017-07-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-0\", \"ta_list\": \"Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2376, \"last_scrape\": \"2018-12-13T16:40:09\", \"url\": \"http://www.ncpe.ie/drugs/liquid-paraffin-ointment-vita-pos-opthalmic/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Liquid Paraffin Ointment (VitA-POS Opthalmic\", \"trade_name\": \"VitA-POS Opthalmic\", \"indication\": \"Liquid Paraffin Ointment (VitA-POS Opthalmic\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2377, \"last_scrape\": \"2018-12-13T16:40:13\", \"url\": \"http://www.ncpe.ie/drugs/liraglutide-victoza/\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-10-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-09-01, 2009-10-07\", \"rr_multiple\": 0, \"drug_name\": \"Liraglutide (Victoza\", \"trade_name\": \"Victoza\", \"indication\": \"Victoza\", \"ncpe_year\": 2018, \"eu_market\": \"2009-06-30T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2009-09-01T00:00:00\", \"latest\": \"2018-10-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/victoza\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"id\": 2378, \"last_scrape\": \"2018-12-13T16:40:17\", \"url\": \"http://www.ncpe.ie/drugs/lixisenatide-lyxumia/\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Lixisenatide (Lyxumia\", \"trade_name\": \"Lyxumia\", \"indication\": \"Lixisenatide (Lyxumia\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-08-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2379, \"last_scrape\": \"2018-12-13T16:40:19\", \"url\": \"http://www.ncpe.ie/drugs/lomitapide-lojuxta/\", \"rr_start\": \"2014-09-09T00:00:00\", \"rr_end\": \"2014-09-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-09-09, 2014-09-15\", \"rr_multiple\": 0, \"drug_name\": \"Lomitapide (Lojuxta\", \"trade_name\": \"Lojuxta\", \"indication\": \"Lojuxta\", \"ncpe_year\": 2014, \"eu_market\": \"2013-07-31T00:00:00\", \"company\": \"Amryt\", \"orphan\": 0, \"earliest\": \"2014-09-09T00:00:00\", \"latest\": \"2014-09-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2380, \"last_scrape\": \"2018-12-13T16:40:22\", \"url\": \"http://www.ncpe.ie/drugs/lornoxicam-xefo/\", \"rr_start\": \"2011-06-23T00:00:00\", \"rr_end\": \"2011-07-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-06-23, 2011-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Lornoxicam (Xefo\", \"trade_name\": \"Xefo\", \"indication\": \" Lornoxicam (Xefo\", \"ncpe_year\": 2011, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-06-23T00:00:00\", \"latest\": \"2011-07-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA\"}, {\"id\": 2381, \"last_scrape\": \"2018-12-13T16:40:24\", \"url\": \"http://www.ncpe.ie/drugs/lotemax-0-5-eye-drops-suspension-loteprednol/\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2011-12-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-11-15, 2011-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Lotemax 0.5% eye drops suspension (Loteprednol)\", \"trade_name\": \"Loteprednol\", \"indication\": \" Indicated for treatment of post-operative inflammation following ocular surgery.\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2011-12-05T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2382, \"last_scrape\": \"2018-12-13T16:40:30\", \"url\": \"http://www.ncpe.ie/drugs/loxapine-inhalation-powder-adasuve/\", \"rr_start\": \"2016-06-21T00:00:00\", \"rr_end\": \"2016-07-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-06-21, 2016-07-28\", \"rr_multiple\": 0, \"drug_name\": \"Loxapine inhalation powder (Adasuve\", \"trade_name\": \"Adasuve\", \"indication\": \"Inhaled loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-02-20T00:00:00\", \"company\": \"Ferrer\", \"orphan\": 0, \"earliest\": \"2016-06-21T00:00:00\", \"latest\": \"2016-07-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve\", \"ta_list\": \"Schizophrenia; Bipolar Disorder\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2383, \"last_scrape\": \"2018-12-13T16:40:34\", \"url\": \"http://www.ncpe.ie/drugs/lumacaftorivacaftor-orkambi/\", \"rr_start\": \"2015-11-26T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-26, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Lumacaftor/ivacaftor (Orkambi\", \"trade_name\": \"Orkambi\", \"indication\": \"Orkambi\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Vertex\", \"orphan\": 0, \"earliest\": \"2015-11-26T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/orkambi\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2384, \"last_scrape\": \"2018-12-13T16:40:36\", \"url\": \"http://www.ncpe.ie/drugs/lutetium-177lu-oxodotreotide-lutathera/\", \"rr_start\": \"2018-10-23T00:00:00\", \"rr_end\": \"2018-11-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-10-23, 2018-11-16\", \"rr_multiple\": 0, \"drug_name\": \"Lutetium (177Lu) Oxodotreotide (Lutathera\", \"trade_name\": \"Lutathera\", \"indication\": \"Lutetium (177Lu) Oxodotreotide (Lutathera\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-26T00:00:00\", \"company\": \"Advanced\", \"orphan\": 1, \"earliest\": \"2018-10-23T00:00:00\", \"latest\": \"2018-11-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2385, \"last_scrape\": \"2018-12-13T16:40:41\", \"url\": \"http://www.ncpe.ie/drugs/macitentan-opsumit/\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-10, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Macitentan (Opsumit\", \"trade_name\": \"Opsumit\", \"indication\": \"Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-12-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2386, \"last_scrape\": \"2018-12-13T16:40:43\", \"url\": \"http://www.ncpe.ie/drugs/melatonin-circadin/\", \"rr_start\": \"\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Melatonin (Circadin\", \"trade_name\": \"Circadin\", \"indication\": \"A Review of the Economic Evaluation of Prolonged Release Melatonin (Circadin\", \"ncpe_year\": 2008, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"RAD\", \"orphan\": 0, \"earliest\": \"2008-08-01T00:00:00\", \"latest\": \"2008-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/circadin\", \"ta_list\": \"Sleep Initiation and Maintenance Disorders\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2387, \"last_scrape\": \"2018-12-13T16:40:45\", \"url\": \"http://www.ncpe.ie/drugs/mepolizumab-nucala/\", \"rr_start\": \"2016-03-16T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-03-16, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Mepolizumab (Nucala\", \"trade_name\": \"Nucala\", \"indication\": \"Mepolizumab (Nucala\", \"ncpe_year\": 2018, \"eu_market\": \"2015-12-01T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-03-16T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nucala\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2388, \"last_scrape\": \"2018-12-13T16:40:51\", \"url\": \"http://www.ncpe.ie/drugs/methoxyflurane-penthrox/\", \"rr_start\": \"2015-11-23T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-11-23, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Methoxyflurane (Penthrox\", \"trade_name\": \"Penthrox\", \"indication\": \"Penthrox\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2015-11-23T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"id\": 2389, \"last_scrape\": \"2018-12-13T16:40:56\", \"url\": \"http://www.ncpe.ie/drugs/midostaurin-rydapt-for-aml/\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF MIDOSTAURIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin (Rydapt\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin (Rydapt\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2390, \"last_scrape\": \"2018-12-13T16:41:02\", \"url\": \"http://www.ncpe.ie/drugs/midostaurin-rydapt-for-asm/\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF MIDOSTAURIN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin (Rydapt\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin (Rydapt\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2391, \"last_scrape\": \"2018-12-13T16:41:04\", \"url\": \"http://www.ncpe.ie/drugs/mifamurtide-mepact/\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-07-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-06-22, 2010-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Mifamurtide (Mepact\", \"trade_name\": \"Mepact\", \"indication\": \"Mifamurtide (Meptact\", \"ncpe_year\": 2010, \"eu_market\": \"2009-03-06T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2010-06-22T00:00:00\", \"latest\": \"2010-07-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mepact\", \"ta_list\": \"Osteosarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2392, \"last_scrape\": \"2018-12-13T16:41:06\", \"url\": \"http://www.ncpe.ie/drugs/migalastat-galafold/\", \"rr_start\": \"2016-07-14T00:00:00\", \"rr_end\": \"2016-08-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-07-14, 2016-08-18\", \"rr_multiple\": 0, \"drug_name\": \"Migalastat (Galafold\", \"trade_name\": \"Galafold\", \"indication\": \"Migalastat is indicated for the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-05-25T00:00:00\", \"company\": \"Amicus\", \"orphan\": 1, \"earliest\": \"2016-07-14T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/galafold\", \"ta_list\": \"Fabry Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2393, \"last_scrape\": \"2018-12-13T16:41:13\", \"url\": \"http://www.ncpe.ie/drugs/mirabegron-betmiga/\", \"rr_start\": \"2012-12-19T00:00:00\", \"rr_end\": \"2013-03-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2012-12-19, 2013-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Mirabegron (Betmiga\", \"trade_name\": \"Betmiga\", \"indication\": \"Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome\", \"ncpe_year\": 2013, \"eu_market\": \"2012-12-20T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-12-19T00:00:00\", \"latest\": \"2013-03-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga\", \"ta_list\": \"Urinary Bladder, Overactive\", \"rr_status\": \"No HTA\"}, {\"id\": 2394, \"last_scrape\": \"2018-12-13T16:41:15\", \"url\": \"http://www.ncpe.ie/drugs/nab-paclitaxel-abraxane/\", \"rr_start\": \"2014-01-23T00:00:00\", \"rr_end\": \"2014-03-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-01-23, 2014-03-02\", \"rr_multiple\": 0, \"drug_name\": \"Nab-paclitaxel (Abraxane\", \"trade_name\": \"Abraxane\", \"indication\": \"Nab-paclitaxel (Abraxane\", \"ncpe_year\": 2015, \"eu_market\": \"2008-01-10T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2014-01-23T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane\", \"ta_list\": \"Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2395, \"last_scrape\": \"2018-12-13T16:41:18\", \"url\": \"http://www.ncpe.ie/drugs/nalmefene-selincro/\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Nalmefene (Selincro\", \"trade_name\": \"Selincro\", \"indication\": \"Nalmefene (Selincro\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-24T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2014-04-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/selincro\", \"ta_list\": \"Alcohol-Related Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2396, \"last_scrape\": \"2018-12-13T16:41:24\", \"url\": \"http://www.ncpe.ie/drugs/naloxegel-moventig/\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-04-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-02-10, 2015-04-13\", \"rr_multiple\": 0, \"drug_name\": \"Naloxegel (Moventig\", \"trade_name\": \"Moventig\", \"indication\": \"Naloxegel (Moventiq\", \"ncpe_year\": 2015, \"eu_market\": \"2014-12-07T00:00:00\", \"company\": \"Kyowa\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-04-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/moventig\", \"ta_list\": \"Constipation; Opioid-Related Disorders\", \"rr_status\": \"No HTA\"}, {\"id\": 2397, \"last_scrape\": \"2018-12-13T16:41:26\", \"url\": \"http://www.ncpe.ie/drugs/naltrexone-bupropion-mysimba/\", \"rr_start\": \"2017-03-12T00:00:00\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-12, 2017-03-28\", \"rr_multiple\": 0, \"drug_name\": \"Naltrexone / bupropion (Mysimba\", \"trade_name\": \"Mysimba\", \"indication\": \"Naltrexone / bupropion (Mysimba\", \"ncpe_year\": 2018, \"eu_market\": \"2015-03-26T00:00:00\", \"company\": \"Orexigen\", \"orphan\": 0, \"earliest\": \"2017-03-12T00:00:00\", \"latest\": \"2018-05-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba\", \"ta_list\": \"Obesity; Overweight\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2398, \"last_scrape\": \"2018-12-13T16:41:30\", \"url\": \"http://www.ncpe.ie/drugs/natalizumab-tysabri/\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Natalizumab (Tysabri\", \"trade_name\": \"Tysabri\", \"indication\": \" Economic Evaluation of Natalizumab (Tysabri\", \"ncpe_year\": 2007, \"eu_market\": \"2006-06-27T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2007-01-01T00:00:00\", \"latest\": \"2007-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2399, \"last_scrape\": \"2018-12-13T16:41:35\", \"url\": \"http://www.ncpe.ie/drugs/ncpe-inhaled-insulin-exubera-assessment/\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Inhaled insulin (Exubera\", \"trade_name\": \"Exubera\", \"indication\": \"In April 2006, Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin (Exubera\", \"ncpe_year\": 2006, \"eu_market\": \"2006-01-24T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-03-01T00:00:00\", \"latest\": \"2006-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/exubera\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2400, \"last_scrape\": \"2018-12-13T16:41:38\", \"url\": \"http://www.ncpe.ie/drugs/nepafenac-nevanac-2/\", \"rr_start\": \"2011-06-14T00:00:00\", \"rr_end\": \"2011-06-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-06-14, 2011-06-27\", \"rr_multiple\": 0, \"drug_name\": \"Nepafenac (Nevanac\", \"trade_name\": \"Nevanac\", \"indication\": \"Nepafenac (Nevanac\", \"ncpe_year\": 2011, \"eu_market\": \"2007-12-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2011-06-14T00:00:00\", \"latest\": \"2011-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac\", \"ta_list\": \"Pain, Postoperative; Ophthalmologic Surgical Procedures\", \"rr_status\": \"No HTA\"}, {\"id\": 2401, \"last_scrape\": \"2018-12-13T16:41:41\", \"url\": \"http://www.ncpe.ie/drugs/netupitantpalonosetron-akynzeo/\", \"rr_start\": \"2015-08-26T00:00:00\", \"rr_end\": \"2015-10-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-08-26, 2015-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Netupitant/palonosetron (Akynzeo\", \"trade_name\": \"Akynzeo\", \"indication\": \"Akynzeo\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Helsinn\", \"orphan\": 0, \"earliest\": \"2015-08-26T00:00:00\", \"latest\": \"2015-10-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo\", \"ta_list\": \"Vomiting; Cancer; Nausea\", \"rr_status\": \"No HTA\"}, {\"id\": 2402, \"last_scrape\": \"2018-12-13T16:41:44\", \"url\": \"http://www.ncpe.ie/drugs/nilotinib-tasigna-newly-diagnosed-cml/\", \"rr_start\": \"2010-10-06T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2010-10-06, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib (Tasigna\", \"trade_name\": \"Tasigna\", \"indication\": \"Nilotinib (Tasigna\", \"ncpe_year\": 2010, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-10-06T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2403, \"last_scrape\": \"2018-12-13T16:41:51\", \"url\": \"http://www.ncpe.ie/drugs/nilotinib-tasigna/\", \"rr_start\": \"\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib (Tasigna\", \"trade_name\": \"Tasigna\", \"indication\": \"Cost-effectiveness of Nilotinib (Tasigna\", \"ncpe_year\": 2008, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2404, \"last_scrape\": \"2018-12-13T16:41:53\", \"url\": \"http://www.ncpe.ie/drugs/nintedanib-ofev/\", \"rr_start\": \"2015-01-30T00:00:00\", \"rr_end\": \"2015-02-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-30, 2015-02-18\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib (Ofev\", \"trade_name\": \"Ofev\", \"indication\": \"Nintedanib (Ofev\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 1, \"earliest\": \"2015-01-30T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ofev\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2405, \"last_scrape\": \"2018-12-13T16:41:56\", \"url\": \"http://www.ncpe.ie/drugs/nintedanib-vargatef/\", \"rr_start\": \"2015-01-02T00:00:00\", \"rr_end\": \"2015-02-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-02, 2015-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib (Vargatef\", \"trade_name\": \"Vargatef\", \"indication\": \"Nintedanib (Vargatef\", \"ncpe_year\": 2017, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-01-02T00:00:00\", \"latest\": \"2017-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2406, \"last_scrape\": \"2018-12-13T16:42:00\", \"url\": \"http://www.ncpe.ie/drugs/niraparib-zejula/\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF NIRAPARIB COMPARED WITH THE CURRENT STANDARD OF CARE\", \"rr_dates\": \"2018-06-01, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Niraparib (Zejula\", \"trade_name\": \"Zejula\", \"indication\": \"Niraparib (Zejula\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-16T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 1, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zejula\", \"ta_list\": \"Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2407, \"last_scrape\": \"2018-12-13T16:42:06\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-melanoma/\", \"rr_start\": \"2015-05-28T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-05-28, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-05-28T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2408, \"last_scrape\": \"2018-12-13T16:42:13\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-non-squamous-nsclc/\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-03-03, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2409, \"last_scrape\": \"2018-12-13T16:42:20\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivio-for-nsclc/\", \"rr_start\": \"2015-07-02T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-07-02, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-07-02T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2410, \"last_scrape\": \"2018-12-13T16:42:26\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-as-monotherapy-for-the-adjuvant-treatment-of-adults-with-melanoma/\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF NIVOLUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-09, 2018-07-27\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-11-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2411, \"last_scrape\": \"2018-12-13T16:42:31\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-advanced-renal-cell-carcinoma/\", \"rr_start\": \"2016-04-27T00:00:00\", \"rr_end\": \"2016-05-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-04-27, 2016-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-04-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2412, \"last_scrape\": \"2018-12-13T16:42:33\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-classical-hodgkin-lymphoma/\", \"rr_start\": \"2016-11-22T00:00:00\", \"rr_end\": \"2017-01-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-11-22, 2017-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-11-22T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2413, \"last_scrape\": \"2018-12-13T16:42:36\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-head-and-neck-cancer/\", \"rr_start\": \"2017-05-03T00:00:00\", \"rr_end\": \"2017-05-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-05-03, 2017-05-30\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-05-03T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2414, \"last_scrape\": \"2018-12-13T16:42:41\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-for-urothelial-carcinoma/\", \"rr_start\": \"2017-06-28T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-06-28, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab (Opdivo\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-06-28T00:00:00\", \"latest\": \"2018-09-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2415, \"last_scrape\": \"2018-12-13T16:42:46\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-opdivo-in-combination-with-ipilimumab-yervoy/\", \"rr_start\": \"2018-11-28T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2018-11-28, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab (Opdivo\", \"trade_name\": \"Yervoy\", \"indication\": \"Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).\", \"ncpe_year\": 2018, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-11-28T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy\", \"ta_list\": \"Melanoma\", \"rr_status\": \"Unknown\"}, {\"id\": 2416, \"last_scrape\": \"2018-12-13T16:42:51\", \"url\": \"http://www.ncpe.ie/drugs/nivolumab-plus-ipilimumab-opdivio-plus-yervoy/\", \"rr_start\": \"\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab plus ipilimumab (Opdivo\", \"trade_name\": \"Opdivo plus Yervoy\", \"indication\": \"Opdivo\", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-06-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2417, \"last_scrape\": \"2018-12-13T16:42:56\", \"url\": \"http://www.ncpe.ie/drugs/nomace2-zoely/\", \"rr_start\": \"2011-12-08T00:00:00\", \"rr_end\": \"2012-01-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-12-08, 2012-01-03\", \"rr_multiple\": 0, \"drug_name\": \"Nomegestrol acetate/estradiol (Zoely\", \"trade_name\": \"Zoely\", \"indication\": \"Nomegestrol acetate/estradiol (Zoely\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-26T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2011-12-08T00:00:00\", \"latest\": \"2012-01-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zoely\", \"ta_list\": \"Contraception\", \"rr_status\": \"No HTA\"}, {\"id\": 2418, \"last_scrape\": \"2018-12-13T16:43:02\", \"url\": \"http://www.ncpe.ie/drugs/nusinersin-spinraza/\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-11, 2017-08-02\", \"rr_multiple\": 0, \"drug_name\": \"Nusinersin (Spinraza\", \"trade_name\": \"Spinraza\", \"indication\": \"Nusinersen (Spinraza\", \"ncpe_year\": 2017, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 1, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-12-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza\", \"ta_list\": \"Muscular Atrophy, Spinal\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2419, \"last_scrape\": \"2018-12-13T16:43:07\", \"url\": \"http://www.ncpe.ie/drugs/obeticholic-acid-ocaliva/\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-18, 2016-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Obeticholic acid (Ocaliva\", \"trade_name\": \"Ocaliva\", \"indication\": \"Obeticholic acid is indicated for the treatment of primary biliary cirrhosis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Intercept\", \"orphan\": 1, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocaliva\", \"ta_list\": \"Liver Cirrhosis, Biliary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2420, \"last_scrape\": \"2018-12-13T16:43:10\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-follicular-lymphoma/\", \"rr_start\": \"2016-05-11T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-05-11, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (in combination with bendamustine) followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2016-05-11T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2421, \"last_scrape\": \"2018-12-13T16:43:15\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-previously-untreated-advanced-follicular-lymphoma/\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-09-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-08-08, 2017-09-13\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (Gazyvaro\", \"ncpe_year\": 2018, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2422, \"last_scrape\": \"2018-12-13T16:43:21\", \"url\": \"http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro/\", \"rr_start\": \"2014-08-08T00:00:00\", \"rr_end\": \"2014-09-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-08-08, 2014-09-11\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab (Gazyvaro\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab (Gazyvaro\", \"ncpe_year\": 2015, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2014-08-08T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2423, \"last_scrape\": \"2018-12-13T16:43:24\", \"url\": \"http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-ppms/\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab (Ocrevus\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab (Ocrevus\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2424, \"last_scrape\": \"2018-12-13T16:43:30\", \"url\": \"http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-rms/\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab (Ocrevus\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab (Ocrevus\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2425, \"last_scrape\": \"2018-12-13T16:43:34\", \"url\": \"http://www.ncpe.ie/drugs/ocriplasmin-jetrea/\", \"rr_start\": \"2013-06-12T00:00:00\", \"rr_end\": \"2013-07-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-06-12, 2013-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Ocriplasmin (Jetrea\", \"trade_name\": \"Jetrea\", \"indication\": \"Ocriplasmin (Jetrea\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-13T00:00:00\", \"company\": \"ThromboGenics\", \"orphan\": 0, \"earliest\": \"2013-06-12T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea\", \"ta_list\": \"Retinal Diseases\", \"rr_status\": \"No HTA\"}, {\"id\": 2426, \"last_scrape\": \"2018-12-13T16:43:39\", \"url\": \"http://www.ncpe.ie/drugs/ofatumumab-arzerra-previously-untreated-chronic-lymphocytic-leukaemia/\", \"rr_start\": \"2014-10-13T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2014-10-13, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab (Arzerra\", \"trade_name\": \"Arzerra\", \"indication\": \"Ofatumumab (Arzerra\", \"ncpe_year\": 2014, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-10-13T00:00:00\", \"latest\": \"2014-12-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2427, \"last_scrape\": \"2018-12-13T16:43:46\", \"url\": \"http://www.ncpe.ie/drugs/ofatumumab-arzerra/\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-06-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-06-22, 2010-06-01\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab (Arzerra\", \"trade_name\": \"Arzerra\", \"indication\": \"Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-06-01T00:00:00\", \"latest\": \"2010-06-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2428, \"last_scrape\": \"2018-12-13T16:43:52\", \"url\": \"http://www.ncpe.ie/drugs/oladaterol-striverdi-respimat/\", \"rr_start\": \"2014-04-07T00:00:00\", \"rr_end\": \"2014-05-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-04-07, 2014-05-02\", \"rr_multiple\": 0, \"drug_name\": \"Oladaterol (Striverdi\", \"trade_name\": \"Striverdi, Respimat\", \"indication\": \"Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-04-07T00:00:00\", \"latest\": \"2014-05-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2429, \"last_scrape\": \"2018-12-13T16:43:57\", \"url\": \"http://www.ncpe.ie/drugs/olaparib-lynparza-2/\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-01-05, 2015-02-19\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib (Lynparza\", \"trade_name\": \"Lynparza\", \"indication\": \"Lynparza\", \"ncpe_year\": 2017, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2430, \"last_scrape\": \"2018-12-13T16:44:03\", \"url\": \"http://www.ncpe.ie/drugs/olaparib-lynparza-for-platinum-sensitive-relapsed-ovarian-cancer/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"THE NCPE RECOMMEND  A FULL HTA TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF OLAPARIB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib (Lynparza\", \"trade_name\": \"Lynparza\", \"indication\": \"Olaparib (Lynparza\", \"ncpe_year\": 2018, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2431, \"last_scrape\": \"2018-12-13T16:44:08\", \"url\": \"http://www.ncpe.ie/drugs/omalizumab-xolair-for-the-treatment-of-severe-allergic-asthma/\", \"rr_start\": \"\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab (Xolair\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab is indicated as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1<80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.\", \"ncpe_year\": 2015, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-08-22T00:00:00\", \"latest\": \"2015-06-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xolair\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2432, \"last_scrape\": \"2018-12-13T16:44:14\", \"url\": \"http://www.ncpe.ie/drugs/omalizumab-xolair/\", \"rr_start\": \"2014-03-25T00:00:00\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED FOR THIS INDICATION.\", \"rr_dates\": \"2014-03-25, 2014-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab (Xolair\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab (Xolair\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-03-25T00:00:00\", \"latest\": \"2014-04-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xolair\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"No HTA\"}, {\"id\": 2433, \"last_scrape\": \"2018-12-13T16:44:19\", \"url\": \"http://www.ncpe.ie/drugs/oral-oxycodonenaloxone-targin/\", \"rr_start\": \"\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Oxycodone/naloxone (Targin\", \"trade_name\": \"Targin\", \"indication\": \"Cost-effectiveness of oral oxycodone/naloxone prolonged release tablet (Targin\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-05-05T00:00:00\", \"latest\": \"2010-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2434, \"last_scrape\": \"2018-12-13T16:44:22\", \"url\": \"http://www.ncpe.ie/drugs/osimertinib-tagrisso-for-the-first-line-treatment-of-metastatic-nsclc/\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-07T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF OSIMERTINIB FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WITH ACTIVATING EGFR MUTATIONS COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-07-19, 2018-08-07\", \"rr_multiple\": 0, \"drug_name\": \"Osimertinib (Tagrisso\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib (Tagrisso\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2435, \"last_scrape\": \"2018-12-13T16:44:39\", \"url\": \"http://www.ncpe.ie/drugs/osimertinib-tagrisso/\", \"rr_start\": \"2016-02-26T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-26, 2016-03-22, 2017-01-10\", \"rr_multiple\": 1, \"drug_name\": \"Osimertinib (Tagrisso\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib (Tagrisso\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-26T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2436, \"last_scrape\": \"2018-12-13T16:44:40\", \"url\": \"http://www.ncpe.ie/drugs/ozenoxacin-dubine/\", \"rr_start\": \"2018-11-12T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"FULL HTA IS NOT RECOMMENDED. THE NCPE RECOMMENDS THAT OZENOXACIN CREAM NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE.  THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013.\", \"rr_dates\": \"2018-11-12, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ozenoxacin (Dubine\", \"trade_name\": \"Dubine\", \"indication\": \"Ozenoxacin (Dubine\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-12T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"id\": 2437, \"last_scrape\": \"2018-12-13T16:44:43\", \"url\": \"http://www.ncpe.ie/drugs/p-drugs/pegylated-interferon-b-1a-plegridy/\", \"rr_start\": \"2014-11-25T00:00:00\", \"rr_end\": \"2014-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-11-25, 2014-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Pegylated Interferon beta-1a (Plegridy \", \"trade_name\": \"Plegridy\", \"indication\": \"Treatment of adult patients with relapsing remitting multiple sclerosis\", \"ncpe_year\": 2014, \"eu_market\": \"2014-07-17T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-11-25T00:00:00\", \"latest\": \"2014-12-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"No HTA\"}, {\"id\": 2438, \"last_scrape\": \"2018-12-13T16:44:47\", \"url\": \"http://www.ncpe.ie/drugs/palbociclib-ibrance/\", \"rr_start\": \"2016-09-10T00:00:00\", \"rr_end\": \"2016-09-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-09-10, 2016-09-28\", \"rr_multiple\": 0, \"drug_name\": \"Palbociclib (Ibrance\", \"trade_name\": \"Ibrance\", \"indication\": \"Palbociclib is indicated for the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-11-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2016-09-10T00:00:00\", \"latest\": \"2017-07-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2439, \"last_scrape\": \"2018-12-13T16:44:53\", \"url\": \"http://www.ncpe.ie/drugs/paliperidone-palmitate-xeplion/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Paliperidone palmitate (Xeplion\", \"trade_name\": \"Xeplion\", \"indication\": \"Paliperidone palmitate (Xeplion\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-04T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeplion\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"id\": 2440, \"last_scrape\": \"2018-12-13T16:44:57\", \"url\": \"http://www.ncpe.ie/drugs/panobinostat-farydak/\", \"rr_start\": \"2016-01-26T00:00:00\", \"rr_end\": \"2016-02-09T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-26, 2016-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Panobinostat (Farydak\", \"trade_name\": \"Farydak\", \"indication\": \"Panobinostat in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-01-26T00:00:00\", \"latest\": \"2016-02-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/farydak\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2441, \"last_scrape\": \"2018-12-13T16:45:01\", \"url\": \"http://www.ncpe.ie/drugs/paritaprevir-boosted-with-ritonavir-and-ombitasvir-vierkirax-with-or-without-dasabuvir-exviera/\", \"rr_start\": \"2014-12-21T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-21, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Paritaprevir boosted with ritonavir and ombitasvir (Vierkirax\", \"trade_name\": \"Exviera\", \"indication\": \"Exviera\", \"ncpe_year\": 2016, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2014-12-21T00:00:00\", \"latest\": \"2016-02-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/exviera\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2442, \"last_scrape\": \"2018-12-13T16:45:07\", \"url\": \"http://www.ncpe.ie/drugs/patiromer-veltassa/\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT\\nRECOMMENDED\", \"rr_dates\": \"2017-10-11, 2017-11-17\", \"rr_multiple\": 0, \"drug_name\": \"Patiromer (Veltassa\", \"trade_name\": \"Veltassa\", \"indication\": \"Patiromer (Veltassa\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-19T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-11-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/veltassa\", \"ta_list\": \"Hyperkalemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2443, \"last_scrape\": \"2018-12-13T16:45:10\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-1l-nsclc-with-chemotherapy/\", \"rr_start\": \"2018-08-14T00:00:00\", \"rr_end\": \"2018-08-29T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-08-14, 2018-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-08-14T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2444, \"last_scrape\": \"2018-12-13T16:45:15\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-adjuvant-melanoma/\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-07T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-11-19, 2018-12-07\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizuma (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2445, \"last_scrape\": \"2018-12-13T16:45:18\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-classical-hodgkin-lymphoma/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2446, \"last_scrape\": \"2018-12-13T16:45:23\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-first-line-nsclc/\", \"rr_start\": \"2016-12-19T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-12-19, 2017-01-10\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-12-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2447, \"last_scrape\": \"2018-12-13T16:45:28\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-nsclc/\", \"rr_start\": \"2016-08-03T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-08-03, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-03T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2448, \"last_scrape\": \"2018-12-13T16:45:31\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-the-treatment-of-unresectable-or-advanced-metastatic-melanoma-in-adults-refractory-to-ipilimumab/\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2449, \"last_scrape\": \"2018-12-13T16:45:36\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-uc-1l/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PEMBROLIZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES\", \"rr_dates\": \"2017-12-06, 2017-12-21, 2018-06-21, 2018-07-10, 2018-07-27\", \"rr_multiple\": 1, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-07-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2450, \"last_scrape\": \"2018-12-13T16:45:38\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-urothelial-carcinoma-2l/\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab (Keytruda \", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2451, \"last_scrape\": \"2018-12-13T16:45:45\", \"url\": \"http://www.ncpe.ie/drugs/pembrolizumab-keytruda/\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab (Keytruda\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-02-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2452, \"last_scrape\": \"2018-12-13T16:45:50\", \"url\": \"http://www.ncpe.ie/drugs/perampanel-fycompa/\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Perampanel (Fycompa\", \"trade_name\": \"Fycompa\", \"indication\": \"Perampanel (Fycompa\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-23T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa\", \"ta_list\": \"Epilepsies, Partial\", \"rr_status\": \"No HTA\"}, {\"id\": 2453, \"last_scrape\": \"2018-12-13T16:45:56\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta-for-her2-positive-breast-cancer/\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF PERTUZUMAB COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-06-01, 2018-06-22\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab  (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.\", \"ncpe_year\": 2018, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-12-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2454, \"last_scrape\": \"2018-12-13T16:46:02\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta-in-neoadjuvant-her2-positive-breast-cancer/\", \"rr_start\": \"2015-08-10T00:00:00\", \"rr_end\": \"2015-09-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-08-10, 2015-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"Perjeta (pertuzumab) is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2015-08-10T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2455, \"last_scrape\": \"2018-12-13T16:46:04\", \"url\": \"http://www.ncpe.ie/drugs/pertuzumab-perjeta/\", \"rr_start\": \"2013-01-14T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-01-14, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab (Perjeta\", \"trade_name\": \"Perjeta\", \"indication\": \"The proposed licensed indication is for use (in combination with trastuzumab and docetaxel) in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. \", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-01-14T00:00:00\", \"latest\": \"2013-08-28T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2456, \"last_scrape\": \"2018-12-13T16:46:09\", \"url\": \"http://www.ncpe.ie/drugs/phenylephrine-hydrochloride-tropicamide-lidocaine-hydrochloride-fydrane/\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-19T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-11-18, 2016-12-19\", \"rr_multiple\": 0, \"drug_name\": \"Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride (Fydrane\", \"trade_name\": \"Fydrane\", \"indication\": \"Fydrane\", \"ncpe_year\": 2016, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2016-12-19T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2457, \"last_scrape\": \"2018-12-13T16:46:11\", \"url\": \"http://www.ncpe.ie/drugs/pirfenidone-esbriet/\", \"rr_start\": \"2011-12-15T00:00:00\", \"rr_end\": \"2012-01-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-12-15, 2012-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Pirfenidone (Esbriet\", \"trade_name\": \"Esbriet\", \"indication\": \"Pirfenidone has been licensed by the European Medicines Agency (EMA) for the treatment of mild to moderate idiopathic pulmonary fibrosis.\", \"ncpe_year\": 2015, \"eu_market\": \"2011-02-27T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2011-12-15T00:00:00\", \"latest\": \"2015-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esbriet\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2458, \"last_scrape\": \"2018-12-13T16:46:14\", \"url\": \"http://www.ncpe.ie/drugs/pitavastatin-livazo/\", \"rr_start\": \"2010-12-22T00:00:00\", \"rr_end\": \"2010-12-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2010-12-22, 2010-12-24\", \"rr_multiple\": 0, \"drug_name\": \"Pitavastatin (Livazo\", \"trade_name\": \"Livazo\", \"indication\": \"Pitavastatin is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined (mixed) dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-12-22T00:00:00\", \"latest\": \"2010-12-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2459, \"last_scrape\": \"2018-12-13T16:46:20\", \"url\": \"http://www.ncpe.ie/drugs/pitolisant-wakix/\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-06-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-06-12, 2017-06-15\", \"rr_multiple\": 0, \"drug_name\": \"Pitolisant hydrochloride (Wakix\", \"trade_name\": \"Wakix\", \"indication\": \"Pitolisant hydrochloride (Wakix\", \"ncpe_year\": 2017, \"eu_market\": \"2016-03-31T00:00:00\", \"company\": \"Bioprojet\", \"orphan\": 1, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-06-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/wakix\", \"ta_list\": \"Narcolepsy\", \"rr_status\": \"No HTA\"}, {\"id\": 2460, \"last_scrape\": \"2018-12-13T16:46:24\", \"url\": \"http://www.ncpe.ie/drugs/pixantrone-pixuvri/\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-03-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-02-10, 2015-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Pixantrone (Pixuvri\", \"trade_name\": \"Pixuvri\", \"indication\": \"Pixurvi\", \"ncpe_year\": 2015, \"eu_market\": \"2012-05-10T00:00:00\", \"company\": \"CTI\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-03-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri\", \"ta_list\": \"Lymphoma, Non-Hodgkin\", \"rr_status\": \"No HTA\"}, {\"id\": 2461, \"last_scrape\": \"2018-12-13T16:46:27\", \"url\": \"http://www.ncpe.ie/drugs/polynuclear-ironiii-oxyhydroxide-pn-feooh-velphoro/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-08T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-09-12, 2014-10-08\", \"rr_multiple\": 0, \"drug_name\": \"Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro\", \"trade_name\": \"Velphoro\", \"indication\": \"Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro\", \"ncpe_year\": 2014, \"eu_market\": \"2014-08-26T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-10-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/velphoro\", \"ta_list\": \"Hyperphosphatemia; Renal Dialysis\", \"rr_status\": \"No HTA\"}, {\"id\": 2462, \"last_scrape\": \"2018-12-13T16:46:30\", \"url\": \"http://www.ncpe.ie/drugs/pomalidomide-imnovid/\", \"rr_start\": \"2013-09-20T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-20, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Pomalidomide (Imnovid\", \"trade_name\": \"Imnovid\", \"indication\": \"Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-09-20T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2463, \"last_scrape\": \"2018-12-13T16:46:32\", \"url\": \"http://www.ncpe.ie/drugs/ponatinib-iclusig/\", \"rr_start\": \"2013-10-02T00:00:00\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED\", \"rr_dates\": \"2013-10-02, 2013-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Ponatinib (Iclusig\", \"trade_name\": \"Iclusig\", \"indication\": \"Ponatinib (Iclusig\", \"ncpe_year\": 2016, \"eu_market\": \"2013-07-01T00:00:00\", \"company\": \"Incyte\", \"orphan\": 1, \"earliest\": \"2013-10-02T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig\", \"ta_list\": \"Leukemia, Myeloid; Leukemia, Lymphoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2464, \"last_scrape\": \"2018-12-13T16:46:38\", \"url\": \"http://www.ncpe.ie/drugs/prasugrel-efient/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Prasugrel (Efient\", \"trade_name\": \"Efient\", \"indication\": \"Economic Evaluation of Prasugrel (Efient\", \"ncpe_year\": 2010, \"eu_market\": \"2009-02-24T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2010-02-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/efient\", \"ta_list\": \"Acute Coronary Syndrome; Angina, Unstable; Myocardial Infarction\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2465, \"last_scrape\": \"2018-12-13T16:46:46\", \"url\": \"http://www.ncpe.ie/drugs/pregabalin-lyrica-2/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin (Lyrica\", \"trade_name\": \"Lyrica\", \"indication\": \"Lyrica\", \"ncpe_year\": 2015, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-30T00:00:00\", \"latest\": \"2015-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2466, \"last_scrape\": \"2018-12-13T16:46:52\", \"url\": \"http://www.ncpe.ie/drugs/pregabalin-lyrica-for-the-treatment-of-generalised-anxiety-disorder/\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin (Lyrica\", \"trade_name\": \"Lyrica\", \"indication\": \"Pregabalin (Lyrica\", \"ncpe_year\": 2014, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-12-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2467, \"last_scrape\": \"2018-12-13T16:46:58\", \"url\": \"http://www.ncpe.ie/drugs/prucalopride-resolor/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-01-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-01-17\", \"rr_multiple\": 0, \"drug_name\": \"Prucalopride (Resolor\", \"trade_name\": \"Resolor\", \"indication\": \"Prucalopride (Resolor\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-14T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2011-01-17T00:00:00\", \"latest\": \"2011-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/resolor\", \"ta_list\": \"Constipation\", \"rr_status\": \"No HTA\"}, {\"id\": 2468, \"last_scrape\": \"2018-12-13T16:47:00\", \"url\": \"http://www.ncpe.ie/drugs/radium-223-xofigo/\", \"rr_start\": \"2013-11-28T00:00:00\", \"rr_end\": \"2013-12-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2013-11-28, 2013-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Radium-223 (Xofigo\", \"trade_name\": \"Xofigo\", \"indication\": \"Radium-223 (Xofigo\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-13T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2469, \"last_scrape\": \"2018-12-13T16:47:03\", \"url\": \"http://www.ncpe.ie/drugs/ramucirumab-cyramza/\", \"rr_start\": \"2014-12-20T00:00:00\", \"rr_end\": \"2014-12-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-20, 2014-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Ramucirumab (Cyramza\", \"trade_name\": \"Cyramza\", \"indication\": \"Indicated in combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction (GEJ) adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-12-19T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2014-12-20T00:00:00\", \"latest\": \"2016-07-26T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2470, \"last_scrape\": \"2018-12-13T16:47:06\", \"url\": \"http://www.ncpe.ie/drugs/ranolazine-ranexa/\", \"rr_start\": \"2009-11-19T00:00:00\", \"rr_end\": \"2009-11-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2009-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ranolazine (Ranexa\", \"trade_name\": \"Ranexa\", \"indication\": \"Cost-effectiveness of Ranolazine (Ranexa\", \"ncpe_year\": 2009, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2009-11-19T00:00:00\", \"latest\": \"2009-11-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2471, \"last_scrape\": \"2018-12-13T16:47:13\", \"url\": \"http://www.ncpe.ie/drugs/regadenoson-rapiscan/\", \"rr_start\": \"2011-09-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-09-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Regadenoson (Rapiscan\", \"trade_name\": \"Rapiscan\", \"indication\": \"Cost-effectiveness of Regadenoson (Rapiscan\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-06T00:00:00\", \"company\": \"GE\", \"orphan\": 0, \"earliest\": \"2011-09-19T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/rapiscan\", \"ta_list\": \"Myocardial Perfusion Imaging\", \"rr_status\": \"No HTA\"}, {\"id\": 2472, \"last_scrape\": \"2018-12-13T16:47:17\", \"url\": \"http://www.ncpe.ie/drugs/regorafenib-stivarga-for-gist/\", \"rr_start\": \"2014-09-18T00:00:00\", \"rr_end\": \"2014-10-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-09-18, 2014-10-06\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib (Stivarga\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib (Stivarga\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2014-09-18T00:00:00\", \"latest\": \"2014-10-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2473, \"last_scrape\": \"2018-12-13T16:47:23\", \"url\": \"http://www.ncpe.ie/drugs/reslizumab-cinqaero/\", \"rr_start\": \"2017-01-23T00:00:00\", \"rr_end\": \"2017-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-01-23, 2017-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Reslizumab (Cinqaero\", \"trade_name\": \"Cinqaero\", \"indication\": \"Cinqaero\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-15T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2017-01-23T00:00:00\", \"latest\": \"2017-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cinqaero\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2474, \"last_scrape\": \"2018-12-13T16:47:27\", \"url\": \"http://www.ncpe.ie/drugs/retigabine-trobalt/\", \"rr_start\": \"2011-04-06T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-04-06, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Retigabine (Trobalt\", \"trade_name\": \"Trobalt\", \"indication\": \"Cost-effectiveness of Retigabine (Trobalt\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-27T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-04-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"No HTA\"}, {\"id\": 2475, \"last_scrape\": \"2018-12-13T16:47:29\", \"url\": \"http://www.ncpe.ie/drugs/ribociclib-kisqali/\", \"rr_start\": \"2017-09-04T00:00:00\", \"rr_end\": \"2017-09-19T00:00:00\", \"rr_outcome\": \"FOLLOWING NCPE ASSESSMENT OF THE COMPANY SUBMISSION, THE NCPE RECOMMENDS THAT RIBOCICLIB (IN COMBINATION WITH AN AROMATASE INHIBITOR) FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR+/HER2- LOCALLY ADVANCED OR METASTATIC BC AS INITIAL ENDOCRINE-BASED THERAPY, NOT BE CONSIDERED FOR REIMBURSEMENT UNLESS COST EFFECTIVENESS CAN BE IMPROVED RELATIVE TO EXISTING TREATMENTS. THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2017-09-04, 2017-09-19\", \"rr_multiple\": 0, \"drug_name\": \"Ribociclib (Kisqali\", \"trade_name\": \"Kisqali\", \"indication\": \"Ribociclib (Kisqali\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2017-09-04T00:00:00\", \"latest\": \"2018-08-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2476, \"last_scrape\": \"2018-12-13T16:47:35\", \"url\": \"http://www.ncpe.ie/drugs/rifaximin-targaxan-2/\", \"rr_start\": \"2013-07-09T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-09, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Rifaximin (Targaxan\", \"trade_name\": \"Targaxan\", \"indication\": \"Rifaximin (Targaxan\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-07-09T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2477, \"last_scrape\": \"2018-12-13T16:47:38\", \"url\": \"http://www.ncpe.ie/drugs/rigorafenib-stivarga/\", \"rr_start\": \"2013-09-12T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-12, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib (Stivarga\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib (Stivarga\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-09-12T00:00:00\", \"latest\": \"2014-06-30T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2478, \"last_scrape\": \"2018-12-13T16:47:42\", \"url\": \"http://www.ncpe.ie/drugs/rilpivirine-edurant/\", \"rr_start\": \"2011-12-14T00:00:00\", \"rr_end\": \"2012-01-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-12-14, 2012-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine (Edurant\", \"trade_name\": \"Edurant\", \"indication\": \"Rilpivirine in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ? 100,000 HIV-1 RNA copies/ml.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-11-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-12-14T00:00:00\", \"latest\": \"2012-01-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/edurant\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"id\": 2479, \"last_scrape\": \"2018-12-13T16:47:45\", \"url\": \"http://www.ncpe.ie/drugs/rilpivirine-r-emtricitabine-f-tenofovir-alafenamide-taf-odefsey/\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMEDED\", \"rr_dates\": \"2016-06-28, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) (Odefsey\", \"trade_name\": \"Odefsey\", \"indication\": \"Odefsey\", \"ncpe_year\": 2016, \"eu_market\": \"2016-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2480, \"last_scrape\": \"2018-12-13T16:47:48\", \"url\": \"http://www.ncpe.ie/drugs/rimonabant-acomplia-2/\", \"rr_start\": \"\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rimonabant (Acomplia\", \"trade_name\": \"Acomplia\", \"indication\": \"In June 2006, Sanofi-Aventis submitted an evaluation of the cost-effectiveness of rimonabant (in addition to diet and exercise) in the management of multiple cardiovascular risks in overweight or obese patients in Ireland, to support its application for reimbursement of rimonabant under the Community Drugs Schemes. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-06-19T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2006-06-01T00:00:00\", \"latest\": \"2006-06-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/acomplia\", \"ta_list\": \"Obesity\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2481, \"last_scrape\": \"2018-12-13T16:47:53\", \"url\": \"http://www.ncpe.ie/drugs/riociguat-adempas/\", \"rr_start\": \"2014-04-11T00:00:00\", \"rr_end\": \"2014-05-16T00:00:00\", \"rr_outcome\": \"FULL HTA RECOMMENDED AT THE CURRENT PRICE.\", \"rr_dates\": \"2014-04-11, 2014-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Riociguat (Adempas\", \"trade_name\": \"Adempas\", \"indication\": \"Riociguat (Adempas\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-27T00:00:00\", \"company\": \"Bayer\", \"orphan\": 1, \"earliest\": \"2014-04-11T00:00:00\", \"latest\": \"2014-05-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adempas\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2482, \"last_scrape\": \"2018-12-13T16:47:59\", \"url\": \"http://www.ncpe.ie/drugs/rituximab-mabthera/\", \"rr_start\": \"2014-05-26T00:00:00\", \"rr_end\": \"2014-09-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-05-26, 2014-09-22\", \"rr_multiple\": 0, \"drug_name\": \"Rituximab (MabThera\", \"trade_name\": \"MabThera\", \"indication\": \"Rituximab (MabThera\", \"ncpe_year\": 2014, \"eu_market\": \"1998-06-02T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-05-26T00:00:00\", \"latest\": \"2014-09-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"No HTA\"}, {\"id\": 2483, \"last_scrape\": \"2018-12-13T16:48:05\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-atrial-fibrillation-patients-undergoing-pci/\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2484, \"last_scrape\": \"2018-12-13T16:48:10\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-dvt/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Economic evaluation of Rivaroxaban (Xarelto\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-02-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2485, \"last_scrape\": \"2018-12-13T16:48:15\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-spaf-2/\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban (Xarelto\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2486, \"last_scrape\": \"2018-12-13T16:48:18\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-the-prevention-of-atherothrombotic-events/\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-11T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF RIVAROXABAN COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-26, 2018-10-11\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban (Xarelto\", \"ncpe_year\": 2018, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2487, \"last_scrape\": \"2018-12-13T16:48:25\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto-low-dose-for-prevention-of-recurrent-venous-thromboembolism/\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2488, \"last_scrape\": \"2018-12-13T16:48:30\", \"url\": \"http://www.ncpe.ie/drugs/rivaroxaban-xarelto/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban (Xarelto\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban (Xarelto\", \"ncpe_year\": 2008, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2008-04-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2489, \"last_scrape\": \"2018-12-13T16:48:33\", \"url\": \"http://www.ncpe.ie/drugs/roflumilast-daxas/\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Roflumilast (Daxas\", \"trade_name\": \"Daxas\", \"indication\": \"Cost Effectiveness of Roflumilast (Daxas\", \"ncpe_year\": 2010, \"eu_market\": \"2010-07-05T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-11T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/daxas\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2490, \"last_scrape\": \"2018-12-13T16:48:40\", \"url\": \"http://www.ncpe.ie/drugs/rolapitant-varuby/\", \"rr_start\": \"2017-05-15T00:00:00\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-05-15, 2017-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Rolapitant (Varuby\", \"trade_name\": \"Varuby\", \"indication\": \"Rolapitant (Varuby\", \"ncpe_year\": 2017, \"eu_market\": \"2017-04-19T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 0, \"earliest\": \"2017-05-15T00:00:00\", \"latest\": \"2017-06-12T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/varuby\", \"ta_list\": \"Vomiting; Nausea; Cancer\", \"rr_status\": \"No HTA\"}, {\"id\": 2491, \"last_scrape\": \"2018-12-13T16:48:43\", \"url\": \"http://www.ncpe.ie/drugs/romiplostim-nplate/\", \"rr_start\": \"\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Romiplostim (Nplate\", \"trade_name\": \"Nplate\", \"indication\": \"Romiplostim (Nplate\", \"ncpe_year\": 2015, \"eu_market\": \"2009-02-04T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-04-02T00:00:00\", \"latest\": \"2015-05-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/nplate\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2492, \"last_scrape\": \"2018-12-13T16:48:47\", \"url\": \"http://www.ncpe.ie/drugs/ropivacaine-readyfusor/\", \"rr_start\": \"2018-11-09T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"FULL HTA IS NOT RECOMMENDED. THE NCPE RECOMMENDS THAT ROPIVICAINE READYFUSOR NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE.  THIS RECOMMENDATION SHOULD BE CONSIDERED WHILE ALSO HAVING REGARD TO THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS ACT) 2013.\", \"rr_dates\": \"2018-11-09, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ropivacaine Readyfusor\", \"trade_name\": \"Ropivacaine Readyfusor\", \"indication\": \"Ropivacaine Readyfusor for acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block (CPNB) via a continuous infusion.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-09T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"id\": 2493, \"last_scrape\": \"2018-12-13T16:48:50\", \"url\": \"http://www.ncpe.ie/drugs/ruxolitinib-jakavi-for-polycythaemia-vera/\", \"rr_start\": \"2015-04-15T00:00:00\", \"rr_end\": \"2015-05-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-04-15, 2015-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib (Jakavi\", \"trade_name\": \"Jakavi\", \"indication\": \"Jakavi\", \"ncpe_year\": 2016, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2015-04-15T00:00:00\", \"latest\": \"2016-08-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2494, \"last_scrape\": \"2018-12-13T16:48:55\", \"url\": \"http://www.ncpe.ie/drugs/ruxolitinib-jakavi/\", \"rr_start\": \"2012-08-01T00:00:00\", \"rr_end\": \"2012-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2012-08-01, 2012-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib (Jakavi\", \"trade_name\": \"Jakavi\", \"indication\": \"Ruxolitinib (Jakavi\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2012-08-01T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2495, \"last_scrape\": \"2018-12-13T16:48:58\", \"url\": \"http://www.ncpe.ie/drugs/sacubitrilvalsartan-entresto/\", \"rr_start\": \"2015-11-06T00:00:00\", \"rr_end\": \"2015-11-30T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-06, 2015-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Sacubitril/valsartan (Entresto\", \"trade_name\": \"Entresto\", \"indication\": \"Entresto\", \"ncpe_year\": 2017, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-06T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entresto\", \"ta_list\": \"Heart Failure\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2496, \"last_scrape\": \"2018-12-13T16:49:04\", \"url\": \"http://www.ncpe.ie/drugs/safinamide-methansulfonate-xadago/\", \"rr_start\": \"2016-06-14T00:00:00\", \"rr_end\": \"2016-07-06T00:00:00\", \"rr_outcome\": \"REIMBURSEMENT NOT RECOMMENDED.\", \"rr_dates\": \"2016-06-14, 2016-07-06\", \"rr_multiple\": 0, \"drug_name\": \"Safinamide methansulfonate (Xadago\", \"trade_name\": \"Xadago\", \"indication\": \"Xadago\", \"ncpe_year\": 2016, \"eu_market\": \"2015-02-23T00:00:00\", \"company\": \"Zambon\", \"orphan\": 0, \"earliest\": \"2016-06-14T00:00:00\", \"latest\": \"2016-07-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xadago\", \"ta_list\": \"Parkinson Disease\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2497, \"last_scrape\": \"2018-12-13T16:49:07\", \"url\": \"http://www.ncpe.ie/drugs/sapropterin-kuvan/\", \"rr_start\": \"2015-07-14T00:00:00\", \"rr_end\": \"2015-07-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-07-14, 2015-08-14, 2015-07-01\", \"rr_multiple\": 1, \"drug_name\": \"Sapropterin (Kuvan\", \"trade_name\": \"Kuvan\", \"indication\": \"Sapropterin (Kuvan\", \"ncpe_year\": 2017, \"eu_market\": \"2008-12-02T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2009-01-01T00:00:00\", \"latest\": \"2017-09-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kuvan\", \"ta_list\": \"Phenylketonurias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2498, \"last_scrape\": \"2018-12-13T16:49:11\", \"url\": \"http://www.ncpe.ie/drugs/sarilumab-kevzara/\", \"rr_start\": \"2017-08-18T00:00:00\", \"rr_end\": \"2017-10-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2017-08-18, 2017-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Sarilumab (Kevzara\", \"trade_name\": \"Kevzara\", \"indication\": \"Sarilumab (Kevzara\", \"ncpe_year\": 2017, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-08-18T00:00:00\", \"latest\": \"2017-10-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2499, \"last_scrape\": \"2018-12-13T16:49:16\", \"url\": \"http://www.ncpe.ie/drugs/sebelipase-alfa-kanuma/\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-02-08, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Sebelipase alfa (Kanuma\", \"trade_name\": \"Kanuma\", \"indication\": \"Sebelipase alfa is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2018-06-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kanuma\", \"ta_list\": \"Lipid Metabolism, Inborn Errors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2500, \"last_scrape\": \"2018-12-13T16:49:20\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-ankylosing-spondylitis/\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-02, 2015-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"id\": 2501, \"last_scrape\": \"2018-12-13T16:49:25\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-psoriatic-arthritis/\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-12-02, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"id\": 2502, \"last_scrape\": \"2018-12-13T16:49:31\", \"url\": \"http://www.ncpe.ie/drugs/secukinumab-cosentyx/\", \"rr_start\": \"2014-12-19T00:00:00\", \"rr_end\": \"2015-02-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-12-19, 2015-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab (Cosentyx\", \"trade_name\": \"Cosentyx\", \"indication\": \"Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-12-19T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2503, \"last_scrape\": \"2018-12-13T16:49:34\", \"url\": \"http://www.ncpe.ie/drugs/selexipag-uptravi/\", \"rr_start\": \"2016-11-01T00:00:00\", \"rr_end\": \"2016-12-05T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-11-01, 2016-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Selexipag (Uptravi\", \"trade_name\": \"Uptravi\", \"indication\": \"Selexipag (Uptravi\", \"ncpe_year\": 2018, \"eu_market\": \"2016-05-12T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2016-11-01T00:00:00\", \"latest\": \"2018-05-21T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2504, \"last_scrape\": \"2018-12-13T16:49:39\", \"url\": \"http://www.ncpe.ie/drugs/semaglutide-ozempic/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-04-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-03-12, 2018-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Semaglutide (Ozempic\", \"trade_name\": \"Ozempic\", \"indication\": \"Semaglutide (Ozempic\", \"ncpe_year\": 2018, \"eu_market\": \"2018-02-08T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-04-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2505, \"last_scrape\": \"2018-12-13T16:49:44\", \"url\": \"http://www.ncpe.ie/drugs/sildenafil-revatio/\", \"rr_start\": \"2014-04-16T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2014-04-16, 2014-05-23\", \"rr_multiple\": 0, \"drug_name\": \"Sildenafil (Revatio\", \"trade_name\": \"Revatio\", \"indication\": \"Sildenafil (Revatio\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2014-04-16T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revatio\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"id\": 2506, \"last_scrape\": \"2018-12-13T16:49:49\", \"url\": \"http://www.ncpe.ie/drugs/simeprevir-olysio-in-combination-with-sofosbuvir/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir (Olysio\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir (Olysio\", \"ncpe_year\": 2015, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2015-03-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olysio\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2507, \"last_scrape\": \"2018-12-13T16:49:53\", \"url\": \"http://www.ncpe.ie/drugs/simeprevir-olysio/\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED WHEN USED IN TRIPLE THERAPY WITH PEG-INTERFERON AND RIBAVIRIN.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir (Olysio\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir (Olysio\", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2014-07-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/olysio\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2508, \"last_scrape\": \"2018-12-13T16:50:00\", \"url\": \"http://www.ncpe.ie/drugs/sodium-chloride-70mgml-sodium-hyaluronate-1mgml-hyaneb/\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-02-10, 2014-03-19\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml (Hyaneb\", \"trade_name\": \"Hyaneb\", \"indication\": \"Hyaneb\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2509, \"last_scrape\": \"2018-12-13T16:50:06\", \"url\": \"http://www.ncpe.ie/drugs/sodium-hyaluronate-hyloforte-0-2/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate (Hyloforte\", \"trade_name\": \"Hyloforte 0.2%\", \"indication\": \"Sodium Hyaluronate (Hyloforte\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2510, \"last_scrape\": \"2018-12-13T16:50:09\", \"url\": \"http://www.ncpe.ie/drugs/sodium-hyaluronate-hylotear-0-1/\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate (Hylotear\", \"trade_name\": \"Hylotear 0.1%\", \"indication\": \"Sodium Hyaluronate (Hylotear\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2511, \"last_scrape\": \"2018-12-13T16:50:15\", \"url\": \"http://www.ncpe.ie/drugs/sodium-phenylbutyrate-pheburane/\", \"rr_start\": \"2013-07-17T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-07-17, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Sodium phenylbutyrate (Pheburane\", \"trade_name\": \"Pheburane\", \"indication\": \"Sodium phenylbutyrate (Pheburane\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-30T00:00:00\", \"company\": \"Lucane\", \"orphan\": 0, \"earliest\": \"2013-07-17T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/pheburane\", \"ta_list\": \"Carbamoyl-Phosphate Synthase I Deficiency Disease\", \"rr_status\": \"No HTA\"}, {\"id\": 2512, \"last_scrape\": \"2018-12-13T16:50:18\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvir-solvaldi/\", \"rr_start\": \"2014-02-12T00:00:00\", \"rr_end\": \"2014-03-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-02-12, 2014-03-10\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir (Solvaldi\", \"trade_name\": \"Solvaldi\", \"indication\": \"Sofosbuvir (Solvaldi\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-02-12T00:00:00\", \"latest\": \"2014-10-24T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2513, \"last_scrape\": \"2018-12-13T16:50:22\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvirvelpatasvir-epclusa-chronic-hepatitis-c-virus-hcv-pangenotypic/\", \"rr_start\": \"2017-09-05T00:00:00\", \"rr_end\": \"2017-10-19T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-05, 2017-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir (Epclusa\", \"trade_name\": \"Epclusa\", \"indication\": \"Sofosbuvir/velpatasvir (Epclusa\", \"ncpe_year\": 2017, \"eu_market\": \"2016-07-06T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-05T00:00:00\", \"latest\": \"2017-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2514, \"last_scrape\": \"2018-12-13T16:50:26\", \"url\": \"http://www.ncpe.ie/drugs/sofosbuvirvelpatasvirvoxilaprevir-vosevi/\", \"rr_start\": \"2017-09-19T00:00:00\", \"rr_end\": \"2017-11-15T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2017-09-19, 2017-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi\", \"trade_name\": \"Vosevi\", \"indication\": \"Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-19T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vosevi\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"id\": 2515, \"last_scrape\": \"2018-12-13T16:50:32\", \"url\": \"http://www.ncpe.ie/drugs/st-johns-wort-pafica/\", \"rr_start\": \"2015-04-14T00:00:00\", \"rr_end\": \"2015-05-29T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-04-14, 2015-05-29\", \"rr_multiple\": 0, \"drug_name\": \"St Johns Wort (Pacifa\", \"trade_name\": \"Pacifa\", \"indication\": \"Pacifa\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-04-14T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2516, \"last_scrape\": \"2018-12-13T16:50:38\", \"url\": \"http://www.ncpe.ie/drugs/stiripentol-diacomit/\", \"rr_start\": \"2017-07-06T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-07-06, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Stiripentol (Diacomit\", \"trade_name\": \"Diacomit\", \"indication\": \"Stiripentol (Diacomit\", \"ncpe_year\": 2018, \"eu_market\": \"2007-01-03T00:00:00\", \"company\": \"Biocodex\", \"orphan\": 1, \"earliest\": \"2017-07-06T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/diacomit\", \"ta_list\": \"Myoclonic Epilepsy, Juvenile\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2517, \"last_scrape\": \"2018-12-13T16:50:43\", \"url\": \"http://www.ncpe.ie/drugs/stribild-elvitegravircobicistatemtricitabinetenofovir-disoproxil-as-fumarate/\", \"rr_start\": \"2013-04-28T00:00:00\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-04-28, 2013-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumarate)(Stribild\", \"trade_name\": \"Stribild\", \"indication\": \"Indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-na\", \"ncpe_year\": 2013, \"eu_market\": \"2013-05-24T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2013-04-28T00:00:00\", \"latest\": \"2013-12-06T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stribild\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2518, \"last_scrape\": \"2018-12-13T16:50:49\", \"url\": \"http://www.ncpe.ie/drugs/sublingual-immunotherapy-grazax/\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sublingual Immunotherapy (Grazax\", \"trade_name\": \"Grazax\", \"indication\": \"A Review of the Cost-Effectiveness of Sublingual Immunotherapy (Grazax\", \"ncpe_year\": 2007, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2007-09-01T00:00:00\", \"latest\": \"2007-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2519, \"last_scrape\": \"2018-12-13T16:50:50\", \"url\": \"http://www.ncpe.ie/drugs/suboxone-buprenorphinenaloxone/\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Buprenorphine/naloxone (Suboxone\", \"trade_name\": \"Suboxone\", \"indication\": \"An economic evaluation of suboxone for the management of opiate addiction.\", \"ncpe_year\": 2014, \"eu_market\": \"2006-09-26T00:00:00\", \"company\": \"Indivior\", \"orphan\": 0, \"earliest\": \"2007-11-01T00:00:00\", \"latest\": \"2014-05-22T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/suboxone\", \"ta_list\": \"Opioid-Related Disorders\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2520, \"last_scrape\": \"2018-12-13T16:50:54\", \"url\": \"http://www.ncpe.ie/drugs/sufentanil-zalviso/\", \"rr_start\": \"2016-03-14T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-03-14, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Sufentanil (Zalviso\", \"trade_name\": \"Zalviso\", \"indication\": \"Sufentanil (Zalviso\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Gr\", \"orphan\": 0, \"earliest\": \"2016-03-14T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zalviso\", \"ta_list\": \"Pain, Postoperative\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2521, \"last_scrape\": \"2018-12-13T16:50:59\", \"url\": \"http://www.ncpe.ie/drugs/sunitinib-sutent/\", \"rr_start\": \"\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sunitinib (Sutent\", \"trade_name\": \"Sutent\", \"indication\": \"In September 2006, Pfizer Healthcare Ireland submitted an evaluation of the cost-effectiveness and budget impact of sunitinib as second-line treatment of patients with gastro-intestinal stromal tumours (GIST). Data on the cost-effectiveness and budget impact of sutinitinib as second line treatment for patients with metastatic renal cell carcinoma (mRCC) was also presented. The purpose of the submission was to support an application for reimbursement under the High Tech Drug Scheme. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-07-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-09-01T00:00:00\", \"latest\": \"2006-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sutent\", \"ta_list\": \"Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2522, \"last_scrape\": \"2018-12-13T16:51:04\", \"url\": \"http://www.ncpe.ie/drugs/tadalafil-adcirca-2/\", \"rr_start\": \"2011-07-13T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2011-07-13, 2011-09-21, 2014-05-09, 2014-05-23\", \"rr_multiple\": 1, \"drug_name\": \"Tadalafil (Adcirca\", \"trade_name\": \"Adcirca\", \"indication\": \"Tadalafil (Adcirca\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-07-13T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2523, \"last_scrape\": \"2018-12-13T16:51:09\", \"url\": \"http://www.ncpe.ie/drugs/tafamadis-meglumine-vyndaqel/\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED UNTIL ADDITIONAL EFFICACY AND/OR SAFETY DATA IS SUBMITTED. ON THE BASIS OF CURRENT EVIDENCE, THE NCPE RECOMMENDS THAT TAFAMIDIS NOT BE CONSIDERED FOR REIMBURSEMENT IN ACCORDANCE WITH THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Tafamadis meglumine (Vyndaqel\", \"trade_name\": \"Vyndaqel\", \"indication\": \"Tafamadis meglumine (Vyndaqel\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-16T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel\", \"ta_list\": \"Amyloidosis\", \"rr_status\": \"No HTA until more evidence\"}, {\"id\": 2524, \"last_scrape\": \"2018-12-13T16:51:15\", \"url\": \"http://www.ncpe.ie/drugs/tafluprost-saflutan/\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-25T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2011-03-11, 2011-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Tafluprost (Saflutan\", \"trade_name\": \"Saflutan\", \"indication\": \"Tafluoprost (Salflutan\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-25T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"id\": 2525, \"last_scrape\": \"2018-12-13T16:51:24\", \"url\": \"http://www.ncpe.ie/drugs/talimogene-laherparepvec-imlygic/\", \"rr_start\": \"2016-02-16T00:00:00\", \"rr_end\": \"2016-03-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2016-02-16, 2016-03-14\", \"rr_multiple\": 0, \"drug_name\": \"Talimogene Laherparepvec (Imlygic\", \"trade_name\": \"Imlygic\", \"indication\": \"Talimogene laherparepvec (Imlygic\", \"ncpe_year\": 2016, \"eu_market\": \"2015-12-16T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-02-16T00:00:00\", \"latest\": \"2016-03-14T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2526, \"last_scrape\": \"2018-12-13T16:51:28\", \"url\": \"http://www.ncpe.ie/drugs/tapentadol-palexia/\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Tapentadol (Palexia\", \"trade_name\": \"Palexia\", \"indication\": \"Economic evaluation of oral tapentadol (Palexia\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2011-04-08T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2527, \"last_scrape\": \"2018-12-13T16:51:34\", \"url\": \"http://www.ncpe.ie/drugs/tedizolid-phosphate-sivextro/\", \"rr_start\": \"2015-05-07T00:00:00\", \"rr_end\": \"2015-07-07T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2015-05-07, 2015-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Tedizolid phosphate (Sivextro\", \"trade_name\": \"Sivextro\", \"indication\": \"Tedizolid phosphate (Sivextro\", \"ncpe_year\": 2015, \"eu_market\": \"2015-03-23T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-05-07T00:00:00\", \"latest\": \"2015-07-07T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/sivextro\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"No HTA\"}, {\"id\": 2528, \"last_scrape\": \"2018-12-13T16:51:38\", \"url\": \"http://www.ncpe.ie/drugs/teduglutide-revestive/\", \"rr_start\": \"2017-03-13T00:00:00\", \"rr_end\": \"2017-04-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2017-03-13, 2017-04-12\", \"rr_multiple\": 0, \"drug_name\": \"Teduglutide (Revestive\", \"trade_name\": \"Revestive\", \"indication\": \"Teduglutide (Revestive\", \"ncpe_year\": 2018, \"eu_market\": \"2012-08-30T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2017-03-13T00:00:00\", \"latest\": \"2018-03-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/revestive\", \"ta_list\": \"Malabsorption Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2529, \"last_scrape\": \"2018-12-13T16:51:44\", \"url\": \"http://www.ncpe.ie/drugs/tegafurgimeraciloteracil-teysuno/\", \"rr_start\": \"2012-02-27T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED.\", \"rr_dates\": \"2012-02-27, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Tegafur/Gimeracil/Oteracil (Teysuno\", \"trade_name\": \"Teysuno\", \"indication\": \"Teysuno is indicated in adults for the treatment of advanced gastric cancer.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-03-14T00:00:00\", \"company\": \"Nordic\", \"orphan\": 0, \"earliest\": \"2012-02-27T00:00:00\", \"latest\": \"2012-03-23T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2530, \"last_scrape\": \"2018-12-13T16:51:48\", \"url\": \"http://www.ncpe.ie/drugs/telapravir/\", \"rr_start\": \"2011-10-28T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-10-28, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Telaprevir (Incivo\", \"trade_name\": \"Incivo\", \"indication\": \"Economic evaluation of Telaprevir (Incivo\", \"ncpe_year\": 2012, \"eu_market\": \"2011-09-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-28T00:00:00\", \"latest\": \"2012-01-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/incivo\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2531, \"last_scrape\": \"2018-12-13T16:51:52\", \"url\": \"http://www.ncpe.ie/drugs/telavancin-vibativ/\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-12-08, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Telavancin (Vibativ\", \"trade_name\": \"Vibativ\", \"indication\": \"Indicated for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumomia, known or suspended to be caused by methicillin-resistant Staphylococcus aureas (MRSA).  Vabitiv\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Theravance\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2015-01-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/vibativ-0\", \"ta_list\": \"Pneumonia, Bacterial; Cross Infection\", \"rr_status\": \"No HTA\"}, {\"id\": 2532, \"last_scrape\": \"2018-12-13T16:51:56\", \"url\": \"http://www.ncpe.ie/drugs/teriflunomide-aubagio/\", \"rr_start\": \"2013-08-27T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-08-27, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Teriflunomide (Aubagio\", \"trade_name\": \"Aubagio\", \"indication\": \"Aubagio\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2013-08-27T00:00:00\", \"latest\": \"2014-09-05T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2533, \"last_scrape\": \"2018-12-13T16:51:58\", \"url\": \"http://www.ncpe.ie/drugs/ticagrelor-brilique-2/\", \"rr_start\": \"2016-02-29T00:00:00\", \"rr_end\": \"2016-05-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-02-29, 2016-05-04\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor (Brilique\", \"trade_name\": \"Brilique\", \"indication\": \"Ticagrelor (Brilique\", \"ncpe_year\": 2016, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-29T00:00:00\", \"latest\": \"2016-05-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brilique\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2534, \"last_scrape\": \"2018-12-13T16:52:01\", \"url\": \"http://www.ncpe.ie/drugs/ticagrelor-brilique/\", \"rr_start\": \"2010-11-25T00:00:00\", \"rr_end\": \"2011-01-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-11-25, 2011-01-20\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor (Brilique\", \"trade_name\": \"Brilique\", \"indication\": \"Economic Evaluation of Ticagrelor (Brilique\", \"ncpe_year\": 2011, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-11-25T00:00:00\", \"latest\": \"2011-10-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brilique\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2535, \"last_scrape\": \"2018-12-13T16:52:07\", \"url\": \"http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-all/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-19T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TISAGENLECLEUCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel (Kymriah\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel (Kymriah\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2536, \"last_scrape\": \"2018-12-13T16:52:13\", \"url\": \"http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-dlbcl/\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TISAGENLECLEUCEL COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-19, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel (Kymriah\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel (Kymriah\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2537, \"last_scrape\": \"2018-12-13T16:52:19\", \"url\": \"http://www.ncpe.ie/drugs/tobramycin-tobi-podhaler/\", \"rr_start\": \"2010-11-10T00:00:00\", \"rr_end\": \"2010-11-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2010-11-10, 2010-11-03\", \"rr_multiple\": 0, \"drug_name\": \"Tobramycin (TOBI Podhaler\", \"trade_name\": \"TOBI Podhaler\", \"indication\": \"Tobramycin (TOBI Podhaler\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-11-01T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2538, \"last_scrape\": \"2018-12-13T16:52:24\", \"url\": \"http://www.ncpe.ie/drugs/tocilizumab-sc-roactemra/\", \"rr_start\": \"2014-04-28T00:00:00\", \"rr_end\": \"2014-07-16T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THESUBMITTED PRICE.\", \"rr_dates\": \"2014-04-28, 2014-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Tocilizumab SC (RoActemra\", \"trade_name\": \"RoActemra\", \"indication\": \"It is licensed for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.  It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-04-28T00:00:00\", \"latest\": \"2014-07-16T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra\", \"ta_list\": \"Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2539, \"last_scrape\": \"2018-12-13T16:52:30\", \"url\": \"http://www.ncpe.ie/drugs/tofacitinib-xeljanz-for-ulcerative-colitis/\", \"rr_start\": \"2018-07-16T00:00:00\", \"rr_end\": \"2018-09-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF TOFACITINIB COMPARED WITH THE CURRENT STANDARD OF CARE, ON THE BASIS OF THE PROPOSED PRICE RELATIVE TO CURRENTLY AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-07-16, 2018-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib (Xeljanz\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy (i.e. corticosteroids, azathioprine, 6-mercaptopurine) or a biologic agent (i.e. TNF inhibitor).\", \"ncpe_year\": 2018, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2018-07-16T00:00:00\", \"latest\": \"2018-09-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2540, \"last_scrape\": \"2018-12-13T16:52:35\", \"url\": \"http://www.ncpe.ie/drugs/tofacitinib-xeljanz/\", \"rr_start\": \"2017-03-08T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-03-08, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib (Xeljanz\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib (Xeljanz\", \"ncpe_year\": 2017, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-03-08T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2541, \"last_scrape\": \"2018-12-13T16:52:40\", \"url\": \"http://www.ncpe.ie/drugs/tolvaptan-jinarc/\", \"rr_start\": \"2016-01-04T00:00:00\", \"rr_end\": \"2016-01-12T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2016-01-04, 2016-01-12\", \"rr_multiple\": 0, \"drug_name\": \"Tolvaptan (Jinarc\", \"trade_name\": \"Jinarc\", \"indication\": \"Jinarc\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2016-01-04T00:00:00\", \"latest\": \"2018-09-13T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc\", \"ta_list\": \"Polycystic Kidney, Autosomal Dominant\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2542, \"last_scrape\": \"2018-12-13T16:52:45\", \"url\": \"http://www.ncpe.ie/drugs/tramadol-hydrochloridedexketoprofen-skudexa/\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"REIMURSEMENT NOT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2017-10-17, 2017-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Tramadol hydrochloride/dexketoprofen (Skudexa\", \"trade_name\": \"Skudexa\", \"indication\": \"Tramadol hydrochloride/dexketoprofen (Skudexa \", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2017-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"id\": 2543, \"last_scrape\": \"2018-12-13T16:52:51\", \"url\": \"http://www.ncpe.ie/drugs/trametinib-mekinist/\", \"rr_start\": \"2015-11-27T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2015-11-27, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Trametinib (Mekinist\", \"trade_name\": \"Mekinist\", \"indication\": \"Mekinist\", \"ncpe_year\": 2018, \"eu_market\": \"2014-06-30T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-27T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2544, \"last_scrape\": \"2018-12-13T16:52:56\", \"url\": \"http://www.ncpe.ie/drugs/trastuzumab-emtansine-kadcyla/\", \"rr_start\": \"2013-09-25T00:00:00\", \"rr_end\": \"2013-10-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-09-25, 2013-10-24\", \"rr_multiple\": 0, \"drug_name\": \"Trastuzumab emtansine (Kadcyla\", \"trade_name\": \"Kadcyla\", \"indication\": \"Trastuzumab emtansine (Kadcyla\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-09-25T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2545, \"last_scrape\": \"2018-12-13T16:53:00\", \"url\": \"http://www.ncpe.ie/drugs/trifluridinetipiracil-lonsurf/\", \"rr_start\": \"2016-06-10T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT THE SUBMITTED PRICE\", \"rr_dates\": \"2016-06-10, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Trifluridine/tipiracil (Lonsurf\", \"trade_name\": \"Lonsurf\", \"indication\": \"Trifluridine/tipiracil (Lonsurf\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2016-06-10T00:00:00\", \"latest\": \"2016-07-11T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2546, \"last_scrape\": \"2018-12-13T16:53:04\", \"url\": \"http://www.ncpe.ie/drugs/ulipristal-acetate-esmya-2/\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2016-05-17, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate (Esmya \", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate is indicated for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-05-31T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esmya\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2547, \"last_scrape\": \"2018-12-13T16:53:08\", \"url\": \"http://www.ncpe.ie/drugs/ulipristal-acetate-esmya/\", \"rr_start\": \"2013-09-03T00:00:00\", \"rr_end\": \"2013-10-18T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2013-09-03, 2013-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate (Esmya\", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate (Esmya\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2013-09-03T00:00:00\", \"latest\": \"2013-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/esmya\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"id\": 2548, \"last_scrape\": \"2018-12-13T16:53:10\", \"url\": \"http://www.ncpe.ie/drugs/umeclidiniumvilanterol-anoro/\", \"rr_start\": \"2014-06-11T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED\", \"rr_dates\": \"2014-06-11, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Umeclidinium/vilanterol (Anoro\", \"trade_name\": \"Anoro\", \"indication\": \"Umeclidinium/vilanterol (Anoro\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-06-11T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"id\": 2549, \"last_scrape\": \"2018-12-13T16:53:12\", \"url\": \"http://www.ncpe.ie/drugs/urea-glucorx-allpresan/\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-24T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT NOT RECOMMENDED. THE NCPE RECOMMENDS THAT GLUCORX ALLPRESAN DIABETIC FOAM CREAM NOT BE CONSIDERED FOR REIMBURSEMENT AT THE SUBMITTED PRICE IN ACCORDANCE WITH THE CRITERIA SPECIFIED IN THE HEALTH (PRICING AND SUPPLY OF MEDICAL GOODS) ACT 2013.\", \"rr_dates\": \"2018-07-09, 2018-07-24\", \"rr_multiple\": 0, \"drug_name\": \"Urea (GlucoRx Allpresan\", \"trade_name\": \"GlucoRx Allpresan\", \"indication\": \"GlucoRx Allpresan\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-07-24T00:00:00\", \"ema_url\": \"\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA at submitted price\"}, {\"id\": 2550, \"last_scrape\": \"2018-12-13T16:53:17\", \"url\": \"http://www.ncpe.ie/drugs/ustekinumab-stelara-2/\", \"rr_start\": \"2016-11-28T00:00:00\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED AT SUBMITTED PRICE\", \"rr_dates\": \"2016-11-28, 2017-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab (Stelara\", \"trade_name\": \"Stelara\", \"indication\": \"Ustekinumab is indicated for the treatment of adult patients with moderately to severely active Crohn\", \"ncpe_year\": 2017, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2016-11-28T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stelara\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2551, \"last_scrape\": \"2018-12-13T16:53:23\", \"url\": \"http://www.ncpe.ie/drugs/ustekinumab-stelara/\", \"rr_start\": \"\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab (Stelara\", \"trade_name\": \"Stelara\", \"indication\": \"Cost-effectiveness of Ustekinumab (Stelara\", \"ncpe_year\": 2009, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2009-11-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/stelara\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"RR not conducted\"}, {\"id\": 2552, \"last_scrape\": \"2018-12-13T16:53:29\", \"url\": \"http://www.ncpe.ie/drugs/vandetanib-caprelsa/\", \"rr_start\": \"2013-06-06T00:00:00\", \"rr_end\": \"2013-07-03T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-06-06, 2013-07-03\", \"rr_multiple\": 0, \"drug_name\": \"Vandetanib (Caprelsa\", \"trade_name\": \"Caprelsa\", \"indication\": \"Vandetanib (Caprelsa\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-16T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2013-06-06T00:00:00\", \"latest\": \"2013-07-03T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2553, \"last_scrape\": \"2018-12-13T16:53:32\", \"url\": \"http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-crohns-disease/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab (Entyvio\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab (Entyvio\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2554, \"last_scrape\": \"2018-12-13T16:53:39\", \"url\": \"http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-ulcerative-colitis/\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab (Entyvio\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab (Entyvio\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2555, \"last_scrape\": \"2018-12-13T16:53:45\", \"url\": \"http://www.ncpe.ie/drugs/velaglucerase-alfa-vpriv-2/\", \"rr_start\": \"2011-04-26T00:00:00\", \"rr_end\": \"2011-06-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED.\", \"rr_dates\": \"2011-04-26, 2011-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Velaglucerase Alfa (VPRIV\", \"trade_name\": \"VPRIV\", \"indication\": \"VPRIV is indicated for long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-04-26T00:00:00\", \"latest\": \"2011-06-20T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2556, \"last_scrape\": \"2018-12-13T16:53:49\", \"url\": \"http://www.ncpe.ie/drugs/venetoclax-venclyxto-in-combination-with-rituximab/\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"FULL HTA IS RECOMMENDED TO ASSESS THE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS OF VENETOCLAX COMPARED WITH THE CURRENT STANDARD OF CARE.\", \"rr_dates\": \"2018-09-26, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax (Venclyxto\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax (Venclyxto\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2557, \"last_scrape\": \"2018-12-13T16:53:52\", \"url\": \"http://www.ncpe.ie/drugs/venetoclax-venclyxto/\", \"rr_start\": \"2018-05-08T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"FOLLOWING A RESUBMISSION OF THE RAPID REVIEW A FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED ON THE BASIS OF THE PROPOSED PRICE, WHICH IS NOT COMPARABLE WITH CURRENT AVAILABLE THERAPIES.\", \"rr_dates\": \"2018-05-08, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax (Venclyxto\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL)\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2558, \"last_scrape\": \"2018-12-13T16:53:58\", \"url\": \"http://www.ncpe.ie/drugs/vermurafenib-zelboraf/\", \"rr_start\": \"2011-12-23T00:00:00\", \"rr_end\": \"2012-01-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2011-12-23, 2012-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Vemurafenib (Zelboraf\", \"trade_name\": \"Zelboraf\", \"indication\": \"Vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\", \"ncpe_year\": 2014, \"eu_market\": \"2012-02-17T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2011-12-23T00:00:00\", \"latest\": \"2014-09-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2559, \"last_scrape\": \"2018-12-13T16:54:00\", \"url\": \"http://www.ncpe.ie/drugs/vernakalant-brinavess/\", \"rr_start\": \"2010-10-26T00:00:00\", \"rr_end\": \"2010-11-04T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2010-10-26, 2010-11-04\", \"rr_multiple\": 0, \"drug_name\": \"Vernakalant (Brinavess\", \"trade_name\": \"Brinavess\", \"indication\": \"Economic evaluation of Vernakalant (Brinavess\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Cardiome\", \"orphan\": 0, \"earliest\": \"2010-10-26T00:00:00\", \"latest\": \"2011-05-04T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2560, \"last_scrape\": \"2018-12-13T16:54:04\", \"url\": \"http://www.ncpe.ie/drugs/vismodegib-erivedge/\", \"rr_start\": \"2013-05-02T00:00:00\", \"rr_end\": \"2013-05-20T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2013-05-02, 2013-05-20\", \"rr_multiple\": 0, \"drug_name\": \"Vismodegib (Erivedge\", \"trade_name\": \"Erivedge\", \"indication\": \"Vismodegib (Erivedge\", \"ncpe_year\": 2017, \"eu_market\": \"2013-07-12T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-05-02T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge\", \"ta_list\": \"Carcinoma, Basal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"id\": 2561, \"last_scrape\": \"2018-12-13T16:54:11\", \"url\": \"http://www.ncpe.ie/drugs/vortioxetine-brintellix/\", \"rr_start\": \"2014-10-01T00:00:00\", \"rr_end\": \"2014-11-14T00:00:00\", \"rr_outcome\": \"FULL PHARMACOECONOMIC ASSESSMENT RECOMMENDED\", \"rr_dates\": \"2014-10-01, 2014-11-14\", \"rr_multiple\": 0, \"drug_name\": \"Vortioxetine (Brintellix\", \"trade_name\": \"Brintellix\", \"indication\": \"Vortioxetine (Brintellix\", \"ncpe_year\": 2017, \"eu_market\": \"2013-12-18T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2014-10-01T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ema_url\": \"https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"HTA recommended at submitted price\"}]}};\n",
       "var opt = {};\n",
       "var type = \"vega-lite\";\n",
       "var id = \"bf38b270-f11d-4c5e-8536-f32a8fc0597e\";\n",
       "\n",
       "var output_area = this;\n",
       "\n",
       "require([\"nbextensions/jupyter-vega/index\"], function(vega) {\n",
       "  var target = document.createElement(\"div\");\n",
       "  target.id = id;\n",
       "  target.className = \"vega-embed\";\n",
       "\n",
       "  var style = document.createElement(\"style\");\n",
       "  style.textContent = [\n",
       "    \".vega-embed .error p {\",\n",
       "    \"  color: firebrick;\",\n",
       "    \"  font-size: 14px;\",\n",
       "    \"}\",\n",
       "  ].join(\"\\\\n\");\n",
       "\n",
       "  // element is a jQuery wrapped DOM element inside the output area\n",
       "  // see http://ipython.readthedocs.io/en/stable/api/generated/\\\n",
       "  // IPython.display.html#IPython.display.Javascript.__init__\n",
       "  element[0].appendChild(target);\n",
       "  element[0].appendChild(style);\n",
       "\n",
       "  vega.render(\"#\" + id, spec, type, opt, output_area);\n",
       "}, function (err) {\n",
       "  if (err.requireType !== \"scripterror\") {\n",
       "    throw(err);\n",
       "  }\n",
       "});\n"
      ],
      "text/plain": [
       "<vega.vegalite.VegaLite at 0x24583246860>"
      ]
     },
     "metadata": {
      "jupyter-vega": "#bf38b270-f11d-4c5e-8536-f32a8fc0597e"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": []
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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"
     },
     "metadata": {
      "jupyter-vega": "#bf38b270-f11d-4c5e-8536-f32a8fc0597e"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "alt.Chart(drugs,title=\"Count Drugs by Company & Status\").mark_bar().encode(\n",
    "    alt.Y('company', sort=alt.EncodingSortField(field=\"company\", op=\"count\", order='descending'),\n",
    "          axis=alt.Axis(title='Drug Company')),\n",
    "    alt.X('count(rr_status)',\n",
    "          axis=alt.Axis(title='Count Drugs')),\n",
    "    alt.Color(\"rr_status\",title=\"Status\",\n",
    "          scale=Scale(domain=['HTA recommended at submitted price','No HTA','No HTA at submitted price','No HTA until more evidence','RR not conducted','Reimbursement not recommended','Reimbursement without HTA','Unknown'],\n",
    "                      range=[rgb_to_hex((255,215,40)),rgb_to_hex((205,131,131)),rgb_to_hex((131,175,131)),rgb_to_hex((131,131,195)),rgb_to_hex((185,141,30)),rgb_to_hex((80,185,151)),rgb_to_hex((131,100,145)),rgb_to_hex((125,101,101))]))).properties(width=650,height=3000).interactive()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
